[
  {
    "id": "Core.6.1.1",
    "category": "General Anesthesia & Postop",
    "subcategory": "Awareness and depth monitoring",
    "difficulty": "medium",
    "questionText": "A 38-year-old woman (ASA II) undergoes laparoscopic appendectomy under sevoflurane anesthesia (air/O<sub>2</sub>). After induction with propofol, fentanyl, and rocuronium, maintenance is with sevoflurane. Thirty minutes into the case, the team lowers the vaporizer due to hypotension. Current monitors show MAP 58 mmHg, HR 68/min, end-tidal sevoflurane 0.6% (machine displays age-adjusted MAC 0.3), BIS 42, and TOF 0/4 after a recent rocuronium redose. A phenylephrine infusion is started, and MAP increases to 70 mmHg without movement or hemodynamic reactivity.\n\nTo minimize the risk of intraoperative awareness while maintaining hemodynamic stability, which of the following is the most appropriate next step?",
    "answers": [
      {
        "text": "Give additional rocuronium to ensure there is no movement during surgical stimulation",
        "isCorrect": false,
        "explanation": "Neuromuscular blockade prevents movement but does not provide hypnosis or amnesia; increasing paralysis can mask light anesthesia and increase awareness risk."
      },
      {
        "text": "Increase sevoflurane to achieve an end-tidal age-adjusted MAC ≥0.7 while continuing phenylephrine and giving fluids as needed",
        "isCorrect": true,
        "explanation": "Maintaining ≥0.7 age-adjusted MAC reliably reduces awareness risk; vasopressors treat hypotension but do not deepen hypnosis. With NMB present (TOF 0/4), movement is abolished and BIS may be artifactually low, so ET MAC is a safer guide to hypnotic adequacy."
      },
      {
        "text": "Administer 2 mg midazolam and keep sevoflurane at 0.3 MAC to avoid further hypotension",
        "isCorrect": false,
        "explanation": "A benzodiazepine bolus offers uncertain, short-lived amnesia and does not ensure adequate intraoperative hypnosis; reliance on benzos while maintaining low MAC risks awareness and delayed emergence."
      },
      {
        "text": "Replace phenylephrine with ephedrine to treat hypotension while maintaining sevoflurane at 0.3 MAC",
        "isCorrect": false,
        "explanation": "Pressor selection may affect HR/CO but does not address inadequate hypnotic dosing; leaving ET MAC at 0.3 still risks awareness."
      },
      {
        "text": "Maintain the current anesthetic because BIS <50 indicates adequate hypnotic depth",
        "isCorrect": false,
        "explanation": "Processed EEG can be confounded by neuromuscular blockade (reduced EMG lowers the index) and vasoactive changes; a low BIS does not guarantee sufficient hypnosis when ET MAC is 0.3."
      }
    ],
    "didactic": "Treating hypotension by turning down inhaled agent increases the risk of intraoperative awareness, especially when neuromuscular blockade abolishes movement. **Vasopressors restore MAP but do not deepen anesthesia**, and relying on stable blood pressure alone can mask insufficient hypnotic dosing. With **TOF 0/4**, EMG activity is reduced, which can artifactually lower processed EEG indices (eg, BIS), giving a **false sense of adequate depth** despite a low end-tidal anesthetic concentration.\n\nA practical and evidence-supported strategy to reduce awareness is to maintain an **age-adjusted end-tidal MAC ≥0.7** for volatile-based anesthetics while simultaneously managing hypotension with **vasopressors and fluids**. End-tidal agent concentration is a direct, continuous measure of anesthetic partial pressure equilibrating with the brain and is less susceptible to confounders than processed EEG when NMB is present. In this case, ET sevoflurane 0.6% in a young adult corresponds to ~0.3 MAC, which is below the typical threshold for reliable amnesia and hypnosis.\n\nKey points to minimize awareness risk when vasopressors are needed:\n- Prefer maintaining **adequate ET anesthetic (≥0.7 MAC)** and support blood pressure with **phenylephrine/ephedrine**, fluids, and surgical optimization.\n- Recognize that **NMB eliminates movement** and can **lower BIS**; confirm depth using **age-adjusted MAC** rather than processed EEG alone.\n- If temporarily unable to maintain volatile ≥0.7 MAC (eg, severe hemodynamic instability), consider adding short-acting **IV hypnotic supplementation** (eg, propofol bolus) rather than relying on benzodiazepines, and reassess frequently.\n- Avoid substituting **opioids or additional NMB** for hypnosis; opioids treat nociception, and NMB only prevents movement.\n\nBy prioritizing adequate hypnotic concentration and using vasopressors to maintain perfusion, clinicians reduce the risk of awareness without compromising hemodynamics.",
    "educationalObjective": "Adjust anesthetic plan when vasopressors are used to treat hypotension so depth is not inadvertently reduced."
  },
  {
    "id": "Core.6.1.2",
    "category": "General Anesthesia & Postop",
    "subcategory": "Awareness and depth monitoring",
    "difficulty": "hard",
    "questionText": "A 63-year-old man with severe ischemic cardiomyopathy (EF 20%) is undergoing urgent CABG for NSTEMI. After etomidate–fentanyl induction and rocuronium, he is intubated and maintained on isoflurane 0.3 MAC in 50% O<sub>2</sub>/air; norepinephrine is running at 0.08 μg/kg/min to keep MAP 65–70 mmHg. A processed EEG monitor shows BIS 75 with good signal quality and low EMG. Sternotomy is imminent, and the surgical team is concerned about intraoperative awareness, but the patient is hemodynamically marginal.\n\nWhich of the following is the most appropriate next step to reduce awareness risk while preserving hemodynamic stability?",
    "answers": [
      {
        "text": "Add 50% nitrous oxide to increase anesthetic depth while keeping volatile low",
        "isCorrect": false,
        "explanation": "Nitrous oxide reduces FiO<sub>2</sub>, can increase PVR, and is generally avoided in cardiac surgery; BIS is less reliable with N<sub>2</sub>O and it offers limited amnesia compared with benzodiazepines."
      },
      {
        "text": "Start dexmedetomidine infusion at 0.7 μg/kg/h to deepen anesthesia",
        "isCorrect": false,
        "explanation": "Dexmedetomidine is sympatholytic and commonly causes bradycardia and hypotension, which is undesirable in a patient dependent on vasopressors."
      },
      {
        "text": "Administer midazolam 2 mg IV now and titrate small additional doses to target BIS 40–60",
        "isCorrect": true,
        "explanation": "Benzodiazepines provide reliable amnesia with relatively modest hemodynamic effects; titration guided by processed EEG can mitigate awareness risk without large drops in MAP."
      },
      {
        "text": "Administer ketamine 0.5 mg/kg IV bolus for amnesia and sympathetic support",
        "isCorrect": false,
        "explanation": "Ketamine increases HR and BP, raising myocardial O<sub>2</sub> demand and risk of ischemia in CAD; it also confounds BIS by increasing high-frequency activity."
      },
      {
        "text": "Increase isoflurane to 1.0 MAC to target BIS 40–60",
        "isCorrect": false,
        "explanation": "Volatile up-titration to 1 MAC in severe LV dysfunction risks significant myocardial depression and hypotension, jeopardizing coronary perfusion and stability."
      }
    ],
    "didactic": "In high-risk cardiac and obstetric anesthesia, anesthetic depth is often intentionally limited to avoid hypotension (cardiac ischemia, low EF, severe valvular disease) or uterine atony and reduced uteroplacental perfusion. This restraint increases the risk of intraoperative awareness. A practical approach is to use **processed EEG** to titrate hypnotic depth (target BIS 40–60) and select adjuncts that provide **amnesia with minimal hemodynamic penalty**.\n\n- **Volatile anesthetics** are myocardial depressants; increasing to 1 MAC in a patient supported by norepinephrine can precipitate hypotension and reduce coronary perfusion pressure.\n- **Benzodiazepines (eg, midazolam)** provide reliable anterograde amnesia with relatively modest decreases in SVR/BP at small doses. In hemodynamically tenuous patients, 1–2 mg IV boluses titrated to a BIS in the 40–60 range reduce awareness risk without large hemodynamic swings. Opioids alone are not dependable for amnesia.\n- **Dexmedetomidine** is sympatholytic (bradycardia/hypotension) and is poorly tolerated in vasopressor-dependent patients.\n- **Ketamine** increases sympathetic tone and myocardial O<sub>2</sub> demand, which can worsen ischemia in CAD; it also elevates high-frequency EEG activity, making BIS falsely high and potentially prompting harmful over-anesthetizing.\n- **Nitrous oxide** offers limited amnesia, reduces FiO<sub>2</sub> (undesirable in ischemic heart disease), increases PVR, and is generally avoided in cardiac surgery; BIS is less reliable when N<sub>2</sub>O is used.\n\nProcessed EEG should be interpreted in context (good signal quality, low EMG). If hypotension occurs, prefer **vasopressors** over deepening volatile in these high-risk settings. In obstetrics, similar principles apply: limit volatile pre-delivery to preserve uterine tone and fetal perfusion, use depth monitoring, and give amnestic agents (eg, midazolam, opioids) promptly after cord clamp to mitigate awareness risk without neonatal depression.",
    "educationalObjective": "Balance light anesthesia risks against hemodynamic goals in high-risk obstetric or cardiac cases."
  },
  {
    "id": "Core.6.1.3",
    "category": "General Anesthesia & Postop",
    "subcategory": "Awareness and depth monitoring",
    "difficulty": "medium",
    "questionText": "A 45-year-old woman undergoes laparoscopic cholecystectomy under general anesthesia with sevoflurane, fentanyl, and rocuronium. During pneumoperitoneum, her MAP transiently falls to 55 mmHg; vasopressors are given, and the end-tidal sevoflurane is reduced to 0.6% for ~10 minutes while neuromuscular blockade is maintained. Emergence is uneventful.\n\nIn the PACU, she calmly reports hearing staff voices and feeling the endotracheal tube without the ability to move for a short period, with her next memory being arrival to PACU. She is hemodynamically stable and comfortable. She asks what happened. Which is the most appropriate next step to address this report?",
    "answers": [
      {
        "text": "Schedule BIS monitoring for future anesthetics and close the encounter now without further discussion.",
        "isCorrect": false,
        "explanation": "Planning future strategies alone does not address the current report; immediate structured evaluation, support, documentation, and follow-up are required."
      },
      {
        "text": "Reassure her that 1 MAC of sevoflurane prevents awareness, so no further action is needed.",
        "isCorrect": false,
        "explanation": "Dismissal is inappropriate; brief periods of low anesthetic concentration, especially with neuromuscular blockade, can result in awareness and warrant structured assessment and follow-up."
      },
      {
        "text": "Conduct a structured Brice interview (eg, last memory before sleep, first after waking, any recall in between, dreams, most unpleasant), validate her experience, document the event, and arrange timely follow-up and psychological support.",
        "isCorrect": true,
        "explanation": "A structured, empathetic interview using Brice questions, followed by documentation, notification/QA reporting, and arranging follow-up and counseling is the appropriate immediate management of suspected intraoperative awareness."
      },
      {
        "text": "Administer midazolam 2 mg IV to induce amnesia and reassure her that such experiences are dreams that will fade.",
        "isCorrect": false,
        "explanation": "Benzodiazepines produce anterograde—not retrograde—amnesia and do not treat established explicit recall; minimizing the report undermines appropriate evaluation and support."
      },
      {
        "text": "Order a postoperative EEG and neurology consult to assess for persistent cortical activation during surgery.",
        "isCorrect": false,
        "explanation": "EEG after the fact cannot diagnose prior awareness events and is not part of the evaluation; management hinges on structured interview, documentation, and follow-up."
      }
    ],
    "didactic": "Intraoperative awareness (explicit recall of events under general anesthesia) is uncommon but clinically significant, particularly when neuromuscular blockade masks purposeful movement. Risk increases with reduced anesthetic delivery (eg, hypotension prompting volatile reduction), TIVA without reliable delivery confirmation, use of NMBs, emergency/trauma, obstetrics, cardiac surgery, and hemodynamic instability. Brief reductions in end-tidal volatile concentration—especially to sub-MAC fractions—can permit cortical perception despite immobility.\n\nWhen a patient reports possible awareness, the immediate response should be supportive and structured:\n\n- **Validate and apologize** for the distress; avoid minimizing or attributing the experience to dreams.\n- **Conduct a Brice interview** to characterize recall:\n  - What was the last thing you remember before going to sleep?\n  - What is the first thing you remember after waking?\n  - Do you remember anything in between?\n  - Did you have any dreams?\n  - What was the worst thing about your operation?\n- **Document** the details in the medical record, including timing, sensations (pain, paralysis), and emotional response, and **review the anesthetic record** (eg, end-tidal agent, hemodynamics, NMB use, vasopressors, technical issues).\n- **Arrange follow-up** (eg, within 24 hours and again at 1–2 weeks) to reassess recall, screen for anxiety/PTSD symptoms, and **offer psychological support** or counseling.\n- **Notify quality/risk management** to facilitate systems review and prevention.\n\nBenzodiazepines do not provide retrograde amnesia and should not be used to “erase” established recall. Postoperative EEG does not diagnose prior awareness. While tools like processed EEG (eg, BIS) may be considered in future high-risk cases, they do not replace appropriate immediate evaluation and support. Early recognition, validation, and structured follow-up can reduce long-term psychological morbidity and improve patient trust.",
    "educationalObjective": "Conduct a structured postoperative interview for reported awareness and arrange follow-up and support."
  },
  {
    "id": "Core.6.1.4",
    "category": "General Anesthesia & Postop",
    "subcategory": "Awareness and depth monitoring",
    "difficulty": "hard",
    "questionText": "A 32-year-old woman undergoes posterior spinal fusion with motor-evoked potential monitoring. Total IV anesthesia with propofol and remifentanil is used via a syringe pump connected to a 3-way stopcock that also carries crystalloid. At lunch handoff, a prophylactic cefazolin dose is started through the shared stopcock. Minutes later, heart rate and blood pressure rise with patient movement; processed EEG index increases to the 80s. The propofol pump displays “RUN,” with no occlusion alarm. Inspection reveals the stopcock was turned away from the TIVA limb during the antibiotic infusion.\n\nWhich practice change would most effectively reduce the risk of intraoperative awareness in future TIVA cases like this?",
    "answers": [
      {
        "text": "Mount the syringe pump above patient level and disable high-pressure occlusion alarms to minimize nuisance alarms with long tubing runs.",
        "isCorrect": false,
        "explanation": "Elevating the pump increases hydrostatic gradients and risk of siphon/free flow without anti-siphon protection; disabling alarms removes critical safety nets."
      },
      {
        "text": "Increase the propofol target by ~20% and titrate to BIS 40–60 while continuing to share the line with maintenance fluids.",
        "isCorrect": false,
        "explanation": "Increasing dose does not protect against delivery interruptions from stopcock mispositioning or line disconnections; processed EEG cannot compensate for absent drug delivery."
      },
      {
        "text": "Add 0.2 MAC sevoflurane as insurance against awareness despite MEP monitoring.",
        "isCorrect": false,
        "explanation": "Volatile anesthetics degrade MEPs and are often contraindicated; this does not address the root cause of TIVA failures (delivery reliability) and may compromise monitoring goals."
      },
      {
        "text": "Run a pressurized carrier at 200 mL/h through the same stopcock to ensure forward flow if the syringe pump pauses.",
        "isCorrect": false,
        "explanation": "A high-rate carrier through a shared manifold increases risks of drug dilution, reverse flow, and inadvertent bolus; it masks, rather than fixes, delivery failures."
      },
      {
        "text": "Route propofol through a dedicated, labeled line with inline anti-siphon/check valves (no shared stopcocks), and require a pump-and-line trace with verification at every handoff.",
        "isCorrect": true,
        "explanation": "A dedicated TIVA line with anti-siphon/check valves prevents inadvertent diversion/backflow and free flow, and eliminating shared manifolds avoids stopcock errors; mandatory pump/line checks at handoffs catch latent failures before awareness occurs."
      }
    ],
    "didactic": "TIVA-associated awareness most often stems from failures in drug delivery rather than insufficient dose. Unlike volatile anesthesia (with continuous end-tidal agent monitoring), TIVA lacks a direct breath-by-breath surrogate for hypnotic concentration, making line reliability and handoff discipline central to safety. Closed-claims reviews repeatedly implicate stopcock mispositioning, line disconnections, shared manifolds, and siphon/free-flow events during repositioning or transport.\n\nHigh-yield safeguards for TIVA include:\n- Dedicated IV line: Route the hypnotic via a separate, clearly labeled tubing from syringe to vein. Avoid shared stopcocks/manifolds that invite diversion, dilution, or closure of the TIVA limb.\n- Anti-siphon and check valves: Place an anti-siphon valve distal to the syringe to prevent unintended free flow when downstream negative pressure or height changes occur; use one-way check valves to prevent backflow or mixing when multiple infusions converge.\n- Pump and line checks at handoffs: Require a deliberate trace from syringe to patient, confirm the correct port is open, verify pump settings/alarms, and document infusion rate and remaining volume. Many TIVA awareness events occur shortly after a handoff.\n- Maintain alarm integrity: Keep occlusion/air-in-line alarms enabled and set appropriately; do not mask problems with high-rate carrier fluids through shared manifolds.\n- Physical organization: Color-code and label the TIVA tubing, minimize connectors, secure luer-locks, and keep the infusion hardware at consistent height relative to the patient to limit hydrostatic effects.\n\nProcessed EEG can assist titration but cannot prevent awareness when drug delivery ceases. In cases requiring neuromonitoring (eg, MEPs), the most effective strategy is to make delivery robust: a dedicated, labeled TIVA line with anti-siphon/check valves and mandatory pump-and-line verification at every handoff.",
    "educationalObjective": "Implement TIVA-specific safeguards: dedicated IV line, anti-siphon valves, and pump and line checks at handoffs."
  },
  {
    "id": "Core.6.1.5",
    "category": "General Anesthesia & Postop",
    "subcategory": "Awareness and depth monitoring",
    "difficulty": "medium",
    "questionText": "A 62-year-old man with ischemic cardiomyopathy (EF 20%) presents for urgent CABG. After induction with etomidate, fentanyl, and rocuronium, the team plans maintenance with propofol and remifentanil infusions during cardiopulmonary bypass. End-tidal agent monitoring will not be available, and they elect not to use a processed EEG monitor. Because of anticipated vasopressor-dependent hypotension, they plan to decrease hypnotic dosing during low MAP periods while maintaining paralysis.\n\nWhich factor in this plan most increases this patient’s risk of intraoperative awareness?",
    "answers": [
      {
        "text": "Hypothermia to 32°C during cardiopulmonary bypass",
        "isCorrect": false,
        "explanation": "Hypothermia reduces MAC and decreases anesthetic requirements; by itself, it does not increase awareness risk and may lower hypnotic needs if doses are adjusted."
      },
      {
        "text": "Total intravenous anesthesia without processed EEG (eg, BIS) monitoring",
        "isCorrect": true,
        "explanation": "TIVA without an objective hypnotic-depth surrogate lacks real-time titration feedback (unlike end-tidal volatile/MAC), making underdosing more likely—especially during hemodynamic instability and CPB—thereby markedly increasing awareness risk."
      },
      {
        "text": "High-dose remifentanil infusion for hemodynamic control",
        "isCorrect": false,
        "explanation": "Opioids provide analgesia but unreliable amnesia; however, their use does not inherently increase awareness risk compared with the absence of an objective hypnotic-depth monitor during TIVA."
      },
      {
        "text": "Continuous neuromuscular blockade throughout maintenance anesthesia",
        "isCorrect": false,
        "explanation": "Paralysis eliminates movement as a sign of inadequate hypnosis and is associated with underrecognition of awareness, but it is not as strong or modifiable a risk factor as unmonitored TIVA."
      },
      {
        "text": "Vasopressor-dependent hypotension prompting reduced anesthetic dosing",
        "isCorrect": false,
        "explanation": "Hemodynamic instability is a recognized risk because clinicians may lighten anesthesia, but the lack of an objective measure during TIVA is a stronger, modifiable driver of unrecognized underdosing."
      }
    ],
    "didactic": "Intraoperative awareness results from insufficient hypnotic effect in the setting of intact memory formation. Major, repeatedly identified risk factors include:\n\n- **TIVA without monitoring of hypnotic depth**: Unlike volatiles, which permit end-tidal concentration and age-adjusted MAC tracking (eg, maintain ≥0.7 MAC when feasible), TIVA lacks a pharmacokinetic end-tidal surrogate. Without processed EEG (eg, BIS), clinicians may inadvertently underdose—especially during transitions (eg, induction, incision, CPB initiation) or pump changes—substantially increasing awareness risk.\n- **Hemodynamic instability/vasopressors**: Fear of cardiovascular depression often leads to reduced anesthetic dosing. In shock or low cardiac output, effect-site delivery during TIVA can be unpredictable, further compounding risk.\n- **Obstetric general anesthesia**: Rapid-sequence induction, minimized volatile before delivery to mitigate uterine atony and neonatal depression, and frequent hemorrhage/hypotension combine to create light anesthesia risk.\n- **Cardiac surgery**: CPB alters drug delivery and clearance; volatiles may be interrupted or omitted, and TIVA is common. Depth monitoring is recommended when end-tidal agent/MAC cannot be tracked.\n\nAdditional contributors include prior awareness, chronic substance use (alcohol, stimulants, benzodiazepines/opioids), emergency/trauma, equipment or infusion failure, and deep neuromuscular blockade masking movement. Neuromuscular blockade itself does not increase anesthetic requirement but obscures clinical signs of inadequate hypnosis.\n\nPrevention strategies focus on ensuring adequate hypnotic depth and reliable monitoring:\n\n- For volatiles, use age-adjusted **end-tidal MAC** targets (commonly ≥0.7 MAC when hemodynamics allow).\n- For **TIVA**, employ **processed EEG** to titrate hypnosis; use target-controlled infusions or dose models, and verify pump function/lines.\n- In high-risk moments (eg, postinduction, pre-incision, tourniquet release, CPB initiation/termination), reassess depth; consider a **benzodiazepine** if light anesthesia is unavoidable (recognizing it doesn’t guarantee amnesia).\n\nEarly disclosure and postoperative screening are important if awareness is suspected.",
    "educationalObjective": "List major risk factors for intraoperative awareness (TIVA without monitoring, hemodynamic instability, obstetrics, cardiac)."
  },
  {
    "id": "Core.6.1.6",
    "category": "General Anesthesia & Postop",
    "subcategory": "Awareness and depth monitoring",
    "difficulty": "medium",
    "questionText": "A 72-year-old man undergoing laparoscopic inguinal hernia repair is intubated, mechanically ventilated, and paralyzed with a rocuronium infusion (train-of-four 0/4). Anesthesia is maintained with sevoflurane in air/O<sub>2</sub> and a remifentanil infusion at 0.05 µg/kg/min (no N<sub>2</sub>O). Twenty minutes after insufflation, his HR increases from 68 to 98/min and BP from 122/70 to 162/88 mmHg; tearing and diaphoresis are noted. End-tidal sevoflurane is 0.8% and the processed EEG monitor reads 52.\n\nWhich of the following is the most appropriate next step to reduce the risk of intraoperative awareness?",
    "answers": [
      {
        "text": "Give an additional rocuronium bolus to prevent movement during peritoneal stimulation",
        "isCorrect": false,
        "explanation": "Neuromuscular blockade suppresses motor signs but does not provide hypnosis or amnesia and can increase the risk of unrecognized awareness."
      },
      {
        "text": "Increase the sevoflurane to target an end-tidal 1.2% (≈0.7 age-adjusted MAC) and reassess hemodynamics",
        "isCorrect": true,
        "explanation": "End-tidal agent is the best real-time surrogate for brain volatile concentration; for a 72-year-old, sevoflurane MAC ≈1.6%, so 0.8% is ~0.5 MAC. Increasing to ≥0.7 age-adjusted MAC reduces awareness risk, especially in a paralyzed patient with sympathetic signs of light anesthesia."
      },
      {
        "text": "Administer midazolam 2 mg for amnesia and continue the current anesthetic",
        "isCorrect": false,
        "explanation": "Benzodiazepines can cause anterograde amnesia but have delayed, unpredictable effect in older adults and do not promptly correct light volatile anesthesia."
      },
      {
        "text": "Administer fentanyl 50 µg and esmolol to blunt the sympathetic response while maintaining the current end-tidal sevoflurane",
        "isCorrect": false,
        "explanation": "Treating hemodynamics without deepening hypnosis risks awareness; opioids and β-blockers can mask signs but do not reliably ensure unconsciousness."
      },
      {
        "text": "Increase the remifentanil infusion to 0.2 µg/kg/min to reduce the MAC requirement for noxious stimulation",
        "isCorrect": false,
        "explanation": "Opioids reduce MAC for movement but are unreliable for amnesia; increasing only analgesia does not address inadequate hypnotic depth and may further mask clinical signs."
      }
    ],
    "didactic": "End-tidal volatile anesthetic concentration (ETAC) approximates alveolar partial pressure and, after equilibration, brain partial pressure; it is the most practical intraoperative surrogate for hypnotic depth with inhaled agents. **MAC** is defined as the alveolar concentration that prevents movement to incision in 50% of patients with no other drugs. MAC decreases ~6% per decade after age 40, so sevoflurane MAC falls from ≈2.0% at age 40 to ≈1.6% at age 72. In this patient, an ET sevoflurane of 0.8% corresponds to ~0.5 age‑adjusted MAC, a range associated with elevated risk of awareness.\n\nTo reduce awareness risk with volatiles, target ≥0.7–1.0 age-adjusted MAC unless contraindicated. Clinical signs (tachycardia, hypertension, tearing, diaphoresis) suggest light anesthesia; however, in paralyzed patients, motor responses are absent and sympathetic surrogates may be the only visible signs. **Neuromuscular blockers do not provide hypnosis or amnesia** and can make processed EEG indices appear lower by reducing electromyographic artifact, potentially giving **falsely reassuring BIS values**. Thus, when ETAC and clinical signs indicate inadequate depth, the priority is to increase volatile concentration to a safe age-adjusted MAC fraction.\n\nKey points:\n- **Age-adjusted MAC:** ≈6% decrease per decade >40; for sevoflurane at 72 years, MAC ≈1.6%.\n- **Awareness risk:** Increases at ETAC <0.5 MAC; targeting ≥0.7 MAC reduces risk during volatile anesthesia.\n- **Opioids vs hypnosis:** Opioids decrease MAC for movement but are unreliable for amnesia; β-blockers only blunt signs. Neither substitutes for adequate hypnotic depth.\n- **Processed EEG:** Use as an adjunct, not a replacement for ETAC and clinical assessment; NMB can artifactually lower indices.\n\nAccordingly, increasing sevoflurane to an ET ≈1.2% (≈0.75 age-adjusted MAC) addresses inadequate hypnotic depth and is preferred over masking hemodynamics with opioids/β-blockers or adding more NMB.",
    "educationalObjective": "Prevent awareness with end-tidal agent monitoring targeting age-adjusted MAC and attention to clinical signs."
  },
  {
    "id": "Core.6.1.7",
    "category": "General Anesthesia & Postop",
    "subcategory": "Awareness and depth monitoring",
    "difficulty": "hard",
    "questionText": "A 56-year-old man undergoing laparoscopic colectomy is maintained on sevoflurane in air/O<sub>2</sub> with a remifentanil infusion. A BIS monitor is in place. Earlier in the case, during monopolar electrocautery, BIS intermittently spiked >90 with a low signal quality index (SQI); between cautery bursts, BIS was 55–60. The patient is hemodynamically stable (MAP 72 mmHg) with ETCO₂ 34 mmHg. At the surgeon’s request, you administer additional rocuronium for abdominal wall relaxation. Within 1 minute, the BIS falls abruptly from 58 to 28 while the EMG indicator drops to near zero and SQI remains 100%; end‑tidal sevoflurane is unchanged at an age‑adjusted 0.6 MAC.\n\nThe resident proposes turning down the volatile agent to avoid “excessive depth.” Which is the most appropriate management now?",
    "answers": [
      {
        "text": "Convert to TIVA with propofol to eliminate electrocautery interference with the BIS",
        "isCorrect": false,
        "explanation": "Electrocautery can artifactually elevate BIS regardless of anesthetic technique; conversion to TIVA is unnecessary here and does not address the current EMG‑related low BIS."
      },
      {
        "text": "Increase volatile anesthetic to target an age‑adjusted MAC ≈1.0 while monitoring hemodynamics",
        "isCorrect": true,
        "explanation": "Neuromuscular blockade reduces frontal EMG, artifactually lowering BIS; with a low MAC fraction (0.6), hypnosis is likely inadequate. The appropriate response is to base depth on end‑tidal MAC and clinical context, not the EMG‑suppressed BIS, and increase volatile as tolerated."
      },
      {
        "text": "Replace the BIS sensor because the sudden drop indicates electrode failure",
        "isCorrect": false,
        "explanation": "Good SQI and the immediate temporal relationship to rocuronium argue against electrode failure; the change is explained by EMG suppression from neuromuscular blockade."
      },
      {
        "text": "Decrease sevoflurane to raise BIS toward 40–60 and avoid EEG suppression",
        "isCorrect": false,
        "explanation": "Titrating down volatile to chase a low BIS ignores neuromuscular blockade–related EMG suppression and the low age‑adjusted MAC (0.6), increasing the risk of awareness despite a low BIS value."
      },
      {
        "text": "Administer sugammadex to partially reverse neuromuscular blockade and restore EMG activity",
        "isCorrect": false,
        "explanation": "Reversing paralysis to normalize BIS is inappropriate and jeopardizes surgical conditions; neuromuscular blockers are not anesthetics, and restoring EMG does not address inadequate hypnotic dosing."
      }
    ],
    "didactic": "BIS is a proprietary processed EEG index that integrates spectral and bispectral features along with electromyography (EMG) activity from the frontalis. Because high‑frequency EMG contaminates the EEG band, **facial muscle activity tends to increase BIS**, whereas **neuromuscular blockade (NMB) reduces EMG and can artifactually lower BIS**, sometimes to values suggesting deep hypnosis. Importantly, NMB has no hypnotic properties; it can both suppress movement (masking awareness) and remove EMG that would otherwise elevate the BIS number.\n\nWhen processed EEG conflicts with other data, prioritize context and corroborating signals:\n- Check **signal quality index (SQI)** and the EMG indicator; low SQI and high EMG suggest artifact. In this scenario, SQI is excellent and EMG fell to near zero immediately after rocuronium, explaining the BIS drop without any change in hypnotic dosing.\n- Correlate with **age‑adjusted MAC** for inhaled agents. An ET volatile of 0.6 MAC is likely insufficient for hypnosis in many patients, particularly if analgesia is high (eg, remifentanil), and should not be decreased solely to “treat” a low BIS.\n- Recognize other confounders: **monopolar electrocautery**, pacemakers, forced‑air warmers, and nerve stimulators can transiently elevate BIS and degrade SQI; **ketamine** and **nitrous oxide** can raise BIS despite adequate hypnosis; **hypothermia** and cerebral hypoperfusion can lower BIS.\n\nManagement should avoid chasing the BIS in isolation. Here, the correct action is to **increase volatile to an age‑adjusted MAC near 1.0** (as tolerated) or add hypnotic, using hemodynamics and surgical stimuli to guide dosing. Do not reverse paralysis to normalize BIS, and do not reduce hypnotic concentration based on an EMG‑suppressed low BIS, which risks awareness. Continuous vigilance for artifacts and cross‑checking with end‑tidal agent, analgesia, and clinical signs prevents misinterpretation.",
    "educationalObjective": "Recognize artifacts and confounders in depth monitors (NMB, electrocautery, EMG) and avoid misinterpretation."
  },
  {
    "id": "Core.6.1.8",
    "category": "General Anesthesia & Postop",
    "subcategory": "Awareness and depth monitoring",
    "difficulty": "medium",
    "questionText": "A 45-year-old woman (BMI 28) is undergoing laparoscopic cholecystectomy under general anesthesia with sevoflurane in air/O<sub>2</sub> after induction with propofol, fentanyl, and rocuronium. She did not receive a preoperative benzodiazepine. Forty-five minutes into pneumoperitoneum, her HR increases from 70→110/min and MAP from 75→105 mmHg. She has lacrimation and a BIS that rises from 45 to 72. ETCO<sub>2</sub> is 38 mmHg. End-tidal sevoflurane is 0.6% (age-adjusted MAC ≈2.0%), FGF is 1 L/min, and TOF is 0/4.\n\nYou suspect intraoperative awareness. Which of the following is the most appropriate immediate management to minimize recall and address the cause?",
    "answers": [
      {
        "text": "Increase fresh gas flow to 10 L/min and wait for end-tidal sevoflurane to reach ≥0.7 MAC before giving additional drugs.",
        "isCorrect": false,
        "explanation": "Raising FGF helps alveolar uptake, but delaying an amnestic/analgesic bolus allows further memory encoding during ongoing stimulation."
      },
      {
        "text": "Administer midazolam 2 mg IV and fentanyl 100 μg IV immediately, and increase sevoflurane to target end-tidal ≈1.0 MAC.",
        "isCorrect": true,
        "explanation": "Prompt amnestic and analgesic dosing, along with rapid deepening of volatile anesthetic, best mitigates recall risk and treats inadequate anesthetic depth."
      },
      {
        "text": "Give labetalol 10 mg IV to control hypertension, then increase sevoflurane once hemodynamics stabilize.",
        "isCorrect": false,
        "explanation": "Treating sympathetic signs with antihypertensive alone masks awareness and delays amnestic therapy, increasing risk of explicit recall."
      },
      {
        "text": "Administer rocuronium 10 mg IV to prevent movement and reduce BIS artifact, maintaining current anesthetic settings.",
        "isCorrect": false,
        "explanation": "Increasing neuromuscular blockade can hide the only clinical sign (movement) without improving hypnosis or analgesia; awareness risk persists."
      },
      {
        "text": "Titrate sevoflurane to maintain BIS 40–60 without additional medications or documentation during the case.",
        "isCorrect": false,
        "explanation": "BIS guidance is useful, but suspected awareness warrants immediate amnestic dosing and subsequent documentation/counseling; BIS alone is insufficient."
      }
    ],
    "didactic": "Suspected intraoperative awareness requires rapid, decisive action to both prevent further memory consolidation and correct inadequate anesthetic depth. Clinical signs (tachycardia, hypertension, lacrimation, sweating) plus a rising BIS and very low end-tidal volatile concentration strongly suggest insufficient hypnosis/analgesia—especially when neuromuscular blockade removes movement as a warning sign. In this case, end‑tidal sevoflurane 0.6% in a 45-year-old (~0.3 MAC when MAC ≈2.0%) is inadequate for surgical stimulation.\n\nImmediate management should include: \n- Administer an IV amnestic/hypnotic (eg, midazolam 0.02–0.04 mg/kg or propofol 0.5–1 mg/kg) to reduce further memory encoding. Benzodiazepines do not produce retrograde amnesia but can block additional recall if given promptly.\n- Provide analgesia (eg, fentanyl 50–100 μg IV) to blunt nociception and sympathetic surge.\n- Rapidly deepen the primary anesthetic: increase vaporizer concentration and fresh gas flow to speed alveolar rise, targeting ≥1.0 MAC end‑tidal; confirm vaporizer on, pipeline/cylinder pressure, circuit continuity, and IV infusions if using TIVA.\n\nAvoid strategies that only mask signs (antihypertensives, additional neuromuscular blocker) without treating the cause, as these can worsen the risk of explicit recall. BIS monitoring (target 40–60) can help, but EMG activity and NMB can confound readings; clinical context and end‑tidal agent are paramount.\n\nAfter stabilization, document the event comprehensively (timing, signs, anesthetic concentrations, interventions) and conduct a postoperative interview to assess recall, express empathy, and outline follow-up. Arrange support resources if needed and report the event for quality review. This approach aligns with practice advisories: give immediate amnestic/analgesic therapy, correct delivery of anesthesia, avoid masking signs with paralysis or antihypertensives alone, and ensure thorough documentation and postoperative counseling.",
    "educationalObjective": "Respond to suspected awareness intraoperatively with amnestic/analgesic dosing and documentation."
  },
  {
    "id": "Core.6.1.9",
    "category": "General Anesthesia & Postop",
    "subcategory": "Awareness and depth monitoring",
    "difficulty": "medium",
    "questionText": "A 70-year-old man (ASA II) undergoes laparoscopic cholecystectomy under general anesthesia. Maintenance includes sevoflurane with end-tidal 1.0%, nitrous oxide 60% (FiO<sub>2</sub> 0.4), remifentanil 0.08 µg/kg/min, and rocuronium with TOF 0/4 at the adductor pollicis. Ten minutes after insufflation, the BIS monitor shows a stable value of 72–78 with a high signal quality index (≈95%) and a minimal EMG bar. Blood pressure is 120/65 mmHg and heart rate is 65 bpm without lacrimation or tearing. Age-adjusted MAC(sevo) is ≈1.4%. Which of the following best explains the persistently elevated BIS value in this patient?",
    "answers": [
      {
        "text": "Electrocautery interference with the processed EEG algorithm",
        "isCorrect": false,
        "explanation": "Electrocautery typically causes transient spikes or erratic BIS values rather than a sustained elevation; it also is not occurring at the time described."
      },
      {
        "text": "Nitrous oxide provides MAC without proportionally lowering frontal EEG-derived indices",
        "isCorrect": true,
        "explanation": "N<sub>2</sub>O (and potent opioids) reduce anesthetic requirement but have minimal effect on frontal EEG; BIS may remain high despite adequate depth when N<sub>2</sub>O contributes substantially to MAC."
      },
      {
        "text": "Elevated EMG activity from insufficient neuromuscular blockade",
        "isCorrect": false,
        "explanation": "Deep neuromuscular blockade (TOF 0/4) and a minimal EMG bar on the monitor make EMG contamination an unlikely cause of the high BIS."
      },
      {
        "text": "Inadequate hypnosis due to low end-tidal sevoflurane concentration",
        "isCorrect": false,
        "explanation": "Although 1.0% sevoflurane alone would be sub-MAC in a 70-year-old (≈0.7 MAC), concurrent 60% N<sub>2</sub>O (~0.6 MAC) yields a combined MAC ≈1.3, making insufficient hypnosis unlikely."
      },
      {
        "text": "Poor electrode contact causing high-impedance artifact",
        "isCorrect": false,
        "explanation": "A high signal quality index (~95%) argues against poor contact or high-impedance artifact as the cause of the elevated BIS."
      }
    ],
    "didactic": "Processed EEG indices (eg, **BIS**) estimate hypnotic depth from frontal EEG, with typical targets of 40–60 during general anesthesia. They augment, but do not replace, clinical assessment and end-tidal anesthetic concentration. Importantly, BIS primarily tracks cortical hypnotic effect and is not equally sensitive to all anesthetic components.\n\nKey limitations relevant to this scenario:\n- **Nitrous oxide (N<sub>2</sub>O)**: Provides MAC-sparing effect yet has minimal impact on frontal EEG. BIS may remain in the 60–80 range despite adequate depth when N<sub>2</sub>O contributes substantially to MAC.\n- **Opioids**: Reduce response to surgical stimulation but often do not lower BIS proportionally, especially with potent agents (eg, remifentanil).\n- **EMG and artifacts**: Facial EMG elevates BIS; neuromuscular blockade reduces EMG contamination. Electrocautery/pacers cause transient spikes. Poor electrode contact lowers signal quality.\n- **Physiologic states**: Hypothermia, cerebral hypoperfusion, and burst suppression (eg, propofol) lower BIS.\n\nWhen using multiple agents, MAC fractions are additive. For example, in a 70-year-old, sevoflurane 1.0% is ~0.7 MAC and 60% N<sub>2</sub>O is ~0.6 MAC; combined MAC ≈1.3, consistent with adequate hypnotic depth even if BIS remains ~70. In paralyzed patients, movement is absent and hemodynamic responses may be blunted by opioids and β-blockade, so integrating **age-adjusted end-tidal MAC**, surgical stimulation, vitals, and artifacts with processed EEG is essential.\n\nBottom line: A persistently elevated BIS in a patient receiving significant N<sub>2</sub>O (and opioids) does not necessarily indicate inadequate anesthesia. BIS should be interpreted in context; avoid chasing a numeric BIS target when other validated markers (eg, adequate combined MAC, high signal quality, minimal EMG) indicate sufficient depth.",
    "educationalObjective": "Use processed EEG (e.g., BIS) appropriately, understanding what values represent and common limitations."
  },
  {
    "id": "Core.6.2.1",
    "category": "General Anesthesia & Postop",
    "subcategory": "Emergence and extubation",
    "difficulty": "medium",
    "questionText": "A 45-year-old man is emerging from general anesthesia after functional endoscopic sinus surgery with septoplasty. Bilateral nasal packs are in place, and a throat pack was inserted at the start of the case. Estimated blood loss is 150 mL with continued light oozing expected. The patient is hemodynamically stable, has full reversal of neuromuscular blockade, and follows commands with a strong cough. The surgeon plans to keep the nasal packs for 24 hours. One Yankauer suction is available at the head of the bed.\n\nWhich extubation strategy is most appropriate to minimize aspiration and airway obstruction risk in this setting?",
    "answers": [
      {
        "text": "Remove the nasal packs to reduce airflow resistance and proceed with routine extubation under light anesthesia.",
        "isCorrect": false,
        "explanation": "Removing nasal packs can precipitate hemorrhage; light/deep extubation in a bleeding airway increases aspiration risk."
      },
      {
        "text": "Confirm and document removal of the throat pack with the surgeon; obtain a second suction source; thoroughly clear the oropharynx; then extubate fully awake in a lateral/head-down position with suction ready.",
        "isCorrect": true,
        "explanation": "Awake extubation with intact reflexes, shared confirmation of throat pack removal, meticulous suctioning with redundant suction, and favorable positioning best mitigates aspiration and obstruction risk."
      },
      {
        "text": "Exchange the endotracheal tube for a supraglottic airway to allow smoother emergence and remove the device awake in the PACU.",
        "isCorrect": false,
        "explanation": "A supraglottic airway does not protect against aspiration and exchanging devices in a bleeding airway adds risk."
      },
      {
        "text": "Perform deep extubation to minimize coughing and hypertension, then place an oral airway and transport with the head elevated.",
        "isCorrect": false,
        "explanation": "Deep extubation in the presence of blood and surgical packing increases aspiration and airway obstruction risk; protective reflexes are needed when blood may pool."
      },
      {
        "text": "Place an orogastric tube to empty the stomach, then extubate supine once the patient is following commands.",
        "isCorrect": false,
        "explanation": "Gastric decompression can be helpful but does not address pooled oropharyngeal blood or packing; supine positioning without robust suction and plan increases aspiration risk."
      }
    ],
    "didactic": "Airway bleeding and surgical packing at emergence create a high-risk environment for aspiration and airway obstruction. The safest strategy is an awake extubation with intact protective reflexes, a shared plan with the surgeon, and robust suction readiness. Before extubation, communicate explicitly with the surgeon to confirm and document removal of any throat/oropharyngeal pack and to assess hemostasis; a retained throat pack can cause catastrophic airway obstruction and aspiration.\n\nKey steps include:\n- Ensure full reversal of neuromuscular blockade and readiness for awake extubation (following commands, strong cough/gag).\n- Prepare two functioning suction sources (eg, Yankauer and flexible catheter) and perform meticulous oropharyngeal suctioning under direct vision. Keep suction immediately available during and after tube removal.\n- Consider gentle orogastric suctioning as an adjunct, but prioritize clearing the pharynx where blood accumulates.\n- Extubate in a lateral or slight head-down position to promote drainage away from the glottis; maintain continuous vigilance for laryngospasm.\n- If nasal packs occlude nasal airflow, ensure oral patency postextubation (eg, oral airway if needed) and monitor closely for obstruction.\n\nAvoid deep extubation or device exchanges (eg, to an LMA) when blood or packing is present; these strategies remove airway protection and increase aspiration risk. If bleeding is brisk, visualization is poor, or airway patency is uncertain, the safest plan may be to delay extubation and transport intubated until bleeding is controlled. A deliberate, shared plan with the surgeon and redundant suction readiness are essential to minimize aspiration, laryngospasm, and negative-pressure pulmonary edema in ENT cases with expected oozing or packing.",
    "educationalObjective": "Address airway bleeding or surgical packing at emergence with shared plan and suction readiness."
  },
  {
    "id": "Core.6.2.2",
    "category": "General Anesthesia & Postop",
    "subcategory": "Emergence and extubation",
    "difficulty": "medium",
    "questionText": "A 56-year-old woman has been intubated for 48 hours in the ICU following extensive neck dissection with flap reconstruction. She received 6 L crystalloid intraoperatively and was positioned prone for several hours. She is awake, following commands, hemodynamically stable, and meeting standard ventilator weaning criteria. On volume control ventilation (Vt 500 mL, PEEP 5 cm H2O, FiO<sub>2</sub> 30%), a cuff leak test is performed after oropharyngeal suctioning. With the cuff inflated, average exhaled Vt is 480 mL; with the cuff deflated, average exhaled Vt is 455 mL over several breaths (leak ≈25 mL, ~5%). No audible leak is heard at peak inspiratory pressure ≈20 cm H2O. Which is the most appropriate next step?",
    "answers": [
      {
        "text": "Proceed with extubation to high-flow nasal cannula with racemic epinephrine available",
        "isCorrect": false,
        "explanation": "Supplemental oxygen does not treat fixed upper-airway obstruction; racemic epinephrine provides only transient benefit and is a rescue therapy, not a strategy to overcome absent cuff leak."
      },
      {
        "text": "Exchange the endotracheal tube for a laryngeal mask airway and complete extubation in the OR",
        "isCorrect": false,
        "explanation": "An LMA does not bypass laryngeal edema and may worsen obstruction at the glottic inlet; it is not a solution for an unsafe extubation due to suspected edema."
      },
      {
        "text": "Repeat the test under deeper anesthesia with lower PEEP and extubate if an audible leak is present",
        "isCorrect": false,
        "explanation": "Depth of anesthesia does not resolve structural edema, and lowering PEEP to elicit a ‘leak’ can be misleading; extubation should be performed awake once a satisfactory leak is demonstrated."
      },
      {
        "text": "Administer IV dexamethasone and delay extubation, repeating the cuff leak test in 4–6 hours",
        "isCorrect": true,
        "explanation": "A minimal cuff leak (<110 mL or <10–15% of Vt) suggests clinically significant laryngeal edema and high risk of postextubation obstruction; prophylactic corticosteroids given several hours before extubation reduce stridor and reintubation."
      },
      {
        "text": "Extubate over an airway exchange catheter to facilitate rapid reintubation if needed",
        "isCorrect": false,
        "explanation": "An AEC can aid reintubation but does not prevent airway obstruction from edema; when a cuff leak is absent and extubation is elective, delaying extubation is safer and guideline-concordant."
      }
    ],
    "didactic": "Patients at high risk for laryngeal edema (eg, prolonged intubation, airway/neck surgery, prone positioning, large-volume resuscitation, female sex) benefit from a cuff leak test before extubation. The test assesses the patency of the glottic/supraglottic airway once the tube cuff no longer forms a seal. A practical approach is to use volume control ventilation with a stable Vt (eg, 6–8 mL/kg PBW) and PEEP ≤5 cm H2O, suction the oropharynx, then deflate the cuff and average several exhaled Vt measurements. The leak is the difference between exhaled Vt with the cuff inflated vs deflated. Thresholds commonly used to indicate an inadequate leak (suggesting significant edema) are an absolute leak <110 mL or a relative leak <10–15% of Vt.\n\nThe cuff leak test has limited sensitivity (a normal leak does not fully exclude edema) but reasonable specificity—an absent/minimal leak correlates with postextubation stridor and reintubation. In such cases, the safest course is to delay extubation, treat presumptive edema, and reassess. Short-course corticosteroids (eg, dexamethasone 4–10 mg IV, often repeated every 6 hours) given at least 4 hours prior to planned extubation reduce the incidence of stridor and reintubation. Additional measures include head-up positioning, judicious diuresis if volume overloaded, and repeating the cuff leak test once therapy has taken effect.\n\nIf extubation is unavoidable despite a poor leak, a staged approach in a controlled setting (eg, OR) with an airway exchange catheter and immediate reintubation capability may mitigate risk, but it does not prevent obstruction. Nebulized racemic epinephrine is best reserved for rescue treatment of postextubation stridor. When feasible, extubate the patient awake after demonstrating an adequate cuff leak and confirming standard readiness criteria.",
    "educationalObjective": "Assess airway edema with a cuff leak test in prolonged intubation or airway surgery and delay extubation if unsafe."
  },
  {
    "id": "Core.6.2.3",
    "category": "General Anesthesia & Postop",
    "subcategory": "Emergence and extubation",
    "difficulty": "medium",
    "questionText": "A 72-year-old man undergoes right VATS wedge resection with a left-sided double-lumen tube. One-lung ventilation was used for 2 hours. The case is complete, chest tubes are placed, and two-lung ventilation has been reestablished. The patient is hemodynamically stable, with SpO<sub>2</sub> 93% on FiO<sub>2</sub> 0.5. Auscultation reveals diminished basilar breath sounds with coarse crackles, and thick secretions are visible in the airway. You plan to extubate in the OR.\n\nWhich of the following is the most appropriate next step to minimize postextubation atelectasis and optimize oxygenation?",
    "answers": [
      {
        "text": "Extubate now while the patient is awake and immediately apply 10 cm H2O CPAP via face mask",
        "isCorrect": false,
        "explanation": "Postextubation CPAP may improve oxygenation but does not address retained secretions or re-expand atelectatic lung before extubation; extubating without airway toilet and recruitment risks hypoxemia and obstruction."
      },
      {
        "text": "Increase FiO<sub>2</sub> to 1.0 and extubate immediately to reduce time under anesthesia",
        "isCorrect": false,
        "explanation": "Although preoxygenation is appropriate, immediate extubation without recruitment and suctioning fails to address atelectasis/secretions and can worsen absorption atelectasis."
      },
      {
        "text": "Deliver nebulized albuterol via the circuit to treat suspected bronchospasm, then proceed with extubation",
        "isCorrect": false,
        "explanation": "Normal pressures and coarse secretions without wheeze do not suggest bronchospasm; bronchodilators will not re-expand atelectasis or clear retained secretions."
      },
      {
        "text": "Perform an alveolar recruitment maneuver (sustained inflation to 30–40 cm H2O for 10–15 s), apply 5–8 cm H2O PEEP, and thoroughly suction the trachea/oropharynx (including both lumens) prior to extubation",
        "isCorrect": true,
        "explanation": "Pre-extubation lung recruitment with continued PEEP plus comprehensive airway suctioning re-expands the previously collapsed lung and clears secretions after OLV, reducing atelectasis and improving oxygenation."
      },
      {
        "text": "Administer 20 mg IV furosemide to reduce interstitial lung water before extubation",
        "isCorrect": false,
        "explanation": "There is no evidence of cardiogenic pulmonary edema; the primary issues are airway secretions and atelectasis after OLV, for which diuresis is not beneficial."
      }
    ],
    "didactic": "After one-lung ventilation, the nondependent lung is intentionally collapsed and the dependent lung endures compression and reduced functional residual capacity. At the end of the case, failing to re-expand alveoli and clear secretions before extubation predisposes to hypoxemia, shunt, and postoperative atelectasis.\n\nThe optimal pre-extubation sequence includes:\n- Reinstitute two-lung ventilation and ensure full reversal of neuromuscular blockade.\n- **Comprehensive airway toilet**: suction the endotracheal tube and oropharynx; with a double-lumen tube, suction both tracheal and bronchial lumens. Consider flexible bronchoscopy if secretions are copious or persistent.\n- **Alveolar recruitment maneuver**: provide a sustained inflation to 30–40 cm H2O for 10–15 s to open atelectatic units; repeat as needed while monitoring hemodynamics.\n- **Maintain PEEP 5–8 cm H2O** afterwards to keep alveoli open and reduce cyclic atelectasis.\n- Confirm bilateral breath sounds and adequate ventilation, then proceed to extubation when criteria are met.\n\nPreoxygenation with 100% O<sub>2</sub> prior to extubation is reasonable for safety, but oxygen alone does not reverse atelectasis and may promote absorption atelectasis if PEEP and recruitment are omitted. Postextubation CPAP/NIV can be helpful in high-risk patients but should supplement—not replace—pre-extubation recruitment and secretion clearance. Diuretics are indicated for hydrostatic pulmonary edema, not for atelectasis from lung collapse. Bronchodilators treat bronchospasm (wheezing, high airway pressures) and do not correct airway plugging or alveolar collapse.\n\nIn patients after OLV or long cases, proactively combining **airway suctioning + recruitment maneuver + PEEP** before extubation most effectively restores aeration, improves oxygenation, and reduces postoperative pulmonary complications.",
    "educationalObjective": "Clear secretions and re-expand lungs before extubation after one-lung ventilation or long cases to reduce atelectasis."
  },
  {
    "id": "Core.6.2.4",
    "category": "General Anesthesia & Postop",
    "subcategory": "Emergence and extubation",
    "difficulty": "medium",
    "questionText": "A 54-year-old man (BMI 42) with severe OSA on home CPAP 12 cm H2O undergoes an uncomplicated laparoscopic cholecystectomy under general anesthesia with desflurane, fentanyl 200 µg, and rocuronium. At the end, he is breathing spontaneously on pressure support with ETCO<sub>2</sub> 42 mmHg and SpO<sub>2</sub> 98% on FiO<sub>2</sub> 0.6. Quantitative neuromuscular monitoring shows a train-of-four ratio of 0.88 after initial reversal; he is responsive to commands. He is currently supine on the OR table.\n\nWhich extubation strategy is most appropriate to minimize postextubation airway obstruction and hypoxemia in this patient?",
    "answers": [
      {
        "text": "Deep extubation while supine to avoid coughing, followed by CPAP in the PACU",
        "isCorrect": false,
        "explanation": "Deep extubation in OSA risks upper airway collapse and obstruction due to loss of tone; delaying CPAP until PACU misses the vulnerable immediate postextubation period."
      },
      {
        "text": "Awake supine extubation after confirming 4/4 TOF and a sustained 5-second head lift, with supplemental oxygen by nasal cannula",
        "isCorrect": false,
        "explanation": "Qualitative TOF and clinical tests do not exclude residual block; supine positioning and lack of CPAP increase risk of airway obstruction and atelectasis in obesity/OSA."
      },
      {
        "text": "Awake extubation in head-up position without further reversal because a TOF count of 4/4 is present, followed by high-flow nasal oxygen",
        "isCorrect": false,
        "explanation": "A TOF count of 4/4 can still correspond to a TOF ratio <0.9; HFNO does not provide the pharyngeal stenting of CPAP needed for OSA."
      },
      {
        "text": "Administer naloxone to counteract residual fentanyl and perform deep extubation with an oral airway, then transition to CPAP in PACU",
        "isCorrect": false,
        "explanation": "Routine naloxone is not indicated and may cause pain and sympathetic activation; deep extubation still risks airway collapse and delays CPAP when it is most needed."
      },
      {
        "text": "Fully awake extubation in 25–30° head-up (ramped) position after confirming quantitative TOF ratio ≥0.95, with immediate application of CPAP at his home setting in the OR",
        "isCorrect": true,
        "explanation": "Head-up positioning increases FRC, full quantitative reversal reduces residual weakness, and immediate CPAP stents the upper airway and limits atelectasis—key for obese/OSA patients."
      }
    ],
    "didactic": "Obesity and OSA markedly increase the risk of postextubation airway obstruction, atelectasis, and hypoxemia due to reduced FRC, increased closing volume, and pharyngeal collapsibility. A safe extubation strategy integrates three pillars:\n\n- **Optimal positioning:** Extubation in a head-up (25–30°) or ramped position increases FRC, improves oxygenation, and reduces airway collapse compared with supine. This is particularly beneficial in patients with reduced end-expiratory lung volume (eg, obesity, OSA).\n- **Complete reversal of neuromuscular blockade:** Residual paralysis exacerbates upper airway obstruction and hypoventilation. Relying on qualitative TOF or clinical tests (eg, 5-second head lift) is insensitive. Use **quantitative** monitoring and target a TOF ratio ≥0.9 (preferably ≥0.95) before extubation; administer additional reversal (eg, appropriate-dose sugammadex for rocuronium) as needed. Even minimal residual weakness impairs genioglossus function more than diaphragm, predisposing to obstruction.\n- **Immediate positive airway pressure:** Applying **CPAP** at the patient’s usual setting immediately after extubation maintains upper airway patency, counters atelectasis, and improves oxygenation. CPAP provides pharyngeal stenting not achieved by supplemental O<sub>2</sub> or high-flow nasal oxygen alone.\n\nAdditional best practices include extubating the patient fully awake with intact airway reflexes, adequate spontaneous ventilation (appropriate tidal volumes, ETCO<sub>2</sub>, and respiratory rate), hemodynamic stability, and thorough pharyngeal suctioning. Avoid deep extubation in OSA because loss of upper airway tone increases obstruction risk. Routine naloxone is unnecessary unless there is clear opioid-induced ventilatory depression and may worsen pain and hemodynamics.\n\nFor obese/OSA patients, the combination of head-up positioning, **quantitatively confirmed full reversal** (TOF ratio ≥0.9–0.95), and **immediate CPAP** availability in the OR provides the most effective strategy to reduce respiratory complications after extubation.",
    "educationalObjective": "Extubate the obese/OSA patient in head-up position with full reversal and immediate CPAP availability."
  },
  {
    "id": "Core.6.2.5",
    "category": "General Anesthesia & Postop",
    "subcategory": "Emergence and extubation",
    "difficulty": "hard",
    "questionText": "A 45-year-old woman (160 cm, 62 kg) undergoes a 3-hour laparoscopic hysterectomy in steep Trendelenburg with a 7.5-mm cuffed ETT. At the end of the case, a cuff leak is minimal but she is extubated awake after full reversal (TOF ratio >0.9). Ten minutes in PACU she develops hoarseness, marked inspiratory stridor, suprasternal retractions, and agitation. SpO₂ is 92% on 6 L/min O<sub>2</sub> by facemask, HR 110/min, BP 142/86 mmHg, RR 28/min; the neck is soft without hematoma and lung exam shows no wheeze. Which of the following is the most appropriate immediate intervention to relieve her airway obstruction?",
    "answers": [
      {
        "text": "Initiate heliox (70:30) via a tight-fitting nonrebreather mask",
        "isCorrect": false,
        "explanation": "Heliox lowers gas density and work of breathing but does not treat edema and provides only 30% O<sub>2</sub>; with SpO₂ 92% on 6 L/min, reducing FiO<sub>2</sub> may worsen hypoxemia. It is an adjunct after epinephrine if oxygenation allows."
      },
      {
        "text": "Proceed to immediate reintubation with a smaller ETT in the operating room",
        "isCorrect": false,
        "explanation": "Reintubation is indicated for impending respiratory failure or failure of medical therapy; this patient is oxygenating marginally but stable enough to trial nebulized epinephrine first while preparing for possible reintubation."
      },
      {
        "text": "Give IV dexamethasone 10 mg and observe for clinical improvement",
        "isCorrect": false,
        "explanation": "Steroids decrease inflammation but have a delayed onset (hours) and will not acutely relieve critical upper-airway edema; they should be given in addition to immediate therapies, not as the sole initial step."
      },
      {
        "text": "Administer nebulized racemic epinephrine 2.25%, 0.5 mL diluted in 3 mL normal saline via facemask",
        "isCorrect": true,
        "explanation": "Nebulized epinephrine provides rapid α<sub>1</sub>-mediated mucosal vasoconstriction that reduces laryngeal edema within minutes and is first-line for symptomatic postextubation stridor; it can be repeated while steroids and backup airway plans are initiated."
      },
      {
        "text": "Start bilevel noninvasive ventilation (BiPAP 10/5 cm H₂O with 40% O<sub>2</sub>)",
        "isCorrect": false,
        "explanation": "Noninvasive ventilation is ineffective for fixed upper-airway obstruction, can worsen laryngeal collapse, causes gastric insufflation, and may delay definitive management."
      }
    ],
    "didactic": "Postextubation stridor most commonly reflects laryngeal edema from mucosal trauma and high cuff pressures, especially in women, prolonged intubations, larger ETT sizes, or Trendelenburg positioning. Clinical features include hoarseness, inspiratory stridor, and suprasternal retractions shortly after extubation. A soft neck and normal lung exam help exclude compressive neck hematoma and bronchospasm.\n\nImmediate management priorities are to relieve obstruction, support oxygenation, and prepare for a potential difficult reintubation. The fastest-acting medical therapy is nebulized epinephrine, which causes α<sub>1</sub>-mediated vasoconstriction of edematous subglottic mucosa and reduces airway swelling within minutes. Typical adult dosing is racemic epinephrine 2.25%, 0.5 mL diluted in 3–5 mL normal saline via nebulizer; L-epinephrine 1 mg/mL (1:1000) at 5 mL is an effective alternative. Continuous monitoring is required due to potential tachycardia or hypertension; doses can be repeated if needed.\n\nIV corticosteroids (eg, dexamethasone 4–10 mg) should be administered early to attenuate ongoing inflammation, but their onset is delayed (≈4–6 hours), so they do not address acute obstruction. Heliox (eg, 70:30 or 80:20 helium:oxygen) reduces gas density, lowers Reynolds number, and transitions turbulent to more laminar flow, thereby decreasing airway resistance and work of breathing. It is a useful bridge when oxygenation is acceptable; however, low FiO<sub>2</sub> limits its use in hypoxemic patients.\n\nNoninvasive ventilation is generally ineffective in fixed upper-airway narrowing and may worsen obstruction or delay definitive care. If the patient deteriorates (worsening hypoxemia, fatigue, hypercapnia) or fails to improve promptly with nebulized epinephrine and supportive measures (upright positioning, humidified O<sub>2</sub>), proceed to reintubation—ideally with a smaller ETT and full difficult-airway preparedness. This stepwise approach prioritizes rapid edema reduction, stabilization, and readiness for definitive airway control.",
    "educationalObjective": "Manage postextubation stridor with nebulized epinephrine, steroids, and heliox as needed."
  },
  {
    "id": "Core.6.2.6",
    "category": "General Anesthesia & Postop",
    "subcategory": "Emergence and extubation",
    "difficulty": "hard",
    "questionText": "A 58-year-old man (BMI 38) with severe OSA and prior neck radiation undergoes a 5-hour thyroidectomy with neck dissection. Induction was notable for difficult mask ventilation requiring 2 providers and video laryngoscopy with a bougie after 2 attempts. At case end, he is normothermic, following commands with TOF ratio 0.95, and in head-up position. There is mild neck edema; cuff leak is minimal. ENT requests extubation in the OR to assess voice. An airway exchange catheter and capnography adapters are available.\n\nTo maximize safety if reintubation is required and to provide backup oxygenation, which extubation strategy is most appropriate?",
    "answers": [
      {
        "text": "Perform an awake extubation over a hollow airway exchange catheter, leave it in situ, and insufflate low-flow O<sub>2</sub> (eg, 1–2 L/min) with capnography monitoring",
        "isCorrect": true,
        "explanation": "An airway exchange catheter provides a tracheal conduit for rapid reintubation and permits gentle oxygen insufflation and CO<sub>2</sub> monitoring while assessing airway patency after awake extubation."
      },
      {
        "text": "Extubate to high-flow nasal cannula (60 L/min, FiO<sub>2</sub> 0.6) without an exchange catheter, keeping a video laryngoscope ready",
        "isCorrect": false,
        "explanation": "HFNC improves oxygenation but does not provide a conduit for rapid reintubation; relying on repeat laryngoscopy alone is risky after a difficult intubation with edema."
      },
      {
        "text": "Administer dexamethasone and racemic epinephrine, confirm a cuff-leak >10% of V<sub>T</sub>, then remove the ETT to nasal cannula",
        "isCorrect": false,
        "explanation": "Steroids may reduce edema, but cuff-leak testing has limited predictive value and this approach lacks a secured reintubation pathway in a high-risk airway."
      },
      {
        "text": "Deep extubation followed by insertion of a second-generation LMA as a bridge while edema resolves",
        "isCorrect": false,
        "explanation": "Deep extubation removes protective reflexes and an LMA may be ineffective with supraglottic edema; losing the tracheal tube in a known difficult airway risks a cannot ventilate/cannot intubate scenario."
      },
      {
        "text": "Leave the patient intubated and transport to the ICU for delayed extubation due to minimal cuff leak",
        "isCorrect": false,
        "explanation": "Deferring extubation may be reasonable in select cases, but when awake and stable, extubation over an exchange catheter offers a safer, proactive plan with an immediate path for reintubation."
      }
    ],
    "didactic": "In patients with a known or suspected difficult airway, extubation carries substantial risk because loss of the endotracheal tube removes both the secure airway and the optimal route for oxygenation. The safest strategy integrates awake extubation with a plan for immediate reintubation and backup oxygenation. An **airway exchange catheter (AEC)** is a hollow, semi-rigid tracheal stylet that can remain in the trachea after the endotracheal tube is removed, providing a **conduit for rapid reintubation** without repeat laryngoscopy. It also permits **low-flow oxygen insufflation** (eg, 1–2 L/min) and may be coupled to capnography to confirm ongoing tracheal placement and ventilation.\n\nKey elements of a high-reliability difficult extubation plan include:\n- **Awake extubation** with intact reflexes and spontaneous ventilation in a head-up position after full neuromuscular recovery (TOF ratio ≥0.9–0.95)\n- **AEC placement** to approximately the prior ETT depth (avoid deep/bronchial placement); leave in situ until airway patency is assured\n- **Backup oxygenation**: gentle O<sub>2</sub> insufflation via AEC and external oxygen (eg, facemask or HFNC) to optimize FiO<sub>2</sub>\n- **Readiness to reintubate**: video laryngoscope, fiberoptic scope, and drugs immediately available\n- **Edema mitigation**: consider dexamethasone; recognize that cuff-leak testing has limited predictive value\n\nAvoid high-pressure jet ventilation through an AEC unless specifically designed and the glottis is patent, as **barotrauma** can occur if the upper airway is obstructed. Deep extubation or LMA bridging is ill-advised when mask ventilation was difficult or supraglottic edema is likely. While delayed extubation in the ICU may be appropriate for severe edema or airway surgery, in an awake, stable patient the **AEC-assisted awake extubation** best balances oxygenation, monitoring, and a rapid, reliable path to reintubation if deterioration occurs.",
    "educationalObjective": "Plan extubation for the known or suspected difficult airway using an airway exchange catheter and backup oxygenation."
  },
  {
    "id": "Core.6.2.7",
    "category": "General Anesthesia & Postop",
    "subcategory": "Emergence and extubation",
    "difficulty": "medium",
    "questionText": "A 32-year-old woman undergoes brief gynecologic laparoscopy with a supraglottic airway. At emergence, volatile anesthetic is discontinued and the device is removed when she is breathing spontaneously. Immediately, she develops inspiratory stridor with paradoxical chest/abdominal movement, absent capnography, and a rapidly falling SpO<sub>2</sub> from 98% to 86%. You apply a firm jaw thrust with bilateral Larson’s notch pressure and deliver 100% O<sub>2</sub> with CPAP 15 cm H2O while suctioning oral secretions, but there is no chest rise or ETCO<sub>2</sub> return.\n\nWhich of the following is the most appropriate next step to rapidly relieve the airway obstruction?",
    "answers": [
      {
        "text": "Lidocaine 1.5 mg/kg IV",
        "isCorrect": false,
        "explanation": "IV lidocaine may reduce airway reflexes and coughing but is unreliable for established laryngospasm and too slow for worsening hypoxemia."
      },
      {
        "text": "Succinylcholine 0.5 mg/kg IV bolus",
        "isCorrect": true,
        "explanation": "A small dose of succinylcholine rapidly breaks refractory laryngospasm and permits ventilation; it is the definitive next step when SUCTION–CPAP–jaw thrust fails."
      },
      {
        "text": "Insert an oropharyngeal airway and continue CPAP 15–20 cm H2O",
        "isCorrect": false,
        "explanation": "An oropharyngeal airway relieves tongue obstruction but does not open closed vocal cords; continued CPAP alone risks gastric insufflation and negative-pressure injury."
      },
      {
        "text": "Nebulized racemic epinephrine",
        "isCorrect": false,
        "explanation": "Racemic epinephrine treats subglottic edema but has delayed onset and will not promptly relieve acute glottic closure."
      },
      {
        "text": "Propofol 0.5 mg/kg IV bolus",
        "isCorrect": false,
        "explanation": "Propofol can relieve partial laryngospasm by deepening anesthesia, but with persistent complete obstruction and desaturation despite CPAP–jaw thrust, a neuromuscular blocker is faster and more reliable."
      }
    ],
    "didactic": "Laryngospasm is a reflex closure of the vocal cords triggered by airway stimulation during light anesthesia, commonly at induction or emergence. Prompt recognition (absent ETCO<sub>2</sub>, paradoxical chest movement, high negative inspiratory effort, increasing hypoxemia) and a structured response are critical. First, remove the stimulus and secretions (suction) and deliver 100% O<sub>2</sub>. Apply firm jaw thrust with pressure at Larson’s notch to stimulate glottic opening and provide CPAP 10–20 cm H2O to splint the cords. If the spasm persists, pharmacologic therapy is indicated.\n\nSmall doses of either **propofol** or **succinylcholine** can break laryngospasm. Propofol 0.5–1 mg/kg is helpful for partial laryngospasm when ventilation is possible. For refractory or complete laryngospasm with desaturation despite SUCTION–CPAP–jaw thrust, **succinylcholine 0.1–0.5 mg/kg IV** rapidly relaxes laryngeal muscles and restores ventilation; if severe or no response, 0.5–1 mg/kg IV can be used. When IV access is unavailable (eg, in children), IM succinylcholine 3–4 mg/kg into the deltoid or thigh is effective; in pediatrics, consider atropine 0.02 mg/kg to mitigate bradycardia. After relief, resume gentle positive-pressure ventilation with 100% O<sub>2</sub> and reassess.\n\nAvoid prolonged forceful mask ventilation alone, which risks gastric insufflation and **negative-pressure pulmonary edema**. Nebulized racemic epinephrine and IV lidocaine have roles in airway edema prevention and blunting reflexes but are not reliable for immediate relief of glottic closure. Prevention strategies include minimizing oropharyngeal secretions/blood, extubating either fully awake or deep (not in-between), topical lidocaine when appropriate, and ensuring adequate depth during airway manipulation. Early, stepwise management—SUCTION–CPAP–jaw thrust followed by small-dose propofol or succinylcholine—reduces hypoxemia and complications.",
    "educationalObjective": "Prevent and treat laryngospasm using SUCTION–CPAP–jaw thrust and small doses of propofol or succinylcholine."
  },
  {
    "id": "Core.6.2.8",
    "category": "General Anesthesia & Postop",
    "subcategory": "Emergence and extubation",
    "difficulty": "easy",
    "questionText": "A 3-year-old boy (14 kg) with obstructive sleep apnea is undergoing tonsillectomy/adenoidectomy under sevoflurane anesthesia. Intraoperative analgesia includes IV acetaminophen and surgeon-performed local infiltration; you plan an awake extubation and wish to minimize postoperative airway obstruction. As skin closure begins, the child is hemodynamically stable (HR 110/min, BP 88/50 mmHg, SpO<sub>2</sub> 99% on FiO<sub>2</sub> 0.5) with no history of heart block. To reduce the risk of emergence agitation while limiting respiratory depression, which intraoperative intervention is most appropriate?",
    "answers": [
      {
        "text": "Administer dexmedetomidine 0.5 μg/kg IV over 10 minutes during closure",
        "isCorrect": true,
        "explanation": "Dexmedetomidine, an α<sup>2</sup>-agonist, reliably reduces pediatric emergence agitation after sevoflurane, provides opioid-sparing analgesia, and has minimal respiratory depression at this dose."
      },
      {
        "text": "Increase sevoflurane to 1.5 MAC for a smoother emergence",
        "isCorrect": false,
        "explanation": "Higher end-tidal sevoflurane exacerbates emergence agitation; sevoflurane is an independent risk factor, and deepening the anesthetic near the end increases risk rather than preventing it."
      },
      {
        "text": "Administer fentanyl 2 μg/kg IV before dressing application",
        "isCorrect": false,
        "explanation": "Opioids may reduce pain-related agitation but increase risk of airway obstruction and apnea in children with obstructive sleep apnea."
      },
      {
        "text": "Administer midazolam 0.05 mg/kg IV 5 minutes before emergence",
        "isCorrect": false,
        "explanation": "Benzodiazepines have inconsistent efficacy for emergence agitation and can delay emergence or cause paradoxical agitation in young children."
      },
      {
        "text": "Maintain nitrous oxide 70% until extubation",
        "isCorrect": false,
        "explanation": "Nitrous oxide does not prevent emergence agitation and may increase postoperative nausea/vomiting; it does not address the dysphoric arousal seen with sevoflurane."
      }
    ],
    "didactic": "Emergence agitation (EA), also termed emergence delirium, is a transient state of inconsolability, restlessness, and disorientation occurring minutes after emergence, most commonly in children aged 2–6 years. It is strongly associated with low-solubility volatile agents (especially **sevoflurane** and desflurane), rapid awakening, certain procedures (ophthalmologic, ENT), preoperative anxiety, and inadequate analgesia. EA is not purely pain-mediated; dysphoric arousal from volatiles and immature cortical integration are key contributors.\n\nThe most effective, practical intraoperative prevention for sevoflurane-based anesthesia is an **α<sup>2</sup>-agonist**. **Dexmedetomidine** 0.3–0.5 μg/kg IV given as a slow bolus over 5–10 minutes near the end of the case (or infused at 0.2–1 μg/kg/h) reduces the incidence and severity of EA, improves parent/nurse satisfaction, and provides opioid-sparing analgesia with minimal respiratory depression—an advantage in children with obstructive sleep apnea. Expected effects include mild bradycardia and hypotension; avoid rapid boluses and use caution in patients with conduction disease. Extubation may be delayed by a few minutes but with smoother behavior and fewer rescue medications.\n\nOther strategies have limitations:\n- Adequate multimodal analgesia (eg, acetaminophen, NSAIDs, local/regional) is essential but may not fully prevent EA.\n- A brief **propofol** bolus at the end (e.g., 1–2 mg/kg) can reduce EA but offers less opioid-sparing analgesia than dexmedetomidine and more respiratory depression.\n- **Midazolam** helps preoperative anxiety but inconsistently prevents EA and may cause paradoxical reactions in toddlers.\n- Deepening or prolonging **sevoflurane** and maintaining **nitrous oxide** do not prevent EA and may worsen dysphoric emergence or postoperative nausea/vomiting.\n\nIn a child with OSA after tonsillectomy, dexmedetomidine optimally balances EA prevention and analgesia while minimizing respiratory risk, aligning with a multimodal, opioid-sparing plan.",
    "educationalObjective": "Prevent pediatric emergence agitation with appropriate analgesia and agents such as dexmedetomidine."
  },
  {
    "id": "Core.6.2.9",
    "category": "General Anesthesia & Postop",
    "subcategory": "Emergence and extubation",
    "difficulty": "easy",
    "questionText": "A 58-year-old man undergoes laparoscopic hernia repair with sevoflurane anesthesia and rocuronium. Rocuronium (10 mg) was last given 50 minutes ago. At the end of the case, the anesthetic is discontinued and the patient is ventilating spontaneously on 100% O<sub>2</sub>. He received neostigmine 50 µg/kg with glycopyrrolate 25 minutes earlier. He has shallow tidal volumes (3 mL/kg), weak handgrip, and SpO₂ 92%. Quantitative acceleromyography at the adductor pollicis shows a train-of-four (TOF) count of 4 with a TOF ratio of 0.48. Temperature is 36.4°C. No residual volatile anesthetic is detected on the gas analyzer.\n\nWhich is the best next step to facilitate safe extubation?",
    "answers": [
      {
        "text": "Administer calcium chloride 10 mg/kg to improve neuromuscular strength",
        "isCorrect": false,
        "explanation": "Calcium does not reverse nondepolarizing neuromuscular block and is not an appropriate therapy for residual blockade."
      },
      {
        "text": "Administer an additional 50 µg/kg neostigmine with glycopyrrolate",
        "isCorrect": false,
        "explanation": "Neostigmine has a ceiling effect and is unreliable once dosed appropriately; additional dosing provides little benefit and risks cholinergic side effects or paradoxical weakness near recovery."
      },
      {
        "text": "Wait 15 minutes for further spontaneous recovery and reassess",
        "isCorrect": false,
        "explanation": "Spontaneous recovery is unpredictable after neostigmine has reached peak effect; the patient is symptomatic with TOF ratio 0.48 and requires active reversal rather than delay."
      },
      {
        "text": "Administer sugammadex 2 mg/kg and extubate only when the TOF ratio is ≥0.9",
        "isCorrect": true,
        "explanation": "A TOF ratio <0.9 indicates residual block despite prior neostigmine. Sugammadex 2 mg/kg effectively reverses a moderate aminosteroid block (TOF count ≥2), enabling achievement of a quantitative TOF ratio ≥0.9 before extubation."
      },
      {
        "text": "Proceed with extubation and apply jaw thrust with supplemental O<sub>2</sub> in the PACU",
        "isCorrect": false,
        "explanation": "Extubation with TOF ratio <0.9 is unsafe and associated with airway obstruction, hypoventilation, and hypoxemia despite supplemental oxygen."
      }
    ],
    "didactic": "Residual neuromuscular block (rNMB) is common and increases the risk of airway obstruction, hypoventilation, hypoxemia, and postoperative pulmonary complications. Qualitative assessments (eg, 4 visible twitches, head lift) are insensitive; patients can demonstrate 4/4 TOF yet have significant fade with a quantitative TOF ratio <0.9. Extubation should occur only when a quantitative monitor (eg, acceleromyography) demonstrates a TOF ratio ≥0.9–0.95 at the adductor pollicis.\n\nNeostigmine requires partial spontaneous recovery to be effective and has a **ceiling effect**; typical dosing is 40–60 µg/kg with peak effect in ~10 minutes. Additional neostigmine after an adequate dose provides minimal further benefit and may cause muscarinic side effects or paradoxical weakness as recovery nears. In contrast, **sugammadex** encapsulates rocuronium/vecuronium and reverses block rapidly and predictably, independent of acetylcholine. It is effective even if neostigmine was previously administered.\n\nDose sugammadex according to block depth measured at the adductor pollicis:\n- TOF count ≥2 (moderate block): 2 mg/kg\n- No TOF responses but post-tetanic count (PTC) 1–2 (deep block): 4 mg/kg\n- Immediate reversal after a large rocuronium dose (eg, cannot intubate/cannot ventilate): 16 mg/kg\n\nIn this patient, a TOF ratio of 0.48 with 4 twitches after adequate neostigmine indicates persistent moderate aminosteroid block. The best management is to give **sugammadex 2 mg/kg**, continue quantitative monitoring, and extubate only once the TOF ratio is ≥0.9 with appropriate clinical signs. Avoid relying on clinical tests or proceeding with extubation when the TOF ratio is <0.9. Be aware of sugammadex considerations (eg, rare hypersensitivity, bradycardia, and reduced clearance in severe renal impairment).",
    "educationalObjective": "Recognize residual neuromuscular block on emergence and treat based on quantitative monitoring."
  },
  {
    "id": "Core.6.2.10",
    "category": "General Anesthesia & Postop",
    "subcategory": "Emergence and extubation",
    "difficulty": "medium",
    "questionText": "A 52-year-old man undergoes elective frontal craniotomy for meningioma resection. The surgeon requests a smooth, rapid wake-up for an immediate neurologic exam and emphasizes avoiding coughing and hypertension at extubation to minimize the risk of intracranial bleeding. At skin closure, sevoflurane is reduced to 0.3 MAC, the last fentanyl dose was >2 hours ago, and the patient’s BP is trending upward to 155/90 mmHg (baseline 125/75) with HR 82/min. Which of the following is the most appropriate intraoperative strategy to minimize both coughing and hypertension at extubation while allowing prompt neurologic assessment?",
    "answers": [
      {
        "text": "Start a remifentanil infusion 0.05–0.1 μg/kg/min and discontinue at extubation",
        "isCorrect": true,
        "explanation": "Remifentanil suppresses cough and blunts the sympathetic response at emergence, with rapid offset (context-sensitive half-time ~3–5 minutes) allowing prompt neurologic assessment and minimal residual respiratory depression."
      },
      {
        "text": "Start dexmedetomidine 0.5 μg/kg IV over 10 minutes before extubation",
        "isCorrect": false,
        "explanation": "Dexmedetomidine can reduce coughing and sympathetic surges but often causes bradycardia/hypotension and sedation that may delay an immediate neurologic exam."
      },
      {
        "text": "Administer labetalol 10 mg IV at the end of closure",
        "isCorrect": false,
        "explanation": "Labetalol has a longer and less titratable effect, increasing the risk of prolonged hypotension postextubation and does not specifically reduce coughing."
      },
      {
        "text": "Administer esmolol 0.5 mg/kg IV 2 minutes before extubation",
        "isCorrect": false,
        "explanation": "Esmolol effectively attenuates tachycardia and hypertension without respiratory depression but does not reliably suppress cough or airway reflexes; it is better as an adjunct when cough suppression is not the primary goal."
      },
      {
        "text": "Administer lidocaine 1.5 mg/kg IV 90 seconds before extubation",
        "isCorrect": false,
        "explanation": "IV lidocaine reduces cough and airway reactivity but does not reliably attenuate the hypertensive response to extubation; hemodynamic control may still be inadequate for neurosurgical goals."
      }
    ],
    "didactic": "Smooth emergence is crucial after intracranial surgery because coughing and hypertension can increase intracranial pressure and precipitate hemorrhage. The ideal strategy limits airway reflexes and sympathetic surges while preserving a rapid, reliable wake-up.\n\n- **Short-acting opioids (remifentanil):** A low-dose remifentanil infusion (eg, 0.03–0.1 μg/kg/min) titrated through skin closure and discontinued at extubation suppresses cough and blunts tachycardia/hypertension. Due to its unique metabolism by nonspecific blood/tissue esterases, remifentanil has a context-sensitive half-time of ~3–5 minutes regardless of infusion duration, enabling prompt neurologic assessment with minimal residual respiratory depression.\n- **β-blockers:** **Esmolol** (eg, 0.5 mg/kg IV) effectively attenuates tachycardia and hypertension without affecting ventilation or level of consciousness but does not reliably suppress cough. **Labetalol** has a longer duration (hours) and less titratability at emergence, risking prolonged hypotension; it also does not address cough.\n- **Dexmedetomidine:** This α<sub>2</sub>-agonist reduces sympathetic outflow and coughing but commonly causes bradycardia and hypotension. Its sedative effect can delay extubation and confound an immediate neurologic exam, especially when bolused near emergence.\n- **Lidocaine:** IV 1–1.5 mg/kg within 1–2 minutes of extubation reduces airway reactivity and coughing but has inconsistent effects on the hemodynamic response; it is best as an adjunct when hypertension control is less critical.\n\nIn a patient requiring both cough suppression and tight hemodynamic control with a rapid wake-up (eg, post-craniotomy), a **remifentanil infusion discontinued at extubation** most directly meets all goals. Esmolol can be added if tachycardia persists, while dexmedetomidine or longer-acting β-blockers are less suitable when an immediate neurologic assessment is required.",
    "educationalObjective": "Reduce emergence coughing and hypertension using lidocaine, short-acting opioids, beta-blockers, or dexmedetomidine."
  },
  {
    "id": "Core.6.2.11",
    "category": "General Anesthesia & Postop",
    "subcategory": "Emergence and extubation",
    "difficulty": "medium",
    "questionText": "A 36-year-old man with moderate persistent asthma and symptomatic GERD (hiatal hernia) undergoes functional endoscopic sinus surgery under general anesthesia with a cuffed endotracheal tube. Intraoperatively he received sevoflurane, fentanyl, and dexmedetomidine; bronchodilator therapy was administered preinduction. At case end, there is moderate oozing in the nasopharynx despite packing, and an orogastric tube returns blood-tinged fluid after suctioning. He is hemodynamically stable and breathing spontaneously with EtCO<sub>2</sub> 38 mmHg, SpO<sub>2</sub> 99% on FiO<sub>2</sub> 0.5. Neuromuscular blockade has been fully reversed.\n\nWhich extubation strategy is most appropriate for this patient now?",
    "answers": [
      {
        "text": "Extubate during stage 2 with a small propofol bolus to suppress bucking and expedite removal before coughing begins",
        "isCorrect": false,
        "explanation": "Extubation in stage 2 increases risk of laryngospasm, airway obstruction, and aspiration, especially when blood is present."
      },
      {
        "text": "Awake extubation after thorough pharyngeal and gastric suctioning with confirmed return of airway reflexes and ability to follow commands",
        "isCorrect": true,
        "explanation": "Blood in the airway and symptomatic GERD increase aspiration risk; an awake extubation after meticulous suctioning and full return of protective reflexes best protects the airway while minimizing aspiration."
      },
      {
        "text": "Deep extubation after IV lidocaine to blunt cough, followed by mask ventilation until fully spontaneous",
        "isCorrect": false,
        "explanation": "Lidocaine may attenuate cough/bronchospasm, but deep extubation still leaves the airway unprotected in the setting of active bleeding and GERD."
      },
      {
        "text": "Exchange the endotracheal tube for a second-generation LMA while deep, then remove the LMA when fully awake",
        "isCorrect": false,
        "explanation": "An LMA does not protect against aspiration of blood or gastric contents and the exchange itself increases risk during a vulnerable period."
      },
      {
        "text": "Deep extubation under sevoflurane with an oral airway in place and lateral positioning to reduce aspiration risk",
        "isCorrect": false,
        "explanation": "Deep extubation reduces coughing/bronchospasm but removes airway protection when blood is present; lateral positioning and an oral airway do not mitigate aspiration risk."
      }
    ],
    "didactic": "Selecting deep versus awake extubation requires balancing aspiration risk, airway reactivity, and surgical factors. Deep extubation (removing the tube while the patient remains anesthetized with suppressed airway reflexes) decreases coughing, bucking, and bronchospasm, which can be advantageous in patients with **reactive airways** and after procedures where coughing may be harmful. However, it also increases risks of **airway obstruction, laryngospasm, and aspiration** because protective reflexes are absent.\n\nIn this case, two factors increase aspiration risk: **active oropharyngeal blood** from sinonasal surgery and **symptomatic GERD**. ENT cases with blood in the pharynx are classic scenarios where the airway should remain protected until reflexes return. An LMA does not provide reliable protection from blood or gastric contents, and device exchange introduces additional exposure risk. Stage 2 extubation is unsafe due to heightened laryngospasm and unpredictable airway responses.\n\nAn **awake extubation** is preferred when aspiration risk is present, airway reintubation may be challenging, or surgical bleeding/edema threatens the airway. Best practices include:\n- Thorough suctioning of the oropharynx and, when indicated, gastric contents\n- Full reversal of neuromuscular blockade and confirmation of purposeful responsiveness with intact protective reflexes\n- Head-up or lateral positioning, supplemental oxygen, and readiness for reintubation\n- Mitigating bronchospasm risk despite awake removal (eg, pre-extubation β-agonist, IV lidocaine 1–1.5 mg/kg, warm humidified gases, gentle suction)\n\nDeep extubation is better suited to low-aspiration-risk patients in whom cough suppression is paramount (eg, well-fasted, no bleeding, easily ventilated mask). In contrast, when **aspiration risk** is elevated by blood, gastric contents, or reflux, the safest choice is a carefully executed **awake extubation** with meticulous suctioning and full return of airway reflexes.",
    "educationalObjective": "Select deep versus awake extubation based on aspiration risk, airway reactivity, and surgical factors."
  },
  {
    "id": "Core.6.2.12",
    "category": "General Anesthesia & Postop",
    "subcategory": "Emergence and extubation",
    "difficulty": "medium",
    "questionText": "A 45-year-old man (BMI 28 kg/m²) undergoes laparoscopic appendectomy under general anesthesia with sevoflurane, fentanyl, and rocuronium. The last dose of rocuronium was given 70 minutes ago. At the end of the case, sevoflurane is discontinued (end-tidal 0.2%), and neostigmine 3 mg with glycopyrrolate 0.6 mg is administered. Ten minutes later, quantitative acceleromyography at the adductor pollicis shows a train-of-four (TOF) ratio of 0.82. On pressure support, he is awake and follows commands with tidal volumes 400–500 mL, respiratory rate 14/min, ETCO<sub>2</sub> 44 mmHg, and SpO<sub>2</sub> 96% on FiO<sub>2</sub> 0.40. Hemodynamics and temperature are stable.\n\nWhich is the most appropriate next step to ensure readiness for extubation?",
    "answers": [
      {
        "text": "Extubate now based on adequate tidal volumes, normocapnia, and responsiveness",
        "isCorrect": false,
        "explanation": "Despite acceptable ventilation and responsiveness, a quantitative TOF ratio <0.9 indicates residual neuromuscular blockade and increased risk of airway obstruction and hypoventilation after extubation."
      },
      {
        "text": "Increase FiO<sub>2</sub> to 1.0 and extubate to supplemental oxygen",
        "isCorrect": false,
        "explanation": "Improving oxygenation does not address residual neuromuscular blockade; hypoventilation and airway collapse can still occur after extubation."
      },
      {
        "text": "Allow additional time for neostigmine to work and reassess extubation in 15 minutes",
        "isCorrect": false,
        "explanation": "Neostigmine’s effect typically peaks within ~7–10 minutes at appropriate doses; waiting may help but does not reliably or promptly correct a TOF ratio of 0.82, prolonging emergence without ensuring safety."
      },
      {
        "text": "Administer sugammadex 2 mg/kg and confirm quantitative TOF ratio ≥0.9 before extubation",
        "isCorrect": true,
        "explanation": "Sugammadex rapidly and reliably reverses residual rocuronium, enabling achievement of a TOF ratio ≥0.9–1.0, which is an objective criterion for safe extubation."
      },
      {
        "text": "Administer an additional 1 mg of neostigmine",
        "isCorrect": false,
        "explanation": "Further neostigmine after adequate dosing has limited benefit due to a ceiling effect and risks bradycardia and paradoxical weakness without reliably achieving TOF ≥0.9."
      }
    ],
    "didactic": "Safe extubation requires objective confirmation of neuromuscular recovery in addition to adequate ventilation, oxygenation, and responsiveness. Quantitative monitoring with acceleromyography or electromyography should demonstrate a TOF ratio ≥0.9 (many aim for ≥1.0 with acceleromyography due to its tendency to overestimate recovery). Qualitative assessment (eg, head lift, grip strength) is unreliable and does not ensure pharyngeal muscle recovery.\n\nKey readiness criteria include:\n- Neuromuscular recovery: quantitative TOF ratio ≥0.9–1.0\n- Ventilation: adequate spontaneous tidal volume (≈5–7 mL/kg IBW), appropriate respiratory rate, ETCO<sub>2</sub> near normal\n- Oxygenation: SpO<sub>2</sub> ≥92% on ≤0.4 FiO<sub>2</sub>\n- Responsiveness: follows commands, intact airway reflexes\n- Stability: hemodynamics and temperature within acceptable range\n\nResidual neuromuscular blockade (TOF ratio <0.9) is associated with airway obstruction, hypoventilation, and aspiration after extubation. In this scenario, despite acceptable ETCO<sub>2</sub>, SpO<sub>2</sub>, and responsiveness, a TOF ratio of 0.82 indicates unsafe residual block. Neostigmine has a ceiling effect and typically reaches near-peak effect within ~7–10 minutes; additional neostigmine offers limited benefit and may cause bradycardia or paradoxical weakness. In contrast, **sugammadex** provides rapid, predictable reversal of aminosteroid neuromuscular blockers (eg, rocuronium) by encapsulation, with 2 mg/kg appropriate for shallow block with TOF counts present.\n\nOxygenation strategies (eg, increasing FiO<sub>2</sub>) do not correct residual paralysis and may mask hypoventilation. Volatile anesthetics potentiate neuromuscular blockade, so minimizing end-tidal agent supports recovery but does not replace objective confirmation. The best approach is to administer sugammadex 2 mg/kg, verify a quantitative TOF ratio ≥0.9–1.0, and then proceed with extubation once ventilation, oxygenation, and responsiveness remain adequate.",
    "educationalObjective": "Verify readiness for extubation with objective criteria: TOF ratio ≥0.9–1.0, adequate ventilation, oxygenation, and responsiveness."
  },
  {
    "id": "Core.6.3.1",
    "category": "General Anesthesia & Postop",
    "subcategory": "Maintenance: inhaled vs TIVA",
    "difficulty": "medium",
    "questionText": "A 32-year-old woman (BMI 24 kg/m²), nonsmoker, with a history of severe postoperative nausea and vomiting (PONV) and motion sickness is scheduled for a 2-hour tympanoplasty under general anesthesia. The otologist emphasizes that stable middle-ear pressure is critical for graft integrity throughout the case and during emergence. She requests early ambulation and minimal nausea. Which anesthetic maintenance plan is most appropriate to achieve these goals?",
    "answers": [
      {
        "text": "Nitrous oxide (70%) with short-acting opioids and ondansetron to facilitate rapid emergence",
        "isCorrect": false,
        "explanation": "N<sub>2</sub>O hastens emergence due to low solubility but substantially raises PONV risk and disrupts closed gas spaces such as the middle ear."
      },
      {
        "text": "Propofol–remifentanil total intravenous anesthesia (TIVA) with air/O<sub>2</sub> carrier gas and no N<sub>2</sub>O",
        "isCorrect": true,
        "explanation": "Propofol-based TIVA reduces PONV compared with volatile agents and avoids N<sub>2</sub>O–related middle-ear pressure changes that can disrupt a tympanoplasty graft."
      },
      {
        "text": "Sevoflurane at ~1.0 MAC in 50% N<sub>2</sub>O/50% O<sub>2</sub> to reduce volatile requirements",
        "isCorrect": false,
        "explanation": "Although N<sub>2</sub>O lowers volatile MAC, it increases PONV and diffuses into the middle ear, risking graft displacement during and after discontinuation."
      },
      {
        "text": "Sevoflurane at 0.5 MAC plus propofol infusion with 70% N<sub>2</sub>O for hypnosis and opioid-sparing",
        "isCorrect": false,
        "explanation": "High-concentration N<sub>2</sub>O markedly increases PONV and exerts significant middle-ear pressure effects, making it inappropriate for tympanoplasty."
      },
      {
        "text": "Desflurane at ~1.0 MAC in air/O<sub>2</sub> with a small-dose N<sub>2</sub>O (≤20%) admixture for MAC reduction",
        "isCorrect": false,
        "explanation": "Any N<sub>2</sub>O admixture can alter middle-ear pressure and increases PONV risk; it should be avoided in ear surgery and high-risk PONV patients."
      }
    ],
    "didactic": "Nitrous oxide (N<sub>2</sub>O) has a low blood–gas partition coefficient, enabling rapid uptake and emergence, and provides analgesic effects that reduce volatile requirements. When used at 50%–70%, it can substantially decrease the required volatile MAC and facilitate titration. However, N<sub>2</sub>O diffuses into air-filled cavities faster than nitrogen diffuses out, increasing the volume or pressure of closed spaces (eg, middle ear, pneumothorax, intracranial air, intraocular gas, bowel lumen). In middle-ear surgery, N<sub>2</sub>O can raise middle-ear pressure during administration and create negative pressure upon discontinuation, both of which risk **tympanoplasty graft displacement** and postoperative conductive hearing changes.\n\nN<sub>2</sub>O also consistently increases **PONV**, an effect that is clinically meaningful in patients with multiple risk factors (female sex, nonsmoker, history of motion sickness/PONV) and in procedures already associated with higher PONV burden. In such patients, avoiding N<sub>2</sub>O and volatile agents helps reduce emetogenic stimuli.\n\nA **propofol-based TIVA** technique (eg, propofol–remifentanil) with an air/O<sub>2</sub> carrier avoids middle-ear pressure fluctuations and decreases PONV compared with volatile anesthesia. Additional benefits include smooth emergence and compatibility with multimodal antiemetic prophylaxis (eg, dexamethasone, 5-HT<sub>3</sub> antagonist, ± scopolamine or droperidol depending on risk).\n\nSelective N<sub>2</sub>O use is reasonable in patients without closed-space concerns and with low PONV risk when MAC-sparing or rapid emergence is desired. In contrast, for tympanoplasty with high PONV risk, the optimal approach is to **avoid N<sub>2</sub>O** and consider TIVA, reserving volatiles only when benefits clearly outweigh risks. This strategy aligns anesthetic maintenance with surgical requirements (pressure stability) and patient-centered outcomes (minimal PONV, rapid recovery).",
    "educationalObjective": "Avoid nitrous oxide in closed-space surgery or high PONV risk and use it selectively for MAC reduction."
  },
  {
    "id": "Core.6.3.2",
    "category": "General Anesthesia & Postop",
    "subcategory": "Maintenance: inhaled vs TIVA",
    "difficulty": "medium",
    "questionText": "A 28-year-old woman (BMI 22) with a history of severe PONV after prior anesthesia and motion sickness presents for outpatient suspension microlaryngoscopy with CO<sub>2</sub> laser excision of laryngeal papillomas. The surgeon plans a tubeless field with intermittent apnea and high-frequency jet ventilation and requests avoidance of N<sub>2</sub>O because of airway fire risk. The patient strongly prefers a plan that minimizes PONV and allows rapid recovery. You anticipate intermittent neuromuscular blockade only for intubation and will otherwise maintain a motionless field. Which maintenance anesthetic technique is most appropriate to meet these goals?",
    "answers": [
      {
        "text": "Sevoflurane 1.0 MAC in 50% N<sub>2</sub>O via LMA with spontaneous ventilation",
        "isCorrect": false,
        "explanation": "N<sub>2</sub>O increases airway fire risk and middle ear pressure; LMA is unsuitable for suspension microlaryngoscopy, and volatile delivery is interrupted during tubeless periods; higher PONV risk versus propofol."
      },
      {
        "text": "Sevoflurane 0.5 MAC plus propofol infusion (75 µg/kg/min) and intermittent fentanyl; no processed EEG",
        "isCorrect": false,
        "explanation": "Balanced technique still suffers from unreliable volatile delivery during apnea and greater PONV with fentanyl; omitting processed EEG with TIVA components increases awareness risk in a tubeless/jet ventilation case."
      },
      {
        "text": "Propofol (100–200 µg/kg/min) and remifentanil (0.1–0.2 µg/kg/min) TIVA with processed EEG monitoring; avoid N<sub>2</sub>O",
        "isCorrect": true,
        "explanation": "TIVA provides stable hypnosis during tubeless/jet ventilation when volatile delivery is unreliable, reduces PONV (propofol), allows rapid titration (remifentanil), lowers airway fire risk by avoiding N<sub>2</sub>O, and processed EEG reduces awareness risk during apnea."
      },
      {
        "text": "Ketamine infusion (0.5 mg/kg/hr) with midazolam supplementation; maintain spontaneous ventilation",
        "isCorrect": false,
        "explanation": "This regimen provides inconsistent immobility for microlaryngoscopy, increases secretions that can obscure the field, and does not address PONV or airway fire considerations as effectively as propofol–remifentanil TIVA."
      },
      {
        "text": "Desflurane 1.0 MAC via laser ETT with intermittent jet ventilation as needed",
        "isCorrect": false,
        "explanation": "Volatile delivery becomes unreliable during apnea/jet ventilation, risking awareness and movement; desflurane is airway-irritating and is associated with higher PONV compared with propofol-based TIVA."
      }
    ],
    "didactic": "For shared-airway microlaryngoscopy with a tubeless technique (intermittent apnea or jet ventilation), total intravenous anesthesia (TIVA) with propofol–remifentanil is preferred. During apnea or jet ventilation, inspired volatile concentration drops to zero, making end-tidal MAC tracking unreliable and risking light anesthesia, coughing/movement, and awareness. In contrast, TIVA maintains a steady effect-site concentration independent of tracheal gas flow.\n\nPropofol provides smooth hypnosis with intrinsic antiemetic properties, lowering PONV versus volatile agents. Remifentanil allows tight moment-to-moment control of analgesia and immobility with rapid emergence. Because the airway is in the laser field, avoiding N<sub>2</sub>O reduces oxidizer load and airway fire risk; minimizing FiO<sub>2</sub> is also prudent. When using TIVA—especially in cases with intermittent or absent ventilation—adding a processed EEG monitor (eg, BIS) helps reduce awareness risk because standard anesthetic concentration monitors (eg, ET agent) are unavailable.\n\nChoosing inhaled anesthesia versus TIVA should balance surgery, PONV risk, comorbidities, and monitoring:\n- Airway surgery (tubeless/jet, open airway): Favor TIVA; volatile delivery is unreliable and increases fire risk, particularly with N<sub>2</sub>O.\n- High PONV risk (female, non-smoker, prior PONV, opioids): Propofol-based TIVA plus multimodal prophylaxis reduces PONV versus volatiles.\n- Comorbidities: MH susceptibility mandates TIVA (avoid volatile agents and succinylcholine); severe bronchospasm may favor a volatile (bronchodilation) if airway conditions permit.\n- Neuromonitoring: MEPs/SSEPs are depressed by volatiles; TIVA optimizes signal quality.\n\nDesflurane or sevoflurane techniques are disadvantaged here due to unreliable delivery during apnea and higher PONV. Ketamine–midazolam provides inconsistent immobility and more secretions. A “balanced” low-MAC volatile plus propofol still suffers from volatile interruptions and, without processed EEG, higher awareness risk in this setting.",
    "educationalObjective": "Choose inhaled anesthesia versus TIVA by balancing airway surgery needs, PONV risk, comorbidities, and monitoring requirements."
  },
  {
    "id": "Core.6.3.3",
    "category": "General Anesthesia & Postop",
    "subcategory": "Maintenance: inhaled vs TIVA",
    "difficulty": "medium",
    "questionText": "A 36-year-old woman with moderate persistent asthma (FEV<sub>1</sub> 62% predicted) is scheduled for laparoscopic cholecystectomy. She uses budesonide–formoterol and as-needed albuterol; her last exacerbation was 3 months ago. After 2 puffs of albuterol in preop, she is asymptomatic with clear lungs. She will require endotracheal intubation for pneumoperitoneum and positioning. Induction is planned with IV propofol, fentanyl, and rocuronium; there is no history of malignant hyperthermia and she is hemodynamically stable.\n\nWhich maintenance anesthetic plan will most effectively minimize the risk of intraoperative bronchospasm in this patient?",
    "answers": [
      {
        "text": "Total IV anesthesia with propofol 100–150 μg/kg/min and remifentanil 0.1 μg/kg/min, avoiding volatiles",
        "isCorrect": false,
        "explanation": "Propofol suppresses airway reflexes and modestly bronchodilates, but it lacks the reliable, continuous bronchodilation seen with sevoflurane; TIVA is reasonable if volatiles are contraindicated."
      },
      {
        "text": "Sevoflurane at 1.0–1.5 MAC in O<sub>2</sub>/air with intermittent fentanyl and pre-induction inhaled albuterol",
        "isCorrect": true,
        "explanation": "Sevoflurane is nonpungent and a potent dose-dependent bronchodilator; pairing with a β-agonist reduces airway reactivity and is preferred for reactive airways when volatiles are not contraindicated."
      },
      {
        "text": "Desflurane at 1.0 MAC in O<sub>2</sub>/air with a remifentanil infusion",
        "isCorrect": false,
        "explanation": "Desflurane is pungent and increases airway resistance, especially in asthmatics and smokers, raising the risk of coughing and bronchospasm despite adequate depth."
      },
      {
        "text": "Sevoflurane ≤0.5 MAC with 70% N<sub>2</sub>O and remifentanil infusion to minimize volatile exposure",
        "isCorrect": false,
        "explanation": "Low-dose sevoflurane reduces its bronchodilatory effect, and high N<sub>2</sub>O offers no airway benefit; minimizing volatile exposure forfeits a key advantage in asthmatics."
      },
      {
        "text": "Isoflurane at 1.0 MAC in 50% N<sub>2</sub>O with morphine boluses for analgesia",
        "isCorrect": false,
        "explanation": "Isoflurane bronchodilates, but morphine’s histamine release can provoke bronchospasm; N<sub>2</sub>O provides no bronchodilation and may limit FiO<sub>2</sub> without benefit for reactive airways."
      }
    ],
    "didactic": "Patients with reactive airways benefit from anesthetic techniques that reduce airway smooth muscle tone, blunt vagal reflexes, and avoid airway irritants. **Volatile anesthetics (sevoflurane, isoflurane)** produce **dose-dependent bronchodilation** by relaxing airway smooth muscle (reduced intracellular Ca<sup>2+</sup>) and attenuating reflex bronchoconstriction. Among them, **sevoflurane** is preferred in asthmatics because it is **nonpungent**, well tolerated, and reliably decreases airway resistance at 1–1.5 MAC. In contrast, **desflurane** is pungent and can increase airway resistance, precipitating coughing, laryngospasm, and bronchospasm—particularly in smokers and those with asthma—so it should be avoided in reactive airways.\n\n**TIVA with propofol** suppresses airway reflexes and provides some bronchodilation, and **ketamine** can be added for additional bronchodilatory and sympathomimetic effects when bronchospasm is severe or hypotension is a concern. However, when there is no contraindication to inhaled agents, **sevoflurane maintenance offers more consistent, titratable bronchodilation** throughout surgery. If volatiles are contraindicated (eg, malignant hyperthermia risk), a propofol–remifentanil TIVA with optional low-dose ketamine is an appropriate alternative.\n\nAdjunct measures further lower risk:\n- Pre-induction **β<sub>2</sub>-agonist** (eg, albuterol) and consider **anticholinergic** (eg, ipratropium) if control is suboptimal.\n- Use **fentanyl or remifentanil** for analgesia; avoid **histamine-releasing opioids** (eg, morphine) that can trigger bronchospasm.\n- Ensure adequate anesthetic depth before airway manipulation; consider IV **lidocaine** to blunt reflexes.\n\nN<sub>2</sub>O does not bronchodilate and may reduce available FiO<sub>2</sub> without benefit. For this patient requiring an ETT and laparoscopy, **sevoflurane 1.0–1.5 MAC with β-agonist pretreatment** most effectively minimizes intraoperative bronchospasm risk.",
    "educationalObjective": "Choose maintenance strategies for reactive airways, leveraging volatile bronchodilation versus TIVA with adjuncts."
  },
  {
    "id": "Core.6.3.4",
    "category": "General Anesthesia & Postop",
    "subcategory": "Maintenance: inhaled vs TIVA",
    "difficulty": "hard",
    "questionText": "A 72-kg man is scheduled for a 5-hour posterior spinal fusion with motor-evoked potential monitoring. Due to the neuromonitoring plan and a history of malignant hyperthermia in a sibling, you plan total intravenous anesthesia with propofol (induction 2 mg/kg; maintenance 125–175 μg/kg/min) and remifentanil (0.05–0.15 μg/kg/min) via syringe pumps. He currently has a single 18G IV in the right forearm. The case will be prone with both arms tucked and the IV sites draped out of view. The OR has emergency (red) power outlets; routine monthly generator testing occurs during today’s schedule. Pumps are on mobile stands and not yet plugged in.\n\nWhich of the following is the most appropriate next step to minimize the risk of intraoperative awareness and ensure safe delivery of TIVA in this case?",
    "answers": [
      {
        "text": "Add processed EEG monitoring and administer 1 mg midazolam before induction to reduce awareness risk",
        "isCorrect": false,
        "explanation": "BIS/processed EEG can help titrate hypnosis, and midazolam reduces recall, but neither addresses the highest-risk failure mode for TIVA here—unrecognized loss of IV delivery from an infiltrated or disconnected line when IV sites are nonvisible."
      },
      {
        "text": "Route propofol and remifentanil through a single 3-way manifold with a 100 mL/h carrier to limit occlusion alarms",
        "isCorrect": false,
        "explanation": "Combining infusions into high–dead space manifolds with carrier flows increases risk of mixing errors, inadvertent boluses after line flush, and unrecognized delivery interruption—contraindicated for TIVA reliability."
      },
      {
        "text": "Plug syringe pumps into red emergency outlets, verify battery status, and prepare backup syringes for manual bolus during any power interruption",
        "isCorrect": false,
        "explanation": "Ensuring emergency power and battery readiness is important, but in this case the more imminent risk is unrecognized IV failure when arms are tucked and sites are hidden; power reliability alone does not secure drug delivery to the patient."
      },
      {
        "text": "Increase planned propofol maintenance to 200 μg/kg/min to account for surgical stimulation with neuromonitoring",
        "isCorrect": false,
        "explanation": "Higher dose may deepen hypnosis but does not mitigate the central hazard of TIVA (interrupted drug delivery). Overdosing risks hypotension and delayed emergence without improving reliability."
      },
      {
        "text": "Place a second, visible peripheral IV on a non-tucked extremity and run propofol via a dedicated, low–dead space line with one-way/anti-siphon valves; secure the site to remain in view throughout",
        "isCorrect": true,
        "explanation": "Redundant, visible IV access with a dedicated low–dead space propofol line best mitigates the most common and dangerous TIVA failure—unrecognized loss of IV delivery when access is hidden—thereby reducing awareness risk."
      }
    ],
    "didactic": "Safe TIVA requires planning for uninterrupted drug delivery, reliable monitoring, and power contingencies. The most consequential failure mode is unrecognized interruption of IV delivery (eg, infiltration, disconnection, line occlusion) because there is no exhaled anesthetic to detect and awareness may occur rapidly. When arms are tucked or sites are draped, risk increases.\n\nKey elements to improve reliability:\n\n- IV access and line strategy\n  - Use redundant access: 2 peripheral IVs on separate extremities; keep at least one site visible and accessible at all times (consider foot/ankle or external jugular if arms will be tucked).\n  - Dedicate a low–dead space line to hypnotic (eg, propofol) with one-way/anti-siphon valves and minimal connectors; avoid large manifolds/Y-sites and high carrier flows that can cause mixing, delayed onset, or inadvertent boluses after flushes.\n  - Secure lines meticulously (transparent dressing, strain relief loops, tape to skin and drapes) and document/communicate which line delivers anesthetic.\n\n- Infusion pump practices\n  - Program weight-based rates appropriately (eg, propofol 100–200 μg/kg/min; remifentanil 0.05–0.2 μg/kg/min) and verify syringe size, drug concentration, and channel labels.\n  - Set tight occlusion alarm limits and confirm downstream occlusion detection. Maintain line patency with minimal carrier flow through non-anesthetic ports as needed.\n  - Place pumps on emergency (red) power and confirm battery health; prepare prefilled backup syringes for manual bolus if needed.\n\n- Monitoring and emergence\n  - Use capnography, hemodynamics, and consider processed EEG to titrate hypnosis (adjunct, not a substitute for reliable delivery).\n  - Plan for smooth emergence: taper/remifentanil off near closure, reduce propofol as stimulation decreases, and ensure analgesia/antiemetics are provided.\n\nAmong these, redundant, visible IV access with a dedicated low–dead space anesthetic line most directly addresses the principal TIVA hazard—interrupted delivery—thereby reducing awareness risk, especially when access would otherwise be hidden during long, tucked-arm cases.",
    "educationalObjective": "Construct a safe TIVA plan (induction, maintenance, emergence) including infusion pumps, IV access security, and backup power."
  },
  {
    "id": "Core.6.3.5",
    "category": "General Anesthesia & Postop",
    "subcategory": "Maintenance: inhaled vs TIVA",
    "difficulty": "easy",
    "questionText": "A 38-year-old woman (BMI 32) is scheduled for elective laparoscopic sigmoid colectomy under an Enhanced Recovery After Surgery (ERAS) pathway. She is a nonsmoker with a history of severe postoperative nausea and vomiting and mild obstructive sleep apnea. The surgeon requests early feeding and ambulation and wants to avoid bowel distention intraoperatively. You plan multimodal analgesia and standard monitors.\n\nWhich anesthetic maintenance plan best supports the ERAS goals of opioid-sparing and early recovery in this patient?",
    "answers": [
      {
        "text": "Sevoflurane at ~1 MAC with 50% N<sub>2</sub>O and intermittent fentanyl boluses; single-agent antiemetic; no regional techniques",
        "isCorrect": false,
        "explanation": "Volatile anesthetics and N<sub>2</sub>O both increase PONV risk, and N<sub>2</sub>O can worsen bowel distention; intermittent fentanyl adds opioid burden and delays gut recovery."
      },
      {
        "text": "Isoflurane maintenance without regional techniques; morphine PCA initiated in PACU; metoclopramide alone for PONV prophylaxis",
        "isCorrect": false,
        "explanation": "Volatile anesthesia plus systemic opioids increases PONV and ileus risk; limited PONV prophylaxis and lack of regional/adjunctive opioid-sparing strategies are not ERAS-consistent."
      },
      {
        "text": "Propofol-based TIVA with dexmedetomidine and IV lidocaine infusions, avoidance of N<sub>2</sub>O, minimal opioids, bilateral TAP blocks, and dual-class PONV prophylaxis",
        "isCorrect": true,
        "explanation": "Propofol TIVA reduces PONV versus volatiles; dexmedetomidine and IV lidocaine provide opioid-sparing analgesia and may hasten return of bowel function; regional analgesia and multimodal antiemetics align with ERAS goals."
      },
      {
        "text": "Desflurane maintenance with a high-dose remifentanil infusion; no antiemetics to expedite discharge; no regional techniques",
        "isCorrect": false,
        "explanation": "High-dose remifentanil increases risk of opioid-induced hyperalgesia and ileus; omitting prophylactic antiemetics in a high-risk patient contradicts ERAS and increases PONV-related delays."
      },
      {
        "text": "Sevoflurane maintenance with low-dose ketamine infusion, avoidance of N<sub>2</sub>O, and 0.1 mg/kg hydromorphone before closure; standard single-agent PONV prophylaxis",
        "isCorrect": false,
        "explanation": "Although ketamine is opioid-sparing and N<sub>2</sub>O is avoided, volatile maintenance and long-acting hydromorphone increase PONV and delay gut recovery; single-agent PONV prophylaxis is inadequate for high risk."
      }
    ],
    "didactic": "ERAS emphasizes minimizing opioids, reducing PONV, and facilitating rapid return of bowel function and mobilization. Anesthetic maintenance should be tailored to support these outcomes.\n\n- Propofol-based TIVA lowers PONV compared with volatile agents, which is critical for high-risk patients and early feeding. Avoiding N<sub>2</sub>O further reduces PONV and prevents bowel distention during laparoscopy.\n- Opioid-sparing adjuncts improve analgesia and gut recovery. **Dexmedetomidine** provides anxiolysis and analgesia with minimal respiratory depression, reducing perioperative opioid needs. **Intravenous lidocaine** (particularly in abdominal surgery) decreases pain, opioid consumption, and ileus, supporting earlier return of bowel function.\n- Regional techniques such as **bilateral TAP blocks** reduce somatic pain from trocar sites and further limit opioids. Neuraxial analgesia is effective for open surgery; for laparoscopy, fascial plane blocks are often sufficient within ERAS.\n- High-dose or long-acting opioids (eg, hydromorphone, morphine) prolong ileus and increase PONV, delaying mobilization and feeding. If short-acting opioids are required, use the lowest effective dose and pair with adjuncts to mitigate hyperalgesia.\n- Robust, multimodal PONV prophylaxis (eg, dexamethasone + ondansetron ± a third agent for very high risk) is essential. Single-agent prophylaxis is inadequate in high-risk patients.\n\nCompared with volatile maintenance strategies, a **propofol TIVA** combined with **dexmedetomidine, IV lidocaine, regional analgesia, and dual-class antiemetics** best aligns with ERAS by reducing PONV, sparing opioids, limiting bowel dysmotility, and enabling earlier extubation, feeding, and ambulation.",
    "educationalObjective": "Coordinate maintenance choices with ERAS goals, emphasizing opioid-sparing and early recovery."
  },
  {
    "id": "Core.6.3.6",
    "category": "General Anesthesia & Postop",
    "subcategory": "Maintenance: inhaled vs TIVA",
    "difficulty": "medium",
    "questionText": "A 55-year-old man (82 kg) is undergoing a 4-hour laparoscopic colectomy under TIVA with propofol 110 µg/kg/min and remifentanil 0.15 µg/kg/min. He is hemodynamically stable (MAP 70–75 mmHg), with BIS 45–50 and ETCO₂ 35 mmHg. The surgeon announces 10 minutes remain to skin closure. Acetaminophen and ketorolac were given 30 minutes ago, and you plan a rapid, smooth extubation at the end of dressings.\n\nBased on the differing context-sensitive half-times of propofol and remifentanil, which anesthetic adjustment now best facilitates timely emergence while maintaining intraoperative stability?",
    "answers": [
      {
        "text": "Reduce the propofol infusion by ~50% now to a light plane; maintain remifentanil and discontinue it at skin closure.",
        "isCorrect": true,
        "explanation": "Propofol’s context-sensitive T<sub>1/2</sub> increases with infusion duration, so tapering it earlier allows hypnotic washout; remifentanil’s very short, duration-independent context-sensitive T<sub>1/2</sub> permits continuation until closure to prevent movement, with rapid offset when stopped."
      },
      {
        "text": "Continue both infusions unchanged and stop them together at the end of dressings.",
        "isCorrect": false,
        "explanation": "Stopping both at the end prolongs emergence due to propofol’s longer context-sensitive T<sub>1/2</sub>, despite remifentanil’s rapid offset."
      },
      {
        "text": "Administer fentanyl 100 µg now, stop remifentanil now, and maintain propofol until closure.",
        "isCorrect": false,
        "explanation": "Introducing fentanyl late adds a longer context-sensitive T<sub>1/2</sub> opioid that can delay recovery while also removing remifentanil’s titratable intraoperative analgesia."
      },
      {
        "text": "Stop remifentanil now and maintain the current propofol rate until dressings are placed.",
        "isCorrect": false,
        "explanation": "Stopping remifentanil early removes analgesia during the most stimulating period and does not hasten wake-up; propofol’s longer, duration-dependent context-sensitive T<sub>1/2</sub> will still delay emergence."
      },
      {
        "text": "Stop propofol now and continue remifentanil until extubation.",
        "isCorrect": false,
        "explanation": "Although this leverages remifentanil’s rapid offset, abruptly stopping propofol 10 minutes before closure risks awareness/recall during ongoing surgical stimulation."
      }
    ],
    "didactic": "Context-sensitive half-time (context-sensitive T<sub>1/2</sub>) is the time for a 50% decline in drug concentration after stopping an infusion and depends on the duration (“context”) of the infusion. It better predicts emergence than elimination T<sub>1/2</sub> in the perioperative setting.\n\n- Propofol: The context-sensitive T<sub>1/2</sub> lengthens with infusion duration because peripheral compartments become saturated and redistribution contributes less over time. After brief infusions, emergence is typically rapid (eg, 5–15 minutes), but after 3–4 hours the context-sensitive T<sub>1/2</sub> can extend to ~25–40 minutes, risking slower wake-up if the infusion is maintained to the end.\n- Remifentanil: Hydrolyzed by nonspecific blood/tissue esterases, it has an extremely short context-sensitive T<sub>1/2</sub> (~3–5 minutes) that is essentially independent of infusion duration. Accumulation is negligible, so it can be continued until the final sutures and still dissipate quickly once turned off.\n\nThese properties shape emergence planning during TIVA:\n\n- Begin tapering the hypnotic (propofol) before the end of surgery to account for its longer, duration-dependent context-sensitive T<sub>1/2</sub> and allow effect-site concentrations to decline toward awakening.\n- Maintain the ultra–short-acting opioid (remifentanil) through the stimulating phases near closure to prevent movement and sympathetic responses, then discontinue it at or just before extubation for rapid offset.\n- Avoid switching to longer-acting opioids late (eg, fentanyl) if rapid emergence is a priority, as their context-sensitive T<sub>1/2</sub> will prolong recovery. Provide multimodal analgesia and, if needed, a modest dose of a longer-acting analgesic sufficiently before stopping remifentanil to ensure postoperative pain control without delaying wake-up.\n\nThus, taper propofol earlier while continuing remifentanil until the end—this sequencing aligns with their contrasting context-sensitive T<sub>1/2</sub> profiles to achieve a prompt, smooth emergence.",
    "educationalObjective": "Explain context-sensitive half-times of propofol and remifentanil and how they shape emergence timelines."
  },
  {
    "id": "Core.6.3.7",
    "category": "General Anesthesia & Postop",
    "subcategory": "Maintenance: inhaled vs TIVA",
    "difficulty": "medium",
    "questionText": "A 45-year-old ASA II patient is undergoing a 2-hour laparoscopic cholecystectomy under general anesthesia. The OR has a modern circle system with Et agent monitoring and a contemporary CO<sub>2</sub> absorber; an active scavenging system vents to the outside atmosphere, and there is no anesthetic gas capture/destroy device. After induction and tracheal intubation with a brief high-flow wash-in, you are asked to minimize the case’s environmental footprint while maintaining stable anesthesia. Which maintenance strategy is most appropriate?",
    "answers": [
      {
        "text": "Propofol infusion (TIVA) with air/O<sub>2</sub> at 0.5–1 L/min and vaporizers off; no N<sub>2</sub>O",
        "isCorrect": true,
        "explanation": "TIVA eliminates halogenated anesthetic emissions; pairing with low FGF minimizes carrier gas use. Scavenging is irrelevant to climate impact when no volatiles are used."
      },
      {
        "text": "Desflurane at ~1 MAC (end-tidal 5%–6%) with air/O<sub>2</sub> at 0.5 L/min to exploit low fresh gas flow",
        "isCorrect": false,
        "explanation": "Desflurane’s very high GWP and long atmospheric lifetime make its CO<sub>2</sub>-equivalent emissions far greater than other options, even at low flows."
      },
      {
        "text": "Sevoflurane at FGF 2–3 L/min with active scavenging set high to limit greenhouse emissions",
        "isCorrect": false,
        "explanation": "Scavenging reduces occupational exposure but vents gases to the atmosphere; higher FGF increases agent throughput and emissions."
      },
      {
        "text": "Isoflurane at ~1 MAC (end-tidal 1.1%–1.3%) with 50% N<sub>2</sub>O and FGF 2 L/min to reduce volatile consumption",
        "isCorrect": false,
        "explanation": "N<sub>2</sub>O has significant GWP and a very long atmospheric lifetime; adding it increases overall footprint despite lowering volatile consumption."
      },
      {
        "text": "Sevoflurane at ~1 MAC (end-tidal 1.8%–2.2%) with air/O<sub>2</sub> at 0.5–1 L/min and no N<sub>2</sub>O",
        "isCorrect": false,
        "explanation": "Low-flow sevo without N<sub>2</sub>O substantially reduces emissions and is safe with modern absorbers, but it still releases a halogenated anesthetic to the atmosphere."
      }
    ],
    "didactic": "Anesthetic greenhouse impact depends on three controllable factors: agent selection, fresh gas flow (FGF), and whether gases are captured or simply scavenged. Halogenated agents and N<sub>2</sub>O are potent greenhouse gases; their CO<sub>2</sub>-equivalent impact scales roughly with FGF × agent concentration × time × global warming potential (GWP).\n\n- Agent selection: **Desflurane** has very high GWP (~2540) and long atmospheric lifetime (~14 years), making it the worst environmental choice. **Isoflurane** (GWP ~510; ~3 years) and **sevoflurane** (GWP ~130; ~1 year) are lower but still vented to the atmosphere. **N<sub>2</sub>O** (GWP ~265; ~114 years) substantially worsens footprint despite reducing volatile consumption. When clinically appropriate, **TIVA with propofol** avoids halogenated gases entirely and is the lowest-emission option.\n- Fresh gas flow: After denitrogenation/wash-in, reduce FGF to **≤1 L/min** (often 0.5–1 L/min) with end-tidal agent monitoring. Emissions fall approximately linearly with FGF. Modern CO<sub>2</sub> absorbers (non–strongly basic) permit **low-flow sevoflurane** without meaningful compound A concerns in routine practice.\n- Scavenging vs capture: **Active/passive scavenging protects staff** but typically vents waste gas outdoors; it does **not** reduce climate impact. Only dedicated **capture/destruction systems** decrease atmospheric release.\n\nPractical strategies to minimize footprint:\n- Prefer **TIVA** when suitable; otherwise choose **sevoflurane** over desflurane and avoid N<sub>2</sub>O.\n- Use **low FGF** after a brief high-flow wash-in and avoid unnecessary O<sub>2</sub> flushes.\n- Reduce MAC requirements with multimodal analgesia and adjuncts (eg, opioids, dexmedetomidine), allowing lower agent concentrations.\n\nIn this scenario, a propofol infusion with air/O<sub>2</sub> at 0.5–1 L/min and vaporizers off eliminates halogenated emissions and leverages low-flow techniques, achieving the greatest reduction in greenhouse impact given the absence of gas capture systems.",
    "educationalObjective": "Minimize environmental impact by understanding fresh gas flow, agent selection, and scavenging implications."
  },
  {
    "id": "Core.6.3.8",
    "category": "General Anesthesia & Postop",
    "subcategory": "Maintenance: inhaled vs TIVA",
    "difficulty": "medium",
    "questionText": "A 72-year-old man (BMI 28 kg/m<sup>2</sup>) on metoprolol undergoes open inguinal hernia repair under general anesthesia. Induction was with propofol, fentanyl 100 µg, and rocuronium. Maintenance is sevoflurane in air/O<sub>2</sub> with no ongoing opioid infusion. Thirty minutes into the case, blood loss is <100 mL and urine output is minimal. Vital signs: BP 78/42 mmHg (MAP 54), HR 55/min, SpO<sub>2</sub> 99%, EtCO<sub>2</sub> 34 mmHg. The monitor shows age-adjusted MAC 1.4 and BIS 30. Lungs are clear and pneumoperitoneum is not present.\n\nWhich of the following is the most appropriate next step to stabilize blood pressure while maintaining adequate anesthesia depth?",
    "answers": [
      {
        "text": "Decrease volatile to ~0.8–1.0 MAC, start remifentanil 0.05–0.1 µg/kg/min, and give ephedrine 5–10 mg IV",
        "isCorrect": true,
        "explanation": "This balances anesthesia by reducing volatile-induced vasodilation, providing analgesia with an opioid to maintain depth, and treating bradycardic hypotension with a mixed α/β agonist that supports HR and CO."
      },
      {
        "text": "Switch to propofol infusion at 100 µg/kg/min and discontinue the volatile",
        "isCorrect": false,
        "explanation": "Propofol causes dose-dependent vasodilation and myocardial depression; switching from a high volatile to propofol will likely exacerbate hypotension rather than correct it."
      },
      {
        "text": "Give a 1 L lactated Ringer’s bolus and increase fresh gas flow to 6 L/min",
        "isCorrect": false,
        "explanation": "There is no evidence of hypovolemia, and increasing FGF will wash in more volatile, deepening anesthesia and worsening vasodilatory hypotension."
      },
      {
        "text": "Start dexmedetomidine 0.7 µg/kg/h and reduce volatile to 1.0 MAC",
        "isCorrect": false,
        "explanation": "Dexmedetomidine can reduce MAC but frequently causes bradycardia and hypotension, which is undesirable in a patient already bradycardic and hypotensive."
      },
      {
        "text": "Maintain current volatile and give phenylephrine 100 µg IV boluses",
        "isCorrect": false,
        "explanation": "Phenylephrine may transiently raise MAP but can worsen reflex bradycardia and does not address excessive volatile depth (MAC 1.4, BIS 30), perpetuating vasodilatory hypotension."
      }
    ],
    "didactic": "Volatile anesthetics and propofol produce hypotension primarily via **dose-dependent vasodilation** and some degree of myocardial depression. Elderly patients have a **lower MAC** (≈6% decline per decade after 40), so a monitor reading of age-adjusted MAC 1.4 with BIS 30 indicates excessive hypnotic depth with vasodilatory hypotension. The balanced anesthetic approach is to reduce the offending hypnotic dose, add **analgesic/adjunct** agents to maintain adequate anesthesia, and provide **vasoactive support** tailored to the hemodynamic profile.\n\n- Reducing volatile concentration toward ~0.8–1.0 MAC decreases vasodilation while preserving hypnosis. Adding a short-acting opioid (eg, **remifentanil 0.05–0.1 µg/kg/min**) supplies analgesia, allowing a lower volatile dose without sympathetic surges.\n- For bradycardic hypotension, **ephedrine (5–10 mg IV)** is often preferred over phenylephrine because its mixed α/β effects increase HR and CO in addition to SVR. In contrast, **phenylephrine** (pure α<sub>1</sub>) can worsen bradycardia and may reduce CO.\n- Alternatives to reduce hypnotic requirement include small-dose **ketamine** (eg, 0.2–0.5 mg/kg bolus) or **regional** techniques; however, dexmedetomidine commonly causes bradycardia/hypotension and is ill-suited for acute support in this scenario.\n\nFor propofol-based TIVA, the same principles apply: **decrease propofol** to the lowest effective rate, add opioid/adjuncts (remifentanil, ketamine), and use vasoactive agents (ephedrine, phenylephrine, or norepinephrine infusion) based on HR/CO. A large fluid bolus is reserved for suspected **relative hypovolemia** (bleeding/third spacing), which is not evident here. Thus, the most appropriate step is to lighten the volatile, add opioid analgesia, and treat bradycardic hypotension with ephedrine.",
    "educationalObjective": "Mitigate hypotension from volatiles or propofol using balanced anesthesia (opioids, adjuncts) and vasoactive support."
  },
  {
    "id": "Core.6.3.9",
    "category": "General Anesthesia & Postop",
    "subcategory": "Maintenance: inhaled vs TIVA",
    "difficulty": "hard",
    "questionText": "A 59-year-old man (BMI 38 kg/m²) is scheduled for posterior thoracolumbar fusion with SSEP/MEP monitoring. To preserve evoked potentials, you plan total intravenous anesthesia with propofol and remifentanil and will avoid volatile agents. The resident proposes a single 20-gauge IV with long extension tubing under the drapes, a manual propofol infusion at 50–75 mcg/kg/min based on total body weight, remifentanil 0.05 mcg/kg/min, and monitoring depth via blood pressure and heart rate without a processed EEG.\n\nWhich of the following is the most appropriate strategy to minimize the risk of intraoperative awareness in this patient?",
    "answers": [
      {
        "text": "Initiate a target-controlled infusion of propofol (effect-site 3–5 µg/mL) with remifentanil 0.1–0.2 µg/kg/min, deliver via a dedicated, verified IV line and smart pump, and titrate to maintain processed EEG 40–60.",
        "isCorrect": true,
        "explanation": "Validated TIVA delivery (eg, effect-site TCI), vigilant pump/IV management, and processed EEG targeting 40–60 together reduce awareness risk when inhaled agent monitoring is unavailable."
      },
      {
        "text": "Program a manual propofol infusion (50–75 mcg/kg/min) using total body weight, supplement with remifentanil, and use heart rate/blood pressure to guide anesthetic depth.",
        "isCorrect": false,
        "explanation": "Hemodynamics are unreliable indicators of hypnosis, and 50–75 mcg/kg/min is often inadequate for TIVA without volatiles; TBW-based dosing in obesity is suboptimal and increases variability."
      },
      {
        "text": "Administer midazolam 5 mg at induction and omit depth monitoring to avoid interference with motor evoked potentials.",
        "isCorrect": false,
        "explanation": "A benzodiazepine at induction does not reliably prevent awareness during prolonged TIVA, and processed EEG does not interfere with MEPs."
      },
      {
        "text": "Increase remifentanil to 1–2 mcg/kg/min and reduce propofol to 25 mcg/kg/min to maintain stable hemodynamics.",
        "isCorrect": false,
        "explanation": "Opioids are not hypnotics; high-dose remifentanil with low propofol risks explicit awareness despite stable vital signs."
      },
      {
        "text": "Add 70% nitrous oxide to the current low-dose propofol/remifentanil regimen to reduce awareness risk while preserving evoked potentials.",
        "isCorrect": false,
        "explanation": "Nitrous oxide depresses SSEP/MEP amplitudes and is not a reliable hypnotic substitute; relying on N₂O to prevent awareness is inappropriate."
      }
    ],
    "didactic": "Awareness risk is higher during TIVA than with inhaled anesthesia because there is no end-tidal anesthetic to verify delivery. Prevention requires three pillars: a **validated hypnotic regimen**, **vigilant pump/IV management**, and **processed EEG when appropriate**.\n\n- Use validated TIVA delivery. Effect-site target-controlled infusion (TCI) of propofol (eg, 3–5 µg/mL) paired with remifentanil 0.1–0.2 µg/kg/min provides predictable hypnosis/analgesia for neuromonitoring cases. If TCI is unavailable, use evidence-based manual schemas (eg, propofol 75–150 mcg/kg/min initially, then 50–100 mcg/kg/min) with opioid co-infusion. In obesity, dose propofol to lean/adjusted weight or use TCI models incorporating lean body mass to avoid under/overdosing.\n- Ensure reliable drug delivery. Use a dedicated IV for the hypnotic, minimize extension tubing, confirm IV patency, and program the pump carefully (correct units, concentration, and weight). Monitor for empty syringes, battery/occlusion alarms, and unexpected flow interruptions. These checks are critical because neuromuscular blockade or strong opioids can mask light anesthesia by blunting movement and autonomic responses.\n- Apply processed EEG and target values associated with adequate hypnosis (eg, BIS 40–60). Trend the index and inspect the raw EEG/suppression ratio; recognize artifacts (EMG, electrocautery) that can transiently alter values. Processed EEG is particularly useful when NMBs are used or when relying on opioids that stabilize hemodynamics despite inadequate hypnosis.\n\nCommon pitfalls include relying on heart rate/blood pressure alone, assuming an induction benzodiazepine prevents awareness, or substituting high-dose opioid for hypnotic. Nitrous oxide is not MH-triggering but depresses SSEP/MEP and is not a dependable primary hypnotic. If awareness risk is suspected, promptly verify IV/pump function, administer a propofol bolus (eg, 0.5–1 mg/kg), and adjust the infusion to a validated target while using processed EEG for guidance.",
    "educationalObjective": "Prevent awareness during TIVA with validated infusion regimens, vigilant pump checks, and processed EEG when appropriate."
  },
  {
    "id": "Core.6.3.10",
    "category": "General Anesthesia & Postop",
    "subcategory": "Maintenance: inhaled vs TIVA",
    "difficulty": "hard",
    "questionText": "A 45-year-old man (80 kg) is undergoing elective frontal craniotomy for a meningioma with 8 mm midline shift. After bone flap removal and before dural opening, the surgeon notes a tense, bulging brain that limits exposure. Current maintenance is sevoflurane at 1.0 MAC in 50% air/O<sub>2</sub> with remifentanil 0.1 μg/kg/min. Vital signs: MAP 75 mmHg on norepinephrine 0.05 μg/kg/min, HR 72/min, SpO<sub>2</sub> 100%. ABG shows PaCO<sub>2</sub> 37 mmHg. No nitrous oxide is being used.\n\nTo improve brain relaxation while preserving cerebral perfusion pressure (CPP), which change to the maintenance anesthetic is most appropriate now?",
    "answers": [
      {
        "text": "Transition to TIVA: start propofol 150 μg/kg/min and discontinue the volatile anesthetic",
        "isCorrect": true,
        "explanation": "Propofol decreases CMRO₂ and proportionally reduces CBF, lowering ICP while preserving autoregulation and CO₂ reactivity; with vasopressor support, CPP is maintained."
      },
      {
        "text": "Add 50% nitrous oxide to the current regimen",
        "isCorrect": false,
        "explanation": "Nitrous oxide increases CBF and ICP and can worsen brain swelling despite modest CMRO₂ effects."
      },
      {
        "text": "Increase sevoflurane to 1.5 MAC to further reduce CMRO₂",
        "isCorrect": false,
        "explanation": "At ≥1 MAC, volatile-induced cerebral vasodilation increases CBF and ICP, uncoupling from CMRO₂ reduction and risking worse brain swelling and lower CPP."
      },
      {
        "text": "Switch to desflurane at 1.0 MAC to leverage its lower blood–gas solubility",
        "isCorrect": false,
        "explanation": "Desflurane shares the cerebral vasodilatory effects of other volatiles and does not improve ICP; lower solubility affects kinetics, not intracranial dynamics."
      },
      {
        "text": "Maintain 1.0 MAC sevoflurane and add dexmedetomidine 0.7 μg/kg/h",
        "isCorrect": false,
        "explanation": "Dexmedetomidine may reduce MAP and HR, risking lower CPP, and does not reliably counteract volatile-induced cerebral vasodilation to improve ICP."
      }
    ],
    "didactic": "Volatile anesthetics decrease cerebral metabolic rate of O<sub>2</sub> (CMRO₂) but produce direct cerebral vasodilation that increases cerebral blood flow (CBF) and intracranial pressure (ICP). Above roughly 0.5–1.0 MAC, vasodilation dominates, **uncoupling** CBF from CMRO₂ and worsening brain swelling. Sevoflurane, isoflurane, and desflurane have broadly similar cerebrovascular effects; desflurane’s lower blood–gas solubility speeds kinetics but does not mitigate ICP elevation. Nitrous oxide increases CBF and ICP and should be avoided in patients at risk for intracranial hypertension.\n\nIn contrast, **propofol** reduces CMRO₂ and, through flow–metabolism coupling, proportionally reduces CBF. This lowers cerebral blood volume and ICP, improving brain relaxation. Propofol also preserves **cerebral autoregulation** and **CO<sub>2</sub> reactivity**, allowing predictable responses to blood pressure adjustments and ventilation. CPP is calculated as CPP = MAP − ICP; by lowering ICP, propofol can increase CPP, provided that systemic hypotension is prevented. Because propofol can decrease MAP via systemic vasodilation and myocardial depression, concurrent **vasopressor support** (eg, norepinephrine) is often used to maintain MAP and thus CPP.\n\nPractical approach to a “tight brain” during craniotomy:\n- Favor a propofol-based TIVA (eg, 100–200 μg/kg/min) or reduce volatile to ≤0.5 MAC with adjuncts (eg, opioid) to minimize vasodilation.\n- Avoid nitrous oxide in intracranial pathology.\n- Maintain PaCO<sub>2</sub> in the low-normal range for modest, reversible cerebral vasoconstriction while avoiding excessive hypocapnia.\n\nTherefore, transitioning from volatile maintenance to propofol TIVA best reduces ICP and improves surgical conditions while preserving CPP with appropriate hemodynamic support.",
    "educationalObjective": "Tailor maintenance for neurosurgery by comparing effects of volatiles versus propofol on CMRO₂, CBF, and ICP."
  },
  {
    "id": "Core.6.3.11",
    "category": "General Anesthesia & Postop",
    "subcategory": "Maintenance: inhaled vs TIVA",
    "difficulty": "medium",
    "questionText": "A 72-year-old man (ASA II) undergoes laparoscopic inguinal hernia repair under sevoflurane in air/O<sub>2</sub>. Twenty minutes after induction (propofol, fentanyl, rocuronium), maintenance is sevoflurane at fresh gas flow 1 L/min with the vaporizer dial at 2.0%. During peritoneal insufflation, the patient develops lacrimation, HR 105/min, and BP 165/90 mmHg (baseline 130/70). Monitors show EtCO<sub>2</sub> 38 mmHg, Fi sevo 1.4%, Et sevo 1.0%, and EtMAC (age-adjusted) 0.6. No nitrous oxide is used.\n\nWhich of the following is the most appropriate next step to optimize anesthetic depth?",
    "answers": [
      {
        "text": "Increase the vaporizer to 3.5% to deliver a dial setting equivalent to 1.0 MAC regardless of age.",
        "isCorrect": false,
        "explanation": "Dial setting does not reflect alveolar/brain partial pressure and is not age-adjusted; relying on the dial risks under- or overdosing, especially at low flows with ongoing uptake."
      },
      {
        "text": "Maintain current settings because Fi > Et indicates the anesthetic depth is increasing and will equilibrate shortly.",
        "isCorrect": false,
        "explanation": "Although Fi > Et suggests alveolar concentration is rising, the patient is currently light (EtMAC 0.6) with sympathetic signs; waiting risks awareness and hemodynamic surges."
      },
      {
        "text": "Administer 0.5–1 mg midazolam IV for hypertension and tachycardia while keeping the volatile unchanged.",
        "isCorrect": false,
        "explanation": "Benzodiazepines provide amnesia but are weak anesthetics and poor analgesics; they will not promptly correct inadequate volatile depth or nociceptive response."
      },
      {
        "text": "Increase sevoflurane to raise the end-tidal concentration until EtMAC (age-adjusted) is ≈1.0–1.2 (eg, Et sevo ≈1.3% for this patient), then reassess.",
        "isCorrect": true,
        "explanation": "End-tidal agent (age-adjusted EtMAC) best reflects brain partial pressure. With sympathetic signs and EtMAC 0.6, targeting ≈1.0–1.2 during stimulation is appropriate; adjust the dial to achieve that end-tidal level."
      },
      {
        "text": "Initiate a propofol infusion (TIVA) because low fresh gas flow prevents adequate volatile titration during stimulation.",
        "isCorrect": false,
        "explanation": "Low flow slows changes but does not preclude effective titration; increasing the dial (and transiently FGF if needed) to reach an age-adjusted EtMAC target is simpler and appropriate."
      }
    ],
    "didactic": "Volatile anesthetic depth is best titrated to the end-tidal agent concentration and the monitor’s age-adjusted end-tidal MAC (EtMAC), interpreted alongside clinical signs. The alveolar (end-tidal) partial pressure closely reflects brain partial pressure at steady state, whereas the vaporizer dial and inspired concentration are upstream surrogates influenced by uptake and fresh gas flow (FGF). At low FGF with ongoing tissue uptake, Fi typically exceeds Et; relying on the dial risks underestimating anesthetic requirements.\n\nMAC declines with age (≈6%–7% per decade after age 40). For sevoflurane, MAC is ~2.0% at age 40 and ~1.3–1.4% in the 70s. In this 72-year-old, Et sevo 1.0% corresponds to an EtMAC ≈0.6–0.7, which is inadequate during peritoneal insufflation. Sympathetic signs (tachycardia, hypertension, tearing/movement) corroborate insufficient depth. The appropriate response is to increase sevoflurane to raise the end-tidal concentration to an age-adjusted EtMAC ≈1.0–1.2 (eg, Et sevo ≈1.3%), then reassess hemodynamics and clinical signs.\n\nKey points for titration:\n- Use Et agent and age-adjusted EtMAC as primary guides; they better reflect effect-site concentration than the dial setting.\n- Interpret EtMAC in context of stimulation and adjuncts. Opioids reduce the MAC requirement for immobility; during intense stimulation, target EtMAC near 1.0–1.2 when relying on volatiles for hypnosis/immobility.\n- To speed changes, transiently increase the dial and/or FGF (overpressurization), but the endpoint remains the age-adjusted EtMAC target, not the dial value.\n- Processed EEG (eg, BIS) and benzodiazepines are adjuncts; for volatile-based anesthesia, EtMAC correlates well with hypnotic effect, and benzodiazepines are weak anesthetics.\n\nIn summary, titrate volatile depth to the age-adjusted EtMAC and clinical signs rather than the vaporizer setting; here, raise end-tidal sevo to achieve EtMAC ≈1.0–1.2 during stimulation and reassess.",
    "educationalObjective": "Titrate volatile depth using end-tidal MAC adjusted for age and clinical signs rather than dial setting alone."
  },
  {
    "id": "Core.6.3.12",
    "category": "General Anesthesia & Postop",
    "subcategory": "Maintenance: inhaled vs TIVA",
    "difficulty": "hard",
    "questionText": "A 55-year-old, 90-kg man undergoes laparoscopic colectomy under general anesthesia with a circle system. After 10 minutes of denitrogenation at FGF 4 L/min (50% O<sub>2</sub>), you reduce FGF to 0.5 L/min with air/O<sub>2</sub> (30% O<sub>2</sub>) and sevoflurane 1.7%. Over the next 8 minutes, EtO<sub>2</sub> falls from 42% to 29% while EtCO<sub>2</sub> remains 34 mmHg with zero inspired CO<sub>2</sub>. The reservoir bag is appropriately distended, airway pressures and inspiratory sevoflurane match expected values, and there are no low-pressure/leak alarms. The FiO<sub>2</sub> alarm is set to 25%.\n\nWhich is the most appropriate step to safely continue low-flow anesthesia?",
    "answers": [
      {
        "text": "Replace the CO<sub>2</sub> absorbent and tighten the APL valve, then continue 0.5 L/min with 30% O<sub>2</sub>.",
        "isCorrect": false,
        "explanation": "No inspired CO<sub>2</sub> suggests adequate absorbent; the patient is on the ventilator (APL setting irrelevant). These actions do not address the falling FiO<sub>2</sub>."
      },
      {
        "text": "Add 50% N<sub>2</sub>O to the FGF at 0.5 L/min to reduce sevoflurane requirement while maintaining 30% O<sub>2</sub>.",
        "isCorrect": false,
        "explanation": "O<sub>2</sub> delivery (150 mL/min) remains below consumption, risking a hypoxic mixture; N<sub>2</sub>O uptake wanes over time and can further depress circuit O<sub>2</sub> fraction."
      },
      {
        "text": "Increase the O<sub>2</sub> concentration in FGF to 60% (O<sub>2</sub> flow 0.3 L/min) while keeping total FGF at 0.5 L/min and continue FiO<sub>2</sub>/EtO<sub>2</sub> monitoring.",
        "isCorrect": true,
        "explanation": "At 0.5 L/min FGF, an FiO<sub>2</sub> ≥50% is required to deliver ≥250 mL/min O<sub>2</sub>; a 90-kg adult consumes ≈270 mL/min, so 60% provides a safe margin while preserving low flow."
      },
      {
        "text": "Increase total FGF to 2 L/min with 30% O<sub>2</sub> for 15 minutes, then return to 0.5 L/min.",
        "isCorrect": false,
        "explanation": "Higher FGF will transiently raise FiO<sub>2</sub> but forfeits low-flow benefits and does not correct the underlying O<sub>2</sub> delivery deficit once flows are reduced again."
      },
      {
        "text": "Increase minute ventilation to 8 L/min while maintaining 0.5 L/min FGF with 30% O<sub>2</sub>.",
        "isCorrect": false,
        "explanation": "Changing ventilation affects CO<sub>2</sub> elimination, not the supply–demand balance of O<sub>2</sub> in a circle system at low FGF; FiO<sub>2</sub> will continue to fall."
      }
    ],
    "didactic": "Safe low-flow anesthesia (FGF ≤1 L/min; minimal-flow ≈0.5 L/min) requires a leak-free circle system, functional CO<sub>2</sub> absorbent, and continuous gas monitoring (FiO<sub>2</sub>/EtO<sub>2</sub>, inspired/expired volatile, EtCO<sub>2</sub>). After an initial wash-in/denitrogenation period at higher FGF, flows can be reduced provided O<sub>2</sub> delivery from the FGF meets or exceeds the patient’s O<sub>2</sub> consumption.\n\nAdults consume ≈3 mL/kg/min of O<sub>2</sub> (≈200–300 mL/min). If FGF × FiO<sub>2</sub> is less than this consumption, O<sub>2</sub> in the circuit will be progressively depleted and replaced by other gases, causing FiO<sub>2</sub>/EtO<sub>2</sub> to drift downward despite normal ventilation and CO<sub>2</sub> absorption. For a 90-kg patient (≈270 mL/min O<sub>2</sub> consumption), 0.5 L/min FGF requires FiO<sub>2</sub> ≥0.54 to deliver sufficient O<sub>2</sub>. Setting FiO<sub>2</sub> to 0.60 at 0.5 L/min provides ≈300 mL/min O<sub>2</sub>, a safe cushion that maintains EtO<sub>2</sub> without abandoning low flow.\n\nKey elements of safe practice:\n- Confirm a leak-free circuit (reservoir bag not collapsing, stable airway pressures, inspired volatile ≈ set, no low-pressure alarms) before reducing FGF.\n- Ensure the CO<sub>2</sub> absorbent is functional (zero inspired CO<sub>2</sub>); rebreathing causes hypercarbia, not falling FiO<sub>2</sub>.\n- Adjust FiO<sub>2</sub> so that O<sub>2</sub> delivery (FGF × FiO<sub>2</sub>) ≥ O<sub>2</sub> consumption; use EtO<sub>2</sub>/FiO<sub>2</sub> alarms (eg, EtO<sub>2</sub> ≥30%–35%).\n- Be cautious with N<sub>2</sub>O at low flows; as N<sub>2</sub>O uptake declines, circuit O<sub>2</sub> can fall, risking hypoxic mixtures despite hypoxic guards.\n\nIncreasing minute ventilation does not correct an O<sub>2</sub> supply–demand mismatch, and raising FGF forfeits low-flow benefits without addressing the underlying issue once flows are reduced again. The most appropriate intervention is to raise the FGF O<sub>2</sub> fraction so O<sub>2</sub> delivery matches consumption while maintaining continuous gas monitoring.",
    "educationalObjective": "Use low fresh gas flows safely during volatile maintenance with continuous gas monitoring and leak-free circuits."
  },
  {
    "id": "Core.6.4.1",
    "category": "General Anesthesia & Postop",
    "subcategory": "PACU complications and management",
    "difficulty": "easy",
    "questionText": "A 68-year-old man with benign prostatic hyperplasia undergoes open inguinal hernia repair under general anesthesia (fentanyl 100 μg intraoperatively). In the PACU 45 minutes later, he is restless and diaphoretic with BP 188/102 mmHg (baseline 132/78), HR 112/min, RR 16/min, SpO₂ 98% on room air, and T 36.7°C. He reports suprapubic pressure and a strong urge to void; his incision pain is 3/10. Bladder ultrasound reveals 750 mL of urine, and he has not voided since surgery. Which management is most appropriate to control his hypertension and tachycardia?",
    "answers": [
      {
        "text": "Perform straight catheterization with bladder decompression",
        "isCorrect": true,
        "explanation": "Bladder distention causes a sympathetic surge with hypertension and tachycardia; prompt decompression removes the trigger and rapidly normalizes vital signs."
      },
      {
        "text": "Start dexmedetomidine infusion 0.2–0.7 μg/kg/h",
        "isCorrect": false,
        "explanation": "Sedation may blunt signs but does not treat the underlying trigger; dexmedetomidine can cause bradycardia and hypotension without resolving urinary retention."
      },
      {
        "text": "Administer IV labetalol 10 mg",
        "isCorrect": false,
        "explanation": "β/α-blockade may acutely lower BP and HR but does not address the precipitating stimulus (bladder distention) and risks hypotension once the cause is relieved."
      },
      {
        "text": "Administer IV hydromorphone 0.5 mg",
        "isCorrect": false,
        "explanation": "Opioids may modestly reduce sympathetic tone from discomfort but do not resolve urinary retention and can worsen post-op urinary retention via μ-agonism."
      },
      {
        "text": "Administer IV esmolol 30 mg",
        "isCorrect": false,
        "explanation": "Short-acting β-blockade treats the numbers but not the cause; targeted correction of the precipitant should precede antihypertensives."
      }
    ],
    "didactic": "Postoperative hypertension and tachycardia in the PACU are most often due to increased sympathetic tone from **pain**, **bladder distention/urinary retention**, **hypoxia/hypercarbia**, **shivering**, or **drug withdrawal** (eg, alcohol/benzodiazepine, clonidine, β-blocker). Management should prioritize rapid identification and correction of the precipitating stimulus rather than reflexively treating vital sign abnormalities.\n\nBladder distention triggers pelvic afferents and catecholamine release, producing restlessness, diaphoresis, suprapubic discomfort, hypertension, and tachycardia. A bladder scan volume ≥400–600 mL strongly suggests retention; volumes ≥700–800 mL warrant immediate decompression. **Straight catheterization or Foley placement** removes the stimulus and typically normalizes BP/HR within minutes. Analgesics alone are insufficient and opioids can exacerbate urinary retention via μ-receptor effects on detrusor tone.\n\nA practical PACU approach includes:\n- Assess oxygenation/ventilation (SpO₂, airway, consider capnography) and temperature.\n- Evaluate common triggers: pain score, bladder scan, shivering, agitation/withdrawal history, and withheld home medications (eg, clonidine, β-blocker).\n- Provide **targeted therapy**:\n  - Pain: multimodal analgesia (eg, IV opioids in small titrated doses, acetaminophen, NSAIDs if appropriate).\n  - Bladder distention: immediate bladder decompression.\n  - Withdrawal: treat the specific syndrome (benzodiazepines for alcohol/benzodiazepine withdrawal; restart clonidine or β-blocker if withheld; short-acting opioids for opioid withdrawal).\n\nNonselective BP/HR control (eg, labetalol, esmolol) may be considered if severe hypertension persists after addressing reversible causes, but initial use can mask the diagnosis and precipitate hypotension once the trigger is removed. Dexmedetomidine provides sedation and sympatholysis but is not first-line when a clear, correctable stimulus is present. Targeted correction improves hemodynamics and avoids unnecessary medications and adverse effects.",
    "educationalObjective": "Control hypertension and tachycardia due to pain, bladder distention, or withdrawal with targeted therapy."
  },
  {
    "id": "Core.6.4.2",
    "category": "General Anesthesia & Postop",
    "subcategory": "PACU complications and management",
    "difficulty": "medium",
    "questionText": "A 58-year-old man (BMI 36) with obstructive sleep apnea undergoes laparoscopic cholecystectomy under general anesthesia with rocuronium. At case end, qualitative ulnar nerve train-of-four (TOF) showed 4 twitches with fade; he received neostigmine 40 mcg/kg with glycopyrrolate 8 mcg/kg and was extubated. In the PACU 15 minutes later, he is somnolent with shallow respirations (RR 6/min) and SpO<sub>2</sub> 90% on 4 L/min nasal cannula. Quantitative acceleromyography at the adductor pollicis shows TOF count 4 with a TOF ratio of 0.45. Which is the most appropriate next step to rapidly correct the underlying cause of his hypoventilation?\n\n",
    "answers": [
      {
        "text": "Apply CPAP at 10 cm H2O and observe",
        "isCorrect": false,
        "explanation": "CPAP may stent the airway but does not treat hypoventilation from residual neuromuscular blockade; delaying definitive reversal risks worsening hypercapnia and hypoxemia."
      },
      {
        "text": "Administer sugammadex 2 mg/kg IV",
        "isCorrect": true,
        "explanation": "A TOF count of 4 with TOF ratio 0.45 indicates moderate residual block from rocuronium; sugammadex 2 mg/kg provides rapid and reliable reversal while airway/ventilatory support is maintained."
      },
      {
        "text": "Reintubate and admit to the ICU",
        "isCorrect": false,
        "explanation": "Immediate reintubation is unnecessary because the block can be rapidly and safely reversed with appropriately dosed sugammadex in a monitored setting."
      },
      {
        "text": "Administer naloxone 0.04 mg IV",
        "isCorrect": false,
        "explanation": "Although opioids can depress respiration, the quantitative TOF ratio of 0.45 confirms significant residual neuromuscular block as the primary cause; naloxone will not restore ventilatory muscle strength."
      },
      {
        "text": "Administer additional neostigmine 50 mcg/kg IV with glycopyrrolate",
        "isCorrect": false,
        "explanation": "Neostigmine exhibits a ceiling effect, and additional dosing after an adequate initial dose is unlikely to meaningfully increase reversal at a TOF ratio of 0.45; it may worsen weakness or cause muscarinic side effects."
      }
    ],
    "didactic": "Residual neuromuscular blockade (rNMB) is common in the PACU and increases the risk of airway obstruction, hypoxemia, hypercarbia, and aspiration. Clinical signs (eg, 5-second head lift, handgrip, tidal volume) are insensitive; patients can appear “strong” with a TOF ratio (TOFR) as low as 0.4–0.6. Therefore, **quantitative** neuromuscular monitoring should be used to guide extubation and PACU management. A TOFR <0.9 indicates clinically important rNMB; many advocate targeting ≥0.95 to optimize airway protective reflexes.\n\nFor aminosteroid neuromuscular blockers (rocuronium, vecuronium), **sugammadex** encapsulates the relaxant, producing rapid, predictable reversal across a wide range of block depths:\n- 2 mg/kg for moderate block (TOF count ≥2 or TOFR <0.9 with 4 twitches)\n- 4 mg/kg for deep block with 0 TOF but 1–2 post-tetanic counts\n- 16 mg/kg for immediate rescue after large-dose rocuronium\n\nAnticholinesterases (eg, **neostigmine**) increase acetylcholine but have a **ceiling effect**; once near-maximal inhibition of acetylcholinesterase is achieved, extra dosing does not meaningfully accelerate recovery and may worsen weakness if given at near-complete recovery or cause bradycardia, secretions, and bronchospasm without adequate antimuscarinic. Neostigmine is most reliable when the block is shallow and quantitative monitoring confirms recovery is already well underway; it is slow and unreliable for moderate-to-deep rNMB.\n\nIn the PACU, a TOFR of 0.45 following rocuronium despite prior neostigmine confirms significant rNMB as the principal cause of hypoventilation. The best next step is **sugammadex 2 mg/kg IV**, with immediate airway support (jaw thrust, supplemental O<sub>2</sub>, assisted ventilation) until TOFR recovers to ≥0.9. CPAP can help pharyngeal collapse (eg, OSA) but does not correct ventilatory muscle weakness. Sugammadex is ineffective for benzylisoquinoliniums (eg, cisatracurium), for which anticholinesterases or time/supportive ventilation are required.",
    "educationalObjective": "Detect residual neuromuscular blockade with quantitative monitoring and administer appropriate reversal or support ventilation."
  },
  {
    "id": "Core.6.4.3",
    "category": "General Anesthesia & Postop",
    "subcategory": "PACU complications and management",
    "difficulty": "medium",
    "questionText": "A 62-year-old man with obesity and obstructive sleep apnea undergoes laparoscopic hernia repair under general anesthesia with sevoflurane and fentanyl; 1 mg hydromorphone was given in the PACU. Forty-five minutes later, he is somnolent but arousable, has shallow respirations, and repeatedly removes his facemask. On room air, vitals are BP 128/76 mmHg, HR 74/min, RR 6/min, SpO<sub>2</sub> 88%. Pupils are 2 mm and reactive; lungs are clear without crackles or wheeze. Capnography shows ETCO<sub>2</sub> 58 mmHg. An arterial blood gas on room air reveals pH 7.25, PaCO<sub>2</sub> 60 mmHg, PaO<sub>2</sub> 62 mmHg, HCO<sub>3</sub><sup>−</sup> 26 mEq/L.\n\nWhich of the following is the most appropriate next step to correct this patient’s hypoxemia?",
    "answers": [
      {
        "text": "Apply CPAP at 10 cm H2O with 40% oxygen",
        "isCorrect": false,
        "explanation": "CPAP improves atelectasis-related V/Q mismatch (elevated A–a gradient) but does not treat alveolar hypoventilation with hypercapnia; it may worsen CO<sub>2</sub> retention if hypoventilation persists."
      },
      {
        "text": "Order CT pulmonary angiography",
        "isCorrect": false,
        "explanation": "Pulmonary embolism typically causes an increased A–a gradient and often a low ETCO<sub>2</sub> from increased dead space; immediate imaging is not indicated in clear opioid-induced hypoventilation."
      },
      {
        "text": "Initiate therapeutic enoxaparin",
        "isCorrect": false,
        "explanation": "Empiric anticoagulation is inappropriate without clinical/imaging evidence of thromboembolism and could cause harm postoperatively."
      },
      {
        "text": "Administer naloxone 40 μg IV boluses, titrated to adequate ventilation",
        "isCorrect": true,
        "explanation": "Normal A–a gradient with hypercapnia, bradypnea, somnolence, and miosis indicates opioid-induced hypoventilation; titrated naloxone reverses respiratory depression while minimizing acute pain and sympathetic surge."
      },
      {
        "text": "Start furosemide 20 mg IV",
        "isCorrect": false,
        "explanation": "Pulmonary edema presents with crackles, pink frothy sputum, and chest radiograph changes; this patient has clear lungs and isolated hypoventilation."
      }
    ],
    "didactic": "Postoperative hypoxemia should be approached with a structured differential and targeted therapy. First, determine if the problem is **alveolar hypoventilation** or **impaired oxygenation (V/Q mismatch/shunt/diffusion)**. In this patient, the ABG on room air shows PaCO<sub>2</sub> 60 mmHg and PaO<sub>2</sub> 62 mmHg. Using the alveolar gas relationship (PAO<sub>2</sub> = FiO<sub>2</sub> × [P<sub>b</sub> − P<sub>H2O</sub>] − PaCO<sub>2</sub>/R), PAO<sub>2</sub> ≈ 75 mmHg on room air; thus, the A–a gradient is ~13 mmHg, which is normal for age. A normal A–a gradient with hypercapnia indicates **alveolar hypoventilation**, not intrinsic oxygenation failure.\n\nThe clinical picture (somnolence, RR 6/min, miosis, elevated ETCO<sub>2</sub>) points to **opioid-induced respiratory depression**. The most appropriate intervention is **titrated naloxone** (eg, 20–40 μg IV increments every 2–3 minutes) to restore ventilatory drive while avoiding abrupt pain, hypertension, and acute withdrawal. Provide airway support (jaw thrust, supplemental O<sub>2</sub>) during reversal.\n\nContrast with other PACU causes:\n\n- **Atelectasis (V/Q mismatch):** Increased A–a gradient; basilar crackles or decreased breath sounds; improves with recruitment, head-up positioning, CPAP/NIPPV, and incentive spirometry.\n- **Pulmonary embolism (dead space):** Sudden hypoxemia with increased A–a gradient, tachycardia, pleuritic pain; ETCO<sub>2</sub> often low due to increased dead space; evaluate with risk stratification and imaging when indicated.\n- **Pulmonary edema:** Crackles, pink frothy sputum, CXR interstitial/alveolar edema; treat with PEEP/CPAP; add diuretics if cardiogenic/volume overload; consider negative-pressure edema if recent upper airway obstruction.\n\nKey stepwise approach: assess ventilation (RR, ETCO<sub>2</sub>, PaCO<sub>2</sub>), calculate the **A–a gradient**, and then select therapy that directly addresses the mechanism. Here, reversing opioid effect corrects both hypercapnia and secondary hypoxemia.",
    "educationalObjective": "Evaluate hypoxemia using a stepwise differential (atelectasis, hypoventilation, PE, edema) and targeted treatments."
  },
  {
    "id": "Core.6.4.4",
    "category": "General Anesthesia & Postop",
    "subcategory": "PACU complications and management",
    "difficulty": "medium",
    "questionText": "A 72-year-old man is in the PACU 20 minutes after open reduction and internal fixation of a hip fracture under general anesthesia. He is thrashing, pulling at monitors, and not following commands. He is disoriented to place and time and cannot reliably report pain, but he grimaces and guards with light palpation near the incision. Vitals: BP 165/90, HR 110, RR 16, SpO<sub>2</sub> 98% on 3 L/min NC, nasal EtCO<sub>2</sub> 38 mmHg, T 37.0 °C. Fingerstick glucose is 110 mg/dL; pupils are equal/reactive; he moves all extremities to command when briefly calmed. Bladder scan shows 120 mL. History includes mild cognitive impairment and presbycusis; intraoperative medications included midazolam 2 mg, fentanyl 200 μg, and hydromorphone 0.6 mg. The nurse requests medication to “calm him down.” Which is the most appropriate next step?",
    "answers": [
      {
        "text": "Give haloperidol 5 mg IV and apply physical restraints",
        "isCorrect": false,
        "explanation": "Antipsychotics are reserved for severe agitation jeopardizing safety after reversible causes and pain are addressed. A 5 mg IV dose is excessive for an elderly patient; typical initial doses are 0.5–1 mg IV with QT monitoring."
      },
      {
        "text": "Start dexmedetomidine infusion 0.4 μg/kg/h for sedation",
        "isCorrect": false,
        "explanation": "Dexmedetomidine can be useful for refractory agitation with minimal respiratory depression, but initial management of emergence delirium prioritizes reorientation and analgesia. Starting a continuous infusion before addressing pain is premature."
      },
      {
        "text": "Provide calm reorientation (glasses/hearing aids, family presence), reduce stimuli, and treat suspected pain with low-dose IV fentanyl 25–50 μg",
        "isCorrect": true,
        "explanation": "This presentation is hyperactive emergence delirium likely exacerbated by undertreated pain. First-line management is nonpharmacologic reorientation and environmental optimization plus analgesia with small, titrated opioid doses while avoiding deliriogenic sedatives."
      },
      {
        "text": "Administer naloxone 0.4 mg IV to reverse opioid effect",
        "isCorrect": false,
        "explanation": "The patient is not hypoventilating or somnolent; naloxone may precipitate severe pain and worsen agitation. Undertreated pain is a common driver of delirium and should be addressed rather than antagonized."
      },
      {
        "text": "Administer midazolam 2 mg IV for agitation control",
        "isCorrect": false,
        "explanation": "Benzodiazepines are deliriogenic in older adults and often worsen delirium; they should be avoided unless treating benzodiazepine or alcohol withdrawal."
      }
    ],
    "didactic": "Emergence delirium is an acute disturbance of attention and awareness occurring shortly after anesthesia. In older adults, it commonly presents as **hyperactive** agitation (thrashing, pulling lines) or **hypoactive** inattention and somnolence. Risk factors include advanced age, baseline cognitive or sensory impairment, polypharmacy, benzodiazepines/anticholinergics, sleep disruption, hemodynamic or respiratory derangements, and **undertreated pain**.\n\nManagement is stepwise and prioritizes correction of reversible causes, nonpharmacologic measures, and targeted analgesia while minimizing deliriogenic drugs:\n\n- Ensure physiology is adequate: oxygenate/ventilate (SpO<sub>2</sub>/EtCO<sub>2</sub>), check glucose and temperature, assess hemodynamics, and exclude focal neurologic deficits and urinary retention.\n- Provide **calm reorientation** and environmental optimization: reduce noise/overhead pages, restore glasses/hearing aids, use clocks/calendars, and engage family or a familiar staff member. Avoid physical restraints when possible.\n- **Treat pain** with multimodal strategies (eg, acetaminophen, regional analgesia, low-dose, titrated IV opioids). Undertreated pain increases catecholamines and delirium risk; small opioid doses that improve comfort are less deliriogenic than persistent severe pain.\n- **Avoid benzodiazepines and anticholinergics** unless specifically indicated (eg, alcohol withdrawal). Minimize high-dose opioids and consider nonopioid adjuncts.\n- If agitation threatens safety despite the above, consider short-acting agents: low-dose **haloperidol** (0.5–1 mg IV; monitor QTc) or **dexmedetomidine** (eg, 0.2–0.7 μg/kg/h; watch for bradycardia/hypotension) because they provide control with minimal respiratory depression. Brief propofol boluses may be used in closely monitored settings.\n\nHypoactive delirium requires the same diagnostic approach but emphasizes avoiding sedatives, optimizing analgesia, early mobilization, and frequent reorientation. Early recognition with reorientation and pain control, while minimizing deliriogenic drugs, reduces complications and length of stay.",
    "educationalObjective": "Identify emergence delirium or hypoactive delirium and manage with reorientation, pain control, and minimal deliriogenic drugs."
  },
  {
    "id": "Core.6.4.5",
    "category": "General Anesthesia & Postop",
    "subcategory": "PACU complications and management",
    "difficulty": "medium",
    "questionText": "A 58-year-old man (BMI 38) with obstructive sleep apnea (uses home CPAP) and CKD stage 3 (creatinine 1.8 mg/dL) undergoes laparoscopic ventral hernia repair under general anesthesia. In the PACU 30 minutes postextubation, he reports pain 8/10. He is arousable to voice but drowsy. Vitals: BP 145/82 mmHg, HR 88/min, RR 10/min with shallow breaths. On 3 L/min nasal cannula, SpO<sub>2</sub> is 97%. Nasal capnography shows ETCO<sub>2</sub> 52 mmHg. He has received fentanyl 200 μg intraoperatively and hydromorphone 1.5 mg IV in PACU.\n\nThe team plans to start patient-controlled analgesia (PCA). Which of the following is the most appropriate next step to safely initiate PCA-based multimodal analgesia for this patient in the PACU?",
    "answers": [
      {
        "text": "Use morphine PCA with a basal infusion only (1 mg/h) to provide steady analgesia overnight; schedule acetaminophen and add low-dose diazepam for muscle spasm.",
        "isCorrect": false,
        "explanation": "Basal-only PCA is unsafe in opioid-naïve/OSA patients, and benzodiazepines with opioids increase respiratory depression risk."
      },
      {
        "text": "Start hydromorphone PCA with 0.2 mg demand dose plus a 10 μg/kg/h basal infusion; monitor with pulse oximetry only; avoid acetaminophen due to hepatotoxicity risk.",
        "isCorrect": false,
        "explanation": "Basal infusions increase respiratory depression risk in opioid-naïve or OSA patients. Pulse oximetry alone may miss hypoventilation on O<sub>2</sub>, and acetaminophen is safe in the absence of significant liver disease when dosed appropriately."
      },
      {
        "text": "Increase nasal O<sub>2</sub> to maintain SpO<sub>2</sub> >98% and continue nurse-administered IV opioid boluses as needed; avoid capnography due to false alarms.",
        "isCorrect": false,
        "explanation": "Increasing O<sub>2</sub> may delay detection of hypoventilation. Nurse-administered boluses have greater variability and oversedation risk; capnography detects early ventilatory depression."
      },
      {
        "text": "Defer PCA due to OSA; give gabapentin 600 mg and ketorolac 30 mg IV for multimodal analgesia; monitor with pulse oximetry.",
        "isCorrect": false,
        "explanation": "Gabapentinoids can worsen sedation and respiratory depression when combined with opioids, and ketorolac is inappropriate with CKD. PCA can be used safely in OSA if configured and monitored correctly."
      },
      {
        "text": "Start hydromorphone PCA with 0.2 mg demand dose, 6-min lockout, no basal infusion; schedule IV acetaminophen; continue supplemental O<sub>2</sub> with continuous capnography monitoring.",
        "isCorrect": true,
        "explanation": "In an opioid-naïve patient with OSA and hypercapnia, initiate PCA without a basal infusion, use conservative demand dosing/lockout, add nonopioid adjuncts (eg, acetaminophen), and monitor ventilation with capnography because supplemental O<sub>2</sub> can mask hypoventilation."
      }
    ],
    "didactic": "Effective and safe PACU analgesia combines opioid-sparing multimodal therapy with vigilant respiratory monitoring. Patients with **OSA, obesity, or opioid naïvety** are at increased risk of opioid-induced ventilatory impairment. In these patients, avoid **basal (background) infusions** on PCA because they increase cumulative opioid exposure and blunt arousal responses. Instead, use a conservative demand dose (eg, hydromorphone 0.1–0.2 mg with a 6–10 min lockout) and no basal infusion; set reasonable hourly limits and reassess sedation frequently.\n\nSupplemental O<sub>2</sub> improves saturation but may **mask hypoventilation**; sedation and hypercapnia typically precede desaturation. Continuous **capnography** (eg, nasal ETCO<sub>2</sub>) detects early hypoventilation/apnea more reliably than pulse oximetry alone in patients receiving O<sub>2</sub>. PACU protocols should include sedation scoring before opioid dosing, hold parameters (eg, RR <8/min, ETCO<sub>2</sub> rising >50–55 mmHg or waveform apnea), and ready access to **naloxone**.\n\nImplement **multimodal analgesia** to reduce opioid needs:\n- **Acetaminophen** (IV or PO) on a scheduled basis is safe without significant liver disease.\n- **NSAIDs** can be effective but should be avoided or used cautiously in CKD, bleeding risk, or when surgical concerns exist.\n- **Gabapentinoids** may increase sedation and respiratory depression when combined with opioids, particularly in OSA; avoid routine PACU initiation.\n- Consider **regional techniques** (eg, TAP block) or low-dose **ketamine** infusion in appropriate patients to spare opioids.\n\nFor OSA, resume **CPAP** when sleeping as soon as feasible and maintain continuous oximetry and capnography while titrating analgesia. This approach—no basal PCA, conservative demand dosing, nonopioid adjuncts, and ventilatory monitoring—optimizes pain control while minimizing oversedation and respiratory compromise in high-risk PACU patients.",
    "educationalObjective": "Initiate multimodal analgesia and PCA safely in PACU, including monitoring for oversedation."
  },
  {
    "id": "Core.6.4.6",
    "category": "General Anesthesia & Postop",
    "subcategory": "PACU complications and management",
    "difficulty": "medium",
    "questionText": "A 72-year-old man with hypertension, diabetes, and HFrEF (EF 35%) undergoes total hip arthroplasty with combined spinal–epidural anesthesia and light sedation. In the PACU, 30 minutes after starting an epidural infusion of bupivacaine 0.1% with fentanyl, he becomes lightheaded. Vitals: BP 78/42 mmHg, HR 56/min, RR 14/min, SpO<sub>2</sub> 97% on 2 L/min O<sub>2</sub>. Exam shows warm, flushed extremities with brisk capillary refill, clear lungs, regular heart sounds, and a sensory block to cold at T3 with mild motor weakness in both legs. Surgical dressings are dry; EBL 300 mL intraop; he received 1.5 L LR intraop and a 500 mL LR bolus in PACU with minimal BP change. ECG is unchanged from baseline without ischemia.\n\nWhich is the most appropriate next step to treat this hypotension?",
    "answers": [
      {
        "text": "Start a dobutamine infusion at 2–5 μg/kg/min",
        "isCorrect": false,
        "explanation": "Dobutamine treats cardiogenic shock with low contractility; this patient’s warm extremities, neuraxial level, and lack of pulmonary congestion suggest vasodilation rather than pump failure."
      },
      {
        "text": "Give phenylephrine boluses or start a phenylephrine infusion",
        "isCorrect": false,
        "explanation": "Pure α-agonism may worsen bradycardia and decrease cardiac output by increasing afterload, which is undesirable in HFrEF and in neuraxial-induced bradycardia."
      },
      {
        "text": "Administer an additional 1 L bolus of balanced crystalloid",
        "isCorrect": false,
        "explanation": "Large-volume fluid is unlikely to correct neuraxial-induced vasodilation after an ineffective initial bolus and risks fluid overload in HFrEF without addressing low SVR."
      },
      {
        "text": "Administer atropine 0.5 mg followed by ephedrine 5–10 mg IV",
        "isCorrect": false,
        "explanation": "Mild bradycardia is not the primary driver of hypotension; ephedrine’s β-effects may be blunted by β-blockade and it is less reliable/titratable than norepinephrine for significant vasodilation."
      },
      {
        "text": "Start a norepinephrine infusion at 0.02–0.05 μg/kg/min",
        "isCorrect": true,
        "explanation": "Norepinephrine is first-line for vasodilatory hypotension from high neuraxial sympathectomy, restoring SVR while providing modest β<sub>1</sub> support; it is titratable and preferable in bradycardic patients with reduced EF."
      }
    ],
    "didactic": "Postoperative hypotension should be approached by identifying the dominant physiology in MAP = CO × SVR. Common PACU etiologies include hypovolemia (low preload), vasodilation (low SVR), and cardiogenic shock (low CO). Clinical context and bedside cues help distinguish these:\n\n- Hypovolemia: tachycardia, cool clammy skin, narrow pulse pressure, flat neck veins, orthostasis, and improvement with small fluid boluses.\n- Vasodilation (eg, neuraxial sympathectomy, residual anesthetics, sepsis, anaphylaxis): warm/flushed extremities, brisk capillary refill, often normal or high CO with low SVR, and bradycardia if high sympathetic block or concurrent β-blockade.\n- Cardiogenic: cool extremities, pulmonary edema, elevated JVP, new murmur, ischemic ECG changes, and low urine output despite adequate preload.\n\nHigh neuraxial blockade (eg, epidural local anesthetic to T3–T4) causes venodilation and decreased SVR via sympathetic blockade, often accompanied by relative bradycardia from unopposed vagal tone. A small crystalloid bolus is reasonable initially; however, if hypotension persists or the patient has limited cardiac reserve (HFrEF), escalating fluids risks pulmonary edema and does not correct the primary problem of low SVR. **Norepinephrine** is the preferred vasoactive agent in significant vasodilatory hypotension because it provides strong α-adrenergic vasoconstriction to restore SVR with modest β<sub>1</sub> support to maintain CO and heart rate stability, and it is easily titrated.\n\nIn contrast, **phenylephrine** (pure α-agonist) may worsen bradycardia and reduce stroke volume by increasing afterload, particularly problematic in HFrEF. **Ephedrine** relies on endogenous catecholamine release; its β-effects are blunted by β-blockade and it is less predictable for sustained hypotension. **Dobutamine** is reserved for cardiogenic physiology with low contractility. Identifying a warm, well-perfused patient with a high neuraxial level and poor response to initial fluid should prompt early norepinephrine rather than additional fluids or pure α-agonists.",
    "educationalObjective": "Manage hypotension by distinguishing hypovolemia, vasodilation, and cardiogenic causes and giving appropriate fluids or vasoactives."
  },
  {
    "id": "Core.6.4.7",
    "category": "General Anesthesia & Postop",
    "subcategory": "PACU complications and management",
    "difficulty": "easy",
    "questionText": "A 45-year-old man is shivering vigorously 20 minutes after arrival to the PACU following an uncomplicated laparoscopic inguinal hernia repair under sevoflurane anesthesia. He received fentanyl 150 µg intraoperatively and reports pain 2/10. Vital signs: T 35.1°C, BP 94/58 mmHg, HR 106/min, RR 16/min, SpO<sub>2</sub> 98% on 6 L/min via facemask. The PACU nurse has applied a forced‑air warming blanket, but the patient continues to shiver and appears uncomfortable. Which of the following is the most appropriate medication to reduce this patient’s postoperative shivering?",
    "answers": [
      {
        "text": "Hydromorphone 0.2 mg IV",
        "isCorrect": false,
        "explanation": "Although an effective analgesic, hydromorphone does not specifically treat thermoregulatory shivering and may increase sedation and respiratory depression without resolving the shivering."
      },
      {
        "text": "Ondansetron 4 mg IV",
        "isCorrect": false,
        "explanation": "Ondansetron has modest anti-shivering effects in some studies but is inferior to meperidine and is not considered first-line therapy for significant postoperative shivering."
      },
      {
        "text": "Meperidine 12.5 mg IV",
        "isCorrect": true,
        "explanation": "Meperidine is first-line for postoperative shivering; small IV doses (12.5–25 mg) effectively reduce the shivering threshold via κ- and α<sub>2</sub>-mediated mechanisms with minimal hemodynamic effect at low doses."
      },
      {
        "text": "Clonidine 75 µg IV",
        "isCorrect": false,
        "explanation": "Clonidine can reduce shivering via α<sub>2</sub>-agonism but commonly causes hypotension and bradycardia; with BP 94/58 mmHg, it is less appropriate than meperidine."
      },
      {
        "text": "Propofol 30 mg IV",
        "isCorrect": false,
        "explanation": "Propofol may transiently suppress motor activity but does not address thermoregulatory shivering and risks worsening hypotension and oversedation in the PACU."
      }
    ],
    "didactic": "Postanesthesia shivering is common and typically driven by redistribution hypothermia and a widened interthreshold range caused by volatile anesthetics and opioids. Vigorous shivering increases metabolic rate and O<sub>2</sub> consumption by 100–400%, elevates CO<sub>2</sub> production, and triggers catecholamine release—potentially precipitating myocardial ischemia and hypoxemia in vulnerable patients. Management aims to restore thermoregulatory balance and attenuate the shivering response.\n\nInitial measures include active warming (eg, forced‑air warming, warmed IV fluids, higher ambient temperature) and supplemental O<sub>2</sub>. When shivering is persistent or severe, pharmacologic therapy is indicated. **Meperidine** is the most effective agent; low IV doses (12.5–25 mg) reliably reduce the shivering threshold through κ-opioid and α<sub>2</sub>-adrenergic activity. Advantages include rapid onset and generally minimal hemodynamic change at small doses. Important cautions are respiratory depression, nausea, and avoidance in patients with MAOI use or significant renal impairment due to risk of normeperidine accumulation and seizures; monitor for serotonergic drug interactions.\n\n**α<sub>2</sub>-agonists** (clonidine, dexmedetomidine) also blunt shivering but can cause hypotension and bradycardia, which may be problematic in PACU patients with marginal blood pressure. Other agents with variable or adjunctive benefit include tramadol, ketamine, magnesium, and ondansetron; these are typically considered when meperidine or α<sub>2</sub>-agonists are contraindicated.\n\nClinical differentiation from other causes of motor activity is essential. Unlike malignant hyperthermia (hypercarbia, hyperthermia, rigidity) or drug-induced rigors, postoperative shivering usually occurs with hypothermia and normal ventilation parameters. For most patients, the optimal approach is combined therapy: continue **active warming** and administer a targeted anti-shivering drug—most commonly meperidine—to promptly reduce O<sub>2</sub> demand and improve comfort.",
    "educationalObjective": "Recognize and treat shivering with active warming and drugs such as meperidine or clonidine."
  },
  {
    "id": "Core.6.4.8",
    "category": "General Anesthesia & Postop",
    "subcategory": "PACU complications and management",
    "difficulty": "hard",
    "questionText": "A 32-year-old woman with Graves disease who missed several doses of methimazole undergoes urgent laparoscopic cholecystectomy. Induction is with propofol and succinylcholine; maintenance uses sevoflurane. Intraoperatively, ETCO<sub>2</sub> remains 34–38 mmHg without unexplained acidosis or rigidity; temperature at case end is 37.9°C.\n\nForty-five minutes in the PACU, she becomes agitated and delirious with profuse diaphoresis. Vital signs: T 40.3°C, HR 170/min (irregularly irregular), BP 168/78 mmHg, SpO₂ 98% on 2 L O<sub>2</sub>. Fine tremor is noted. ECG shows atrial fibrillation with RVR. ABG: pH 7.47, PaCO<sub>2</sub> 31 mmHg, HCO₃⁻ 22 mEq/L. Labs: K 3.1 mEq/L, CK 110 U/L, glucose 215 mg/dL; urine is clear. She takes no serotonergic or antipsychotic medications. Which of the following is the most appropriate next step in management?",
    "answers": [
      {
        "text": "Initiate malignant hyperthermia protocol with 100% O<sub>2</sub>, active cooling, and dantrolene 2.5 mg/kg IV",
        "isCorrect": false,
        "explanation": "Malignant hyperthermia typically presents with rapidly rising ETCO<sub>2</sub>, generalized or masseter rigidity, mixed acidosis, hyperkalemia, and markedly elevated CK/myoglobinuria. This patient’s normal intraoperative ETCO<sub>2</sub>, absence of rigidity, normal CK, and atrial fibrillation point away from MH."
      },
      {
        "text": "Treat neuroleptic malignant syndrome with bromocriptine and dantrolene plus external cooling",
        "isCorrect": false,
        "explanation": "NMS follows dopamine antagonist exposure over days, with lead-pipe rigidity and very high CK. This patient lacks the exposure history and characteristic rigidity/CK elevation."
      },
      {
        "text": "Initiate thyroid storm protocol: titrated esmolol infusion and PTU load, then sodium iodide (given ≥1 h later) and hydrocortisone",
        "isCorrect": true,
        "explanation": "This is classic postoperative thyroid storm precipitated by stress and medication nonadherence, with hyperthermia, AF with RVR, tremor, and normal/low PaCO<sub>2</sub>. Disease-specific therapy includes β-blockade, a thionamide (PTU preferred acutely), iodide after thionamide, and glucocorticoids."
      },
      {
        "text": "Treat serotonin syndrome with benzodiazepines and cyproheptadine after stopping serotonergic agents",
        "isCorrect": false,
        "explanation": "Serotonin syndrome requires serotonergic exposure and features inducible/spontaneous clonus and hyperreflexia with ocular clonus. These exposures and neuromuscular findings are absent; AF with RVR and thyrotoxic history suggest thyroid storm."
      },
      {
        "text": "Begin empiric broad-spectrum antibiotics and 30 mL/kg crystalloid for presumed septic hyperthermia",
        "isCorrect": false,
        "explanation": "Sepsis may cause fever and tachycardia but typically presents with hypotension, altered perfusion, and does not explain AF with RVR, fine tremor, and the thyrotoxic context. Antibiotics and fluids alone do not address life-threatening thyrotoxicosis."
      }
    ],
    "didactic": "Thyroid storm is an endocrine emergency precipitated by surgery/anesthesia, infection, trauma, or withdrawal of antithyroid medications. It presents with **hyperthermia**, severe **tachyarrhythmias** (often atrial fibrillation with RVR), **CNS agitation/delirium**, **diaphoresis**, **tremor**, gastrointestinal symptoms, and potential high-output heart failure. In contrast to malignant hyperthermia (MH), **ETCO<sub>2</sub> and PaCO<sub>2</sub> are not elevated** and muscle rigidity is absent. Labs may show **hyperglycemia**, mild leukocytosis, and sometimes mild lactic acidosis; **CK and K** are usually not markedly elevated.\n\nDifferentiate from MH, which is triggered by volatile anesthetics or succinylcholine and classically shows rapidly rising ETCO<sub>2</sub>, **generalized rigidity**, **hyperkalemia**, **acidosis**, and **marked CK/myoglobinuria**. MH treatment is disease-specific with **dantrolene**, discontinuation of triggers, 100% O<sub>2</sub>, aggressive cooling, and management of hyperkalemia; calcium channel blockers should be avoided with dantrolene.\n\nManagement of thyroid storm must be **prompt and multipronged**:\n- **β-blockade**: Esmolol infusion (rapidly titratable) or propranolol to control adrenergic effects and rate in AF.\n- **Thionamide**: PTU (eg, 500–1000 mg load, then 250 mg q4h) preferred acutely because it also inhibits peripheral T<sub>4</sub>→T<sub>3</sub> conversion; methimazole if PTU unavailable or contraindicated.\n- **Iodine**: Give sodium iodide or SSKI **at least 1 hour after** thionamide to block new hormone release (Wolff–Chaikoff effect).\n- **Glucocorticoids**: Hydrocortisone (eg, 100 mg IV q8h) to reduce T<sub>4</sub>→T<sub>3</sub> conversion and treat relative adrenal insufficiency.\n- Supportive care: Active cooling, IV fluids, electrolyte/glucose management, and treat precipitants.\n\nRecognizing the pattern—postoperative hyperthermia with AF, tremor, diaphoresis, normal/low PaCO<sub>2</sub>, and normal CK—in a patient with hyperthyroidism should trigger the **thyroid storm protocol**, not MH management.",
    "educationalObjective": "Recognize postoperative malignant hyperthermia or thyroid storm and initiate disease-specific protocols promptly."
  },
  {
    "id": "Core.6.4.9",
    "category": "General Anesthesia & Postop",
    "subcategory": "PACU complications and management",
    "difficulty": "medium",
    "questionText": "A 45-year-old woman with obesity (BMI 38) and obstructive sleep apnea undergoes laparoscopic cholecystectomy under general anesthesia with sevoflurane and fentanyl. She received dexamethasone 8 mg IV at induction and ondansetron 4 mg IV at closure. In the PACU she develops severe nausea and emesis. Metoclopramide 10 mg IV is administered with minimal improvement after 15 minutes. She is awake, hemodynamically stable, and breathing comfortably on 2 L/min O<sub>2</sub> by nasal cannula; QTc is 430 ms on the monitor.\n\nWhich is the most appropriate next medication to treat her PONV now?",
    "answers": [
      {
        "text": "Haloperidol 1 mg IV",
        "isCorrect": true,
        "explanation": "After failure of prophylaxis (5‑HT3 antagonist + corticosteroid) and initial rescue with a dopamine partial agonist/prokinetic, a different-class rescue antiemetic with rapid onset is indicated. Low-dose haloperidol (0.5–1 mg IV) is effective for refractory PONV, with minimal sedation and acceptable QT risk at this dose in a patient with normal QTc."
      },
      {
        "text": "Ondansetron 4 mg IV (repeat dose)",
        "isCorrect": false,
        "explanation": "Repeating the same 5‑HT3 antagonist used for prophylaxis provides limited incremental benefit in early rescue; guidelines recommend switching to a different pharmacologic class when prophylaxis fails."
      },
      {
        "text": "Scopolamine transdermal patch",
        "isCorrect": false,
        "explanation": "Scopolamine has a delayed onset (several hours) and is better for prophylaxis; it is not useful for rapid relief of established PONV in the PACU."
      },
      {
        "text": "Propofol 20 mg IV bolus",
        "isCorrect": false,
        "explanation": "Small propofol boluses can transiently reduce nausea but provide short-lived relief and increase sedation/airway risk, which is undesirable in this OSA patient; targeted antiemetic therapy from a new class is preferred."
      },
      {
        "text": "Aprepitant 40 mg PO",
        "isCorrect": false,
        "explanation": "NK1 antagonists are effective prophylactics when given preoperatively but have delayed onset and limited utility for immediate PACU rescue of active PONV."
      }
    ],
    "didactic": "Effective PACU management of postoperative nausea and vomiting (PONV) emphasizes rescue therapy from a different pharmacologic class than the agents used for prophylaxis. Mechanistically distinct options target complementary pathways involved in emesis:\n\n- 5‑HT3 antagonists: ondansetron, palonosetron\n- Dopamine D2 antagonists: haloperidol, droperidol, metoclopramide (also prokinetic)\n- Antihistamines: dimenhydrinate, promethazine\n- Anticholinergics: scopolamine (transdermal)\n- NK1 antagonists: aprepitant/fosaprepitant\n- Corticosteroids: dexamethasone\n\nWhen prophylaxis with a 5‑HT3 antagonist and dexamethasone fails, rescue should use a different class. If initial rescue with metoclopramide is ineffective, low-dose **haloperidol 0.5–1 mg IV** is an evidence-based, rapid-onset option for refractory PONV. Compared with sedating antihistamines (eg, promethazine), haloperidol provides effective antiemesis with minimal sedation at these doses—valuable in patients with obstructive sleep apnea or those at risk for airway obstruction. Both haloperidol and droperidol can prolong QT, but the absolute risk at low antiemetic doses is small; obtain or review QTc when feasible and avoid in marked QT prolongation, torsades history, or concomitant QT-prolonging drugs.\n\nScopolamine is useful for prophylaxis (eg, placed preoperatively in high-risk patients) but has a delayed onset (≥2–4 h), limiting utility for acute PACU rescue. NK1 antagonists are similarly more effective when administered before incision and do not provide immediate relief. Repeating ondansetron shortly after prophylaxis offers little additional benefit because the same pathway has already been saturated. Propofol boluses can transiently suppress nausea but are short-lived and may worsen airway obstruction or hypotension.\n\nIn summary, for active PONV after multimodal prophylaxis, choose a different-class agent with rapid onset; low-dose IV **haloperidol** is a strong rescue choice in refractory cases when QTc is acceptable and there is no contraindication (eg, Parkinson disease).",
    "educationalObjective": "Treat PONV in PACU with agents from a different class than prophylaxis and consider haloperidol in refractory cases."
  },
  {
    "id": "Core.6.4.10",
    "category": "General Anesthesia & Postop",
    "subcategory": "PACU complications and management",
    "difficulty": "easy",
    "questionText": "A 55-year-old man (BMI 38) with known OSA using home CPAP undergoes laparoscopic cholecystectomy under general anesthesia with sevoflurane and fentanyl 150 μg. He is extubated awake and arrives to the PACU on 2 L/min nasal cannula. Ten minutes later, SpO₂ falls to 88% with loud snoring and paradoxical chest–abdominal motion. He arouses to voice, follows commands, and transiently improves, but obstructs again when drowsy. You apply a head tilt–chin lift, perform a jaw thrust, place an oropharyngeal airway, and switch to a tight facemask at 10 L/min O<sub>2</sub>. Despite these maneuvers, he continues to obstruct intermittently with SpO₂ 90–92%.\n\nWhich of the following is the most appropriate next step to relieve his airway obstruction?",
    "answers": [
      {
        "text": "Initiate CPAP 8–10 cm H₂O via facemask with supplemental O<sub>2</sub>",
        "isCorrect": true,
        "explanation": "Positive pressure splints the pharynx open, treating persistent upper airway collapse in OSA despite repositioning and oral airway. It addresses the mechanism of obstruction rather than only increasing FiO₂."
      },
      {
        "text": "Administer naloxone 0.4 mg IV bolus",
        "isCorrect": false,
        "explanation": "Opioid reversal may be considered for clear opioid-induced hypoventilation, but this patient has obstructive signs (snoring, paradoxical motion) and is arousable; a large bolus risks severe pain and sympathetic surge without resolving airway collapse."
      },
      {
        "text": "Proceed with endotracheal intubation",
        "isCorrect": false,
        "explanation": "Definitive airway is not yet indicated; noninvasive CPAP is the appropriate next escalation after positioning and oral/nasal airways in an arousable OSA patient."
      },
      {
        "text": "Administer flumazenil 0.5 mg IV",
        "isCorrect": false,
        "explanation": "There is no clear benzodiazepine effect causing hypoventilation, and flumazenil will not treat mechanical airway obstruction; it also carries seizure risk in predisposed patients."
      },
      {
        "text": "Increase nasal cannula flow to 6 L/min",
        "isCorrect": false,
        "explanation": "Raising O<sub>2</sub> flow increases FiO₂ but does not relieve mechanical upper airway obstruction; hypoxemia will persist when the airway remains occluded."
      }
    ],
    "didactic": "Postanesthesia upper airway obstruction is common due to residual anesthetics, opioids, and loss of pharyngeal dilator muscle tone—effects that are accentuated in patients with **OSA** and obesity. Typical findings include loud snoring, paradoxical chest–abdominal motion, and desaturation that improves with arousal and worsens when drowsy. The primary problem is mechanical collapse of the pharynx, not inadequate FiO₂.\n\nInitial management focuses on relieving the obstruction:\n- **Repositioning**: head tilt–chin lift and **jaw thrust** advance the mandible and tongue off the posterior pharyngeal wall.\n- **Airway adjuncts**: an **oropharyngeal** or **nasopharyngeal airway** prevents soft-tissue collapse; suction secretions if present.\n- **Supplemental O<sub>2</sub>** improves reserve but does not correct the obstruction.\n\nIf obstruction persists despite proper positioning and an oral/nasal airway, the next escalation is **continuous positive airway pressure (CPAP) 5–10 cm H₂O** via a tight-fitting facemask (or the patient’s home device). CPAP provides pneumatic splinting of the upper airway, increases functional residual capacity, and improves oxygenation. It is particularly effective in OSA, where recurrent pharyngeal collapse is the dominant mechanism.\n\nPharmacologic reversal is reserved for clear ventilatory depression from sedatives/opiates. For suspected opioid-induced respiratory depression, **titrate naloxone in small doses** (eg, 40 μg IV increments) to avoid abrupt pain and sympathetic surge. **Flumazenil** is appropriate only for isolated benzodiazepine excess and is contraindicated in patients at risk for seizures. Reintubation is indicated if noninvasive measures fail, mental status worsens, or ventilation/oxygenation cannot be maintained.\n\nIn summary, treat PACU upper airway obstruction stepwise: **reposition → jaw thrust → oral/nasal airway → CPAP**. Escalate to definitive airway if noninvasive strategies do not promptly restore adequate ventilation and oxygenation.",
    "educationalObjective": "Treat upper airway obstruction in PACU with repositioning, jaw thrust, oral/nasal airway, and escalate to CPAP if needed."
  },
  {
    "id": "Core.6.5.1",
    "category": "General Anesthesia & Postop",
    "subcategory": "PONV prevention and treatment",
    "difficulty": "medium",
    "questionText": "A 34-year-old woman (BMI 26 kg/m²) presents for outpatient laparoscopic cholecystectomy under volatile-based general anesthesia. She is a nonsmoker with a history of severe motion sickness and prior postoperative nausea/vomiting. Postoperative opioids are anticipated. Baseline ECG shows normal sinus rhythm with QTc 420 ms. Pregnancy test is negative; she has no diabetes or Parkinson disease. The case will start in 20 minutes; the patient has taken no preoperative medications and remains NPO. Oral medications cannot be administered now, and IV NK<sub>1</sub> antagonists are not available.\n\nWhich prophylactic regimen and timing is most appropriate to minimize this patient’s PONV risk?",
    "answers": [
      {
        "text": "Aprepitant 40 mg PO now; ondansetron 4 mg IV at the end; dexamethasone 8 mg IV after induction",
        "isCorrect": false,
        "explanation": "Aprepitant requires oral administration 1–3 hours preoperatively; this patient remains NPO with insufficient time, and IV NK1 antagonists are not available."
      },
      {
        "text": "Dexamethasone 8 mg IV after induction; ondansetron 4 mg IV and droperidol 0.625 mg IV near the end of surgery",
        "isCorrect": true,
        "explanation": "Multimodal prophylaxis using different classes is recommended in moderate–high risk patients: steroid at induction plus a 5-HT3 antagonist and a dopamine antagonist (droperidol) given near the end of surgery."
      },
      {
        "text": "Ondansetron 4 mg IV after induction; dexamethasone 4 mg IV at the end of surgery; promethazine 12.5 mg IV at the end",
        "isCorrect": false,
        "explanation": "5-HT3 antagonists are more effective when given near the end of surgery, and dexamethasone is best at induction. Promethazine (H1 blocker) is sedating and not preferred as part of first-line multimodal prophylaxis."
      },
      {
        "text": "Scopolamine transdermal patch now; ondansetron 4 mg IV at the end; dexamethasone 4 mg IV after induction",
        "isCorrect": false,
        "explanation": "Scopolamine patch requires several hours for optimal effect; placing it immediately before surgery offers limited benefit in this time frame."
      },
      {
        "text": "Ondansetron 4 mg IV and granisetron 1 mg IV near the end; dexamethasone 4 mg IV after induction",
        "isCorrect": false,
        "explanation": "Using two 5-HT3 antagonists provides little additional benefit versus combining different classes; a dopamine antagonist (eg, droperidol or haloperidol) should be used instead of duplicating 5-HT3 therapy."
      }
    ],
    "didactic": "This patient has multiple Apfel risk factors for PONV (female sex, nonsmoker, history of PONV/motion sickness, and anticipated postoperative opioids), placing her at moderate–high risk. In such patients, guidelines support **multimodal prophylaxis** with agents from different classes to target distinct emetogenic pathways.\n\n- **Dexamethasone (4–8 mg IV)** is most effective when given at induction; its onset is delayed relative to other agents.\n- **5-HT3 antagonists** (eg, ondansetron 4 mg IV) are optimally administered **near the end of surgery** to cover the high-risk emergence/early postoperative period.\n- **Dopamine (D2) antagonists** such as **droperidol 0.625–1.25 mg IV** (or haloperidol 0.5–1 mg IV) given **near the end of surgery** provide additive benefit when combined with a steroid and a 5-HT3 antagonist.\n\nThe selected regimen (dexamethasone at induction; ondansetron + droperidol near case end) aligns with recommended timing and class diversification. Low-dose droperidol is effective and, with a normal QTc and standard monitoring, has a favorable safety profile despite the black box warning; avoid in prolonged QT or significant arrhythmia risk. \n\nCommon pitfalls include: \n- Administering a 5-HT3 antagonist at induction (reduced efficacy) \n- Duplicating the same class (eg, ondansetron + granisetron) rather than combining different mechanisms \n- Using agents whose onset doesn’t match the clinical context (eg, scopolamine patch requires 2–4 hours for effect; ideally applied the night before) \n- Relying on oral NK1 antagonists (eg, aprepitant) when timing and NPO status preclude adequate preoperative dosing; IV fosaprepitant is an alternative if available.\n\nFor rescue therapy, choose a drug from a **different class** than those used for prophylaxis to avoid pharmacologic redundancy.",
    "educationalObjective": "Administer multimodal prophylaxis by combining drug classes (5-HT3 antagonist, dexamethasone, droperidol) in moderate–high risk."
  },
  {
    "id": "Core.6.5.2",
    "category": "General Anesthesia & Postop",
    "subcategory": "PONV prevention and treatment",
    "difficulty": "medium",
    "questionText": "A 5-year-old (20 kg) boy is scheduled for ambulatory bilateral strabismus repair under general anesthesia with sevoflurane. He had no prior anesthetics. You plan opioid-sparing analgesia and adequate IV hydration. Given the high risk of postoperative vomiting with this procedure in children, which prophylaxis regimen is most appropriate to minimize postoperative nausea and vomiting (PONV)?",
    "answers": [
      {
        "text": "Transdermal scopolamine patch placed preoperatively",
        "isCorrect": false,
        "explanation": "Scopolamine has delayed onset and limited pediatric use with anticholinergic adverse effects; it is not first-line PONV prophylaxis in young children."
      },
      {
        "text": "Dexamethasone 0.6 mg/kg near the end of surgery as single-agent prophylaxis",
        "isCorrect": false,
        "explanation": "High-dose dexamethasone with late administration is suboptimal; onset is delayed, and monotherapy is inferior to combination therapy in high-risk children."
      },
      {
        "text": "Metoclopramide 0.2 mg/kg after induction as single-agent prophylaxis",
        "isCorrect": false,
        "explanation": "Metoclopramide provides limited antiemetic efficacy and is not recommended as sole prophylaxis in high-risk pediatric cases; extrapyramidal effects are a concern."
      },
      {
        "text": "Dexamethasone 0.15 mg/kg after induction and ondansetron 0.1 mg/kg near the end of surgery",
        "isCorrect": true,
        "explanation": "Combining agents with different mechanisms is recommended for high-risk pediatric cases (eg, strabismus). Dexamethasone is best given early (after induction) for onset by emergence, and ondansetron is most effective when dosed near the end of surgery."
      },
      {
        "text": "Ondansetron 0.1 mg/kg after induction as single-agent prophylaxis",
        "isCorrect": false,
        "explanation": "Single-agent prophylaxis is inadequate for high-risk pediatric procedures and ondansetron is optimally timed near the end of surgery, not at induction."
      }
    ],
    "didactic": "Children undergoing high-risk procedures such as **strabismus repair** or **tonsillectomy** have a markedly increased incidence of PONV, particularly when age ≥3 years and volatile anesthetics/opioids are used. In these settings, **multimodal prophylaxis** is indicated. The most evidence-based pediatric regimen pairs a **5-HT3 antagonist** with a **corticosteroid** administered with appropriate timing.\n\n- **Dexamethasone** 0.15 mg/kg (max 8–10 mg) should be given early (eg, after induction). Its antiemetic onset requires ≥30–60 minutes; early dosing ensures efficacy by emergence, and it also improves pain and decreases swelling.\n- **Ondansetron** 0.1 mg/kg (max 4 mg) should be given near the end of surgery for peak effect during emergence and early recovery.\n\nThis combination targets different pathways (central 5-HT3 receptor blockade plus corticosteroid modulation of prostaglandins/neurokinin pathways) and outperforms either agent alone in pediatric high-risk procedures. Additional strategy layers further reduce risk: avoid **nitrous oxide** when feasible, minimize **volatile exposure** or consider **propofol TIVA**, limit **opioids** with nonopioid analgesics, and ensure adequate **IV hydration**.\n\nCommon pitfalls include mistiming antiemetics (eg, giving ondansetron at induction) and relying on monotherapy despite high risk. Alternatives such as **scopolamine** have delayed onset and limited pediatric applicability; **metoclopramide** has modest efficacy and extrapyramidal risk; **droperidol** is effective but less commonly used in children due to regulatory warnings. For **tonsillectomy**, dexamethasone at typical antiemetic doses (0.15 mg/kg) reduces PONV and pain without a clinically significant increase in bleeding in most analyses.\n\nTherefore, for a child undergoing strabismus surgery, the most appropriate prophylaxis is **dexamethasone after induction plus ondansetron near case end**.",
    "educationalObjective": "Apply special strategies in pediatrics (ondansetron + dexamethasone) and high-risk procedures (strabismus, tonsillectomy)."
  },
  {
    "id": "Core.6.5.3",
    "category": "General Anesthesia & Postop",
    "subcategory": "PONV prevention and treatment",
    "difficulty": "medium",
    "questionText": "A 45-year-old woman undergoes outpatient laparoscopic cholecystectomy. She received dexamethasone 8 mg IV at induction and ondansetron 4 mg IV at closure for PONV prophylaxis. Thirty minutes in PACU she has persistent nausea and emesis despite adequate analgesia. Vitals are stable (BP 128/76 mmHg, HR 78/min, SpO₂ 99% on room air). A rhythm strip shows a QTc of 520 ms.\n\nWhich of the following is the most appropriate rescue antiemetic?",
    "answers": [
      {
        "text": "Metoclopramide 10 mg IV",
        "isCorrect": false,
        "explanation": "A dopamine antagonist from a different class, but it can prolong QT and is less desirable with QTc 520 ms; extrapyramidal effects are also possible."
      },
      {
        "text": "Transdermal scopolamine 1.5 mg patch",
        "isCorrect": false,
        "explanation": "Different class (anticholinergic) but has delayed onset (2–4 hours), making it ineffective for immediate rescue in PACU."
      },
      {
        "text": "Propofol 20 mg IV",
        "isCorrect": true,
        "explanation": "Subhypnotic propofol provides rapid antiemetic effect via a different mechanism, has no QT-prolonging effect, and is effective as PACU rescue after 5-HT<sub>3</sub> failure."
      },
      {
        "text": "Repeat ondansetron 4 mg IV",
        "isCorrect": false,
        "explanation": "Repeating a 5-HT<sub>3</sub> antagonist within 6 hours after prophylaxis failure offers limited additional efficacy and compounds QT prolongation risk."
      },
      {
        "text": "Droperidol 0.625 mg IV",
        "isCorrect": false,
        "explanation": "Although mechanistically different, droperidol is contraindicated in marked QT prolongation due to torsades risk (black box warning)."
      }
    ],
    "didactic": "When PONV prophylaxis fails, rescue therapy should use an agent from a **different pharmacologic class** and avoid repeating the same mechanism for at least 6 hours. After intraoperative dexamethasone and a 5-HT<sub>3</sub> antagonist (eg, ondansetron), repeating ondansetron provides minimal additional benefit and increases **QT prolongation** risk. Selecting a rapid-onset agent with a different mechanism and a favorable safety profile is key.\n\n- 5-HT<sub>3</sub> antagonists (ondansetron, palonosetron): effective prophylaxis; avoid repeating within 6 hours after failure; class effect of QT prolongation (notable with ondansetron).\n- Dopamine (D<sub>2</sub>) antagonists (droperidol, haloperidol, prochlorperazine, metoclopramide): different class but many prolong QT; droperidol/haloperidol carry higher torsades risk, especially with QTc prolongation.\n- Anticholinergic (scopolamine): delayed onset (hours), better for prophylaxis or motion-related nausea rather than immediate PACU rescue.\n- NK<sub>1</sub> antagonists (aprepitant/fosaprepitant): primarily prophylactic; onset is not ideal for acute rescue in PACU.\n- Propofol: subhypnotic dosing (eg, 10–20 mg IV bolus or 10–20 μg/kg/min infusion) provides rapid antiemetic effect via GABAergic mechanisms, with **no QT prolongation**. Brief sedation and hypotension can occur but are typically mild with small boluses in monitored settings.\n\nIn a patient with marked QTc prolongation after receiving dexamethasone and ondansetron, the best rescue is a **different-class, rapid-onset agent that does not prolong QT**. A small propofol bolus meets these criteria and is effective in PACU. If propofol is unsuitable (eg, severe hypotension or tenuous airway), alternative classes may be used cautiously, matching mechanism, onset, and safety to patient-specific risks.",
    "educationalObjective": "Choose a rescue antiemetic from a different class when prophylaxis fails and avoid repeating the same mechanism."
  },
  {
    "id": "Core.6.5.4",
    "category": "General Anesthesia & Postop",
    "subcategory": "PONV prevention and treatment",
    "difficulty": "easy",
    "questionText": "A 28-year-old woman is scheduled for elective laparoscopic cholecystectomy under general anesthesia with sevoflurane. She is a nonsmoker and reports a history of motion sickness and severe nausea after a prior anesthetic. The plan includes fentanyl intraoperatively and hydromorphone for postoperative analgesia. She has no diabetes or contraindication to steroids.\n\nTo reduce this patient’s risk of postoperative nausea and vomiting (PONV), which perioperative strategy is most appropriate?",
    "answers": [
      {
        "text": "Dexamethasone 4–8 mg IV at induction plus ondansetron 4 mg IV at the end of surgery",
        "isCorrect": true,
        "explanation": "This provides guideline-supported multimodal prophylaxis (two classes, optimally timed) for very high PONV risk."
      },
      {
        "text": "No prophylaxis; provide rescue antiemetics only if nausea develops",
        "isCorrect": false,
        "explanation": "With 4 Apfel risk factors (female, nonsmoker, history of PONV/motion sickness, postoperative opioids), predicted risk is very high (~80%); rescue-only is inadequate."
      },
      {
        "text": "Use propofol total intravenous anesthesia (TIVA) and omit antiemetics",
        "isCorrect": false,
        "explanation": "TIVA reduces baseline emetogenic stimuli but does not replace antiemetics in patients with very high Apfel risk; antiemetics are still indicated."
      },
      {
        "text": "Apply a scopolamine patch in the PACU if nausea occurs",
        "isCorrect": false,
        "explanation": "Transdermal scopolamine has delayed onset and should be applied preoperatively for prophylaxis; it is not effective as a PACU rescue strategy."
      },
      {
        "text": "Ondansetron 4 mg IV at the end of surgery as a single agent",
        "isCorrect": false,
        "explanation": "Single-agent prophylaxis is insufficient for Apfel ≥3; multimodal therapy from different classes is recommended."
      }
    ],
    "didactic": "The simplified Apfel score estimates PONV risk using 4 predictors: female sex, nonsmoking status, history of PONV or motion sickness, and planned postoperative opioid use. Each factor increases risk in roughly additive fashion, with approximate predicted risks of 10%, 20%, 40%, 60%, and 80% for 0–4 factors, respectively. This patient has all 4 factors (female, nonsmoker, prior motion sickness/“PONV,” and postoperative opioids), placing her at very high risk (~80%). In such patients, **multimodal prophylaxis** with ≥2 antiemetics from different classes is indicated.\n\nEffective, guideline-supported combinations include:\n- 5‑HT<sub>3</sub> receptor antagonist (eg, ondansetron 4 mg IV at end of surgery)\n- Corticosteroid (eg, dexamethasone 4–8 mg IV at induction)\n- Dopamine antagonist (eg, droperidol 0.625–1.25 mg IV at end) or haloperidol\n- Anticholinergic (eg, transdermal scopolamine applied preop)\n- NK<sub>1</sub> receptor antagonist (eg, aprepitant 40 mg PO preop) for very high risk or prior prophylaxis failure\n\nTiming improves efficacy: dexamethasone is best at induction, whereas ondansetron and droperidol are typically given near case end. Transdermal scopolamine requires preoperative placement due to delayed onset. Although **propofol TIVA** (and avoidance of volatile agents/nitrous oxide) lowers baseline emetogenic stimuli, it should be considered an adjunct rather than a substitute for antiemetics in high-risk patients. Rescue therapy should use a drug with a different mechanism than agents used for prophylaxis.\n\nFor this patient (Apfel 4), the most appropriate prophylaxis is dexamethasone at induction plus ondansetron at the end of surgery. Additional strategies (opioid-sparing multimodal analgesia, TIVA) can further decrease risk but do not obviate the need for at least two prophylactic antiemetics from different classes.",
    "educationalObjective": "Identify PONV risk using simplified scores (e.g., Apfel) and stratify prophylaxis intensity."
  },
  {
    "id": "Core.6.5.5",
    "category": "General Anesthesia & Postop",
    "subcategory": "PONV prevention and treatment",
    "difficulty": "easy",
    "questionText": "A 28-year-old woman (nonsmoker) undergoes outpatient laparoscopic cholecystectomy with fentanyl for analgesia. She received dexamethasone 4 mg after induction and ondansetron 4 mg at skin closure. In the PACU, she reports severe nausea without vomiting; BP 118/70 mmHg, HR 84/min, SpO₂ 99% on 2 L/min O<sub>2</sub>. Her ECG shows congenital long QT syndrome with QTc 515 ms. Her IV has just infiltrated, and nursing is obtaining new access. She requests rapid relief now and prefers to avoid sedating medications.\n\nWhich adjunctive intervention is the most appropriate next step to quickly reduce her nausea while minimizing risk?",
    "answers": [
      {
        "text": "Administer promethazine 25 mg IM",
        "isCorrect": false,
        "explanation": "Promethazine can be given IM but is sedating and anticholinergic, undesirable in an ambulatory patient seeking rapid, clear-headed relief."
      },
      {
        "text": "Have her inhale isopropyl alcohol vapors from an alcohol pad",
        "isCorrect": true,
        "explanation": "Isopropyl alcohol aromatherapy provides rapid, short-term reduction in postoperative nausea, is safe, requires no IV access, and does not affect QT interval or cause sedation."
      },
      {
        "text": "Place a P<sub>6</sub> acupressure wristband",
        "isCorrect": false,
        "explanation": "P<sub>6</sub> acupressure is a low-risk adjunct that can reduce PONV, but its effect is variable and typically less immediate than alcohol inhalation for active nausea."
      },
      {
        "text": "Apply a transdermal scopolamine patch behind the ear",
        "isCorrect": false,
        "explanation": "Scopolamine has a delayed onset (several hours) and is not useful for immediate rescue; anticholinergic effects and sedation are possible."
      },
      {
        "text": "Give droperidol 0.625 mg IV",
        "isCorrect": false,
        "explanation": "Droperidol prolongs QT and requires IV access, making it inappropriate in a patient with congenital long QT and an infiltrated IV."
      }
    ],
    "didactic": "Nonpharmacologic adjuncts are valuable, low-risk complements for PONV prevention and rescue, especially when drug options are limited by side effects, access, or contraindications. Two options with supportive evidence are isopropyl alcohol aromatherapy and P<sub>6</sub> (Neiguan) acupressure.\n\n- Isopropyl alcohol aromatherapy: Having the patient take several deep inhalations from an alcohol pad placed a few centimeters below the nares provides rapid (minutes) reduction in nausea severity compared with saline or standard care. The effect is short-lived but useful as a bridge while establishing IV access or awaiting longer-acting therapies. It does not prolong QT, cause sedation, or interact with other antiemetics, making it ideal in patients with QT prolongation or in ambulatory settings.\n- P<sub>6</sub> acupressure: Applied 2–3 fingerbreadths proximal to the volar wrist crease between the palmaris longus and flexor carpi radialis tendons, via a wristband or manual pressure. It reduces PONV incidence and rescue antiemetic use with minimal risk. Its onset can be variable and generally less immediate than alcohol inhalation for active nausea, but it is a reasonable adjunct for prevention and ongoing management.\n\nIn patients at high risk for PONV (eg, female sex, nonsmoker, postoperative opioids) who have already received guideline-concordant pharmacologic prophylaxis, layering nonpharmacologic measures can provide additional benefit with minimal downside. Isopropyl alcohol inhalation is particularly helpful for rapid rescue when IV access is lost, when further QT-prolonging drugs (eg, ondansetron, droperidol) are undesirable, or when sedation (eg, from promethazine) is not acceptable. Nonpharmacologic measures should complement, not replace, multimodal antiemetic strategies once access and contraindications are addressed.",
    "educationalObjective": "Integrate nonpharmacologic adjuncts (acupressure P6, aromatherapy) as low-risk complements to drugs."
  },
  {
    "id": "Core.6.5.6",
    "category": "General Anesthesia & Postop",
    "subcategory": "PONV prevention and treatment",
    "difficulty": "medium",
    "questionText": "A 34-year-old woman undergoes ambulatory laparoscopic cholecystectomy under general anesthesia. She is a nonsmoker with prior postoperative nausea and vomiting after wisdom tooth extraction. In the PACU, she receives IV hydromorphone for pain and reports mild nausea that resolves without emesis. She is expected to be discharged in 45 minutes and asks for a plan to avoid nausea and vomiting at home. Vital signs are stable; she will receive oral acetaminophen and ibuprofen for analgesia. \n\nWhich peri-discharge plan best reduces postdischarge nausea and vomiting (PDNV) risk and provides appropriate rescue therapy and instructions?",
    "answers": [
      {
        "text": "Give dexamethasone 8 mg IV now; encourage oral fluids; no discharge antiemetics.",
        "isCorrect": false,
        "explanation": "Dexamethasone is most effective when given early; administering it late without a long-acting agent or home rescue does not address high PDNV risk."
      },
      {
        "text": "Administer droperidol 0.625 mg IV; prescribe promethazine 25 mg PO q6h PRN; advise no driving for 24 h.",
        "isCorrect": false,
        "explanation": "Droperidol is effective but short acting and carries QT/sedation concerns; promethazine is sedating and anticholinergic, which is less desirable for ambulatory recovery without long-acting prophylaxis."
      },
      {
        "text": "Give ondansetron 4 mg IV now; prescribe ondansetron ODT 4 mg q8h PRN; no additional measures.",
        "isCorrect": false,
        "explanation": "Short-acting 5-HT3 therapy alone has limited duration and repeating the same class for rescue after prophylaxis is less effective for breakthrough symptoms."
      },
      {
        "text": "Administer palonosetron 0.075 mg IV and apply a transdermal scopolamine 1.5 mg patch; discharge with metoclopramide 10 mg PO q6–8h PRN nausea, instructions to limit opioids, and to remove the patch if visual changes or confusion develop.",
        "isCorrect": true,
        "explanation": "Combining long-acting prophylaxis (palonosetron and scopolamine) targets PDNV risk for 48–72 h; a dopamine antagonist for home rescue uses a different class than prophylaxis and clear instructions support safe outpatient management."
      },
      {
        "text": "Give aprepitant 40 mg PO now and prescribe ondansetron ODT 4 mg q8h PRN; no patch.",
        "isCorrect": false,
        "explanation": "Aprepitant is best given preoperatively; starting it at discharge delays effect and the rescue plan again relies on a short-acting 5-HT3 without continuous coverage."
      }
    ],
    "didactic": "Patients at high risk for postdischarge nausea and vomiting (PDNV) benefit from a plan that extends protection beyond PACU discharge and provides clear rescue instructions. The validated PDNV risk score includes 5 predictors: **female sex**, **age <50 years**, **history of PONV**, **nausea in PACU**, and **opioid use in PACU**. This patient has all 5, indicating high risk (≈60%–80%).\n\nEffective outpatient strategies combine long-acting prophylaxis with multimodal analgesia to reduce opioids and a rescue medication from a different class:\n\n- Long-acting 5-HT3 antagonist: **palonosetron 0.075 mg IV** (t<sub>1/2</sub> ≈ 40 h) provides coverage into the home period and is superior to short-acting 5-HT3 agents for PDNV.\n- Anticholinergic: **transdermal scopolamine 1.5 mg patch** delivers drug for ≈72 h and complements 5-HT3 blockade. Place behind the ear; counsel to wash hands after handling and to remove the patch if blurred vision, confusion, or urinary retention occurs.\n- Corticosteroid: **dexamethasone** works best at induction; giving it late is less effective for PDNV, so it should not be relied upon peri-discharge as the sole measure.\n- NK<sub>1</sub> antagonists: **aprepitant 40 mg PO** (preop) or **fosaprepitant 150 mg IV** (intraop) reduce early and late vomiting but are most effective when administered before incision.\n- Rescue therapy: If prophylaxis included a 5-HT3 antagonist, use a different class at home (eg, **metoclopramide 10 mg PO q6–8 h PRN**, or prochlorperazine 10 mg). Avoid duplicating the same class for early rescue, which is less effective.\n\nProvide written instructions: take rescue medication at first symptoms; maintain hydration; limit opioids with scheduled acetaminophen/NSAIDs; and seek care for persistent vomiting, inability to keep fluids, or signs of dehydration. The combination of palonosetron plus scopolamine with non–5-HT3 rescue optimally addresses high PDNV risk in ambulatory patients.",
    "educationalObjective": "Plan for PDNV after ambulatory surgery with long-acting prophylaxis and clear rescue instructions."
  },
  {
    "id": "Core.6.5.7",
    "category": "General Anesthesia & Postop",
    "subcategory": "PONV prevention and treatment",
    "difficulty": "hard",
    "questionText": "A 46-year-old woman with congenital long QT syndrome presents for laparoscopic cholecystectomy. She is a nonsmoker with prior severe PONV. Intraoperatively she received dexamethasone 8 mg IV at induction and fentanyl 150 μg. In the PACU, she has severe nausea and retching. Telemetry shows sinus bradycardia at 52/min with QT<sub>c</sub> 520 ms. Labs: K 3.1 mEq/L, Mg 1.5 mg/dL, Ca 9.0 mg/dL. She has not yet received any 5-HT3 antagonists.\n\nWhich of the following is the most appropriate medication to treat her PONV now?",
    "answers": [
      {
        "text": "Scopolamine transdermal patch",
        "isCorrect": false,
        "explanation": "Scopolamine does not prolong QT<sub>c</sub> but has delayed onset (hours), making it unsuitable for immediate symptom relief in the PACU."
      },
      {
        "text": "Droperidol 0.625 mg IV",
        "isCorrect": false,
        "explanation": "Butyrophenones carry a strong risk of QT<sub>c</sub> prolongation and torsades de pointes; they are contraindicated in patients with marked QT<sub>c</sub> prolongation."
      },
      {
        "text": "Metoclopramide 10 mg IV",
        "isCorrect": false,
        "explanation": "Metoclopramide has modest QT‑prolonging potential and dopamine antagonism; it is not preferred in a high‑risk long QT setting with electrolyte abnormalities."
      },
      {
        "text": "Propofol 10–20 mg IV bolus",
        "isCorrect": true,
        "explanation": "A small propofol bolus has rapid antiemetic effect without clinically significant QT<sub>c</sub> prolongation, making it appropriate for immediate rescue in high‑risk patients."
      },
      {
        "text": "Ondansetron 4 mg IV",
        "isCorrect": false,
        "explanation": "5‑HT3 antagonists (eg, ondansetron) block IKr and can prolong QT<sub>c</sub>, especially in the setting of hypokalemia/bradycardia, increasing torsades risk."
      }
    ],
    "didactic": "Patients with prolonged QT<sub>c</sub> (congenital or acquired) are susceptible to torsades de pointes (TdP), particularly when multiple risk factors coexist (female sex, bradycardia, hypokalemia/hypomagnesemia, high‑dose or combined QT‑prolonging drugs). Many common antiemetics prolong QT<sub>c</sub> by blocking cardiac IKr (hERG) potassium channels. In this high‑risk patient (QT<sub>c</sub> 520 ms, bradycardia, K 3.1 mEq/L, Mg 1.5 mg/dL), agents that further prolong repolarization should be avoided for rescue treatment.\n\n- QT‑prolonging antiemetics: 5‑HT3 antagonists (ondansetron, granisetron), dopamine antagonists (droperidol, haloperidol), and phenothiazines (promethazine, prochlorperazine). Metoclopramide can also prolong QT<sub>c</sub> modestly.\n- QT‑neutral or safer options: propofol bolus, dexamethasone, scopolamine, and NK1 antagonists (aprepitant/fosaprepitant). Palonosetron has minimal/no clinically relevant QT effect compared with other 5‑HT3 agents but is not ideal for immediate PACU rescue.\n\nA small propofol bolus (eg, 10–20 mg) provides rapid antiemetic benefit without meaningful QT<sub>c</sub> effects and is appropriate for acute rescue. Scopolamine and NK1 antagonists are useful for prophylaxis or delayed PONV but have slower onset, limiting utility for immediate symptoms. Dexamethasone is most effective as prophylaxis rather than rescue.\n\nPractical management in long QT:\n- Treat correctable risks: replete electrolytes (target K ≥4.0 mEq/L, Mg ≥2.0 mg/dL), avoid bradycardia, and minimize QT‑prolonging drug combinations.\n- Choose QT‑neutral rescue in PACU (propofol bolus) and use nonpharmacologic adjuncts (eg, supplemental oxygen, reduce opioids, consider isopropyl alcohol inhalation) when appropriate.\n- If TdP occurs: give magnesium sulfate 1–2 g IV, correct electrolytes, increase heart rate (overdrive pacing/isoproterenol), and stop offending drugs.\n\nIn patients with established QT<sub>c</sub> prolongation and electrolyte abnormalities, propofol rescue is the safest and fastest option to relieve PONV while mitigating arrhythmic risk.",
    "educationalObjective": "Recognize and manage QT prolongation risk when combining antiemetics or in susceptible patients."
  },
  {
    "id": "Core.6.5.8",
    "category": "General Anesthesia & Postop",
    "subcategory": "PONV prevention and treatment",
    "difficulty": "medium",
    "questionText": "A 29-year-old nonsmoking woman undergoing elective laparoscopic cholecystectomy reports severe prior postoperative nausea and vomiting (PONV) and motion sickness. She requests that you minimize PONV. The surgeon anticipates a 90-minute procedure with pneumoperitoneum. Vitals and labs are normal, and she has no contraindications to NSAIDs. You plan standard multimodal antiemetic prophylaxis.\n\nWhich intraoperative anesthetic plan best reduces this patient’s baseline PONV risk while providing adequate analgesia?",
    "answers": [
      {
        "text": "Sevoflurane in 50% N<sub>2</sub>O/O<sub>2</sub> with fentanyl 2–3 μg/kg and hydromorphone 0.5–1 mg; ondansetron + dexamethasone at case end",
        "isCorrect": false,
        "explanation": "Nitrous oxide and higher intra/postoperative opioid use increase baseline PONV risk; antiemetics mitigate but do not offset these risk factors."
      },
      {
        "text": "Propofol TIVA (no N<sub>2</sub>O) with intraoperative morphine 0.2 mg/kg to ensure long-acting analgesia, minimal IV fluids, and avoid dexamethasone",
        "isCorrect": false,
        "explanation": "TIVA helps, but large doses of long-acting opioids and fluid minimization increase PONV; avoiding a single dose of dexamethasone is not justified and forfeits additional benefit."
      },
      {
        "text": "Propofol TIVA (air/O<sub>2</sub>, no N<sub>2</sub>O) with multimodal opioid-sparing analgesia (acetaminophen, ketorolac, low-dose ketamine), rescue-only small-dose hydromorphone, dexamethasone + ondansetron, and 1–2 L balanced crystalloid",
        "isCorrect": true,
        "explanation": "Propofol TIVA reduces baseline PONV risk, avoidance of N<sub>2</sub>O and opioid-sparing multimodal analgesia further decrease risk, and adequate hydration modestly lowers PONV after laparoscopy."
      },
      {
        "text": "Desflurane in 70% N<sub>2</sub>O/O<sub>2</sub> to speed emergence with scopolamine patch and ondansetron; restrict fluids to 2–3 ml/kg/h",
        "isCorrect": false,
        "explanation": "High N<sub>2</sub>O and fluid restriction increase baseline PONV risk; antiemetics do not compensate for these proemetic factors."
      },
      {
        "text": "Sevoflurane in air/O<sub>2</sub> (no N<sub>2</sub>O) with remifentanil 0.2–0.3 μg/kg/min and planned PACU hydromorphone 1–2 mg; ondansetron only",
        "isCorrect": false,
        "explanation": "Avoiding N<sub>2</sub>O helps, but heavy intra/postoperative opioid exposure (and potential remifentanil hyperalgesia) increases PONV and undercuts baseline risk reduction."
      }
    ],
    "didactic": "This patient has an Apfel score of 4 (female sex, nonsmoker, PONV history, postoperative opioids), conferring a very high baseline PONV risk. In addition to guideline-recommended multimodal antiemetic prophylaxis, modifying the anesthetic to reduce baseline risk factors is high-yield and synergistic.\n\nKey baseline risk–reducing strategies:\n- Use **propofol TIVA**: Propofol has intrinsic antiemetic properties and consistently lowers PONV versus volatile anesthesia. TIVA reduces early and late PONV and is a primary technique in high-risk patients.\n- **Avoid nitrous oxide** when feasible: N<sub>2</sub>O increases PONV (likely via bowel distension and vestibular effects). Omitting N<sub>2</sub>O offers additive benefit beyond TIVA or antiemetics.\n- Implement **opioid-sparing multimodal analgesia**: Acetaminophen and NSAIDs reduce opioid requirements and PONV; low-dose ketamine can decrease opioid consumption without increasing PONV. Consider local infiltration or regional blocks when applicable.\n- Provide **adequate hydration**: Liberal-to-balanced crystalloid (eg, 10–20 ml/kg or 1–2 L for a 90-minute laparoscopy) modestly reduces PONV, particularly in laparoscopic gynecologic/biliary surgery, likely by improving splanchnic perfusion and mitigating gut ischemia.\n\nWhy the correct plan is best:\n- Propofol TIVA with air/O<sub>2</sub> (no N<sub>2</sub>O) directly addresses volatile/N<sub>2</sub>O-related emetogenicity.\n- Multimodal, opioid-sparing analgesia reduces the strongest modifiable PONV driver (opioid exposure), while still allowing small rescue doses.\n- Balanced crystalloids further lower risk without compromising hemodynamics.\n\nCommon pitfalls illustrated by distractors:\n- Relying on antiemetics while continuing **N<sub>2</sub>O and higher opioids** leaves baseline risk high.\n- **Remifentanil-heavy** intraoperative plans often increase postoperative opioid needs and can worsen PONV.\n- **Fluid restriction** and high N<sub>2</sub>O fractions exacerbate PONV despite antiemetics.\n\nIn high-risk patients, combine antiemetics with baseline risk reduction: **TIVA**, **no N<sub>2</sub>O**, **opioid-sparing multimodal analgesia**, and **adequate hydration**.",
    "educationalObjective": "Reduce baseline risk with TIVA, opioid-sparing analgesia, hydration, and avoidance of nitrous when feasible."
  },
  {
    "id": "Core.6.5.9",
    "category": "General Anesthesia & Postop",
    "subcategory": "PONV prevention and treatment",
    "difficulty": "easy",
    "questionText": "A 35-year-old nonsmoking woman with a history of severe postoperative nausea and vomiting (PONV) is undergoing a 90-minute laparoscopic cholecystectomy under volatile-based general anesthesia with planned intraoperative opioids. You plan multimodal prophylaxis with dexamethasone and ondansetron. To maximize efficacy and immediate postoperative coverage, when should each antiemetic be administered?\n\nWhich timing strategy is most appropriate?",
    "answers": [
      {
        "text": "Administer dexamethasone at induction and ondansetron at skin closure",
        "isCorrect": true,
        "explanation": "Dexamethasone’s antiemetic effect has a delayed onset and is best given at induction, whereas ondansetron has rapid onset and provides optimal coverage when given near the end of surgery."
      },
      {
        "text": "Administer dexamethasone and ondansetron at induction of anesthesia",
        "isCorrect": false,
        "explanation": "Ondansetron given early may wear off by emergence/PACU for a 90-minute case; its optimal effect is when dosed near case end. Dexamethasone at induction is appropriate, but pairing both early is suboptimal."
      },
      {
        "text": "Administer dexamethasone at induction and ondansetron at skin incision",
        "isCorrect": false,
        "explanation": "Ondansetron at incision is still too early for best immediate postoperative coverage. Dexamethasone at induction is correct."
      },
      {
        "text": "Administer dexamethasone at the end of surgery and ondansetron at induction",
        "isCorrect": false,
        "explanation": "This reverses optimal timing: dexamethasone given late misses early postoperative benefit, and ondansetron given at induction may not provide peak effect at emergence."
      },
      {
        "text": "Administer dexamethasone and ondansetron in the PACU if nausea develops",
        "isCorrect": false,
        "explanation": "Treating only after symptoms appear forfeits effective prophylaxis and increases risk of PONV; timing is key to prevention."
      }
    ],
    "didactic": "High-risk patients (eg, female sex, nonsmoker, prior PONV, volatile anesthetics, opioids, laparoscopic surgery) benefit from **multimodal prophylaxis** and appropriate timing of agents with different mechanisms and pharmacokinetics.\n\n- **Dexamethasone (4–8 mg IV)**: Corticosteroid with a delayed antiemetic onset (≈1–2 hours). Giving it **at induction** allows its effect to develop by emergence and early PACU, when PONV risk is highest.\n- **Ondansetron (4 mg IV)**: 5-HT3 antagonist with **rapid onset** and relatively short half-life. Administer **near the end of surgery (eg, at skin closure)** to maximize effect during emergence and the immediate postoperative period.\n\nOther agents illustrate why timing matters:\n\n- **Transdermal scopolamine**: Onset 2–4 hours; apply the evening before or ≥2 hours preop to prevent early PONV.\n- **Droperidol**: Rapid onset; typically dosed near case end for immediate postoperative coverage.\n- **NK1 antagonists (eg, aprepitant)**: Oral dosing 1–3 hours preop extends coverage into the postoperative period; reserve for very high-risk patients or when prior prophylaxis failed.\n\nAdditional strategies enhance prophylaxis: use **TIVA with propofol** when feasible, minimize **opioids**, avoid **nitrous oxide** in high-risk patients, and ensure adequate **hydration**. Selection and timing should be tailored to case duration: for short cases, 5-HT3 early dosing may wear off by PACU, while late dexamethasone may not be active in time. Therefore, pairing **dexamethasone at induction** with **ondansetron at closure** provides complementary onset/coverage and is the preferred approach for most moderate-duration surgeries.",
    "educationalObjective": "Time antiemetics correctly (e.g., dexamethasone at induction; ondansetron near case end) to maximize efficacy."
  },
  {
    "id": "Core.6.5.10",
    "category": "General Anesthesia & Postop",
    "subcategory": "PONV prevention and treatment",
    "difficulty": "medium",
    "questionText": "A 45-year-old woman is scheduled for ambulatory laparoscopic cholecystectomy under general anesthesia. She has severe motion sickness, a prior episode of significant postoperative nausea and vomiting after laparoscopy, is a nonsmoker, and will receive postoperative opioids. She anticipates a 2-hour, winding car ride home after discharge. She has no glaucoma, urinary retention, or cognitive impairment. You plan multimodal PONV prophylaxis.\n\nWhich perioperative plan regarding scopolamine use is most appropriate to reduce her postoperative and motion-related nausea?",
    "answers": [
      {
        "text": "Avoid scopolamine due to QT-prolongation risk and use ondansetron 4 mg IV alone at the end of the case.",
        "isCorrect": false,
        "explanation": "Scopolamine does not prolong QT; high-risk patients warrant multimodal prophylaxis rather than 5‑HT3 monotherapy."
      },
      {
        "text": "Apply a transdermal scopolamine 1.5 mg patch 1 hour before surgery and remove it on PACU arrival to limit anticholinergic toxicity.",
        "isCorrect": false,
        "explanation": "One hour is insufficient for onset, and early removal forfeits protection during the car ride; most side effects are mild and manageable with counseling."
      },
      {
        "text": "Place the transdermal scopolamine patch in the PACU to minimize preoperative side effects while covering the ride home.",
        "isCorrect": false,
        "explanation": "The patch’s delayed onset (2–4 hours) makes PACU placement ineffective for early postoperative nausea or near-term transport."
      },
      {
        "text": "Give glycopyrrolate 0.2 mg IV at induction instead of scopolamine to avoid central anticholinergic effects while still reducing PONV.",
        "isCorrect": false,
        "explanation": "Glycopyrrolate poorly penetrates the CNS and is not effective for motion-related nausea or PONV prophylaxis."
      },
      {
        "text": "Apply a transdermal scopolamine 1.5 mg patch the evening before surgery and use dexamethasone at induction plus ondansetron at closure; counsel about anticholinergic effects and proper handling.",
        "isCorrect": true,
        "explanation": "Transdermal scopolamine has a 2–4 hour onset and peaks around 6 hours; applying it the night before ensures coverage at emergence and during the ride home. Counseling addresses dry mouth, blurred vision/mydriasis (avoid ocular contamination), urinary retention, and confusion risks."
      }
    ],
    "didactic": "Patients with high PONV risk (eg, female sex, nonsmoker, prior PONV/motion sickness, postoperative opioids) benefit from **multimodal prophylaxis**. Motion-related nausea is mediated by vestibular pathways with cholinergic (M1) transmission; **scopolamine**, a central antimuscarinic, is particularly effective for motion sickness and as an adjunct for PONV prevention.\n\nTransdermal scopolamine (1.5 mg) delivers drug over ~72 hours with a delayed **onset of 2–4 hours** and **peak effect around 6 hours**. Therefore, timing is critical: apply the patch the night before surgery (or at least ≥2–4 hours preoperatively) so that therapeutic levels are present at emergence and during early recovery/transport. Placing the patch in the PACU or only 1 hour preop yields subtherapeutic exposure during the highest-risk period. The patch can remain on postoperatively to cover ongoing motion exposure (eg, car ride) and opioid use.\n\nUse scopolamine as part of a multimodal regimen in high-risk patients:\n- Dexamethasone 4–8 mg IV at induction\n- 5‑HT3 antagonist (eg, ondansetron 4 mg IV) near the end of the case\n- Consider TIVA/propofol and opioid-sparing strategies when feasible\n\nAnticholinergic adverse effects include **dry mouth**, **blurred vision/mydriasis**, **urinary retention**, **tachycardia**, and **confusion/delirium** (especially in older adults). Counsel patients to wash hands after handling to avoid ocular contamination that can cause unilateral mydriasis; remove the patch if troublesome visual symptoms or confusion occur. Important cautions/contraindications include **narrow-angle glaucoma**, significant urinary outflow obstruction, and frailty with baseline cognitive impairment. Scopolamine is not associated with QT prolongation.\n\nGlycopyrrolate does not meaningfully prevent PONV because it minimally penetrates the CNS and does not target vestibular pathways. Proper timing and counseling make transdermal scopolamine a high-yield component of PONV prophylaxis for motion-sensitive, high-risk outpatients.",
    "educationalObjective": "Use transdermal scopolamine for motion-related nausea with attention to timing and anticholinergic side effects."
  },
  {
    "id": "Core.6.6.1",
    "category": "General Anesthesia & Postop",
    "subcategory": "RSI and aspiration risk",
    "difficulty": "hard",
    "questionText": "A 45-year-old man (BMI 40) with small-bowel obstruction presents for emergent laparotomy. After thorough preoxygenation, RSI is induced with propofol 2 mg/kg and succinylcholine 1.5 mg/kg while an assistant applies firm cricoid pressure. Direct laryngoscopy yields a Cormack–Lehane grade 3 view and a bougie cannot be advanced. SpO<sub>2</sub> falls to 84% and mask ventilation is difficult with poor chest rise despite an oropharyngeal airway. The patient begins retching and gastric contents are seen pooling in the oropharynx. \n\nWhich adjustment to cricoid pressure is most appropriate at this time?",
    "answers": [
      {
        "text": "Slide cricoid pressure laterally to improve esophageal occlusion while continuing intubation attempts",
        "isCorrect": false,
        "explanation": "Lateral displacement is not recommended and may further distort the airway; in this scenario, releasing pressure is necessary to manage regurgitation and restore ventilation."
      },
      {
        "text": "Reduce cricoid pressure to ≈10 N while keeping it midline to balance aspiration protection with improved laryngoscopy",
        "isCorrect": false,
        "explanation": "Partial reduction may help the view when oxygenation is adequate, but during active vomiting and difficult ventilation, complete release is indicated to prevent esophageal injury and enable effective ventilation."
      },
      {
        "text": "Maintain cricoid pressure and add BURP to the thyroid cartilage to improve the view while attempting bougie-assisted intubation",
        "isCorrect": false,
        "explanation": "Adding BURP without addressing the inability to ventilate and ongoing regurgitation risks further airway obstruction and aspiration; oxygenation takes priority over continued intubation attempts."
      },
      {
        "text": "Maintain firm cricoid pressure (≈30–40 N) and increase mask pressure to overcome the obstruction",
        "isCorrect": false,
        "explanation": "Maintaining or increasing cricoid pressure in the setting of regurgitation and difficult ventilation can worsen airway obstruction and increases the risk of esophageal rupture during active vomiting."
      },
      {
        "text": "Immediately release cricoid pressure and suction the airway to permit expulsion of gastric contents and facilitate ventilation or supraglottic airway insertion",
        "isCorrect": true,
        "explanation": "With regurgitation and inability to ventilate, cricoid pressure should be released to prevent esophageal rupture and relieve upper airway obstruction, prioritizing oxygenation with suction, mask ventilation, or SGA placement."
      }
    ],
    "didactic": "Cricoid pressure (Sellick maneuver) aims to compress the esophagus against the vertebral body to reduce passive regurgitation during induction. Recommended force is ≈10 N in the awake patient and ≈30 N after loss of consciousness. However, the esophagus is often lateral to the trachea, and imaging studies show that cricoid pressure inconsistently occludes it. Importantly, cricoid pressure can worsen laryngoscopic view, impede mask ventilation, and hinder placement of supraglottic airways (SGAs) or endotracheal tubes.\n\nIn RSI, cricoid pressure is applied with induction and maintained until a cuffed endotracheal tube is placed and verified. It must be dynamically managed. If cricoid pressure degrades the glottic view or prevents ETT/SGA passage, the force should be eased or released to facilitate airway management. When oxygenation is threatened, oxygenation takes priority over aspiration prophylaxis.\n\nTwo situations mandate complete release:\n- Cannot intubate and cannot ventilate: Release cricoid pressure to relieve upper airway obstruction and permit effective mask ventilation or SGA insertion.\n- Active vomiting/retching: Release immediately to avoid esophageal rupture and allow expulsion of gastric contents; suction and position the head laterally as feasible.\n\nWhen conditions are stable (adequate oxygenation without vomiting), partial reduction or conversion to external laryngeal manipulation (on the thyroid cartilage) can improve the view while maintaining some protection. BURP can improve laryngeal exposure but is distinct from cricoid pressure and should not be conflated with esophageal occlusion.\n\nBottom line: Apply ≈30 N after unconsciousness, but continuously reassess. **Ease or release if it impedes laryngoscopy or ventilation, and release immediately for vomiting or CICO**. Maintain until cuff inflation and confirmation of tracheal placement, then discontinue.",
    "educationalObjective": "Apply and manage cricoid pressure correctly, including when to ease or release it to improve laryngoscopy or ventilation."
  },
  {
    "id": "Core.6.6.2",
    "category": "General Anesthesia & Postop",
    "subcategory": "RSI and aspiration risk",
    "difficulty": "medium",
    "questionText": "A 58-year-old man with a 2-day history of crampy abdominal pain, progressive distension, and multiple episodes of bilious emesis is brought for urgent laparotomy for high-grade small-bowel obstruction. He last ate 18 hours ago but vomited 1 hour ago. Vitals are stable; the abdomen is markedly distended and tympanitic. No nasogastric tube has been placed. The team plans a rapid-sequence induction with endotracheal intubation. Which of the following is the most effective strategy to reduce aspiration risk for this patient?",
    "answers": [
      {
        "text": "Administer metoclopramide 10 mg IV 5 minutes before induction and proceed with RSI",
        "isCorrect": false,
        "explanation": "Metoclopramide may increase lower esophageal sphincter tone and gastric motility but is contraindicated in mechanical obstruction and is unlikely to empty a markedly distended stomach acutely."
      },
      {
        "text": "Proceed with RSI using high-dose rocuronium and firm cricoid pressure to prevent regurgitation",
        "isCorrect": false,
        "explanation": "Endotracheal intubation protects the airway, but cricoid pressure has uncertain efficacy and does not reduce gastric volume; it may also worsen laryngoscopic view."
      },
      {
        "text": "Give sodium citrate 30 mL and proceed with RSI without gastric decompression",
        "isCorrect": false,
        "explanation": "Sodium citrate rapidly raises gastric pH but does not reduce volume and may increase intragastric volume; it does not mitigate regurgitation of large-volume contents."
      },
      {
        "text": "Insert a large-bore nasogastric tube and suction to empty the stomach immediately before RSI",
        "isCorrect": true,
        "explanation": "In small-bowel obstruction, gastric decompression removes large-volume contents—the principal driver of aspiration risk—and is the most effective immediate intervention before induction."
      },
      {
        "text": "Perform awake fiberoptic intubation in the supine position to preserve protective reflexes",
        "isCorrect": false,
        "explanation": "Awake intubation preserves reflexes but does not address large gastric volume; aspiration can still occur, and the supine position increases regurgitation risk without prior decompression."
      }
    ],
    "didactic": "Patients with small-bowel obstruction, gastroparesis (eg, diabetes, opioids), or severe GERD have high aspiration risk due to increased gastric volume and delayed emptying. Classic risk correlates with gastric volume ≥25 mL (≈≥0.4 mL/kg) and pH ≤2.5; although modern thresholds vary, large-volume, acidic contents are most harmful. In obstruction, fasting does not ensure an empty stomach.\n\nThe most effective immediate intervention is removal of gastric contents via nasogastric/orogastric decompression. In small-bowel obstruction, continuous suction reduces intragastric volume, intragastric pressure, and the likelihood of regurgitation during induction. Positioning the patient head-up 20–30° further lowers gastroesophageal gradient and promotes passive drainage.\n\nPharmacologic prophylaxis is adjunctive:\n- Sodium citrate rapidly neutralizes acid but increases volume and does not prevent regurgitation of large volumes.\n- H<sub>2</sub> blockers/PPIs reduce acidity (and eventually volume) but need ≥30–60 minutes or longer for effect—insufficient for urgent cases.\n- Metoclopramide may enhance gastric emptying and increase LES tone, but it is contraindicated in mechanical obstruction and is minimally effective for markedly distended stomachs.\n\nAirway strategy should prioritize a cuffed endotracheal tube. RSI reduces the unprotected time; have suction immediately available, preoxygenate with 100% O<sub>2</sub> (consider PEEP), and use head-up positioning. Gentle mask ventilation at low inspiratory pressures (eg, ≤10–12 cmH<sub>2</sub>O) may be used if needed to prevent hypoxia, balancing aspiration risk. Cricoid pressure has uncertain efficacy and may obstruct the view; release if it impedes ventilation or laryngoscopy.\n\nAwake intubation is chosen for difficult airways, not primarily to mitigate aspiration, and does not substitute for gastric decompression. In patients with obstruction or severe gastroparesis, decompress the stomach first, then perform RSI with appropriate adjuncts to meaningfully reduce aspiration risk.",
    "educationalObjective": "Assess and reduce aspiration risk in gastroparesis, bowel obstruction, or severe GERD, including gastric decompression when indicated."
  },
  {
    "id": "Core.6.6.3",
    "category": "General Anesthesia & Postop",
    "subcategory": "RSI and aspiration risk",
    "difficulty": "medium",
    "questionText": "An urgent exploratory laparotomy is planned for a 62-year-old man with high-grade small-bowel obstruction. He had an ischemic stroke 3 weeks ago with persistent right-sided weakness (3/5). He is nauseated with abdominal distention; last oral intake was 6 hours ago. Airway exam is unremarkable. Vitals are stable; K 4.4 mEq/L; creatinine normal. Sugammadex is available in the operating room. You plan a rapid-sequence induction.\n\nWhich neuromuscular blockade strategy is most appropriate to minimize aspiration risk while accounting for this patient’s comorbidities and to provide a viable rescue if intubation fails?",
    "answers": [
      {
        "text": "Defasciculated succinylcholine: rocuronium 0.1 mg/kg followed by succinylcholine 1.0 mg/kg",
        "isCorrect": false,
        "explanation": "A defasciculating dose does not prevent succinylcholine-induced K<sup>+</sup> release and hyperkalemia in denervation; succinylcholine remains contraindicated."
      },
      {
        "text": "Rocuronium 0.6 mg/kg IV with plan for neostigmine reversal if needed",
        "isCorrect": false,
        "explanation": "A 0.6 mg/kg dose has a slower onset unsuitable for RSI, and neostigmine cannot rapidly reverse profound neuromuscular block and is ineffective in a can’t-intubate/can’t-ventilate scenario."
      },
      {
        "text": "Avoid neuromuscular blocker; perform deep inhalational induction to maintain spontaneous ventilation",
        "isCorrect": false,
        "explanation": "In a full-stomach patient, inhalational induction prolongs time to secure the airway and increases aspiration risk; RSI with an appropriate neuromuscular blocker is preferred."
      },
      {
        "text": "Succinylcholine 1.5 mg/kg IV for RSI, allow spontaneous recovery if cannot intubate/cannot ventilate",
        "isCorrect": false,
        "explanation": "Succinylcholine is contraindicated after denervation injuries (eg, stroke >48 h) due to upregulated extrajunctional receptors and risk of life-threatening hyperkalemia; waiting for spontaneous recovery does not mitigate this risk."
      },
      {
        "text": "Rocuronium 1.2 mg/kg IV for RSI with immediate availability of sugammadex 16 mg/kg for rescue reversal",
        "isCorrect": true,
        "explanation": "High-dose rocuronium provides RSI-level onset comparable to succinylcholine while avoiding denervation-related hyperkalemia; sugammadex 16 mg/kg can immediately reverse profound block if airway control fails."
      }
    ],
    "didactic": "For rapid-sequence induction in full-stomach patients, both succinylcholine (1.0–1.5 mg/kg) and high-dose rocuronium (1.0–1.2 mg/kg) achieve rapid conditions for intubation. However, agent selection must incorporate comorbidities and rescue options. After denervation injuries (eg, stroke, spinal cord injury) and in conditions with upregulated extrajunctional acetylcholine receptors (eg, major burns after 24–48 h, neuromuscular diseases, critical illness myopathy), **succinylcholine is contraindicated** due to exaggerated K<sup>+</sup> efflux that can precipitate severe hyperkalemia, ventricular arrhythmias, or cardiac arrest. A defasciculating dose of a nondepolarizer does not prevent this potassium rise. Baseline serum K may be normal but does not predict safety.\n\nHigh-dose **rocuronium 1.2 mg/kg** provides an onset similar to succinylcholine for RSI but has a longer spontaneous duration (≈45–90 minutes). The availability of **sugammadex**, a γ-cyclodextrin that encapsulates rocuronium/vecuronium, fundamentally changes rescue planning: at **16 mg/kg**, sugammadex can rapidly reverse even profound neuromuscular block within 2–3 minutes, offering a pharmacologic bailout in a can’t-intubate/can’t-ventilate scenario. Lower doses (2 mg/kg for TOF ≥2, 4 mg/kg for deep block with post-tetanic counts) are inadequate for immediate reversal of a just-induced profound block. In contrast, **neostigmine** requires some spontaneous recovery (reappearance of twitches) and has an onset of several minutes, making it unsuitable for emergent rescue.\n\nTherefore, in a patient 3 weeks post-stroke requiring RSI for small-bowel obstruction, the optimal approach is **rocuronium 1.2 mg/kg with immediate availability of sugammadex 16 mg/kg**. This strategy achieves rapid intubating conditions while avoiding succinylcholine-associated hyperkalemia and provides an effective, rapid reversal option if airway control fails.",
    "educationalObjective": "Choose succinylcholine versus high-dose rocuronium for RSI and plan for sugammadex rescue when appropriate."
  },
  {
    "id": "Core.6.6.4",
    "category": "General Anesthesia & Postop",
    "subcategory": "RSI and aspiration risk",
    "difficulty": "medium",
    "questionText": "A 56-year-old man with a small-bowel obstruction presents for urgent laparotomy. He has persistent vomiting and abdominal distension. BMI is 48 kg/m<sup>2</sup>, SpO<sub>2</sub> is 93% on room air, and he has severe obstructive sleep apnea. Airway exam suggests a potentially difficult laryngoscopy. You plan a rapid sequence induction with full preoxygenation in a head-up position. Given his high risk for both aspiration and rapid desaturation, what is the most appropriate approach to ventilation between induction and laryngoscopy to prevent hypoxemia while minimizing gastric insufflation?",
    "answers": [
      {
        "text": "Place a nasogastric tube before induction to decompress the stomach, then provide standard mask ventilation as needed",
        "isCorrect": false,
        "explanation": "Preinduction NG placement in bowel obstruction can provoke regurgitation and does not justify aggressive mask ventilation; it does not eliminate the risk of aspiration during induction."
      },
      {
        "text": "Apply cricoid pressure and deliver tidal volumes 8–10 mL/kg ideal body weight with peak inspiratory pressures up to 25 cm H<sub>2</sub>O",
        "isCorrect": false,
        "explanation": "High inspiratory pressures increase gastric insufflation despite cricoid pressure; cricoid may also worsen laryngoscopy and is not reliably protective."
      },
      {
        "text": "Use apneic oxygenation via 15 L/min nasal cannula without mask ventilation until the trachea is intubated",
        "isCorrect": false,
        "explanation": "Apneic oxygenation can augment preoxygenation but does not provide PEEP or alveolar ventilation; in morbid obesity it is often insufficient to prevent desaturation without gentle positive-pressure support."
      },
      {
        "text": "Provide gentle two-hand mask ventilation with jaw thrust using PEEP 5–10 cm H<sub>2</sub>O and limit inspiratory pressure to ≤15 cm H<sub>2</sub>O",
        "isCorrect": true,
        "explanation": "Gentle ventilation with low inspiratory pressures and modest PEEP maintains oxygenation and minimizes gastric insufflation; this modified RSI approach is recommended for patients at high risk of rapid desaturation."
      },
      {
        "text": "Avoid any mask ventilation (classic RSI) and proceed directly to laryngoscopy during apnea",
        "isCorrect": false,
        "explanation": "Strict apneic RSI increases the risk of hypoxemia in patients with low FRC (eg, morbid obesity) and anticipated prolonged intubation, without reducing aspiration compared with careful gentle ventilation."
      }
    ],
    "didactic": "In morbidly obese, pregnant, pediatric, or critically ill patients, the risk of rapid desaturation during rapid sequence induction (RSI) often outweighs the theoretical benefit of strict apnea. A **modified RSI** with gentle mask ventilation is appropriate when hypoxemia risk is high or a difficult laryngoscopy is anticipated. Evidence from operating room and emergency airway studies shows that carefully applied bag-mask ventilation during RSI reduces severe hypoxemia without increasing aspiration.\n\nTo limit gastric insufflation while maintaining oxygenation:\n- Use a **two-hand mask seal** with jaw thrust and an oropharyngeal airway to minimize leak and required pressures.\n- Apply **PEEP 5–10 cm H<sub>2</sub>O** to preserve FRC and maintain alveolar recruitment.\n- Deliver small tidal volumes at 10–12 breaths/min and **cap inspiratory pressure at ≤10–15 cm H<sub>2</sub>O**. Gastric insufflation is uncommon below ≈15–20 cm H<sub>2</sub>O because esophageal opening (barrier) pressure is typically higher; lowering inspiratory pressure reduces insufflation risk even in patients with reduced lower esophageal sphincter tone.\n- Maintain a head-up, ramped position and continue apneic oxygenation (eg, nasal cannula) as adjuncts, not replacements, for gentle ventilation.\n\nAvoid strategies that raise insufflation risk, such as high inspiratory pressures (≥20–25 cm H<sub>2</sub>O) or large tidal volumes. **Cricoid pressure** is variably effective, may worsen laryngoscopic view, and should not be used to justify aggressive bagging. Routine preinduction gastric tubes in small-bowel obstruction can precipitate regurgitation and do not eliminate aspiration risk. Thus, in high hypoxemia-risk RSI, carefully titrated mask ventilation with low pressures and modest PEEP best balances oxygenation against aspiration risk.",
    "educationalObjective": "Decide when gentle mask ventilation during RSI is justified to prevent hypoxemia and how to limit insufflation."
  },
  {
    "id": "Core.6.6.5",
    "category": "General Anesthesia & Postop",
    "subcategory": "RSI and aspiration risk",
    "difficulty": "medium",
    "questionText": "A 54-year-old man with abdominal distension and persistent bilious emesis is scheduled for urgent laparotomy for small-bowel obstruction. He last ate 12 hours ago but has ongoing nasogastric output. History is notable for GERD and diabetic gastroparesis. He is 178 cm, 120 kg (BMI 38) with SpO<sub>2</sub> 95% on room air. Airway exam: Mallampati IV, interincisor distance 2 cm, limited neck extension from prior cervical fusion, and a dense beard.\n\nGiven his high aspiration risk and anticipated difficult airway, which initial airway management strategy is most appropriate to minimize aspiration while maximizing safety?",
    "answers": [
      {
        "text": "Modified RSI with gentle mask ventilation (≤12–15 cmH2O) after IV induction and neuromuscular blockade",
        "isCorrect": false,
        "explanation": "Modified RSI is reasonable when oxygen reserve is limited but the airway is expected to be straightforward; it still commits the patient to apnea and paralysis in a predicted difficult airway."
      },
      {
        "text": "Placement of a supraglottic airway after routine IV induction as a bridge to intubation",
        "isCorrect": false,
        "explanation": "Supraglottic airways do not protect against aspiration and may worsen gastric insufflation; they are not appropriate as a primary strategy in small-bowel obstruction."
      },
      {
        "text": "Standard RSI with cricoid pressure, no mask ventilation, and immediate laryngoscopy",
        "isCorrect": false,
        "explanation": "RSI limits regurgitation in full-stomach patients with an expected easy airway; here, the high likelihood of difficult laryngoscopy/ventilation makes a no-ventilation approach unsafe."
      },
      {
        "text": "Inhalational induction maintaining spontaneous ventilation, followed by asleep intubation",
        "isCorrect": false,
        "explanation": "A prolonged inhalational induction in a full-stomach patient increases aspiration risk and may cause gastric insufflation; it does not reliably mitigate regurgitation during airway manipulation."
      },
      {
        "text": "Awake flexible bronchoscopy–guided tracheal intubation in 20–30° head-up after topicalization and antisialagogue, then induction",
        "isCorrect": true,
        "explanation": "Awake intubation preserves airway reflexes and spontaneous ventilation, secures the airway before induction, and minimizes positive-pressure insufflation—optimal when aspiration risk coexists with a predicted difficult airway."
      }
    ],
    "didactic": "Rapid sequence induction (RSI) is intended to minimize the time between loss of consciousness and cuffed tracheal intubation in patients at high risk of aspiration (eg, small-bowel obstruction, recent/unknown NPO, pregnancy, trauma, GERD/gastroparesis). Classic components include adequate preoxygenation, induction, fast-onset neuromuscular blockade, avoidance of mask ventilation, and prompt intubation; cricoid pressure is optional and may be released if it impedes ventilation or view.\n\nWhen aspiration risk coexists with a predicted difficult airway, **awake tracheal intubation** is safer than RSI. Maintaining spontaneous ventilation and airway reflexes allows oxygenation while securing the tube before induction, avoiding a cannot-intubate/cannot-oxygenate scenario. Best practices include:\n- 20–30° head-up positioning, meticulous topicalization, and an antisialagogue (eg, glycopyrrolate)\n- Continuous suction and nasogastric decompression (which reduces but does not eliminate risk)\n- Minimal, titrated sedation as needed and a backup plan (eg, video-assisted or flexible bronchoscopy)\n\nA **modified RSI** (gentle mask ventilation with peak inspiratory pressure ≤12–15 cmH2O) is reasonable when oxygen reserve is limited (eg, morbid obesity, late pregnancy, severe hypoxemia) and the airway is expected to be uncomplicated. It reduces atelectasis and desaturation but still entails paralysis and apnea; thus, it is not ideal when difficult intubation/ventilation is anticipated.\n\nAdditional considerations:\n- Optimize preoxygenation (head-up/ramped, PEEP, nasal apneic oxygenation) to increase safe apnea time.\n- Cricoid pressure may decrease regurgitation but can worsen laryngoscopic view and impede ventilation; prioritize oxygenation and release if obstructive.\n- Supraglottic airways do not protect against aspiration and are poor primary choices in high-risk patients.\n\nIn this patient with small-bowel obstruction and multiple predictors of difficult airway, awake intubation most effectively balances aspiration prevention with airway safety.",
    "educationalObjective": "Identify clinical indications for rapid sequence induction (RSI) and when modified RSI or awake intubation is safer."
  },
  {
    "id": "Core.6.6.6",
    "category": "General Anesthesia & Postop",
    "subcategory": "RSI and aspiration risk",
    "difficulty": "hard",
    "questionText": "A 24-year-old man presents after a high-speed motorcycle crash with vomiting and progressive hypoxemia (SpO<sub>2</sub> 90% on nonrebreather). He is somnolent (GCS 7), tachycardic, and has a rigid cervical collar. Physical exam shows periorbital ecchymoses and hemotympanum. He requires emergent airway control for airway protection and oxygenation; cervical spine injury is suspected and no imaging is available.\n\nWhich of the following airway management strategies best minimizes aspiration risk while maintaining cervical spine protection in this patient?",
    "answers": [
      {
        "text": "Place the patient in the sniffing position to optimize laryngoscopy and perform RSI with vigorous bag-mask ventilation to ensure oxygenation.",
        "isCorrect": false,
        "explanation": "Sniffing position risks cervical spine movement and vigorous BMV promotes gastric insufflation and aspiration; neutral alignment with MILS and gentle ventilation is preferred."
      },
      {
        "text": "Remove the anterior collar, apply manual in-line stabilization, perform RSI with video laryngoscopy using apneic oxygenation, and provide low-pressure mask ventilation (≤10–12 cm H2O) if needed while adjusting/releasing cricoid pressure if it impedes laryngoscopy or ventilation.",
        "isCorrect": true,
        "explanation": "This approach balances aspiration mitigation and cervical spine protection: MILS with the anterior collar removed, neutral alignment, VL to minimize neck motion, cautious BMV to prevent hypoxemia, and judicious cricoid pressure that can be modified if it obstructs the view or ventilation."
      },
      {
        "text": "Delay induction to place an orogastric tube for gastric decompression before intubation to reduce aspiration risk.",
        "isCorrect": false,
        "explanation": "Gastric tube placement before securing the airway increases aspiration risk during active emesis and airway manipulation; decompression should occur after the cuffed endotracheal tube is in place."
      },
      {
        "text": "Perform awake nasotracheal fiberoptic intubation with the collar in place to avoid neck movement.",
        "isCorrect": false,
        "explanation": "Awake fiberoptic is unsafe in a vomiting, low-GCS patient and nasotracheal passage is contraindicated with suspected basilar skull fracture (periorbital ecchymosis, hemotympanum)."
      },
      {
        "text": "Maintain the rigid collar intact and perform direct laryngoscopy in neutral position with firm cricoid pressure while strictly avoiding any positive pressure ventilation.",
        "isCorrect": false,
        "explanation": "Keeping the full collar limits mouth opening and worsens glottic exposure; strict avoidance of ventilation risks severe hypoxemia. Cricoid pressure may impede laryngoscopy and should be adjusted or released if it interferes."
      }
    ],
    "didactic": "In trauma patients with a presumed full stomach and suspected cervical spine injury, the safest approach is a **modified rapid-sequence induction (RSI)** that preserves oxygenation while minimizing aspiration and neck movement. Key elements include:\n\n- **Cervical precautions:** Remove the anterior portion of the rigid collar to allow mouth opening and apply **manual in-line stabilization (MILS)** to maintain neutral alignment. Avoid the sniffing position. \n- **Device choice:** **Video laryngoscopy (VL)** reduces the need for head/neck extension and improves glottic visualization with MILS compared with direct laryngoscopy.\n- **Aspiration mitigation:** Preoxygenate (e.g., tight-seal mask, 100% O<sub>2</sub>) and consider **apneic oxygenation** via nasal cannula. In hypoxemia, use **gentle two-hand mask ventilation** with low inspiratory pressures (≤10–12 cm H2O) to limit gastric insufflation; preventing severe desaturation takes precedence over rigidly avoiding ventilation.\n- **Cricoid pressure (Sellick maneuver):** Evidence for aspiration prevention is limited; it can degrade the laryngoscopic view and hinder ventilation. Apply only with a trained assistant and **adjust or release** if it interferes with laryngoscopy or ventilation.\n- **Gastric decompression:** Place an orogastric tube **after** securing a cuffed endotracheal tube. Avoid nasogastric/nasotracheal routes when **basilar skull fracture** is suspected (e.g., raccoon eyes, hemotympanum) due to intracranial passage risk.\n- **Induction considerations:** Choose agents appropriate to hemodynamics (e.g., etomidate or ketamine in borderline MAP) and use a fast-onset neuromuscular blocker. RSI should include firm teamwork, suction readiness, and backup plans for failed intubation while maintaining MILS.\n\nThis strategy integrates aspiration risk reduction with cervical spine protection: anterior collar removal with MILS, VL to minimize neck movement, permissive low-pressure ventilation if needed to prevent hypoxemia, and flexible use of cricoid pressure based on its effect on laryngoscopy and ventilation.",
    "educationalObjective": "Integrate cervical spine precautions and aspiration risk mitigation in the trauma patient requiring RSI."
  },
  {
    "id": "Core.6.6.7",
    "category": "General Anesthesia & Postop",
    "subcategory": "RSI and aspiration risk",
    "difficulty": "hard",
    "questionText": "A 28-year-old G3P2 at 39 weeks with BMI 41 is rushed to the OR for a category-1 cesarean delivery due to persistent fetal bradycardia (FHR 80 bpm). She ate a full meal 2 hours ago. Standard monitors are applied and rapid preoxygenation with 100% O<sub>2</sub> is initiated. When positioned supine, her MAP falls to 55 mmHg and she becomes lightheaded; airway exam shows Mallampati III, adequate mouth opening, and normal neck mobility. The team plans general anesthesia. \n\nWhich immediate airway/anesthetic approach best minimizes maternal aspiration risk while optimizing maternal–fetal hemodynamics in this scenario?",
    "answers": [
      {
        "text": "Perform an awake fiberoptic intubation in the sitting position with topical anesthesia to maximize airway safety.",
        "isCorrect": false,
        "explanation": "Awake intubation is time-consuming and unsuitable for a category-1 cesarean with fetal bradycardia; it delays delivery and does not address immediate aortocaval compression."
      },
      {
        "text": "Administer sodium citrate, perform RSI with manual left uterine displacement, apply cricoid pressure after loss of consciousness, and use gentle mask ventilation with peak inspiratory pressure ≤15–20 cm H2O until laryngoscopy.",
        "isCorrect": true,
        "explanation": "This approach immediately reduces aspiration risk (nonparticulate antacid), prevents aortocaval compression (left uterine displacement), applies cricoid at the correct time, and permits low-pressure ventilation to mitigate rapid desaturation."
      },
      {
        "text": "Insert a size-4 laryngeal mask airway after induction to facilitate additional preoxygenation, then remove it and proceed to tracheal intubation.",
        "isCorrect": false,
        "explanation": "Elective supraglottic airway use in a full-stomach obstetric patient increases aspiration risk and adds unnecessary steps and delay in an emergent scenario."
      },
      {
        "text": "Delay incision to administer ranitidine and metoclopramide and wait at least 60 minutes before proceeding with RSI.",
        "isCorrect": false,
        "explanation": "Although H<sub>2</sub> blockers and prokinetics reduce acidity and volume, delaying a category-1 cesarean for pharmacologic prophylaxis is inappropriate and risks fetal harm."
      },
      {
        "text": "Proceed with rapid-sequence induction (RSI) in the supine position, apply cricoid pressure before induction, and avoid mask ventilation prior to intubation.",
        "isCorrect": false,
        "explanation": "Supine positioning worsens aortocaval compression, cricoid pressure should begin after loss of consciousness, and strict avoidance of mask ventilation risks rapid desaturation in obese parturients."
      }
    ],
    "didactic": "Full-stomach obstetric patients are at high risk for aspiration due to pregnancy-related decreases in LES tone and delayed gastric emptying during labor. Emergent cesarean delivery demands rapid, coordinated management that balances aspiration prevention with oxygenation and uteroplacental perfusion. The key elements are:\n\n- Immediate left uterine displacement (LUD) or 15° left tilt to relieve aortocaval compression, improving venous return and uteroplacental blood flow; treat hypotension promptly to protect fetal oxygen delivery.\n- Aspiration prophylaxis tailored to urgency: nonparticulate antacid (eg, sodium citrate 30 mL) acts immediately to raise gastric pH; H<sub>2</sub> blockers and metoclopramide help if time allows but should not delay a category-1 cesarean.\n- RSI with 100% O<sub>2</sub> preoxygenation. Apply cricoid pressure after loss of consciousness and maintain until the cuff is inflated and correct placement is confirmed. Although the efficacy of cricoid pressure is debated, it remains standard for high-risk patients.\n- Gentle mask ventilation is appropriate in parturients at high risk of rapid desaturation (eg, obesity, decreased FRC). Use low peak inspiratory pressures (≤15–20 cm H<sub>2</sub>O) with cricoid pressure to minimize gastric insufflation while preventing hypoxemia.\n- Anticipate difficult laryngoscopy: use a smaller ETT (eg, 6.5–7.0) due to airway edema, optimize positioning (ramped), and ensure skilled help and backup plans. Supraglottic airways are not first-line in full-stomach obstetrics but may be lifesaving in cannot-intubate–cannot-oxygenate scenarios.\n\nIn this scenario, sodium citrate provides immediate pH buffering, LUD corrects hemodynamic compromise from aortocaval compression, and correctly timed cricoid pressure with low-pressure mask ventilation balances aspiration precautions with the need to avoid rapid desaturation. Delays for pharmacologic prophylaxis or time-intensive awake techniques are inappropriate in a category-1 cesarean where expedited delivery is critical.",
    "educationalObjective": "Manage the full-stomach obstetric patient with left uterine displacement and aspiration precautions."
  },
  {
    "id": "Core.6.6.8",
    "category": "General Anesthesia & Postop",
    "subcategory": "RSI and aspiration risk",
    "difficulty": "easy",
    "questionText": "A 52-year-old man with BMI 45 and small-bowel obstruction has had multiple episodes of emesis and is brought for urgent laparotomy. You plan a rapid-sequence induction. In the OR he is placed supine and preoxygenated with 100% O<sub>2</sub> via face mask at 6 L/min for 2 minutes using a one-handed mask hold; end-tidal O<sub>2</sub> reaches 70%. After induction and cricoid pressure, no mask ventilation is provided; SpO<sub>2</sub> decreases to 88% within 45 seconds. Before a second attempt, you re-establish spontaneous breathing and plan to re-preoxygenate.\n\nWhich modification will most increase the safe apnea time while minimizing aspiration risk?",
    "answers": [
      {
        "text": "Add standard nasal cannula at 5 L/min for apneic oxygenation while keeping the current technique",
        "isCorrect": false,
        "explanation": "Low-flow apneic oxygenation provides modest benefit but is less impactful than correcting the inadequate preoxygenation technique (seal/flow/CPAP) that failed to achieve adequate end-tidal O<sub>2</sub>."
      },
      {
        "text": "Apply firm cricoid pressure throughout preoxygenation to reduce regurgitation",
        "isCorrect": false,
        "explanation": "Cricoid pressure does not enhance oxygenation and can worsen mask seal and glottic view; it may impede effective preoxygenation and should not be relied upon to extend safe apnea time."
      },
      {
        "text": "Elevate the head of bed 25° (reverse Trendelenburg) during preoxygenation",
        "isCorrect": false,
        "explanation": "Head-up positioning increases FRC and delays desaturation, but with a loose seal and low flows (end-tidal O<sub>2</sub> 70%), inadequate denitrogenation remains the primary limitation; optimizing seal/flow/CPAP yields greater benefit."
      },
      {
        "text": "Use 8 vital-capacity breaths over 60 seconds with a one-handed mask hold",
        "isCorrect": false,
        "explanation": "The vital-capacity technique can be effective in healthy patients, but in obesity and aspiration risk, a one-handed seal without CPAP is inferior to prolonged preoxygenation with a tight seal and CPAP."
      },
      {
        "text": "Preoxygenate with a two-handed mask seal using 100% O<sub>2</sub> at 15 L/min and 10 cm H2O CPAP (no positive-pressure breaths)",
        "isCorrect": true,
        "explanation": "A tight two-handed seal with high fresh gas flow and CPAP improves denitrogenation (target end-tidal O<sub>2</sub> ≥90%), recruits alveoli, and increases FRC without providing positive-pressure breaths that risk gastric insufflation."
      }
    ],
    "didactic": "For high-risk rapid-sequence induction, the primary goal of preoxygenation is to maximize alveolar O<sub>2</sub> content and functional residual capacity (FRC) to prolong safe apnea time. The most effective, immediately actionable change here is improving preoxygenation quality by eliminating room-air entrainment and adding lung-recruiting pressure. A two-handed mask hold (V–E grip with jaw thrust) forms a tight seal, allowing delivery of 100% O<sub>2</sub> at high fresh gas flows (≥10–15 L/min) and the application of CPAP/PEEP 5–10 cm H2O without positive-pressure breaths. This combination increases end-tidal O<sub>2</sub> (target ≥90%), prevents atelectasis, raises FRC, and significantly delays desaturation while respecting aspiration concerns by avoiding mask ventilation.\n\nHead-up (reverse Trendelenburg 20–30° or ramped) positioning is also beneficial—especially in obesity and pregnancy—because it increases FRC and reduces airway closure. However, when end-tidal O<sub>2</sub> remains low (eg, 70%) due to a loose mask and low flows, correcting the seal and adding CPAP with high flows provides a larger, more immediate impact on safe apnea time. Cricoid pressure does not improve oxygenation and can worsen mask seal; it should not compromise preoxygenation. The “8 vital-capacity breaths” technique can accelerate preoxygenation in healthy patients but is inferior to CPAP-based preoxygenation in obese or shunt-prone patients. Apneic oxygenation via nasal cannula can be a useful adjunct, but low flows (eg, 5 L/min) offer modest benefit compared with optimized preoxygenation; high-flow nasal oxygen provides greater effect when available.\n\nPractical approach in high aspiration risk: preoxygenate 3–5 minutes with 100% O<sub>2</sub>, two-handed seal, high flows, CPAP 5–10 cm H2O, and head-up positioning; avoid N<sub>2</sub>O; aim for end-tidal O<sub>2</sub> ≥90%. If ventilation is needed, use low pressures to limit gastric insufflation.",
    "educationalObjective": "Optimize preoxygenation with head-up positioning and tight-seal techniques to prolong safe apnea time."
  },
  {
    "id": "Core.6.6.9",
    "category": "General Anesthesia & Postop",
    "subcategory": "RSI and aspiration risk",
    "difficulty": "medium",
    "questionText": "During rapid-sequence induction for emergent laparotomy in a 58-year-old man with small-bowel obstruction, copious bilious material regurgitates into the oropharynx. The trachea is intubated on the first attempt with a cuffed endotracheal tube, but SpO<sub>2</sub> falls to 86% on 100% O<sub>2</sub>, peak inspiratory pressure is 32 cm H2O with expiratory wheeze, and frothy brown secretions are suctioned through the tube. Blood pressure is 128/74 mmHg and heart rate is 104/min. A chest radiograph has not yet been obtained.\n\nWhich of the following is the most appropriate immediate management to minimize further lung injury and improve oxygenation?",
    "answers": [
      {
        "text": "Place a nasogastric tube and proceed with surgery without changes to ventilation",
        "isCorrect": false,
        "explanation": "Gastric decompression may help prevent further regurgitation, but immediate priorities are airway suctioning and oxygenation with PEEP."
      },
      {
        "text": "Administer IV methylprednisolone to attenuate inflammatory lung injury",
        "isCorrect": false,
        "explanation": "Corticosteroids have not shown benefit in aspiration pneumonitis and are not recommended routinely."
      },
      {
        "text": "Begin broad-spectrum antibiotics and perform bronchoalveolar lavage via the endotracheal tube",
        "isCorrect": false,
        "explanation": "Prophylactic antibiotics and lavage are not indicated for aspiration pneumonitis and lavage can disseminate contents and worsen hypoxemia."
      },
      {
        "text": "Aggressively suction the oropharynx and endotracheal tube, ventilate with 100% O<sub>2</sub> with PEEP, and perform bronchoscopy if particulate material is suspected",
        "isCorrect": true,
        "explanation": "Immediate airway suctioning and supportive ventilation with PEEP limit further contamination and shunt; bronchoscopy is reserved for suspected particulate obstruction."
      },
      {
        "text": "Extubate the trachea to allow lateral positioning and recover with supplemental oxygen",
        "isCorrect": false,
        "explanation": "Maintaining a cuffed endotracheal tube protects the airway and facilitates suctioning; extubation risks re-aspiration and loss of airway."
      }
    ],
    "didactic": "Acute aspiration of gastric contents causes chemical pneumonitis with surfactant inactivation, alveolar collapse, and increased intrapulmonary shunt. The cornerstone of management is prompt airway control and supportive ventilation rather than empiric anti-infective or anti-inflammatory therapy.\n\nKey steps include:\n- Immediately suction the oropharynx and endotracheal tube to remove aspirate; maintain a cuffed tube to prevent further contamination and consider head-down lateral positioning if feasible.\n- Provide 100% O<sub>2</sub> initially and apply **PEEP** to recruit collapsed alveoli, improve V/Q matching, and reduce shunt-related hypoxemia. Use lung-protective settings (eg, low tidal volumes) and treat bronchospasm with inhaled bronchodilators as needed.\n- Avoid routine bronchoalveolar lavage; it can spread aspirate distally and worsen gas exchange. **Bronchoscopy** is appropriate when particulate material (eg, food) is suspected or when there is persistent lobar collapse/obstruction despite suctioning.\n- Do not administer **prophylactic antibiotics** or **steroids** for aspiration pneumonitis. Most cases improve within 24–48 hours with supportive care. Start antibiotics only if there is evidence of secondary infection (fever, leukocytosis, purulent secretions, or new/progressive consolidation), typically after 48 hours, or if another source of infection is suspected.\n- Obtain a chest radiograph when feasible (often normal early), monitor oxygenation, and admit for observation. Consider arterial blood gas analysis if hypoxemia is severe or worsening.\n\nThis approach prioritizes airway clearance and oxygenation, limits further lung injury via **PEEP-mediated recruitment**, and reserves bronchoscopy for solid debris. It also reinforces antibiotic stewardship—treat infection, not sterile chemical pneumonitis—aligning with best practices in perioperative aspiration management.",
    "educationalObjective": "Outline post-aspiration management: suctioning, oxygenation, PEEP, bronchoscopy as needed, and antibiotics only for infection."
  },
  {
    "id": "Core.6.6.10",
    "category": "General Anesthesia & Postop",
    "subcategory": "RSI and aspiration risk",
    "difficulty": "hard",
    "questionText": "A 62-year-old man with small-bowel obstruction and persistent emesis presents for emergent laparotomy. He is preoxygenated with 100% O<sub>2</sub> and undergoes RSI with rocuronium and propofol while cricoid pressure is applied. Videolaryngoscopy yields a Cormack-Lehane grade 3 view, and an esophageal intubation is immediately recognized and the tube removed. A brief two-hand mask ventilation attempt with low inspiratory pressures produces poor chest rise, no ETCO<sub>2</sub>, and worsening gastric distention. SpO<sub>2</sub> falls to 78% with HR 45/min and BP 90/55 mmHg despite jaw thrust and an oral airway.\n\nWhich of the following is the most appropriate next step to prioritize oxygenation in this failed RSI?",
    "answers": [
      {
        "text": "Place a nasogastric tube to decompress the stomach before further airway attempts",
        "isCorrect": false,
        "explanation": "Gastric decompression is secondary to restoring oxygenation and may be difficult or hazardous during active airway compromise; it should follow, not precede, effective oxygenation."
      },
      {
        "text": "Proceed directly to emergency front-of-neck access (cricothyrotomy)",
        "isCorrect": false,
        "explanation": "Emergency front-of-neck access is indicated when both facemask and SGA ventilation fail to provide oxygenation; an SGA should be attempted first in this scenario."
      },
      {
        "text": "Reattempt laryngoscopy using a different blade and a bougie under sustained cricoid pressure",
        "isCorrect": false,
        "explanation": "Repeated attempts delay restoration of oxygenation and risk airway trauma; in a failed RSI with desaturation, the priority is an oxygenation rescue pathway rather than immediate re-laryngoscopy."
      },
      {
        "text": "Insert a second-generation supraglottic airway and provide low-pressure ventilation to restore oxygenation, then plan definitive airway",
        "isCorrect": true,
        "explanation": "Second-generation SGAs offer a better seal and gastric drainage channel, allowing rapid oxygenation with lower insufflation pressures; oxygenation takes precedence over aspiration concerns in a failed RSI."
      },
      {
        "text": "Increase mask ventilation pressures while maintaining cricoid pressure to improve chest rise",
        "isCorrect": false,
        "explanation": "Escalating mask pressures will preferentially insufflate the stomach, exacerbate regurgitation risk, and is unlikely to reverse hypoxemia given ineffective mask ventilation."
      }
    ],
    "didactic": "In a failed RSI with rapidly worsening hypoxemia, the immediate goal is to re-establish oxygenation via a predefined rescue pathway rather than to persist with intubation attempts. Contemporary difficult airway algorithms emphasize prioritizing ventilation/oxygenation over aspiration concerns once desaturation occurs. After failure of endotracheal intubation and ineffective facemask ventilation, a **second-generation supraglottic airway (SGA)** should be inserted promptly.\n\nSecond-generation SGAs (eg, ProSeal, LMA Supreme, i-gel) provide:\n- A higher oropharyngeal leak pressure, enabling effective ventilation with lower inspiratory pressures (eg, ≤15–20 cm H<sub>2</sub>O)\n- A gastric drainage channel that permits suctioning and may reduce insufflation and regurgitation risk\n\nKey principles in failed RSI oxygenation rescue:\n- **Oxygenation first**: Hypoxemia causes immediate harm; the theoretical risk of aspiration is secondary. Use the best available lifeline that can oxygenate quickly (facemask → SGA → ETT).\n- **Limit repeated laryngoscopy**: Additional attempts without oxygenation worsen hypoxemia and trauma. Switch early to SGA when intubation and mask ventilation are ineffective.\n- **Optimize SGA ventilation**: Apply two-hand seal, low tidal volumes, and low pressures; consider releasing or adjusting cricoid pressure if it impedes placement/ventilation. Use the gastric port to suction the stomach once oxygenation is restored.\n- **Plan the definitive airway** once stable: Options include intubation through the SGA (eg, fiberoptic Aintree) or awakening if appropriate and feasible.\n- **Escalate to emergency front-of-neck access (eFONA)** if oxygenation fails with both mask and SGA. The scalpel–bougie–tube technique is the fastest, most reliable method in the “can’t intubate, can’t oxygenate” state.\n\nIn this scenario, mask ventilation is ineffective and desaturation is severe. Inserting a second-generation SGA to restore oxygenation is the best next step; eFONA is reserved for failure of SGA oxygenation.",
    "educationalObjective": "Recognize failed RSI and initiate a predefined rescue pathway prioritizing oxygenation (SGA or front-of-neck access)."
  },
  {
    "id": "Core.6.6.11",
    "category": "General Anesthesia & Postop",
    "subcategory": "RSI and aspiration risk",
    "difficulty": "medium",
    "questionText": "A 32-year-old man with blunt abdominal trauma is brought emergently to the OR for exploratory laparotomy. He vomited en route and last ate 1 hour ago. He is tachycardic and hypotensive despite 2 units of PRBCs and a norepinephrine infusion (0.05 µg/kg/min). Vitals: HR 122/min, BP 88/50 mmHg (MAP 63), SpO₂ 96% on nonrebreather. Ophthalmology notes a right open-globe injury with positive Seidel sign. Neurologic exam is nonfocal. You plan a rapid-sequence intubation with cricoid pressure and controlled ventilation. \n\nWhich induction agent is most appropriate to facilitate RSI in this patient?",
    "answers": [
      {
        "text": "Etomidate 0.3 mg/kg IV",
        "isCorrect": true,
        "explanation": "Etomidate provides rapid hypnosis with minimal hemodynamic depression and lowers CMRO<sub>2</sub>, CBF, ICP, and IOP—ideal for hemorrhagic shock and open-globe injury during RSI."
      },
      {
        "text": "Propofol 2 mg/kg IV",
        "isCorrect": false,
        "explanation": "Propofol decreases ICP and IOP but causes marked vasodilation and myocardial depression, risking profound hypotension and reduced CPP in hemorrhagic shock."
      },
      {
        "text": "Midazolam 0.2 mg/kg IV",
        "isCorrect": false,
        "explanation": "High-dose midazolam has slower onset and can cause hypotension; it is less reliable for RSI compared with agents that provide rapid hypnosis and stable hemodynamics."
      },
      {
        "text": "Thiopental 4 mg/kg IV",
        "isCorrect": false,
        "explanation": "Thiopental reduces ICP and IOP but can cause significant hypotension from venodilation and myocardial depression, which is unsafe in hypovolemic shock."
      },
      {
        "text": "Ketamine 2 mg/kg IV",
        "isCorrect": false,
        "explanation": "Ketamine preserves blood pressure via sympathetic stimulation, but it can increase IOP and is generally avoided with open-globe injury; evidence for ICP effects is mixed but not a contraindication when ocular injury is absent."
      }
    ],
    "didactic": "In RSI for high aspiration risk, the induction agent should enable rapid hypnosis while maintaining hemodynamics and addressing intracranial/ocular goals. For trauma with hemorrhagic shock and an open-globe injury, the priorities are to preserve MAP (and therefore CPP = MAP − ICP), avoid increasing IOP, and allow swift airway control.\n\nEtomidate (0.2–0.3 mg/kg) is preferred in this setting because it produces rapid unconsciousness with minimal change in MAP/HR and reduces CMRO<sub>2</sub>, CBF, ICP, and IOP. Maintaining MAP safeguards CPP and reduces secondary brain injury risk, while lower IOP protects the integrity of the open globe. Although etomidate transiently suppresses adrenal steroidogenesis, a single induction dose has not shown worse outcomes and is acceptable for emergent RSI.\n\nAgent comparisons:\n- Etomidate: Hemodynamically neutral; ↓ CMRO<sub>2</sub>/CBF/ICP; ↓ IOP; rapid onset.\n- Ketamine: Sympathomimetic (helps BP) but may increase IOP; modern data suggest no clinically significant ICP rise with controlled ventilation in TBI; generally avoided in open globe.\n- Propofol: ↓ ICP/IOP but causes vasodilation and myocardial depression → hypotension and ↓ CPP in shock.\n- Thiopental: ↓ ICP/IOP but significant hypotension in hypovolemia.\n- Midazolam: Slower onset and less predictable for RSI; hypotension at higher doses.\n\nFor neuromuscular blockade, succinylcholine increases IOP and is traditionally avoided in open-globe injury; high-dose rocuronium (1.2 mg/kg) is a common alternative. Regardless of paralytic, the hypnotic choice drives initial hemodynamic stability and neuro-ocular protection. In a hypotensive, full-stomach trauma patient with an open globe, etomidate best balances rapid onset, stable blood pressure, and favorable ICP/IOP effects.",
    "educationalObjective": "Select induction agents for RSI based on hemodynamics and intracranial/ocular considerations."
  },
  {
    "id": "Core.6.6.12",
    "category": "General Anesthesia & Postop",
    "subcategory": "RSI and aspiration risk",
    "difficulty": "medium",
    "questionText": "A 56-year-old man with a small-bowel obstruction and persistent vomiting presents for emergent laparotomy. He is obese (BMI 42) with obstructive sleep apnea; room-air SpO<sub>2</sub> is 92%. After 3 minutes of tight mask preoxygenation with PEEP 10 cm H2O in a 20° head-up position, end-tidal O<sub>2</sub> is 86% and SpO<sub>2</sub> is 100%. You plan a rapid-sequence induction with succinylcholine and video laryngoscopy and prefer to avoid bag-mask ventilation during the attempt due to high aspiration risk.\n\nWhich additional measure at induction will most increase the duration before desaturation during the apneic laryngoscopy period?",
    "answers": [
      {
        "text": "Apply firm cricoid pressure and remove all nasal devices to improve the laryngoscopic view",
        "isCorrect": false,
        "explanation": "Cricoid pressure does not improve oxygenation and may worsen the glottic view; removing nasal oxygen eliminates apneic oxygenation and shortens safe apnea time."
      },
      {
        "text": "Use a nonrebreather mask at 15 L/min between preoxygenation and laryngoscopy, then remove it for the attempt",
        "isCorrect": false,
        "explanation": "A nonrebreather mask does not provide oxygen during the apneic laryngoscopy; once removed, it offers no benefit to extend safe apnea time."
      },
      {
        "text": "Apply high-flow nasal cannula at 60 L/min (FiO<sub>2</sub> 1.0) starting before induction and continue during laryngoscopy",
        "isCorrect": true,
        "explanation": "High-flow nasal oxygen (THRIVE) maintains apneic oxygenation, generates flow-dependent pharyngeal CPAP, and washes out dead space, prolonging safe apnea time more than standard cannula—particularly in obese patients."
      },
      {
        "text": "Leave a standard nasal cannula in place at 15 L/min throughout laryngoscopy",
        "isCorrect": false,
        "explanation": "Apneic oxygenation with a standard nasal cannula helps, but it provides limited flow and minimal positive airway pressure; high-flow nasal oxygen confers a larger benefit, especially in obesity."
      },
      {
        "text": "Insert an oropharyngeal airway after induction without supplemental oxygen",
        "isCorrect": false,
        "explanation": "An oropharyngeal airway can reduce soft-tissue collapse but does not deliver O<sub>2</sub>; without supplemental oxygen, it does not extend the safe apnea time."
      }
    ],
    "didactic": "Obesity reduces functional residual capacity (FRC) and increases shunt and atelectasis, shortening the safe apnea time despite good preoxygenation. During rapid-sequence induction, maintaining oxygen delivery during the apneic interval is critical because ongoing O<sub>2</sub> uptake (~250 mL/min) creates a negative alveolar pressure that can entrain O<sub>2</sub> from the pharynx to the alveoli if a patent pathway is present (**apneic oxygenation**). High-flow nasal cannula (HFNC) at 40–70 L/min and FiO<sub>2</sub> 1.0 provides several advantages over standard nasal cannula:\n\n- Continuous O<sub>2</sub> delivery throughout laryngoscopy, sustaining a high pharyngeal O<sub>2</sub> reservoir\n- Flow-dependent pharyngeal CPAP (≈2–7 cm H2O), which helps counteract airway collapse and atelectasis in obesity\n- Nasopharyngeal dead space washout, improving delivered FiO<sub>2</sub> and facilitating diffusion of O<sub>2</sub> to alveoli\n\nThese mechanisms collectively prolong the time to desaturation without applying positive-pressure ventilation, which is desirable in patients at high risk of aspiration. Standard nasal cannula at 10–15 L/min (\"NODESAT\") is reasonable when HFNC is unavailable, but it offers less CPAP effect and less effective washout, making it less effective in severely obese patients. Nonrebreather masks and cricoid pressure do not provide oxygen during laryngoscopy; removing nasal oxygen eliminates apneic oxygenation. Oropharyngeal airways may aid patency but do not deliver O<sub>2</sub>.\n\nHFNC should be initiated before induction and continued during the apneic period. It does not prevent aspiration and does not meaningfully remove CO<sub>2</sub> (expect PaCO<sub>2</sub> to rise ~3–6 mmHg initially, then ~3–4 mmHg/min), so it complements but does not replace thorough preoxygenation and timely intubation. In high-risk patients (eg, obesity, pregnancy, critical illness), combining head-up preoxygenation with HFNC apneic oxygenation maximizes safe apnea time.",
    "educationalObjective": "Use apneic oxygenation (e.g., nasal cannula/HFNC) during laryngoscopy to extend safe apnea time."
  },
  {
    "id": "Core.13.1.1",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Benzodiazepines and alpha-2 agonists",
    "difficulty": "hard",
    "questionText": "A 58-year-old man with decompensated cirrhosis (Child-Pugh C, albumin 2.5 g/dL) and anuric end-stage renal disease on hemodialysis is scheduled for ERCP under monitored anesthesia care. He is receiving voriconazole for invasive aspergillosis. Baseline mental status is normal; vital signs are stable. The endoscopist requests midazolam for anxiolysis and amnesia. You anticipate a short but stimulus-dense procedure and wish to minimize delayed emergence and respiratory depression.\n\nWhich of the following is the most appropriate midazolam dosing strategy for this patient?",
    "answers": [
      {
        "text": "Use standard bolus dosing and rely on postprocedure hemodialysis to clear midazolam and its metabolites",
        "isCorrect": false,
        "explanation": "Hemodialysis does not reliably clear midazolam and only partially removes the glucuronidated metabolite; redistribution and protein binding limit effectiveness, so delayed emergence can still occur."
      },
      {
        "text": "Give full-dose midazolam and plan routine flumazenil at case end to prevent residual sedation",
        "isCorrect": false,
        "explanation": "Prophylactic flumazenil is unsafe; its shorter half-life than midazolam/metabolites risks resedation and does not address accumulation. Dose reduction and careful titration are preferred."
      },
      {
        "text": "Administer usual bolus dosing but reduce any infusion rate by 50% (eg, 0.025 mg/kg/h) to limit accumulation",
        "isCorrect": false,
        "explanation": "Even reduced infusion rates can accumulate substantially in cirrhosis with concurrent CYP3A inhibition and renal failure; avoiding infusions altogether is safer for short procedures."
      },
      {
        "text": "Administer 2 mg IV midazolam, then 1 mg every 2 minutes as needed, and start an infusion at 0.05 mg/kg/h",
        "isCorrect": false,
        "explanation": "Standard bolus plus infusion risks marked accumulation because cirrhosis (↓CYP3A4 clearance), voriconazole (strong CYP3A inhibitor), and renal failure (active metabolite accumulation) all prolong effect, increasing oversedation and respiratory depression."
      },
      {
        "text": "Titrate 0.5 mg IV midazolam boluses no more often than every 5–10 minutes to a maximum of 1 mg; avoid a continuous infusion",
        "isCorrect": true,
        "explanation": "Severe hepatic impairment, ESRD, and CYP3A4 inhibition markedly reduce clearance and allow active metabolite accumulation. Small, infrequent boluses with a low total dose and avoidance of infusion minimize prolonged sedation and hypoventilation."
      }
    ],
    "didactic": "Midazolam is a highly lipophilic, high–hepatic-extraction benzodiazepine metabolized by **CYP3A4** to **1‑hydroxymidazolam (1‑OH‑M)**, which retains significant pharmacologic activity. 1‑OH‑M is subsequently glucuronidated to **1‑OH‑M‑glucuronide**, a water-soluble but still clinically active metabolite that is **renally excreted**. In **cirrhosis**, reduced CYP3A activity, portosystemic shunting, and **hypoalbuminemia** (↑free fraction) all increase midazolam’s effect and duration. Concomitant **CYP3A inhibitors** (eg, voriconazole, macrolides, protease inhibitors) can further raise plasma concentrations several-fold. Although parent midazolam is hepatically cleared, **ESRD** allows substantial accumulation of the glucuronidated metabolite, which can produce prolonged sedation and respiratory depression. Intermittent hemodialysis does not reliably normalize recovery because of protein binding, redistribution, and ongoing metabolite formation.\n\nFor short procedures in patients with combined hepatic and renal impairment, the safest approach is to **reduce the dose and slow the redosing interval**, targeting the minimum effective total dose while **avoiding continuous infusions**. Practical strategies include 0.5 mg IV boluses spaced every 5–10 minutes, with a low maximum (eg, 1 mg), and close monitoring for hypoventilation. Avoid assuming dialysis will clear sedatives; anticipate **delayed emergence** and consider postprocedure observation.\n\nAlternatives may be preferable when deeper or longer sedation is expected. **Dexmedetomidine** provides cooperative sedation with minimal respiratory depression but also has reduced clearance in severe hepatic dysfunction and may cause bradycardia/hypotension, necessitating dose reduction. **Propofol** avoids active metabolites but can worsen hypotension; careful titration is required. **Diazepam** is unfavorable due to long-acting active metabolites (eg, desmethyldiazepam) and very prolonged recovery in liver disease. Overall, in hepatic or renal impairment—especially with **CYP3A4 inhibition**—midazolam should be titrated in small increments with extended intervals and infusions avoided.",
    "educationalObjective": "Adjust midazolam dosing in hepatic or renal impairment due to active metabolites and altered clearance."
  },
  {
    "id": "Core.13.1.2",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Benzodiazepines and alpha-2 agonists",
    "difficulty": "easy",
    "questionText": "A 68-year-old man (BMI 34) with untreated obstructive sleep apnea presents for screening colonoscopy under monitored anesthesia care. He is opioid-naïve and very anxious. You plan to provide sedation with midazolam and fentanyl. Baseline SpO₂ is 98% on room air and he is hemodynamically stable. To minimize the risk of hypoventilation while still achieving anxiolysis and analgesia, which initial dosing strategy is most appropriate?\n\nWhich of the following is the best initial approach?",
    "answers": [
      {
        "text": "Midazolam 2 mg IV now; after placing nasal O<sub>2</sub> at 4 L/min, give fentanyl 50–100 µg IV as needed",
        "isCorrect": false,
        "explanation": "Supplemental O<sub>2</sub> can mask hypoventilation; standard dosing of both agents still creates high apnea risk from synergy."
      },
      {
        "text": "Fentanyl 100 µg IV now, wait 3 min, then give midazolam 2 mg IV if needed",
        "isCorrect": false,
        "explanation": "Giving full doses sequentially does not mitigate synergy; each full dose still markedly blunts ventilatory drive."
      },
      {
        "text": "Midazolam 0.5 mg IV, then fentanyl 12.5–25 µg IV, titrating in small increments every 2–3 min as needed",
        "isCorrect": true,
        "explanation": "Opioids and benzodiazepines have synergistic respiratory depression; initial doses of each should be reduced and titrated slowly with adequate time for peak effect."
      },
      {
        "text": "Midazolam 2 mg IV and fentanyl 100 µg IV given together to achieve rapid sedation",
        "isCorrect": false,
        "explanation": "Simultaneous standard boluses increase the risk of apnea due to pharmacodynamic synergy, especially in elderly/OSA patients."
      },
      {
        "text": "Midazolam 2 mg IV with remifentanil 0.5–1 µg/kg IV bolus to shorten opioid duration and reduce apnea",
        "isCorrect": false,
        "explanation": "Remifentanil produces profound, rapid-onset respiratory depression; shortening duration does not prevent initial apnea."
      }
    ],
    "didactic": "Benzodiazepines and opioids produce **pharmacodynamic synergy** for both sedation and respiratory depression at brainstem respiratory centers. Midazolam decreases the ventilatory response to CO₂ and upper airway muscle tone; opioids (eg, fentanyl) depress the hypercapnic and hypoxic drives and blunt arousal. When combined, the magnitude of ventilatory depression is more than additive, so doses that are safe alone can cause apnea together—particularly in older adults, patients with OSA, obesity, or underlying pulmonary disease.\n\nThe safest approach is to **reduce the initial dose of each drug and titrate slowly** to effect. Practical strategies include:\n- Start with midazolam 0.5 mg IV and fentanyl 12.5–25 µg IV, separated by 2–3 min, then give small increments at similar intervals while observing ventilation.\n- Allow time for peak effect (fentanyl ~3–5 min; midazolam ~3–5 min) before redosing to avoid stacking.\n- Anticipate greater sensitivity in the elderly or OSA; consider even smaller increments or using a single agent plus a non-opioid adjunct.\n\nAvoid simultaneous “standard” boluses (eg, midazolam 2 mg with fentanyl 100 µg), which frequently precipitate hypoventilation/apnea. Switching to a short-acting opioid (eg, remifentanil) does not prevent initial apnea because its effect-site concentration rises rapidly. Supplemental O<sub>2</sub> is appropriate but can mask hypoventilation; continuous capnography (EtCO₂) is preferred to detect early hypoventilation.\n\nIf significant respiratory depression occurs, support ventilation and consider **titrated reversal**: naloxone in 20–40 µg increments for opioid effect and flumazenil 0.2 mg IV increments for benzodiazepine effect, recognizing potential resedation as drug levels redistribute. Anticipating synergy and **front-end dose reduction with slow titration** is the key preventive strategy.",
    "educationalObjective": "Anticipate respiratory depression synergy when combining benzodiazepines with opioids and adjust dosing."
  },
  {
    "id": "Core.13.1.3",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Benzodiazepines and alpha-2 agonists",
    "difficulty": "medium",
    "questionText": "A 52-year-old man (BMI 38) with severe OSA on CPAP and prior head-and-neck radiation presents for total laryngectomy. He has trismus (interincisor distance 2 cm) and limited neck extension. An awake fiberoptic nasal intubation is planned after thorough airway topicalization. He is anxious but cooperative, with stable vitals and SpO₂ 97% on room air. The anesthesiologist wants sedation that maintains spontaneous ventilation and preserves airway reflexes to minimize the risk of airway loss.\n\nWhich sedation regimen is most appropriate to achieve cooperative sedation while preserving spontaneous ventilation and airway reflexes in this patient?",
    "answers": [
      {
        "text": "Dexmedetomidine 1 μg/kg over 10 min, then 0.4–0.7 μg/kg/h infusion",
        "isCorrect": true,
        "explanation": "Dexmedetomidine provides cooperative sedation with minimal respiratory depression, maintains airway reflexes, and offers modest analgesia—ideal for awake fiberoptic intubation in OSA."
      },
      {
        "text": "Remifentanil infusion 0.15 μg/kg/min after 1 μg/kg IV bolus",
        "isCorrect": false,
        "explanation": "Although titratable, remifentanil can cause apnea and chest wall rigidity, especially after bolus dosing, jeopardizing spontaneous ventilation in a difficult airway."
      },
      {
        "text": "Midazolam 2 mg IV with fentanyl 50 μg IV, titrated to comfort",
        "isCorrect": false,
        "explanation": "Benzodiazepine–opioid combinations have synergistic respiratory depression and blunt airway reflexes; in OSA, they increase the risk of airway obstruction and hypoventilation."
      },
      {
        "text": "Ketamine 0.5 mg/kg IV with glycopyrrolate 0.2 mg IV",
        "isCorrect": false,
        "explanation": "Ketamine often preserves ventilatory drive, but can increase secretions and cause dysphoria or movement that may hinder fiberoptic intubation despite antisalagogue use."
      },
      {
        "text": "Propofol target-controlled infusion to 2–3 μg/mL",
        "isCorrect": false,
        "explanation": "Propofol reliably causes dose-dependent respiratory depression, loss of airway tone, and diminished protective reflexes—undesirable for awake fiberoptic intubation."
      }
    ],
    "didactic": "For awake fiberoptic intubation, the sedative must provide anxiolysis and comfort while maintaining spontaneous ventilation and protective airway reflexes. **Dexmedetomidine**, an α<sub>2</sub>-agonist, produces a sleep-like, cooperative sedation with minimal effect on ventilatory drive and the ventilatory response to CO<sub>2</sub>. Patients remain arousable and follow commands, facilitating scope passage and tube advancement. Typical dosing is a 0.5–1 μg/kg loading dose over 10–15 min, followed by 0.2–0.7 μg/kg/h. Adverse effects include bradycardia and hypotension from reduced sympathetic tone, which are usually manageable with dose adjustment or small doses of anticholinergic/vasopressor.\n\nIn contrast:\n- **Benzodiazepines (eg, midazolam)** provide anxiolysis and amnesia but depress respiration and attenuate airway reflexes, especially when combined with opioids—risky in OSA and difficult airways.\n- **Propofol** reduces pharyngeal muscle tone and blunts protective reflexes, with a narrow margin between sedation and apnea; even low-dose infusions can precipitate obstruction in OSA.\n- **Opioids (eg, remifentanil)** offer titratability and cough suppression but can cause hypoventilation and chest wall rigidity (particularly with bolus dosing), threatening spontaneous ventilation during critical airway moments.\n- **Ketamine** tends to preserve respiratory drive and bronchodilate, but it increases salivation, may cause nystagmus/movement, and can produce dysphoria; secretions can obscure the view, complicating fiberoptic passage.\n\nOptimal awake fiberoptic technique pairs **robust topical airway anesthesia** with **cooperative sedation**. Dexmedetomidine uniquely combines anxiolysis, modest analgesia, and preservation of airway reflexes and ventilation, making it the preferred agent for patients with OSA and anticipated difficult airways when maintaining spontaneous ventilation is paramount.",
    "educationalObjective": "Choose dexmedetomidine for awake fiberoptic intubation to preserve spontaneous ventilation and airway reflexes."
  },
  {
    "id": "Core.13.1.4",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Benzodiazepines and alpha-2 agonists",
    "difficulty": "easy",
    "questionText": "A 68-year-old man (ASA II) presents for elective total knee arthroplasty. In the preoperative area he receives midazolam 2 mg IV for anxiolysis. Within 2 minutes, he becomes increasingly agitated, verbally disinhibited, and attempts to get off the stretcher despite stable vital signs (HR 82/min, BP 146/78 mmHg, SpO<sub>2</sub> 98%). He repeatedly asks the same questions and is unable to remember instructions given after the injection. Which is the most appropriate immediate management?",
    "answers": [
      {
        "text": "Administer an additional 2 mg midazolam IV to deepen sedation",
        "isCorrect": false,
        "explanation": "Paradoxical agitation is a recognized reaction to benzodiazepines; giving more midazolam typically worsens disinhibition and agitation rather than resolving it."
      },
      {
        "text": "Administer flumazenil 0.2 mg IV and titrate to effect",
        "isCorrect": true,
        "explanation": "Flumazenil rapidly reverses benzodiazepine effects, including paradoxical reactions and anterograde amnesia; small, titrated doses (eg, 0.2 mg IV every 1 min to 0.6–1 mg) are appropriate if there is no benzodiazepine dependence or seizure risk."
      },
      {
        "text": "Wait 10 minutes for the peak effect to pass without intervention",
        "isCorrect": false,
        "explanation": "Expectant management risks patient and staff safety; paradoxical agitation may persist or worsen and should be actively treated by reversing the benzodiazepine."
      },
      {
        "text": "Administer dexmedetomidine 1 µg/kg IV loading dose over 10 minutes",
        "isCorrect": false,
        "explanation": "Dexmedetomidine does not reverse benzodiazepine effects and a loading dose may cause bradycardia/hypotension; it is better as an alternative sedative rather than acute treatment here."
      },
      {
        "text": "Administer haloperidol 5 mg IV for behavioral control",
        "isCorrect": false,
        "explanation": "Haloperidol is not first-line for benzodiazepine-induced paradoxical reactions and has delayed onset and adverse effects (eg, QT prolongation); reversal of the offending agent is preferred."
      }
    ],
    "didactic": "Midazolam is an imidazobenzodiazepine with **pH-dependent solubility**: it is water soluble in the vial (acidic pH) and becomes lipophilic at physiologic pH, enabling **rapid CNS penetration**. After IV administration, onset of sedation and anterograde amnesia occurs within **1–2 minutes**, with peak effect at **3–5 minutes** and clinical duration of sedation typically **15–30 minutes**. It provides **anxiolysis, sedation, and anterograde amnesia**, but no analgesia.\n\nPharmacokinetically, midazolam has a large Vd and is extensively metabolized by **CYP3A4** to 1‑hydroxymidazolam (active), with renal excretion. Effects are prolonged by advanced age, hepatic impairment, obesity, and **CYP3A4 inhibitors** (eg, azoles, macrolides, grapefruit). **CYP3A4 inducers** (eg, rifampin) shorten effect. Titrate small IV doses (eg, 0.5–1 mg) in older or frail patients.\n\nA **paradoxical reaction** (agitation, aggression, disinhibition, myoclonus) occurs in a minority of patients, more commonly in the elderly, children, those with psychiatric disease, or alcohol use. The mechanism likely involves **cortical disinhibition** from uneven GABAergic modulation. Adding more benzodiazepine often **worsens** the reaction.\n\nImmediate management is **flumazenil** to reverse benzodiazepine effects, including anterograde amnesia and agitation: give **0.2 mg IV**, repeat every 1 minute to 0.6–1 mg as needed, and monitor for re-sedation since flumazenil’s duration may be shorter than midazolam’s. Avoid or use extreme caution with flumazenil in patients with **chronic benzodiazepine use**, seizure disorders, or **TCA overdose** due to withdrawal seizures. \n\nα<sub>2</sub>-agonists (eg, dexmedetomidine) provide cooperative sedation without respiratory depression and can be used as an **alternative** sedative strategy, but they do not reverse benzodiazepine effects and loading doses may cause bradycardia/hypotension. Recognizing rapid-onset amnesia and promptly treating paradoxical reactions improves safety and operating room flow.",
    "educationalObjective": "Describe midazolam pharmacokinetics, onset, and amnestic properties and recognize paradoxical reactions."
  },
  {
    "id": "Core.13.1.5",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Benzodiazepines and alpha-2 agonists",
    "difficulty": "medium",
    "questionText": "A 72-year-old man without a seizure history undergoes elective inguinal hernia repair under MAC. He received diazepam 10 mg the night before for anxiety and intraoperative midazolam 4 mg IV with fentanyl 25 μg IV. In the PACU, he is somnolent, arouses to painful stimulation, and hypoventilating (RR 6/min, EtCO<sub>2</sub> 58 mmHg). SpO<sub>2</sub> is 92% on 4 L/min O<sub>2</sub> via nasal cannula; BP 142/76 mmHg, HR 68/min. Analgesia appears adequate. Which medication strategy is most appropriate to reverse his benzodiazepine effect while minimizing adverse events and accounting for resedation risk?",
    "answers": [
      {
        "text": "Administer naloxone 0.4 mg IV bolus and avoid flumazenil due to seizure risk in the elderly.",
        "isCorrect": false,
        "explanation": "Opioid reversal may not address the predominant benzodiazepine effect. Flumazenil can be safely used in small, titrated doses; seizure risk is greatest with chronic benzodiazepine dependence or coingestion of proconvulsants (eg, TCAs)."
      },
      {
        "text": "Administer flumazenil 0.2 mg IV over 15 s; repeat 0.2 mg every 1 min to a total of 0.6–1 mg as needed, and observe for ≥2 h for resedation given diazepam’s long half-life; if sedation recurs, give repeat boluses or start a low-dose infusion.",
        "isCorrect": true,
        "explanation": "Titrated flumazenil reverses benzodiazepine effect with minimal withdrawal risk. Flumazenil’s shorter duration than diazepam necessitates extended observation and possible repeat dosing or infusion for resedation."
      },
      {
        "text": "Give a single flumazenil 1 mg IV bolus and discharge from PACU after 30 minutes if improved.",
        "isCorrect": false,
        "explanation": "A large, non-titrated bolus increases withdrawal/seizure risk and may overshoot. Monitoring for only 30 minutes is inadequate because flumazenil’s duration is shorter than long-acting benzodiazepines, risking resedation after discharge."
      },
      {
        "text": "Avoid antagonists and provide stimulation and supplemental O<sub>2</sub>, as midazolam’s effect will wear off within 30–60 minutes.",
        "isCorrect": false,
        "explanation": "The patient is hypoventilating with elevated EtCO<sub>2</sub>, which warrants active reversal rather than expectant management—especially with concomitant long-acting diazepam that can prolong sedation."
      },
      {
        "text": "Begin a flumazenil infusion at 0.5 mg/h without prior bolus titration to effect.",
        "isCorrect": false,
        "explanation": "Infusions are reserved for recurrent resedation after successful bolus reversal. Starting an infusion without confirming response risks overshoot and obscures etiology."
      }
    ],
    "didactic": "Flumazenil is a competitive antagonist at the benzodiazepine site of the GABA<sub>A</sub> receptor that reverses sedation, amnesia, and respiratory depression from benzodiazepines. For iatrogenic oversedation, the recommended dosing is incremental 0.2 mg IV over 15 seconds, repeated every 1 minute until the desired level of consciousness is achieved (typical total 0.6–1 mg; maximum 3 mg for diagnostic/overdose scenarios). Titration minimizes abrupt withdrawal and seizures while tailoring effect to clinical need.\n\nA key pharmacokinetic consideration is that flumazenil’s duration (approximately 40–80 minutes) is often shorter than that of many benzodiazepines. **Diazepam** has active metabolites (eg, desmethyldiazepam) with very long half-lives (30–100 hours), creating a significant **resedation** risk once flumazenil wears off. Accordingly, after successful reversal, patients should be observed for at least 2 hours; with long-acting agents, plan for longer monitoring and be prepared to administer repeat boluses or start a **low-dose infusion** (eg, 0.1–0.5 mg/h) if resedation recurs.\n\nImportant safety points:\n- Use flumazenil cautiously in patients with chronic benzodiazepine dependence, seizure disorders, or suspected coingestion of proconvulsants (eg, tricyclic antidepressants), where seizure risk is higher.\n- Lack of response after approximately 1 mg should prompt reassessment for alternative or concurrent causes (eg, opioids), which may require naloxone.\n- Provide supportive care (airway positioning, supplemental O<sub>2</sub>, capnography) during reversal, as ventilation may not immediately normalize.\n\nIn this PACU patient with hypoventilation after midazolam and recent diazepam, the best approach is **titrated flumazenil boluses** with extended observation for resedation due to the long-acting benzodiazepine, reserving infusion for recurrent sedation after an initial response.",
    "educationalObjective": "Dose flumazenil to reverse benzodiazepine effects and monitor for resedation with long-acting agents."
  },
  {
    "id": "Core.13.1.6",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Benzodiazepines and alpha-2 agonists",
    "difficulty": "medium",
    "questionText": "A 58-year-old man with untreated OSA (BMI 34 kg/m²) undergoes laparoscopic cholecystectomy under general anesthesia with sevoflurane in air/O<sub>2</sub>. After induction (propofol, fentanyl, rocuronium), a dexmedetomidine infusion is started at 0.6 μg/kg/h without a loading dose. Over the next 10 minutes, end-tidal sevoflurane is decreased from 1.2% to 0.8% to maintain similar depth, and the remifentanil infusion is reduced by 30% while hemodynamics remain stable.\n\nWhich mechanism best explains dexmedetomidine’s locus coeruleus–mediated sedation and its opioid-sparing effect in this patient?",
    "answers": [
      {
        "text": "β<sub>1</sub>-adrenergic blockade in the locus coeruleus to suppress arousal, combined with voltage-gated Na+ channel blockade in dorsal horn neurons to reduce nociceptive transmission.",
        "isCorrect": false,
        "explanation": "Dexmedetomidine is an α<sub>2</sub> agonist, not a β-blocker or sodium channel blocker; its actions are adrenergic (α<sub>2</sub>) and G-protein mediated."
      },
      {
        "text": "Noncompetitive NMDA receptor antagonism in the locus coeruleus reducing central sensitization, resulting in analgesia and MAC reduction similar to ketamine.",
        "isCorrect": false,
        "explanation": "NMDA antagonism is the mechanism of ketamine, not α<sub>2</sub> agonists; dexmedetomidine does not block NMDA receptors."
      },
      {
        "text": "Activation of α<sub>2A</sub> receptors that couple to Gi/o in the locus coeruleus, opening GIRK K+ channels and inhibiting Ca<sup>2+</sup> entry (↓cAMP), hyperpolarizing noradrenergic neurons (sedation), while presynaptic α<sub>2</sub> receptors in the dorsal horn reduce substance P/glutamate release (analgesia).",
        "isCorrect": true,
        "explanation": "Dexmedetomidine’s α<sub>2A</sub>-Gi signaling in the locus coeruleus decreases noradrenergic firing (natural sleep-like sedation) and spinal presynaptic α<sub>2</sub> activation inhibits nociceptive neurotransmitter release, producing MAC and opioid sparing."
      },
      {
        "text": "Positive allosteric modulation of GABA<sub>A</sub> receptors in the locus coeruleus causing Cl− influx (sedation) and direct GABAergic inhibition of nociceptive pathways (analgesia).",
        "isCorrect": false,
        "explanation": "Benzodiazepines act at GABA<sub>A</sub> receptors and provide anxiolysis/amnesia with minimal analgesia; α<sub>2</sub> agonists do not act via GABA<sub>A</sub>."
      },
      {
        "text": "Partial μ-opioid receptor agonism in the brainstem and spinal cord producing analgesia and sedation with reduced volatile requirement.",
        "isCorrect": false,
        "explanation": "Dexmedetomidine has no μ-agonist activity; opioid sparing arises from α<sub>2</sub>-mediated antinociception, not μ-receptor activation."
      }
    ],
    "didactic": "α<sub>2</sub>-agonists (eg, dexmedetomidine, clonidine) produce cooperative sedation and analgesia via distinct but complementary sites of action. In the brainstem, the **locus coeruleus (LC)** is the primary noradrenergic nucleus regulating arousal. Dexmedetomidine selectively activates **α<sub>2A</sub> receptors** on LC neurons, which couple to **Gi/o** proteins to inhibit adenylyl cyclase (↓cAMP), **open G-protein–gated inwardly rectifying K+ (GIRK) channels**, and **inhibit voltage-gated Ca<sup>2+</sup> channels**. The result is neuronal hyperpolarization and reduced norepinephrine release, producing a calm, easily arousable sedation that resembles non-REM sleep rather than GABAergic hypnosis. This LC effect contributes to reduced sympathetic outflow and lower volatile anesthetic requirements (MAC-sparing).\n\nAnalgesia and opioid sparing arise primarily from **spinal α<sub>2</sub> receptor activation** in the dorsal horn (substantia gelatinosa). Presynaptic α<sub>2</sub> receptors on primary afferents inhibit Ca<sup>2+</sup>-dependent release of **substance P** and **glutamate**, while postsynaptic α<sub>2</sub> activation hyperpolarizes second-order neurons. These actions attenuate nociceptive transmission and synergize with μ-opioids, allowing **lower opioid dosing** and reducing hyperalgesia. Clinically, dexmedetomidine infusions (eg, 0.2–0.7 μg/kg/h) can decrease volatile requirements and perioperative opioid consumption without significant respiratory depression—an advantage in OSA.\n\nKey contrasts:\n- **α<sub>2</sub> agonists**: Gi/o signaling, LC sedation, spinal antinociception, MAC/opioid sparing, bradycardia/hypotension risk.\n- **Benzodiazepines**: GABA<sub>A</sub> modulation (Cl−), amnesia/anxiolysis, minimal analgesia.\n- **Ketamine**: NMDA antagonism, dissociative anesthesia, analgesia with sympathetic stimulation.\n\nThus, α<sub>2</sub>-mediated LC hyperpolarization explains the sedative, MAC-sparing profile, while spinal presynaptic α<sub>2</sub> inhibition of excitatory transmitters explains the **analgesia-sparing** (opioid-sparing) effect.",
    "educationalObjective": "Explain alpha-2 agonist mechanism at the locus coeruleus and its analgesia-sparing effect."
  },
  {
    "id": "Core.13.1.7",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Benzodiazepines and alpha-2 agonists",
    "difficulty": "hard",
    "questionText": "A 68-year-old man undergoes laparoscopic cholecystectomy with sevoflurane 0.7 MAC and remifentanil. After induction, 2 mg midazolam is given for agitation; the BIS increases from 55 to 68 while the raw frontal EEG shows increased high-frequency (≈20–30 Hz) activity without EMG artifact. Later, sevoflurane is reduced to 0.4 MAC as a dexmedetomidine infusion (0.7 μg/kg/h) is started. The BIS drifts to 72, but the raw EEG displays continuous slow-delta (≈0.5–1.5 Hz) with superimposed 12–15 Hz sleep spindles and minimal EMG; the patient remains hemodynamically stable without movement.\n\nWhich interpretation of these BIS/EEG findings is most accurate for benzodiazepines versus α<sub>2</sub>-agonists?",
    "answers": [
      {
        "text": "Midazolam lowers BIS by generating frontal α oscillations similar to propofol; dexmedetomidine raises BIS by increasing β activity.",
        "isCorrect": false,
        "explanation": "Midazolam typically increases β (13–30 Hz) activity that can increase BIS; dexmedetomidine does not produce β activation but rather spindles with slow-delta."
      },
      {
        "text": "Dexmedetomidine commonly causes burst suppression at sedation doses, which BIS algorithms misread as higher values.",
        "isCorrect": false,
        "explanation": "Burst suppression is uncommon at typical dexmedetomidine doses; if present, BIS would generally decrease due to increased suppression ratio, not rise."
      },
      {
        "text": "BIS reliably tracks hypnotic depth with dexmedetomidine, so a BIS of 70 indicates inadequate anesthesia requiring higher volatile concentration.",
        "isCorrect": false,
        "explanation": "Dexmedetomidine produces sleep-like EEG (slow waves + spindles) with potentially arousable patients and variable BIS; BIS may not reliably reflect hypnotic state under α<sub>2</sub>-agonists."
      },
      {
        "text": "Midazolam can increase β activity and falsely elevate BIS despite sedation; dexmedetomidine produces slow-delta with spindles and may show higher-than-expected BIS despite adequate hypnosis—interpret depth from the raw EEG, not the BIS alone.",
        "isCorrect": true,
        "explanation": "Benzodiazepines enhance β power and can raise BIS despite deeper sedation, whereas dexmedetomidine creates sleep-like spindles with slow-delta where BIS may not track arousability; the raw EEG pattern is more reliable for depth assessment."
      },
      {
        "text": "The elevated BIS in both periods most likely reflects EMG artifact; neuromuscular blockade should normalize the values.",
        "isCorrect": false,
        "explanation": "EMG artifact can elevate BIS, but the scenario specifies minimal EMG; the observed changes align with drug-specific EEG effects rather than muscle activity."
      }
    ],
    "didactic": "BIS was trained primarily on propofol and volatile anesthetics and performs best when the EEG resembles their stereotypical patterns. With agents that alter spectral content differently, BIS may not track hypnotic depth reliably. Understanding drug-specific raw EEG signatures helps avoid misinterpretation.\n\n- Benzodiazepines (eg, midazolam) enhance GABA<sub>A</sub>–mediated inhibition and characteristically increase **β activity (≈13–30 Hz)** on the frontal EEG. The BIS algorithm weights a β ratio, so β augmentation can **paradoxically increase BIS** despite deeper sedation and amnesia.\n- α<sub>2</sub>-agonists (eg, dexmedetomidine) produce a state resembling **non-REM stage 2 sleep**, with **slow-delta (≈0.5–4 Hz)** activity and **sleep spindles (≈12–15 Hz)** and often **K-complexes**, typically with low EMG. Patients may be arousable despite these slow oscillations. BIS values during dexmedetomidine sedation are **variable and may read higher than expected** for the apparent depth on the raw EEG.\n- In contrast, propofol and volatile agents commonly show **frontal α (≈8–12 Hz) plus slow-delta** at surgical levels, and BIS correlates more consistently with clinical hypnosis.\n\nPractical implications:\n- When midazolam is given, a rise in BIS accompanied by new β dominance does not necessarily indicate lighter anesthesia.\n- Under dexmedetomidine, slow-delta with spindles and minimal EMG suggests adequate hypnosis even if BIS is in the 60–70 range.\n- Always cross-check the **raw EEG** and clinical signs (movement, hemodynamics) rather than titrating solely to a BIS target, especially with benzodiazepines or α<sub>2</sub>-agonists.\n\nIn this scenario, the increased β after midazolam explains the BIS rise, and the spindle–slow pattern under dexmedetomidine reflects sleep-like sedation with potentially misleading BIS values.",
    "educationalObjective": "Interpret BIS and EEG effects of benzodiazepines versus alpha-2 agonists when assessing anesthetic depth."
  },
  {
    "id": "Core.13.1.8",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Benzodiazepines and alpha-2 agonists",
    "difficulty": "medium",
    "questionText": "An 82-year-old woman with hypertension, stage 3 CKD, obstructive sleep apnea (uses CPAP), and mild neurocognitive disorder (MoCA 23) presents for urgent hemiarthroplasty after a hip fracture. She is anxious in the preoperative area. Vitals are stable (BP 138/72, HR 68, SpO<sub>2</sub> 97% on room air). You plan a spinal anesthetic with light intraoperative sedation and want to minimize postoperative delirium and respiratory depression.\n\nWhich perioperative anxiolysis/sedation regimen is most appropriate for this patient?",
    "answers": [
      {
        "text": "Midazolam 2 mg IV in preop, repeat 1–2 mg IV as needed for anxiety",
        "isCorrect": false,
        "explanation": "Fixed or escalating benzodiazepine dosing in older adults increases delirium and respiratory depression risk, especially with OSA and planned neuraxial sympathectomy."
      },
      {
        "text": "Dexmedetomidine 1 µg/kg loading dose over 10 min followed by 0.7 µg/kg/hr infusion",
        "isCorrect": false,
        "explanation": "A loading dose and higher infusion rates increase bradycardia and hypotension, which can be pronounced with neuraxial sympathectomy in older adults."
      },
      {
        "text": "Midazolam 0.5 mg IV immediately before spinal placement, then avoid further benzodiazepines",
        "isCorrect": false,
        "explanation": "Although dose-reduced, benzodiazepines still increase delirium risk in older adults with cognitive impairment; prefer benzodiazepine-sparing strategies when feasible."
      },
      {
        "text": "Dexmedetomidine infusion 0.2–0.4 µg/kg/hr without a loading dose during spinal anesthesia",
        "isCorrect": true,
        "explanation": "Low-dose dexmedetomidine provides cooperative sedation and anxiolysis with minimal respiratory depression and has delirium-sparing benefits; omitting a loading dose reduces bradycardia/hypotension risk in older adults receiving neuraxial anesthesia."
      },
      {
        "text": "Clonidine 0.2 mg PO 60–90 minutes preop for anxiolysis, no intraoperative sedation",
        "isCorrect": false,
        "explanation": "Oral clonidine is less titratable with variable onset and can cause hypotension/bradycardia; it is less supported for delirium reduction compared with dexmedetomidine in this setting."
      }
    ],
    "didactic": "Older adults exhibit increased pharmacodynamic sensitivity to benzodiazepines and reduced hepatic/renal clearance, making them prone to oversedation, respiratory depression, and **postoperative delirium**. Preoperative midazolam is consistently associated with higher delirium rates in older patients, particularly those with cognitive impairment or obstructive sleep apnea. When benzodiazepines are unavoidable, use the lowest effective dose (eg, midazolam 0.25–0.5 mg IV) titrated slowly with close monitoring; however, a **benzodiazepine-sparing approach is preferred** in high-risk patients.\n\nDexmedetomidine, an α<sub>2</sub>-agonist, provides cooperative sedation, anxiolysis, and modest analgesia with minimal effect on ventilation—beneficial for patients with OSA undergoing neuraxial anesthesia. Evidence suggests dexmedetomidine may reduce the incidence and severity of postoperative delirium compared with benzodiazepines. In older adults, hemodynamic effects (bradycardia, hypotension) are dose-related and can be exacerbated by the sympathectomy of spinal anesthesia. Therefore, start a **low infusion (0.2–0.4 µg/kg/hr) without a loading dose** and titrate to light sedation, which mitigates cardiovascular instability while achieving anxiolysis.\n\nKey points:\n- **Avoid routine benzodiazepines** in older adults to reduce delirium risk; if used, apply lower dosing and slow titration.\n- **Prefer dexmedetomidine** for sedation with neuraxial anesthesia when delirium and respiratory depression are concerns; omit the loading dose and use the low end of the infusion range.\n- Monitor for bradycardia/hypotension and treat promptly (reduce/hold infusion, fluids/vasopressors as needed).\n\nIn this scenario, a low-dose dexmedetomidine infusion without a loading dose best balances anxiolysis, delirium prevention, and respiratory safety, whereas benzodiazepines—even in reduced doses—remain deliriogenic in this high-risk patient.",
    "educationalObjective": "Limit benzodiazepines in older adults to reduce delirium risk and apply lower dosing strategies."
  },
  {
    "id": "Core.13.1.9",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Benzodiazepines and alpha-2 agonists",
    "difficulty": "medium",
    "questionText": "A 68-year-old man (80 kg) with hypertension and coronary artery disease on metoprolol undergoes awake fiberoptic intubation for anticipated difficult airway. Sedation was initiated with dexmedetomidine: 1 µg/kg over 10 min followed by 0.7 µg/kg/h. Ten minutes later, he is calm and follows commands (RASS −2), breathing spontaneously with SpO<sub>2</sub> 98% on 2 L/min nasal cannula. Vitals: HR 42 bpm, BP 78/42 mmHg, RR 14/min. There is no bleeding, and IV access is patent. The team wishes to proceed while maintaining cooperative sedation.\n\nWhich of the following is the most appropriate next step to improve hemodynamics while preserving cooperative sedation?",
    "answers": [
      {
        "text": "Administer a 0.5 µg/kg dexmedetomidine bolus and increase the infusion to 1.2 µg/kg/h",
        "isCorrect": false,
        "explanation": "A bolus and higher infusion rate will exacerbate α<sub>2</sub>-mediated bradycardia/hypotension (and may cause transient hypertension with reflex bradycardia), worsening instability."
      },
      {
        "text": "Decrease dexmedetomidine to 0.2 µg/kg/h and give ephedrine 5 mg IV",
        "isCorrect": true,
        "explanation": "Reducing the infusion treats the cause, and ephedrine’s mixed α/β activity increases HR and BP, restoring MAP while preserving cooperative sedation."
      },
      {
        "text": "Switch to propofol 75 µg/kg/min with small fentanyl boluses",
        "isCorrect": false,
        "explanation": "Propofol commonly worsens hypotension and risks respiratory depression/apnea, compromising the goal of cooperative, spontaneous ventilation."
      },
      {
        "text": "Start a phenylephrine infusion at 0.5 µg/kg/min while maintaining the current dexmedetomidine rate",
        "isCorrect": false,
        "explanation": "Pure α-agonism raises SVR but can worsen bradycardia and reduce CO in this setting; it also fails to reduce the offending dexmedetomidine dose."
      },
      {
        "text": "Treat bradycardia with atropine 0.5 mg IV and continue dexmedetomidine at 0.7 µg/kg/h",
        "isCorrect": false,
        "explanation": "Atropine may increase HR but does not address dexmedetomidine-induced hypotension or its ongoing cause if the infusion continues at a high rate."
      }
    ],
    "didactic": "Dexmedetomidine is a selective **α<sub>2</sub>-agonist** that produces locus coeruleus–mediated sedation with minimal respiratory depression, enabling **cooperative sedation** (arousable, follows commands). Its sympatholytic effects decrease norepinephrine release, leading to **bradycardia and hypotension**. A rapid loading dose can cause transient **hypertension (α<sub>2B</sub>-mediated vasoconstriction)** followed by reflex bradycardia. Risk factors for hemodynamic instability include advanced age, baseline bradycardia, β-blockade, hypovolemia, and high vagal tone.\n\nTo maintain sedation while correcting instability, first mitigate the cause: **reduce or pause the infusion** (typical maintenance 0.2–0.7 µg/kg/h; avoid loading in high-risk patients). When both **bradycardia and hypotension** are present, a vasoactive with β and α activity (eg, **ephedrine 5–10 mg IV**) is preferred because it increases HR and BP, improving CO and **MAP = CO × SVR** without deepening sedation. Pure α-agonists (eg, phenylephrine) primarily raise SVR and may worsen reflex bradycardia, further lowering CO. Anticholinergics (eg, atropine) can treat severe bradycardia but do not correct vasodilation or negative chronotropy if the dexmedetomidine infusion remains high; they are adjuncts, not definitive management of drug-induced hypotension.\n\nPractical approach to dexmedetomidine-induced bradycardia/hypotension:\n- Reduce or stop the infusion; avoid further boluses.\n- Assess volume status; give a small crystalloid bolus if hypovolemia suspected.\n- If bradycardia + hypotension: use **ephedrine** (mixed α/β). If hypotension with adequate HR: a titrated **phenylephrine** bolus/infusion is reasonable.\n- Reserve atropine/glycopyrrolate for persistent symptomatic bradycardia.\n\nOnce stable, restart dexmedetomidine at a **lower rate** (eg, 0.2–0.4 µg/kg/h) to maintain cooperative sedation while minimizing recurrence.",
    "educationalObjective": "Manage dexmedetomidine infusions to avoid bradycardia and hypotension while maintaining cooperative sedation."
  },
  {
    "id": "Core.13.1.10",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Benzodiazepines and alpha-2 agonists",
    "difficulty": "medium",
    "questionText": "A 58-year-old man with generalized anxiety disorder takes alprazolam 1 mg three times daily for 5 years. He presents with a small-bowel obstruction requiring urgent exploratory laparotomy under general anesthesia. He has been vomiting and last took alprazolam 36 hours ago. He is anxious and tremulous; HR 110/min, BP 158/92 mmHg, SpO<sub>2</sub> 98% on room air. He is NPO with an NG tube to low suction. Basic labs and liver function are normal. He will be admitted to the ICU postoperatively. Which perioperative strategy is most appropriate to prevent benzodiazepine withdrawal in this patient?",
    "answers": [
      {
        "text": "Administer IV diazepam on a scheduled basis with gradual taper postoperatively",
        "isCorrect": true,
        "explanation": "Substituting a long-acting benzodiazepine (eg, diazepam) on a scheduled regimen maintains GABAergic tone and best prevents withdrawal in a chronic user who is NPO."
      },
      {
        "text": "Treat agitation as needed with small IV boluses of midazolam only",
        "isCorrect": false,
        "explanation": "Intermittent short-acting dosing risks interdose withdrawal and does not provide steady coverage; scheduled long-acting substitution is preferred."
      },
      {
        "text": "Initiate a dexmedetomidine infusion at 0.2–0.7 µg/kg/h for sympatholysis without benzodiazepines",
        "isCorrect": false,
        "explanation": "α<sub>2</sub>-agonists attenuate sympathetic symptoms but do not replace GABAergic activity; they do not prevent seizures or delirium from benzodiazepine withdrawal."
      },
      {
        "text": "Give flumazenil 0.2 mg IV at the end of the case to minimize residual sedation",
        "isCorrect": false,
        "explanation": "Flumazenil can precipitate acute withdrawal and seizures in chronic benzodiazepine users and should be avoided unless life-saving reversal is required."
      },
      {
        "text": "Withhold benzodiazepines to minimize postoperative delirium risk",
        "isCorrect": false,
        "explanation": "Abrupt discontinuation of chronic benzodiazepines increases risk of withdrawal, agitation, seizures, and delirium; continuation or substitution is recommended."
      }
    ],
    "didactic": "Chronic benzodiazepine users are at significant risk for **perioperative withdrawal** when therapy is interrupted, particularly with short-acting agents like alprazolam. Withdrawal may begin within 24–48 hours of the last dose and presents with tremor, anxiety, tachycardia, hypertension, insomnia, and in severe cases **delirium and seizures**. The guiding principle is to **continue the home benzodiazepine** or **substitute a long-acting agent** on a scheduled basis when oral administration is not feasible.\n\nFor NPO patients, IV **diazepam** is an effective substitute due to its rapid onset and long elimination half-life with active metabolites, providing a smooth serum level and reducing interdose withdrawal risk. A practical approach is scheduled dosing (eg, 5–10 mg IV every 6–8 hours, titrated to symptoms and sedation), followed by a gradual taper postoperatively. If hepatic dysfunction is present, prefer agents undergoing phase II conjugation (the “LOT” drugs—**lorazepam, oxazepam, temazepam**), with IV lorazepam as a reasonable substitute; avoid diazepam/chlordiazepoxide due to prolonged sedation from impaired metabolism.\n\nAdjuncts such as **dexmedetomidine or clonidine** can mitigate sympathetic overactivity but do not correct GABAergic deficiency and will not prevent seizures; they should not replace benzodiazepines for withdrawal prophylaxis. **Flumazenil** is contraindicated in chronic users except for life-threatening situations, as it can precipitate acute withdrawal and seizures. Intermittent PRN dosing of short-acting benzodiazepines (eg, midazolam) risks **interdose withdrawal** and inadequate coverage.\n\nPerioperatively, anticipate pharmacodynamic interactions: benzodiazepines synergize with opioids and volatile agents, increasing respiratory depression and hypotension risk. Titrate to effect with close monitoring, particularly in the ICU. In summary, to prevent benzodiazepine withdrawal in chronic users who are NPO, use a **scheduled, long-acting benzodiazepine substitution** with a planned taper and vigilant monitoring.",
    "educationalObjective": "Prevent benzodiazepine withdrawal in chronic users by continuing therapy or substituting long-acting agents."
  },
  {
    "id": "Core.13.1.11",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Benzodiazepines and alpha-2 agonists",
    "difficulty": "hard",
    "questionText": "A 64-year-old man with resistant hypertension and stable CAD is scheduled for elective lumbar laminectomy. Home medications include clonidine 0.2 mg three times daily and metoprolol 50 mg twice daily. He was instructed to hold all medications and last took clonidine ~18 hours ago. In the preoperative area he is anxious and diaphoretic with BP 198/112 mmHg and HR 112 beats/min; ECG shows sinus tachycardia. He has been NPO for 10 hours. Which is the most appropriate immediate management to address his hemodynamics and prevent perioperative clonidine-withdrawal complications?",
    "answers": [
      {
        "text": "Treat BP with IV hydralazine and hold clonidine until postoperative day 1",
        "isCorrect": false,
        "explanation": "Vasodilators may transiently lower BP but do not reverse withdrawal; hypertension and tachycardia are likely to recur and may worsen around induction and emergence."
      },
      {
        "text": "Administer IV metoprolol and fentanyl to blunt the sympathetic surge",
        "isCorrect": false,
        "explanation": "β-blockade alone does not treat clonidine withdrawal and may worsen hypertension due to unopposed α-adrenergic activity; it fails to address central sympathetic overactivity."
      },
      {
        "text": "Cancel surgery to taper clonidine over 1–2 weeks before rescheduling",
        "isCorrect": false,
        "explanation": "Elective delay is unnecessary; the safer strategy is to continue clonidine. Tapering is reserved for planned discontinuation, not routine perioperative management."
      },
      {
        "text": "Give oral clonidine 0.2 mg with a sip of water and continue clonidine throughout the perioperative period",
        "isCorrect": true,
        "explanation": "Reinstating α<sub>2</sub>-agonism reverses withdrawal, controls BP/HR, and prevents rebound; essential therapy should be continued perioperatively even when NPO (with a small sip of water)."
      },
      {
        "text": "Apply a transdermal clonidine patch now and proceed to induction",
        "isCorrect": false,
        "explanation": "Transdermal clonidine has a delayed onset (≈12–24 h to therapeutic levels) and will not treat acute withdrawal; it requires oral bridging."
      }
    ],
    "didactic": "Clonidine is a central α<sub>2</sub>-adrenergic agonist that decreases sympathetic outflow and norepinephrine release. Abrupt discontinuation after chronic use causes a marked catecholamine surge (rebound hypertension, tachycardia, agitation, headache, diaphoresis), often peaking 12–48 hours after the last dose. Perioperative stress amplifies this response and increases risks of myocardial ischemia and arrhythmia.\n\nKey perioperative principles for clonidine:\n- Continue therapy, including the morning of surgery. Essential antihypertensives can be given with a small sip of water despite NPO status.\n- If oral intake is not possible, bridge thoughtfully. Transdermal clonidine has a slow onset (≈12–24 h) and requires oral overlap for 24–48 h when initiating; a patch alone will not treat acute withdrawal.\n- Treat withdrawal by reinstating clonidine (eg, 0.1–0.2 mg PO) and titrating to effect. For intraoperative control or if oral administration is not feasible, a dexmedetomidine infusion can temporarily restore α<sub>2</sub>-agonism and blunt sympathetic outflow while definitive clonidine therapy is re-established.\n- Avoid isolated β-blockade for withdrawal hypertension; it leaves α-mediated vasoconstriction unopposed and can worsen BP. If additional BP control is needed while clonidine is restarted, use agents that address both α and β effects (eg, labetalol) or titratable vasodilators alongside clonidine.\n- Benefits of α<sub>2</sub>-agonists include reduced anesthetic and opioid requirements, decreased shivering, and improved hemodynamic stability; adverse effects are bradycardia, hypotension, and sedation.\n\nTherefore, the best immediate management is to administer oral clonidine and continue it through the perioperative period. This reverses the withdrawal physiology, stabilizes hemodynamics, and prevents recurrent rebound around induction and emergence.",
    "educationalObjective": "Recognize clonidine perioperative roles and prevent withdrawal hypertension by continuing therapy or tapering."
  },
  {
    "id": "Core.13.1.12",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Benzodiazepines and alpha-2 agonists",
    "difficulty": "medium",
    "questionText": "A 4-year-old boy (16 kg) with severe obstructive sleep apnea (AHI 18/h) is undergoing adenotonsillectomy under sevoflurane anesthesia with spontaneous ventilation (FiO<sub>2</sub> 0.5). Hemodynamics are stable (HR 100/min, BP 85/50 mmHg). As the surgeon places the last suture, you plan an awake extubation and want to reduce sevoflurane requirements during closure while minimizing the risk of pediatric emergence delirium and avoiding respiratory depression. Which intraoperative intervention is most appropriate?",
    "answers": [
      {
        "text": "Start a ketamine infusion at 0.5 mg/kg/h during closure",
        "isCorrect": false,
        "explanation": "Ketamine may provide analgesia but has inconsistent effects on emergence delirium, can increase secretions and dysphoria, and does not predictably reduce volatile MAC as effectively as dexmedetomidine."
      },
      {
        "text": "Administer dexmedetomidine 0.5 µg/kg IV over 10 minutes and reduce sevoflurane to ~0.5 MAC during closure",
        "isCorrect": true,
        "explanation": "Dexmedetomidine (α<sub>2</sub>-agonist) decreases volatile MAC in a dose-dependent fashion and reliably attenuates pediatric emergence delirium with minimal respiratory depression—ideal for a child with OSA when given as a slow infusion to limit bradycardia/hypotension."
      },
      {
        "text": "Give fentanyl 2 µg/kg IV and maintain the current sevoflurane concentration",
        "isCorrect": false,
        "explanation": "Opioids treat pain but do not reliably prevent emergence delirium and increase the risk of airway obstruction and hypoventilation in OSA; they also do not deliberately reduce MAC unless the volatile is titrated down."
      },
      {
        "text": "Give propofol 1 mg/kg IV on arrival to the PACU if agitation occurs",
        "isCorrect": false,
        "explanation": "Propofol can temporarily calm agitation but does not prevent emergence delirium or reduce intraoperative MAC; postextubation dosing risks airway obstruction and apnea in OSA."
      },
      {
        "text": "Administer midazolam 0.05 mg/kg IV 10 minutes before emergence",
        "isCorrect": false,
        "explanation": "Benzodiazepines are not effective prophylaxis for sevoflurane-associated emergence delirium and can paradoxically worsen agitation or delay recovery without reducing volatile requirements."
      }
    ],
    "didactic": "Dexmedetomidine is a highly selective α<sub>2</sub>-adrenergic agonist that produces cooperative sedation and analgesia via reduced norepinephrine release and inhibition of the locus coeruleus. In children, it reliably decreases the incidence and severity of sevoflurane- and desflurane-associated emergence delirium (ED), a nonpainful dissociative agitation seen commonly in preschool-aged patients after rapid emergence. Importantly, dexmedetomidine causes minimal respiratory depression, making it particularly advantageous for patients with OSA who are vulnerable to opioid- and propofol-induced hypoventilation and airway obstruction.\n\nDexmedetomidine reduces anesthetic requirements in a dose-dependent manner, lowering volatile MAC by roughly 20%–50% depending on dose and timing. A practical strategy to both attenuate ED and reduce MAC is to administer 0.3–0.5 µg/kg IV over about 10 minutes near the end of the case, then titrate sevoflurane down to ~0.3–0.5 MAC during closure. This provides smoother emergence and facilitates awake or awake-criteria extubation with preserved ventilatory drive. Anticipate and mitigate adverse effects by avoiding rapid boluses and monitoring for bradycardia and hypotension; these are typically modest with slow administration.\n\nCommon alternatives are less effective or carry trade-offs:\n- Midazolam does not prevent ED and may prolong recovery or worsen agitation.\n- Opioids address pain but do not reliably prevent ED and increase risk of postoperative airway obstruction, especially in OSA.\n- Propofol can transiently treat agitation but does not prevent ED or reduce intraoperative MAC; it also depresses respiration.\n- Ketamine provides analgesia but has inconsistent ED prevention, can increase secretions and dysphoria, and does not reduce volatile requirements as predictably as dexmedetomidine.\n\nTherefore, slow titration of dexmedetomidine near the end of pediatric volatile anesthetics is an evidence-based approach to decrease MAC and attenuate emergence delirium while preserving ventilation.",
    "educationalObjective": "Use dexmedetomidine to reduce MAC and attenuate pediatric emergence delirium when appropriate."
  },
  {
    "id": "Core.13.2.1",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "IV induction agents",
    "difficulty": "hard",
    "questionText": "A 78-year-old woman (155 cm, 120 kg; BMI 50) with symptomatic severe aortic stenosis (valve area 0.7 cm², mean gradient 45 mmHg) and obstructive sleep apnea presents for urgent hip fracture fixation. She takes metoprolol; preinduction BP is 135/70 mmHg and HR 62/min. You aim to avoid both hypotension and tachycardia during induction. Considering her morbid obesity and advanced age, which initial induction plan is most appropriate?",
    "answers": [
      {
        "text": "Ketamine 2 mg/kg using ideal body weight",
        "isCorrect": false,
        "explanation": "Ketamine may support blood pressure but often increases heart rate and contractility, which is undesirable in severe aortic stenosis; IBW scaling is reasonable for ketamine bolus, but the agent choice is suboptimal here."
      },
      {
        "text": "Propofol 1 mg/kg using lean body weight",
        "isCorrect": false,
        "explanation": "Using lean body weight avoids TBW overdosing, but propofol still causes significant vasodilation and myocardial depression; even reduced doses risk hypotension poorly tolerated in severe aortic stenosis."
      },
      {
        "text": "Propofol 2 mg/kg using total body weight",
        "isCorrect": false,
        "explanation": "Dosing propofol to total body weight in morbid obesity causes excessive bolus and profound vasodilation/negative inotropy, risking severe hypotension—especially hazardous in severe aortic stenosis."
      },
      {
        "text": "Etomidate 0.3 mg/kg using total body weight",
        "isCorrect": false,
        "explanation": "Etomidate is hemodynamically stable, but TBW-based bolusing overdoses in morbid obesity; elderly patients also require dose reduction rather than the high end of the range."
      },
      {
        "text": "Etomidate 0.15 mg/kg using lean body weight",
        "isCorrect": true,
        "explanation": "Etomidate preserves hemodynamics in severe aortic stenosis, and bolus dosing should be based on lean body weight in morbid obesity with reduction for advanced age to avoid overshoot and hypotension."
      }
    ],
    "didactic": "Obesity and advanced age substantially alter the pharmacokinetics and pharmacodynamics of IV induction agents. In morbid obesity, the central compartment and vessel-rich group do not expand in proportion to adipose tissue, so an initial bolus based on total body weight (TBW) can markedly overshoot the effect site. For lipophilic induction agents, **lean body weight (LBW)** best correlates with the initial distribution space and peak effect, while TBW risks overdose. Advanced age further reduces induction requirements due to increased brain sensitivity, smaller central compartment, and decreased clearance.\n\n- Propofol: LBW for bolus in obesity (avoid TBW). Potent vasodilation/negative inotropy → high hypotension risk in fixed outflow lesions. Elderly typically require ≈25–50% dose reduction.\n- Etomidate: Minimal hemodynamic depression makes it preferred for severe aortic stenosis. Use LBW for bolus in obesity; reduce dose in the elderly (eg, ≈0.1–0.2 mg/kg). Avoid TBW-based boluses.\n- Ketamine: Sympathomimetic effects often preserve BP but can increase HR and myocardial O<sub>2</sub> demand—undesirable in severe AS. For obesity, many use IBW or LBW for bolus; avoid TBW.\n\nA practical approach for obese patients:\n\n- Initial bolus (effect-site driven): use LBW for propofol, etomidate, thiopental; use IBW/LBW for ketamine.\n- Infusions (clearance-driven): titrate to effect; some agents (eg, propofol) may correlate better with TBW for maintenance, but start conservatively and titrate.\n\nIn this elderly, morbidly obese patient with severe aortic stenosis, the safest induction strategy is **etomidate with an age-reduced bolus scaled to LBW** (eg, 0.15 mg/kg LBW). This balances obesity-appropriate dosing with the hemodynamic goals of avoiding hypotension and tachycardia in fixed outflow obstruction.",
    "educationalObjective": "Adjust induction dosing for extremes of age and body habitus by using lean or adjusted body weight as appropriate."
  },
  {
    "id": "Core.13.2.2",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "IV induction agents",
    "difficulty": "medium",
    "questionText": "A 45-year-old man (80 kg) with hypertension and obstructive sleep apnea undergoes endoscopic sinus surgery. The surgeon requests a smooth, awake extubation to minimize coughing and hypertension that could precipitate postoperative bleeding. The anesthetic has been weaned, and the patient is breathing spontaneously with stable vital signs. You plan to use IV lidocaine to blunt airway reflexes and the sympathetic response during extubation.\n\nWhich IV lidocaine dosing strategy is most appropriate to reduce cough and the pressor response at extubation in this patient?",
    "answers": [
      {
        "text": "Administer 0.5 mg/kg IV lidocaine immediately before tracheal suctioning",
        "isCorrect": false,
        "explanation": "The dose is subtherapeutic and the timing is too late; suctioning can trigger coughing before lidocaine reaches peak effect."
      },
      {
        "text": "Start an IV lidocaine infusion at 2 mg/min 20 minutes before extubation and stop at cuff deflation",
        "isCorrect": false,
        "explanation": "A low-rate infusion is not targeted to the brief stimulus of extubation and risks either inadequate effect or unnecessary exposure without proven benefit for cough suppression."
      },
      {
        "text": "Administer 1 mg/kg IV lidocaine at the start of skin closure",
        "isCorrect": false,
        "explanation": "Given too early; the effect on airway reflexes will wane by the time of extubation because the clinically useful antitussive effect lasts only several minutes."
      },
      {
        "text": "Administer 1.5 mg/kg IV lidocaine 2–3 minutes before planned extubation",
        "isCorrect": true,
        "explanation": "This timing matches lidocaine’s effect-site peak for cough suppression and attenuation of the sympathetic surge at emergence; a 1.5 mg/kg dose provides reliable effect with low toxicity risk."
      },
      {
        "text": "Administer 1.5 mg/kg IV lidocaine immediately after cuff deflation",
        "isCorrect": false,
        "explanation": "Too late; most coughing and sympathetic activation occur with stimulation during cuff deflation and tube removal, before lidocaine can take effect."
      }
    ],
    "didactic": "Laryngoscopy and extubation activate airway and autonomic reflexes, causing tachycardia, hypertension, coughing, bronchospasm, and increases in ICP and IOP. IV lidocaine attenuates these responses by blocking voltage-gated Na<sup>+</sup> channels in airway afferents (reduced cough reflex) and exerting modest central/peripheral sympatholytic effects. Its IV onset is rapid (≈45–90 s), with peak effect around 1–2 minutes and a clinically meaningful antitussive/hemodynamic blunting window of roughly 5–10 minutes.\n\nFor brief, predictable noxious stimuli, timing to effect-site is critical:\n- Laryngoscopy: 1–1.5 mg/kg IV given 1–2 minutes before instrumentation can modestly blunt the pressor response.\n- Extubation: 1.5–2 mg/kg IV given 2–3 minutes before extubation best reduces coughing and the sympathetic surge, especially when awake extubation is required (eg, after sinus surgery where bleeding risk is high).\n\nDoses substantially lower than 1 mg/kg are often ineffective, and administration too early leads to waning effect by emergence. Giving lidocaine after cuff deflation or at the moment of suctioning is too late to prevent reflex activation. Continuous low-dose infusions are not targeted to the short-lived stimulus of extubation and have uncertain benefit for cough suppression.\n\nWhen used appropriately, IV lidocaine is a useful adjunct to opioids, β-blockers, and inhaled anesthetics for smooth emergence. Exercise caution in severe hepatic dysfunction, low-flow states, and advanced heart block without pacing. Signs of toxicity (eg, circumoral numbness, tinnitus, altered mental status, seizures) are unlikely at 1–2 mg/kg bolus dosing but warrant vigilance. Proper dosing and timing—1.5 mg/kg IV 2–3 minutes before extubation—optimize suppression of airway reflexes and sympathetic responses while maintaining safety.",
    "educationalObjective": "Administer IV lidocaine to blunt airway reflexes and sympathetic response during laryngoscopy and extubation."
  },
  {
    "id": "Core.13.2.3",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "IV induction agents",
    "difficulty": "easy",
    "questionText": "A 58-year-old man (BMI 36 kg/m²) with obstructive sleep apnea on home CPAP presents for elective umbilical hernia repair under general anesthesia. Baseline SpO₂ is 95% on room air, and airway exam is unremarkable. The plan is IV induction with fentanyl and propofol and placement of a supraglottic airway without a neuromuscular blocker. You anticipate transient apnea and loss of upper airway tone after the propofol bolus.\n\nImmediately before induction, which preparation best reduces the risk of hypoxemia if apnea occurs?",
    "answers": [
      {
        "text": "Administer prophylactic naloxone 0.04 mg IV to prevent propofol-induced respiratory depression",
        "isCorrect": false,
        "explanation": "Naloxone reverses opioids, not propofol; it will not prevent propofol-induced apnea and may precipitate pain/tachycardia if opioids are given."
      },
      {
        "text": "Apply low-flow nasal cannula at 2 L/min for supplemental O<sub>2</sub> and proceed without mask ventilation equipment to minimize aerosolization",
        "isCorrect": false,
        "explanation": "Low-flow nasal O<sub>2</sub> provides minimal reservoir or apneic oxygenation, and lack of immediate bag-mask capability is unsafe if apnea/obstruction occurs."
      },
      {
        "text": "Preoxygenate with 100% O<sub>2</sub> to EtO<sub>2</sub> ≥ 90% in a head-elevated position and ensure bag-mask ventilation with airway adjuncts and suction is ready",
        "isCorrect": true,
        "explanation": "Effective denitrogenation increases the O<sub>2</sub> reservoir, and readiness to provide positive-pressure ventilation mitigates hypoxemia from propofol-induced apnea and airway obstruction, especially in obesity/OSA."
      },
      {
        "text": "Reduce the propofol induction dose to 0.5 mg/kg and avoid preoxygenation to limit absorption atelectasis",
        "isCorrect": false,
        "explanation": "Dose reduction alone does not reliably prevent apnea, and avoiding preoxygenation greatly increases desaturation risk; absorption atelectasis is a lesser concern than hypoxemia."
      },
      {
        "text": "Give succinylcholine 1 mg/kg immediately after propofol to facilitate ventilation and prevent obstruction",
        "isCorrect": false,
        "explanation": "Paralysis abolishes spontaneous breathing and may worsen hypoxemia if mask ventilation is not established; it is unnecessary unless intubation is planned."
      }
    ],
    "didactic": "Propofol causes dose- and rate-dependent respiratory depression by suppressing central ventilatory drive and blunting both hypercapnic and hypoxic responses. It also reduces pharyngeal dilator muscle tone, predisposing to upper airway obstruction. The risk of apnea is increased by rapid bolus dosing, concurrent opioids/benzodiazepines, obesity, obstructive sleep apnea, and advanced age. Because apnea and obstruction after induction are common and often predictable, preparation to maintain oxygenation and ventilation is critical.\n\nThe most effective single preparation is thorough preoxygenation and readiness to provide positive-pressure ventilation. Preoxygenate with 100% O<sub>2</sub> via a well-sealed mask until EtO<sub>2</sub> ≥ 90% (eg, 3–5 minutes of tidal breathing or 8 vital-capacity breaths). This denitrogenates the functional residual capacity, creating a large intrapulmonary O<sub>2</sub> reservoir that prolongs the safe apnea time, which is especially important in obesity/OSA where FRC is reduced and O<sub>2</sub> consumption is higher. A head-elevated (ramped) position further improves FRC and delays desaturation. Having suction, an oropharyngeal/nasopharyngeal airway, and a functioning bag-mask circuit with 100% O<sub>2</sub> and PEEP immediately available allows rapid correction of obstruction (jaw thrust, airway adjunct) and ventilation if apnea occurs. Consider apneic oxygenation (eg, nasal cannula at 10–15 L/min under the mask) to extend safe apnea time, but this does not replace proper preoxygenation or mask ventilation readiness.\n\nCommon pitfalls include relying on low-flow nasal O<sub>2</sub> (insufficient reservoir), avoiding preoxygenation due to concerns about absorption atelectasis (minor relative to hypoxemia risk), administering naloxone (ineffective against propofol), or giving neuromuscular blocker reflexively (eliminates spontaneous effort and can worsen hypoxemia if ventilation is not secured). Anticipate apnea with propofol and prioritize oxygenation and immediate ventilatory support readiness.",
    "educationalObjective": "Anticipate apnea and respiratory depression after propofol and prepare airway and ventilation support."
  },
  {
    "id": "Core.13.2.4",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "IV induction agents",
    "difficulty": "hard",
    "questionText": "A 28-year-old woman with known acute intermittent porphyria (AIP) presents with severe diffuse abdominal pain, nausea, and dark urine. She requires urgent laparotomy for suspected bowel ischemia. She has been fasting for 18 hours and is receiving D5LR at 125 mL/h. On arrival to the OR, she is anxious and tachycardic. Vitals: BP 82/46 mmHg on norepinephrine 0.06 μg/kg/min, HR 118/min, SpO<sub>2</sub> 98% on facemask O<sub>2</sub>. Serum Na 123 mEq/L. You plan a rapid-sequence induction. To minimize risk of precipitating a porphyric crisis while maintaining hemodynamic stability, which induction agent is most appropriate?",
    "answers": [
      {
        "text": "Propofol 1.5 mg/kg",
        "isCorrect": false,
        "explanation": "Propofol is considered safe in AIP; however, in a catecholamine-dependent, vasoplegic patient, it can cause profound hypotension and is not the best choice here."
      },
      {
        "text": "Ketamine 1.5 mg/kg",
        "isCorrect": true,
        "explanation": "Ketamine is regarded as safe in AIP and provides sympathetic support, making it preferable for induction in hemodynamic instability requiring RSI."
      },
      {
        "text": "Methohexital 1 mg/kg",
        "isCorrect": false,
        "explanation": "Like other barbiturates, methohexital is porphyrinogenic and contraindicated in acute hepatic porphyrias."
      },
      {
        "text": "Thiopental 4 mg/kg",
        "isCorrect": false,
        "explanation": "Barbiturates are strongly porphyrinogenic (induce ALA synthase) and can precipitate life-threatening AIP attacks; additionally, thiopental may worsen hypotension."
      },
      {
        "text": "Etomidate 0.3 mg/kg",
        "isCorrect": false,
        "explanation": "Despite relative hemodynamic stability, etomidate is considered porphyrinogenic and should be avoided in AIP, especially during an acute attack."
      }
    ],
    "didactic": "Acute intermittent porphyria (AIP) is an acute hepatic porphyria caused by porphobilinogen deaminase deficiency. Accumulation of δ-aminolevulinic acid (ALA) and porphobilinogen leads to neurovisceral symptoms (abdominal pain, autonomic instability, neuropsychiatric findings, hyponatremia). Many precipitants upregulate hepatic ALA synthase and exacerbate attacks, including fasting, infection, stress, hormonal changes, alcohol, and **porphyrinogenic drugs**.\n\nFor induction of anesthesia in AIP, **avoid agents that induce ALA synthase**:\n- **Barbiturates** (thiopental, methohexital) – classic precipitants of AIP crises\n- **Etomidate** – in vitro and clinical data suggest porphyrinogenic potential; most authorities recommend avoidance in acute hepatic porphyrias\n\nAgents considered **safe** include:\n- **Propofol** (safe but may cause significant hypotension in vasoplegia/sepsis)\n- **Ketamine** (safe, supports BP/HR via sympathetic stimulation)\n- **Benzodiazepines** and **opioids**\n- **Volatile anesthetics**, **nitrous oxide**, and commonly used **neuromuscular blockers** (eg, succinylcholine, rocuronium)\n- **Local anesthetics** and **ondansetron** for PONV\n\nIn hemodynamically unstable AIP patients requiring RSI, **ketamine** is preferred because it is non-porphyrinogenic and provides cardiovascular support. Propofol is safe from a porphyria standpoint but can precipitate severe hypotension in catecholamine-dependent states. Etomidate’s hemodynamic profile is attractive, but its porphyrinogenic risk makes it inappropriate during an acute attack. Barbiturates are contraindicated.\n\nBroader management priorities include reversing triggers: administer carbohydrates (eg, dextrose infusion), continue hemodynamic resuscitation, treat infection, and consult for **hemin** if an acute attack is suspected. For seizures, avoid porphyrinogenic antiepileptics (eg, phenytoin); use benzodiazepines or levetiracetam. Maintain normonatremia, normothermia, and adequate analgesia. Careful drug selection and avoidance of fasting/stress help prevent life-threatening AIP exacerbations during the perioperative period.",
    "educationalObjective": "Avoid barbiturates in acute intermittent porphyria and choose alternatives for induction."
  },
  {
    "id": "Core.13.2.5",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "IV induction agents",
    "difficulty": "hard",
    "questionText": "A 58-year-old man with perforated diverticulitis presents for emergent laparotomy. He was intubated in the emergency department 6 hours ago with etomidate 0.3 mg/kg and rocuronium. He received 30 mL/kg of balanced crystalloid and is on norepinephrine 0.2 μg/kg/min with MAP 65–70 mmHg and lactate 4.2 mmol/L. In the OR, he is lightly sedated and begins to move with surgical stimulation. Vitals: HR 102/min, MAP 68 mmHg on current vasopressor, SpO<sub>2</sub> 98% on FiO<sub>2</sub> 0.6.\n\nTo deepen anesthesia promptly while maintaining hemodynamic stability and minimizing adrenal suppression risk in this septic patient, which IV strategy is most appropriate now?",
    "answers": [
      {
        "text": "Start dexmedetomidine 1 μg/kg loading dose over 10 min followed by 0.7 μg/kg/h",
        "isCorrect": false,
        "explanation": "Dexmedetomidine loading can cause bradycardia and hypotension and has a delayed onset; it is not appropriate for rapid deepening in unstable sepsis."
      },
      {
        "text": "Administer propofol 1.5 mg/kg IV bolus before incision",
        "isCorrect": false,
        "explanation": "Propofol causes vasodilation and myocardial depression and commonly precipitates hypotension in catecholamine-dependent septic shock."
      },
      {
        "text": "Administer etomidate 0.2 mg/kg IV bolus before incision",
        "isCorrect": false,
        "explanation": "Although etomidate is hemodynamically stable, repeated dosing in sepsis prolongs adrenal suppression via 11β-hydroxylase inhibition and is associated with increased vasopressor requirements; avoid additional doses within 24–48 hours if alternatives exist."
      },
      {
        "text": "Administer midazolam 0.1 mg/kg IV bolus before incision",
        "isCorrect": false,
        "explanation": "Midazolam has slower, less predictable induction, can worsen hypotension in shock, and does not reliably provide adequate depth for surgical incision alone."
      },
      {
        "text": "Administer ketamine 1 mg/kg IV bolus before incision",
        "isCorrect": true,
        "explanation": "Ketamine preserves blood pressure via sympathomimetic effects and avoids adrenal steroidogenesis inhibition; in a patient who already received etomidate, ketamine is preferred to prevent prolonged adrenal suppression."
      }
    ],
    "didactic": "Etomidate is favored for induction in unstable patients because it produces minimal changes in MAP, HR, and CO at typical doses (0.2–0.3 mg/kg). However, etomidate inhibits adrenal steroidogenesis by blocking 11β-hydroxylase (CYP11B1) and 17α-hydroxylase (CYP17), decreasing cortisol and aldosterone synthesis. Even a single induction dose can suppress cortisol production for 6–24+ hours. In sepsis, where endogenous cortisol is critical to maintain vascular tone and respond to stress, this suppression can increase vasopressor requirements and has been associated in observational studies with worse outcomes. While a single dose may be justifiable when profound hypotension is likely with other agents, prolonged infusions or repeated boluses in septic patients should be avoided.\n\nIn a septic patient who already received etomidate, subsequent deepening should use an alternative that preserves hemodynamics without further adrenal suppression. Ketamine (0.5–1.5 mg/kg IV) is preferred: it supports BP via indirect sympathomimetic effects (catecholamine reuptake inhibition) and maintains airway reflexes. Although ketamine has direct negative inotropy, this is usually unmasked only in catecholamine-depleted states; ongoing vasopressor support mitigates this risk, and ketamine remains safer than redosing etomidate.\n\nIn contrast:\n- Propofol often causes vasodilation and myocardial depression, precipitating hypotension in vasopressor-dependent sepsis.\n- Midazolam has slower onset and can worsen hypotension; it is inadequate as a sole agent for surgical incision depth.\n- Dexmedetomidine has a delayed onset and loading-dose bradycardia/hypotension—unsuitable for rapid deepening.\n\nPractical approach:\n- If etomidate is used for initial induction in shock, avoid repeated doses or infusions in sepsis.\n- Prefer ketamine for subsequent boluses in the next 24–48 hours.\n- In refractory septic shock after etomidate exposure, consider stress-dose hydrocortisone based on clinical context rather than routine prophylaxis.",
    "educationalObjective": "Balance etomidate hemodynamic stability against adrenal suppression and avoid prolonged or repeated dosing in sepsis."
  },
  {
    "id": "Core.13.2.6",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "IV induction agents",
    "difficulty": "medium",
    "questionText": "A 52-year-old woman (165 cm, 122 kg; BMI 44 kg/m<sup>2</sup>) with OSA and well-controlled HTN presents for urgent laparoscopic cholecystectomy. She is euvolemic, ASA II, and hemodynamically stable (MAP 88 mmHg) after preoxygenation with FiO<sub>2</sub> 1.0. You plan an IV induction and are deciding between propofol and etomidate depending on real-time hemodynamics. To avoid under- or overdosing in severe obesity, you elect to calculate per‑kg doses using appropriate weight scalars for the initial induction bolus. Which combination of dosing scalars is most appropriate for propofol and etomidate?",
    "answers": [
      {
        "text": "Propofol by total body weight; etomidate by total body weight",
        "isCorrect": false,
        "explanation": "TBW-based boluses for both agents risk excessive dosing because the central compartment does not expand in proportion to adipose mass, especially problematic with propofol (hypotension/apnea)."
      },
      {
        "text": "Propofol by lean body weight; etomidate by lean body weight",
        "isCorrect": true,
        "explanation": "For induction boluses, effect-site exposure correlates best with LBW for both agents; TBW overestimates initial dose and IBW may underdose in severe obesity."
      },
      {
        "text": "Propofol by total body weight; etomidate by lean body weight",
        "isCorrect": false,
        "explanation": "Propofol bolus should not be dosed by TBW due to exaggerated hypotension and deep anesthesia; LBW is preferable for both agents."
      },
      {
        "text": "Propofol by ideal body weight; etomidate by ideal body weight",
        "isCorrect": false,
        "explanation": "IBW for both agents risks underdosing in severe obesity because central compartment size and cardiac output exceed IBW-based estimates."
      },
      {
        "text": "Propofol by ideal body weight; etomidate by total body weight",
        "isCorrect": false,
        "explanation": "IBW often underdoses propofol in morbid obesity, risking awareness; TBW for etomidate can overshoot effect-site concentrations."
      }
    ],
    "didactic": "Obesity increases adipose mass and cardiac output but does not proportionally expand the central (effect) compartment. For lipophilic IV induction agents, initial hypnotic effect depends on the peak effect-site concentration achieved by the bolus, which correlates more closely with lean body weight (LBW) than with total body weight (TBW). Dosing by TBW tends to overshoot the desired effect-site concentration, whereas ideal body weight (IBW) often underestimates requirements in severe obesity.\n\n- Propofol (induction): Use LBW to calculate the initial bolus. Propofol is highly lipophilic; although its steady-state volume of distribution increases with TBW, the early distribution into the central compartment—and thus the induction effect—is better predicted by LBW. TBW-based boluses are associated with excessive depth, apnea, and hypotension. For maintenance infusions, clearance scales more with body size; many clinicians titrate to effect and often tolerate higher weight scalars (eg, TBW or adjusted body weight) as needed.\n- Etomidate (induction): Use LBW for the initial bolus. Despite lipophilicity, the central compartment and early effect-site kinetics track LBW. TBW dosing can oversedate, while IBW may underdose in morbid obesity. Etomidate’s relative cardiovascular stability does not justify TBW-based boluses.\n\nKey scalars:\n- TBW: actual measured weight; risks overdosing bolus anesthetics in obesity.\n- IBW: height-based; may underdose in severe obesity.\n- LBW: fat-free mass; best single scalar for most IV induction boluses in obesity.\n\nPractical approach: For the initial induction bolus, use LBW for both propofol and etomidate, then titrate additional doses or infusions to clinical effect, recognizing that maintenance requirements may scale with larger body size. ",
    "educationalObjective": "Choose dosing scalars for propofol and etomidate in obesity to avoid under or overdosing."
  },
  {
    "id": "Core.13.2.7",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "IV induction agents",
    "difficulty": "medium",
    "questionText": "A 24-year-old man with severe traumatic brain injury from a motorcycle crash is brought to the OR for emergent evacuation of an acute subdural hematoma. He is obtunded (GCS 6) and has an external ventricular drain showing ICP 25 mmHg. Current vitals: HR 110/min, BP 85/50 mmHg (MAP ≈ 60), SpO<sub>2</sub> 98% on FiO<sub>2</sub> 1.0. Despite a fluid bolus, his MAP remains low. You plan a rapid-sequence induction and want to reduce ICP without further compromising cerebral perfusion pressure (CPP = MAP − ICP).\n\nWhich IV induction agent is most appropriate to optimize CPP while controlling ICP in this patient?",
    "answers": [
      {
        "text": "Ketamine 2 mg/kg IV",
        "isCorrect": false,
        "explanation": "Ketamine tends to increase CBF and ICP (especially without controlled ventilation), and although it supports BP, it risks worsening intracranial hypertension during induction."
      },
      {
        "text": "Midazolam 0.2 mg/kg IV",
        "isCorrect": false,
        "explanation": "Midazolam can reduce CBF/ICP but has slower onset and can cause hypotension, making it suboptimal for rapid control of ICP with tenuous CPP."
      },
      {
        "text": "Etomidate 0.3 mg/kg IV",
        "isCorrect": true,
        "explanation": "Etomidate lowers CMRO<sub>2</sub>, CBF, and ICP while preserving MAP due to minimal cardiovascular depression, thereby improving CPP in hypotensive TBI patients."
      },
      {
        "text": "Propofol 2 mg/kg IV",
        "isCorrect": false,
        "explanation": "Propofol decreases CMRO<sub>2</sub>, CBF, and ICP but commonly causes hypotension; in a patient with MAP 60 mmHg, further BP reduction would lower CPP."
      },
      {
        "text": "Thiopental 4 mg/kg IV",
        "isCorrect": false,
        "explanation": "Thiopental markedly reduces CMRO<sub>2</sub>/CBF/ICP but frequently causes significant hypotension, risking critical reductions in CPP in this unstable patient."
      }
    ],
    "didactic": "In traumatic brain injury, maintaining cerebral perfusion pressure (CPP) while limiting intracranial pressure (ICP) is paramount. CPP is defined as MAP − ICP; when ICP is elevated, even modest declines in MAP can critically reduce CPP. Both propofol and etomidate decrease cerebral metabolic rate (CMRO<sub>2</sub>), producing coupled decreases in cerebral blood flow (CBF) and ICP through cerebral vasoconstriction. However, their systemic hemodynamic effects differ substantially.\n\n- Etomidate: Minimizes cardiovascular depression, typically preserving MAP. It decreases CMRO<sub>2</sub>, CBF, and ICP, making it well suited for patients with intracranial hypertension and tenuous blood pressure. In hypotensive TBI, etomidate helps maintain CPP while still lowering ICP.\n- Propofol: Potently decreases CMRO<sub>2</sub>, CBF, and ICP, but causes dose-dependent vasodilation and myocardial depression that reduce MAP. In the setting of elevated ICP and low MAP, propofol can decrease CPP despite lowering ICP unless aggressive vasopressor support is immediately available.\n\nOther agents:\n- Ketamine: Historically associated with increased CBF and ICP; contemporary data suggest that with controlled ventilation and sedation, ICP rise may be minimal. Nonetheless, in acute, severe intracranial hypertension, ketamine is not first-line when alternatives that reliably lower ICP are available.\n- Thiopental: Strongly reduces CMRO<sub>2</sub>/CBF/ICP but often causes profound hypotension; it is more appropriate for refractory intracranial hypertension in hemodynamically supported patients.\n- Benzodiazepines (eg, midazolam): Can decrease CBF/ICP but have slower onset and can worsen hypotension, limiting utility for rapid-sequence induction in unstable TBI.\n\nFor this patient (MAP ≈ 60 mmHg, ICP 25 mmHg), CPP is already marginal. Etomidate provides ICP reduction with minimal MAP change, optimizing CPP, whereas propofol and thiopental risk further CPP compromise via hypotension.",
    "educationalObjective": "Compare cerebral effects of propofol and etomidate on CBF and ICP and select agents for intracranial pathology."
  },
  {
    "id": "Core.13.2.8",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "IV induction agents",
    "difficulty": "medium",
    "questionText": "A 78-year-old man (70 kg) with severe calcific aortic stenosis (valve area 0.7 cm², mean gradient 42 mmHg), concentric LVH, and preserved EF presents for urgent hemiarthroplasty after a femoral neck fracture. He is NPO >12 hours and takes metoprolol and furosemide. Vitals: BP 138/70 mmHg, HR 58/min. You plan general anesthesia with endotracheal intubation. Due to a formulary shortage, the only IV induction hypnotic immediately available is propofol.\n\nWhich induction approach is most appropriate to minimize hypotension and preserve coronary perfusion in this patient?",
    "answers": [
      {
        "text": "Propofol 2 mg/kg preceded by ephedrine 10 mg IV",
        "isCorrect": false,
        "explanation": "Ephedrine’s β-effects can increase HR and myocardial oxygen demand; combined with a full propofol bolus, this strategy risks hypotension and tachycardia in severe aortic stenosis."
      },
      {
        "text": "Propofol 0.5 mg/kg given in small, slow increments to loss of eyelash reflex while starting a phenylephrine infusion at 0.5 μg/kg/min",
        "isCorrect": true,
        "explanation": "Slowly titrating a reduced propofol dose limits vasodilation and negative inotropy, and prophylactic α-agonist support maintains SVR and coronary perfusion without tachycardia—ideal for severe aortic stenosis."
      },
      {
        "text": "Propofol 0.5 mg/kg with simultaneous increase of sevoflurane to 1.2 MAC to supplement hypnosis",
        "isCorrect": false,
        "explanation": "Inhaled anesthetics further decrease SVR and can compound propofol-induced hypotension; this is undesirable in fixed outflow lesions."
      },
      {
        "text": "Propofol 2 mg/kg rapid bolus with fentanyl 2 μg/kg immediately prior to laryngoscopy",
        "isCorrect": false,
        "explanation": "A full, rapid bolus of propofol plus opioid commonly produces marked venous and arterial vasodilation with blunted baroreflex, risking profound hypotension in severe aortic stenosis."
      },
      {
        "text": "Propofol 1.5 mg/kg rapid bolus after a 1 L crystalloid preload",
        "isCorrect": false,
        "explanation": "Preloading may help, but a large, rapid propofol bolus still causes abrupt SVR/preload reduction and myocardial depression that can destabilize severe aortic stenosis."
      }
    ],
    "didactic": "Propofol commonly causes hypotension via three synergistic mechanisms: (1) venodilation that reduces preload, (2) arterial vasodilation that lowers SVR, and (3) direct myocardial depression (negative inotropy). It also suppresses sympathetic outflow and blunts the baroreflex, so reflex tachycardia is attenuated. The net effect is a rapid drop in MAP (MAP = CO × SVR), which can be poorly tolerated in patients with hypovolemia, advanced age, or fixed outflow obstruction (eg, severe aortic stenosis).\n\nSevere aortic stenosis requires maintaining preload, sinus rhythm, and SVR to preserve coronary perfusion pressure. Even modest decreases in SVR or preload can precipitate myocardial ischemia and hemodynamic collapse because the hypertrophied LV depends on diastolic perfusion pressure and forward flow across a fixed orifice.\n\nCompared with healthy adults (typical induction 1.5–2.5 mg/kg), elderly, hypovolemic, and severe aortic stenosis patients require substantial propofol dose reduction (often 0.25–1 mg/kg) with slow titration to effect. Small, incremental dosing blunts abrupt venous and arterial dilation and limits negative inotropy. Prophylactic vasoconstrictor support with a pure α-agonist (eg, phenylephrine infusion 0.25–1 μg/kg/min) helps maintain SVR and coronary perfusion without increasing HR. In contrast, ephedrine’s β<sub>1</sub>-mediated chronotropy can be harmful in aortic stenosis by increasing myocardial O<sub>2</sub> demand and shortening diastole.\n\nAdditional strategies include ensuring adequate preload (cautiously), minimizing synergistic vasodilators (eg, high-dose volatile agents), and using high-opioid/low-propofol techniques. When available, etomidate is often preferred for high-risk aortic stenosis due to relative hemodynamic stability; however, if propofol must be used, reduced, slowly titrated dosing with α-agonist support best mitigates hypotension risk.",
    "educationalObjective": "Describe propofol-mediated hypotension mechanisms and reduce dose in hypovolemia, elderly, and severe aortic stenosis."
  },
  {
    "id": "Core.13.2.9",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "IV induction agents",
    "difficulty": "medium",
    "questionText": "A healthy 32-year-old woman (BMI 24 kg/m²) receives propofol 2 mg/kg IV over 20 s for closed shoulder reduction. She becomes unresponsive within 30 s. The procedure is aborted at 5 min without further sedatives, and she follows commands 6 min after the bolus. One week later, she undergoes a 3-hour TIVA with propofol at 100–125 µg/kg/min; after stopping the infusion, she requires ~15 min to obey commands. Which pharmacokinetic explanation best accounts for the rapid onset and the difference in recovery after a bolus versus a prolonged infusion of propofol?",
    "answers": [
      {
        "text": "High hepatic extraction causes rapid awakening; elimination half-life predicts emergence independent of infusion duration.",
        "isCorrect": false,
        "explanation": "Hepatic clearance determines elimination, but emergence after propofol is not predicted by terminal elimination half-life and is highly dependent on redistribution and infusion duration."
      },
      {
        "text": "Rapid renal excretion of unchanged drug accounts for quick offset; accumulation during infusion reflects saturable renal transporters.",
        "isCorrect": false,
        "explanation": "Propofol is extensively metabolized hepatically (and extrahepatically); negligible unchanged drug is renally excreted, and renal transporter saturation does not explain emergence."
      },
      {
        "text": "High lipid solubility enables rapid brain effect; after a bolus, offset reflects redistribution from the vessel-rich group to muscle/fat, whereas prolonged infusion fills peripheral compartments and increases context-sensitive half-time.",
        "isCorrect": true,
        "explanation": "Propofol’s lipophilicity produces fast onset; brief exposures end via redistribution. With longer infusions, peripheral compartments equilibrate, reducing the redistribution gradient and prolonging context-sensitive half-time."
      },
      {
        "text": "Low protein binding accelerates both onset and offset; with longer infusions, protein binding falls further, delaying emergence.",
        "isCorrect": false,
        "explanation": "Propofol is highly protein bound (~98%); changes in binding do not primarily drive onset or emergence patterns after bolus or infusion."
      },
      {
        "text": "A small volume of distribution makes effect-site concentrations fall rapidly after any dose, so recovery is independent of infusion length.",
        "isCorrect": false,
        "explanation": "Propofol has a large volume of distribution; recovery depends on redistribution early and increases in context-sensitive half-time with infusion duration."
      }
    ],
    "didactic": "Propofol’s clinical kinetics are dominated by lipophilicity, redistribution, and context-sensitive half-time rather than by terminal elimination half-life. Highly lipophilic drugs rapidly equilibrate with the vessel-rich group (brain, heart, kidney) due to high perfusion, producing loss of consciousness within ~30 s of an IV bolus. After a brief exposure, the effect-site concentration declines primarily because drug redistributes from the brain to less-well-perfused, larger-capacity tissues (muscle, then fat). This redistribution lowers the brain concentration below the hypnotic threshold within minutes, even though the terminal elimination half-life is several hours.\n\nDuring a prolonged infusion, peripheral compartments (muscle and fat) partially fill and approach equilibration with plasma. When the infusion stops, the concentration gradient driving redistribution out of the brain is reduced. As a result, the time required for the plasma/effect-site concentration to decrease by 50%—the context-sensitive half-time—increases with infusion duration. Propofol’s context-sensitive half-time remains relatively short for brief infusions but lengthens with hours-long administration, explaining slower emergence after prolonged TIVA compared with a single bolus.\n\nKey contrasts:\n- Elimination half-life (hours) reflects terminal clearance and does not predict wake-up after typical anesthetic exposures.\n- High hepatic extraction contributes to overall clearance but is not the primary reason for rapid offset after a bolus (redistribution is).\n- Renal excretion of unchanged propofol is minimal; metabolites are renally eliminated.\n- Protein binding is high (~98%) and relatively constant; it does not explain the duration-dependent emergence.\n\nThus, propofol’s rapid onset stems from lipophilicity and delivery to the vessel-rich group, while offset is driven by redistribution after a bolus and by an infusion-duration–dependent increase in context-sensitive half-time.",
    "educationalObjective": "Explain why propofol has rapid onset and offset due to redistribution and context-sensitive half-time."
  },
  {
    "id": "Core.13.2.10",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "IV induction agents",
    "difficulty": "hard",
    "questionText": "A 38-year-old man presents for urgent laparoscopic appendectomy. He reports an IgE-mediated egg allergy since adulthood with immediate hives and wheeze after scrambled eggs requiring intramuscular epinephrine 2 years ago. He tolerates soy products (eg, tofu, soy milk) and has never received propofol or lipid emulsions. He has no other drug allergies. You plan rapid, smooth induction and anticipate giving an IV antibiotic before incision.\n\nWhich is the most appropriate plan regarding propofol use in this patient?",
    "answers": [
      {
        "text": "Delay surgery to obtain immediate preoperative skin testing for propofol, egg, and soy to determine safety",
        "isCorrect": false,
        "explanation": "Skin testing to propofol and foods does not reliably predict perioperative anaphylaxis risk and is impractical for an urgent case; management decisions should rely on existing evidence and preparedness."
      },
      {
        "text": "Premedicate with methylprednisolone and diphenhydramine, then perform propofol induction to reduce risk of IgE-mediated anaphylaxis",
        "isCorrect": false,
        "explanation": "Steroids and H1 blockers do not prevent IgE-mediated anaphylaxis and can provide false reassurance; they are not recommended as prophylaxis for suspected propofol allergy."
      },
      {
        "text": "Administer graded test dosing of propofol in 10–20 mg increments with epinephrine at bedside to minimize reaction severity",
        "isCorrect": false,
        "explanation": "Anaphylaxis can occur with small doses and graded challenges have not been shown to reduce severity; standard dosing with vigilant monitoring and readiness is preferred."
      },
      {
        "text": "Proceed with standard propofol induction without prophylactic antihistamines or steroids, administer other potential triggers sequentially, and ensure readiness to treat anaphylaxis",
        "isCorrect": true,
        "explanation": "Food allergens are proteins; refined soybean oil and egg lecithin in propofol contain negligible protein. Large studies and allergy society guidelines support using propofol safely in egg/soy-allergic patients, with general anaphylaxis preparedness and thoughtful sequencing of agents."
      },
      {
        "text": "Avoid propofol and induce with etomidate due to high cross-reactivity risk with egg and soy components",
        "isCorrect": false,
        "explanation": "Cross-reactivity is minimal because propofol’s emulsion contains highly refined lipids with negligible protein; avoiding propofol solely for egg/soy allergy is not evidence-based."
      }
    ],
    "didactic": "Propofol is formulated in a lipid emulsion containing refined soybean oil and purified egg lecithin (phosphatide). **Food allergy is mediated by IgE to proteins**, whereas these refined lipids contain negligible residual protein. Egg allergy is typically directed at egg white proteins (eg, ovalbumin, ovomucoid), not yolk phosphatides. Consequently, **cross-reactivity between egg/soy food allergy and propofol is biologically implausible** and not supported by clinical data.\n\nMultiple cohort studies and pharmacovigilance analyses have found that patients with egg or soy allergy do not have increased rates of adverse reactions to propofol compared with nonallergic controls. Most perioperative reactions attributed to propofol are thought to involve the **phenol or isopropyl moieties** of the propofol molecule rather than the emulsion components. Current guidance from allergy societies (eg, AAAAI) and anesthesia organizations indicates that **propofol need not be avoided** in patients with egg, soy, or peanut allergy, including those with prior anaphylaxis to these foods. The main contraindication is a prior reaction to propofol itself.\n\nRisk mitigation focuses on general anaphylaxis preparedness rather than premedication or testing. There is **no role for routine preoperative skin testing** to propofol or foods to determine safety, and antihistamine/steroid prophylaxis does not prevent IgE-mediated anaphylaxis. For urgent cases, use propofol as clinically indicated, with:\n- Standard dosing and vigilant monitoring\n- Immediate availability of epinephrine, airway equipment, and IV access\n- Sequencing of potential triggers (eg, administer antibiotic and neuromuscular blocker separately from induction) to aid culprit identification if a reaction occurs\n\nIf a reaction occurs, manage per anaphylaxis algorithms and arrange **postevent allergy referral** for confirmatory testing and counseling.",
    "educationalObjective": "Interpret the evidence regarding egg and soy allergy and propofol safety and formulate a risk mitigation plan."
  },
  {
    "id": "Core.13.2.11",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "IV induction agents",
    "difficulty": "medium",
    "questionText": "A 34-year-old woman (BMI 27 kg/m²), nonsmoker, with a prior history of severe postoperative nausea and vomiting (PONV) after general anesthesia presents for ambulatory laparoscopic cholecystectomy (expected duration 60–90 minutes). She will receive nonopioid multimodal analgesia (acetaminophen and an NSAID) and asks to do “whatever best prevents nausea.” She has no cardiopulmonary disease and normal baseline vitals. Planned airway is endotracheal general anesthesia with controlled ventilation on air/O<sub>2</sub>.\n\nWhich anesthetic maintenance plan best minimizes this patient’s PONV risk?",
    "answers": [
      {
        "text": "Desflurane at 0.8 MAC with low-flow anesthesia plus scopolamine patch and ondansetron",
        "isCorrect": false,
        "explanation": "Low-flow delivery does not change the emetogenicity of volatile agents; despite prophylaxis, inhaled anesthetics still confer higher PONV risk than propofol TIVA."
      },
      {
        "text": "Ketamine infusion 0.3 mg/kg/h with sevoflurane at 1.0 MAC to minimize opioids; no antiemetics required",
        "isCorrect": false,
        "explanation": "Opioid-sparing helps, but maintaining a volatile anesthetic without prophylaxis leaves a high baseline PONV risk; ketamine does not meaningfully counteract volatile-induced PONV."
      },
      {
        "text": "Total IV anesthesia: propofol infusion 100–150 µg/kg/min in air/O<sub>2</sub>, avoiding volatile agents and N<sub>2</sub>O; maintain multimodal nonopioid analgesia and standard dual antiemetic prophylaxis",
        "isCorrect": true,
        "explanation": "Propofol-based TIVA both avoids emetogenic inhaled agents and leverages propofol’s intrinsic antiemetic effect, providing the greatest PONV reduction in high-risk patients."
      },
      {
        "text": "Sevoflurane at 0.7 MAC in air/O<sub>2</sub> with dual prophylaxis (dexamethasone at induction, ondansetron at case end)",
        "isCorrect": false,
        "explanation": "Lower MAC and dual prophylaxis reduce risk, but volatile anesthetics remain independently emetogenic compared with propofol-based TIVA."
      },
      {
        "text": "Sevoflurane at 1.0 MAC in a 50% N<sub>2</sub>O/O<sub>2</sub> mixture with intermittent fentanyl; ondansetron at case end",
        "isCorrect": false,
        "explanation": "N<sub>2</sub>O and volatile agents both increase PONV; adding an antiemetic does not offset the emetogenic effect of N<sub>2</sub>O and inhaled anesthetics in a high-risk patient."
      }
    ],
    "didactic": "High-risk PONV patients (eg, Apfel score ≥3: female sex, nonsmoker, prior PONV/motion sickness, and postoperative opioid use) benefit most from eliminating emetogenic anesthetics and layering multimodal prophylaxis. Volatile agents (sevoflurane, desflurane, isoflurane) and N<sub>2</sub>O independently increase PONV compared with propofol. In contrast, propofol has an intrinsic antiemetic effect and, when used for maintenance (TIVA), reduces PONV by roughly 30%–50% versus inhaled anesthesia.\n\nThe optimal strategy here is propofol-based TIVA with air/O<sub>2</sub>, explicitly avoiding both volatile agents and N<sub>2</sub>O. A typical maintenance rate is 75–150 µg/kg/min (titrate to effect, often with processed EEG targeting BIS 40–60). Propofol’s short context-sensitive half-time supports rapid, smooth emergence suitable for ambulatory surgery. Combine TIVA with multimodal nonopioid analgesia (eg, acetaminophen, NSAID; consider local infiltration or regional techniques) to further limit postoperative opioids, a major PONV risk factor. Standard guideline-based prophylaxis still applies: administer ≥2 classes in high-risk patients (eg, dexamethasone 4–8 mg at induction and ondansetron 4 mg near the end; consider a scopolamine patch preop if very high risk).\n\nCommon pitfalls include: \n- Adding N<sub>2</sub>O to “spare” volatile dose—N<sub>2</sub>O is itself emetogenic and worsens PONV.\n- Simply lowering MAC or using low-flow anesthesia—reducing fresh gas flow or MAC fraction does not negate the emetogenic nature of volatiles.\n- Relying solely on opioid-sparing (eg, ketamine) while maintaining a volatile—volatile exposure remains the dominant driver.\n\nTherefore, for a high-risk ambulatory laparoscopic case, propofol TIVA with avoidance of volatiles and N<sub>2</sub>O, plus multimodal analgesia and dual antiemetic prophylaxis, provides the greatest reduction in PONV and supports timely discharge.",
    "educationalObjective": "Leverage TIVA with propofol to reduce postoperative nausea and vomiting in high-risk patients."
  },
  {
    "id": "Core.13.2.12",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "IV induction agents",
    "difficulty": "hard",
    "questionText": "A 72-year-old man with severe calcific aortic stenosis (valve area 0.7 cm², mean gradient 55 mmHg, EF 60%) presents for urgent open reduction and internal fixation of a femoral neck fracture. He reports exertional angina and presyncope. Medications include metoprolol; ACE inhibitor was held. He is euvolemic, NPO 8 h, and an arterial line is placed preinduction. Vitals: BP 148/76 (MAP 100) and HR 60/min in sinus rhythm. You plan general anesthesia with endotracheal intubation. The primary goals are to preserve afterload and sinus rhythm, avoid tachycardia and significant bradycardia, and prevent myocardial ischemia.\n\nWhich induction strategy best aligns with these hemodynamic goals in severe aortic stenosis?",
    "answers": [
      {
        "text": "Initiate a phenylephrine infusion 0.25–0.5 µg/kg/min before induction; administer fentanyl 1 µg/kg and etomidate 0.2 mg/kg in small increments to intubation while maintaining HR 60–70/min and MAP ≥80–90 mmHg.",
        "isCorrect": true,
        "explanation": "Preemptive α-agonist support maintains afterload and coronary perfusion; slow, titrated etomidate with modest opioid blunts sympathetic surges without vasodilation or tachycardia, optimizing sinus rhythm and MAP in severe AS."
      },
      {
        "text": "Give etomidate 0.3 mg/kg and a remifentanil 2 µg/kg bolus; start a nitroglycerin infusion during laryngoscopy to prevent hypertension.",
        "isCorrect": false,
        "explanation": "Remifentanil boluses can cause bradycardia/hypotension, and nitroglycerin reduces preload/afterload, jeopardizing coronary perfusion pressure in severe AS."
      },
      {
        "text": "Induce with propofol 2 mg/kg and lidocaine 1 mg/kg; treat hypotension with intermittent phenylephrine boluses as needed.",
        "isCorrect": false,
        "explanation": "Propofol causes marked vasodilation and myocardial depression, risking profound hypotension in fixed outflow obstruction; reactive vasopressor boluses are inferior to proactive afterload support."
      },
      {
        "text": "Administer midazolam 0.05 mg/kg and fentanyl 10 µg/kg to blunt the response; start norepinephrine 0.05 µg/kg/min only if MAP falls below 65 mmHg.",
        "isCorrect": false,
        "explanation": "Very high-dose opioid may cause bradycardia and rigidity; delaying vasopressor until MAP <65 mmHg risks inadequate coronary perfusion—severe AS generally requires higher MAP targets with proactive afterload support."
      },
      {
        "text": "Induce with ketamine 1.5 mg/kg and support blood pressure with ephedrine boluses; target HR 80–90/min to maintain cardiac output.",
        "isCorrect": false,
        "explanation": "Ketamine and ephedrine increase HR and contractility, which shortens diastole and raises myocardial O<sub>2</sub> demand; tachycardia worsens ischemia and is particularly harmful in severe AS."
      }
    ],
    "didactic": "Severe aortic stenosis (AS) creates a fixed obstruction to LV outflow; cardiac output cannot rapidly increase to compensate for vasodilation or negative inotropy. Coronary perfusion depends on diastolic arterial pressure and adequate LV diastolic time. Thus, the key hemodynamic goals during induction are:\n\n- Maintain sinus rhythm with HR ~60–70/min to optimize diastolic filling and coronary perfusion.\n- Preserve or slightly augment afterload (MAP ≥80–90 mmHg) to sustain coronary perfusion pressure.\n- Avoid significant vasodilation, bradycardia, or tachycardia and prevent large swings in preload.\n\nEtomidate is preferred for induction because it is hemodynamically stable with minimal effects on SVR and contractility. Modest opioid co-induction (eg, fentanyl 1–2 µg/kg) blunts sympathetic stimulation from laryngoscopy without precipitating bradycardia or vasodilation. Proactive α-agonist support with a phenylephrine infusion started before induction helps maintain afterload and diastolic pressure, supporting coronary perfusion in the face of any modest anesthetic-induced vasodilation.\n\nIn contrast, propofol commonly causes dose-dependent vasodilation and myocardial depression, provoking precipitous hypotension that can be catastrophic in severe AS. Ketamine’s sympathomimetic effects increase HR and contractility, which can reduce diastolic time and raise myocardial O<sub>2</sub> demand—undesirable in a pressure-overloaded, often hypertrophied LV. Short-acting potent opioids (eg, remifentanil) given as large boluses may produce bradycardia and hypotension; vasodilators such as nitroglycerin further decrease preload/afterload and threaten coronary perfusion pressure. Ephedrine increases HR and is generally less suitable than pure α-agonists. Norepinephrine can be appropriate, but early, goal-directed support (rather than reactive rescue at MAP <65 mmHg) is preferred.\n\nIn summary, slow, titrated etomidate with modest opioid and preemptive phenylephrine infusion best meets the physiologic goals of severe AS: preserved afterload, stable sinus rhythm, and avoidance of vasodilatory agents that could jeopardize coronary perfusion.",
    "educationalObjective": "Plan induction for severe aortic stenosis prioritizing afterload, sinus rhythm, and cautious use of vasodilatory agents."
  },
  {
    "id": "Core.13.2.13",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "IV induction agents",
    "difficulty": "hard",
    "questionText": "A 28-year-old man with severe traumatic brain injury has been mechanically ventilated in the ICU for 72 hours with a propofol infusion at 80 μg/kg/min. Tube feeds have been intermittently held for ICP management. He is receiving norepinephrine and methylprednisolone. He develops progressive hypotension and sinus bradycardia with widening QRS. Labs: pH 7.16, HCO<sub>3</sub><sup>-</sup> 12 mEq/L, PaCO<sub>2</sub> 34 mmHg, lactate 9 mmol/L, K 6.1 mEq/L, creatinine 2.3 mg/dL, CK 22,000 U/L, triglycerides 850 mg/dL. Urine is dark. Which of the following is the most appropriate immediate management to prevent further deterioration?",
    "answers": [
      {
        "text": "Administer 20% lipid emulsion bolus and infusion for suspected lipophilic drug toxicity",
        "isCorrect": false,
        "explanation": "Lipid emulsion treats local anesthetic systemic toxicity, not PRIS; it may aggravate hypertriglyceridemia and does not address mitochondrial failure."
      },
      {
        "text": "Administer dantrolene for malignant hyperthermia",
        "isCorrect": false,
        "explanation": "Malignant hyperthermia requires volatile agents or succinylcholine exposure and presents with hypercarbia, rigidity, and hyperthermia; the findings here are more consistent with PRIS."
      },
      {
        "text": "Continue propofol and start a sodium bicarbonate infusion to correct lactic acidosis",
        "isCorrect": false,
        "explanation": "Bicarbonate may transiently raise pH but does not treat the underlying cause; propofol must be discontinued immediately in suspected PRIS."
      },
      {
        "text": "Immediately discontinue propofol and transition to dexmedetomidine sedation, while initiating supportive therapy for acidosis and hyperkalemia",
        "isCorrect": true,
        "explanation": "This presentation is classic for propofol infusion syndrome; immediate cessation of propofol and alternative sedation with targeted supportive care is the key early intervention."
      },
      {
        "text": "Increase the propofol infusion to deepen sedation and reduce sympathetic demand",
        "isCorrect": false,
        "explanation": "Continuing or escalating propofol in suspected PRIS worsens mitochondrial dysfunction and increases risk of cardiac collapse; the causative agent must be stopped."
      }
    ],
    "didactic": "Propofol infusion syndrome (PRIS) is a rare but often fatal complication of high-dose or prolonged propofol infusion characterized by impaired mitochondrial fatty acid oxidation and electron transport, leading to failure of oxidative phosphorylation. The clinical triad includes rapidly progressive metabolic acidosis (often lactic), cardiac failure/arrhythmias (bradycardia, widening QRS, heart block), and skeletal muscle injury (rhabdomyolysis) with secondary renal failure. Additional features include hyperkalemia, hypertriglyceridemia, hepatomegaly, and lipemia.\n\nMajor risk factors include:\n- High-dose propofol (>4 mg/kg/h ≈ 67 μg/kg/min) and duration >48 h\n- Critical illness (TBI, sepsis), catecholamine infusions, and corticosteroids\n- Low carbohydrate intake/fasting, ketogenic states, or inborn errors of metabolism\n- Young age and high lipid burden\n\nImmediate management is to **stop propofol** and transition to alternative sedation (eg, **dexmedetomidine**, **midazolam**, or **ketamine**). Initiate supportive care: treat hyperkalemia (calcium, insulin–dextrose), manage severe acidosis (judicious sodium bicarbonate), aggressive fluids for rhabdomyolysis, and vasopressors/inotropes as needed. Consider **CRRT** for refractory acidosis or renal failure and **ECMO** for cardiogenic shock. Carnitine has limited evidence; **lipid emulsion is not indicated** in PRIS.\n\nPrevention focuses on minimizing exposure and metabolic stress:\n- Limit dose (<4 mg/kg/h) and duration; use the lowest effective dose\n- Ensure adequate carbohydrate delivery (eg, dextrose infusion or enteral nutrition) to suppress lipolysis\n- Avoid or minimize catecholamines and corticosteroids when feasible\n- Monitor for early warning signs: rising lactate/base deficit, CK, triglycerides, new EKG conduction changes/bradyarrhythmias, unexplained renal dysfunction\n\nEarly recognition of the risk pattern (high-dose/long-duration propofol plus catecholamines/steroids and low carbohydrate intake) and prompt discontinuation with supportive therapy are crucial to prevent irreversible cardiac failure and death.",
    "educationalObjective": "Recognize propofol infusion syndrome, list risk factors, and outline prevention and early management."
  },
  {
    "id": "Core.13.2.14",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "IV induction agents",
    "difficulty": "easy",
    "questionText": "A 26-year-old healthy woman (ASA I) presents for knee arthroscopy. A 20G IV is in the dorsum of the hand. She reports severe burning during a prior propofol induction and asks to avoid that experience. You plan induction with fentanyl and propofol. The team is ready to proceed, and there is no time to place additional IV access.\n\nWhich intervention will most effectively minimize pain from the propofol injection under these circumstances?",
    "answers": [
      {
        "text": "Inject propofol rapidly as a bolus through the hand IV to minimize contact time with the endothelium",
        "isCorrect": false,
        "explanation": "Rapid bolus in a small hand vein does not reliably reduce pain and may worsen burning due to high local propofol concentration."
      },
      {
        "text": "Cool propofol to 4°C before injection through the hand IV",
        "isCorrect": false,
        "explanation": "Cooling may modestly reduce pain but is less effective than lidocaine techniques and is not practical immediately before induction."
      },
      {
        "text": "Apply a forearm venous tourniquet, inject lidocaine 0.5 mg/kg into the occluded vein, wait 60 s, release the tourniquet, then administer propofol",
        "isCorrect": true,
        "explanation": "Lidocaine pretreatment with brief venous occlusion anesthetizes the peripheral vein and attenuates the bradykinin-mediated pain response, providing the greatest reduction in propofol injection pain."
      },
      {
        "text": "Mix lidocaine 40 mg with propofol and inject slowly through the hand IV",
        "isCorrect": false,
        "explanation": "Admixture decreases pain, but slow injection and use of a small hand vein increase pain; overall this is less effective than lidocaine pretreatment with venous occlusion."
      },
      {
        "text": "Place a new 18G antecubital IV and inject propofol through the larger vein",
        "isCorrect": false,
        "explanation": "Using a large antecubital vein reduces pain, but the scenario precludes additional IV placement; among feasible options now, venous occlusion with lidocaine is superior."
      }
    ],
    "didactic": "Propofol injection pain is common (up to 70%) and is mediated by direct venous endothelial irritation and a **kinin cascade** (eg, bradykinin) that increases venous permeability and activates C-fiber nociceptors. The most effective, practical method to reduce this pain is **lidocaine pretreatment with brief venous occlusion**. Applying a forearm tourniquet (or BP cuff at venous occlusion pressure) for 30–60 s after injecting lidocaine 0.5 mg/kg traps the local anesthetic within the peripheral vein, providing intimal anesthesia and attenuating the bradykinin response; after releasing the tourniquet, propofol can be administered with significantly less discomfort.\n\nOther strategies are helpful but less effective:\n- **Lidocaine–propofol admixture**: Mixing 10–40 mg lidocaine into propofol reduces pain via local anesthesia and dilution of the aqueous phase but is inferior to lidocaine with venous occlusion. Prepare immediately before use to maintain emulsion stability, and avoid excessive lidocaine doses.\n- **Use of larger, proximal veins**: Injecting through an antecubital 18G reduces pain by higher flow, larger diameter, and faster central dilution. When time permits, this is a good alternative; however, it is often less effective than venous occlusion with lidocaine.\n- **Avoid slow injection in small hand veins**: Slow administration and small distal veins increase contact time and local concentration, worsening pain.\n- **Other adjuncts** (eg, opioids, ketamine, cooling, dilution via running IV) offer modest benefit but are generally inferior to lidocaine with venous occlusion or larger-vein injection.\n\nBest practice: when a hand IV must be used, pretreat with lidocaine under venous occlusion for 30–60 s, then release and induce with propofol; if feasible, use a larger antecubital vein and/or consider lidocaine admixture for additional benefit.",
    "educationalObjective": "Reduce propofol injection pain using lidocaine admixture, larger veins, and venous occlusion techniques."
  },
  {
    "id": "Core.13.2.15",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "IV induction agents",
    "difficulty": "hard",
    "questionText": "A 68-year-old man with septic shock from a perforated sigmoid diverticulitis is brought to the OR for emergent laparotomy. He is obtunded, RR 28, SpO<sub>2</sub> 94% on a nonrebreather, HR 118, BP 82/46 (MAP 58) after 3 L balanced crystalloid. He is on norepinephrine 0.25 µg/kg/min and vasopressin 0.03 units/min via a central line. Point-of-care echocardiography shows LVEF 30% with global hypokinesis; no RV dilation or severe TR. Labs: pH 7.20, HCO<sub>3</sub><sup>−</sup> 15 mEq/L, lactate 6.8 mmol/L, K 4.6 mEq/L, Cr 2.1 mg/dL. The surgical team requests a rapid-sequence induction due to peritonitis and aspiration risk.\n\nWhich IV induction approach will best minimize further hypotension at laryngoscopy?",
    "answers": [
      {
        "text": "Ketamine 0.5 mg/kg plus fentanyl 2 µg/kg for RSI",
        "isCorrect": false,
        "explanation": "Lower-dose ketamine reduces sympathetic support and the added fentanyl blunts compensatory tone, increasing risk of hypotension at induction in vasoplegic shock."
      },
      {
        "text": "Ketamine 1.5 mg/kg for RSI to leverage sympathetic stimulation",
        "isCorrect": false,
        "explanation": "In profound septic shock with catecholamine depletion and acidosis, ketamine’s direct negative inotropy may predominate, causing hypotension despite its usual sympathetic stimulation."
      },
      {
        "text": "Etomidate 0.2 mg/kg for RSI, avoiding additional opioid bolus",
        "isCorrect": true,
        "explanation": "Etomidate produces minimal vasodilation and myocardial depression, maintaining MAP in severe shock and reduced EF; although it transiently inhibits 11β-hydroxylase, a single dose is generally favored when immediate hemodynamic stability is paramount."
      },
      {
        "text": "“Ketofol”: ketamine 0.5 mg/kg plus propofol 0.5 mg/kg for RSI",
        "isCorrect": false,
        "explanation": "Combining agents dampens ketamine’s sympathetic effect while retaining propofol-induced vasodilation, making hypotension likely in severe shock with impaired ventricular function."
      },
      {
        "text": "Propofol 0.5 mg/kg with push-dose phenylephrine 100 µg for RSI",
        "isCorrect": false,
        "explanation": "Even reduced-dose propofol causes venodilation and myocardial depression; phenylephrine may worsen cardiac output in low EF and may be insufficient in severe vasoplegia."
      }
    ],
    "didactic": "Septic shock presents combined **vasoplegia** and often **myocardial dysfunction**; both are exacerbated by anesthetic-induced vasodilation and negative inotropy. Choosing an induction agent requires prioritizing immediate hemodynamic stability while acknowledging downstream trade-offs.\n\n- **Etomidate**: Minimal effect on SVR and contractility, making it the most hemodynamically stable induction agent in severe shock and low EF. It transiently inhibits adrenal 11β-hydroxylase, reducing cortisol synthesis for 12–24 hours. While observational data link etomidate to increased vasopressor needs and possible mortality in sepsis, randomized evidence is mixed; when immediate stability is critical (eg, MAP <60 mmHg on multiple pressors), a single dose is generally preferred. Consider stress-dose steroids in patients with chronic steroid use or suspected adrenal insufficiency, but do not delay induction.\n- **Ketamine**: Usually raises BP/HR via endogenous catecholamine release and has bronchodilatory properties. However, ketamine is a **direct myocardial depressant**; in catecholamine-depleted or β-blocked patients, the unmasked negative inotropy can precipitate severe hypotension. It is better suited to hemorrhagic shock with intact sympathetic reserve than to late septic shock with acidosis and high-dose vasopressors.\n- **Propofol**: Causes potent **vasodilation** and **myocardial depression**, leading to precipitous hypotension in shock even at “reduced” doses. Co-administration of pure α-agonists (eg, phenylephrine) may increase afterload and reduce cardiac output in low EF and frequently does not offset propofol’s profound venodilation.\n\nFor this unstable, vasoplegic patient on norepinephrine and vasopressin with depressed LVEF, **etomidate (≈0.2–0.3 mg/kg)** best minimizes peri-induction hypotension. Avoid additional opioid boluses during RSI, maintain ongoing vasopressor infusions, and be prepared with push-dose vasopressors (eg, epinephrine) to treat laryngoscopy-induced cardiovascular collapse.",
    "educationalObjective": "Select induction agents in hemodynamic instability by comparing ketamine, etomidate, and propofol trade-offs."
  },
  {
    "id": "Core.13.2.16",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "IV induction agents",
    "difficulty": "medium",
    "questionText": "A 58-year-old woman with treatment-resistant major depression returns for her second electroconvulsive therapy (ECT) session. During the first session, induction with propofol 2 mg/kg and succinylcholine 1 mg/kg produced an EEG seizure of 18 s and a nadir MAP of 52 mmHg requiring phenylephrine. Medical history includes coronary artery disease with a prior stent, well-controlled hypertension, and polymyalgia rheumatica treated with prednisone 15 mg daily. Baseline vitals today are BP 138/78 mmHg and HR 66/min; electrolytes are normal. The team wants to improve seizure quality while minimizing hypotension and avoiding medication-related adverse effects during a series of treatments. Which induction agent is most appropriate for today’s ECT?",
    "answers": [
      {
        "text": "Ketamine 1 mg/kg",
        "isCorrect": false,
        "explanation": "Ketamine may lengthen seizures and has intrinsic antidepressant effects, but its sympathomimetic properties (↑HR/BP) are undesirable in a patient with CAD and can exacerbate the ECT-induced sympathetic surge."
      },
      {
        "text": "Methohexital 1 mg/kg",
        "isCorrect": true,
        "explanation": "Methohexital is the first-line ECT induction agent because it lowers seizure threshold, supports adequate seizure duration, and provides greater hemodynamic stability compared with propofol, with rapid recovery for serial treatments."
      },
      {
        "text": "Propofol 2 mg/kg",
        "isCorrect": false,
        "explanation": "Propofol has potent anticonvulsant effects that shorten seizure duration and commonly causes hypotension, which was problematic in her prior session."
      },
      {
        "text": "Thiopental 3 mg/kg",
        "isCorrect": false,
        "explanation": "Thiopental has greater anticonvulsant properties than methohexital, tends to shorten seizures, and leads to more hypotension and prolonged recovery, making it less suitable for ECT."
      },
      {
        "text": "Etomidate 0.2 mg/kg",
        "isCorrect": false,
        "explanation": "Etomidate preserves hemodynamics and can prolong seizures but inhibits 11β-hydroxylase, risking adrenal suppression over serial ECT sessions—particularly concerning in a patient on chronic steroids; it is typically reserved for inadequate seizures despite methohexital."
      }
    ],
    "didactic": "ECT requires a brief general anesthetic and a controlled generalized seizure; adequate EEG seizure duration is typically ≥25–30 s. The ideal induction agent for ECT provides rapid onset/offset, maintains hemodynamic stability through the sympathetic surge, and does not excessively suppress seizure activity. **Methohexital** (0.75–1 mg/kg) is the preferred agent because it is an ultrashort-acting barbiturate with rapid recovery, relatively minimal anticonvulsant effect for a barbiturate, and a tendency to **lower the seizure threshold** compared with agents like propofol. It thus supports longer, higher-quality seizures while causing less hypotension than propofol.\n\nBy contrast, **propofol** strongly enhances GABA<sub>A</sub> activity, **shortening seizure duration** and often producing **hypotension** from vasodilation and myocardial depression. Propofol may be chosen selectively to blunt extreme hypertension/tachycardia from the ECT stimulus but risks inadequate seizures, as seen here.\n\n**Etomidate** preserves BP/HR and can **prolong seizure duration**, but it inhibits 11β-hydroxylase, reducing cortisol synthesis for 6–24 hours after even a single dose. During serial ECT, this can accumulate and is undesirable in patients with hypothalamic–pituitary–adrenal axis vulnerability (eg, chronic prednisone). Etomidate also increases myoclonus and PONV, so it is generally reserved when seizures remain too short despite methohexital.\n\n**Ketamine** (NMDA antagonist) may lengthen seizures and has antidepressant properties, but its **sympathomimetic** effects (↑MAP/HR) can be hazardous in CAD and compound the ECT-induced surge; it also increases secretions and can cause emergence phenomena. **Thiopental** is more anticonvulsant than methohexital, shortens seizures, and prolongs recovery with more hypotension.\n\nBottom line: For routine ECT—especially after a short seizure and hypotension with propofol—**methohexital** optimizes seizure quality and **preserves hemodynamics** for repeated treatments.",
    "educationalObjective": "Use methohexital for ECT to lower seizure threshold and preserve hemodynamics compared with propofol."
  },
  {
    "id": "Core.13.2.17",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "IV induction agents",
    "difficulty": "easy",
    "questionText": "A 72-year-old man (BMI 32) with well-controlled hypertension and high OSA risk (STOP-BANG 5) presents for elective laparoscopic cholecystectomy. He is anxious, NPO 8 hours, SpO<sub>2</sub> 96% on room air, BP 148/78 mmHg, HR 72/min. You plan IV induction with propofol and tracheal intubation after preoxygenation. You want to decrease propofol requirements while minimizing hypotension and prolonged apnea in this elderly, OSA-prone patient.\n\nWhich of the following induction plans best achieves these goals?",
    "answers": [
      {
        "text": "Preoxygenate to end-tidal O<sub>2</sub> > 80%; administer fentanyl 50 mcg IV; then titrate propofol in 20–30 mg aliquots to loss of consciousness (≈0.75–1 mg/kg total).",
        "isCorrect": true,
        "explanation": "Small-dose opioid co-induction reduces propofol requirement and blunts laryngoscopy response; slow, incremental propofol after thorough preoxygenation minimizes hypotension and apnea in a vulnerable patient."
      },
      {
        "text": "Proceed without co-induction; give propofol 2.5 mg/kg as a rapid bolus to achieve a swift, smooth induction.",
        "isCorrect": false,
        "explanation": "A large propofol bolus increases the risk of profound hypotension and apnea, particularly in elderly patients and those with OSA."
      },
      {
        "text": "Preoxygenate; administer midazolam 1 mg IV; then give propofol 2 mg/kg as a single bolus to minimize awareness.",
        "isCorrect": false,
        "explanation": "Even modest midazolam combined with a full propofol bolus can produce significant hypotension and prolonged apnea in the elderly and OSA patients; titration is safer."
      },
      {
        "text": "Preoxygenate; administer fentanyl 2 mcg/kg IV; then give propofol 1.5 mg/kg rapidly to blunt the pressor response to laryngoscopy.",
        "isCorrect": false,
        "explanation": "High-dose fentanyl increases risk of apnea and chest wall rigidity; combined with a sizable propofol bolus it can still cause hypotension and difficult ventilation."
      },
      {
        "text": "Preoxygenate; administer midazolam 2 mg IV and fentanyl 100 mcg IV; then give propofol 2 mg/kg as a rapid bolus.",
        "isCorrect": false,
        "explanation": "Combining relatively large benzodiazepine and opioid doses with a full propofol bolus in an elderly, OSA-prone patient markedly increases synergistic respiratory depression and hypotension."
      }
    ],
    "didactic": "Co-induction with a small dose of a benzodiazepine or opioid reduces the propofol requirement by exploiting pharmacodynamic synergy at GABA<sub>A</sub> and μ-receptor pathways. Propofol causes dose-dependent vasodilation, myocardial depression, and apnea—effects amplified in the elderly, hypovolemic patients, and those with OSA. Using modest co-induction allows a lower propofol dose and smoother hemodynamics while acknowledging the trade-off of increased respiratory depression.\n\nA practical, safety-focused approach is:\n- Thorough preoxygenation (eg, end-tidal O<sub>2</sub> > 80%) to extend safe apnea time.\n- Small-dose opioid co-induction (eg, fentanyl 0.5–1 mcg/kg or 25–100 mcg) or small-dose benzodiazepine (eg, midazolam 0.5–1 mg) to reduce propofol needs and blunt airway instrumentation responses.\n- Titrated propofol in small aliquots (eg, 20–30 mg every 15–20 seconds), targeting a reduced total dose (often ≈25%–50% less than standard), rather than a large single bolus.\n\nFor an elderly, OSA-prone patient, a small fentanyl dose followed by incremental propofol is often preferred over benzodiazepine because midazolam may prolong sedation and worsen airway obstruction. Opioids still increase apnea risk, so slow titration after robust preoxygenation and readiness to assist ventilation are essential. Avoid high-dose fentanyl (≥2–3 mcg/kg) given rapidly, which can cause chest wall rigidity and difficult mask ventilation; avoid combining sizeable benzodiazepine doses with full propofol boluses, which potentiates hypotension and prolonged apnea.\n\nBottom line: To decrease propofol requirements while maintaining safety, use small-dose benzodiazepine or opioid co-induction and titrate propofol to effect. Preoxygenation and incremental dosing are key to minimizing hypotension and respiratory compromise, especially in elderly or OSA patients.",
    "educationalObjective": "Use small-dose benzodiazepine or opioid co-induction to decrease propofol requirements while maintaining safety."
  },
  {
    "id": "Core.13.3.1",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Inhaled agents: PK/PD and MAC",
    "difficulty": "hard",
    "questionText": "A healthy 27-year-old volunteer in a phase I study undergoes a standardized skin incision under general anesthesia. After induction and intubation, maintenance includes 50% N<sub>2</sub>O/O<sub>2</sub> and a novel fluorinated alkane (Agent X). Preclinical data show an oil–gas partition coefficient of 200 (for comparison: desflurane ≈18, sevoflurane ≈50, isoflurane ≈98) and a blood–gas partition coefficient ≈0.7 (similar to sevoflurane). Based on the Meyer–Overton correlation, the team estimated a MAC ≈0.5% for Agent X and equilibrated to end-tidal Agent X 0.5% and N<sub>2</sub>O 50% for 15 minutes at normothermia. The patient exhibits purposeful movement to incision despite stable end-tidal values.\n\nWhich concept best explains the marked discrepancy between high oil–gas solubility and lack of immobility in this scenario?",
    "answers": [
      {
        "text": "Rapid metabolic clearance of Agent X lowering effective cerebral partial pressure despite adequate end-tidal",
        "isCorrect": false,
        "explanation": "Volatile anesthetics produce effects based on inspired/alveolar partial pressures; metabolism is typically minimal and cannot explain discordance between stable end-tidal and lack of immobility."
      },
      {
        "text": "Cutoff phenomenon producing nonimmobilizers among highly fluorinated alkanes that fail to engage critical protein targets despite high lipid solubility",
        "isCorrect": true,
        "explanation": "Some fluorinated alkanes become nonimmobilizers beyond a molecular size/shape cutoff, breaking the Meyer–Overton prediction; despite very high lipid solubility, they do not produce immobility because they do not sufficiently modulate key protein targets (eg, GABA<sub>A</sub>, K<sub>2P</sub>)."
      },
      {
        "text": "Experimentally elevated core temperature increasing MAC enough to overcome predicted potency",
        "isCorrect": false,
        "explanation": "Temperature increases shift MAC only modestly (~5–7% per °C); normothermia makes this insufficient to explain failure at concentrations expected to exceed 1 MAC when combined with 50% N<sub>2</sub>O."
      },
      {
        "text": "Stereoselective differences in enantiomer composition reducing efficacy at relevant ion channels",
        "isCorrect": false,
        "explanation": "Stereoselectivity causes modest potency differences between enantiomers but does not typically convert a predicted potent agent into one incapable of producing immobility at multiples of MAC."
      },
      {
        "text": "Delayed brain equilibration due to high blood–gas solubility leading to apparent resistance",
        "isCorrect": false,
        "explanation": "Kinetic delays relate to blood–gas solubility; however, Agent X’s blood–gas coefficient (~0.7) and 15 minutes of stable end-tidal make inadequate brain equilibration unlikely to explain absent immobility."
      }
    ],
    "didactic": "The Meyer–Overton correlation states that inhaled anesthetic potency (low MAC) increases with lipid solubility, often indexed by the oil–gas partition coefficient. Agents with higher oil–gas solubility (eg, isoflurane ≈98) are generally more potent (lower MAC) than those with lower oil–gas solubility (eg, desflurane ≈18). Importantly, oil–gas solubility reflects potency, whereas blood–gas solubility governs kinetics (wash-in/wash-out) and is not a direct determinant of MAC.\n\nIn clinical practice, MAC fractions are additive. Fifty percent N<sub>2</sub>O contributes roughly 0.5 MAC (50% ÷ 104%), so combining it with an agent expected to be ≈1.0 MAC at 0.5% should be sufficient to prevent movement to incision. If purposeful movement persists at steady end-tidal values, the assumption that potency follows oil–gas solubility is likely invalid for that compound.\n\nKey exceptions to the Meyer–Overton correlation include:\n- **Cutoff phenomenon/nonimmobilizers:** Within homologous series of halogenated alkanes, potency rises with lipid solubility until a size/shape cutoff is reached, after which further increases produce compounds that do not cause immobility despite high oil solubility. These **nonimmobilizers** undermine purely lipid theories and support protein target interactions (eg, GABA<sub>A</sub>, glycine receptors, K<sub>2P</sub> channels) as primary mediators.\n- **Stereoselectivity:** Enantiomers can have different MACs, indicating chiral protein binding; differences are typically modest rather than abolishing immobility.\n- **Other modulators independent of lipid solubility:** Age, temperature, sodium, and pressure (eg, **pressure reversal** of anesthesia) alter MAC without changing lipid solubility.\n\nThus, a compound with very high oil–gas solubility that fails to produce immobility despite apparently adequate MAC fractions is best explained by the **cutoff/nonimmobilizer** phenomenon, not by kinetics, temperature, or metabolism.",
    "educationalObjective": "Apply the Meyer-Overton correlation between oil-gas solubility and potency and recognize clinical exceptions."
  },
  {
    "id": "Core.13.3.2",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Inhaled agents: PK/PD and MAC",
    "difficulty": "easy",
    "questionText": "A 32-year-old man undergoes laparoscopic appendectomy with sevoflurane in a 50% N<sub>2</sub>O/50% O<sub>2</sub> mixture. At skin incision, he moves despite an end-tidal sevoflurane of 1.0%. You decide to increase anesthetic depth to achieve a 95% probability of immobility (≈1.3 MAC). Assume adult MAC values: sevoflurane 2.0%, desflurane 6.0%, isoflurane 1.15%, and N<sub>2</sub>O 104%. While maintaining end-tidal N<sub>2</sub>O at 50%, which end-tidal sevoflurane concentration should you target?",
    "answers": [
      {
        "text": "2.6%",
        "isCorrect": false,
        "explanation": "Computes 1.3 × 2.0% = 2.6% as if no N<sub>2</sub>O were present; fails to account for additive MAC from N<sub>2</sub>O."
      },
      {
        "text": "3.0%",
        "isCorrect": false,
        "explanation": "Substantially exceeds the 1.3 MAC target even without N<sub>2</sub>O and risks unnecessary cardiovascular depression."
      },
      {
        "text": "1.6%",
        "isCorrect": true,
        "explanation": "N<sub>2</sub>O at 50% provides ≈0.48 MAC; 1.3 − 0.48 = 0.82 MAC of sevo. 0.82 × 2.0% ≈ 1.64% (≈1.6%)."
      },
      {
        "text": "2.0%",
        "isCorrect": false,
        "explanation": "Represents ≈1.0 MAC of sevo alone and, with 0.48 MAC from N<sub>2</sub>O, overshoots to ≈1.48 MAC; calculation ignores the 1.3 MAC target and additivity correctly."
      },
      {
        "text": "1.2%",
        "isCorrect": false,
        "explanation": "Underdoses by targeting ≈1.0 MAC instead of 1.3 MAC (0.52 MAC from sevo + 0.48 MAC from N<sub>2</sub>O ≈ 1.0 MAC)."
      }
    ],
    "didactic": "Minimum alveolar concentration (MAC) is the alveolar concentration of an inhaled anesthetic that prevents movement to surgical incision in 50% of subjects. For surgical immobility in ≈95% of patients, a depth of ≈1.3 MAC is typically required. End-tidal concentration is used clinically as a surrogate for alveolar and, at steady state, brain partial pressure.\n\nTypical adult MAC values at sea level are approximately:\n- Sevoflurane: 2.0%\n- Desflurane: 6.0%\n- Isoflurane: 1.15%\n- N<sub>2</sub>O: 104%\n\nMAC fractions from different inhaled agents are additive. To target a given depth, sum MAC fractions contributed by each agent:\n- MAC fraction = end-tidal (%) ÷ MAC (%)\n- Total MAC = Σ(MAC fractions)\n\nIn this case, 50% N<sub>2</sub>O provides ≈50 ÷ 104 ≈ 0.48 MAC. To reach 1.3 MAC, the sevoflurane fraction must supply the remainder: 1.3 − 0.48 = 0.82 MAC. Therefore, target sevoflurane ≈0.82 × 2.0% ≈ 1.64% (≈1.6%). The initial setting (1.0% sevo) provided ≈0.5 MAC of sevo, and with 0.48 MAC from N<sub>2</sub>O, totaled ≈0.98 MAC—consistent with movement at incision.\n\nKey points:\n- **1 MAC = no movement in 50%; 1.3 MAC ≈ 95%.**\n- **MAC values are additive** across volatiles and N<sub>2</sub>O.\n- End-tidal values approximate effect-site once equilibration is achieved.\n- MAC decreases with age, hypothermia, and CNS depressants (eg, opioids, benzodiazepines), and increases with hyperthermia and chronic alcohol use; when present, adjust targets accordingly.\n\nApplying these principles allows rapid, quantitative titration of inhaled agents to reliably achieve surgical immobility while avoiding unnecessary overdose.",
    "educationalObjective": "Compare MAC values among common agents and use the concept of 1.3 MAC for surgical immobility."
  },
  {
    "id": "Core.13.3.3",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Inhaled agents: PK/PD and MAC",
    "difficulty": "medium",
    "questionText": "A 62-year-old man with CAD (on β-blocker), HTN, and normal LV function is undergoing laparoscopic cholecystectomy. He is normothermic and normovolemic with HR 70/min, MAP 80 mmHg, ETCO<sub>2</sub> 35 mmHg. During insufflation, you rapidly deepen the inhaled anesthetic from 0.7 MAC to 1.3 MAC within 1 minute using 8 L/min fresh gas flow. Immediately after the step increase, HR surges to 120/min and MAP rises to 110 mmHg despite unchanged surgical stimulation and adequate ventilation.\n\nWhich inhaled agent, when rapidly increased, most likely accounts for this hemodynamic response?",
    "answers": [
      {
        "text": "Desflurane",
        "isCorrect": true,
        "explanation": "Rapid increases in desflurane can trigger acute sympathetic activation (↑ catecholamines), causing tachycardia and hypertension despite a deeper anesthetic level; this effect is accentuated with large step changes and high fresh gas flows."
      },
      {
        "text": "Sevoflurane",
        "isCorrect": false,
        "explanation": "Sevoflurane produces modest vasodilation with minimal change in HR; increasing its concentration generally decreases MAP without provoking a sympathetic surge."
      },
      {
        "text": "Isoflurane",
        "isCorrect": false,
        "explanation": "Isoflurane causes dose-dependent vasodilation with a fall in MAP and baroreflex-mediated tachycardia; a rapid increase typically lowers MAP rather than producing concurrent hypertension."
      },
      {
        "text": "Halothane",
        "isCorrect": false,
        "explanation": "Halothane depresses myocardial contractility and often causes bradycardia with decreased MAP rather than tachycardia and hypertension after dose increases."
      },
      {
        "text": "Nitrous oxide",
        "isCorrect": false,
        "explanation": "N<sub>2</sub>O may mildly increase sympathetic tone, but a rapid increase in N<sub>2</sub>O is less likely to cause a marked, paradoxical rise in both HR and MAP compared with desflurane."
      }
    ],
    "didactic": "Volatile anesthetics share dose-dependent vasodilation and reductions in MAP, but they differ in their effects on HR and sympathetic tone.\n\n- Isoflurane: Prominent systemic vasodilation decreases SVR and MAP. HR typically increases via the baroreflex to help maintain CO. Rapid increases in isoflurane deepen anesthesia and lower MAP; they do not characteristically produce hypertension.\n- Sevoflurane: Modest vasodilation with minimal change in HR; slightly greater direct myocardial depression than isoflurane at equipotent doses. Hemodynamics are generally stable, and HR remains relatively unchanged as MAP decreases.\n- Desflurane: Similar vasodilatory profile to isoflurane, but with a unique, concentration-dependent sympathetic activation when its end-tidal concentration is increased rapidly. Large step increases (especially to >1 MAC) and high fresh gas flows accelerate FA/Fi rise due to desflurane’s very low blood:gas λ, provoking catecholamine release with abrupt tachycardia and hypertension.\n\nThis desflurane-specific response is more pronounced in younger patients and in the absence of opioids or β-blockade and can be blunted by opioids, β<sub>1</sub>-blockers, α<sub>2</sub>-agonists, or by using gradual increments rather than step changes. In contrast, sevoflurane remains HR-neutral and isoflurane elicits baroreflex tachycardia in proportion to vasodilation without direct sympathetic surges.\n\nClinical implications:\n- Need to avoid tachycardia (eg, CAD, aortic stenosis): Prefer sevoflurane or carefully titrated isoflurane; avoid rapid desflurane increases.\n- Anticipated hypotension from vasodilation: All three may decrease MAP; iso/des more via ↓ SVR, sevo via modest vasodilation plus some myocardial depression.\n\nBottom line: Rapid step increases in desflurane uniquely cause transient sympathetic stimulation with ↑ HR and ↑ MAP, whereas isoflurane and sevoflurane primarily produce vasodilation with decreased MAP and minimal direct sympathetic activation.",
    "educationalObjective": "Contrast hemodynamic profiles of sevoflurane, desflurane, and isoflurane including vasodilation and sympathetic stimulation."
  },
  {
    "id": "Core.13.3.4",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Inhaled agents: PK/PD and MAC",
    "difficulty": "medium",
    "questionText": "A junior resident asks whether adding nitrous oxide will materially speed mask induction with sevoflurane. Consider the following situations, each using a circle system and fresh gas flow 6–8 L/min. In which scenario will adding 70% N<sub>2</sub>O most meaningfully accelerate the rise of alveolar sevoflurane (second gas effect)?",
    "answers": [
      {
        "text": "70-year-old with severe COPD and significant V/Q mismatch under controlled ventilation receiving 70% N<sub>2</sub>O and 2% sevoflurane",
        "isCorrect": false,
        "explanation": "V/Q mismatch slows volatile uptake and mixes poorly ventilated with well-ventilated units, attenuating the impact of the second gas effect; N<sub>2</sub>O also poses risks of gas trapping in bullous disease."
      },
      {
        "text": "35-year-old under controlled ventilation receiving 70% N<sub>2</sub>O and 8% sevoflurane after tracheal intubation",
        "isCorrect": false,
        "explanation": "With a very high sevo FI (8%), F<sub>A</sub>/F<sub>I</sub> rises rapidly regardless; the incremental benefit of the second gas effect is small and not clinically meaningful compared with simply delivering high sevo."
      },
      {
        "text": "Healthy 4-year-old undergoing inhalation induction with spontaneous ventilation using 70% N<sub>2</sub>O and 2% sevoflurane via face mask",
        "isCorrect": true,
        "explanation": "High inspired N<sub>2</sub>O (70%) with spontaneous ventilation during mask induction produces substantial N<sub>2</sub>O uptake, causing alveolar volume contraction and augmented inflow that measurably increases alveolar sevo (second gas effect). The effect is clinically meaningful in pediatric mask inductions."
      },
      {
        "text": "50-year-old spontaneously breathing via mask receiving 30% N<sub>2</sub>O and 1% isoflurane",
        "isCorrect": false,
        "explanation": "Low inspired N<sub>2</sub>O (30%) yields modest N<sub>2</sub>O uptake, so the concentration/second gas effects are small; isoflurane’s higher solubility further blunts early alveolar rise."
      },
      {
        "text": "65-year-old with a 20% right-to-left cardiac shunt under controlled ventilation receiving 70% N<sub>2</sub>O and 2% sevoflurane",
        "isCorrect": false,
        "explanation": "R→L shunt slows arterial rise of volatile agents by mixing shunted venous blood; the second gas effect operates only in ventilated units and cannot overcome shunt-related dilution, so clinical acceleration is limited."
      }
    ],
    "didactic": "The concentration effect describes how increasing the inspired fraction (F<sub>I</sub>) of a gas accelerates the rise of its alveolar fraction (F<sub>A</sub>). With high F<sub>I</sub> N<sub>2</sub>O (eg, 50%–70%), rapid uptake of N<sub>2</sub>O from alveoli contracts alveolar volume, concentrating the remaining gases. Simultaneously, bulk flow replacement of the removed volume draws in more fresh gas (augmented inflow). These processes make N<sub>2</sub>O’s own F<sub>A</sub>/F<sub>I</sub> rise faster at higher F<sub>I</sub> (the concentration effect).\n\nThe second gas effect is the spillover of this phenomenon to a coadministered agent: as N<sub>2</sub>O is rapidly taken up, the alveolar partial pressure of the “second gas” (eg, sevoflurane) rises faster than it would alone. The magnitude depends on:\n- High N<sub>2</sub>O concentration (≥50%–70%) and rapid early uptake\n- Spontaneous ventilation during mask induction (greater alveolar wash-in, less mixing with large-volume circuits)\n- Lower inspired concentration of the second gas (relative acceleration is more noticeable when F<sub>I</sub> of the second gas is modest)\n- Minimal V/Q abnormalities (R→L shunt and significant V/Q mismatch blunt arterial rise regardless of alveolar effects)\n\nClinically, N<sub>2</sub>O meaningfully accelerates uptake during pediatric inhalation inductions using high N<sub>2</sub>O with sevoflurane, improving the early rise in alveolar and effect-site partial pressure and facilitating mask tolerance. Its impact is small when the second gas is already delivered at very high F<sub>I</sub> (eg, sevo 6%–8%), during maintenance after equilibration, or in the presence of a right-to-left shunt. N<sub>2</sub>O has little ability to overcome shunt-related dilution because the second gas effect occurs only in ventilated alveoli. Practical implications: use 50%–70% N<sub>2</sub>O to speed mask induction with sevoflurane; expect minimal benefit in shunt/V/Q mismatch or when delivering very high F<sub>I</sub> of the volatile; avoid N<sub>2</sub>O in closed gas spaces (eg, severe bullous disease, pneumothorax).",
    "educationalObjective": "Describe the concentration effect and second gas effect and when nitrous oxide meaningfully accelerates uptake."
  },
  {
    "id": "Core.13.3.5",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Inhaled agents: PK/PD and MAC",
    "difficulty": "hard",
    "questionText": "A 70-year-old man (CAD on metoprolol) undergoes suspension microlaryngoscopy. After propofol–rocuronium induction, anesthesia is maintained with sevoflurane in 60% N₂O (ET N₂O 60%) and FiO<sub>2</sub> 0.4. With ET sevoflurane 1.0%, the patient is immobile, but during suspension laryngoscopy his HR rises from 62 to 98 bpm and MAP from 75 to 105 mmHg. You elect to deepen inhaled anesthesia (avoid additional opioids) specifically to blunt this autonomic response.\n\nAssuming MAC additivity and age adjustment, what end-tidal sevoflurane concentration best approximates MAC-BAR for this patient under 60% N₂O?",
    "answers": [
      {
        "text": "1.3%",
        "isCorrect": false,
        "explanation": "1.3% sevo is ~0.79 MAC; plus 0.57 MAC from 60% N₂O yields ≈1.36 MAC, still below MAC-BAR, so tachycardia/hypertension may persist."
      },
      {
        "text": "1.7%",
        "isCorrect": false,
        "explanation": "1.7% sevo is ~1.04 MAC; plus 0.57 MAC from N₂O totals ≈1.61 MAC—more than needed, increasing risk of hypotension and delayed emergence without added benefit."
      },
      {
        "text": "2.5%",
        "isCorrect": false,
        "explanation": "This ignores N₂O additivity and age-related MAC reduction; total would exceed 2 MAC, greatly overshooting MAC-BAR and risking hemodynamic instability."
      },
      {
        "text": "1.0%",
        "isCorrect": false,
        "explanation": "At age 70, sevo MAC ≈1.64%. ET sevo 1.0% is ~0.61 MAC; with 60% N₂O (~0.57 MAC), total ≈1.18 MAC—adequate for immobility but insufficient to block autonomic responses (MAC-BAR ≈1.5 MAC)."
      },
      {
        "text": "1.5%",
        "isCorrect": true,
        "explanation": "Sevo MAC at 70 years ≈1.64%. ET sevo 1.5% ≈0.92 MAC; adding 0.57 MAC from 60% N₂O gives ≈1.49 MAC, closely targeting MAC-BAR (~1.5 MAC) for autonomic reflex suppression."
      }
    ],
    "didactic": "Minimum alveolar concentration (MAC) benchmarks different clinical endpoints that guide titration of inhaled agents.\n\n- **MAC-awake (~0.3–0.5 MAC):** Alveolar concentration at which 50% respond to verbal command; airway/protective reflexes re-emerge around this range.\n- **MAC (~1.0 MAC):** Prevents movement to surgical incision in 50% of subjects (immobility endpoint), not a measure of analgesia or autonomic suppression.\n- **MAC-BAR (~1.5 MAC):** Blocks adrenergic/autonomic responses (eg, tachycardia, hypertension) to noxious stimuli in 50% of subjects; reduced substantially by opioids, α<sub>2</sub>-agonists, and regional anesthesia.\n\nMAC is **age dependent** (≈6% decrease per decade after age 40) and **approximately additive** among inhaled agents for immobility; this additivity is commonly used pragmatically for targeting MAC-BAR as well. End-tidal (ET) concentration approximates effect-site partial pressure after equilibration, making it a practical surrogate for titration.\n\nIn this case, sevoflurane MAC at age 70 ≈ 2.0% × (1 − 0.06×3) = 1.64%. N₂O MAC ≈105%, so ET N₂O 60% ≈ 0.57 MAC. To blunt the autonomic response (target **MAC-BAR ≈1.5 MAC**), the sevoflurane contribution should be ≈1.5 − 0.57 = 0.93 MAC. Thus, ET sevo ≈ 0.93 × 1.64% ≈ 1.5–1.6% is appropriate.\n\nClinically, choose the endpoint that matches the goal:\n\n- For preventing movement: target ~1.0 MAC (adjusted for age/adjuvants).\n- For airway reflex suppression (eg, laryngoscopy, deep extubation): typically ≥1.0–1.2 MAC of volatile or supplement with hypnotic/opioid/lidocaine.\n- For autonomic blunting: target ~1.5 MAC (MAC-BAR) or use short-acting opioids/remifentanil to reduce the volatile requirement and avoid hypotension/prolonged emergence. In CAD, balancing volatile depth with opioid/β-blockade often optimizes hemodynamics while minimizing myocardial oxygen demand.",
    "educationalObjective": "Differentiate MAC-awake, MAC, and MAC-BAR and use them to titrate depth for airway and autonomic reflex suppression."
  },
  {
    "id": "Core.13.3.6",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Inhaled agents: PK/PD and MAC",
    "difficulty": "medium",
    "questionText": "A 54-year-old man with a large frontal glioma undergoes craniotomy under general anesthesia with sevoflurane at 1.3 MAC in 50% air/O<sub>2</sub>. Shortly after dural opening, the brain appears tense and swollen. Monitors show MAP 75 mmHg, SpO<sub>2</sub> 99%, and ETCO<sub>2</sub> 50 mmHg. There are no signs of venous obstruction, and the head is level with the heart.\n\nWhich intraoperative adjustment will most effectively reduce intracranial pressure (ICP) while maintaining adequate anesthesia?",
    "answers": [
      {
        "text": "Add 50% nitrous oxide and reduce sevoflurane to 0.7 MAC.",
        "isCorrect": false,
        "explanation": "N<sub>2</sub>O increases CMRO<sub>2</sub> and CBF, raising ICP despite a lower volatile requirement; it is generally avoided in patients at risk for elevated ICP."
      },
      {
        "text": "Switch to desflurane 1.0 MAC and allow ETCO<sub>2</sub> 45–50 mmHg to avoid hypocapnia-induced ischemia.",
        "isCorrect": false,
        "explanation": "Desflurane, like other volatiles, causes dose-dependent cerebral vasodilation; permissive hypercapnia increases CBF and ICP and is counterproductive in this setting."
      },
      {
        "text": "Increase sevoflurane to 2.0 MAC to achieve greater CMRO<sub>2</sub> suppression and reduce ICP.",
        "isCorrect": false,
        "explanation": "Although volatiles decrease CMRO<sub>2</sub>, higher MAC produces more cerebral vasodilation and increases CBF, often worsening ICP; CMRO<sub>2</sub> reduction plateaus before isoelectric EEG and hypotension risk increases."
      },
      {
        "text": "Increase minute ventilation to target PaCO<sub>2</sub> 30–35 mmHg while maintaining sevoflurane ≤1.0 MAC.",
        "isCorrect": true,
        "explanation": "Mild hyperventilation produces cerebral vasoconstriction that lowers CBF and ICP within minutes and counteracts volatile-induced vasodilation; keeping sevo ≤1 MAC limits further vasodilation while preserving anesthesia."
      },
      {
        "text": "Administer labetalol to reduce MAP to 60 mmHg while keeping current ventilation and anesthetic depth.",
        "isCorrect": false,
        "explanation": "Lowering MAP reduces CPP (CPP = MAP − ICP) and does not address hypercapnia-driven cerebral vasodilation; ICP may not improve and cerebral perfusion can worsen."
      }
    ],
    "didactic": "Volatile anesthetics produce opposing effects on cerebral physiology: they **decrease CMRO<sub>2</sub>** (dose dependent, plateauing as the EEG approaches burst suppression) but **increase CBF** via cerebral vasodilation, which can **increase ICP**. This flow–metabolism **uncoupling** is most pronounced as MAC increases; halothane is the strongest vasodilator, but isoflurane, desflurane, and sevoflurane also increase CBF at ≳1 MAC. In contrast, **N<sub>2</sub>O increases both CMRO<sub>2</sub> and CBF**, typically worsening ICP.\n\nControlled ventilation modifies this physiology by changing PaCO<sub>2</sub>. **Hyperventilation (lower PaCO<sub>2</sub>) causes cerebral vasoconstriction**, reducing CBF and ICP within minutes; **CBF changes ~2–4% per mmHg** change in PaCO<sub>2</sub> between ~20–60 mmHg. This effect attenuates over hours as CSF bicarbonate equilibrates, so hyperventilation is best used as a **temporary** measure. In patients with brain swelling under volatile anesthesia, targeting **mild hypocapnia (PaCO<sub>2</sub> 30–35 mmHg)** effectively offsets volatile-induced vasodilation and lowers ICP. Avoid severe hypocapnia (<25–30 mmHg), which risks cerebral ischemia, especially in regions with impaired autoregulation.\n\nPractical implications:\n- Intraoperative brain swelling with ETCO<sub>2</sub> 50 mmHg reflects hypercapnia-driven vasodilation superimposed on volatile vasodilation; promptly increase alveolar ventilation to lower PaCO<sub>2</sub>.\n- Maintain volatile concentration at or below ~1 MAC and supplement with adjuncts (eg, opioids or propofol) if needed; increasing MAC further often worsens ICP as CMRO<sub>2</sub> suppression plateaus while vasodilation progresses.\n- Avoid N<sub>2</sub>O when ICP is a concern.\n- Optimize CPP (CPP = MAP − ICP); lowering MAP with vasodilators without treating hypercapnia can reduce CPP without improving ICP.\n\nThus, the best immediate step is to increase minute ventilation to achieve PaCO<sub>2</sub> 30–35 mmHg while avoiding excessive volatile depth.",
    "educationalObjective": "Explain effects on CMRO<sub>2</sub>, CBF, and ICP and how controlled ventilation modifies cerebral physiology."
  },
  {
    "id": "Core.13.3.7",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Inhaled agents: PK/PD and MAC",
    "difficulty": "medium",
    "questionText": "A 62-year-old man (90 kg) undergoes laparoscopic colectomy. After intubation, sevoflurane is started at 2% using a circle system with fresh gas flow (FGF) 1 L/min (air/O<sub>2</sub>), circuit volume ≈6 L, and alveolar ventilation 4 L/min. Two minutes later, end-tidal sevoflurane is 0.4% and rising slowly. The goal is to reach an end-tidal of 1.5% as quickly as possible while maintaining the circle system.\n\nWhich intervention will most rapidly increase the early Fa/Fi in the next few minutes?",
    "answers": [
      {
        "text": "Increase FGF to 10 L/min through the circle until inspired and end-tidal sevoflurane equilibrate, then return to low-flow",
        "isCorrect": true,
        "explanation": "High FGF shortens the circuit time constant (τ = volume/flow) and minimizes rebreathing, making Fi quickly approach the vaporizer setting and steepening the early Fa/Fi rise."
      },
      {
        "text": "Add N<sub>2</sub>O 70% at the same FGF to exploit the second gas and concentration effects",
        "isCorrect": false,
        "explanation": "Second gas/concentration effects with N<sub>2</sub>O provide only modest acceleration for volatile agents and are outweighed by the slow circuit wash-in at low FGF."
      },
      {
        "text": "Keep FGF 1 L/min but halve the breathing circuit volume from 6 L to 3 L",
        "isCorrect": false,
        "explanation": "Reducing circuit volume shortens τ (6→3 min), but increasing FGF to 10 L/min shortens τ far more (to ≈0.6 min), producing a faster Fa/Fi rise."
      },
      {
        "text": "Maintain FGF 1 L/min and double alveolar ventilation from 4 to 8 L/min",
        "isCorrect": false,
        "explanation": "Hyperventilation improves alveolar turnover, but with low FGF the inspired concentration remains low due to rebreathing; the circuit, not the alveoli, is the rate-limiting step early on."
      },
      {
        "text": "Switch to a Mapleson D (Bain) circuit with FGF 2 L/min (minute ventilation ≈6 L/min)",
        "isCorrect": false,
        "explanation": "At FGF below minute ventilation, Mapleson D has substantial rebreathing, so inspired agent changes slowly and Fa/Fi rises more slowly than with high-flow circle."
      }
    ],
    "didactic": "The early rise of Fa/Fi is shaped by how quickly the inspired concentration (Fi) in the breathing system approaches the vaporizer setting and how efficiently the alveoli exchange that gas with blood. In a circle system, the breathing circuit behaves like a mixing chamber with a time constant τ = circuit volume/FGF. Low FGF makes τ long, so circuit Fi lags the vaporizer setting and a large fraction of each breath is rebreathed, flattening the early Fa/Fi curve. Increasing FGF to 8–10 L/min greatly shortens τ, minimizes rebreathing, and rapidly drives Fi toward the dialed concentration, producing a steep early Fa/Fi rise.\n\nAlveolar mixing has its own time constant (τ ≈ FRC/alveolar ventilation). In most adults under anesthesia, τ for the alveoli (eg, 2–3 L/4–6 L·min⁻¹) is already short compared with a low-flow circuit. Thus, during early wash-in with low FGF, the circuit—not the lungs—is the rate-limiting step; hyperventilation helps less than increasing FGF. The concentration and second gas effects principally apply to N<sub>2</sub>O and provide only modest acceleration for volatile agents compared with simply increasing FGF.\n\nCircuit configuration also matters. Mapleson systems lack CO<sub>2</sub> absorption; rebreathing depends on FGF relative to minute ventilation. For controlled ventilation with a Mapleson D, FGF must be ≈1.5–2× minute ventilation to minimize rebreathing; lower flows slow changes in Fi and flatten Fa/Fi.\n\nDuring wash-out, the same principles apply in reverse. Strategies that steepen wash-in also speed wash-out: increase FGF (eg, 8–10 L/min), open the APL to flush the circuit, and increase alveolar ventilation to enhance elimination. Switching to a nonrebreathing configuration (eg, Mapleson with FGF ≥ minute ventilation) can also accelerate wash-out. Reducing circuit volume helps, but the largest, most practical lever is high FGF in the circle to rapidly change circuit gas composition.",
    "educationalObjective": "Explain how fresh gas flow and circuit configuration shape the Fa/Fi curve during wash-in and wash-out."
  },
  {
    "id": "Core.13.3.8",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Inhaled agents: PK/PD and MAC",
    "difficulty": "medium",
    "questionText": "A 67-year-old man presents for urgent open reduction–internal fixation of a tibia fracture under general anesthesia. Ten days ago he underwent pars plana vitrectomy with injection of sulfur hexafluoride (SF6) for retinal detachment; he was told a gas bubble remains and to avoid flying. He has no pulmonary disease and normal examination. The anesthesia team considers adding 50% N<sub>2</sub>O to reduce volatile requirement and facilitate a rapid emergence.\n\nWhich of the following is the most appropriate management regarding N<sub>2</sub>O use in this patient?",
    "answers": [
      {
        "text": "Proceed with N<sub>2</sub>O if its partial pressure is kept below the alveolar N<sub>2</sub> partial pressure",
        "isCorrect": false,
        "explanation": "Incorrect. Expansion is driven by the N<sub>2</sub>O gradient and its high blood solubility relative to N<sub>2</sub>; manipulating alveolar N<sub>2</sub> does not prevent clinically significant bubble growth."
      },
      {
        "text": "Use N<sub>2</sub>O for induction only, then discontinue after intubation to minimize exposure",
        "isCorrect": false,
        "explanation": "Incorrect. Even brief exposure can rapidly enlarge a closed gas space; expansion occurs within minutes and may be catastrophic despite early discontinuation."
      },
      {
        "text": "Administer high FiO<sub>2</sub> along with N<sub>2</sub>O to mitigate intraocular gas expansion",
        "isCorrect": false,
        "explanation": "Incorrect. Increasing FiO<sub>2</sub> does not counteract N<sub>2</sub>O’s rapid diffusion into the bubble and may further reduce alveolar N<sub>2</sub>, offering no protection against expansion."
      },
      {
        "text": "Avoid N<sub>2</sub>O entirely until the ophthalmologist confirms complete resorption of the intraocular gas bubble",
        "isCorrect": true,
        "explanation": "Correct. N<sub>2</sub>O diffuses into closed gas spaces much faster than N<sub>2</sub> leaves, expanding intraocular gas bubbles and potentially causing vision-threatening increases in pressure; it should be avoided until confirmed resolution."
      },
      {
        "text": "Proceed with 50% N<sub>2</sub>O; ocular gas diffusion is negligible 10 days after SF6 injection",
        "isCorrect": false,
        "explanation": "Incorrect. Intraocular gas bubbles often persist for ≥1–2 weeks (longer with perfluorocarbons), and N<sub>2</sub>O can rapidly expand the bubble, acutely raising intraocular pressure and risking retinal ischemia."
      }
    ],
    "didactic": "Nitrous oxide (N<sub>2</sub>O) diffuses into gas-filled spaces far more rapidly than nitrogen (N<sub>2</sub>) leaves because N<sub>2</sub>O is ~34× more soluble in blood than N<sub>2</sub>. This creates a steep partial pressure gradient favoring N<sub>2</sub>O entry, causing gas volume to increase in compliant cavities or pressure to rise in noncompliant spaces. In the eye, an intraocular gas bubble (eg, SF6, C<sub>3</sub>F<sub>8</sub>) is a closed space with limited compliance; N<sub>2</sub>O can markedly expand the bubble within minutes, acutely elevating intraocular pressure and risking central retinal artery occlusion and permanent vision loss.\n\nKey clinical implications of N<sub>2</sub>O in closed gas spaces:\n- Intraocular gas bubble after retinal surgery: absolute contraindication until the surgeon confirms complete resorption (SF6 often persists ≥1–2 weeks; perfluoropropane [C<sub>3</sub>F<sub>8</sub>] can persist for several weeks).\n- Pneumothorax (especially undrained): avoid N<sub>2</sub>O; it can rapidly enlarge and precipitate tension physiology.\n- Intracranial air (eg, after craniotomy or sitting craniotomy with venous air entry): N<sub>2</sub>O can expand pneumocephalus and worsen mass effect.\n- Middle ear surgery or recent tympanoplasty: rising middle ear pressure can dislodge grafts—avoid or discontinue before graft placement.\n- Bowel obstruction: N<sub>2</sub>O worsens intestinal distention and compromises ventilation/surgical exposure—prefer to avoid.\n- Endotracheal tube cuffs and pneumoperitoneum: N<sub>2</sub>O increases cuff pressure and intra-abdominal gas volume; mitigate by cuff pressure monitoring or avoiding N<sub>2</sub>O.\n\nManagement principles:\n- Do not use N<sub>2</sub>O in patients with known closed gas spaces (eg, intraocular bubble, untreated pneumothorax, intracranial air, middle ear grafts, bowel obstruction).\n- For prior retinal gas, avoid N<sub>2</sub>O until ophthalmology confirms resolution; brief exposure or lower concentrations do not eliminate risk.\n- When N<sub>2</sub>O is used, monitor and adjust ETT cuff pressure and be cautious in procedures that create or trap gas.",
    "educationalObjective": "Identify situations where nitrous oxide expands closed gas spaces and list clinical contraindications."
  },
  {
    "id": "Core.13.3.9",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Inhaled agents: PK/PD and MAC",
    "difficulty": "hard",
    "questionText": "A 70-kg man undergoes laparoscopic cholecystectomy with a circle system and CO<sub>2</sub> absorber. The machine’s automated preuse check passes with a negligible circuit leak. After denitrogenation and wash-in at 6 L/min for 10 minutes, fresh gas flow (FGF) is reduced to 0.5 L/min using O<sub>2</sub>/air 50/50 with sevoflurane 2%. Over the next 8 minutes, the inspired O<sub>2</sub> at the Y-piece declines from 40% to 28%, end-tidal sevoflurane is 1.2%, EtCO<sub>2</sub> is 35 mmHg with zero inspired CO<sub>2</sub>, and hemodynamics are stable. You wish to continue low-flow anesthesia safely while maintaining adequate anesthetic depth.\n\nWhich adjustment best addresses the cause of the falling inspired O<sub>2</sub> without abandoning the low-flow strategy?",
    "answers": [
      {
        "text": "Increase the sevoflurane vaporizer to 3% to reduce whole-body O<sub>2</sub> consumption",
        "isCorrect": false,
        "explanation": "Deeper anesthesia has minimal and slow effects on V̇O<sub>2</sub> and does not correct the immediate delivery–consumption mismatch causing FiO<sub>2</sub> decline; it risks hypotension without solving the problem."
      },
      {
        "text": "Increase the FGF O<sub>2</sub> concentration to 80% while maintaining total FGF at 0.5 L/min",
        "isCorrect": true,
        "explanation": "At 0.5 L/min total flow, 50% O<sub>2</sub> delivers ~250 mL O<sub>2</sub>/min, approximating a 70-kg adult’s V̇O<sub>2</sub> (~200–250 mL/min). Raising the O<sub>2</sub> fraction to 80% provides ~400 mL/min, ensuring O<sub>2</sub> delivery exceeds consumption and preventing further FiO<sub>2</sub> drift while preserving low-flow anesthesia."
      },
      {
        "text": "Switch the carrier gas to N<sub>2</sub>O 50% with O<sub>2</sub> 50% at the same total flow",
        "isCorrect": false,
        "explanation": "Replacing air with N<sub>2</sub>O does not increase O<sub>2</sub> inflow (still ~250 mL/min) and early high N<sub>2</sub>O uptake can further reduce circuit O<sub>2</sub> fraction; it may also complicate emergence with diffusion hypoxia risk."
      },
      {
        "text": "Repeat a circuit leak test and change the CO<sub>2</sub> absorbent to address possible rebreathing",
        "isCorrect": false,
        "explanation": "The capnogram shows zero inspired CO<sub>2</sub>, indicating effective CO<sub>2</sub> absorption and no clinically significant rebreathing. The preuse leak test was acceptable; the FiO<sub>2</sub> fall is expected when O<sub>2</sub> inflow ≈ V̇O<sub>2</sub> at low FGF."
      },
      {
        "text": "Increase total FGF to 2 L/min while maintaining 50% O<sub>2</sub>",
        "isCorrect": false,
        "explanation": "Raising FGF would increase O<sub>2</sub> delivery and fix FiO<sub>2</sub>, but it abandons the low-flow strategy. Adjusting the O<sub>2</sub> fraction at the same low FGF more directly addresses the cause."
      }
    ],
    "didactic": "Low-flow anesthesia (<1 L/min) relies on a leak-free circle system, functional CO<sub>2</sub> absorber, and continuous gas monitoring at the Y-piece to maintain safe inspired O<sub>2</sub> (FiO<sub>2</sub>) and anesthetic concentrations. After denitrogenation, the circuit is largely devoid of N<sub>2</sub>, and the patient’s O<sub>2</sub> consumption (V̇O<sub>2</sub>) becomes the dominant sink for O<sub>2</sub> in the system.\n\n- Adult V̇O<sub>2</sub> ≈ 3–4 mL/kg/min (eg, 70 kg → ~210–280 mL/min). At 0.5 L/min total FGF with O<sub>2</sub>/air 50/50, O<sub>2</sub> inflow ≈ 250 mL/min, which can approximate or undershoot V̇O<sub>2</sub>.\n- When O<sub>2</sub> inflow ≈ V̇O<sub>2</sub>, the circuit O<sub>2</sub> fraction drifts downward despite normal ventilation and an intact absorber, leading to falling FiO<sub>2</sub>. This is expected physiology, not a leak, when the preuse leak test is acceptable and inspired CO<sub>2</sub> is zero.\n\nTo safely continue low-flow anesthesia, ensure that O<sub>2</sub> delivery exceeds consumption. At a fixed low FGF, this is achieved by increasing the O<sub>2</sub> fraction of the inflow. For example, 0.5 L/min total with 80% O<sub>2</sub> delivers ~400 mL/min O<sub>2</sub>, preventing further FiO<sub>2</sub> decline and allowing the clinician to titrate FiO<sub>2</sub> using the inspired O<sub>2</sub> monitor.\n\nPractical implementation:\n- Perform and confirm a passed machine leak test before initiating low flows; verify proper absorber function (zero inspired CO<sub>2</sub>).\n- Start with high FGF to denitrogenate and achieve target end-tidal anesthetic, then reduce FGF.\n- During low-flow, titrate FGF O<sub>2</sub>% upward so O<sub>2</sub> inflow exceeds V̇O<sub>2</sub>; avoid assuming that 50% O<sub>2</sub> at very low FGF will maintain FiO<sub>2</sub>.\n- Use continuous inspired/expired agent and O<sub>2</sub> monitoring; transiently increase FGF if rapid changes in anesthetic depth are needed.\n\nThis approach integrates PK/PD principles of inhaled agent uptake (slower changes at low FGF) with system safety checks, enabling safe, efficient low-flow anesthesia while maintaining adequate FiO<sub>2</sub> and MAC fraction.",
    "educationalObjective": "Implement low-flow anesthesia safely with continuous gas monitoring and leak testing."
  },
  {
    "id": "Core.13.3.10",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Inhaled agents: PK/PD and MAC",
    "difficulty": "medium",
    "questionText": "A 58-year-old man presents for urgent laparotomy for small-bowel obstruction. He drinks 8–10 beers daily and has done so for 20 years, with his last drink last evening. Preoperative temperature is 35.2°C after several hours in the emergency department. He took his home clonidine the morning of surgery. General anesthesia with sevoflurane is planned.\n\nWhich concurrent factor in this patient would increase the sevoflurane MAC requirement?",
    "answers": [
      {
        "text": "Intraoperative dexmedetomidine infusion",
        "isCorrect": false,
        "explanation": "Dexmedetomidine, an α<sub>2</sub>-agonist, reduces volatile anesthetic requirements and lowers MAC."
      },
      {
        "text": "Chronic daily alcohol consumption",
        "isCorrect": true,
        "explanation": "Chronic alcohol use increases MAC due to CNS tolerance and neuroadaptive changes; more anesthetic is required to achieve the same effect."
      },
      {
        "text": "Core hypothermia (35.2°C)",
        "isCorrect": false,
        "explanation": "Hypothermia decreases MAC by reducing CNS metabolic activity and anesthetic requirements."
      },
      {
        "text": "Age 58 years",
        "isCorrect": false,
        "explanation": "Advancing age decreases MAC; MAC declines roughly 6% per decade after age 40."
      },
      {
        "text": "Chronic clonidine therapy",
        "isCorrect": false,
        "explanation": "α<sub>2</sub>-agonists (eg, clonidine) decrease MAC by reducing central noradrenergic activity and sympathetic tone."
      }
    ],
    "didactic": "Minimum alveolar concentration (MAC) is the alveolar concentration of an inhaled anesthetic at 1 atm that prevents movement to a midline skin incision in 50% of subjects. It is a measure of anesthetic potency and provides a common scale across volatile agents. Several patient and physiologic factors predictably shift MAC requirements.\n\nKey MAC modifiers:\n- Decrease MAC: **advanced age**, **hypothermia**, **pregnancy/puerperium**, **α<sub>2</sub>-agonists** (eg, clonidine, dexmedetomidine), **opioids**, **benzodiazepines**, **acute alcohol intoxication**, **hypoxemia** (severe), and **hyponatremia**.\n- Increase MAC: **chronic alcohol use** (tolerance), **hyperthermia**, **hypernatremia**, and (modestly) **natural red hair**. Younger age also corresponds to higher MAC compared with older adults.\n\nIn this case, multiple concurrent factors would lower anesthetic requirements: core hypothermia (35.2°C) lessens CNS metabolic activity and reduces MAC; clonidine (an α<sub>2</sub>-agonist) decreases MAC by diminishing central sympathetic outflow. Age 58 years also trends toward lower MAC because MAC declines approximately 6% per decade after age 40. In contrast, **chronic daily alcohol consumption** increases MAC due to neuroadaptation and tolerance (ie, reduced sensitivity to GABAergic and enhanced glutamatergic tone), requiring higher end-tidal concentrations to achieve the same anesthetic depth. Notably, this differs from **acute alcohol intoxication**, which decreases MAC.\n\nClinically, anticipate lower volatile requirements in the elderly, hypothermic, pregnant, or α<sub>2</sub>-treated patient, and higher requirements in patients with long-standing heavy alcohol use. Adjust end-tidal volatile concentration rather than relying on dial settings alone, and monitor processed EEG and hemodynamics to titrate depth appropriately.",
    "educationalObjective": "List factors that decrease MAC (age, hypothermia, pregnancy, alpha-2 agonists) and factors that increase MAC (chronic alcohol)."
  },
  {
    "id": "Core.13.3.11",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Inhaled agents: PK/PD and MAC",
    "difficulty": "medium",
    "questionText": "A 52-year-old man (BMI 29) is undergoing laparoscopic inguinal hernia repair. After induction with propofol, fentanyl 100 µg, and rocuronium, he is intubated and mechanically ventilated with air/O<sub>2</sub>. Maintenance is begun with desflurane at 4% and FGF 2 L/min. To deepen anesthesia quickly before trocar insertion, you increase desflurane to 12% and FGF to 8 L/min. Over the next minute, end-tidal desflurane rises from 3% to 7% and the monitor displays age-adjusted MAC ≈1.1. Blood pressure increases from 130/75 to 180/95 mmHg and HR from 70 to 125/min; V<sub>T</sub>, end-tidal CO<sub>2</sub>, and airway pressures are unchanged.\n\nWhich of the following is the most appropriate immediate intervention to blunt this response while allowing rapid anesthetic wash-in to continue?",
    "answers": [
      {
        "text": "Increase desflurane further to 15%",
        "isCorrect": false,
        "explanation": "Abrupt step-ups in desflurane exacerbate airway irritation and sympathetic activation, worsening tachycardia and hypertension despite adequate MAC."
      },
      {
        "text": "Administer fentanyl 100 µg IV bolus",
        "isCorrect": false,
        "explanation": "An opioid may help but has slower onset, longer duration, and risks delayed emergence; it is less titratable than esmolol for the acute desflurane-mediated tachycardia/hypertension."
      },
      {
        "text": "Administer esmolol 0.5 mg/kg IV bolus",
        "isCorrect": true,
        "explanation": "Esmolol provides rapid, short-acting β<sub>1</sub>-blockade that attenuates desflurane-induced sympathetic surge without impairing ongoing alveolar wash-in."
      },
      {
        "text": "Add N<sub>2</sub>O 50% to the anesthetic",
        "isCorrect": false,
        "explanation": "N<sub>2</sub>O can increase sympathetic tone and PVR and will not reliably blunt desflurane’s hemodynamic surge; it may also increase PONV risk."
      },
      {
        "text": "Switch to sevoflurane 2% at FGF 2 L/min",
        "isCorrect": false,
        "explanation": "Sevoflurane is less pungent, but low-flow wash-in is slow and will not immediately control the hemodynamics; a short-acting β-blocker is superior acutely."
      }
    ],
    "didactic": "Rapid step increases in desflurane concentration can trigger a marked **sympathetic surge** (tachycardia, hypertension) due to airway irritation and direct stimulation of the sympathetic nervous system. This effect is most pronounced when the rate-of-rise of alveolar concentration (F<sub>A</sub>) is high, such as with large inspired concentration (F<sub>I</sub>) steps and high fresh gas flow (FGF). In the vignette, the monitor already shows an age-adjusted MAC ≈1.1 at end-tidal 7%, indicating that the hemodynamic response is not due to inadequate depth but rather desflurane’s unique pharmacodynamics during rapid wash-in.\n\nImmediate management should blunt the adrenergic response while preserving rapid alveolar uptake. **Esmolol** provides rapid, titratable β<sub>1</sub>-blockade with a short half-life, attenuating tachycardia and hypertension without interfering with the desired F<sub>A</sub>/F<sub>I</sub> rise. Opioids (eg, fentanyl) can help but have slower onset, longer duration, and may prolong recovery; remifentanil is an alternative but can cause rigidity with bolus dosing. Increasing desflurane further worsens the surge. Adding N<sub>2</sub>O does not reliably blunt the response and can increase sympathetic tone and PONV. Switching to sevoflurane may reduce airway irritation, but in the acute setting it delays control unless coupled with high FGF and does not address the immediate hypertension/tachycardia.\n\nTo prevent this phenomenon:\n- Use **smaller step increases** in desflurane (eg, 1–2% increments every 1–2 min).\n- Employ **adjuncts** that blunt sympathetic output (eg, esmolol, short-acting opioids, dexmedetomidine) when rapid deepening is anticipated.\n- Consider starting with **sevoflurane or propofol** for induction/transition, then switch to desflurane once the airway is secure and depth is adequate.\n- Use high FGF to speed wash-in, but balance against the risk of excessive rate-of-rise with large F<sub>I</sub> steps.\n\nUnderstanding how F<sub>A</sub>/F<sub>I</sub>, MAC, and FGF interact helps distinguish **desflurane-induced sympathetic activation** from inadequate anesthetic depth and guides targeted, rapid therapy.",
    "educationalObjective": "Manage airway irritation and sympathetic surge during rapid increases in desflurane concentration."
  },
  {
    "id": "Core.13.3.12",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Inhaled agents: PK/PD and MAC",
    "difficulty": "hard",
    "questionText": "A 68-year-old man with CKD stage 3 (Cr 1.8 mg/dL) is scheduled for a 4-hour laparoscopic colectomy under general anesthesia with sevoflurane in a circle system. Two CO<sub>2</sub> absorbents are available: standard hydrated soda lime (contains NaOH) and Amsorb Plus (calcium hydroxide, KOH/NaOH-free). The team prefers low fresh gas flows to reduce cost but wants to minimize compound A exposure given the patient’s renal disease. Which intraoperative management best limits compound A during this prolonged sevoflurane anesthetic?",
    "answers": [
      {
        "text": "Use KOH/NaOH-free absorbent (Amsorb Plus) and run low-flow sevoflurane (FGF 0.7–1.0 L/min)",
        "isCorrect": true,
        "explanation": "Amsorb lacks strong bases, essentially preventing sevoflurane degradation to compound A and permitting low-flow anesthesia with minimal compound A exposure during prolonged cases."
      },
      {
        "text": "Use soda lime at FGF 1 L/min for ≤2 MAC-hours, then decrease to 0.5 L/min thereafter",
        "isCorrect": false,
        "explanation": "Limiting MAC-hours at 1 L/min does not address ongoing compound A formation with soda lime, and further decreasing FGF increases accumulation in the circuit."
      },
      {
        "text": "Keep soda lime, add 50% N<sub>2</sub>O to lower sevoflurane requirements, and run FGF 0.5 L/min",
        "isCorrect": false,
        "explanation": "Reducing sevo concentration does not prevent base-catalyzed degradation at very low flows; soda lime will still generate and allow accumulation of compound A."
      },
      {
        "text": "Use hydrated soda lime and maintain FGF ≥2 L/min for the duration",
        "isCorrect": false,
        "explanation": "Higher fresh gas flows reduce compound A accumulation with soda lime but do not eliminate its formation; stronger-base absorbents still catalyze sevoflurane degradation."
      },
      {
        "text": "Use desiccated baralyme and maintain FGF 2 L/min",
        "isCorrect": false,
        "explanation": "Baralyme (strong base) markedly increases sevo degradation and heat generation; desiccation worsens byproducts and has been associated with fires and toxic degradation products."
      }
    ],
    "didactic": "Sevoflurane undergoes base-catalyzed degradation in CO<sub>2</sub> absorbents containing strong alkali (KOH, NaOH), forming vinyl ethers such as compound A. Production is favored by low FGF (<2 L/min), prolonged sevoflurane exposure, increased absorbent temperature, and desiccation. Although clinically significant nephrotoxicity has been demonstrated primarily in rats, prudence is warranted—especially in patients with renal disease and during long, low-flow cases.\n\nTwo levers mitigate risk: fresh gas flow and absorbent chemistry.\n\n- Fresh gas flow: Higher FGF dilutes and washes out compound A. Traditional labeling for sevoflurane advises avoiding FGF <1 L/min and limiting 1–2 L/min to ≤2 MAC-hours. Very low flows with strong-base absorbents allow compound A to accumulate in the circuit.\n- Absorbent choice: **KOH/NaOH-free absorbents (eg, Amsorb Plus; calcium hydroxide–based)** do not meaningfully degrade sevoflurane, thereby preventing compound A formation even at low flows. In contrast, soda lime (NaOH) and especially baralyme (historical; KOH/Ba(OH)<sub>2</sub>) catalyze degradation; desiccation further increases byproducts and heat generation.\n\nBest practice to minimize compound A during prolonged sevo anesthesia is to select a **strong-base–free absorbent** and then use low-flow anesthesia as desired, because the root cause (base-catalyzed degradation) has been removed. If strong-base absorbents must be used, maintain FGF ≥2 L/min for prolonged cases and ensure the absorbent is fresh and not desiccated. Adding N<sub>2</sub>O or modestly lowering end-tidal sevoflurane does not reliably prevent compound A formation at very low flows. Also distinguish this issue from **carbon monoxide** formation, which is greatest with desiccated strong-base absorbents and desflurane/isoflurane; sevoflurane primarily poses a compound A and heat/fire risk with baralyme. Selecting Amsorb and running FGF 0.7–1.0 L/min effectively minimizes compound A while preserving the advantages of low-flow anesthesia.",
    "educationalObjective": "Mitigate compound A concerns during sevoflurane use by appropriate fresh gas flows and absorbent choice."
  },
  {
    "id": "Core.13.3.13",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Inhaled agents: PK/PD and MAC",
    "difficulty": "hard",
    "questionText": "A 62-year-old man with septic shock on norepinephrine and dobutamine undergoes emergent laparotomy under general anesthesia. Cardiac output is 9 L/min (baseline 5 L/min). Ventilation and fresh gas flow are unchanged. The vaporizer is set to deliver approximately 1 MAC of either isoflurane (1.2%) or desflurane (6%) for maintenance. Shortly after the dobutamine increase, the end-tidal agent monitor shows a slower rise in FA/FI.\n\nWhich of the following best describes the expected effect of the increased cardiac output on the alveolar partial pressure rise and time to reach anesthetic depth for isoflurane compared with desflurane?",
    "answers": [
      {
        "text": "Isoflurane will have a slower FA/FI rise but a similar time to anesthetic depth as desflurane because its higher potency offsets the kinetic effect.",
        "isCorrect": false,
        "explanation": "Potency (MAC) does not offset kinetic effects on FA/FI; higher solubility still produces a greater delay in reaching anesthetic depth in high-output states."
      },
      {
        "text": "Isoflurane will have a larger slowing of FA/FI rise and a longer time to anesthetic depth than desflurane.",
        "isCorrect": true,
        "explanation": "Increased cardiac output increases uptake from the alveoli, slowing FA/FI and delaying induction, with the greatest effect on more soluble agents (isoflurane > desflurane)."
      },
      {
        "text": "Both agents will be largely unaffected because FA/FI is determined primarily by alveolar ventilation and fresh gas flow.",
        "isCorrect": false,
        "explanation": "Alveolar ventilation and FGF matter, but uptake is also proportional to cardiac output; increased CO significantly slows FA/FI, especially for soluble agents."
      },
      {
        "text": "Isoflurane will have minimal change, whereas desflurane will have a larger slowing of FA/FI and longer time to depth.",
        "isCorrect": false,
        "explanation": "The opposite is true; the effect of increased cardiac output is more pronounced for agents with higher blood:gas solubility, not lower."
      },
      {
        "text": "Both agents will show a faster FA/FI rise and shorter time to anesthetic depth due to increased delivery to the brain with higher cardiac output.",
        "isCorrect": false,
        "explanation": "Although brain blood flow increases, the alveolar partial pressure is the driving force; higher cardiac output increases uptake and slows FA/FI rise."
      }
    ],
    "didactic": "Inhaled anesthetic uptake from the alveoli is proportional to blood:gas solubility (λ), cardiac output (Q), and the alveolar–mixed venous partial pressure gradient. A useful relationship is: uptake ∝ λ × Q × (P_A − P_v̄). When cardiac output increases (eg, distributive/septic states or inotrope use), total uptake from the alveoli increases, which lowers the alveolar partial pressure (P_A) relative to the inspired partial pressure (P_I). The result is a slower rise in FA/FI and a delayed time to anesthetic depth.\n\nThis effect is agent-dependent. Agents with higher **blood:gas partition coefficients** (eg, isoflurane) experience a larger increase in uptake for a given rise in Q, so their FA/FI curves are depressed more than those of low-solubility agents (eg, desflurane). Therefore, in high-output states, isoflurane shows a more pronounced delay in the rise of alveolar partial pressure and a longer time to reach 1 MAC at the effect site compared with desflurane.\n\nKey implications:\n- Increased CO slows FA/FI and delays anesthetic depth; the magnitude is greatest for more soluble agents (halothane > isoflurane > sevoflurane > desflurane ≈ N₂O).\n- Decreased CO does the opposite—FA/FI rises rapidly, risking overdose with soluble agents during inhalation induction.\n- MAC (potency) is not changed by cardiac output; what changes is the time to reach the target partial pressure in the brain.\n- Mitigation strategies when CO is high: increase P_I (higher vaporizer setting), increase alveolar ventilation, use a low-solubility agent, and ensure adequate fresh gas flow.\n\nClinically, a high-output septic patient may appear “resistant” to volatile anesthesia during induction/early maintenance because the alveolar partial pressure rises slowly despite constant settings. Conversely, low-output states can cause unexpectedly rapid deepening of anesthesia with soluble agents.",
    "educationalObjective": "Predict the effect of increased cardiac output on alveolar partial pressure rise and time to anesthetic depth."
  },
  {
    "id": "Core.13.3.14",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Inhaled agents: PK/PD and MAC",
    "difficulty": "hard",
    "questionText": "A 54-year-old man presents for the first case on Monday for laparoscopic cholecystectomy. Over the weekend, the anesthesia machine’s fresh gas flow was inadvertently left running at 10 L/min. Anesthesia is maintained with desflurane in O<sub>2</sub>/air. Thirty minutes into the case, the patient remains hemodynamically stable with SpO<sub>2</sub> 100% on FiO<sub>2</sub> 1.0, but venous blood appears bright red. ABG shows pH 7.28, PaCO<sub>2</sub> 39 mmHg, PaO<sub>2</sub> 320 mmHg; co-oximetry reveals carboxyhemoglobin 18%. The CO<sub>2</sub> absorbent canister feels hot and the granules are brittle.\n\nWhich equipment change would best prevent recurrence of this complication even if the absorbent becomes desiccated?",
    "answers": [
      {
        "text": "Replace soda lime with a calcium hydroxide–based absorbent that contains no NaOH/KOH (eg, Amsorb).",
        "isCorrect": true,
        "explanation": "Strong base–free absorbents do not form carbon monoxide with desiccated absorbent, even with desflurane; they also limit sevoflurane degradation and heat generation."
      },
      {
        "text": "Add a heated humidifier to the inspiratory limb to prevent absorber drying.",
        "isCorrect": false,
        "explanation": "Circuit humidification does not rehydrate the CO<sub>2</sub> absorbent; desiccation results from prolonged dry fresh gas flow through the canister, not lack of patient-derived humidity."
      },
      {
        "text": "Maintain fresh gas flows ≥6 L/min during volatile anesthesia.",
        "isCorrect": false,
        "explanation": "High flows do not prevent CO formation in a dry absorber and can worsen desiccation; CO production occurs within the absorber regardless of rebreathing fraction."
      },
      {
        "text": "Perform an automated anesthesia machine self-test before the first case each day.",
        "isCorrect": false,
        "explanation": "Machine self-tests do not assess absorber hydration or detect CO production; a normal test cannot exclude risk from desiccated absorbent."
      },
      {
        "text": "Use sevoflurane rather than desflurane for maintenance anesthesia.",
        "isCorrect": false,
        "explanation": "Sevoflurane produces far less CO than desflurane, but desiccated strong-base absorbents can still degrade volatiles (and may overheat with sevo), so risk is reduced, not eliminated."
      }
    ],
    "didactic": "Desiccated CO<sub>2</sub> absorbents that contain strong bases (NaOH, KOH) can degrade volatile anesthetics and generate carbon monoxide, with the highest yields from desflurane (enflurane > isoflurane >> halothane ≈ sevoflurane). The classic “Monday-morning” scenario follows prolonged fresh gas flow left on over a weekend, which dries the absorber. Clinical clues include unexpectedly bright red blood, rising lactate and metabolic acidosis despite normal ventilation, and a discordance between true oxygenation and monitors: SpO<sub>2</sub> is falsely high because pulse oximetry counts carboxyhemoglobin as oxyhemoglobin, and ABG-calculated saturation (without co-oximetry) can appear normal when PaO<sub>2</sub> is high. Definitive diagnosis requires co-oximetry to quantify carboxyhemoglobin.\n\nThe most effective equipment-based prevention is to use a calcium hydroxide–based absorbent (eg, Amsorb) that lacks strong bases. These formulations do not produce CO even when desiccated and also minimize sevoflurane degradation, heat generation, and the risk of exothermic events. Additional preventive practices include: \n- Turn off fresh gas flows when the machine is idle; replace the absorbent if high flows were left on. \n- Do not rely solely on color indicators—dyes can revert, making dry granules appear “fresh.” \n- Feel/inspect the canister; desiccated absorbent is often warm, hard, and brittle.\n\nIntraoperative management of suspected CO exposure includes discontinuing the volatile agent, replacing the absorbent canister, providing 100% O<sub>2</sub>, increasing minute ventilation, and sending co-oximetry. High fresh gas flows do not prevent CO generation in a dry canister, and switching from desflurane to sevoflurane reduces but does not eliminate risk with strong-base absorbents. Selecting a strong base–free absorbent directly addresses the root chemical mechanism and offers the most reliable prevention.",
    "educationalObjective": "Prevent carbon monoxide production from desiccated absorbent and recognize the associated diagnostic clues."
  },
  {
    "id": "Core.13.3.15",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Inhaled agents: PK/PD and MAC",
    "difficulty": "easy",
    "questionText": "A healthy 24-year-old man undergoes knee arthroscopy under general anesthesia with sevoflurane and 70% N<sub>2</sub>O/30% O<sub>2</sub>. At skin closure, N<sub>2</sub>O is turned off. He is hemodynamically stable with EtCO<sub>2</sub> 38 mmHg and beginning to breathe spontaneously. The team plans emergence and extubation in the operating room.\n\nTo minimize the risk of diffusion hypoxia in the first several minutes after discontinuing N<sub>2</sub>O, which management is most appropriate?",
    "answers": [
      {
        "text": "Ventilate with air (FiO<sub>2</sub> 0.21) and apply 5–8 cm H<sub>2</sub>O PEEP to prevent atelectasis",
        "isCorrect": false,
        "explanation": "PEEP may reduce atelectasis but does not prevent the immediate dilution of alveolar O<sub>2</sub> by N<sub>2</sub>O washout; FiO<sub>2</sub> 0.21 permits diffusion hypoxia."
      },
      {
        "text": "Hyperventilate with air to reduce PaCO<sub>2</sub> and increase P<sub>A</sub>O<sub>2</sub> before extubation",
        "isCorrect": false,
        "explanation": "Lowering PaCO<sub>2</sub> with air does not counteract the dilutional fall in alveolar O<sub>2</sub> from N<sub>2</sub>O efflux and may further depress drive after CO<sub>2</sub> washout."
      },
      {
        "text": "Switch to 100% O<sub>2</sub> at high fresh gas flow (8–10 L/min) and maintain normocapnic minute ventilation for 5–10 min before extubation",
        "isCorrect": true,
        "explanation": "Administering 100% O<sub>2</sub> and ensuring adequate alveolar ventilation for 5–10 min offsets dilution of alveolar O<sub>2</sub> by rapidly diffusing N<sub>2</sub>O and counters reduced ventilatory drive from CO<sub>2</sub> washout."
      },
      {
        "text": "Maintain 30% O<sub>2</sub>/70% N<sub>2</sub>O at low flows through transport to avoid abrupt alveolar gas changes",
        "isCorrect": false,
        "explanation": "Continuing N<sub>2</sub>O prolongs anesthetic exposure and does not address diffusion hypoxia, which occurs when N<sub>2</sub>O is discontinued."
      },
      {
        "text": "Extubate to room air once the patient follows commands and apply supplemental O<sub>2</sub> by nasal cannula in PACU",
        "isCorrect": false,
        "explanation": "Early extubation to room air risks transient hypoxemia during peak N<sub>2</sub>O washout; prophylactic 100% O<sub>2</sub> in the OR is preferred."
      }
    ],
    "didactic": "Nitrous oxide is delivered at a high inspired fraction and, despite a low blood–gas partition coefficient, a large quantity is taken up during maintenance. When N<sub>2</sub>O is discontinued, its rapid diffusion from blood to alveoli dilutes alveolar gases, acutely lowering alveolar O<sub>2</sub> (dilutional hypoxia) and CO<sub>2</sub>. The fall in alveolar CO<sub>2</sub> transiently decreases ventilatory drive, which can compound hypoxemia if spontaneous ventilation is inadequate. This phenomenon—diffusion hypoxia—is most pronounced in the first 5–10 minutes after turning off N<sub>2</sub>O.\n\nPrevention relies on two coordinated actions:\n- Deliver high FiO<sub>2</sub> (ideally 100% O<sub>2</sub>) to offset dilution of alveolar O<sub>2</sub> by N<sub>2</sub>O.\n- Ensure adequate alveolar ventilation (assisted or controlled) to maintain normocapnia and avoid the secondary hypoventilation that follows CO<sub>2</sub> washout.\n\nUsing high fresh gas flows with 100% O<sub>2</sub> accelerates N<sub>2</sub>O elimination and minimizes rebreathing. In contrast, strategies that rely on room air (eg, extubation to air, hyperventilation with air, PEEP with air) do not prevent the immediate drop in alveolar O<sub>2</sub> caused by N<sub>2</sub>O efflux. PEEP may improve atelectasis but does not address dilutional hypoxia. Continuing N<sub>2</sub>O simply prolongs anesthetic exposure and defers, rather than prevents, the problem.\n\nPractically, after discontinuing N<sub>2</sub>O, switch to FiO<sub>2</sub> 1.0 at 8–10 L/min and support ventilation to keep EtCO<sub>2</sub> ~35–45 mmHg for 5–10 minutes before or immediately after extubation, then titrate FiO<sub>2</sub> as the patient awakens. This approach directly targets the mechanism of diffusion hypoxia and is a standard, low-risk intervention to maintain adequate oxygenation during emergence.",
    "educationalObjective": "Prevent diffusion hypoxia when discontinuing nitrous oxide by using supplemental oxygen and adequate ventilation."
  },
  {
    "id": "Core.13.3.16",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Inhaled agents: PK/PD and MAC",
    "difficulty": "medium",
    "questionText": "A 68-year-old man with CKD stage 3b (creatinine 1.8 mg/dL, eGFR 38 mL/min/1.73 m<sup>2</sup>) is scheduled for a 4-hour laparoscopic colectomy. You plan to maintain anesthesia with sevoflurane at low flows (fresh gas flow 1 L/min) using a fresh, hydrated calcium hydroxide–based CO<sub>2</sub> absorbent that contains no strong bases. He asks about the risks of “kidney damage” and “toxic hepatitis” from the anesthetic gas. Hemodynamics are stable; AST/ALT are 32/36 U/L, bilirubin is normal. Which statement is the most appropriate counseling point to include in your discussion?",
    "answers": [
      {
        "text": "With hydrated calcium hydroxide–based absorbent and FGF ≥1 L/min, clinically meaningful renal toxicity from sevoflurane (compound A or fluoride) has not been demonstrated, and immune-mediated hepatitis is exceedingly rare with modern agents (sevoflurane does not form TFA adducts).",
        "isCorrect": true,
        "explanation": "Modern absorbents minimize compound A; human studies have not shown clinically significant renal injury from sevoflurane at standard flows/durations, and immune-mediated hepatitis is vanishingly rare with current agents—sevoflurane does not form trifluoroacetylated adducts."
      },
      {
        "text": "Because compound A production is unavoidable during low-flow sevoflurane, the safest plan is to switch to isoflurane, which has no risk of hepatic injury.",
        "isCorrect": false,
        "explanation": "Compound A formation is minimized with modern, hydrated absorbents, and isoflurane forms TFA adducts with rare immune-mediated hepatitis reported."
      },
      {
        "text": "Sevoflurane at 1 MAC markedly reduces renal blood flow and can precipitate postoperative renal failure; total intravenous anesthesia is required in CKD to avoid hepatic and renal toxicity.",
        "isCorrect": false,
        "explanation": "Volatiles cause modest, dose-dependent decreases in organ blood flow, but clinically significant renal failure is not expected at typical doses when hemodynamics are maintained; TIVA is not required solely to avoid renal/hepatic toxicity."
      },
      {
        "text": "Because sevoflurane defluorinates, it frequently causes fluoride nephrotoxicity in CKD; using desflurane eliminates renal and hepatic risks.",
        "isCorrect": false,
        "explanation": "Sevoflurane increases fluoride levels but has not been shown to cause clinically meaningful nephrotoxicity in humans at typical exposures; desflurane does not eliminate risk of immune-mediated hepatitis and can generate carbon monoxide with desiccated absorbent."
      },
      {
        "text": "To prevent nephrotoxicity from compound A, FGF must be maintained at 4–6 L/min; however, all modern volatiles still carry a substantial risk of immune-mediated hepatitis similar to halothane.",
        "isCorrect": false,
        "explanation": "High flows are unnecessary with calcium hydroxide–based absorbents, and modern volatiles have a very low incidence of immune-mediated hepatitis compared with halothane."
      }
    ],
    "didactic": "Modern volatile anesthetics have a favorable hepatic and renal safety profile when used with current equipment and techniques. Historically, toxicity concerns arose from two mechanisms:\n\n- Renal: inorganic fluoride release and degradation byproducts (eg, compound A)\n- Hepatic: immune-mediated injury after formation of trifluoroacetyl (TFA)–protein adducts\n\nKey points for current practice:\n\n- Sevoflurane metabolism (~3%–5%) increases serum fluoride, but human studies have not demonstrated clinically meaningful nephrotoxicity at typical MAC exposures and durations. Methoxyflurane (not used) caused fluoride nephrotoxicity; this has not translated to sevoflurane.\n- Compound A forms when sevoflurane contacts strong-base CO<sub>2</sub> absorbents (eg, desiccated soda lime/baralyme). Risk is minimized by using hydrated, calcium hydroxide–based absorbents without strong bases (eg, Amsorb) and avoiding desiccation. With such absorbents and FGF ≥1–2 L/min, clinically significant renal injury has not been shown.\n- All volatiles cause dose-dependent decreases in hepatic and renal blood flow, but maintaining MAP and avoiding deep anesthesia typically prevents ischemic injury.\n- Immune-mediated “halothane hepatitis” results from TFA-protein adducts. Halothane carries the highest risk. Isoflurane and desflurane rarely form TFA adducts with extremely low incidence of severe hepatitis. Sevoflurane does not form TFA adducts and is not linked to immune-mediated hepatitis.\n- Additional absorbent-related hazards include carbon monoxide production with desflurane/isoflurane when strong-base absorbents are desiccated; modern calcium hydroxide absorbents largely prevent this.\n\nPractical counseling: With hydrated, modern absorbents and reasonable low flows (≥1 L/min), sevoflurane has not been shown to cause clinically important kidney injury from compound A or fluoride, and the risk of immune-mediated hepatitis with modern agents is exceedingly low. Optimizing hemodynamics (eg, MAP ≥65 mmHg) further protects hepatic and renal perfusion.",
    "educationalObjective": "Recognize hepatic and renal effects of modern volatiles and counsel on the low clinical incidence of toxicity with current practice."
  },
  {
    "id": "Core.13.3.17",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Inhaled agents: PK/PD and MAC",
    "difficulty": "medium",
    "questionText": "A 3-year-old boy (12 kg) is undergoing bilateral myringotomy tube placement under sevoflurane mask anesthesia. He had severe agitation and inconsolable crying for 20 minutes in the PACU after a prior sevoflurane anesthetic. Intraoperative vitals are stable (HR 110/min, BP 90/55 mmHg, SpO<sub>2</sub> 100%), and end-tidal sevoflurane is 2.5% (~1.1 MAC for age). Acetaminophen was given, and the surgeon anticipates 10 minutes to completion. Which intraoperative intervention is most effective to reduce the risk of emergence agitation in this child?",
    "answers": [
      {
        "text": "Administer midazolam 0.05 mg/kg IV at the end of the case",
        "isCorrect": false,
        "explanation": "Peri-emergence benzodiazepines do not reliably prevent sevoflurane emergence agitation and may paradoxically worsen disinhibition or delay recovery."
      },
      {
        "text": "Administer fentanyl 1 mcg/kg IV during closure",
        "isCorrect": false,
        "explanation": "Opioids treat pain but are less effective for emergence agitation, which is often non–pain-related with sevoflurane; they increase risk of respiratory depression and PONV without reliably preventing agitation."
      },
      {
        "text": "Administer dexmedetomidine 0.5 mcg/kg IV over 10 minutes before emergence",
        "isCorrect": true,
        "explanation": "Dexmedetomidine (α<sub>2</sub>-agonist) given near case end consistently reduces sevoflurane-associated emergence agitation independent of pain, with modestly prolonged emergence and acceptable hemodynamics at 0.3–0.5 mcg/kg."
      },
      {
        "text": "Use high fresh gas flows to hasten washout and achieve a faster wake-up",
        "isCorrect": false,
        "explanation": "Rapid washout and abrupt awakening after sevoflurane increase agitation risk; smoother, not faster, emergence reduces emergence delirium."
      },
      {
        "text": "Administer propofol 1 mg/kg IV at the end of the case",
        "isCorrect": false,
        "explanation": "A propofol bolus can blunt rapid sevoflurane offset and reduce agitation, but it is generally less effective than dexmedetomidine and provides no analgesia; it is reasonable if α<sub>2</sub>-agonists are contraindicated."
      }
    ],
    "didactic": "Sevoflurane in preschool-aged children is strongly associated with emergence agitation (EA) or delirium, characterized by inconsolability, disorientation, and nonpurposeful movements typically within 10–20 minutes of wake-up. Risk is highest with rapid offset volatile anesthetics (sevoflurane, desflurane), preschool age, ophthalmologic/ENT procedures, preoperative anxiety, and poorly controlled pain. Importantly, EA is often not primarily pain-driven, so treating only with opioids is insufficient and may add hypoventilation or PONV.\n\nAmong pharmacologic adjuncts, **dexmedetomidine** is most effective for prevention. A dose of 0.3–0.5 mcg/kg IV given over ~10 minutes near case end reliably reduces EA incidence and severity by providing cooperative sedation, anxiolysis, and sympatholysis while sparing opioids and lowering MAC. Typical trade-offs include mild bradycardia/hypotension and a small increase in time to eye opening (often minutes), but overall PACU recovery quality improves. **Clonidine** is an alternative when IV access or dexmedetomidine is unavailable, with slower onset.\n\nOther strategies have mixed or lesser benefit:\n- **Propofol 1 mg/kg IV** at end of case can “smooth” volatile washout and reduce EA, but results are less robust than α<sub>2</sub>-agonists and it lacks analgesia.\n- **Opioids** should target pain; they do not reliably prevent EA in nonpainful procedures and carry respiratory risks.\n- **Benzodiazepines** (eg, midazolam) do not prevent EA and may worsen dysphoria at emergence.\n- **Rapid wake-up techniques** (eg, high flows, abrupt discontinuation) increase EA by accentuating sudden consciousness without context.\n\nPractical approach for sevoflurane pediatric cases:\n- Provide multimodal analgesia appropriate to procedure.\n- Administer dexmedetomidine 0.3–0.5 mcg/kg IV before emergence to reduce EA.\n- Avoid unnecessarily abrupt emergence; maintain a calm environment and gentle stimulation.\n- Consider deep removal of airway devices when safe to limit stimulation.\n\nThese steps reduce sevoflurane-associated EA while maintaining efficient, high-quality recovery.",
    "educationalObjective": "Reduce pediatric emergence agitation risk with sevoflurane by using adjuncts and smooth emergence strategies."
  },
  {
    "id": "Core.13.3.18",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Inhaled agents: PK/PD and MAC",
    "difficulty": "easy",
    "questionText": "A healthy 28-year-old (ASA II) is scheduled for a 20-minute knee arthroscopy in an ambulatory center. General anesthesia with an LMA is planned, FiO<sub>2</sub> 0.5, and maintenance at approximately 1 MAC with fresh gas flow 2 L/min. You anticipate minimal opioid use and want the fastest possible, predictable emergence to expedite PACU readiness after this brief case.\n\nSelecting among the halogenated volatile anesthetics, which agent will most reliably provide the quickest emergence based on its blood-gas solubility?",
    "answers": [
      {
        "text": "Halothane",
        "isCorrect": false,
        "explanation": "Halothane has a high blood-gas partition coefficient, causing slow induction and emergence; it is also rarely used due to adverse effects."
      },
      {
        "text": "Isoflurane",
        "isCorrect": false,
        "explanation": "Isoflurane is significantly more soluble in blood than desflurane or sevoflurane, which slows changes in alveolar and brain partial pressures and prolongs emergence."
      },
      {
        "text": "Desflurane",
        "isCorrect": true,
        "explanation": "Desflurane has the lowest blood-gas partition coefficient among commonly used volatiles, producing the fastest rise and fall in alveolar and brain partial pressures and thus the quickest induction and emergence."
      },
      {
        "text": "Sevoflurane",
        "isCorrect": false,
        "explanation": "Sevoflurane is relatively insoluble and allows smooth inhalation induction, but its blood-gas solubility is higher than desflurane, leading to slower wash-in and wash-out."
      },
      {
        "text": "Enflurane",
        "isCorrect": false,
        "explanation": "Enflurane has greater blood solubility than desflurane and sevoflurane, resulting in slower uptake and elimination and thus slower emergence."
      }
    ],
    "didactic": "The blood-gas partition coefficient (λ) quantifies how soluble an inhaled anesthetic is in blood relative to alveolar gas. Lower λ means less uptake into blood at a given alveolar partial pressure, so the alveolar concentration (F<sub>A</sub>) rises more rapidly toward the inspired concentration (F<sub>I</sub>). Because the brain partial pressure tracks F<sub>A</sub>, agents with low blood solubility produce faster induction and, critically, faster emergence when the vaporizer is turned off. This relationship holds most clearly in short cases where tissue saturation is limited.\n\nAmong commonly used halogenated volatiles, blood-gas solubility ranks: \n- Desflurane (≈0.42) < Sevoflurane (≈0.65) ≪ Isoflurane (≈1.46) < Halothane (≈2.4)\nNitrous oxide is also relatively insoluble (≈0.47) but is not a halogenated volatile and is not typically used as the primary sole anesthetic.\n\nFor a brief ambulatory procedure with minimal opioid use, choosing the least soluble volatile (desflurane) yields the most rapid on/off control, minimizing time to eye opening and PACU discharge readiness. Sevoflurane, while favored for inhalation induction due to airway tolerability, is slightly more soluble and therefore slower than desflurane under identical conditions. Isoflurane, enflurane, and halothane are progressively more soluble, leading to slower wash-in and wash-out.\n\nOther factors that influence the speed of anesthetic partial pressure change include alveolar ventilation (faster ventilation speeds both induction and emergence), cardiac output (higher CO slows induction with soluble agents), fresh gas flow (higher FGF hastens wash-out), and the duration of anesthesia (longer cases allow more tissue uptake, which can slow emergence). Under the same ventilatory and flow settings for a short case, the agent with the lowest blood-gas partition coefficient will provide the fastest emergence—favoring desflurane.",
    "educationalObjective": "Relate blood-gas partition coefficient to speed of induction and emergence and apply this to agent selection."
  },
  {
    "id": "Core.13.4.1",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Ketamine and special uses",
    "difficulty": "hard",
    "questionText": "A 32-year-old man on high-dose methadone presents for tibial intramedullary nailing. You plan a subanesthetic ketamine infusion for opioid-sparing analgesia but he reports severe hallucinations and agitation during a prior procedure when he received racemic ketamine (0.3 mg/kg bolus, then 0.2 mg/kg/h). Your institution has S-ketamine available. Compared with racemic ketamine, which perioperative effect is most likely when switching to S-ketamine for analgesia?",
    "answers": [
      {
        "text": "Approximately half dosing, but greater salivation and postoperative nausea than with racemate",
        "isCorrect": false,
        "explanation": "S-ketamine is generally associated with less hypersalivation and nausea/vomiting compared with racemic ketamine at equipotent analgesia."
      },
      {
        "text": "Similar dosing but greater increases in cerebral blood flow and intracranial pressure",
        "isCorrect": false,
        "explanation": "Both enantiomers can increase CBF; S-ketamine does not produce greater ICP/CBF increases and may have slightly less psychotomimetic and neurocognitive disturbance than racemate."
      },
      {
        "text": "Equivalent opioid-sparing at approximately half the racemic dose with a lower incidence of hallucinations/emergence reactions",
        "isCorrect": true,
        "explanation": "S-ketamine has higher NMDA affinity and ~2× analgesic potency, allowing equipotent analgesia at lower doses and is associated with fewer psychotomimetic effects than racemic ketamine."
      },
      {
        "text": "Similar dosing but lower rates of hypertension/tachycardia, with greater risk of dysphoria",
        "isCorrect": false,
        "explanation": "Hemodynamic effects are broadly similar between enantiomers at equipotent effect; S-ketamine does not increase dysphoria and typically reduces psychotomimetic reactions."
      },
      {
        "text": "Higher dosing requirement because S-ketamine is less potent at NMDA receptors than racemate",
        "isCorrect": false,
        "explanation": "S-ketamine has greater (not lesser) affinity for the NMDA receptor and greater analgesic/anesthetic potency than the racemic mixture."
      }
    ],
    "didactic": "Ketamine is a racemic mixture of R(−) and S(+) enantiomers that produce dissociative anesthesia primarily via noncompetitive NMDA receptor antagonism. S-ketamine has 3–4× higher affinity for the NMDA phencyclidine site and provides roughly 2× the analgesic/anesthetic potency of racemic ketamine. Clinically, this allows equivalent opioid-sparing analgesia at approximately half the racemic dose (eg, if using 0.2–0.5 mg/kg bolus and 0.1–0.3 mg/kg/h infusion with racemate, S-ketamine can often be dosed at ~50% of those ranges).\n\nCompared with racemic ketamine, S-ketamine is associated with a more favorable neuropsychiatric and recovery profile at equipotent effect:\n- Lower incidence and severity of psychotomimetic phenomena (hallucinations, dysphoria, emergence agitation)\n- Faster psychomotor recovery and less cognitive impairment\n- Less hypersalivation and typically less nausea/vomiting\n\nHemodynamic and respiratory effects are broadly similar for both preparations at equipotent analgesia (sympathomimetic increases in HR/BP with preservation of respiratory drive). Historical concerns about large ICP rises are context dependent; with controlled ventilation and normal PaCO<sub>2</sub>, clinically significant ICP elevation is uncommon, and S-ketamine does not worsen this compared with racemate.\n\nKey practical points when substituting S-ketamine for racemic ketamine:\n- Dose reduction: target ~50% of the racemic dose to achieve similar analgesia/opioid-sparing\n- Side-effect profile: anticipate fewer emergence reactions and less salivation; routine benzodiazepine coadministration can further mitigate psychotomimetic effects\n- Expect comparable hemodynamics; continue standard cautions in patients where sympathetic stimulation is undesirable\n\nThus, S-ketamine offers the potential for equivalent or improved analgesia with fewer neuropsychiatric and secretory side effects at lower doses relative to racemic ketamine.",
    "educationalObjective": "Compare racemic ketamine with S-ketamine and describe potential advantages in analgesia and side-effect profile."
  },
  {
    "id": "Core.13.4.2",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Ketamine and special uses",
    "difficulty": "hard",
    "questionText": "A 68-year-old man with critical multivessel coronary disease (left main 80%, prior MI, EF 35%) presents after a fall with declining mental status (GCS 7) and anisocoria. Head CT shows a large acute subdural hematoma with 10 mm midline shift. He is hypertensive (SBP 165 mmHg), HR 96 bpm, SpO<sub>2</sub> 98% on supplemental O<sub>2</sub>. He is breathing spontaneously with irregular respirations; ETCO<sub>2</sub> is 45 mmHg. He requires emergent intubation and craniotomy. The team plans to use ketamine for induction.\n\nWhich induction approach best balances intracranial and myocardial risk in this patient?",
    "answers": [
      {
        "text": "Ketamine 1 mg/kg IV with avoidance of β-blockers to prevent unmasking direct myocardial depression",
        "isCorrect": false,
        "explanation": "Direct myocardial depression is a concern in catecholamine-depleted states, not from β-blocker use; β-blockade appropriately blunts tachycardia and reduces ischemic risk."
      },
      {
        "text": "Etomidate 0.3 mg/kg IV without adjuncts, accept brief laryngoscopy-induced tachycardia as unavoidable",
        "isCorrect": false,
        "explanation": "Etomidate is hemodynamically stable and lowers ICP, but unmitigated laryngoscopy-induced sympathetic surges jeopardize severe CAD and may spike ICP."
      },
      {
        "text": "Propofol 2 mg/kg IV with lidocaine, permissive hypercapnia to avoid blood pressure swings",
        "isCorrect": false,
        "explanation": "Propofol risks hypotension and reduced CPP; hypercapnia increases CBF and ICP, worsening herniation risk."
      },
      {
        "text": "Ketamine 2 mg/kg IV alone, allow spontaneous ventilation to avoid hypotension from positive pressure",
        "isCorrect": false,
        "explanation": "Unblunted ketamine can cause tachycardia/hypertension and spontaneous ventilation risks hypercapnia, both of which may worsen ICP and myocardial ischemia."
      },
      {
        "text": "Ketamine 1–1.5 mg/kg IV plus fentanyl 2 µg/kg and esmolol 0.5 mg/kg, with controlled ventilation to PaCO<sub>2</sub> 32–35 mmHg and head-up positioning",
        "isCorrect": true,
        "explanation": "Blunting the sympathetic surge with opioid/β-blockade mitigates myocardial O<sub>2</sub> demand while ketamine supports MAP/CPP; controlled ventilation prevents hypercapnia-related ICP rise."
      }
    ],
    "didactic": "Ketamine is a dissociative anesthetic with potent sympathomimetic effects (↑HR, ↑BP, ↑SVR) that typically preserve MAP and thus cerebral perfusion pressure (CPP = MAP − ICP). Historically, ketamine was avoided in intracranial pathology due to reports of increased intracranial pressure (ICP). However, more recent data show that when ventilation is controlled (avoiding hypercapnia) and adequate anesthesia/analgesia are provided, ketamine does not increase ICP and may improve CPP by supporting MAP. The earlier ICP concerns largely arose from spontaneously breathing, lightly anesthetized patients in whom hypercapnia and nociception increased CBF and ICP.\n\nIn severe coronary artery disease, ketamine’s catecholamine-mediated tachycardia and hypertension can escalate myocardial O<sub>2</sub> demand and provoke ischemia. This is a relative caution rather than an absolute contraindication. The hemodynamic profile can be optimized by:\n\n- Blunting the sympathetic response to laryngoscopy with short-acting opioid (eg, fentanyl) and β-blocker (eg, esmolol), and considering lidocaine.\n- Using moderate ketamine dosing (eg, 1–1.5 mg/kg IV) to support MAP while minimizing excessive catecholamine surge.\n- Implementing head-up positioning and controlled ventilation targeting PaCO<sub>2</sub> 32–35 mmHg to avoid hypercapnia-driven ICP increases while maintaining cerebral blood flow.\n\nBy contrast, propofol may reduce ICP but frequently lowers MAP, risking CPP. Etomidate is neutral on MAP and lowers ICP, but unmitigated laryngoscopy still triggers tachycardia and hypertension, endangering severe CAD and potentially raising ICP. Direct myocardial depression from ketamine can be unmasked in catecholamine-depleted states (eg, prolonged shock), but β-blockers do not cause this effect. Thus, in neuroemergencies with concomitant severe CAD, ketamine can be used safely when paired with opioid/β-blockade and controlled ventilation to protect both brain and myocardium.",
    "educationalObjective": "Discuss relative cautions such as severe coronary disease and evolving evidence on intracranial pressure effects."
  },
  {
    "id": "Core.13.4.3",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Ketamine and special uses",
    "difficulty": "medium",
    "questionText": "A 62-year-old man (BMI 34) with obstructive sleep apnea (uses CPAP) and hypertension undergoes laparoscopic colectomy. In the PACU, pain is 9/10 despite a hydromorphone PCA (2 mg in 30 min). He is arousable but somnolent with RR 10/min and SpO<sub>2</sub> 93% on 2 L O<sub>2</sub>. BP is 160/95 mmHg (baseline 135/80), HR 88/min. He is nauseated after opioids; there is no psychiatric history. To reduce opioid requirements while minimizing respiratory depression and adverse effects, which of the following is the most appropriate regimen now?",
    "answers": [
      {
        "text": "Start dexmedetomidine infusion 0.6 µg/kg/hr to spare opioids and lower blood pressure.",
        "isCorrect": false,
        "explanation": "Dexmedetomidine can reduce opioid needs but commonly causes bradycardia/hypotension and deepens sedation in OSA; it does not address opioid-induced nausea and is not as directly anti-hyperalgesic as ketamine."
      },
      {
        "text": "Give ketamine 0.5 mg/kg IV bolus followed by 0.5 mg/kg/hr infusion to rapidly control pain.",
        "isCorrect": false,
        "explanation": "These doses are excessive for analgesia and increase risks of hypertension, dysphoria/hallucinations, and nausea, especially in a somnolent, OSA patient."
      },
      {
        "text": "Increase hydromorphone infusion rate and add promethazine for nausea control.",
        "isCorrect": false,
        "explanation": "Escalating opioids worsens somnolence and ventilatory depression in OSA; antiemetics do not mitigate opioid-induced hyperalgesia or reduce opioid requirements."
      },
      {
        "text": "Start ketamine infusion 0.1 mg/kg/hr without a bolus; administer ondansetron and monitor for psychotomimetic symptoms and blood pressure.",
        "isCorrect": true,
        "explanation": "Subanesthetic ketamine infusion provides opioid-sparing analgesia with minimal respiratory depression; avoiding a bolus limits sympathomimetic and psychotomimetic effects, and antiemetic prophylaxis addresses nausea."
      },
      {
        "text": "Start ketamine 0.2 mg/kg IV bolus over 10 min followed by 0.2 mg/kg/hr; give ondansetron and monitor for hallucinations and blood pressure.",
        "isCorrect": false,
        "explanation": "Effective dosing, but the bolus is more likely to worsen hypertension and psychotomimetic effects in this patient; an infusion without a bolus is safer given elevated BP and OSA-related sedation."
      }
    ],
    "didactic": "Low-dose ketamine is a useful adjunct for acute postoperative pain because it blocks NMDA receptors, attenuating central sensitization and opioid-induced hyperalgesia, which translates to meaningful opioid-sparing and improved pain scores over 24–48 hours. Analgesic (subanesthetic) dosing typically uses a small bolus (0.1–0.35 mg/kg) and/or an infusion of 0.1–0.2 mg/kg/hr (≈1–3 µg/kg/min). In patients with elevated blood pressure or at risk for psychotomimetic effects, omitting the bolus and initiating a low-rate infusion is prudent to minimize transient sympathomimetic surges and dysphoria.\n\nKetamine’s hemodynamic effects reflect indirect sympathomimetic activity (↑HR, ↑BP), which can be clinically significant with rapid bolus or higher doses; use caution in uncontrolled hypertension, coronary disease, and aortic pathology. At subanesthetic doses, ketamine generally preserves respiratory drive and airway reflexes, offering an advantage over escalating opioids in patients with OSA. However, concurrent opioids and sedatives can still depress ventilation, so continuous monitoring of RR, SpO<sub>2</sub>, sedation level, and hemodynamics is essential.\n\nPsychotomimetic effects (eg, dysphoria, vivid dreams, hallucinations) and nausea are dose-related and more common with rapid bolus. Mitigation strategies include:\n- Avoid or slow bolus administration; prefer low-dose infusion.\n- Prophylactic antiemetics (eg, ondansetron) and treatment of sialorrhea if problematic (eg, glycopyrrolate).\n- Consider a small benzodiazepine only if significant dysphoria occurs; routine prophylaxis is avoided in OSA and older adults due to synergistic sedation/delirium risk.\n\nCompared with alternatives like escalating opioids or dexmedetomidine, low-dose ketamine more directly targets central sensitization while limiting respiratory depression and can reduce opioid requirements and PONV burden when paired with standard antiemetic prophylaxis.",
    "educationalObjective": "Employ low-dose ketamine infusions for opioid-sparing analgesia and monitor for psychotomimetic effects and nausea."
  },
  {
    "id": "Core.13.4.4",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Ketamine and special uses",
    "difficulty": "easy",
    "questionText": "A 35-year-old man with moderate persistent asthma undergoes a painful burn dressing change in the procedure suite. After IV administration of an anesthetic at 1 mg/kg, his eyes remain open with roving nystagmus; he does not follow verbal commands but withdraws to painful stimulation. He breathes spontaneously at 14/min with SpO<sub>2</sub> 98% on 2 L/min O<sub>2</sub> via nasal cannula, coughs with oropharyngeal suctioning, and has copious oral secretions. Blood pressure increases from 120/75 to 145/85 mmHg and heart rate from 80 to 105/min.\n\nWhich pharmacologic mechanism and characteristic clinical state best explain this agent’s effects?",
    "answers": [
      {
        "text": "NMDA receptor antagonism producing dissociative anesthesia with preserved airway reflexes and analgesia",
        "isCorrect": true,
        "explanation": "Ketamine is a noncompetitive NMDA antagonist that causes dissociative anesthesia—analgesia and amnesia with relative preservation of spontaneous ventilation and airway reflexes—often with nystagmus, increased secretions, and sympathetic stimulation (↑HR, ↑BP)."
      },
      {
        "text": "α<sub>2</sub>-adrenergic agonism producing cooperative sedation with bradycardia and hypotension",
        "isCorrect": false,
        "explanation": "Dexmedetomidine yields arousable sedation and often bradycardia/hypotension, not hypertension/tachycardia, nystagmus, or dissociation."
      },
      {
        "text": "μ-opioid receptor agonism producing profound analgesia with chest wall rigidity and miosis",
        "isCorrect": false,
        "explanation": "Potent opioids can cause respiratory depression, bradycardia, and rigidity; they do not produce dissociation with nystagmus or sympathetic stimulation and would not reliably preserve airway reflexes."
      },
      {
        "text": "GABA<sub>A</sub> receptor potentiation producing deep hypnosis with marked respiratory depression and loss of airway reflexes",
        "isCorrect": false,
        "explanation": "This profile describes agents like propofol/etomidate; they depress respiration and abolish protective reflexes, which is inconsistent with preserved cough and stable spontaneous ventilation."
      },
      {
        "text": "Voltage-gated Na<sup>+</sup> channel blockade producing complete sensory and motor block with sympathectomy",
        "isCorrect": false,
        "explanation": "This describes neuraxial/local anesthetics; they cause regional, not systemic, anesthesia and do not explain the observed dissociative state with nystagmus and secretions."
      }
    ],
    "didactic": "Ketamine is a phencyclidine derivative that produces anesthesia primarily through noncompetitive antagonism of the **NMDA (glutamate) receptor**, decreasing excitatory neurotransmission in the brain and spinal dorsal horn. This mechanism underlies its unique profile of **dissociative anesthesia**—a functional uncoupling of thalamocortical from limbic pathways—resulting in profound analgesia and amnesia while often preserving spontaneous ventilation and protective airway reflexes.\n\nKey clinical features of ketamine:\n- **Dissociation**: eyes open, nystagmus, and cataleptic posture; unresponsive to commands but withdraws to pain.\n- **Airway/respiration**: relative preservation of airway reflexes and minimal respiratory depression; however, aspiration and obstruction can still occur—airway vigilance is required.\n- **Sympathomimetic effects**: increases HR, BP, and CO via central sympathetic stimulation and inhibition of norepinephrine reuptake; useful in hemodynamic instability but may be harmful in severe coronary disease. In catecholamine-depleted states, direct myocardial depression may emerge.\n- **Bronchodilation**: beneficial in reactive airway disease and status asthmaticus.\n- **Secretions**: increased salivation/airway secretions; anticholinergics (eg, glycopyrrolate) can mitigate.\n- **Emergence phenomena**: vivid dreams, dysphoria; benzodiazepines can reduce incidence. Ketamine increases CBF and CMRO<sub>2</sub>, potentially raising ICP.\n\nSpecial uses leverage ketamine’s combination of **analgesia**, **hemodynamic support**, and **bronchodilation** for brief painful procedures, hypovolemic trauma (with caution), and severe asthma. Compared with GABAergic hypnotics (eg, propofol), ketamine less reliably suppresses airway reflexes and typically does not cause apnea at analgesic/anesthetic doses, making it advantageous for procedural anesthesia where maintaining spontaneous ventilation and airway reflexes is desirable. Nonetheless, clinicians should not rely on “preserved reflexes” for airway protection and must be prepared to manage the airway and secretions.",
    "educationalObjective": "Explain ketamine NMDA receptor antagonism and describe dissociative anesthesia with preserved airway reflexes."
  },
  {
    "id": "Core.13.4.5",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Ketamine and special uses",
    "difficulty": "medium",
    "questionText": "A 34-year-old woman with poorly controlled asthma is undergoing laparoscopic cholecystectomy under volume-controlled ventilation with sevoflurane (≈1 MAC) and rocuronium. Twenty minutes after pneumoperitoneum, peak inspiratory pressure rises to 45 cmH2O with a markedly upsloping capnogram and diffuse expiratory wheeze. Plateau pressure is 20 cmH2O. SpO<sub>2</sub> falls to 88% on FiO<sub>2</sub> 1.0, HR is 118/min, and BP is 110/65 mmHg. Endotracheal tube position is confirmed and suction yields scant secretions. Despite albuterol (8 puffs via MDI through the ETT), IV magnesium sulfate (2 g), and methylprednisolone (125 mg), bronchospasm persists while you hand-ventilate with prolonged exhalation.\n\nWhich of the following is the most appropriate next pharmacologic step to improve ventilation?",
    "answers": [
      {
        "text": "Administer propofol 1 mg/kg IV bolus and start an infusion at 100 μg/kg/min",
        "isCorrect": false,
        "explanation": "Propofol has modest bronchodilatory properties but commonly causes hypotension and is less effective than ketamine for refractory bronchospasm when adequate volatile anesthesia is already in use."
      },
      {
        "text": "Administer IV ketamine 0.5 mg/kg bolus and start an infusion at 0.5 mg/kg/h",
        "isCorrect": true,
        "explanation": "Ketamine provides potent bronchodilation via sympathomimetic and direct smooth muscle effects, preserves hemodynamics, and is effective for refractory intraoperative bronchospasm/status asthmaticus."
      },
      {
        "text": "Administer morphine 5 mg IV to improve analgesia",
        "isCorrect": false,
        "explanation": "Morphine can trigger histamine release and worsen bronchoconstriction; non–histamine-releasing agents or ketamine are preferred in bronchospasm."
      },
      {
        "text": "Start desflurane at 6% while reducing sevoflurane to 0.5 MAC",
        "isCorrect": false,
        "explanation": "Desflurane is pungent and airway-irritating, increasing airway resistance and risk of bronchospasm; it is contraindicated in active bronchospasm."
      },
      {
        "text": "Administer epinephrine 10 μg IV bolus for bronchodilation",
        "isCorrect": false,
        "explanation": "IV epinephrine can be used for life-threatening bronchospasm or anaphylaxis with instability; in a hemodynamically stable patient, ketamine is a safer, targeted next step after inhaled β-agonists, steroids, and magnesium."
      }
    ],
    "didactic": "This patient has severe intraoperative bronchospasm (peak 45 cmH2O, plateau 20 cmH2O, wheeze, upsloping capnogram, hypoxemia) consistent with markedly increased airway resistance. After first-line therapies — 100% O<sub>2</sub>, manual ventilation with prolonged exhalation, inhaled β-agonist via ETT, corticosteroid, and IV magnesium — the next pharmacologic step is ketamine.\n\nKetamine is an NMDA receptor antagonist with **bronchodilatory** properties mediated by several mechanisms:\n- Central sympathomimetic effects increasing endogenous catecholamines\n- Direct airway smooth muscle relaxation (eg, modulation of Ca<sup>2+</sup> flux and inhibition of vagal tone)\n- Attenuation of airway reflexes while preserving respiratory drive\n\nIt also **maintains blood pressure** and heart rate, making it advantageous when volatile anesthetic deepening or propofol could precipitate hypotension. Typical dosing for status asthmaticus/bronchospasm is a 0.2–0.5 mg/kg IV bolus followed by 0.5–1 mg/kg/h infusion (titrate to effect). Adverse effects include sialorrhea (consider glycopyrrolate), tachycardia/hypertension, and emergence phenomena; in catecholamine-depleted states, myocardial depression may emerge.\n\nOther options are less appropriate here:\n- Desflurane is pungent and **worsens** airway resistance; sevoflurane or isoflurane are preferable if using volatiles for bronchodilation.\n- IV epinephrine is indicated for **anaphylaxis or hemodynamic instability** from life-threatening bronchospasm; in a stable patient, ketamine offers bronchodilation with fewer arrhythmogenic risks.\n- Propofol can bronchodilate but often causes **hypotension** and is less reliable than ketamine when adequate volatile anesthesia is already present.\n- Histamine-releasing opioids (eg, morphine) can **exacerbate bronchospasm**; use fentanyl or ketamine instead.\n\nIn parallel, optimize ventilation to minimize dynamic hyperinflation: low V<sub>T</sub>, low–moderate rate, high inspiratory flow (prolong exhalation), and accept permissive hypercapnia. Avoid β-blockers and airway irritants during active bronchospasm.",
    "educationalObjective": "Leverage ketamine bronchodilation to treat severe bronchospasm and status asthmaticus intraoperatively."
  },
  {
    "id": "Core.13.4.6",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Ketamine and special uses",
    "difficulty": "easy",
    "questionText": "A 34-year-old anxious woman presents for incision and drainage of a forearm abscess under procedural sedation. She previously received ketamine for a dental procedure and recalls “vivid scary dreams” and agitation on waking. Vitals are HR 78, BP 124/72, SpO<sub>2</sub> 99% on room air. You plan ketamine 1 mg/kg IV for dissociative sedation. She asks how you can prevent a repeat experience.\n\nWhich of the following is the most appropriate strategy to minimize ketamine emergence reactions in this patient?",
    "answers": [
      {
        "text": "Administer midazolam 1–2 mg IV before ketamine and recover in a quiet, low‑stimulation area with dim lighting",
        "isCorrect": true,
        "explanation": "Benzodiazepine premedication mitigates ketamine-related dysphoria via GABA<sub>A</sub> potentiation, and a calm, low‑stimulus environment reduces sensory misperception—together they lower the incidence/severity of emergence reactions."
      },
      {
        "text": "Increase ketamine to 2 mg/kg IV to ensure deeper dissociation and provide upbeat music via headphones",
        "isCorrect": false,
        "explanation": "Higher ketamine doses increase the risk of emergence phenomena; stimulating music may exacerbate perceptual disturbances rather than prevent them."
      },
      {
        "text": "Avoid benzodiazepines to reduce respiratory depression and expedite discharge after the procedure",
        "isCorrect": false,
        "explanation": "Low‑dose benzodiazepines are effective for preventing/treating emergence reactions and have minimal respiratory impact with ketamine; rushing discharge can worsen confusion/anxiety."
      },
      {
        "text": "Administer glycopyrrolate 0.2 mg IV and place the patient near the nurses’ station for close monitoring",
        "isCorrect": false,
        "explanation": "Glycopyrrolate reduces hypersalivation but does not prevent hallucinations or dysphoria; a noisy, high‑stimulation location can worsen emergence reactions."
      },
      {
        "text": "Give naloxone 0.4 mg IV at the end of the procedure and keep the lights on to maintain orientation",
        "isCorrect": false,
        "explanation": "Naloxone reverses opioids, not ketamine effects; bright lighting and continuous stimulation may intensify emergence delirium."
      }
    ],
    "didactic": "Ketamine is an NMDA receptor antagonist that produces dissociative anesthesia with preserved airway reflexes and sympathetic tone. A well‑recognized adverse effect is **emergence phenomena** (eg, dysphoria, vivid dreams, hallucinations), more common in anxious adults and with higher doses or rapid IV administration. Prevention and treatment focus on attenuating central excitation and reducing sensory misinterpretation.\n\nThe most supported strategies are:\n- **Benzodiazepines (eg, midazolam 1–2 mg IV)** before or with ketamine to enhance GABA<sub>A</sub>–mediated inhibition, reducing the incidence and severity of emergence reactions. Small doses minimize sedation prolongation and respiratory depression, which are typically modest when combined with ketamine.\n- **Quiet, low‑stimulation recovery**: dim lights, minimal noise, calm reassurance, and gentle reorientation decrease external triggers that can amplify perceptual disturbances during emergence.\n\nIf emergence reactions occur despite prophylaxis, additional **benzodiazepine titration** is first‑line. Alternatives that can lower emergence risk include coadministration of **propofol** or **dexmedetomidine**, though these may introduce hypotension/bradycardia or deeper sedation; they are useful adjuncts but not required in most cases. Routine use of anticholinergics (eg, glycopyrrolate) addresses hypersalivation, not dysphoria. Opioid antagonists (eg, naloxone) have no role in ketamine emergence. High‑stimulation environments (bright lights, constant noise) can worsen symptoms and should be avoided.\n\nPractical approach for anxious adults receiving ketamine:\n- Preprocedure counseling to set expectations and reduce anxiety.\n- Midazolam 1–2 mg IV before ketamine, titrated to effect.\n- Maintain a calm, low‑stimulus environment during and after the procedure, with frequent, reassuring reorientation.\n\nThese measures reliably reduce emergence reactions while preserving ketamine’s favorable hemodynamic and respiratory profile (eg, stable MAP, maintained SpO<sub>2</sub>).",
    "educationalObjective": "Prevent or treat emergence reactions using benzodiazepines and a quiet recovery environment."
  },
  {
    "id": "Core.13.4.7",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Ketamine and special uses",
    "difficulty": "easy",
    "questionText": "A 5-year-old (18 kg) with mild reactive airway disease presents for closed reduction of a forearm fracture. He has rhinorrhea and copious oral secretions from a recent upper respiratory infection. The plan is brief procedural anesthesia with IV ketamine while maintaining spontaneous ventilation. Vitals: HR 132/min, BP 98/58 mmHg, SpO<sub>2</sub> 99% on room air.\n\nTo reduce the risk of ketamine-associated sialorrhea and potential laryngospasm while minimizing CNS and hemodynamic side effects, which premedication is most appropriate to administer now?",
    "answers": [
      {
        "text": "Atropine IV shortly before induction",
        "isCorrect": false,
        "explanation": "Atropine reduces secretions but is more chronotropic and crosses the BBB; in a child who is already tachycardic and receiving ketamine (sympathomimetic), it is less desirable unless bradycardia is anticipated."
      },
      {
        "text": "Glycopyrrolate IV shortly before induction",
        "isCorrect": true,
        "explanation": "Glycopyrrolate is a quaternary antimuscarinic with potent antisialagogue effects, minimal CNS penetration, and less tachycardia than atropine—ideal to blunt ketamine-induced secretions and laryngospasm risk."
      },
      {
        "text": "Diphenhydramine IV shortly before induction",
        "isCorrect": false,
        "explanation": "Diphenhydramine has weak anticholinergic properties and is not a reliable antisialagogue; its sedative effects do not address ketamine-related secretions."
      },
      {
        "text": "Scopolamine transdermal patch",
        "isCorrect": false,
        "explanation": "Scopolamine is an antisialagogue but has delayed onset (hours) and central effects (sedation, delirium), making it unsuitable for immediate premedication."
      },
      {
        "text": "Metoclopramide IV shortly before induction",
        "isCorrect": false,
        "explanation": "Metoclopramide reduces gastric volume and promotes emptying but does not meaningfully decrease salivary secretions; it provides no antisialagogue benefit here."
      }
    ],
    "didactic": "Ketamine increases salivary and tracheobronchial secretions, which can pool in the oropharynx and precipitate airway reflex stimulation and laryngospasm—particularly in children, those with recent URI, or during procedures using spontaneous ventilation. Premedication with an **antimuscarinic antisialagogue** is recommended when clinically indicated to mitigate this risk.\n\n- **Glycopyrrolate** is the preferred agent to reduce ketamine-associated sialorrhea. As a **quaternary ammonium** compound, it poorly crosses the blood–brain barrier, minimizing central effects (eg, sedation, delirium). It provides **potent antisialagogue activity** with less tachycardia than atropine, making it advantageous in patients who are already tachycardic or will receive ketamine (which increases HR and BP via sympathetic stimulation). IV onset is rapid (≈1–2 min), suitable for immediate premedication.\n- **Atropine** is effective at drying secretions but is a **tertiary amine** that can cross the BBB and is more chronotropic. It is reasonable when **bradycardia** is a major concern (eg, profound vagal stimulation), but it is less ideal when tachycardia is present or expected.\n- **Scopolamine** patch has significant central effects and a **delayed onset** (several hours), making it inappropriate for short-notice antisialagogue needs.\n- **Diphenhydramine** has weak anticholinergic activity and is unreliable for secretion control.\n- **Metoclopramide** reduces gastric volume and increases lower esophageal sphincter tone but has **no effect on salivary glands**.\n\nIn pediatric or URI patients undergoing ketamine anesthesia, premedication with IV glycopyrrolate—administered shortly before induction—reliably reduces salivary and airway secretions, thereby decreasing airway reactivity and laryngospasm without adding central toxicity or excessive tachycardia.",
    "educationalObjective": "Reduce ketamine-associated sialorrhea with anticholinergic premedication when clinically indicated."
  },
  {
    "id": "Core.13.4.8",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Ketamine and special uses",
    "difficulty": "hard",
    "questionText": "A 58-year-old woman with treatment-resistant depression maintained on intranasal esketamine (84 mg twice weekly under a REMS program) and phenelzine 45 mg daily presents 3 hours after her clinic-administered esketamine dose with acute cholecystitis requiring urgent laparoscopic cholecystectomy. She is afebrile, oriented, and mildly dissociated. Preoperative vitals: BP 168/96 mmHg, HR 102/min, SpO<sub>2</sub> 98% on room air. ECG shows sinus tachycardia; electrolytes and creatinine are normal. General anesthesia with endotracheal intubation is planned.\n\nWhich of the following intraoperative management choices is most appropriate to minimize adverse interactions related to her antidepressant therapy?",
    "answers": [
      {
        "text": "Administer meperidine 25 mg IV for analgesia and to reduce postoperative shivering",
        "isCorrect": false,
        "explanation": "Meperidine is contraindicated with MAOIs due to risk of serotonin toxicity and hyperpyrexia; safer alternatives (eg, fentanyl) should be used."
      },
      {
        "text": "Give ketamine 0.5 mg/kg IV at induction to synergize with her ongoing antidepressant regimen",
        "isCorrect": false,
        "explanation": "Additional ketamine can further increase BP/HR via sympathomimetic effects; with recent intranasal esketamine and MAOI therapy, this increases risk of hypertensive crisis and tachyarrhythmias."
      },
      {
        "text": "Hold phenelzine on the day of surgery to eliminate interaction risk",
        "isCorrect": false,
        "explanation": "Phenelzine is an irreversible MAOI; interaction risk persists for 2–3 weeks after discontinuation. Abrupt cessation provides no immediate benefit and risks psychiatric decompensation."
      },
      {
        "text": "Infiltrate the incision liberally with lidocaine 1% with epinephrine 1:100,000 to minimize bleeding",
        "isCorrect": false,
        "explanation": "Exogenous epinephrine can produce exaggerated pressor responses in MAOI-treated patients; if used, dosing should be conservative and carefully titrated."
      },
      {
        "text": "Treat hypotension with phenylephrine rather than ephedrine to avoid exaggerated catecholamine release",
        "isCorrect": true,
        "explanation": "In patients on an MAOI (phenelzine), direct-acting vasopressors (eg, phenylephrine) are preferred; indirect agents (eg, ephedrine) can cause excessive NE release and severe hypertension, which can be amplified by recent esketamine."
      }
    ],
    "didactic": "Esketamine is the S-enantiomer of ketamine approved for treatment-resistant depression (TRD) via intranasal administration in REMS-certified settings. It produces rapid antidepressant effects through NMDA receptor antagonism with downstream glutamatergic plasticity. Esketamine commonly causes transient hypertension and tachycardia (peak ≈40 minutes, typically resolving by ~4 hours), as well as sedation and dissociation requiring monitored observation after dosing.\n\nPerioperatively, anesthesia teams should anticipate sympathetic stimulation when recent esketamine dosing overlaps with surgery. Additional ketamine (even at “analgesic” doses) can further increase HR/BP. In patients concurrently taking an MAOI (eg, phenelzine), risk is amplified because MAO-A inhibition increases synaptic norepinephrine. Therefore:\n\n- Prefer **direct-acting vasopressors** (phenylephrine, norepinephrine) to treat hypotension; **avoid indirect agents** (ephedrine) that release endogenous catecholamines and can trigger exaggerated pressor responses or arrhythmias.\n- Use **short-acting, titratable antihypertensives** (eg, esmolol, nicardipine) if needed for perioperative hypertension.\n- Avoid serotonergic/monoaminergic drugs contraindicated with MAOIs (eg, **meperidine**, tramadol, dextromethorphan, methylene blue; linezolid also poses risk). Choose nonserotonergic opioids (eg, fentanyl, hydromorphone) and standard volatile/propofol-based techniques.\n- If local anesthetic with epinephrine is used, administer **small, incremental doses** with vigilant hemodynamic monitoring due to potential exaggerated responses.\n\nMost SSRIs/SNRIs are continued perioperatively; MAOI therapy need not be stopped for urgent surgery because irreversible enzyme inhibition persists 2–3 weeks and abrupt cessation risks relapse. For elective cases, scheduling procedures away from esketamine dosing sessions can reduce hemodynamic lability and dissociation. Overall, when TRD therapy includes esketamine—particularly with concurrent MAOI—tailor anesthetic plans to minimize sympathetic surges and rely on direct-acting vasoactive agents.",
    "educationalObjective": "Summarize anesthesia considerations when ketamine is used for refractory depression, including perioperative interactions."
  },
  {
    "id": "Core.13.4.9",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Ketamine and special uses",
    "difficulty": "medium",
    "questionText": "A 3-year-old boy (15 kg) with mild asthma presents for repair of a 2-cm forehead laceration. He is anxious and combative; 2 attempts at IV placement have failed. Parents strongly prefer to avoid injections. He last drank clear juice 3 hours ago. Vitals are normal. A mucosal atomizer is available, and ketamine 50 mg/mL is stocked. The repair is expected to take 10–15 minutes, and you want reliable dissociative sedation without IV access while minimizing delay. \n\nWhich ketamine dosing regimen is most appropriate for this patient?",
    "answers": [
      {
        "text": "Intramuscular ketamine 5 mg/kg",
        "isCorrect": false,
        "explanation": "Although 4–5 mg/kg IM provides reliable dissociation, it requires a painful injection, contrary to the stated constraints and likely to escalate distress."
      },
      {
        "text": "Intranasal ketamine 3 mg/kg via mucosal atomizer",
        "isCorrect": false,
        "explanation": "3 mg/kg IN may provide premedication-level sedation but is often inadequate for dissociative sedation for painful procedures, risking inadequate immobility."
      },
      {
        "text": "Intranasal ketamine 1 mg/kg divided between nares",
        "isCorrect": false,
        "explanation": "This is a subdissociative, analgesic dose and is unlikely to produce reliable procedural dissociation; the child will likely move and resist wound repair."
      },
      {
        "text": "Intranasal ketamine 5 mg/kg via mucosal atomizer",
        "isCorrect": true,
        "explanation": "IN 4–6 mg/kg achieves dissociative sedation with onset in 5–10 min. For 15 kg, 5 mg/kg = 75 mg (1.5 mL of 50 mg/mL), which can be split between nares and is within typical intranasal volume limits."
      },
      {
        "text": "Intramuscular ketamine 1 mg/kg",
        "isCorrect": false,
        "explanation": "This dose is insufficient for IM dissociative sedation and risks procedural failure; IM onset would also not offset the inadequate depth."
      }
    ],
    "didactic": "Ketamine provides dissociative sedation with preservation of airway reflexes, spontaneous ventilation, and cardiovascular stability. For pediatric procedural sedation without IV access, route and dose selection must balance reliability, onset, and practicality.\n\n- Intranasal (IN) ketamine: **4–6 mg/kg** (via mucosal atomizer) yields dissociation for brief, painful procedures. Onset 5–10 min; duration 20–30 min. Volumes >1 mL per nostril reduce absorption and increase runoff; concentration 50 mg/mL helps limit volume. In a 15-kg child, 5 mg/kg = 75 mg = 1.5 mL total (0.75 mL/nostril), within typical intranasal limits.\n- Intramuscular (IM) ketamine: **4–5 mg/kg** produces reliable dissociation with onset 3–5 min and duration 15–30 min; additional 2–3 mg/kg doses can be given if needed. IM is appropriate when IN delivery is not feasible or the required IN volume would be excessive.\n- Subdissociative dosing: IN 1–2 mg/kg or IV 0.25–0.5 mg/kg provides analgesia and mild sedation but is inadequate for immobility during painful procedures.\n\nAdverse effects include hypersalivation, nausea/vomiting, and rare laryngospasm or apnea; prepare suction and consider antiemetics. Ketamine typically increases HR and BP (beneficial in most children), and its bronchodilatory effect is favorable in asthma. Avoid or use caution in children with significant nasal obstruction (for IN route), active URI with copious secretions, or conditions where increased secretions or sympathetic stimulation is undesirable.\n\nFor a short laceration repair in an anxious child with failed IV attempts and a preference to avoid injections, **IN 5 mg/kg** provides predictable dissociation with acceptable volume and timely onset, aligning with recommended dosing ranges and the practical constraints.",
    "educationalObjective": "Use intranasal or IM ketamine for pediatric procedures and outline weight-based dosing ranges."
  },
  {
    "id": "Core.13.4.10",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Ketamine and special uses",
    "difficulty": "hard",
    "questionText": "A 68-year-old man in ICU day 2 with septic shock from cholangitis requires emergent laparotomy for source control. He is receiving norepinephrine 0.25 μg/kg/min and vasopressin 0.03 units/min; lactate is 5.2 mmol/L, urine output is minimal, and his extremities are mottled. In the OR, after preoxygenation with FiO<sub>2</sub> 1.0, his HR is 118/min and MAP is 60–65 mmHg despite pressors. A colleague suggests IV ketamine 1.5 mg/kg for “hemodynamic stability” during rapid-sequence induction.\n\nBased on his physiologic state, which immediate hemodynamic response is most likely after induction with ketamine?",
    "answers": [
      {
        "text": "Minimal change in MAP with mild tachycardia due to balanced direct and indirect effects",
        "isCorrect": false,
        "explanation": "Although ketamine can balance vasodilation and cardiac depression with sympathetic stimulation in some settings, catecholamine depletion in prolonged shock makes neutrality unlikely."
      },
      {
        "text": "Increase in MAP with reflex bradycardia from peripheral vasoconstriction",
        "isCorrect": false,
        "explanation": "Ketamine does not produce isolated peripheral vasoconstriction with reflex bradycardia; its indirect sympathomimetic effect typically raises both HR and BP when catecholamines are available."
      },
      {
        "text": "Increase in MAP and HR with higher CO from sympathetic stimulation",
        "isCorrect": false,
        "explanation": "This is the typical response to ketamine in patients with intact catecholamine stores; it reflects central sympathetic activation and inhibition of norepinephrine reuptake."
      },
      {
        "text": "Decrease in MAP and CO from unmasked direct myocardial depression in catecholamine-depleted shock",
        "isCorrect": true,
        "explanation": "In prolonged septic shock with depleted/numb catecholamine stores, ketamine’s direct negative inotropy can predominate, causing hypotension and reduced CO despite ongoing vasopressors."
      },
      {
        "text": "Acute RV failure with hypotension from marked increase in PVR",
        "isCorrect": false,
        "explanation": "Ketamine may modestly increase PVR, but abrupt RV failure is unlikely without preexisting severe pulmonary hypertension; the dominant concern here is myocardial depression in catecholamine-depleted states."
      }
    ],
    "didactic": "Ketamine is a dissociative anesthetic (NMDA receptor antagonist) that typically increases HR, MAP, and CO by stimulating the sympathetic nervous system and inhibiting norepinephrine reuptake. These **indirect sympathomimetic effects** usually make ketamine a useful induction agent in hemodynamically unstable patients (eg, trauma, hypovolemia) when endogenous catecholamine stores are intact. However, ketamine also has a **direct negative inotropic** effect on the myocardium (impaired Ca<sup>2+</sup> handling and β<sub>1</sub> receptor signaling). In patients with **catecholamine depletion or receptor downregulation**—such as prolonged septic or hemorrhagic shock, chronic critical illness on high-dose vasopressors, or prior sympatholytic therapy—the indirect stimulatory effect is blunted, unmasking ketamine’s myocardial depression and causing **hypotension with reduced CO**.\n\nClinical implications:\n- Use ketamine (eg, 0.5–1 mg/kg) for unstable patients when sympathetic reserves are likely intact; anticipate ↑HR/↑MAP.\n- In catecholamine-depleted states, expect **hypotension** after ketamine. Consider reducing the dose, co-administering a vasopressor bolus, or selecting **etomidate** (0.2–0.3 mg/kg) for more stable induction.\n- Propofol and benzodiazepines predictably lower MAP via vasodilation and myocardial depression and are poor choices in shock without aggressive pressor support.\n- Ketamine provides **bronchodilation** and preserves airway reflexes but increases myocardial O<sub>2</sub> demand; use caution in severe coronary disease.\n\nBottom line: Ketamine’s favorable hemodynamics depend on endogenous catecholamines. In **prolonged septic shock** with depleted stores or receptor desensitization, the direct myocardial depressant effect predominates, leading to **decreased MAP and CO** after induction, despite ongoing norepinephrine/vasopressin. Align induction strategy with the patient’s sympathetic reserve, not just baseline hypotension.",
    "educationalObjective": "Use ketamine for hemodynamic instability while recognizing depression may occur in catecholamine-depleted states."
  },
  {
    "id": "Core.13.5.1",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Neuromuscular blockers",
    "difficulty": "medium",
    "questionText": "A 6‑week‑old, 4‑kg term infant presents for emergent pyloromyotomy after several episodes of projectile emesis. The infant is hemodynamically stable (HR 160/min, BP 70/45 mmHg, SpO<sub>2</sub> 99% on 100% O<sub>2</sub>) with a functioning IV. To avoid succinylcholine, you plan rapid-sequence induction with propofol followed by rocuronium to achieve intubating conditions within ~60 seconds. Considering neonatal/infant pharmacokinetics and pharmacodynamics, which initial rocuronium dose is most appropriate to reliably provide rapid-onset neuromuscular blockade?",
    "answers": [
      {
        "text": "1.2 mg/kg",
        "isCorrect": true,
        "explanation": "Despite increased sensitivity to nondepolarizers, infants have a larger Vd; a higher loading dose (1.0–1.2 mg/kg) is recommended for RSI to ensure rapid onset, with anticipation of a longer duration."
      },
      {
        "text": "1.8 mg/kg",
        "isCorrect": false,
        "explanation": "This excessive dose may prolong blockade substantially in an infant without improving onset meaningfully compared with 1.0–1.2 mg/kg."
      },
      {
        "text": "0.6 mg/kg",
        "isCorrect": false,
        "explanation": "This is a common non-RSI intubating dose; in infants, larger Vd and the need for rapid onset make this dose unreliable for RSI conditions."
      },
      {
        "text": "0.9 mg/kg",
        "isCorrect": false,
        "explanation": "Although closer to an RSI dose, this may still delay onset and provide suboptimal intubating conditions compared with higher dosing used for RSI."
      },
      {
        "text": "0.3 mg/kg",
        "isCorrect": false,
        "explanation": "Near ED95 dosing will not produce rapid-onset intubating conditions in an infant; the onset will be slow and the depth insufficient for RSI."
      }
    ],
    "didactic": "Neonates and young infants differ from adults in both pharmacokinetics and pharmacodynamics of neuromuscular blockers (NMBs), and appropriate dosing requires integrating these opposing effects.\n\n- Pharmacodynamics: Infants are more sensitive to nondepolarizing NMBs at the neuromuscular junction due to immature postjunctional receptors and reduced acetylcholine release.\n- Pharmacokinetics: They have a larger extracellular fluid fraction and total body water, increasing volume of distribution (Vd), along with lower plasma protein binding and immature hepatic/renal clearance, which prolongs duration of action.\n\nFor nondepolarizers (eg, rocuronium, vecuronium, cisatracurium), the increased sensitivity would suggest a lower dose, but the larger Vd necessitates more drug per kg to promptly fill the distribution space. Clinically, the net effect is that initial intubating doses (mg/kg) in neonates/infants are similar to or slightly higher than adults to achieve timely paralysis, whereas the duration is often longer due to reduced clearance. For rapid-sequence induction, rocuronium 1.0–1.2 mg/kg is recommended to achieve rapid onset comparable to succinylcholine, recognizing that paralysis will last significantly longer than in older children or adults. Lower doses (eg, 0.6–0.9 mg/kg) risk delayed onset and suboptimal intubating conditions in this age group.\n\nIn contrast, succinylcholine requires a higher mg/kg dose in infants (typically 2 mg/kg IV; neonates may require 2–3 mg/kg) primarily due to larger Vd and lower but clinically adequate butyrylcholinesterase activity. However, risks include bradycardia (consider anticholinergic pretreatment with repeat dosing) and hyperkalemia in susceptible conditions.\n\nPractical implications:\n- Use RSI rocuronium 1.0–1.2 mg/kg in neonates/infants for rapid onset, and anticipate prolonged block.\n- Titrate maintenance carefully and use quantitative neuromuscular monitoring to avoid overdose.\n- If using succinylcholine, increase dose to 2 mg/kg IV in infants and monitor for bradycardia.",
    "educationalObjective": "Adjust dosing in neonates and infants who have differing sensitivity and volume of distribution compared with adults."
  },
  {
    "id": "Core.13.5.2",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Neuromuscular blockers",
    "difficulty": "medium",
    "questionText": "A 65-year-old man undergoes emergent laparotomy for perforated diverticulitis. He is intubated and ventilated (FiO<sub>2</sub> 0.6) for septic shock on norepinephrine 0.1 µg/kg/min. Labs show creatinine 4.2 mg/dL and total bilirubin 8.0 mg/dL. For abdominal closure and ventilator synchrony, he received vecuronium 0.1 mg/kg and has been on a vecuronium infusion at 1 µg/kg/min for 3 hours. Train-of-four at the adductor pollicis is 0/4 with a post-tetanic count of 2. The plan is to continue neuromuscular blockade for 12 hours in the ICU. Broad-spectrum antibiotics including gentamicin are planned. To minimize prolonged neuromuscular blockade in this patient, which management is best?",
    "answers": [
      {
        "text": "Plan to rely on sugammadex at the end of the infusion to prevent delayed recovery",
        "isCorrect": false,
        "explanation": "Sugammadex encapsulates vecuronium but the complex is renally excreted; severe renal failure limits its safety and predictability, making it inappropriate as a strategy to counter prolonged accumulation."
      },
      {
        "text": "Continue the vecuronium infusion unchanged because increased volume of distribution in sepsis offsets accumulation risk",
        "isCorrect": false,
        "explanation": "Sepsis may increase Vd for loading, but impaired clearance from hepatic/renal dysfunction drives accumulation; maintaining the same rate risks profound, prolonged blockade."
      },
      {
        "text": "Switch to a cisatracurium infusion (eg, 1–3 µg/kg/min) and titrate with TOF monitoring",
        "isCorrect": true,
        "explanation": "Cisatracurium undergoes organ-independent Hofmann elimination and ester hydrolysis, providing predictable offset with minimal accumulation during prolonged infusions, even in hepatic/renal failure."
      },
      {
        "text": "Reduce the vecuronium infusion to 0.3–0.5 µg/kg/min and titrate to TOF 1–2/4",
        "isCorrect": false,
        "explanation": "Lowering the rate will lessen exposure, but vecuronium and its active metabolite (3-desacetyl vecuronium) still accumulate with severe hepatic/renal dysfunction and prolonged infusion, risking delayed recovery."
      },
      {
        "text": "Switch to a rocuronium infusion (5–10 µg/kg/min) to avoid active metabolites",
        "isCorrect": false,
        "explanation": "Rocuronium lacks clinically significant active metabolites but relies on hepatic/biliary elimination and can accumulate in cholestasis; it is not organ-independent and may still prolong recovery."
      }
    ],
    "didactic": "Vecuronium is an intermediate-acting aminosteroidal neuromuscular blocker predominantly cleared by the liver with biliary excretion and partial renal elimination. It forms an active metabolite, **3-desacetyl vecuronium**, which retains substantial potency and is renally excreted. With **prolonged infusions** or **hepatic/renal dysfunction** (eg, cholestasis, acute kidney injury), both parent drug and metabolite accumulate, leading to prolonged paralysis and unpredictable recovery. Critical illness further potentiates blockade via acidosis, hypothermia, and drug interactions (eg, **aminoglycosides**, magnesium), and prolonged exposure increases risk of ICU-acquired weakness.\n\nFor patients requiring ongoing paralysis, the preferred strategy in organ dysfunction is to use **cisatracurium**, a benzylisoquinolinium agent that undergoes **organ-independent Hofmann elimination** and nonspecific ester hydrolysis. Its clearance is largely unaffected by hepatic or renal failure, allowing **predictable offset** and minimal accumulation during long infusions. Typical infusion rates are 1–3 µg/kg/min, titrated to effect with neuromuscular monitoring (eg, TOF 1–2/4 for light block or post-tetanic count 1–3 for deep block as clinically indicated).\n\nIn contrast, simply reducing a vecuronium infusion does not eliminate the accumulation risk in severe organ dysfunction, and switching to **rocuronium** does not solve the problem because rocuronium depends on hepatic/biliary elimination and can also accumulate in liver disease. Planning to rely on **sugammadex** is inadequate in severe renal impairment because the drug–complex is renally cleared, raising concerns for persistence and potential recurarization. To minimize prolonged weakness:\n\n- Prefer cisatracurium for prolonged blockade in hepatic/renal failure.\n- Titrate depth using objective monitoring and avoid unnecessary deep block.\n- Anticipate potentiation by aminoglycosides, magnesium, acidosis, and hypothermia and adjust dosing accordingly.\n- Ensure adequate sedation/analgesia whenever neuromuscular blockers are used.",
    "educationalObjective": "Anticipate vecuronium accumulation with prolonged infusions or organ dysfunction and adjust dosing."
  },
  {
    "id": "Core.13.5.3",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Neuromuscular blockers",
    "difficulty": "medium",
    "questionText": "A 65-year-old man (ICU day 5) with septic shock from perforated diverticulitis is brought for emergent laparotomy. He is on norepinephrine 0.08 μg/kg/min with MAP 64 mmHg, has moderate COPD with wheezing, and will likely require 4–6 hours of intraoperative paralysis and a postoperative infusion for lung-protective ventilation. Labs: Cr 2.6 mg/dL, AST/ALT 240/280 U/L, total bilirubin 4.8 mg/dL. You aim to avoid histamine-mediated hypotension/bronchospasm and limit accumulation of potentially neurotoxic metabolites during prolonged dosing in multiorgan failure.\n\nWhich neuromuscular blocker regimen is most appropriate?",
    "answers": [
      {
        "text": "Atracurium 0.5 mg/kg bolus, then 10 μg/kg/min infusion",
        "isCorrect": false,
        "explanation": "Atracurium causes dose/bolus-related histamine release → hypotension/bronchospasm and generates more laudanosine than cisatracurium; prolonged infusion with hepatic dysfunction increases CNS excitation risk."
      },
      {
        "text": "Vecuronium 0.1 mg/kg bolus, then 1–2 μg/kg/min infusion",
        "isCorrect": false,
        "explanation": "Vecuronium has minimal cardiovascular effects but is hepatically/renally cleared with active metabolites; accumulation is likely in this patient and offers no advantage for prolonged infusion."
      },
      {
        "text": "Mivacurium 0.2 mg/kg bolus with titrated redosing",
        "isCorrect": false,
        "explanation": "Mivacurium produces clinically significant histamine release and is short-acting with pseudocholinesterase metabolism; not ideal for prolonged paralysis or hemodynamic instability."
      },
      {
        "text": "Rocuronium 1.2 mg/kg bolus, then 8–12 μg/kg/min infusion",
        "isCorrect": false,
        "explanation": "Rocuronium is hemodynamically stable but relies on hepatic/biliary and renal clearance; prolonged infusion in multiorgan failure leads to accumulation and unpredictable recovery."
      },
      {
        "text": "Cisatracurium 0.1 mg/kg bolus, then 2–3 μg/kg/min infusion",
        "isCorrect": true,
        "explanation": "Cisatracurium has minimal histamine release, organ-independent Hofmann elimination, and produces substantially less laudanosine than atracurium—providing stable hemodynamics and predictable effect in hepatic/renal failure."
      }
    ],
    "didactic": "In hemodynamically unstable patients—especially those with reactive airways—neuromuscular blockers that trigger histamine release should be avoided because histamine can cause vasodilation, hypotension, and bronchospasm. Among benzylisoquinoliniums, **atracurium** and **mivacurium** produce clinically relevant histamine release (greatest with rapid bolus), whereas **cisatracurium** has minimal histamine effect at clinical doses.\n\nChoice of agent is also influenced by metabolism during prolonged infusions. Atracurium and cisatracurium undergo **Hofmann elimination** (nonenzymatic, pH- and temperature-dependent) and nonspecific ester hydrolysis, providing largely organ-independent termination—useful in hepatic/renal failure. However, both generate the metabolite **laudanosine**, a tertiary amine that crosses the blood–brain barrier and can cause CNS excitation/seizures at high concentrations. Atracurium produces considerably more laudanosine than equipotent cisatracurium. Laudanosine is hepatically metabolized and renally excreted; thus, concentrations rise with high infusion rates, prolonged duration, and hepatic/renal dysfunction.\n\nPractical implications:\n- Histamine release: mivacurium ≈ atracurium > cisatracurium (minimal)\n- Organ dependence: vecuronium/rocuronium depend on hepatic/renal clearance (risk accumulation); atracurium/cisatracurium are relatively organ-independent\n- Laudanosine burden: atracurium ≫ cisatracurium; none with steroidal agents (vec/roc)\n\nGiven septic shock with COPD and multiorgan failure, **cisatracurium** is preferred: it provides stable hemodynamics (minimal histamine), predictable effect despite hepatic/renal dysfunction (Hofmann elimination), and lower **laudanosine** generation than atracurium during prolonged infusions. While rocuronium/vecuronium avoid laudanosine and histamine, they accumulate in organ failure, leading to prolonged paralysis and unpredictable recovery. Mivacurium and atracurium risk histamine-mediated hypotension and bronchospasm; atracurium also carries a higher laudanosine load during extended dosing.",
    "educationalObjective": "Avoid atracurium in patients prone to histamine-mediated hypotension and recognize laudanosine concerns at high doses."
  },
  {
    "id": "Core.13.5.4",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Neuromuscular blockers",
    "difficulty": "hard",
    "questionText": "A 28-year-old man with 40% TBSA deep partial- and full-thickness flame burns sustained 10 days ago is brought to the OR from the burn ICU for emergent debridement and grafting. He is intubated but has a large gastric residual on suctioned tube feeds and you plan a true RSI after exchanging to a new endotracheal tube. Vital signs: HR 118, BP 128/68, SpO<sub>2</sub> 98% on FiO<sub>2</sub> 0.5. Labs: K<sup>+</sup> 4.3 mEq/L, creatinine 1.6 mg/dL, pH 7.28. Which neuromuscular blocker strategy is most appropriate to facilitate rapid, safe intubation in this patient?",
    "answers": [
      {
        "text": "Pretreat with rocuronium 0.03 mg/kg 3 minutes before succinylcholine 1.0 mg/kg to blunt K<sup>+</sup> rise",
        "isCorrect": false,
        "explanation": "Defasciculation reduces myalgias and fasciculations but does not prevent succinylcholine-induced hyperkalemia in receptor-upregulated states."
      },
      {
        "text": "Succinylcholine 1.5 mg/kg IV to achieve the fastest onset and offset for RSI",
        "isCorrect": false,
        "explanation": "Contraindicated 10 days after major burns due to upregulated extrajunctional ACh receptors and risk of life-threatening hyperkalemia, even with a normal baseline K<sup>+</sup>."
      },
      {
        "text": "Vecuronium 0.1 mg/kg IV to avoid prolonged paralysis in burn-associated resistance",
        "isCorrect": false,
        "explanation": "Burns cause resistance to nondepolarizers, requiring higher—not lower—doses; vecuronium also has a slower onset than RSI-dose rocuronium."
      },
      {
        "text": "Cisatracurium 0.2 mg/kg IV, allowing 2–3 minutes for onset because it is organ-independent",
        "isCorrect": false,
        "explanation": "Cisatracurium has a slower onset than rocuronium; waiting 2–3 minutes is suboptimal for RSI with high aspiration risk."
      },
      {
        "text": "Rocuronium 1.2 mg/kg IV for RSI with availability of sugammadex 16 mg/kg if cannot intubate/ventilate",
        "isCorrect": true,
        "explanation": "High-dose rocuronium provides ≈60-second onset comparable to succinylcholine and avoids burn-related hyperkalemia; sugammadex offers rescue reversal if needed."
      }
    ],
    "didactic": "Succinylcholine causes rapid depolarization of the motor endplate with transient K<sup>+</sup> efflux. In healthy muscle, the K<sup>+</sup> rise is typically ≈0.5–1.0 mEq/L. After **major burns, denervation, crush injury, neuromuscular disease, or prolonged immobilization**, muscle expresses abundant **extrajunctional nicotinic ACh receptors** (including immature subtypes), dramatically amplifying K<sup>+</sup> efflux and risking malignant hyperkalemia and arrhythmias—even when baseline serum K<sup>+</sup> is normal.\n\nTime course of succinylcholine risk:\n- **Burns** (≥8–10% TBSA): risk begins at 24–48 h, peaks around 1–2 weeks, and can persist **6–12 months** (longer with larger TBSA).\n- **Denervation** (eg, spinal cord injury, stroke with hemiplegia): begins at 24–48 h and persists **months to years**.\n- **Crush/rhabdomyolysis:** avoid immediately due to existing hyperkalemia from cell lysis; receptor upregulation then adds risk after several days.\n- **Neuromuscular diseases** (eg, Duchenne muscular dystrophy, ALS) and **critical illness myopathy/polyneuropathy:** unpredictable, potentially massive K<sup>+</sup> release—avoid succinylcholine.\n\nNondepolarizer pretreatment (defasciculation) does **not** prevent succinylcholine-induced hyperkalemia in these states. Therefore, succinylcholine is acceptable only during the early window (<24 h) after burns/denervation if no other contraindications exist.\n\nFor RSI when succinylcholine is contraindicated, **rocuronium 1.0–1.2 mg/kg** provides an onset ≈60 seconds comparable to succinylcholine. Having **sugammadex (eg, 16 mg/kg for immediate reversal)** available offers rescue in cannot-intubate/cannot-ventilate scenarios. Burn patients develop **resistance to nondepolarizers**, often requiring higher doses for adequate blockade; thus, standard or higher RSI dosing of rocuronium is appropriate. Agents with slower onset (eg, cisatracurium, vecuronium) are less suitable for true RSI in high aspiration–risk patients.",
    "educationalObjective": "Avoid succinylcholine after burns, crush, denervation, or neuromuscular disease due to hyperkalemia risk and time course."
  },
  {
    "id": "Core.13.5.5",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Neuromuscular blockers",
    "difficulty": "easy",
    "questionText": "A 35-year-old man with small-bowel obstruction undergoes rapid-sequence induction. After preoxygenation and induction with propofol, succinylcholine 1.2 mg/kg is administered. He exhibits brief generalized muscle fasciculations, and direct laryngoscopy is easily performed 45 seconds later. Peripheral nerve stimulation immediately before intubation shows decreased single-twitch height without fade on train-of-four.\n\nWhich mechanism best explains the fasciculations and phase I block observed with succinylcholine in this patient?",
    "answers": [
      {
        "text": "Blockade of presynaptic nicotinic receptors reducing acetylcholine mobilization and release, resulting in tetanic fade",
        "isCorrect": false,
        "explanation": "Presynaptic nicotinic receptor blockade accounts for fade seen with nondepolarizing agents; phase I depolarizing block shows minimal/no fade."
      },
      {
        "text": "Persistent activation of nicotinic ACh receptors at the motor end plate by an agonist not rapidly hydrolyzed by acetylcholinesterase, causing sustained end-plate depolarization and voltage-gated Na+ channel inactivation",
        "isCorrect": true,
        "explanation": "Succinylcholine is a depolarizing nicotinic agonist that keeps the end plate depolarized, producing initial fasciculations followed by flaccid paralysis due to Na+ channel inactivation (phase I)."
      },
      {
        "text": "Inhibition of plasma cholinesterase leading to accumulation of acetylcholine in the synaptic cleft and prolonged depolarization",
        "isCorrect": false,
        "explanation": "Acetylcholine is degraded by acetylcholinesterase at the synapse; plasma cholinesterase (butyrylcholinesterase) metabolizes succinylcholine in plasma. This does not explain the initial mechanism of phase I block."
      },
      {
        "text": "Upregulation of extrajunctional nicotinic receptors producing increased K+ efflux and hyperkalemia",
        "isCorrect": false,
        "explanation": "Extrajunctional receptor upregulation explains hyperkalemia risk (eg, burns, denervation) but not the basic mechanism of fasciculations and phase I block."
      },
      {
        "text": "Competitive antagonism of nicotinic ACh receptors preventing end-plate depolarization and decreasing channel opening probability",
        "isCorrect": false,
        "explanation": "This describes nondepolarizing blockade (eg, rocuronium), which does not cause fasciculations and typically produces fade on train-of-four."
      }
    ],
    "didactic": "Succinylcholine is a depolarizing neuromuscular blocker composed of two acetylcholine (ACh) molecules that acts as a full agonist at the postsynaptic nicotinic ACh receptor (nAChR) of the motor end plate. Because succinylcholine is not rapidly hydrolyzed by acetylcholinesterase in the synaptic cleft, it remains bound to nAChRs and keeps the ion channel open. This produces a persistent increase in end-plate conductance to Na+ and K+, causing an initial synchronous depolarization that manifests as visible muscle fasciculations. Continued depolarization then inactivates voltage-gated Na+ channels, preventing generation of new action potentials and resulting in flaccid paralysis: a phase I depolarizing block.\n\nCharacteristic features of a phase I block include:\n- Decreased twitch response with minimal/no fade on train-of-four and no posttetanic facilitation\n- Fasciculations at onset\n- Potentiation (not reversal) by acetylcholinesterase inhibitors (eg, neostigmine)\n\nSuccinylcholine is rapidly cleared from plasma by butyrylcholinesterase (plasma cholinesterase), not by acetylcholinesterase at the neuromuscular junction. Thus, its effect terminates via diffusion away from the synapse and plasma hydrolysis. With high doses or prolonged infusions, a transition to a phase II block can occur that resembles nondepolarizing blockade (fade, posttetanic facilitation), at which point acetylcholinesterase inhibitors may partially reverse the block.\n\nClinical implications include:\n- Defasciculation doses of a nondepolarizer can reduce fasciculations/myalgias but may require a larger succinylcholine dose to achieve rapid intubating conditions.\n- Conditions with upregulated extrajunctional nAChRs (eg, burns, denervation, prolonged immobilization) predispose to dangerous hyperkalemia from K+ efflux with succinylcholine, but this is separate from the mechanism of the phase I depolarizing block.",
    "educationalObjective": "Describe succinylcholine mechanism producing a phase I depolarizing block and fasciculations."
  },
  {
    "id": "Core.13.5.6",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Neuromuscular blockers",
    "difficulty": "medium",
    "questionText": "A 62-year-old man with decompensated cirrhosis (bilirubin 8 mg/dL, INR 2.1, tense ascites) and end-stage renal disease on hemodialysis presents with septic shock from perforated diverticulitis for emergent exploratory laparotomy. He is intubated and started on norepinephrine 0.12 μg/kg/min (MAP 58 mmHg). Core temperature is 36.6°C, pH 7.35. The surgical team anticipates a 5–6 hour case with a need for a continuous neuromuscular blocker infusion. Which neuromuscular blocker is most appropriate to provide predictable recovery independent of hepatic/renal function while minimizing hemodynamic effects?",
    "answers": [
      {
        "text": "Vecuronium",
        "isCorrect": false,
        "explanation": "Aminosteroid with hepatic metabolism and renal excretion; active metabolite (3-desacetylvecuronium) can accumulate, leading to prolonged blockade in hepatic/renal dysfunction."
      },
      {
        "text": "Pancuronium",
        "isCorrect": false,
        "explanation": "Long-acting aminosteroid that is predominantly renally eliminated and can cause vagolysis (tachycardia); clearance is organ dependent and recovery is unpredictable in ESRD."
      },
      {
        "text": "Rocuronium",
        "isCorrect": false,
        "explanation": "Aminosteroid with primarily hepatic uptake and biliary excretion (some renal); prolonged effect with liver/renal failure during infusion despite hemodynamic stability. Reversal with sugammadex is possible but does not prevent intraoperative accumulation in severe organ failure."
      },
      {
        "text": "Cisatracurium",
        "isCorrect": true,
        "explanation": "Benzylisoquinolinium predominantly cleared by organ-independent Hofmann elimination with minimal histamine release; provides stable hemodynamics and predictable recovery in combined hepatic and renal failure."
      },
      {
        "text": "Atracurium",
        "isCorrect": false,
        "explanation": "Benzylisoquinolinium with organ-independent metabolism (Hofmann elimination and nonspecific esterases) but can cause histamine release, leading to hypotension—undesirable in septic shock."
      }
    ],
    "didactic": "Nondepolarizing neuromuscular blockers fall into two structural classes with distinct metabolism and clinical profiles:\n\n- **Aminosteroids (rocuronium, vecuronium, pancuronium)**: Clearance is largely **organ dependent** (hepatic uptake/metabolism and biliary ± renal excretion). In hepatic and/or renal failure, these agents have prolonged duration, especially during continuous infusions. Vecuronium has an active metabolite (3-desacetylvecuronium) that accumulates. Pancuronium is long-acting and primarily renally eliminated with vagolytic effects (↑HR). Although rocuronium can be reversed with **sugammadex**, this does not prevent intraoperative accumulation or guarantee predictable depth during prolonged cases in multiorgan failure.\n- **Benzylisoquinoliniums (atracurium, cisatracurium, mivacurium)**: Clearance is **organ independent**. Atracurium undergoes **Hofmann elimination** (temperature and pH dependent) and nonspecific ester hydrolysis but can cause **histamine release** (hypotension, flushing) and forms **laudanosine** (CNS excitation risk at high doses). **Cisatracurium** is a stereoisomer with predominantly Hofmann elimination, **minimal histamine release**, and less laudanosine—making it preferred for hemodynamically unstable patients and those with hepatic/renal failure. Mivacurium is metabolized by **plasma cholinesterase**; while organ independent, it is short-acting and may cause histamine-mediated hypotension, and blockade is markedly prolonged in pseudocholinesterase deficiency.\n\nIn septic shock with combined liver and kidney failure, the optimal choice for a continuous infusion is **cisatracurium** due to its **organ-independent** clearance and **hemodynamic neutrality**. Atracurium shares organ independence but is less ideal when hypotension is a concern. Aminosteroids (rocuronium, vecuronium, pancuronium) are prone to accumulation and prolonged effect in this context. Careful attention to temperature and pH is prudent, as Hofmann elimination slows with hypothermia and acidosis, but at normothermia and near-normal pH, cisatracurium provides the most predictable recovery.",
    "educationalObjective": "Differentiate aminosteroid from benzylisoquinolinium nondepolarizers and match organ-dependent versus organ-independent metabolism."
  },
  {
    "id": "Core.13.5.7",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Neuromuscular blockers",
    "difficulty": "hard",
    "questionText": "A 65-year-old man undergoes shoulder arthroscopy under TIVA. For immobility, he receives repeated boluses followed by a continuous succinylcholine infusion for 45 minutes (total dose ≈300 mg). No nondepolarizing neuromuscular blocker is administered. At case end he remains apneic. Ulnar nerve stimulation shows a TOF count of 2/4 with marked fade (TOF ratio ~0.3). A 50-Hz tetanus for 5 s produces prominent fade, followed by posttetanic facilitation with transiently increased single-twitch amplitude. Which of the following best explains these findings?",
    "answers": [
      {
        "text": "Upregulation of extrajunctional nicotinic receptors (eg, burn injury) causing resistance to tetanic stimulation",
        "isCorrect": false,
        "explanation": "Extrajunctional receptor upregulation explains exaggerated K+ release and altered dose requirements for depolarizers, not the presence of TOF/tetanic fade with posttetanic facilitation."
      },
      {
        "text": "Presynaptic muscarinic M<sub>2</sub> autoreceptor inhibition reducing acetylcholine mobilization during high-frequency stimulation",
        "isCorrect": false,
        "explanation": "Fade is primarily due to blockade of presynaptic nicotinic (α<sub>3</sub>β<sub>2</sub>) receptors, not M<sub>2</sub> muscarinic autoreceptors; moreover, the clinical context points to succinylcholine phase II block."
      },
      {
        "text": "Nondepolarizing residual blockade from rocuronium administered during induction",
        "isCorrect": false,
        "explanation": "Nondepolarizers produce TOF/tetanic fade and posttetanic facilitation, but no nondepolarizer was given; the pattern here is better explained by succinylcholine-induced phase II block after prolonged exposure."
      },
      {
        "text": "Phase II block from prolonged succinylcholine exposure mimicking nondepolarizing fade",
        "isCorrect": true,
        "explanation": "After high dose or prolonged succinylcholine, the depolarizing block can transition to phase II, which exhibits TOF/tetanic fade and posttetanic facilitation, resembling a nondepolarizing block."
      },
      {
        "text": "Persistent phase I depolarizing block due to pseudocholinesterase deficiency",
        "isCorrect": false,
        "explanation": "Phase I block shows decreased but uniform twitch height with no TOF or tetanic fade and no posttetanic facilitation (TOF ratio ≈1); pseudocholinesterase deficiency prolongs this pattern rather than producing fade."
      }
    ],
    "didactic": "Monitoring patterns distinguish depolarizing from nondepolarizing block and identify succinylcholine transition to phase II. In a classic depolarizing phase I block (typical after a single succinylcholine dose):\n- Single-twitch: uniformly decreased amplitude\n- TOF and tetanus: no fade (TOF ratio ≈1)\n- Posttetanic: no facilitation\n- Mechanism: persistent end-plate depolarization keeps Na<sup>+</sup> channels inactivated; presynaptic nicotinic receptors remain functional, so ACh mobilization during repetitive stimulation is preserved.\n\nWith prolonged or high-dose succinylcholine, a **phase II** (desensitizing) block can develop:\n- TOF: fade with reduced TOF ratio\n- Tetanus: fade present\n- Posttetanic: facilitation present\n- Mechanism: junction behaves like a nondepolarizing block due to receptor desensitization and channel blockade with secondary presynaptic effects, impairing ACh mobilization during high-frequency stimulation.\n\nNondepolarizing blockers (eg, rocuronium) also show **fade** on TOF and tetanus and **posttetanic facilitation**, primarily from blockade of presynaptic nicotinic (α<sub>3</sub>β<sub>2</sub>) receptors that normally augment ACh release during rapid stimulation. Thus, the pattern cannot by itself distinguish nondepolarizer from succinylcholine phase II; the drug history is essential.\n\nPseudocholinesterase deficiency prolongs succinylcholine activity but typically maintains a **phase I** pattern (no fade) for an extended duration. Extrajunctional receptor upregulation (eg, burns, denervation) predisposes to hyperkalemia with succinylcholine but does not explain TOF/tetanic fade with posttetanic facilitation.\n\nClinical implications:\n- Phase I block is not reliably reversible with anticholinesterases and may be prolonged by them.\n- Phase II block may respond to anticholinesterases, but reversal is variable; continued ventilation and time may be required.\n- Sugammadex does not reverse succinylcholine. Careful correlation of stimulation pattern with drug exposure differentiates nondepolarizing block from succinylcholine phase II.",
    "educationalObjective": "Distinguish depolarizing from nondepolarizing block using TOF fade patterns and recognize phase II block."
  },
  {
    "id": "Core.13.5.8",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Neuromuscular blockers",
    "difficulty": "medium",
    "questionText": "A 48-year-old man (height 170 cm, weight 120 kg; BMI 42 kg/m²) with Child-Pugh B cirrhosis and mild ascites presents for emergent laparotomy after multiple episodes of bilious emesis. He is hemodynamically stable and requires rapid-sequence induction. You plan to use rocuronium for intubation and wish to achieve a rapid onset while avoiding an excessively prolonged block.\n\nWhich dosing strategy is most appropriate?",
    "answers": [
      {
        "text": "Rocuronium 1.2 mg/kg using ideal body weight",
        "isCorrect": true,
        "explanation": "For RSI, 1.0–1.2 mg/kg accelerates onset; in obesity, dosing to IBW (or LBW) limits excessive duration, and cirrhosis warrants the higher end of dosing to offset slower onset."
      },
      {
        "text": "Rocuronium 1.2 mg/kg using adjusted body weight",
        "isCorrect": false,
        "explanation": "Adjusted body weight often overestimates dose for nondepolarizers in obesity and increases risk of prolonged block, particularly with impaired hepatic clearance."
      },
      {
        "text": "Rocuronium 0.6 mg/kg using total body weight",
        "isCorrect": false,
        "explanation": "Still a sub-RSI dose with slower onset; using TBW in obesity increases total dose and risks prolonged duration without reliably achieving rapid onset."
      },
      {
        "text": "Rocuronium 0.6 mg/kg using ideal body weight",
        "isCorrect": false,
        "explanation": "0.6 mg/kg provides reliable intubating conditions for routine induction but slower onset than needed for RSI; cirrhosis can further slow onset due to increased Vd."
      },
      {
        "text": "Rocuronium 1.2 mg/kg using total body weight",
        "isCorrect": false,
        "explanation": "This achieves rapid onset but markedly overdoses an obese patient, especially with hepatic dysfunction, leading to excessively prolonged neuromuscular block."
      }
    ],
    "didactic": "Rocuronium onset is dose-dependent: higher doses speed equilibration at the neuromuscular junction and produce faster intubating conditions. For rapid-sequence induction (RSI), 1.0–1.2 mg/kg achieves conditions approaching succinylcholine within ~60 seconds. Standard 0.6 mg/kg dosing is adequate for routine induction but typically yields slower onset and less reliable conditions for true RSI.\n\nIn obesity, dosing scalars are critical. Nondepolarizing neuromuscular blockers distribute primarily into lean tissue; dosing to total body weight (TBW) disproportionately increases the delivered amount without meaningfully improving onset beyond what an RSI dose already provides, and it markedly prolongs duration. Therefore, rocuronium should be dosed to ideal body weight (IBW) or lean body weight (LBW) in obese patients. In contrast, succinylcholine is dosed to TBW due to increased pseudocholinesterase activity and extracellular fluid volume—an important comparison that highlights drug-specific pharmacology.\n\nHepatic dysfunction affects rocuronium by increasing volume of distribution and reducing clearance. Increased Vd can slow onset (lower initial plasma concentration), while reduced clearance can prolong duration. In cirrhosis, selecting the higher RSI dose (eg, 1.2 mg/kg) helps offset slower onset, but using IBW/LBW avoids excessive total dosing that would unduly prolong paralysis when clearance is impaired.\n\nPutting these principles together for an obese patient with cirrhosis requiring RSI: choose rocuronium 1.2 mg/kg based on IBW (or LBW). This balances the need for rapid onset with the risk of prolonged block. If prolonged paralysis would be particularly undesirable, ensure quantitative neuromuscular monitoring and availability of sugammadex; however, correct initial dosing and appropriate weight scalar remain the primary strategies to optimize both onset and duration.",
    "educationalObjective": "Dose rocuronium for RSI to achieve rapid onset and consider hepatic function and obesity when selecting dose."
  },
  {
    "id": "Core.13.5.9",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Neuromuscular blockers",
    "difficulty": "hard",
    "questionText": "A 28-year-old woman with severe preeclampsia on a magnesium sulfate infusion (6-g load, 2 g/h; serum Mg 5.8 mg/dL) undergoes emergent dilation and curettage under general anesthesia with sevoflurane. Induction included fentanyl, propofol, and rocuronium 0.7 mg/kg; no additional neuromuscular blocker was given. Forty-five minutes later, with end-tidal sevoflurane 1.0 MAC and core temperature 35.1°C, train-of-four shows 0/4 twitches and post-tetanic count is 0. She has normal electrolytes except mild hypocalcemia (ionized Ca 1.0 mmol/L) and moderate chronic kidney disease (Cr 2.2 mg/dL). You need timely recovery to extubate in the OR.\n\nWhich intervention will most effectively facilitate rapid recovery of neuromuscular function in this patient?",
    "answers": [
      {
        "text": "Administer calcium chloride 1 g IV",
        "isCorrect": false,
        "explanation": "Calcium can transiently antagonize magnesium’s presynaptic effect to increase ACh release, but it does not remove the competitive blocker at the receptor and will not reliably reverse a profound nondepolarizing block."
      },
      {
        "text": "Administer neostigmine 0.07 mg/kg with glycopyrrolate",
        "isCorrect": false,
        "explanation": "Anticholinesterases require partial spontaneous recovery (eg, ≥1–2 TOF twitches) and are less effective in the presence of hypermagnesemia; with 0 PTC, reversal is unreliable and may be ineffective."
      },
      {
        "text": "Discontinue the magnesium infusion and hyperventilate to ETCO₂ 25 mmHg",
        "isCorrect": false,
        "explanation": "Stopping magnesium and inducing respiratory alkalosis may modestly antagonize blockade over time, but effects are slow, unreliable, and inadequate for immediate reversal of profound block."
      },
      {
        "text": "Switch from sevoflurane to a propofol infusion",
        "isCorrect": false,
        "explanation": "Volatile anesthetics potentiate nondepolarizing blockade; switching to TIVA reduces potentiation but does not rapidly reverse a deep block and is insufficient when PTC is 0."
      },
      {
        "text": "Administer sugammadex 16 mg/kg IV",
        "isCorrect": true,
        "explanation": "Sugammadex encapsulates rocuronium independent of magnesium level, volatile anesthetic, or temperature, and 16 mg/kg is indicated for immediate reversal of profound block (0 PTC). It is the most effective and rapid option here."
      }
    ],
    "didactic": "Nondepolarizing neuromuscular blockers (NDNMBs) are competitive antagonists at the postsynaptic nicotinic receptor. Several perioperative factors can markedly potentiate or, less commonly, antagonize their effects by altering presynaptic ACh release, postsynaptic receptor sensitivity, or drug kinetics.\n\n- Magnesium inhibits presynaptic voltage-gated Ca<sup>2+</sup> channels, reducing ACh release and synergistically enhancing NDNMBs. Hypermagnesemia also blunts the efficacy of anticholinesterases (less ACh is available to accumulate), making neostigmine unreliable during deep block.\n- Volatile anesthetics (eg, sevoflurane) potentiate NDNMBs via central and peripheral mechanisms and may increase potency by ≈20%–30%.\n- Hypothermia decreases clearance and augments NDNMB effect while slowing recovery.\n\nWhen train-of-four is 0/4 and post-tetanic count (PTC) is 0 (profound block), the recommended strategy for rocuronium is sugammadex 16 mg/kg, which encapsulates free rocuronium and rapidly restores neuromuscular transmission independent of magnesium level, volatile anesthetic, acid–base status, or temperature. In contrast, neostigmine requires partial spontaneous recovery (ideally ≥1–2 twitches) and is particularly ineffective with concurrent hypermagnesemia. Calcium chloride may transiently overcome magnesium’s presynaptic effect but does not displace a competitive antagonist from the receptor and will not reliably reverse a deep block. Adjuncts like discontinuing volatiles or inducing respiratory alkalosis may modestly antagonize blockade but are too slow for immediate needs.\n\nHigh-yield interactions with NDNMBs:\n- Potentiate: magnesium, volatile anesthetics, aminoglycosides, polymyxins, local anesthetics (systemic), lithium, hypothermia, hypokalemia, hypocalcemia, acute respiratory acidosis, advanced age.\n- Antagonize/resistance: chronic anticonvulsants (phenytoin/carbamazepine), burns/denervation (upregulated ACh receptors), hypercalcemia, chronic alcoholism. \n\nFor urgent recovery from rocuronium-induced profound block, sugammadex dosing is guided by depth: 2 mg/kg (TOF 2+), 4 mg/kg (PTC 1–2), and 16 mg/kg (immediate/profound block). Monitor quantitatively and tailor therapy to the interacting factors and block depth.",
    "educationalObjective": "Identify drugs and metabolic states that potentiate or antagonize neuromuscular blockade and adjust therapy."
  },
  {
    "id": "Core.13.5.10",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Neuromuscular blockers",
    "difficulty": "medium",
    "questionText": "A 22-year-old man undergoes emergency appendectomy. Induction is with propofol and succinylcholine; anesthesia is maintained with sevoflurane in O<sub>2</sub>/air at 2 L/min fresh gas flow. Twenty minutes later, ETCO<sub>2</sub> increases rapidly from 36 to 65 mmHg despite increased V<sub>T</sub>, HR is 135/min, generalized rigidity is noted, and temperature rises from 36.9°C to 38.9°C over 10 minutes. Masseter tightness was noted after intubation. Malignant hyperthermia (MH) is suspected, sevoflurane is turned off, and the MH cart is called.\n\nIn addition to discontinuing triggering agents, which immediate action best limits ongoing exposure to triggers from the anesthesia machine while dantrolene is being prepared?",
    "answers": [
      {
        "text": "Switch to total intravenous anesthesia with propofol while maintaining the current circuit and 2 L/min flows.",
        "isCorrect": false,
        "explanation": "TIVA prevents new triggering, but residual volatile in the machine will continue to deliver trigger at low flows unless the system is purged and filtered."
      },
      {
        "text": "Replace the CO<sub>2</sub> absorbent and breathing circuit and continue ventilation with 100% O<sub>2</sub> at 2 L/min.",
        "isCorrect": false,
        "explanation": "Changing the absorbent and circuit alone does not eliminate volatile anesthetic retained within machine components, and low fresh gas flows prolong washout."
      },
      {
        "text": "Administer sodium bicarbonate and initiate external cooling prior to modifying the anesthesia machine.",
        "isCorrect": false,
        "explanation": "Acidosis correction and cooling are supportive, but stopping exposure to triggers is the priority and should occur immediately with high-flow O<sub>2</sub> and machine decontamination."
      },
      {
        "text": "Ventilate with 100% O<sub>2</sub> at ≥10 L/min and place activated charcoal filters on both inspiratory and expiratory limbs after turning vaporizers off/removed.",
        "isCorrect": true,
        "explanation": "High fresh gas flow with activated charcoal filters rapidly reduces anesthetic vapor to negligible levels within minutes, minimizing continued exposure while definitive therapy is initiated."
      },
      {
        "text": "Increase minute ventilation using N<sub>2</sub>O and air to accelerate washout of sevoflurane from the circuit.",
        "isCorrect": false,
        "explanation": "N<sub>2</sub>O is not a trigger, but 100% O<sub>2</sub> at high flow is required; adding N<sub>2</sub>O does not meaningfully hasten machine decontamination and reduces delivered O<sub>2</sub>."
      }
    ],
    "didactic": "Malignant hyperthermia (MH) is triggered by volatile anesthetics (eg, sevoflurane, desflurane, isoflurane) and succinylcholine. Intravenous agents (eg, propofol, opioids, benzodiazepines), nitrous oxide, local anesthetics, and nondepolarizing neuromuscular blockers are not triggers. Early signs include a rapid, unexplained rise in ETCO<sub>2</sub>, tachycardia, muscle rigidity (including masseter spasm), mixed respiratory/metabolic acidosis, hyperkalemia, and a temperature that may increase later.\n\nImmediate management priorities are to stop exposure and blunt the hypermetabolic crisis:\n- Discontinue all triggers (turn vaporizers off and remove them from the machine; avoid succinylcholine) and call for help/MH cart.\n- Deliver 100% O<sub>2</sub> at ≥10 L/min and hyperventilate to lower PaCO<sub>2</sub> and increase O<sub>2</sub> delivery.\n- Place activated charcoal filters on both inspiratory and expiratory limbs; with high fresh gas flows, these reduce volatile anesthetic concentrations to <5 ppm within minutes. If filters are unavailable, use a clean machine or a self-inflating bag with 100% O<sub>2</sub>; merely changing the circuit/absorbent or using low flows will not rapidly clear residual anesthetic from internal components.\n- Administer dantrolene 2.5 mg/kg IV promptly; repeat as needed to control hypermetabolism and maintain urine output. Continue with 1 mg/kg every 6 h or an infusion (eg, 0.25 mg/kg/h) for 24–48 h to prevent recrudescence.\n- Initiate active cooling if temperature >39°C, treat hyperkalemia (eg, insulin/glucose, β-agonist; avoid calcium channel blockers with dantrolene), correct acidosis, and manage arrhythmias (primarily by correcting hyperkalemia and acidosis).\n\nRapid machine decontamination with high-flow O<sub>2</sub> and charcoal filters most effectively limits continued trigger delivery while definitive therapy is prepared, improving outcomes in suspected MH.",
    "educationalObjective": "Identify malignant hyperthermia triggering agents and initiate early treatment steps when suspected."
  },
  {
    "id": "Core.13.5.11",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Neuromuscular blockers",
    "difficulty": "medium",
    "questionText": "A 27-year-old man with a penetrating open-globe injury and a presumed full stomach presents for emergent repair. Rapid-sequence induction is initiated with fentanyl, propofol, and succinylcholine 1.5 mg/kg. Immediately after succinylcholine administration and before laryngoscopy, which physiologic change is most likely to occur?",
    "answers": [
      {
        "text": "Lower incidence of postoperative myalgias compared with rocuronium",
        "isCorrect": false,
        "explanation": "Succinylcholine increases the incidence of postoperative myalgia; defasciculation or avoiding sux can reduce this risk."
      },
      {
        "text": "Decreased lower esophageal sphincter tone with increased aspiration risk",
        "isCorrect": false,
        "explanation": "Succinylcholine transiently increases intragastric pressure but also increases lower esophageal sphincter tone, so the gradient is largely unchanged and aspiration risk is not increased."
      },
      {
        "text": "Sinus tachycardia after a second bolus given within minutes",
        "isCorrect": false,
        "explanation": "Repeat dosing of succinylcholine is more commonly associated with bradycardia, especially in children, due to muscarinic stimulation."
      },
      {
        "text": "Transient increase in intraocular pressure by approximately 5–10 mmHg",
        "isCorrect": true,
        "explanation": "Succinylcholine causes fasciculations and extraocular muscle contraction, transiently increasing IOP by ~5–10 mmHg for several minutes."
      },
      {
        "text": "Persistent elevation of intracranial pressure for >30 minutes",
        "isCorrect": false,
        "explanation": "Succinylcholine may transiently increase ICP, but the effect is brief and can be blunted by adequate anesthetic depth and a defasciculating dose of a nondepolarizer."
      }
    ],
    "didactic": "Succinylcholine is a depolarizing neuromuscular blocker that agonizes nicotinic receptors, producing diffuse fasciculations followed by flaccid paralysis. The fasciculations transiently increase several compartment pressures. Most notably, succinylcholine produces a brief rise in intraocular pressure (IOP) of approximately 5–10 mmHg for several minutes, likely from extraocular muscle contraction and increased choroidal blood volume. Although controversial in open-globe injuries, this effect is short-lived and can be attenuated by a small “defasciculating” dose of a nondepolarizer (eg, rocuronium 0.03–0.06 mg/kg), adequate anesthetic depth, lidocaine, and avoidance of hypoxia/hypercarbia.\n\nSuccinylcholine can also cause a transient increase in intracranial pressure (ICP), mediated by muscle spindle afferent activity and rises in central venous pressure; this is usually brief and clinically modest with appropriate induction conditions. Intra-abdominal mechanics are similarly affected: intragastric pressure (IGP) increases transiently, but lower esophageal sphincter tone rises proportionally, so the gastroesophageal gradient is largely unchanged and aspiration risk is not increased during rapid-sequence induction.\n\nCardiovascular effects include bradycardia, especially in children and with repeat dosing, due to muscarinic stimulation; atropine pretreatment in pediatrics or minimizing repeat doses can mitigate this. Postoperative myalgia is common (eg, in young ambulatory patients) and is related to fasciculations; it can be reduced with a defasciculating dose, NSAIDs, or by using a nondepolarizer when appropriate.\n\nClinical implications: while succinylcholine provides the fastest onset for airway control (1–1.5 mg/kg), clinicians should anticipate and mitigate its adverse effects—bradycardia, myalgia, and transient increases in IOP, ICP, and IGP. In scenarios where increased IOP is particularly concerning, high-dose rocuronium (eg, 1.2 mg/kg) is a reasonable alternative if rapid conditions are required.",
    "educationalObjective": "List succinylcholine adverse effects including bradycardia, myalgia, increased IOP, and transient increases in ICP and IGP."
  },
  {
    "id": "Core.13.5.12",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Neuromuscular blockers",
    "difficulty": "hard",
    "questionText": "A 58-year-old man with severe pneumonia-related ARDS (PaO<sub>2</sub>/FiO<sub>2</sub> 90 on FiO<sub>2</sub> 0.8, PEEP 12 cm H<sub>2</sub>O, plateau 32 cm H<sub>2</sub>O) is deeply sedated (propofol 60 µg/kg/min, fentanyl 150 µg/h) but remains markedly asynchronous with the ventilator. He is on methylprednisolone 60 mg IV q6h for a presumed COPD exacerbation started on admission. Norepinephrine 0.1 µg/kg/min is running; creatinine is 2.1 mg/dL. The ICU team plans a continuous vecuronium infusion for 5 days to facilitate lung-protective ventilation. You are concerned about ICU-acquired weakness.\n\nWhich management change best reduces the risk of ICU-acquired weakness while preserving ventilator synchrony?",
    "answers": [
      {
        "text": "Escalate dexmedetomidine and propofol to avoid neuromuscular blockade while continuing methylprednisolone.",
        "isCorrect": false,
        "explanation": "Sedation alone often fails to achieve synchrony in severe ARDS and may worsen hemodynamics; ongoing steroids still promote myopathy."
      },
      {
        "text": "Switch to a cisatracurium infusion, titrate to TOF 1–2/4, plan discontinuation at ≤48 hours, and discontinue methylprednisolone absent a clear indication.",
        "isCorrect": true,
        "explanation": "Short, time-limited cisatracurium (benzylisoquinolinium; organ-independent clearance) minimizes accumulation, and avoiding concurrent corticosteroids reduces synergistic myopathy risk."
      },
      {
        "text": "Use intermittent rocuronium boluses as needed for the next 5 days while maintaining the current steroid regimen.",
        "isCorrect": false,
        "explanation": "Rocuronium is an aminosteroid; repeated boluses over days result in similar cumulative exposure and steroid synergy, increasing ICU-acquired weakness risk."
      },
      {
        "text": "Continue the vecuronium infusion for 5 days with daily TOF monitoring and reduce the steroid dose by 50%.",
        "isCorrect": false,
        "explanation": "TOF monitoring helps avoid overparalysis but prolonged aminosteroid NMBA exposure plus ongoing corticosteroids still confers high myopathy risk."
      },
      {
        "text": "Switch to a pancuronium infusion due to renal dysfunction and stop corticosteroids after extubation.",
        "isCorrect": false,
        "explanation": "Pancuronium is long-acting and renally cleared, increasing accumulation and weakness risk; delaying steroid cessation preserves harmful synergy."
      }
    ],
    "didactic": "ICU-acquired weakness (critical illness myopathy and/or polyneuropathy) manifests as diffuse flaccid weakness, impaired ventilator weaning, and prolonged rehabilitation. Key modifiable risk factors include prolonged neuromuscular blocker exposure, concomitant systemic corticosteroids (synergistic myotoxicity with aminosteroid NMBAs), sepsis/multiorgan failure, hyperglycemia, and certain antibiotics (eg, aminoglycosides).\n\nWhen neuromuscular blockade is necessary for refractory ventilator dyssynchrony or severe ARDS, prevention focuses on minimizing cumulative exposure and eliminating synergistic insults:\n- Prefer a benzylisoquinolinium agent such as cisatracurium, which undergoes Hofmann elimination and ester hydrolysis (organ-independent clearance), limiting accumulation in renal/hepatic dysfunction.\n- Use a time-limited strategy: in early severe ARDS, continuous cisatracurium for ≤48 hours can improve oxygenation and synchrony; beyond 48 hours, benefit wanes while weakness risk rises.\n- Titrate to the lowest effective depth using peripheral nerve stimulation (target TOF 1–2/4 at the adductor pollicis) and ensure adequate analgesia/sedation to avoid unnecessary paralytic dosing.\n- Avoid or discontinue systemic corticosteroids unless a clear, compelling indication exists, as corticosteroids potentiate NMBA-associated myopathy (particularly with aminosteroid NMBAs such as vecuronium and rocuronium).\n- Avoid concurrent myotoxic drugs (eg, aminoglycosides), maintain normoglycemia and electrolytes, and reassess daily for the earliest feasible discontinuation.\n\nEvidence from ARDS trials supports short-course cisatracurium to facilitate lung-protective ventilation without increasing long-term weakness, provided duration is limited and monitoring is meticulous. In contrast, prolonged infusions of aminosteroid NMBAs combined with corticosteroids markedly increase the incidence of ICU-acquired weakness. Therefore, switching to cisatracurium, capping the duration at ≤48 hours with TOF-guided titration, and stopping nonessential corticosteroids best reduces weakness risk while preserving ventilator synchrony.",
    "educationalObjective": "Prevent ICU-acquired weakness by avoiding unnecessary long-term neuromuscular blocker infusions and corticosteroid synergy."
  },
  {
    "id": "Core.13.5.13",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Neuromuscular blockers",
    "difficulty": "easy",
    "questionText": "A 62-year-old man with chronic severe aortic regurgitation presents for elective open inguinal hernia repair under general anesthesia. Medications include amlodipine and metoprolol. He is comfortable, HR 52/min, BP 150/50 mmHg with bounding pulses, and has a high-pitched, decrescendo diastolic murmur at the left sternal border. You plan IV induction with fentanyl and propofol, followed by neuromuscular blockade. Hemodynamic goals include maintaining forward flow and avoiding bradycardia.\n\nWhich neuromuscular blocker is the most appropriate to facilitate tracheal intubation while supporting these hemodynamic goals?",
    "answers": [
      {
        "text": "Cisatracurium",
        "isCorrect": false,
        "explanation": "Cisatracurium is cardiovascularly stable and organ-independent but will not counter bradycardia; maintaining a higher HR is advantageous in severe aortic regurgitation."
      },
      {
        "text": "Vecuronium",
        "isCorrect": false,
        "explanation": "Vecuronium is hemodynamically neutral and does not address this patient’s bradycardia; in severe aortic regurgitation, a higher HR is preferred to reduce diastolic regurgitation."
      },
      {
        "text": "Atracurium",
        "isCorrect": false,
        "explanation": "Atracurium can cause histamine-mediated hypotension and reflex tachycardia, which is unpredictable; intentional, controlled HR increase with pancuronium is preferred over histamine-related hemodynamic swings."
      },
      {
        "text": "Pancuronium",
        "isCorrect": true,
        "explanation": "Pancuronium’s vagolytic and mild sympathomimetic effects increase HR, which shortens diastole and reduces regurgitant volume in severe aortic regurgitation; it also counters opioid/propofol-induced bradycardia."
      },
      {
        "text": "Rocuronium",
        "isCorrect": false,
        "explanation": "Rocuronium has minimal cardiovascular effects and will not mitigate bradycardia; although useful for rapid sequence, it does not provide the beneficial HR increase desired here."
      }
    ],
    "didactic": "Pancuronium is a long-acting, aminosteroid nondepolarizing neuromuscular blocker with prominent **vagolytic** (cardiac muscarinic blockade) and mild **sympathomimetic** effects. These properties typically lead to increased HR (and sometimes modest increases in CO and BP). In specific clinical contexts, this tachycardia can be leveraged or should be avoided.\n\nIn severe **aortic regurgitation (AR)**, bradycardia prolongs diastole and increases regurgitant volume into the LV. A slightly higher HR shortens diastole, promotes forward flow, and reduces regurgitation. Pancuronium therefore can be advantageous in AR and in other settings where bradycardia is undesirable (eg, high-dose opioid induction, baseline sinus bradycardia, some pediatric cases prone to vagal responses).\n\nHowever, pancuronium’s tachycardia can be harmful when increased myocardial O<sub>2</sub> demand or reduced diastolic perfusion would worsen outcomes:\n- **Ischemic heart disease**: tachycardia increases MVO<sub>2</sub> and reduces coronary perfusion time.\n- **Severe aortic stenosis** and **hypertrophic cardiomyopathy**: tachycardia impairs diastolic filling and can precipitate ischemia or obstruction.\n- Preexisting **tachyarrhythmias** or poorly controlled **hyperthyroidism**: risk of exacerbation.\n\nComparisons:\n- **Vecuronium/rocuronium/cisatracurium**: generally hemodynamically neutral; preferred when HR should remain stable.\n- **Atracurium**: potential histamine release → hypotension and reflex tachycardia, an unreliable method to increase HR.\n\nKey takeaways: Use pancuronium when a controlled, modest increase in HR is beneficial (eg, severe AR, opioid-induced bradycardia). Avoid it when tachycardia is detrimental (eg, CAD, severe AS, HCM). Recognizing these physiology-driven targets allows selection of a neuromuscular blocker that aligns with the case’s hemodynamic goals.",
    "educationalObjective": "Recall pancuronium vagolysis and tachycardia and select cases where this property may be advantageous or harmful."
  },
  {
    "id": "Core.13.5.14",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Neuromuscular blockers",
    "difficulty": "hard",
    "questionText": "A 24-year-old man undergoes outpatient wrist fixation under general anesthesia. Rapid-sequence intubation is performed with propofol and succinylcholine 1.5 mg/kg. No additional neuromuscular blocker is administered. At the end of the 25-minute procedure, he remains flaccid and apneic with no spontaneous respirations; temperature is 36.8°C and electrolytes are normal. He requires mechanical ventilation and sedation for 2 hours until recovery. Postoperative testing shows plasma pseudocholinesterase activity 2100 U/L (reference 3500–8500) and a dibucaine number of 22. Which of the following is the most accurate interpretation and counseling for future anesthetics?",
    "answers": [
      {
        "text": "He is homozygous for an atypical pseudocholinesterase variant; avoid succinylcholine and mivacurium in the future, and expect prolonged effect of ester local anesthetics.",
        "isCorrect": true,
        "explanation": "A dibucaine number ~20–30 indicates a homozygous atypical enzyme with markedly reduced ability to hydrolyze succinylcholine; activity may be low. Management is supportive ventilation and future avoidance of succinylcholine and mivacurium; ester local anesthetics may have prolonged action."
      },
      {
        "text": "The low dibucaine number reflects an acquired pregnancy-related decrease in enzyme; succinylcholine can be used safely at a reduced dose.",
        "isCorrect": false,
        "explanation": "Acquired decreases (eg, pregnancy) lower activity but the dibucaine number remains normal (~70–80). A dibucaine number of 22 indicates a genetic variant, not a physiologic pregnancy effect."
      },
      {
        "text": "Enzyme function is normal; the prolonged blockade is most consistent with unrecognized hypothermia and will be prevented by active warming.",
        "isCorrect": false,
        "explanation": "Both the low activity and very low dibucaine number indicate a pseudocholinesterase abnormality, not hypothermia; temperature was normal."
      },
      {
        "text": "He is heterozygous for an atypical pseudocholinesterase variant; future succinylcholine blockade will be only minimally prolonged.",
        "isCorrect": false,
        "explanation": "Heterozygotes typically have a dibucaine number ~50–60 with modest prolongation. A dibucaine number of 22 is consistent with homozygosity and marked prolongation."
      },
      {
        "text": "The pattern reflects reduced enzyme activity with a normal genetic variant; pretreatment with anticholinesterase (eg, neostigmine) would mitigate future prolonged paralysis.",
        "isCorrect": false,
        "explanation": "Low activity with a normal dibucaine number suggests acquired deficiency, not seen here. Anticholinesterases inhibit pseudocholinesterase and can prolong succinylcholine block."
      }
    ],
    "didactic": "Succinylcholine is rapidly hydrolyzed in plasma by butyrylcholinesterase (pseudocholinesterase). Genetic variants of this enzyme markedly reduce succinylcholine metabolism, converting a brief depolarizing block into prolonged apnea. The dibucaine number is the percent inhibition of pseudocholinesterase activity by the local anesthetic dibucaine and reflects enzyme quality (genotype), whereas the activity level (U/L) reflects enzyme quantity.\n\n- Normal dibucaine number: ~70–80; normal or decreased activity depending on physiologic state\n- Heterozygous atypical variant: dibucaine number ~50–60; modest prolongation of block\n- Homozygous atypical variant: dibucaine number ~20–30; marked prolongation (often >1 hour) after standard succinylcholine dosing\n\nAcquired reductions in enzyme quantity (eg, pregnancy, liver disease, malnutrition, burns, malignancy) lower activity but leave the dibucaine number normal, because the enzyme’s structure is unchanged. In contrast, a very low dibucaine number (eg, 22) indicates an atypical enzyme incapable of normal succinylcholine hydrolysis, explaining prolonged apnea even when the measured activity is only moderately reduced.\n\nManagement of prolonged succinylcholine effect is supportive: maintain sedation and mechanical ventilation until spontaneous recovery. Anticholinesterases (eg, neostigmine) inhibit pseudocholinesterase and can worsen or prolong depolarizing block; they are not indicated. Fresh frozen plasma provides pseudocholinesterase but is rarely necessary if ventilation can be maintained safely.\n\nFor future anesthetics, avoid agents dependent on plasma pseudocholinesterase: succinylcholine and mivacurium. Ester local anesthetics (eg, procaine, chloroprocaine, tetracaine) may have prolonged effects. Alternative strategies include nondepolarizing neuromuscular blockers (eg, rocuronium with sugammadex) for rapid-sequence intubation. Patients should be counseled and the diagnosis documented; family members may consider testing given the inherited nature of the defect.",
    "educationalObjective": "Recognize pseudocholinesterase deficiency causing prolonged apnea and interpret the dibucaine number."
  },
  {
    "id": "Core.13.6.1",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Opioids and antagonists",
    "difficulty": "medium",
    "questionText": "A 55-year-old man with chronic low back pain takes oxycodone controlled-release 40 mg every 12 h and oxycodone 5 mg every 4 h as needed (uses ~4/day). He undergoes open sigmoid colectomy under general anesthesia. He was NPO after midnight and missed his morning dose. Intraoperatively he received fentanyl 250 mcg and hydromorphone 1 mg. In the PACU 1 h after extubation, he reports pain 9/10 with BP 165/90 mmHg, HR 105/min, RR 16/min, SpO<sub>2</sub> 95% on 2 L/min nasal cannula. Creatinine is normal and there is no concern for bleeding.\n\nWhich postoperative analgesic strategy is most appropriate to address opioid tolerance and physical dependence while optimizing pain control?",
    "answers": [
      {
        "text": "Start dexmedetomidine infusion 0.7 mcg/kg/h and defer opioids for 12–24 h to minimize tolerance and hyperalgesia.",
        "isCorrect": false,
        "explanation": "Dexmedetomidine is an adjunct; withholding opioids does not \"reset\" tolerance and may precipitate withdrawal with inadequate analgesia."
      },
      {
        "text": "Start a low-dose naloxone infusion (0.25 mcg/kg/h) to reverse tolerance while running fentanyl 25 mcg/h with no demand dosing.",
        "isCorrect": false,
        "explanation": "Naloxone antagonizes µ-agonists and can worsen pain or precipitate withdrawal; a basal-only fentanyl infusion without patient-controlled dosing is unsafe and insufficient."
      },
      {
        "text": "Start standard opioid-naive PCA: morphine 1 mg demand, 8-min lockout, no basal infusion; withhold home opioids until oral intake resumes.",
        "isCorrect": false,
        "explanation": "This under-treats a tolerant patient and omitting a baseline opioid risks withdrawal; opioid-naive PCA settings without a basal are typically insufficient for established dependence."
      },
      {
        "text": "Initiate hydromorphone PCA with a basal infusion approximating his converted home requirement reduced for incomplete cross-tolerance, add demand boluses, and schedule acetaminophen and ketorolac absent contraindications.",
        "isCorrect": true,
        "explanation": "Converting his home opioid to an IV basal (with 25–50% reduction for incomplete cross-tolerance) prevents withdrawal and addresses tolerance; PCA demand dosing plus multimodal analgesia improves pain control and reduces additional opioid needs."
      },
      {
        "text": "Begin ketamine infusion 0.3 mg/kg/h as the sole analgesic to avoid escalating opioids; use nalbuphine PRN for breakthrough pain.",
        "isCorrect": false,
        "explanation": "Ketamine is an adjunct, not a sole agent for major postoperative pain, and nalbuphine (mixed agonist–antagonist) can precipitate withdrawal in patients on full µ-agonists."
      }
    ],
    "didactic": "Patients with chronic opioid therapy exhibit both **tolerance** (reduced analgesic effect requiring higher doses) and **physical dependence** (withdrawal if baseline opioid is withheld). Perioperative management should 1) continue the patient’s baseline opioid (or provide an equivalent parenteral dose if NPO) to prevent withdrawal and 2) layer on additional analgesia for surgical pain using **multimodal** strategies.\n\nA practical approach is a PCA that includes a **basal infusion** for opioid-tolerant patients, plus patient-initiated boluses. When converting between opioids, use **equianalgesic dosing** and account for **incomplete cross-tolerance** by reducing the calculated dose of the new opioid by 25–50% to improve safety.\n\nExample conversion from this vignette:\n- Home oxycodone: 40 mg q12 h + 5 mg × 4/day ≈ 100 mg/day.\n- Oxycodone PO to morphine PO ≈ 1:1.5 → 100 mg oxycodone ≈ 150 mg morphine (oral) per 24 h.\n- Morphine PO to morphine IV ≈ 3:1 → 150 mg PO morphine ≈ 50 mg IV morphine per 24 h.\n- Morphine IV to hydromorphone IV ≈ 10:1.5 → 50 mg IV morphine ≈ 7.5 mg IV hydromorphone per 24 h.\n- Apply 25–50% reduction for incomplete cross-tolerance → basal ≈ 4–6 mg/24 h (eg, ~0.2 mg/h), with PCA demand doses (eg, 0.2 mg q8–10 min) and reasonable hourly limits.\n\nEnhance analgesia and reduce opioid requirements with scheduled **acetaminophen** and an **NSAID** (if renal function and bleeding risk allow), and consider **regional anesthesia**, **ketamine** (NMDA antagonism), **α<sub>2</sub>-agonists** (dexmedetomidine/clonidine), and cautiously selected **gabapentinoids**. Avoid **mixed agonist–antagonists** (eg, nalbuphine, butorphanol) and **partial agonists** in patients on full µ-agonists, as they can precipitate withdrawal. Low-dose naloxone infusions may have niche roles (eg, pruritus), but they are not used to “reverse tolerance” in the immediate postoperative pain setting.",
    "educationalObjective": "Address opioid tolerance and dependence by escalating baseline doses and emphasizing multimodal analgesia."
  },
  {
    "id": "Core.13.6.2",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Opioids and antagonists",
    "difficulty": "medium",
    "questionText": "A 65-year-old opioid-naïve man with stage 5 chronic kidney disease (eGFR 12 mL/min/1.73 m<sup>2</sup>), obesity (BMI 34), and obstructive sleep apnea undergoes open inguinal hernia repair under general anesthesia. Postoperatively, you plan to use IV morphine for analgesia. Vitals are stable and he is breathing room air comfortably in the PACU. Which morphine dosing strategy is most appropriate to provide analgesia while minimizing the risk of delayed respiratory depression?",
    "answers": [
      {
        "text": "Maintain standard morphine dosing and schedule hemodialysis within 24 h to clear morphine-6-glucuronide",
        "isCorrect": false,
        "explanation": "Dialysis is unreliable for preventing or reversing CNS opioid effects because metabolites redistribute slowly from the CNS; prevention via dose/interval adjustment is preferred."
      },
      {
        "text": "Use usual dosing (eg, 0.1 mg/kg IV boluses or standard PCA settings) with typical lockout interval",
        "isCorrect": false,
        "explanation": "Normal dosing risks accumulation of renally excreted active metabolites (especially morphine-6-glucuronide), leading to delayed and prolonged respiratory depression in advanced CKD."
      },
      {
        "text": "Increase morphine dosing by 25%–50% to offset decreased protein binding in uremia and maintain efficacy",
        "isCorrect": false,
        "explanation": "Uremia may decrease protein binding, increasing free drug and clinical effect; clearance of active metabolites is reduced, so higher dosing increases toxicity risk."
      },
      {
        "text": "Reduce each morphine dose by ~50% and extend the dosing/lockout interval (avoid any PCA basal infusion), titrating to effect with close monitoring",
        "isCorrect": true,
        "explanation": "Renal failure markedly prolongs elimination of active metabolites; reducing the dose and lengthening the interval (and avoiding a basal rate) mitigates accumulation and delayed toxicity while preserving titratable analgesia."
      },
      {
        "text": "Substitute hydromorphone at equianalgesic doses because it lacks active metabolites and is unaffected by renal failure",
        "isCorrect": false,
        "explanation": "Hydromorphone’s 3-glucuronide metabolite accumulates in renal failure and can cause neurotoxicity; it is not metabolite-free nor unaffected by CKD."
      }
    ],
    "didactic": "Morphine undergoes hepatic glucuronidation to morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). M6G is a potent μ-agonist with analgesic and respiratory depressant effects; both M3G and M6G are renally eliminated. In advanced CKD, these metabolites accumulate and have markedly prolonged elimination, leading to delayed-onset and prolonged sedation/respiratory depression that can emerge hours after dosing stops. M6G equilibrates slowly across the blood–brain barrier, so the clinical effect may rise even as plasma levels fall.\n\nAccordingly, morphine dosing must be conservatively titrated in renal failure by reducing each dose and extending the dosing interval to minimize metabolite buildup. For PCA, avoid basal infusions and use demand-only dosing with a longer lockout. Close monitoring is essential, particularly in patients with obstructive sleep apnea and obesity who are more vulnerable to opioid-induced ventilatory impairment.\n\nKey points:\n- **Problem:** Renal failure → accumulation of active M6G (and M3G) → delayed, prolonged opioid effect and respiratory depression.\n- **Strategy:** Reduce morphine dose (eg, ~25%–50%) and lengthen interval/lockout; avoid basal PCA; titrate to effect.\n- **Dialysis:** Although M6G is dialyzable, clinical reversal is unreliable because of slow CNS egress and postdialysis rebound; prevention is superior to treatment.\n- **Alternatives:** Fentanyl and remifentanil lack active renally cleared metabolites and are preferred when feasible. Hydromorphone can be used cautiously but its H3G metabolite may accumulate and cause neuroexcitation; meperidine is contraindicated due to normeperidine accumulation and seizures.\n\nProper dose adjustment of morphine in CKD balances analgesia with safety by limiting metabolite accumulation and anticipating delayed effects.",
    "educationalObjective": "Adjust dosing of morphine in renal failure due to active metabolite accumulation and prolonged effect."
  },
  {
    "id": "Core.13.6.3",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Opioids and antagonists",
    "difficulty": "hard",
    "questionText": "A 64-year-old man (BMI 36) with well-controlled OSA and HTN is undergoing a 4-hour laparoscopic colectomy under general anesthesia. The surgeon requests very stable hemodynamics during pneumoperitoneum. You plan to extubate in the OR within 10 minutes of skin closure while avoiding severe rebound pain in PACU. Hepatic and renal function are normal. Which intraoperative opioid strategy is most likely to achieve rapid emergence with adequate early postoperative analgesia?",
    "answers": [
      {
        "text": "Fentanyl infusion 2 mcg/kg/h for the entire case, stopped at skin closure; no additional opioids",
        "isCorrect": false,
        "explanation": "Fentanyl has a context-sensitive half-time (CSHT) that increases markedly with infusion duration and is prolonged further by obesity, making rapid, predictable emergence unlikely."
      },
      {
        "text": "Remifentanil infusion 0.05 mcg/kg/min until extubation plus hydromorphone 0.02 mg/kg IV given 20–30 minutes before the end of surgery",
        "isCorrect": true,
        "explanation": "Remifentanil’s duration-independent, ultra-short CSHT supports rapid emergence, while timed hydromorphone provides early postoperative analgesia and mitigates remifentanil-associated rebound pain without substantially delaying extubation."
      },
      {
        "text": "Remifentanil infusion 0.1 mcg/kg/min for most of the case, then switch to fentanyl 2 mcg/kg IV every 10 minutes during the last 30 minutes to bridge analgesia",
        "isCorrect": false,
        "explanation": "“Bridging” with fentanyl near the end accumulates and yields a long, duration-dependent CSHT, especially in obesity, making emergence unpredictable and potentially delayed."
      },
      {
        "text": "Remifentanil infusion 0.1 mcg/kg/min until dressings are applied; no additional opioids",
        "isCorrect": false,
        "explanation": "Remifentanil allows the fastest wake-up because its CSHT is essentially independent of infusion duration, but stopping without a bridge often causes severe rebound pain and possible hyperalgesia."
      },
      {
        "text": "Sufentanil infusion 0.3 mcg/kg/h for the entire case, stopped at skin closure; no additional opioids",
        "isCorrect": false,
        "explanation": "Sufentanil’s CSHT increases with infusion duration (less than fentanyl but still substantial after hours), risking delayed extubation and residual respiratory depression without a bridging plan."
      }
    ],
    "didactic": "Context-sensitive half-time (CSHT) is the time for plasma concentration to decrease by 50% after stopping an infusion; unlike elimination half-life, CSHT depends on infusion duration due to redistribution into peripheral compartments. For highly lipophilic opioids, longer infusions saturate tissues, so elimination rather than redistribution governs offset, prolonging recovery.\n\nAmong commonly used intraoperative opioids, the relative CSHT after prolonged infusion is: remifentanil ≪ sufentanil < fentanyl. \n\n- Fentanyl: Very lipophilic with a large volume of distribution; CSHT rises steeply with infusion duration. Obesity further expands peripheral compartments, prolonging emergence and respiratory depression. \n- Sufentanil: Also lipophilic and potent; CSHT increases with duration but is generally shorter than fentanyl because less total drug is required and clearance is high. After hours-long infusions, recovery can still be delayed. \n- Remifentanil: Metabolized rapidly by nonspecific tissue/plasma esterases (not dependent on hepatic or renal function). Its CSHT remains essentially constant (~3–5 minutes) regardless of infusion length, enabling highly predictable, rapid wake-up and extubation.\n\nRelying on remifentanil alone often leads to abrupt loss of analgesia, sympathetic surges, and opioid-induced hyperalgesia (OIH). A best-practice strategy is to continue remifentanil through closure and administer a longer-acting opioid 10–30 minutes before emergence (eg, hydromorphone 0.01–0.02 mg/kg or low-dose fentanyl) and/or multimodal adjuncts (acetaminophen, NSAIDs, ketamine). This timing allows the bridging opioid’s effect-site concentration to rise as remifentanil clears, providing analgesia without materially delaying extubation. In contrast, giving substantial fentanyl during the last 30 minutes of a long case undermines the advantage of remifentanil because fentanyl’s CSHT becomes long and unpredictable, especially in obese patients.\n\nKey implications: use remifentanil for intraoperative control when rapid emergence is needed; always plan a bridge for postoperative analgesia; avoid late high-dose fentanyl or sufentanil if immediate extubation is the goal.",
    "educationalObjective": "Compare fentanyl, sufentanil, and remifentanil using context-sensitive half-time and implications for emergence."
  },
  {
    "id": "Core.13.6.4",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Opioids and antagonists",
    "difficulty": "easy",
    "questionText": "A 72-year-old man with stage 4 chronic kidney disease (eGFR 22 mL/min/1.73 m²), obstructive sleep apnea on home CPAP, and hypertension undergoes open inguinal hernia repair under general anesthesia. In the PACU, he is awake, hemodynamically stable, and has SpO<sub>2</sub> 96% on 2 L/min O<sub>2</sub> by nasal cannula. He reports 8/10 incisional pain after receiving acetaminophen; NSAIDs are being avoided. You plan a single IV opioid dose that provides meaningful relief within ~5–10 minutes and several hours of analgesia while minimizing risk from renally cleared active metabolites.\n\nWhich option is the most appropriate, and what onset/duration should you anticipate?",
    "answers": [
      {
        "text": "Meperidine 25 mg IV; onset ≈5 min; duration ≈3–4 h; minimal renal accumulation",
        "isCorrect": false,
        "explanation": "Meperidine’s metabolite (normeperidine) accumulates in renal failure and is neurotoxic (tremor, seizures); it is not appropriate for CKD analgesia."
      },
      {
        "text": "Morphine 4 mg IV; onset <2 min; duration 1–2 h",
        "isCorrect": false,
        "explanation": "Morphine has a slower onset (≈5–10 min) and longer duration (≈3–4 h) than listed; its active metabolite (M6G) accumulates in renal failure and can cause delayed respiratory depression."
      },
      {
        "text": "Morphine 4 mg IV; onset 5–10 min; duration 4–6 h; safe in renal impairment",
        "isCorrect": false,
        "explanation": "Although the onset is reasonable, morphine is not preferred in CKD due to M6G accumulation, which increases risk of prolonged sedation and respiratory depression."
      },
      {
        "text": "Hydromorphone 2 mg IV; onset 20–30 min; duration ≈12 h",
        "isCorrect": false,
        "explanation": "Dose is excessive for an opioid-naïve older patient with OSA and CKD; onset is not this slow, and duration is overstated, increasing risk of oversedation."
      },
      {
        "text": "Hydromorphone 0.2 mg IV, titrate by 0.2 mg every 3–5 min to effect; onset ≈5 min; duration ≈3–4 h",
        "isCorrect": true,
        "explanation": "Hydromorphone provides similar onset and duration to morphine but lacks a potent renally cleared analgesic metabolite like M6G, making it generally preferable in CKD (though H3G can still accumulate at severe impairment)."
      }
    ],
    "didactic": "Morphine and hydromorphone are both phenanthrene opioids with similar IV onset (≈5–10 minutes to meaningful analgesia) and clinical duration (≈3–4 hours), but they differ importantly in metabolite profiles relevant to renal dysfunction. Morphine undergoes hepatic glucuronidation to morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). M6G is an active analgesic with potency comparable to or greater than morphine and is renally eliminated. In chronic kidney disease, M6G accumulates, crosses the blood–brain barrier slowly, and can produce delayed, prolonged respiratory depression hours after dosing. M3G lacks analgesic effect and may contribute to neuroexcitation at high concentrations.\n\nHydromorphone is glucuronidated to hydromorphone-3-glucuronide (H3G), which has no meaningful analgesic activity but can be neuroexcitatory at very high levels; importantly, hydromorphone does not produce a potent active analgesic metabolite like M6G. Thus, while caution and dose reduction are still prudent in severe renal impairment, hydromorphone is generally preferred over morphine for IV analgesia in CKD to reduce the risk of prolonged respiratory depression from active metabolite accumulation.\n\nTypical PACU titration uses small increments: hydromorphone 0.2–0.4 mg IV every 3–5 minutes to effect (versus morphine 1–2 mg IV increments). Expect onset ≈5 minutes and duration ≈3–4 hours for either drug, with hydromorphone offering similar time course but a safer metabolite profile in renal disease. By contrast, fentanyl provides faster onset (1–2 minutes) but a much shorter duration (30–60 minutes), limiting its utility for longer coverage without infusion. Meperidine should be avoided in CKD due to accumulation of the neurotoxic metabolite normeperidine.\n\n- Key implications in CKD: prefer hydromorphone over morphine; use cautious, incremental dosing; monitor closely for delayed respiratory depression, especially in older patients and those with OSA.",
    "educationalObjective": "Differentiate hydromorphone from morphine in onset and duration and consider renal function in selection."
  },
  {
    "id": "Core.13.6.5",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Opioids and antagonists",
    "difficulty": "medium",
    "questionText": "A 58-year-old man with Child-Pugh B cirrhosis and end-stage renal disease (on intermittent hemodialysis) undergoes a 6-hour laparoscopic colectomy under general anesthesia with sevoflurane and a remifentanil infusion at 0.15 µg/kg/min. At skin closure, the remifentanil infusion is stopped; within a few minutes he follows commands and maintains ventilation without assistance. The team plans extubation in the operating room.\n\nWhich explanation best accounts for the rapid offset of remifentanil’s effect after a prolonged infusion in this patient?",
    "answers": [
      {
        "text": "Its high lipophilicity and large volume of distribution enable rapid redistribution out of the effect site once the infusion stops.",
        "isCorrect": false,
        "explanation": "Termination of remifentanil’s effect is not redistribution-limited; rapid metabolism, not lipophilicity or large Vd, explains its quick offset."
      },
      {
        "text": "It undergoes extensive CYP3A4 hepatic metabolism with high extraction, producing a short elimination half-life regardless of infusion duration.",
        "isCorrect": false,
        "explanation": "Remifentanil clearance is not hepatic; reliance on CYP metabolism would make offset sensitive to liver blood flow/function and infusion duration."
      },
      {
        "text": "Its inactive metabolite is renally eliminated without accumulation, so renal failure does not alter effect-site washout.",
        "isCorrect": false,
        "explanation": "Although the metabolite is inactive, some accumulation can occur in renal failure; rapid offset is due to esterase hydrolysis, not renal elimination."
      },
      {
        "text": "It is metabolized by plasma pseudocholinesterase, producing quick clearance unless the patient has enzyme deficiency.",
        "isCorrect": false,
        "explanation": "Pseudocholinesterase (butyrylcholinesterase) does not metabolize remifentanil; confusing it with succinylcholine/mivacurium leads to this misconception."
      },
      {
        "text": "It is rapidly hydrolyzed by nonspecific blood and tissue esterases, yielding a context-sensitive half-time of ≈3–5 minutes independent of infusion duration.",
        "isCorrect": true,
        "explanation": "Remifentanil undergoes organ-independent hydrolysis by nonspecific esterases, so its context-sensitive half-time remains short (≈3–5 min) regardless of infusion length or hepatic/renal dysfunction."
      }
    ],
    "didactic": "Remifentanil is a uniquely short-acting μ-agonist because its ester linkage is cleaved by **nonspecific blood and tissue esterases** (including red blood cell esterases), producing rapid, organ-independent clearance. Unlike fentanyl or sufentanil, whose termination after infusion increasingly depends on redistribution and slower hepatic/renal clearance, remifentanil’s **context-sensitive half-time remains ≈3–5 minutes** even after many hours of infusion. This property allows predictable, rapid emergence and facilitates on-time extubation despite prolonged cases or significant hepatic/renal dysfunction.\n\nKey contrasts:\n- **Metabolism**: Remifentanil → nonspecific esterases; Fentanyl/Sufentanil → hepatic metabolism (CYP3A4) with context-sensitive half-times that increase with infusion duration.\n- **Organ dependence**: Remifentanil clearance is largely independent of hepatic and renal function. In contrast, other opioids’ clearance is reduced in organ dysfunction, prolonging effect.\n- **Pseudocholinesterase**: Not required for remifentanil metabolism; deficiency does not prolong remifentanil (in contrast to succinylcholine/mivacurium).\n- **Metabolite**: The primary remifentanil metabolite has extremely low μ activity (~1/4600 potency). It may accumulate in renal failure but is **clinically insignificant** for respiratory depression.\n\nClinical implications:\n- Expect rapid offset regardless of infusion duration; plan to transition to longer-acting analgesia before stopping the infusion to prevent acute pain upon emergence.\n- Be aware of potential **acute opioid tolerance and hyperalgesia** after high-dose/prolonged remifentanil infusions; consider multimodal strategies (eg, ketamine, acetaminophen, regional anesthesia) to mitigate rebound pain.\n\nBottom line: Remifentanil’s rapid hydrolysis by nonspecific esterases, not redistribution or organ clearance, explains its consistently short context-sensitive half-time and rapid recovery after prolonged infusion.",
    "educationalObjective": "Explain remifentanil metabolism by nonspecific esterases and its rapid offset regardless of infusion duration."
  },
  {
    "id": "Core.13.6.6",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Opioids and antagonists",
    "difficulty": "medium",
    "questionText": "A 72-year-old man with septic shock (MAP 58 mmHg on norepinephrine 0.1 μg/kg/min) undergoes emergent laparotomy. After etomidate and rocuronium induction, he is intubated and ventilated with FiO<sub>2</sub> 0.6. In the ED he received 10 mg IV morphine, after which he developed flushing, diffuse pruritus, and a transient MAP drop to 48 mmHg that improved with fluids and vasopressor uptitration. He has moderate asthma and no history of true drug allergies.\n\nWhich opioid is most appropriate now to provide titratable analgesia while minimizing histamine-mediated hypotension and pruritus?",
    "answers": [
      {
        "text": "Codeine",
        "isCorrect": false,
        "explanation": "Codeine can cause histamine-mediated flushing/pruritus and is not appropriate for IV intraoperative use; it would not mitigate hypotension risk in this setting."
      },
      {
        "text": "Fentanyl",
        "isCorrect": true,
        "explanation": "Fentanyl (and other fentanyl congeners) produces minimal histamine release, making it hemodynamically stable and easily titratable for analgesia in unstable patients."
      },
      {
        "text": "Hydromorphone",
        "isCorrect": false,
        "explanation": "Hydromorphone has minimal histamine release compared with morphine but has slower onset and longer duration, making it less titratable in acute instability than fentanyl."
      },
      {
        "text": "Meperidine",
        "isCorrect": false,
        "explanation": "Meperidine also releases histamine and can worsen hypotension and pruritus; its neurotoxic metabolite (normeperidine) further limits use, especially in critical illness."
      },
      {
        "text": "Morphine",
        "isCorrect": false,
        "explanation": "Morphine causes direct mast cell degranulation with significant histamine release, leading to vasodilation, hypotension, flushing, and pruritus—undesirable in hemodynamic instability."
      }
    ],
    "didactic": "Certain opioids cause non–IgE-mediated histamine release via direct mast cell degranulation, producing vasodilation, hypotension, flushing, and pruritus, and potentially bronchospasm in reactive airways. The risk is amplified by large or rapid IV boluses and underlying vasodilation (eg, sepsis, neuraxial sympathectomy). In hemodynamically unstable patients, avoiding histamine-releasing opioids is critical.\n\n- Histamine-releasing opioids: **morphine** and **meperidine** (and to a lesser extent codeine). Expect hypotension and pruritus; bronchospasm may occur in susceptible patients (eg, asthma).\n- Minimal histamine release: **fentanyl, sufentanil, alfentanil, remifentanil**, and generally **hydromorphone**. These are preferred when hypotension or pruritus would be problematic.\n\nFentanyl is ideal for intraoperative titration in shock because it is potent, rapid in onset, and hemodynamically neutral with negligible histamine release. Hydromorphone also has low histamine release but has slower onset and longer duration, making it less adaptable during rapidly changing physiology. Meperidine, in addition to histamine effects, has the neurotoxic metabolite normeperidine that can accumulate in critical illness and renal dysfunction.\n\nDistinguish histamine-mediated reactions (flushing, pruritus, hypotension) from true IgE-mediated allergy (urticaria with bronchospasm/hypotension and possible angioedema/anaphylaxis). Most “opioid allergies” are histamine-driven intolerance rather than true allergy. Slower administration, dose reduction, or premedication with H<sub>1</sub>/H<sub>2</sub> blockers may blunt histamine effects, but selecting a non–histamine-releasing opioid is usually safer.\n\nNeuraxial morphine–induced pruritus is primarily a central μ-receptor effect (not histamine), often improved by low-dose naloxone or mixed agonist-antagonists (eg, nalbuphine). However, with IV morphine or meperidine, anticipate histamine-mediated hypotension and pruritus—choose fentanyl congeners to minimize these effects.",
    "educationalObjective": "Identify histamine-releasing opioids and anticipate hypotension and pruritus with morphine and meperidine."
  },
  {
    "id": "Core.13.6.7",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Opioids and antagonists",
    "difficulty": "medium",
    "questionText": "A 28-year-old G2P1 at 39 weeks in active labor presents with severe pain. Platelets are 58,000/μL from preeclampsia, and neuraxial analgesia is deferred. Cervix is 9 cm, station +1, with expected vaginal delivery in ~20 minutes; fetal tracing is reassuring. She requests immediate pain relief. SpO<sub>2</sub> is 99% on room air, and she has no history of substance use.\n\nWhich of the following is the most appropriate intrapartum analgesic strategy to provide effective pain control now while minimizing neonatal respiratory depression, including an appropriate neonatal plan at delivery?",
    "answers": [
      {
        "text": "Administer IV fentanyl 100 μg now and ask pediatrics to have naloxone ready for the newborn.",
        "isCorrect": false,
        "explanation": "Fentanyl crosses the placenta and given close to delivery increases risk of neonatal respiratory depression; naloxone is not recommended for initial neonatal resuscitation—effective ventilation is first-line."
      },
      {
        "text": "Give IV butorphanol 1 mg; it has minimal placental transfer and rarely causes neonatal respiratory depression, so routine newborn care is sufficient.",
        "isCorrect": false,
        "explanation": "Butorphanol crosses the placenta, can cause fetal heart rate changes, and may depress neonatal respiration; it is not risk-free near delivery and does not obviate neonatal preparation."
      },
      {
        "text": "Initiate remifentanil patient-controlled IV analgesia (0.25–0.5 μg/kg demand bolus, 2-min lockout, no basal infusion) with continuous maternal SpO<sub>2</sub> monitoring and 1:1 nursing; notify the neonatal team to prepare for positive-pressure ventilation at birth.",
        "isCorrect": true,
        "explanation": "Remifentanil’s ultra-short action allows titratable labor analgesia when neuraxial is contraindicated, with less sustained neonatal depression; neonatal support should focus on ventilation rather than routine naloxone."
      },
      {
        "text": "Administer IV morphine 2 mg q5 min to a total of 10 mg with supplemental oxygen; neonatal team is not required if maternal oxygenation is adequate.",
        "isCorrect": false,
        "explanation": "Morphine readily crosses the placenta and can depress the neonate despite maternal oxygenation; minimizing neonatal risk requires avoiding longer-acting opioids near delivery and involving neonatal resuscitation as needed."
      },
      {
        "text": "Give IM meperidine 50 mg now and reassure that neonatal depression is unlikely because delivery is imminent.",
        "isCorrect": false,
        "explanation": "Meperidine and its active metabolite cross the placenta and are associated with significant neonatal neurobehavioral and respiratory depression, especially problematic if delivery occurs within a few hours of dosing."
      }
    ],
    "didactic": "When neuraxial analgesia is contraindicated (eg, thrombocytopenia), systemic opioids may be used for intrapartum analgesia, but placental transfer and timing relative to delivery are critical. Most opioids are lipid-soluble weak bases that rapidly cross the placenta; near-delivery dosing increases the risk of neonatal respiratory depression.\n\n- **Remifentanil PCA** (eg, 0.25–0.5 μg/kg demand, 2-min lockout, no basal) is useful for rapid, titratable labor analgesia because it has an ultra-short context-insensitive half-time due to metabolism by nonspecific esterases. Although it crosses the placenta, neonatal depression is typically brief. Strict maternal monitoring (continuous SpO<sub>2</sub>, sedation scoring) and 1:1 nursing are essential due to maternal apnea risk.\n- **Fentanyl**, **morphine**, and **meperidine** cross the placenta and can cause sustained neonatal depression if administered close to delivery. Meperidine’s metabolite (normeperidine) contributes to neonatal neurobehavioral depression and maternal CNS toxicity; IM administration also has delayed, prolonged effects.\n- **Mixed agonist-antagonists** (eg, butorphanol) also cross the placenta and can produce fetal heart rate changes and neonatal respiratory depression; they may precipitate withdrawal in opioid-tolerant patients.\n\nFor the neonate, initial resuscitation prioritizes **effective ventilation** with positive-pressure ventilation rather than routine naloxone. **Naloxone** is not recommended for initial resuscitation because its short duration may be inadequate relative to many opioids and it can precipitate acute withdrawal in opioid-exposed infants. It may be considered for persistent respiratory depression after effective ventilation in cases of known opioid exposure, but only with caution. Therefore, with imminent delivery and neuraxial contraindication, remifentanil PCA with vigilant maternal monitoring and advance neonatal team notification to provide positive-pressure ventilation best balances maternal analgesia and neonatal safety.",
    "educationalObjective": "Manage intrapartum opioid use to minimize neonatal respiratory depression and plan for neonatal support if needed."
  },
  {
    "id": "Core.13.6.8",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Opioids and antagonists",
    "difficulty": "hard",
    "questionText": "A 54-year-old man with obesity and severe OSA (uses CPAP) presents with peritonitis from perforated diverticulitis requiring urgent laparotomy today. He receives extended-release naltrexone 380 mg IM monthly for alcohol use disorder; his last injection was 10 days ago. He is opioid-naïve and reports severe pain. Vitals and coagulation studies are acceptable for surgery. Which perioperative analgesia plan is most appropriate today?",
    "answers": [
      {
        "text": "Delay surgery for ≥2 weeks until the naltrexone effect wanes, then perform routine opioid-based anesthesia and analgesia.",
        "isCorrect": false,
        "explanation": "Deferring urgent/emergent surgery for antagonist washout is unsafe; timing must be driven by surgical urgency, not opioid receptor availability."
      },
      {
        "text": "Run a naloxone infusion intraoperatively to displace naltrexone and enable effective opioid analgesia with standard dosing.",
        "isCorrect": false,
        "explanation": "Naloxone is also a μ-opioid antagonist; it will not reverse naltrexone’s receptor blockade and will not restore opioid analgesia."
      },
      {
        "text": "Administer a large preoperative methadone load to overcome receptor blockade and provide prolonged analgesia.",
        "isCorrect": false,
        "explanation": "Attempting to override receptor blockade with long-acting opioids is unreliable and hazardous (eg, QT prolongation, accumulation, and severe respiratory depression when blockade wanes)."
      },
      {
        "text": "Use multimodal, opioid-sparing anesthesia: acetaminophen and an NSAID (if not contraindicated), ketamine and dexmedetomidine infusions, and bilateral abdominal wall blocks; avoid relying on opioids, and if needed, titrate high-dose short-acting opioids with postoperative monitored care due to delayed respiratory depression risk as blockade wanes.",
        "isCorrect": true,
        "explanation": "In the setting of active μ-receptor blockade, prioritize regional and nonopioid analgesia; if opioids are required, much higher doses may be needed and warrant close monitoring as antagonist effect decreases."
      },
      {
        "text": "Proceed with standard fentanyl-based general anesthesia and routine hydromorphone PCA; typical opioid doses will be effective despite recent naltrexone.",
        "isCorrect": false,
        "explanation": "Extended-release naltrexone produces near-complete μ-receptor blockade for weeks; standard opioid doses will provide little analgesia, leading to uncontrolled pain and dose escalation without benefit."
      }
    ],
    "didactic": "Naltrexone and nalmefene are long-acting competitive μ-opioid receptor antagonists used for alcohol and opioid use disorders. Their receptor occupancy blunts or abolishes the effect of full agonists, creating major perioperative analgesia challenges.\n\n- Oral naltrexone: parent half-life ~4 h; active metabolite 6-β-naltrexol t<sub>1/2</sub> ~13 h. For elective painful surgery, hold for 48–72 h to reduce receptor occupancy and allow opioid responsiveness.\n- Extended-release naltrexone (380 mg IM): sustained blockade for ~4 weeks (most robust during the first 2–3 weeks). Elective cases should be scheduled near the end of the dosing interval when feasible.\n- Nalmefene: t<sub>1/2</sub> ~10–12 h (oral); hold 24–48 h for elective procedures.\n\nFor urgent surgery in a patient with active antagonist effect, opioids will be relatively ineffective at standard doses. The optimal approach is **multimodal, opioid-sparing analgesia**:\n\n- Regional techniques (eg, TAP/QL/ESP blocks; neuraxial if not contraindicated) with local anesthetics.\n- Acetaminophen and NSAIDs (if renal function/bleeding risk permit).\n- NMDA antagonists (ketamine), α<sub>2</sub>-agonists (dexmedetomidine), and, when appropriate, IV lidocaine infusions.\n\nBecause antagonism is competitive, very **high opioid doses** can sometimes overcome blockade; if used, select short-acting, titratable agents (eg, remifentanil intraoperatively) and provide **postoperative monitored care**. As naltrexone’s effect wanes, previously administered opioids can precipitate **delayed respiratory depression**, especially in OSA. Avoid strategies that do not restore analgesia (eg, naloxone infusion) or that create long-acting toxicity (eg, methadone loading). For elective cases, plan antagonist washout (oral naltrexone 2–3 days; nalmefene 1–2 days) or schedule after depot naltrexone’s dosing interval. Coordinate with addiction specialists to restart antagonist therapy once opioids are no longer required and to mitigate relapse risk; anticipate possible **opioid hypersensitivity** after discontinuation due to receptor upregulation.",
    "educationalObjective": "Plan perioperative care in patients on naltrexone or nalmefene including washout or higher opioid requirements."
  },
  {
    "id": "Core.13.6.9",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Opioids and antagonists",
    "difficulty": "medium",
    "questionText": "A 68-year-old man (70 kg) undergoing open abdominal surgery is induced with propofol 2 mg/kg after rapid administration of fentanyl 600 μg. He becomes apneic with minimal chest excursion, very high manual ventilation pressures, and poor bag compliance. Breath sounds are absent bilaterally without wheeze or stridor, pupils are miotic, there is no rash, and blood pressure and heart rate are stable. SpO<sub>2</sub> falls to 88% despite 100% O<sub>2</sub>. Which of the following is the most appropriate immediate intervention to rapidly restore ventilation?",
    "answers": [
      {
        "text": "Administer succinylcholine 1 mg/kg IV and proceed with tracheal intubation",
        "isCorrect": true,
        "explanation": "High-dose, rapidly administered fentanyl can cause generalized skeletal muscle (chest wall and laryngeal) rigidity. Rapid neuromuscular blockade promptly relieves rigidity, improves mask ventilation, and facilitates intubation without reversing analgesia."
      },
      {
        "text": "Insert a supraglottic airway and increase PEEP to 15 cm H2O",
        "isCorrect": false,
        "explanation": "Airway instrumentation without muscle relaxation may be difficult with thoraco-laryngeal rigidity and does not address the underlying cause; high PEEP risks further barotrauma without improving compliance."
      },
      {
        "text": "Increase sevoflurane to 3% while continuing positive-pressure ventilation",
        "isCorrect": false,
        "explanation": "Deepening volatile anesthesia may modestly reduce muscle tone but will not reliably or rapidly relieve severe fentanyl-induced rigidity causing life-threatening hypoventilation."
      },
      {
        "text": "Administer albuterol via MDI and hydrocortisone 100 mg IV",
        "isCorrect": false,
        "explanation": "Bronchospasm presents with wheeze and prolonged expiration; absent breath sounds with high manual pressures after rapid high-dose fentanyl is more consistent with chest wall/laryngeal rigidity, not lower-airway bronchoconstriction."
      },
      {
        "text": "Administer naloxone 40 μg IV boluses, titrated to improved ventilation",
        "isCorrect": false,
        "explanation": "Naloxone reverses opioid-induced rigidity but also reverses analgesia and may precipitate hypertension/tachycardia; in the intubation sequence, immediate neuromuscular blockade is preferred to quickly restore ventilation while preserving intraoperative opioid effect."
      }
    ],
    "didactic": "Rapid, high-dose μ-agonist administration (eg, fentanyl, sufentanil, remifentanil) can precipitate **chest wall and laryngeal muscle rigidity** (“wooden chest”) via central dopaminergic/μ-receptor mechanisms. Risk is increased with large or rapidly given doses, extremes of age, and coadministration during light anesthesia. Clinically, patients develop apnea, very poor chest expansion, high manual ventilation pressures with poor bag compliance, and often **miotic pupils**. Auscultation typically lacks wheeze or stridor, distinguishing it from bronchospasm or laryngospasm; anaphylaxis features hypotension, rash, and airway edema.\n\nImmediate management prioritizes oxygenation and ventilation. The fastest and most reliable intervention is **neuromuscular blockade** (eg, succinylcholine 1 mg/kg IV or high-dose rocuronium 1.2 mg/kg), which promptly abolishes skeletal muscle tone in the chest wall and larynx, restores mask ventilation, and facilitates tracheal intubation while preserving analgesia. In contrast, deepening volatile anesthesia or giving additional sedatives is inconsistent and too slow for rapidly deteriorating oxygenation.\n\n**Naloxone** reverses opioid-induced rigidity but also eliminates analgesia and can provoke sympathetic surges (hypertension, tachycardia) and acute pain. It is appropriate when neuromuscular blockers are unavailable or contraindicated, or when the airway is already secure and reversal of all opioid effects is acceptable; titrate in small increments (eg, 20–40 μg IV) to relieve rigidity while minimizing withdrawal and hemodynamic instability. For remifentanil-associated rigidity, stopping the infusion plus neuromuscular blockade is often sufficient given its ultrashort context-sensitive half-time.\n\nPrevention includes avoiding rapid boluses of potent opioids, using the lowest effective dose, and administering a **neuromuscular blocker before high-dose opioid** when immediate intubation is planned. Recognizing this entity and acting decisively with neuromuscular blockade prevents hypoxemia and facilitates safe airway control.",
    "educationalObjective": "Prevent and treat chest wall rigidity after high-dose fentanyl or remifentanil with neuromuscular blockade or naloxone."
  },
  {
    "id": "Core.13.6.10",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Opioids and antagonists",
    "difficulty": "hard",
    "questionText": "A 54-year-old man (85 kg) is undergoing laparoscopic colectomy under sevoflurane anesthesia with a remifentanil infusion at 0.25–0.3 µg/kg/min for 3 hours. You are 40 minutes from anticipated extubation. The surgeon expects moderate postoperative pain. The team wants to minimize the risk of severe postoperative pain with diffuse hyperalgesia after remifentanil-based anesthesia while maintaining timely emergence. Which intraoperative plan is most likely to reduce opioid-induced hyperalgesia and improve postoperative analgesia in this patient?\n\nSelect the best strategy.",
    "answers": [
      {
        "text": "Administer ketamine 0.3 mg/kg IV bolus and start 0.1 mg/kg/h infusion; taper remifentanil by 50% every 10–15 min; give hydromorphone 0.05 mg/kg IV 20–30 min before emergence plus acetaminophen and ketorolac.",
        "isCorrect": true,
        "explanation": "Combining an NMDA antagonist (ketamine), gradual remifentanil weaning, and scheduled multimodal plus a timely long-acting opioid addresses central sensitization and prevents abrupt opioid offset, reducing OIH risk and improving analgesia."
      },
      {
        "text": "Increase sevoflurane to 1.5 MAC during closure to suppress nociception, stop remifentanil abruptly at extubation, and avoid giving any long-acting opioid until the patient is awake.",
        "isCorrect": false,
        "explanation": "Deepening volatile anesthesia does not mitigate the pronociceptive adaptations from high-dose remifentanil; abrupt cessation without transition increases OIH risk."
      },
      {
        "text": "Continue remifentanil at the current rate until extubation and treat pain with hydromorphone 0.2 mg IV as needed in the PACU.",
        "isCorrect": false,
        "explanation": "Abrupt discontinuation of high-dose remifentanil without preemptive, longer-acting analgesia is associated with opioid-induced hyperalgesia (OIH) and difficult-to-control postoperative pain."
      },
      {
        "text": "Give magnesium sulfate 1 g IV at incision and otherwise maintain the remifentanil infusion until extubation, then stop abruptly.",
        "isCorrect": false,
        "explanation": "Although magnesium has NMDA antagonism, a single low dose without remifentanil taper or longer-acting analgesia is insufficient to reliably prevent OIH."
      },
      {
        "text": "Replace remifentanil with fentanyl 5 µg/kg in divided boluses during closure and stop all opioids at extubation to avoid respiratory depression.",
        "isCorrect": false,
        "explanation": "Large intraoperative opioid boluses may worsen hyperalgesia/tolerance, and stopping opioids at extubation risks rebound pain without preventing OIH."
      }
    ],
    "didactic": "Opioid-induced hyperalgesia (OIH) is a paradoxical increase in pain sensitivity after opioid exposure, classically seen with high-dose, short-acting opioids such as remifentanil. Mechanisms include activation of **NMDA receptors**, increased **spinal glutamate** and **dynorphin**, descending facilitation, and neuroinflammatory signaling. Clinically, OIH manifests as diffuse hyperalgesia/allodynia and pain that seems disproportionate to tissue injury; unlike tolerance (which improves with higher opioid doses), OIH may worsen with escalating opioids.\n\nRisk reduction during remifentanil-based anesthesia centers on blunting central sensitization and avoiding abrupt opioid offset:\n- Use **NMDA antagonists**: ketamine (eg, 0.2–0.35 mg/kg bolus, 0.05–0.15 mg/kg/h) or magnesium (eg, 30–50 mg/kg load, 10 mg/kg/h) reduce wind-up and OIH.\n- **Wean remifentanil** rather than stopping suddenly (eg, ↓ by ~50% every 10–15 min during closure) to limit acute pronociceptive rebound.\n- Provide a **timely long-acting opioid** (eg, hydromorphone 0.02–0.05 mg/kg IV 20–30 min before emergence, or intraoperative methadone) to smooth the transition off remifentanil.\n- Employ **multimodal analgesia**: acetaminophen, NSAIDs (if not contraindicated), gabapentinoids, and IV lidocaine (1–1.5 mg/kg bolus; 1.5–2 mg/kg/h) reduce opioid requirements and central sensitization. **α<sub>2</sub>-agonists** (dexmedetomidine 0.2–0.7 µg/kg/h) can also attenuate OIH.\n\nBy contrast, continuing high-dose remifentanil until extubation and treating pain reactively in the PACU, or substituting large bolus opioids late in the case, does not address the underlying pronociceptive state and may exacerbate OIH. Deepening volatile anesthetic alone is insufficient. The best strategy integrates an NMDA antagonist, a **graded remifentanil taper**, proactive **long-acting analgesia**, and **multimodal non-opioid adjuvants** to reduce OIH and improve postoperative pain control.",
    "educationalObjective": "Recognize opioid-induced hyperalgesia and reduce risk with multimodal analgesia and careful remifentanil weaning."
  },
  {
    "id": "Core.13.6.11",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Opioids and antagonists",
    "difficulty": "medium",
    "questionText": "A 65-year-old man with obstructive sleep apnea (uses CPAP), coronary artery disease s/p drug-eluting stent 2 years ago (on aspirin 81 mg daily), and CKD stage 3 (eGFR 45 mL/min/1.73 m², creatinine 1.6 mg/dL) is scheduled for laparoscopic colectomy. Vitals: BP 130/70 mmHg, HR 50/min; LFTs and platelets are normal. You plan an opioid-sparing strategy. Which regimen best minimizes perioperative opioid use while accounting for his comorbidities?\n\nWhich of the following multimodal analgesic regimens is most appropriate for this patient?",
    "answers": [
      {
        "text": "Preoperative acetaminophen 1 g PO; intraoperative ketamine 0.3 mg/kg IV bolus then 0.1 mg/kg/h infusion; scheduled acetaminophen postoperatively",
        "isCorrect": true,
        "explanation": "Acetaminophen is safe in CKD and reduces opioid needs; low-dose ketamine provides potent opioid-sparing analgesia without respiratory depression and avoids bradycardia seen with α<sub>2</sub>-agonists."
      },
      {
        "text": "Preoperative acetaminophen 1 g PO; intraoperative ketorolac 30 mg IV and dexmedetomidine infusion 0.4 μg/kg/h; scheduled ketorolac postoperatively",
        "isCorrect": false,
        "explanation": "NSAIDs increase bleeding and AKI risk in CKD and abdominal surgery; dexmedetomidine can exacerbate baseline bradycardia."
      },
      {
        "text": "No adjuncts preoperatively; intraoperative remifentanil infusion and postoperative morphine PCA to avoid NSAIDs",
        "isCorrect": false,
        "explanation": "An opioid-centric plan increases risk of postoperative respiratory depression in OSA and misses the benefits of multimodal analgesia."
      },
      {
        "text": "Preoperative acetaminophen 1 g PO and clonidine 0.2 mg PO; intraoperative single ketamine bolus 0.25 mg/kg without infusion",
        "isCorrect": false,
        "explanation": "Clonidine can cause bradycardia and hypotension; a one-time low-dose ketamine bolus provides limited, short-lived opioid-sparing compared with a titratable infusion."
      },
      {
        "text": "Preoperative celecoxib 400 mg PO; intraoperative dexmedetomidine 0.2–0.7 μg/kg/h; avoid ketamine due to CAD",
        "isCorrect": false,
        "explanation": "Even COX-2 inhibitors can worsen renal perfusion in CKD; dexmedetomidine may cause significant bradycardia in a patient with HR 50/min; ketamine is not absolutely contraindicated in stable CAD at analgesic doses."
      }
    ],
    "didactic": "Opioid-sparing multimodal analgesia leverages additive or synergistic mechanisms to reduce perioperative opioid requirements while minimizing adverse effects. Selection must balance efficacy with comorbidity-specific risks.\n\n- Acetaminophen: Central COX inhibition provides reliable analgesia with minimal hemodynamic or bleeding impact. Dose 1 g PO/IV preoperatively and 1 g q6h (max 3–4 g/day; lower if hepatic impairment or frailty). Safe in CKD and in patients on aspirin.\n- NSAIDs: Nonselective agents (eg, ketorolac) and COX-2 inhibitors reduce opioids but can impair renal perfusion (afferent arteriolar constriction), increase bleeding (nonselective), and have been associated with gastrointestinal anastomotic complications in colorectal surgery. Avoid or use cautiously in CKD, hypovolemia, high bleeding risk, or fresh bowel anastomosis.\n- α<sub>2</sub>-agonists (dexmedetomidine, clonidine): Provide analgesia, anxiolysis, and opioid sparing without respiratory depression, but reduce sympathetic tone, causing bradycardia and hypotension. Avoid or minimize in baseline bradycardia, heart block, or tenuous hemodynamics. Dexmedetomidine typical infusion 0.2–0.7 μg/kg/h (no loading dose when bradycardic).\n- Ketamine: At subanesthetic doses (eg, 0.2–0.5 mg/kg IV bolus, then 0.1–0.3 mg/kg/h), it provides robust opioid sparing via NMDA antagonism, prevents central sensitization, and preserves airway reflexes/ventilation—useful in OSA. Sympathomimetic effects (↑HR/↑BP) are generally modest at analgesic doses; use caution in uncontrolled ischemia or severe hypertension.\n\nFor this patient (OSA, CKD stage 3, resting bradycardia, on aspirin), the optimal plan includes scheduled acetaminophen and a low-dose ketamine infusion. This combination offers effective opioid reduction without worsening renal function, bleeding, or bradycardia. In contrast, NSAIDs risk AKI/bleeding, and α<sub>2</sub>-agonists could exacerbate bradycardia. Multimodal regimens should be individualized, titrated to effect, and complemented by regional techniques when feasible to further reduce opioid exposure.",
    "educationalObjective": "Reduce perioperative opioid use by integrating acetaminophen, NSAIDs, alpha-2 agonists, and ketamine when appropriate."
  },
  {
    "id": "Core.13.6.12",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Opioids and antagonists",
    "difficulty": "easy",
    "questionText": "A 72-year-old man (BMI 38) with severe OSA (uses home CPAP) and stage 3 CKD (eGFR 35 mL/min/1.73 m<sup>2</sup>) is opioid-naïve and undergoes open ventral hernia repair. In the PACU he is comfortable on 2 L/min O<sub>2</sub> by nasal cannula and requests a PCA for postoperative analgesia. The nurse asks for initial PCA orders and monitoring parameters; the patient’s spouse offers to press the button while he sleeps.\n\nWhich initial PCA order set and monitoring plan best minimizes oversedation and respiratory depression in this patient?",
    "answers": [
      {
        "text": "Hydromorphone PCA: demand 0.2 mg, lockout 10 min, no basal; pulse oximetry only while on O<sub>2</sub>; start gabapentin 600 mg TID; RN checks q4–6h.",
        "isCorrect": false,
        "explanation": "Omitting capnography on supplemental O<sub>2</sub>, adding sedating gabapentin at high dose, and infrequent assessments increase risk of unrecognized hypoventilation."
      },
      {
        "text": "Hydromorphone PCA: demand 0.2 mg, lockout 10 min, no basal; 1-h limit 1.2 mg; continuous capnography and pulse oximetry; RN sedation/resp assessments q1h × 6 h then q2–4 h; hold for RR <10/min, EtCO<sub>2</sub> >50 mmHg, or SpO<sub>2</sub> <92%; apply home CPAP when asleep; naloxone PRN; patient-only activation.",
        "isCorrect": true,
        "explanation": "Appropriate opioid choice for CKD, avoids basal infusion in an opioid-naïve patient with OSA, uses capnography to detect hypoventilation despite supplemental O<sub>2</sub>, includes clear hold/rescue parameters, CPAP, and prohibits PCA by proxy."
      },
      {
        "text": "Fentanyl PCA: demand 50 μg, lockout 5 min, no basal; continuous pulse oximetry; family assistance allowed during sleep; no capnography.",
        "isCorrect": false,
        "explanation": "High fentanyl demand dose in an opioid-naïve elderly patient plus PCA by proxy elevate risk; pulse oximetry alone may not detect hypoventilation early."
      },
      {
        "text": "Hydromorphone PCA: demand 0.4 mg, lockout 6 min, basal 0.2 mg/h; intermittent pulse oximetry; add lorazepam 0.5 mg q6h PRN for anxiety.",
        "isCorrect": false,
        "explanation": "Basal infusion and large demand dose increase respiratory depression risk; benzodiazepines potentiate opioid-induced sedation; intermittent monitoring is inadequate."
      },
      {
        "text": "Morphine PCA: basal 1 mg/h plus demand 1 mg, lockout 6 min; continuous pulse oximetry only; O<sub>2</sub> 4 L/min; RN checks q4h.",
        "isCorrect": false,
        "explanation": "Basal infusion increases risk in opioid-naïve OSA patients, morphine’s active metabolites accumulate in CKD, and pulse oximetry alone on supplemental O<sub>2</sub> may miss hypoventilation."
      }
    ],
    "didactic": "High-risk features for opioid-induced respiratory depression include **advanced age**, **OSA/obesity**, **opioid-naïve status**, **renal/hepatic impairment**, and **concomitant sedatives**. Safe PCA setup for such patients centers on opioid selection, conservative dosing, and vigilant monitoring.\n\n- **Avoid basal infusions** in opioid-naïve or OSA patients; continuous background dosing increases risk of cumulative oversedation without improving analgesia.\n- **Choose the opioid wisely in CKD.** Morphine’s active metabolite (M6G) accumulates and prolongs respiratory depression; **hydromorphone** or **fentanyl** are preferred, with reduced dosing and close monitoring (hydromorphone-3-glucuronide can accumulate but is less associated with respiratory depression than M6G).\n- **Initial dosing (opioid-naïve adults):** hydromorphone demand 0.1–0.2 mg with 8–10 min lockout; morphine 1 mg with 8–10 min lockout; fentanyl 10–25 μg with 5–10 min lockout. Include a reasonable hourly limit and reserve clinician boluses for monitored settings.\n- **Prohibit PCA by proxy.** Only the patient should activate the demand button; family/nursing activation removes the patient’s protective arousal response.\n- **Monitor ventilation, not just oxygenation.** Continuous pulse oximetry on supplemental O<sub>2</sub> can mask hypoventilation. **Capnography** (nasal EtCO<sub>2</sub>) detects hypoventilation and apnea earlier. Pair with frequent sedation/respiratory assessments (eg, q1h × 6 h, then q2–4 h), especially during the first night.\n- **Set explicit hold/rescue parameters** (eg, hold PCA for RR <10/min, EtCO<sub>2</sub> >50 mmHg, excessive sedation; administer **naloxone** if needed) and **apply home CPAP** whenever sleeping.\n- **Avoid additive sedatives** (benzodiazepines, high-dose gabapentinoids) and favor **multimodal analgesia** (acetaminophen, NSAIDs if renal function permits, regional techniques) to reduce opioid requirement.\n\nThis patient’s optimal plan is hydromorphone PCA with no basal, conservative demand dosing and lockout, continuous capnography plus pulse oximetry, frequent early assessments with clear hold parameters, naloxone rescue, CPAP during sleep, and strict patient-only activation.",
    "educationalObjective": "Set up safe PCA orders and monitoring to reduce oversedation and respiratory depression in high-risk patients."
  },
  {
    "id": "Core.13.6.13",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Opioids and antagonists",
    "difficulty": "medium",
    "questionText": "A 62-year-old man (BMI 38) with obstructive sleep apnea and chronic pain on methadone 30 mg/day undergoes laparoscopic colectomy. In PACU he is somnolent with pinpoint pupils, RR 6/min, SpO<sub>2</sub> 90% on 4 L/min O<sub>2</sub> by nasal cannula. He received hydromorphone 2 mg 30 minutes earlier. You support the airway and administer naloxone 40 μg IV every 2 minutes. After a total of 0.12 mg, he is arousable, follows commands, RR 12/min, SpO<sub>2</sub> 96% on 2 L/min, and reports pain 4/10. Which of the following is the most appropriate next step to minimize renarcotization while preserving analgesia?",
    "answers": [
      {
        "text": "Observe without infusion and provide supplemental O<sub>2</sub>; hold further opioids.",
        "isCorrect": false,
        "explanation": "Naloxone’s duration (30–80 minutes) is shorter than methadone and hydromorphone, so respiratory depression is likely to recur without a maintenance infusion."
      },
      {
        "text": "Administer an additional 0.4 mg naloxone IV bolus now to prevent recurrence.",
        "isCorrect": false,
        "explanation": "Large boluses can precipitate acute withdrawal, severe pain, and sympathetic surge; the patient is already adequately reversed after careful titration."
      },
      {
        "text": "Start a naloxone infusion at 0.12 mg/h to ensure sustained reversal.",
        "isCorrect": false,
        "explanation": "Using the full effective bolus per hour risks over-reversal, pain, and withdrawal; recommended starting rate is approximately two-thirds of the effective dose per hour with bedside titration."
      },
      {
        "text": "Start a naloxone infusion at 0.08 mg/h and titrate to maintain RR 10–12/min with acceptable analgesia.",
        "isCorrect": true,
        "explanation": "An infusion at two-thirds of the effective reversal dose per hour (2/3 × 0.12 mg ≈ 0.08 mg/h) matches naloxone delivery to ongoing opioid effect, limiting renarcotization while avoiding abrupt loss of analgesia and withdrawal."
      },
      {
        "text": "Start a naloxone infusion at 0.08 mg/min.",
        "isCorrect": false,
        "explanation": "This is a unit error (≈4.8 mg/h) that would cause profound reversal, pain, and potential complications (eg, pulmonary edema)."
      }
    ],
    "didactic": "Opioid-induced respiratory depression should be reversed with small, incremental doses of naloxone (eg, 20–40 μg IV every 1–2 minutes) to restore adequate ventilation and arousability while preserving analgesia. Large empiric boluses (eg, 0.4–2 mg) abruptly displace μ-receptor agonists, producing acute pain, withdrawal, tachycardia, hypertension, and rarely noncardiogenic pulmonary edema. Supplemental O<sub>2</sub> and airway support are adjuncts but do not treat hypoventilation.\n\nBecause naloxone’s effect (half-life ~30–80 minutes) is often shorter than that of many opioids (eg, hydromorphone, morphine, methadone, sustained-release formulations, neuraxial morphine), patients are at risk for renarcotization after initial improvement. To prevent recurrence when long-acting or large opioid burdens are present, initiate a naloxone infusion calculated from the effective reversal dose: approximately two-thirds of the total effective bolus per hour. Example: if 0.12 mg restores RR and mental status, start 0.08 mg/h and titrate to maintain RR 10–12/min and SpO<sub>2</sub> targets while preserving acceptable analgesia.\n\nPractical steps:\n- Titrate naloxone in microdoses until the patient is arousable with RR ≥10–12/min, not necessarily fully pain free.\n- If a long-acting opioid effect persists, begin an infusion at ≈(2/3 × effective bolus)/h; reassess frequently and adjust.\n- Continue the infusion for several hours with close monitoring (capnography if available), then wean as opioid burden declines.\n- Avoid overshoot reversal; consider multimodal analgesia (acetaminophen, NSAIDs, regional techniques) to limit further opioid requirements.\n\nThis approach balances reversal of respiratory depression with preservation of analgesia and reduces the risk of renarcotization due to the pharmacokinetic mismatch between naloxone and longer-acting opioids.",
    "educationalObjective": "Titrate naloxone to reverse respiratory depression while preserving analgesia and anticipate renarcotization."
  },
  {
    "id": "Core.13.6.14",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Opioids and antagonists",
    "difficulty": "easy",
    "questionText": "A 27-year-old woman is 12 hours status post primary cesarean delivery performed under spinal anesthesia with hyperbaric bupivacaine and intrathecal morphine 150 μg. In the PACU, she reports severe generalized and facial itching that is very bothersome. Her pain is well controlled (NRS 2/10). She is hemodynamically stable (HR 78/min, BP 118/70 mmHg, RR 14/min, SpO<sub>2</sub> 99% on room air) without rash, wheeze, or hypotension. She plans to breastfeed soon and wishes to avoid sedation. Which of the following is the most appropriate next step to relieve her pruritus while preserving analgesia?",
    "answers": [
      {
        "text": "Propofol 10 mg IV bolus",
        "isCorrect": false,
        "explanation": "Propofol may transiently sedate but does not address the mechanism of neuraxial opioid pruritus and risks oversedation without durable benefit."
      },
      {
        "text": "Ondansetron 4 mg IV",
        "isCorrect": false,
        "explanation": "5-HT3 antagonists have mixed efficacy and are more effective prophylactically than for established pruritus; opioid antagonism provides more reliable treatment."
      },
      {
        "text": "Diphenhydramine 50 mg IV",
        "isCorrect": false,
        "explanation": "Antihistamines offer limited benefit because pruritus is centrally mediated rather than histamine-driven and can cause undesirable sedation in a postpartum patient; they are adjuncts, not first-line."
      },
      {
        "text": "Naloxone 0.4 mg IV bolus",
        "isCorrect": false,
        "explanation": "A full-dose naloxone bolus will acutely reverse μ-mediated analgesia and may precipitate significant pain and nausea; if used, naloxone should be given as a very low-dose infusion."
      },
      {
        "text": "Nalbuphine 2.5 mg IV",
        "isCorrect": true,
        "explanation": "Low-dose nalbuphine (κ-agonist/μ-antagonist) effectively treats neuraxial opioid–induced pruritus while largely preserving analgesia and minimizing sedation."
      }
    ],
    "didactic": "Neuraxial opioid–induced pruritus is common after intrathecal or epidural morphine, particularly in obstetric patients. It is primarily a central, μ-opioid receptor–mediated phenomenon due to cephalad CSF spread to the medullary dorsal horn and trigeminal nucleus, not peripheral histamine release. Consequently, antihistamines have limited efficacy and mainly provide sedation, which is undesirable in postpartum patients and may interfere with early breastfeeding.\n\nFirst-line therapy targets μ receptors while preserving analgesia:\n- Low-dose mixed agonist–antagonists (eg, **nalbuphine**) act as κ-agonists/μ-antagonists, reliably reducing pruritus with minimal impact on neuraxial analgesia. Typical dosing is **2.5–5 mg IV**, repeat as needed.\n- Ultra–low-dose **naloxone infusion** counteracts μ-mediated side effects without abolishing analgesia. Common regimens are **0.25–1 μg/kg/h IV** (titrate to effect). Avoid large boluses, which rapidly reverse analgesia and can induce nausea and sympathetic activation.\n\nAdjuncts:\n- **Antihistamines** (eg, diphenhydramine, hydroxyzine) can be used as adjuncts for symptomatic relief, but they do not treat the central mechanism and increase sedation.\n- **5-HT3 antagonists** (eg, ondansetron) show inconsistent benefit; they are more useful prophylactically than for established pruritus and are less effective than μ antagonism.\n\nManagement priorities are to relieve distressing pruritus while maintaining excellent neuraxial analgesia. In a comfortable, hemodynamically stable postpartum patient without signs of an allergic reaction, **low-dose nalbuphine** is the best initial treatment. When nalbuphine is unavailable or contraindicated, a **very low-dose naloxone infusion** is an effective alternative. Reserve antihistamines as adjuncts when additional symptomatic relief is needed or when mild sedation is acceptable.",
    "educationalObjective": "Treat neuraxial opioid-induced pruritus with low-dose nalbuphine, naloxone infusion, or antihistamines as adjuncts."
  },
  {
    "id": "Core.13.6.15",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Opioids and antagonists",
    "difficulty": "easy",
    "questionText": "A 58-year-old man in the PACU after laparoscopic inguinal hernia repair under sevoflurane/fentanyl anesthesia is shivering vigorously despite forced-air warming and warmed IV fluids. He is alert, reports pain 3/10, and is hemodynamically stable (T 35.5°C, HR 108/min, BP 146/84 mmHg, SpO<sub>2</sub> 98% on 3 L/min O<sub>2</sub> by nasal cannula). Rapid control of shivering is desired to limit increased O<sub>2</sub> demand without causing significant hypotension or oversedation. Which medication–mechanism pair is most appropriate to rapidly stop his postoperative shivering?",
    "answers": [
      {
        "text": "Naloxone — opioid receptor antagonism reverses anesthetic-induced shivering",
        "isCorrect": false,
        "explanation": "Naloxone reverses opioid effects and would not treat hypothermia-related shivering; it risks acute pain and sympathetic activation."
      },
      {
        "text": "Dexmedetomidine — α<sub>2</sub>-adrenergic agonism increases the shivering threshold and causes peripheral vasoconstriction",
        "isCorrect": false,
        "explanation": "Dexmedetomidine can treat shivering by lowering the shivering threshold via central α<sub>2</sub> agonism but often causes bradycardia/hypotension and sedation; the stated mechanism is inaccurate."
      },
      {
        "text": "Tramadol — serotonin/norepinephrine reuptake inhibition increases nonshivering thermogenesis to terminate shivering",
        "isCorrect": false,
        "explanation": "Tramadol may reduce shivering via weak μ agonism plus 5-HT/NE reuptake inhibition, but it is less reliable and slower than meperidine; the mechanism described is incorrect."
      },
      {
        "text": "Meperidine — κ-opioid receptor agonism with central anticholinergic activity lowers the shivering threshold",
        "isCorrect": true,
        "explanation": "Meperidine uniquely attenuates shivering via κ-agonism and central anticholinergic effects, reducing the shivering threshold independent of μ-mediated analgesia; 12.5–25 mg IV is typically effective and rapid."
      },
      {
        "text": "Morphine — μ-opioid receptor agonism suppresses shivering by increasing sweating",
        "isCorrect": false,
        "explanation": "Morphine provides analgesia via μ agonism but has limited, unreliable antishivering effects; the proposed mechanism is incorrect and it is slower with more respiratory depression."
      }
    ],
    "didactic": "Postanesthetic shivering is common after general anesthesia and hypothermia and can increase metabolic rate and O<sub>2</sub> consumption up to 2–3×, raising CO<sub>2</sub> production and myocardial workload. Rapid treatment is desirable, especially in patients with limited cardiopulmonary reserve. Nonpharmacologic measures (forced-air warming, warmed IV fluids) should be instituted, but persistent rigors often require medication.\n\nMeperidine is the classic first-line drug for postoperative shivering. At 12.5–25 mg IV, it reliably and rapidly reduces shivering with minimal hemodynamic instability. Its antishivering action is distinct from μ-mediated analgesia and is attributed to:\n- κ-opioid receptor agonism in thermoregulatory pathways, which lowers the shivering threshold\n- Central anticholinergic activity that further blunts thermoregulatory efferent output\n\nThis combination uniquely suppresses shivering more effectively than equianalgesic doses of other μ-agonists (eg, morphine, fentanyl). Important safety considerations include sedation and respiratory depression, risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, MAOIs), and accumulation of the excitatory metabolite normeperidine in renal impairment predisposing to seizures.\n\nAlternatives when meperidine is undesirable include:\n- Dexmedetomidine or clonidine: central α<sub>2</sub>-agonists that lower the shivering threshold but can cause bradycardia, hypotension, and sedation\n- Tramadol: weak μ agonist plus 5-HT/NE reuptake inhibition; variable efficacy and slower onset\n- Magnesium sulfate: modest benefit; adjunctive role\n\nCompared with these options, meperidine’s mechanism (κ agonism and anticholinergic effects) provides rapid, reliable suppression of shivering without significant hypotension, making it the preferred choice for hemodynamically stable PACU patients once active warming is underway.",
    "educationalObjective": "Treat postoperative shivering with meperidine and explain its mechanism via kappa and anticholinergic activity."
  },
  {
    "id": "Core.13.6.16",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Opioids and antagonists",
    "difficulty": "hard",
    "questionText": "A 68-year-old man is scheduled for laparoscopic colectomy. The anesthetic plan includes giving methadone 0.15 mg/kg at induction to improve postoperative analgesia. Past history includes ischemic cardiomyopathy (EF 35%) and obstructive sleep apnea. Current medications are sertraline 100 mg daily and fluconazole 200 mg daily (started 3 days ago for oral candidiasis). Preoperative ECG shows QTc 495 ms; electrolytes reveal K 3.2 mEq/L and Mg 1.6 mg/dL. Prophylactic ondansetron was planned. He is opioid-naive.\n\nWhich perioperative analgesic plan is most appropriate regarding methadone in this patient?",
    "answers": [
      {
        "text": "Continue with methadone but switch fluconazole to ketoconazole and plan postoperative QT monitoring.",
        "isCorrect": false,
        "explanation": "Ketoconazole is an even stronger CYP3A4 inhibitor and itself prolongs QT, further increasing methadone exposure and torsades risk; monitoring alone is insufficient if risk is avoidable."
      },
      {
        "text": "Administer methadone (0.15 mg/kg) with continuous 5‑lead ECG intraoperatively and 24‑hour postoperative telemetry.",
        "isCorrect": false,
        "explanation": "Enhanced monitoring does not prevent methadone‑induced QT prolongation/torsades in a patient with multiple modifiable risk factors and interacting drugs; risk reduction (avoidance) is preferred."
      },
      {
        "text": "Avoid intraoperative methadone; correct K/Mg and use multimodal analgesia with short-acting opioids while avoiding QT‑prolonging antiemetics.",
        "isCorrect": true,
        "explanation": "Baseline QTc is near 500 ms with hypokalemia, hypomagnesemia, and a strong CYP3A4 inhibitor (fluconazole), all of which increase methadone exposure and torsades risk; alternative multimodal analgesia with correction of electrolytes and avoidance of additional QT‑prolonging drugs is safest."
      },
      {
        "text": "Proceed with methadone after substituting dexamethasone for ondansetron and withholding sertraline on the day of surgery.",
        "isCorrect": false,
        "explanation": "Avoiding ondansetron removes one QT‑prolonging agent, but the major interaction (fluconazole inhibition of methadone metabolism) and baseline QT prolongation remain; holding one SSRI dose does not meaningfully change risk."
      },
      {
        "text": "Give reduced-dose methadone (0.05 mg/kg) after magnesium replacement and proceed with standard monitoring.",
        "isCorrect": false,
        "explanation": "Dose reduction and partial electrolyte correction do not adequately mitigate torsades risk when QTc is already markedly prolonged and K remains low; methadone’s QT effect is not reliably dose‑safe in this context."
      }
    ],
    "didactic": "Methadone is a long‑acting μ‑opioid agonist with NMDA receptor antagonism that provides potent, sustained analgesia from a single intraoperative dose (eg, 0.1–0.2 mg/kg). However, methadone blocks the cardiac I<sub>Kr</sub> (hERG) channel and can prolong QTc in a dose‑ and concentration‑dependent manner, predisposing to torsades de pointes. Even single perioperative doses can unmask risk in susceptible patients.\n\nRisk increases with the combination of:\n- Prolonged baseline QTc (caution ≥450 ms; generally avoid ≥500 ms)\n- Electrolyte abnormalities (low K/Mg), bradycardia, structural heart disease\n- Concomitant QT‑prolonging drugs (eg, ondansetron, droperidol, haloperidol, macrolides)\n- CYP inhibition raising methadone levels (eg, azoles [fluconazole, ketoconazole], macrolides, amiodarone; CYP3A4/2B6/2D6)\n- Serotonergic agents (SSRIs/SNRIs/MAOIs) that add serotonergic toxicity risk\n\nThis patient has a QTc of 495 ms plus hypokalemia, hypomagnesemia, and fluconazole (a strong CYP3A4/2C9 inhibitor that increases methadone concentration) in addition to planned ondansetron. Administering methadone here materially increases torsades risk; “monitoring through the risk” is not appropriate when modifiable factors exist.\n\nSafer management includes:\n- Defer methadone; correct electrolytes (target K >4.0 mEq/L, Mg >2.0 mg/dL)\n- Avoid additional QT‑prolonging agents (consider dexamethasone, scopolamine; minimize/avoid ondansetron)\n- Use multimodal, opioid‑sparing analgesia (regional anesthesia, acetaminophen, NSAID if appropriate, low‑dose ketamine, lidocaine infusion) plus short‑acting opioids (eg, fentanyl, hydromorphone) titrated to effect\n- Reassess QTc and interacting medications before considering methadone in the future\n\nWhen methadone is chosen in lower‑risk patients, obtain a baseline ECG if risk factors are present, avoid interacting drugs, correct electrolytes, and consider postoperative telemetry if QTc approaches 500 ms. The priority is to maximize analgesic benefit while minimizing preventable proarrhythmic risk through careful patient selection and drug interaction management.",
    "educationalObjective": "Use methadone perioperatively for analgesia while monitoring for QT prolongation and drug interactions."
  },
  {
    "id": "Core.13.7.1",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Reversal and block monitoring",
    "difficulty": "medium",
    "questionText": "A 58-year-old man with OSA undergoes laparoscopic cholecystectomy under general anesthesia. Induction included propofol, fentanyl, and rocuronium 0.6 mg/kg. The facial nerve (temporal branch) was monitored to time intubation when the eye muscle response was absent, and laryngoscopy was uneventful.\n\nAt the end of the 2-hour case, the last rocuronium dose was 45 minutes ago. Qualitative train-of-four (TOF) at the facial nerve shows 4/4 with minimal fade, but ulnar nerve stimulation over the adductor pollicis shows a TOF count of 2/4 with clear fade. You plan an awake extubation. Which is the best next step to ensure adequate recovery from neuromuscular blockade?",
    "answers": [
      {
        "text": "Switch to ulnar nerve monitoring and guide reversal to an adductor pollicis TOF ratio ≥0.9 before extubation",
        "isCorrect": true,
        "explanation": "Adductor pollicis (ulnar nerve) is more sensitive to nondepolarizers and lags behind airway muscles; confirming recovery at this site (ideally with quantitative TOF ratio ≥0.9) best predicts safe extubation."
      },
      {
        "text": "Proceed with extubation based on facial nerve recovery because it reflects airway muscle function",
        "isCorrect": false,
        "explanation": "Facial nerve responses recover earlier than adductor pollicis and may overestimate overall recovery; relying on facial nerve risks residual paralysis and airway obstruction, especially in OSA."
      },
      {
        "text": "Administer neostigmine 70 mcg/kg now because facial nerve fade is minimal, then extubate",
        "isCorrect": false,
        "explanation": "Dosing and extubation decisions should be guided by ulnar nerve recovery, not facial nerve. High neostigmine dosing without adequate ulnar recovery can result in incomplete reversal or paradoxical weakness."
      },
      {
        "text": "Extubate deep while maintaining positive pressure ventilation to mitigate airway collapse risk",
        "isCorrect": false,
        "explanation": "Deep extubation in the setting of residual neuromuscular block increases risk of airway obstruction and hypoventilation, particularly in OSA; ensure adequate reversal at the ulnar nerve first."
      },
      {
        "text": "Assess depth with post-tetanic count at the facial nerve and extubate if PTC ≥3",
        "isCorrect": false,
        "explanation": "PTC is used at the ulnar nerve to assess deep block, not to determine readiness for extubation at the facial nerve. Extubation decisions should be based on ulnar TOF recovery."
      }
    ],
    "didactic": "Facial and ulnar nerve sites provide complementary information because different muscle groups have distinct sensitivities to nondepolarizing neuromuscular blockers. **Upper airway and diaphragm/laryngeal muscles** are relatively resistant and recover earlier, whereas **adductor pollicis** (ulnar nerve) is more sensitive and recovers later. The **corrugator supercilii** (facial nerve) tracks laryngeal/diaphragmatic behavior better during onset, while the **adductor pollicis** best predicts global recovery at emergence.\n\n- Onset/intubation: Stimulate the facial nerve (eg, corrugator supercilii). Loss of facial response correlates with adequate laryngeal relaxation, enabling timely intubation even while the adductor pollicis may still twitch.\n- Recovery/extubation: Monitor the ulnar nerve (adductor pollicis). Recovery here lags behind airway muscles; thus, if the adductor pollicis is adequately recovered, the airway muscles will be as well, minimizing residual paralysis.\n\nQualitative TOF (tactile/visual fade) is insensitive to detect a TOF ratio near normal. Objective, quantitative monitoring (eg, acceleromyography, electromyography) is preferred, with a target **TOF ratio ≥0.9** prior to extubation. Relying on facial nerve recovery can overestimate readiness, leading to hypoventilation and airway obstruction—risks amplified in OSA.\n\nReversal should be titrated to the ulnar nerve findings:\n- Moderate block (TOF count 2–4 with fade): neostigmine 40–50 mcg/kg with adequate time for effect or sugammadex 2 mg/kg.\n- Deep block (no TOF, PTC present): sugammadex 4 mg/kg; neostigmine is unreliable.\n\nIn this scenario, discordant findings (facial 4/4, ulnar 2/4 with fade) indicate residual block despite seemingly reassuring facial nerve responses. The safest approach is to base extubation on adductor pollicis recovery and confirm a TOF ratio ≥0.9 at the ulnar nerve after appropriate reversal, rather than extubating on the basis of facial nerve recovery.",
    "educationalObjective": "Choose ulnar nerve monitoring for recovery and facial nerve for onset decisions and interpret differences in response."
  },
  {
    "id": "Core.13.7.2",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Reversal and block monitoring",
    "difficulty": "hard",
    "questionText": "A 25-year-old woman (60 kg) undergoes urgent laparoscopic appendectomy. She takes a combined oral contraceptive (ethinyl estradiol/levonorgestrel) daily and reports taking today’s pill at 07:00. Neuromuscular blockade with rocuronium is reversed at the end of the case with sugammadex 3 mg/kg. In the PACU, she plans unprotected intercourse later this week and asks how to avoid pregnancy after today’s anesthesia.\n\nWhich of the following is the most appropriate contraceptive counseling after intraoperative sugammadex administration today?",
    "answers": [
      {
        "text": "No changes are needed—continue pills as scheduled; backup contraception is unnecessary because sugammadex has a short half-life.",
        "isCorrect": false,
        "explanation": "Despite a short half-life, the interaction is considered equivalent to a missed dose; a 7-day non-hormonal backup is recommended."
      },
      {
        "text": "Take one additional active pill now (from a spare pack) and continue the pack as scheduled; use condoms or abstain for the next 7 days after sugammadex.",
        "isCorrect": true,
        "explanation": "Sugammadex can bind progestins and reduce hormonal contraceptive efficacy; same-day oral dosing should be managed as a missed dose plus a non-hormonal backup method for 7 days."
      },
      {
        "text": "Skip today’s pill and take two pills tomorrow; use backup contraception for only 24 hours.",
        "isCorrect": false,
        "explanation": "This does not follow missed-dose guidance and underestimates the duration of reduced efficacy; backup is needed for 7 days."
      },
      {
        "text": "Switch to depot medroxyprogesterone acetate today and stop the pill; no backup is needed after the injection.",
        "isCorrect": false,
        "explanation": "Sugammadex can bind progestogens regardless of route; switching methods now does not obviate the need for 7 days of non-hormonal backup."
      },
      {
        "text": "Take ulipristal acetate today and stop the pill for 5 days; no additional backup will be needed thereafter.",
        "isCorrect": false,
        "explanation": "Emergency contraception is not indicated in the absence of recent unprotected intercourse, and ulipristal conflicts with ongoing combined pill use."
      }
    ],
    "didactic": "Sugammadex is a modified γ-cyclodextrin that encapsulates aminosteroidal neuromuscular blockers (eg, rocuronium, vecuronium). It can also bind other steroidal molecules, including components of **hormonal contraceptives**. As a result, administering **sugammadex** may transiently lower circulating progestin (and to a lesser degree estrogen), reducing contraceptive efficacy. Regulatory guidance treats this interaction as equivalent to a **missed dose** of hormonal contraception.\n\nKey counseling points after sugammadex:\n- All **hormonal methods** (combined or progestin-only; oral, patch, ring, implant, injection, levonorgestrel IUD) require a **non-hormonal backup method** (eg, condoms, abstinence) for **7 days** after sugammadex.\n- For **oral contraceptives** taken on the same day as sugammadex, manage as a missed dose: take an **additional active pill** as soon as possible (from a spare pack) and continue the current pack on schedule, plus use **7 days** of non-hormonal backup.\n- Non-oral methods (eg, etonogestrel implant, DMPA injection, vaginal ring, transdermal patch, LNG-IUD) should be continued; do **not** remove devices, give extra hormones, or change injection timing. Still advise **7 days** of backup.\n- Do not assume the short plasma half-life of sugammadex eliminates risk; the label-based precaution remains **7 days**.\n- If **unprotected intercourse** occurs within the 7 days after sugammadex, discuss **emergency contraception**. A copper IUD is most effective; oral options can be used when appropriate, but avoid ulipristal if continuing progestin-containing contraception due to antagonistic effects.\n\nFor anesthesia providers, anticipatory counseling in the PACU should clearly document the interaction, the need for **7 days** of non-hormonal backup, and missed-dose actions for same-day oral contraceptive users. This approach minimizes unintended pregnancy risk without unnecessary changes to the patient’s ongoing contraceptive method.",
    "educationalObjective": "Counsel about sugammadex binding interactions with hormonal contraceptives and plan backup contraception."
  },
  {
    "id": "Core.13.7.3",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Reversal and block monitoring",
    "difficulty": "hard",
    "questionText": "A 35-year-old man (80 kg) undergoes RSI for small-bowel obstruction using propofol and rocuronium 1.2 mg/kg. Ninety seconds later, direct laryngoscopy reveals a grade 4 view and bag-mask ventilation with an oral airway and two-handed technique is ineffective; an LMA fails to seat due to massive regurgitation. SpO<sub>2</sub> falls to 84% despite 100% O<sub>2</sub>. Quantitative neuromuscular monitoring shows TOF 0/4 with a post-tetanic count of 0. A cricothyrotomy kit is being opened. Which immediate pharmacologic action is most appropriate to rapidly restore neuromuscular function in this scenario?",
    "answers": [
      {
        "text": "Administer sugammadex 16 mg/kg IV now",
        "isCorrect": true,
        "explanation": "For immediate rescue soon after rocuronium-induced RSI when TOF is 0/4, 16 mg/kg rapidly encapsulates circulating and tissue rocuronium to restore spontaneous ventilation as quickly as possible."
      },
      {
        "text": "Administer neostigmine 0.07 mg/kg with glycopyrrolate IV now",
        "isCorrect": false,
        "explanation": "Anticholinesterases are ineffective in profound block (no twitches) and have a delayed, ceiling-limited effect; they cannot provide rapid rescue here."
      },
      {
        "text": "Wait 20 minutes with continued attempts at mask ventilation and 100% O<sub>2</sub>",
        "isCorrect": false,
        "explanation": "In a CICO scenario with worsening hypoxemia, delaying reversal is unsafe. Passive recovery from 1.2 mg/kg rocuronium is too slow to be lifesaving."
      },
      {
        "text": "Administer sugammadex 2 mg/kg IV now",
        "isCorrect": false,
        "explanation": "2 mg/kg is for moderate block (reappearance of T2). With TOF 0/4 and PTC 0 shortly after RSI, this dose risks incomplete or delayed reversal and recurarization."
      },
      {
        "text": "Administer sugammadex 4 mg/kg IV now",
        "isCorrect": false,
        "explanation": "4 mg/kg is for deep block (TOF 0/4 with PTC 1–2) after some redistribution. Immediately after high-dose rocuronium, substantial plasma drug remains; 4 mg/kg may be too little, too slow."
      }
    ],
    "didactic": "Sugammadex forms a tight 1:1 complex with steroidal neuromuscular blockers (rocuronium ≫ vecuronium), creating a concentration gradient that pulls drug from the neuromuscular junction into plasma and reverses paralysis independent of acetylcholine. Dosing must match the depth of block and clinical context. For moderate block (reappearance of the second twitch, T2), **2 mg/kg** is adequate. For deep block with TOF 0/4 and post-tetanic count (PTC) 1–2, **4 mg/kg** is recommended. When immediate rescue is required shortly after a large rocuronium dose for RSI with TOF 0/4 and PTC 0, **16 mg/kg** should be administered to rapidly bind both junctional and substantial circulating rocuronium. Underdosing in this setting risks incomplete reversal, recurarization, and delays in the return of spontaneous ventilation.\n\nIn a can’t intubate–can’t oxygenate scenario, pharmacologic reversal does not replace front‑of‑neck access; it should be performed in parallel while definitive oxygenation is secured. Nonetheless, **16 mg/kg** is the only sugammadex dose validated to provide the fastest possible recovery immediately after RSI. Anticholinesterases (eg, neostigmine) are ineffective in profound block and have a slower onset with a ceiling effect. Waiting for spontaneous recovery from high-dose rocuronium (eg, 1.2 mg/kg) is too slow to be lifesaving.\n\nPractical points:\n- Dose sugammadex by actual body weight.\n- Expect recovery of tidal breathing within minutes; continue full airway rescue until adequate ventilation is confirmed (quantitative TOF ratio ≥0.9 and clinical signs).\n- Sugammadex does not reverse succinylcholine or benzylisoquinoliniums.\n- After large-dose sugammadex, steroidal NMBs may be ineffective for ≥24 h; if re-paralysis is essential, consider succinylcholine with appropriate precautions.",
    "educationalObjective": "Dose sugammadex based on depth of rocuronium or vecuronium block and use 16 mg/kg for immediate rescue after RSI when needed."
  },
  {
    "id": "Core.13.7.4",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Reversal and block monitoring",
    "difficulty": "easy",
    "questionText": "A 70-kg man is finishing a laparoscopic cholecystectomy after rocuronium neuromuscular blockade. Quantitative monitoring shows TOF count 4 with TOF<sub>R</sub> 0.40. He is hemodynamically stable (HR 62/min, MAP 78 mmHg) and breathing spontaneously on pressure support. Due to a supply shortage, sugammadex is unavailable. You plan to reverse with neostigmine. Which of the following reversal regimens is most appropriate to achieve effective reversal while preventing muscarinic side effects?",
    "answers": [
      {
        "text": "Neostigmine 3 mg IV without an antimuscarinic",
        "isCorrect": false,
        "explanation": "Administering neostigmine alone increases acetylcholine at muscarinic receptors, risking bradycardia, bronchospasm, and secretions; an antimuscarinic must be coadministered."
      },
      {
        "text": "Neostigmine 5 mg IV coadministered with glycopyrrolate 0.2 mg IV",
        "isCorrect": false,
        "explanation": "This uses maximal neostigmine for a moderate block and underdoses glycopyrrolate (0.04 mg per 1 mg neostigmine), predisposing to muscarinic side effects."
      },
      {
        "text": "Neostigmine 3 mg IV coadministered with glycopyrrolate 0.6 mg IV",
        "isCorrect": true,
        "explanation": "This pairs neostigmine within the recommended range for moderate block (≈0.04–0.07 mg/kg) with glycopyrrolate at ≈0.2 mg per 1 mg neostigmine, appropriately mitigating bradycardia, bronchospasm, and secretions."
      },
      {
        "text": "Neostigmine 3 mg IV coadministered with atropine 1.2 mg IV",
        "isCorrect": false,
        "explanation": "Atropine’s rapid onset mismatches neostigmine and at this dose is excessively vagolytic, risking marked tachycardia; glycopyrrolate better matches neostigmine’s onset and avoids central effects."
      },
      {
        "text": "Neostigmine 2.5 mg IV coadministered with glycopyrrolate 0.3 mg IV",
        "isCorrect": false,
        "explanation": "Both neostigmine and glycopyrrolate are underdosed for the degree of block; the glycopyrrolate-to-neostigmine ratio is also below the typical 0.2 mg per 1 mg target."
      }
    ],
    "didactic": "Neostigmine reverses nondepolarizing neuromuscular blockade by inhibiting acetylcholinesterase, increasing acetylcholine (ACh) at nicotinic receptors to outcompete the blocker. However, ACh rises at muscarinic receptors (eg, M<sub>2</sub>, M<sub>3</sub>) as well, causing bradycardia, AV block, bronchospasm, increased secretions, and GI hypermotility. To prevent these effects, an antimuscarinic must be coadministered.\n\nFor neostigmine, the preferred antimuscarinic is glycopyrrolate because its onset and duration better match neostigmine and it does not cross the blood–brain barrier (quaternary amine), minimizing central effects. A practical dosing rule is glycopyrrolate 0.2 mg for each 1 mg of neostigmine (≈0.01 mg/kg glycopyrrolate for 0.05 mg/kg neostigmine). For a 70-kg patient with moderate residual block (TOF count 4 with TOF<sub>R</sub> <0.9), neostigmine 0.04–0.07 mg/kg (≈2.8–4.9 mg) is appropriate; pairing 3 mg neostigmine with 0.6 mg glycopyrrolate follows the 0.2 mg per 1 mg ratio and effectively mitigates muscarinic side effects.\n\nKey points:\n- Use quantitative neuromuscular monitoring to guide dosing: deeper block requires higher neostigmine within the safe range, but reversal is ineffective if given before adequate spontaneous recovery (eg, TOF count ≥3–4).\n- Typical adult pairing: neostigmine 0.04–0.07 mg/kg with glycopyrrolate 0.2 mg per 1 mg neostigmine (administered together or glycopyrrolate just before neostigmine).\n- Avoid excessive neostigmine (ceiling effect; max ≈5 mg in adults), which can cause paradoxical weakness if TOF<sub>R</sub> is already ≥0.9.\n- Atropine pairs better with edrophonium due to faster onset; with neostigmine, atropine may cause problematic tachycardia and central effects.\n\nBy coupling neostigmine with an appropriately dosed glycopyrrolate, clinicians achieve reliable reversal of nicotinic blockade while preventing predictable muscarinic adverse effects.",
    "educationalObjective": "Pair neostigmine with glycopyrrolate to prevent muscarinic side effects and select an appropriate dose ratio."
  },
  {
    "id": "Core.13.7.5",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Reversal and block monitoring",
    "difficulty": "easy",
    "questionText": "A 58-year-old man (BMI 40 kg/m²) with severe OSA on nightly CPAP undergoes laparoscopic ventral hernia repair under sevoflurane, fentanyl, and rocuronium (0.6 mg/kg at induction; 10 mg given 30 minutes before closure). At the end, he is normothermic with EtCO₂ 36 mmHg and FiO₂ 0.5; sevoflurane is discontinued. Quantitative acceleromyography at the adductor pollicis shows TOF count 2 with a TOF ratio of 0.30. Sugammadex and neostigmine/glycopyrrolate are available. Which action best minimizes the risk of residual paralysis at extubation?",
    "answers": [
      {
        "text": "Administer neostigmine 40–50 µg/kg with glycopyrrolate now and extubate once clinical tests (eg, 5-second head lift, strong handgrip) are passed.",
        "isCorrect": false,
        "explanation": "Neostigmine is unpredictable when TOF count is 2 and clinical tests are insensitive; residual block often persists despite seemingly adequate effort."
      },
      {
        "text": "Administer neostigmine 70 µg/kg with glycopyrrolate now and extubate when V<sub>T</sub> and respiratory rate appear adequate.",
        "isCorrect": false,
        "explanation": "Excess neostigmine risks paradoxical weakness and is unreliable for reversing a moderate block; clinical signs (V<sub>T</sub>, RR) poorly predict TOF ratio ≥0.9."
      },
      {
        "text": "Perform a posttetanic count and then administer sugammadex 4 mg/kg for deep block before proceeding to extubation.",
        "isCorrect": false,
        "explanation": "PTC is used when TOF count is 0; with TOF count 2, the appropriate sugammadex dose is 2 mg/kg, not 4 mg/kg."
      },
      {
        "text": "Administer sugammadex 2 mg/kg now and extubate after confirming a quantitative TOF ratio ≥0.9 at the adductor pollicis.",
        "isCorrect": true,
        "explanation": "A TOF count of 2 indicates a moderate rocuronium block that is reliably and rapidly reversed by sugammadex 2 mg/kg; extubation is safest once TOF ratio ≥0.9 is documented."
      },
      {
        "text": "Wait for spontaneous recovery to TOF count 4/4 on qualitative monitoring, then extubate without reversal to avoid bradycardia.",
        "isCorrect": false,
        "explanation": "Even with TOF 4/4, the TOF ratio may be <0.9; omitting reversal increases residual paralysis risk, and bradycardia is preventable with anticholinergic pairing."
      }
    ],
    "didactic": "Preventing residual paralysis requires a standardized approach that combines appropriate pharmacologic reversal with objective, quantitative monitoring. For aminosteroid neuromuscular blockers (rocuronium/vecuronium), **sugammadex** encapsulates free drug and provides depth-dependent reversal: \n- Moderate block (TOF count ≥2): 2 mg/kg \n- Deep block (TOF count 0 with PTC 1–2): 4 mg/kg \n- Immediate reversal after RSI dose: 16 mg/kg \n\nIn this patient, a TOF count of 2 with a TOF ratio of 0.30 indicates moderate block; **sugammadex 2 mg/kg** offers rapid, reliable recovery. Extubation should occur only after a **quantitative TOF ratio ≥0.9** (ideally ≥0.95) is confirmed at the adductor pollicis, as qualitative fade and clinical tests (eg, head lift, grip strength, V<sub>T</sub>) do not reliably exclude residual weakness. \n\nIf sugammadex is unavailable, neostigmine (40–50 µg/kg with glycopyrrolate) should be given only when recovery is shallow (eg, TOF count 4 with minimal fade), with ≥10 minutes allowed for effect and quantitative confirmation of TOF ratio ≥0.9 before extubation. Neostigmine has a ceiling effect and can worsen weakness if administered during deep block or overdosed. \n\nStandardized protocols should specify: \n- Use of **quantitative** train-of-four monitoring at the adductor pollicis for all nondepolarizing NMBs \n- Depth-appropriate reversal selection and dosing \n- Extubation only after TOF ratio ≥0.9 is documented \n- Postoperative observation emphasizing respiratory safety \n\nPatients with OSA, obesity, or pulmonary disease have heightened vulnerability to residual paralysis. Postoperatively, employ head-up positioning, supplemental O<sub>2</sub>, early resumption of CPAP, and continuous pulse oximetry (and capnography when available). Close PACU surveillance for airway obstruction, hypoventilation, and re-sedation reduces adverse events and unplanned admissions.",
    "educationalObjective": "Prevent residual paralysis by standardized monitoring and reversal protocols and postoperative observation."
  },
  {
    "id": "Core.13.7.6",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Reversal and block monitoring",
    "difficulty": "medium",
    "questionText": "A 58-year-old man with BMI 32 and obstructive sleep apnea undergoes laparoscopic cholecystectomy with general anesthesia (sevoflurane, fentanyl 200 μg). Neuromuscular blockade is with rocuronium. At case end, qualitative ulnar nerve stimulation at the adductor pollicis shows TOF 4/4 with fade; neostigmine 3 mg and glycopyrrolate 0.6 mg are administered. He is extubated awake, following commands. Fifteen minutes after PACU arrival on 2 L/min O<sub>2</sub> via nasal cannula, he is somnolent with shallow respirations (RR 6/min), SpO<sub>2</sub> 88%, EtCO<sub>2</sub> 55 mmHg on nasal capnography, weak handgrip, and inability to sustain head lift. Breath sounds are clear without obstruction.\n\nWhich of the following is the most appropriate next step?",
    "answers": [
      {
        "text": "Immediately reintubate the trachea and initiate mechanical ventilation",
        "isCorrect": false,
        "explanation": "Airway control may be required if mask ventilation is inadequate, but the initial step is assisted ventilation with reassessment and targeted reversal of residual blockade."
      },
      {
        "text": "Increase nasal O<sub>2</sub> to 6 L/min and continue observation",
        "isCorrect": false,
        "explanation": "Supplemental O<sub>2</sub> alone does not treat hypoventilation and may mask worsening hypercapnia; it fails to address suspected residual neuromuscular block."
      },
      {
        "text": "Administer an additional 5 mg neostigmine IV to overcome residual blockade",
        "isCorrect": false,
        "explanation": "Neostigmine has a ceiling effect and excessive dosing can worsen weakness and cause cholinergic toxicity; it may also outlast or wear off before the NMBA, leading to recurarization."
      },
      {
        "text": "Administer naloxone 0.4 mg IV for presumed opioid-induced respiratory depression",
        "isCorrect": false,
        "explanation": "Opioid-induced hypoventilation typically presents without generalized weakness; profound weakness (eg, inability to sustain head lift) suggests residual neuromuscular blockade rather than pure opioid effect."
      },
      {
        "text": "Provide assisted ventilation with 100% O<sub>2</sub> via bag-mask, apply quantitative TOF monitoring at the adductor pollicis, and if TOF ratio <0.9 administer sugammadex dosed to depth of block",
        "isCorrect": true,
        "explanation": "Immediate support of ventilation and oxygenation is essential; quantitative monitoring confirms residual block, and sugammadex provides rapid, reliable reversal of rocuronium-related recurarization when TOF ratio is <0.9."
      }
    ],
    "didactic": "Residual neuromuscular block and recurarization are common and clinically significant causes of early PACU hypoventilation. Qualitative train-of-four (TOF) showing 4/4 twitches with fade does not ensure adequate recovery; patients can have a TOF ratio of 0.4–0.6 despite 4/4 twitches. Safe extubation requires a quantitative TOF ratio ≥0.9 at the adductor pollicis. Clinical tests (eg, head lift) are insensitive and, when abnormal, strongly suggest significant residual weakness.\n\nNeostigmine reverses nondepolarizing block by inhibiting acetylcholinesterase, increasing acetylcholine at the neuromuscular junction. Its effect is subject to a ceiling; beyond approximately 60–70 μg/kg, additional dosing provides little benefit and may cause muscarinic side effects or paradoxical weakness. Neostigmine has an onset of ~7–10 minutes and duration of ~45–60 minutes; if rocuronium effect persists longer, the mismatch can produce recurarization after initial recovery, especially in patients with risk factors (eg, obesity/OSA, larger or repeated NMBA dosing, volatile anesthetics).\n\nManagement priorities are:\n- Immediately support ventilation and oxygenation (bag-mask with 100% O<sub>2</sub>), treating hypoventilation rather than only hypoxemia.\n- Reassess with quantitative neuromuscular monitoring; a TOF ratio <0.9 confirms residual block.\n- If residual rocuronium/vecuronium is present, administer sugammadex (eg, 2 mg/kg for TOF ≥2, 4 mg/kg for deeper block with post-tetanic counts 1–2, 16 mg/kg for immediate reversal after RSI dose). Avoid additional neostigmine once an adequate dose has been given.\n- Prepare for reintubation if mask ventilation is inadequate or airway protection fails.\n\nDistinguish residual block from opioid sedation: opioid-induced hypoventilation typically lacks generalized muscle weakness and responds to titrated naloxone, whereas residual neuromuscular block presents with objective weakness and requires ventilatory support and appropriate reversal. Continued monitoring and readiness to support ventilation are essential to prevent hypoxemia and hypercapnia-related complications.",
    "educationalObjective": "Recognize and manage recurarization after reversal by continued monitoring and readiness to support ventilation."
  },
  {
    "id": "Core.13.7.7",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Reversal and block monitoring",
    "difficulty": "medium",
    "questionText": "A 52-year-old woman (BMI 26) is finishing a laparoscopic cholecystectomy under sevoflurane anesthesia. Rocuronium 0.2 mg/kg was last given 20 minutes ago. Quantitative neuromuscular monitoring at the adductor pollicis shows train-of-four (TOF) count 0 with a posttetanic count (PTC) of 3. Core temperature is 36.0°C. Due to formulary restrictions, sugammadex is unavailable. The surgeon requests extubation in 15 minutes. Which management will most reliably achieve safe recovery and avoid paradoxical weakness?",
    "answers": [
      {
        "text": "Give neostigmine 20 µg/kg now and repeat 20 µg/kg once TOF twitches return to avoid overdosing",
        "isCorrect": false,
        "explanation": "Split dosing does not overcome the ceiling effect; early dosing during deep block is ineffective and later redosing near full recovery risks paradoxical weakness."
      },
      {
        "text": "Hyperventilate to EtCO₂ 25–30 mmHg, switch to TIVA, then extubate without reversal once the facial nerve shows 4/4 twitches",
        "isCorrect": false,
        "explanation": "Ventilation strategy does not meaningfully speed NMB recovery, and facial nerve monitoring overestimates recovery relevant to airway muscles; extubation without reversal risks residual paralysis."
      },
      {
        "text": "Administer neostigmine 70 µg/kg with glycopyrrolate immediately to overcome the deep block",
        "isCorrect": false,
        "explanation": "Neostigmine has a ceiling effect; giving it during deep block (TOF = 0, low PTC) is ineffective and will not reliably reverse to a TOF ratio ≥0.9 in the desired timeframe."
      },
      {
        "text": "Allow spontaneous recovery until TOF count ≥2 at the adductor pollicis, then give neostigmine 40–50 µg/kg with glycopyrrolate and reassess quantitatively",
        "isCorrect": true,
        "explanation": "Timing neostigmine to at least moderate block optimizes efficacy and avoids the ceiling-effect limitation; quantitative reassessment confirms adequate recovery (TOF ratio ≥0.9) before extubation."
      },
      {
        "text": "Administer neostigmine 40 µg/kg with glycopyrrolate now because some recovery is present (PTC 3)",
        "isCorrect": false,
        "explanation": "Reversal with neostigmine should be delayed until at least moderate block (TOF count ≥2) at the adductor pollicis; earlier dosing is unreliable due to the ceiling effect."
      }
    ],
    "didactic": "Neostigmine increases acetylcholine at the neuromuscular junction by inhibiting acetylcholinesterase, competitively antagonizing nondepolarizing block. Its reversal capability is limited by a **ceiling effect**: once acetylcholinesterase is maximally inhibited, additional neostigmine does not further increase synaptic acetylcholine. Consequently, giving neostigmine during **deep block** (eg, TOF count 0 with low PTC) is unreliable and often ineffective; adequate recovery requires spontaneous return to at least **moderate block** (TOF count ≥2 at the adductor pollicis) before administration.\n\nPractical approach:\n- Wait for TOF count ≥2 at the adductor pollicis, then give neostigmine 40–50 µg/kg with an antimuscarinic (eg, glycopyrrolate) in a matched dose.\n- Reassess with quantitative monitoring and ensure TOF ratio ≥0.9 prior to extubation.\n- Avoid doses >60–70 µg/kg; higher dosing does not hasten recovery and increases muscarinic adverse effects.\n\nAvoid **paradoxical weakness**: administering neostigmine when there is minimal or no residual block (eg, TOF ratio ≥0.9–1.0) can worsen muscle function by excessive acetylcholine causing depolarization/desensitization at the nicotinic receptor and augmenting upper airway collapsibility. Do not give “prophylactic” neostigmine once adequate recovery is documented.\n\nMonitoring site matters: the **adductor pollicis** recovers later than facial muscles and better reflects upper airway dilator recovery for safe extubation decisions. Using the facial nerve risks overestimating recovery and premature extubation. Volatile anesthetics and hypothermia potentiate neuromuscular block; minimizing volatile concentration and maintaining normothermia support recovery but do not replace appropriate timing of reversal.\n\nIf rapid reversal from deep block is essential and a steroidal NMB was used, **sugammadex** is preferred; when unavailable, waiting for moderate block before neostigmine is the safest evidence-based strategy.",
    "educationalObjective": "Time neostigmine administration to at least moderate block and recognize the ceiling effect to avoid paradoxical weakness."
  },
  {
    "id": "Core.13.7.8",
    "category": "Pharmacology & Neuromuscular",
    "subcategory": "Reversal and block monitoring",
    "difficulty": "medium",
    "questionText": "A 62-year-old man (BMI 34) with obstructive sleep apnea undergoes laparoscopic cholecystectomy under sevoflurane anesthesia. Rocuronium was used for paralysis (50 mg induction; 10 mg 20 minutes ago). At the end of the case, he is normothermic and breathing spontaneously with end-tidal sevoflurane 0.3%. Quantitative electromyography at the adductor pollicis shows a train-of-four (TOF) count of 4 with a TOF ratio of 0.62. The surgeon is ready for extubation.\n\nWhich management is most appropriate to minimize residual neuromuscular blockade risk before extubation?",
    "answers": [
      {
        "text": "Proceed with extubation now because the patient has 4 twitches and is breathing spontaneously",
        "isCorrect": false,
        "explanation": "A TOF count of 4 does not ensure adequate recovery; a TOF ratio ≥0.9 is required to reduce residual weakness and airway obstruction."
      },
      {
        "text": "Administer sugammadex 2 mg/kg and extubate when the quantitative TOF ratio reaches ≥0.9",
        "isCorrect": true,
        "explanation": "Sugammadex 2 mg/kg reliably reverses moderate rocuronium block (TOF count ≥2). Extubation should be delayed until a quantitative TOF ratio ≥0.9, which correlates with adequate upper airway recovery."
      },
      {
        "text": "Perform 50-Hz tetanus; if no fade is perceived, extubate",
        "isCorrect": false,
        "explanation": "Qualitative assessment of tetanic fade is unreliable and cannot confirm adequate recovery; quantitative TOF monitoring is preferred."
      },
      {
        "text": "Increase FiO<sub>2</sub> to 1.0 and apply 10 cm H<sub>2</sub>O CPAP to facilitate safe extubation despite the low TOF ratio",
        "isCorrect": false,
        "explanation": "Optimizing oxygenation does not treat residual neuromuscular block; extubating with TOF ratio 0.62 risks airway obstruction and hypoventilation."
      },
      {
        "text": "Administer neostigmine 70 µg/kg with glycopyrrolate and extubate immediately based on a sustained 5-second head lift",
        "isCorrect": false,
        "explanation": "Neostigmine requires time to work, and clinical tests (eg, head lift) are insensitive. Immediate extubation at a TOF ratio 0.62 risks residual block."
      }
    ],
    "didactic": "Residual neuromuscular blockade (rNMB) is common and clinically important, particularly in patients with OSA and obesity. rNMB impairs upper airway dilator muscle function, blunts ventilatory responses, and increases risks of airway obstruction, hypoxemia, and aspiration. A **quantitative** train-of-four (TOF) ratio at the adductor pollicis of **≥0.9 to 1.0** is the target before tracheal extubation; qualitative assessments (fade by feel/visualization, tetanus, double-burst) and clinical tests (head lift, grip strength, adequate V<sub>T</sub>) are insensitive and should not guide extubation.\n\nKey principles:\n- Use **quantitative monitoring** (acceleromyography, electromyography, or kinemyography) at the adductor pollicis for extubation decisions. Facial muscles recover earlier than the hand; thus, monitoring the hand avoids false reassurance.\n- A TOF count of 4 only indicates shallow-to-moderate block; the **TOF ratio** quantifies recovery. Extubation at TOF ratio <0.9 is associated with increased airway events.\n- For rocuronium with moderate block (TOF count ≥2), **sugammadex 2 mg/kg** provides rapid and reliable reversal. For deeper block (post-tetanic count 1–2), use 4 mg/kg; for immediate reversal after RSI dose, 16 mg/kg.\n- **Neostigmine** (40–70 µg/kg with antimuscarinic) can reverse shallow block but has a ceiling effect and slower, variable onset; extubation must be delayed until TOF ratio ≥0.9 is confirmed. Avoid unnecessary neostigmine when TOF ratio is already ≥0.9.\n- Maintain normothermia and minimize residual volatile anesthetic, which potentiates nondepolarizing block.\n\nIn this patient with TOF ratio 0.62, the safest strategy is to administer an appropriate reversal (eg, sugammadex 2 mg/kg for moderate block) and **delay extubation until a quantitative TOF ratio ≥0.9** is documented.",
    "educationalObjective": "Use quantitative neuromuscular monitoring and target a TOF ratio of at least 0.9 to 1.0 before extubation."
  },
  {
    "id": "Core.3.1.1",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Discharge criteria and follow-up",
    "difficulty": "easy",
    "questionText": "A 45-year-old man undergoes outpatient knee arthroscopy under general anesthesia with an LMA. Preoperative vitals were BP 130/80 mmHg and HR 70/min. Ninety minutes after arrival to Phase II recovery, he is awake and oriented, moving all extremities, taking deep breaths, and on room air with SpO<sub>2</sub> 95%. Current vitals are BP 122/78 mmHg and HR 76/min. Pain is 3/10 after oral oxycodone/acetaminophen; nausea resolved after oral ondansetron, and he tolerates sips of water. The knee dressing has scant strike-through. He ambulated 15 feet with crutches with minimal assistance and no dizziness. He has not voided. His spouse is present to drive him home.\n\nBased on Aldrete and Post-Anesthesia Discharge Scoring System (PADS) thresholds, what is the most appropriate disposition?",
    "answers": [
      {
        "text": "Delay discharge until he can ambulate independently without any assistance",
        "isCorrect": false,
        "explanation": "PADS allows discharge with assisted ambulation if the total score is ≥9; requiring independent ambulation would inappropriately exceed validated thresholds."
      },
      {
        "text": "Keep in PACU until he voids spontaneously before discharge",
        "isCorrect": false,
        "explanation": "Routine voiding is not required by Aldrete or PADS for discharge after general anesthesia; it is considered for high-risk retention (eg, neuraxial anesthesia, urologic procedures)."
      },
      {
        "text": "Discharge home now with standard instructions and a responsible escort",
        "isCorrect": true,
        "explanation": "He meets Aldrete ≥9 (actually 10) and PADS ≥9 (vitals 2, ambulation 1, N/V 2, pain 2, bleeding 2 = 9). Voiding is not required for routine general anesthesia outpatients when other criteria are met."
      },
      {
        "text": "Withhold discharge because an Aldrete score of 10 is required to leave PACU",
        "isCorrect": false,
        "explanation": "Aldrete ≥9 is generally accepted for Phase I discharge; a perfect score of 10 is not required if other criteria are satisfied."
      },
      {
        "text": "Keep for observation because receipt of an oral opioid precludes same-day discharge",
        "isCorrect": false,
        "explanation": "Oral opioids do not preclude discharge if the patient is alert, oxygenating on room air, and has a responsible escort; counseling on sedation risk and instructions are essential."
      }
    ],
    "didactic": "Safe ambulatory discharge is typically a 2-step process using validated scores for Phase I (Aldrete) and Phase II (PADS). The modified **Aldrete score** assesses immediate recovery from anesthesia: activity, respiration, circulation, consciousness, and O<sub>2</sub> saturation. Each domain scores 0–2; a score ≥9 supports Phase I discharge. Key thresholds include BP within ±20% of baseline (2 points) and SpO<sub>2</sub> >92% on room air (2 points). Needing supplemental O<sub>2</sub> to maintain SpO<sub>2</sub> >90% scores 1, which may still allow discharge if the total is ≥9 and causes are addressed.\n\nThe **Post-Anesthesia Discharge Scoring System (PADS/PADSS)** guides home discharge using 5 domains (0–2 points each; total ≥9):\n- Vital signs: within ±20% of baseline (2), ±20–40% (1)\n- Ambulation/mental status: steady gait and baseline mental status (2); dizziness or requires assistance (1)\n- Nausea/vomiting: minimal and controlled orally (2)\n- Pain: minimal/moderate and adequately managed with oral meds (2)\n- Surgical bleeding: minimal (2)\n\nCommon pitfalls include over-requiring criteria not in these systems. **Voiding is not mandatory** for routine general anesthesia outpatients (consider for neuraxial anesthesia, urologic surgery, or high urinary retention risk). **Independent ambulation is not required** if assisted ambulation yields a total PADS ≥9. A perfect Aldrete of 10 is unnecessary; ≥9 suffices. **Oral opioid use does not preclude discharge** if the patient is alert, oxygenating on room air, hemodynamically stable, and has a responsible escort with clear instructions.\n\nIn this case, Aldrete is 10 (2 points in all domains). PADS is 9: vitals 2, ambulation 1 (crutches, no dizziness), nausea/vomiting 2, pain 2, bleeding 2—meeting the validated threshold for safe discharge with an escort and standard postdischarge counseling.",
    "educationalObjective": "Apply Aldrete or Post-Anesthesia Discharge Scoring System (PADS) thresholds for safe discharge."
  },
  {
    "id": "Core.3.1.2",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Discharge criteria and follow-up",
    "difficulty": "medium",
    "questionText": "A 58-year-old man with moderate obstructive sleep apnea (OSA) on nightly CPAP (BMI 35, no kidney/liver disease, no history of peptic ulcer) undergoes ambulatory arthroscopic rotator cuff debridement under general anesthesia with a single-shot interscalene block (20 mL 0.5% ropivacaine). In PACU, pain is 2/10 with a dense block; vitals are stable and he meets discharge criteria. He will go home with his spouse.\n\nWhich discharge analgesic regimen and counseling would best minimize opioid use while maintaining safety?",
    "answers": [
      {
        "text": "Acetaminophen 1 g every 6 h scheduled (4 g/day), ketorolac 10 mg every 6 h for 5 days, and oxycodone 5 mg every 4 h as needed (dispense 15 tablets); begin opioids before the block wears off to stay ahead of pain.",
        "isCorrect": false,
        "explanation": "Preemptive opioid use increases exposure; higher total acetaminophen, additional ketorolac, and generous opioid quantity elevate adverse-event risk without clear benefit."
      },
      {
        "text": "Acetaminophen 1 g every 8 h scheduled (max 3 g/day) and ibuprofen 600 mg every 6 h with food starting tonight before the block wears off; oxycodone 5 mg 1 tab every 6 h only for severe breakthrough pain (dispense 8–10 tabs, ≤3 days); use CPAP whenever sleeping; avoid alcohol/benzodiazepines; provide naloxone nasal spray with instructions; no driving while taking opioids.",
        "isCorrect": true,
        "explanation": "Combining scheduled acetaminophen and NSAID started before block regression is opioid-sparing; a small supply of short-acting pure opioid for rescue with explicit limits plus CPAP adherence and naloxone for OSA optimizes safety."
      },
      {
        "text": "Hydrocodone/acetaminophen 5/325 mg, 1–2 tabs every 4 h as needed; avoid NSAIDs because of bleeding risk; dispense 30 tablets; routine instructions only.",
        "isCorrect": false,
        "explanation": "Large opioid quantity and combination product risk exceeding safe daily acetaminophen; avoiding NSAIDs without a clear contraindication increases opioid exposure and omits multimodal benefits."
      },
      {
        "text": "Ibuprofen 400 mg every 8 h as needed only; tramadol 50 mg every 6 h scheduled for 5 days; may drive if pain is controlled.",
        "isCorrect": false,
        "explanation": "Tramadol is an opioid with serotonergic/sedative effects and should not be scheduled in OSA; PRN-only NSAID and permissive driving while on opioids undermine safety and analgesic efficacy."
      },
      {
        "text": "Acetaminophen 650 mg every 6 h scheduled (max 2.6 g/day) and celecoxib 200 mg once daily; hydromorphone 2 mg every 4 h as needed (dispense 20 tablets); hold CPAP the first night.",
        "isCorrect": false,
        "explanation": "Underdosed non-opioids and a potent rescue opioid increase risk of oversedation; withholding CPAP in OSA is unsafe and contradicts opioid-sparing principles."
      }
    ],
    "didactic": "Effective opioid-sparing ambulatory analgesia uses multimodal therapy, anticipatory timing, and clear limits. For shoulder arthroscopy with a single-shot interscalene block, instruct patients to start non-opioids before block regression to blunt rebound pain. Scheduling acetaminophen (eg, 1 g every 8 h; outpatient max often limited to ≤3 g/day to avoid inadvertent overdose) plus an NSAID (eg, ibuprofen 400–600 mg every 6 h with food) reduces opioid requirements and opioid-related adverse effects.\n\nRescue opioids should be used only for severe breakthrough pain unrelieved by non-opioids. Prescribe a small quantity of a short-acting, single-agent opioid (eg, oxycodone 5 mg) with explicit dosing and duration limits (typically ≤3 days, ~5–10 tablets total). Avoid combination acetaminophen–opioid products to prevent exceeding safe daily acetaminophen and to simplify titration. Do not advise taking opioids preemptively before the block wears off; instead, schedule non-opioids and add opioid only if needed.\n\nPatients with OSA have heightened risk of opioid-induced ventilatory impairment. Emphasize strict CPAP use whenever sleeping, avoidance of alcohol and other sedatives (eg, benzodiazepines, gabapentinoids), no driving or operating machinery while taking opioids, secure storage, and prompt disposal of unused tablets. Consider providing take-home naloxone and brief education when any opioid is prescribed to patients with OSA or other risk factors.\n\nNSAIDs are appropriate in patients without contraindications (eg, active peptic ulcer disease, significant renal dysfunction, high bleeding risk). Ketorolac should be limited to short courses (≤5 days total exposure). Clear counseling, scheduled non-opioids, and a limited rescue opioid supply together minimize opioid exposure while maintaining adequate analgesia and safety.",
    "educationalObjective": "Control pain with multimodal strategies and provide clear opioid-sparing instructions and limits."
  },
  {
    "id": "Core.3.1.3",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Discharge criteria and follow-up",
    "difficulty": "medium",
    "questionText": "A 58-year-old man (BMI 38 kg/m²) with severe OSA (AHI 42/h) treated with nightly CPAP undergoes outpatient open inguinal hernia repair under spinal anesthesia using hyperbaric bupivacaine and intrathecal morphine 0.2 mg. In PACU, after 50 µg IV fentanyl for incisional pain, he has two episodes of upper-airway obstruction with desaturation to 86% on room air requiring jaw thrust and CPAP. Two hours later he is awake, comfortable on acetaminophen/NSAID, RR 14/min, SpO<sub>2</sub> 95% on room air, and hemodynamically stable. He and his spouse wish to go home today.\n\nWhich postoperative disposition is most appropriate to minimize risk of delayed respiratory depression?",
    "answers": [
      {
        "text": "Observe in PACU for 3 additional hours and discharge if no further events on room air",
        "isCorrect": false,
        "explanation": "A brief extended PACU stay may be reasonable for low-risk OSA without long-acting opioids; intrathecal morphine poses risk that peaks beyond this window."
      },
      {
        "text": "Admit to a monitored bed with overnight continuous pulse oximetry and use of CPAP during sleep",
        "isCorrect": true,
        "explanation": "Severe OSA, recurrent PACU airway obstruction on room air, and intrathecal morphine warrant inpatient monitoring (eg, continuous oximetry, CPAP as needed) for delayed respiratory depression over the first postoperative night."
      },
      {
        "text": "Discharge home now with instructions to use CPAP during sleep and avoid opioids",
        "isCorrect": false,
        "explanation": "Same-day discharge is unsafe given severe OSA, recurrent PACU obstruction/hypoxemia on room air, and neuraxial morphine with delayed respiratory depressant effects."
      },
      {
        "text": "Admit to ICU for continuous capnography and telemetry monitoring overnight",
        "isCorrect": false,
        "explanation": "ICU-level monitoring is typically unnecessary without additional risk factors (eg, escalating oxygen needs, hemodynamic instability, or high-dose opioids); a monitored floor bed is appropriate."
      },
      {
        "text": "Observe in PACU until 7 hours after the last hypoxemic episode on room air, then discharge",
        "isCorrect": false,
        "explanation": "The \"7-hour after last event\" approach applies to OSA without long-acting neuraxial opioids; intrathecal morphine can cause respiratory depression 6–12 hours postdose (up to 24 hours)."
      }
    ],
    "didactic": "Patients with OSA are at increased risk for postoperative airway obstruction, hypoventilation, and hypoxemia, especially when exposed to opioids or sedatives. Disposition after ambulatory surgery should integrate: (1) OSA severity and home CPAP adherence, (2) surgical invasiveness and analgesic plan, and (3) PACU course while breathing room air. Recurrent obstruction or hypoxemia on room air in PACU identifies patients at risk for adverse events after discharge.\n\nNeuraxial opioids add a distinct risk of delayed respiratory depression due to rostral spread in CSF. Intrathecal morphine has biphasic effects, with a late peak at 6–12 hours and potential events up to 24 hours postdose. Risk is increased by higher doses, older age, coadministered sedatives or systemic opioids, and OSA. Accordingly, professional guidance recommends enhanced monitoring after neuraxial morphine (eg, frequent sedation/ventilatory assessments for at least 12–24 hours). These timelines extend well beyond routine PACU stays, making same-day discharge unsafe when intrathecal morphine is used in at-risk patients.\n\nFor ambulatory OSA patients without long-acting opioids and without PACU events, extended observation may suffice before discharge (eg, stable on room air with no recurrent obstruction/hypoxemia, use of CPAP during sleep, and minimal opioid needs). However, supplemental O<sub>2</sub> can mask hypoventilation, so readiness must be confirmed on room air.\n\nIn this case, severe OSA, two hypoxemic airway obstruction episodes on room air, and intrathecal morphine (0.2 mg) create overlapping risks for late respiratory depression well after PACU. The safest disposition is admission to a monitored bed with continuous pulse oximetry, use of CPAP during sleep, and avoidance/minimization of systemic opioids. ICU-level care is unnecessary unless there are additional concerns (eg, escalating O<sub>2</sub> needs, hemodynamic instability). This approach aligns with the need for extended observation in OSA, after late neuraxial opioids, or following unexpected PACU respiratory events.",
    "educationalObjective": "Define extended observation needs for OSA, late neuraxial opioids, or unexpected events in PACU."
  },
  {
    "id": "Core.3.1.4",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Discharge criteria and follow-up",
    "difficulty": "easy",
    "questionText": "A 28-year-old man undergoes ambulatory knee arthroscopy under general anesthesia with an LMA. In PACU he is awake and oriented with pain 3/10 on oral acetaminophen/ibuprofen, tolerating liquids, SpO<sub>2</sub> 98% on room air, stable vitals, minimal dressing spotting, Aldrete 10, and a responsible adult escort for the 30-minute trip home. The nurse asks you to provide final discharge counseling.\n\nWhich of the following discharge instructions best addresses key red flags and the appropriate pathways for seeking help?",
    "answers": [
      {
        "text": "Seek immediate care (call 911 or go to the ED) for chest pain, severe shortness of breath, uncontrolled bleeding that soaks ≥2 dressings in 1 hour, or fainting; call the surgeon's 24-hour number for fever ≥38.5 °C, refractory vomiting (>3 episodes or inability to keep fluids), or increasing calf pain/swelling; otherwise continue routine wound care and pain control as instructed.",
        "isCorrect": true,
        "explanation": "Appropriately distinguishes emergencies (911/ED) from urgent surgeon contact, uses practical thresholds for bleeding, fever, and vomiting, and includes a VTE symptom screen."
      },
      {
        "text": "Manage at home unless temperature is ≥39.5 °C or bleeding persists for more than 24 hours; avoid calling 911 and contact the office during business hours for all concerns.",
        "isCorrect": false,
        "explanation": "Dangerously delays recognition of serious complications and discourages emergency activation for life-threatening symptoms."
      },
      {
        "text": "Call the clinic if pain exceeds 5/10, if there is any bleeding at the incision, or if temperature is ≥37.5 °C; use home ondansetron for nausea; avoid driving for 24 hours.",
        "isCorrect": false,
        "explanation": "Sets an inappropriately low fever threshold, overcalls minor expected oozing, and omits escalation for dyspnea or severe bleeding, risking both over- and under-triage."
      },
      {
        "text": "Return to the emergency department for any nausea or any blood on the dressing; otherwise follow up at the scheduled postoperative visit.",
        "isCorrect": false,
        "explanation": "Overutilizes the ED for minor, expected issues and fails to identify life-threatening red flags (dyspnea, chest pain) or provide graded contact pathways."
      },
      {
        "text": "Contact primary care for fevers, call anesthesia for persistent nausea, and call the surgeon only for wound drainage or suture issues.",
        "isCorrect": false,
        "explanation": "Fragmented contact plan increases delays and confusion; perioperative concerns should route to the surgical team with emergency escalation as needed."
      }
    ],
    "didactic": "Effective ambulatory discharge counseling reduces preventable readmissions and complications. Patients should receive concise red-flag guidance with clear contact pathways that distinguish emergencies from routine issues.\n\n- Bleeding: Minor spotting is common; heavy or uncontrolled bleeding (eg, soaking ≥2 dressings in an hour, large/clotted output, or bleeding that does not respond to 10–15 minutes of direct pressure) warrants urgent evaluation. Uncontrolled hemorrhage is an emergency (911/ED).\n- Fever: Low-grade fever can occur immediately post-op, but persistent or higher fevers are concerning. A practical threshold is ≥38.5 °C or fever that persists/worsens beyond the first day; this should prompt a call to the surgeon's 24-hour line for guidance.\n- Refractory vomiting: >3 episodes or inability to keep fluids down risks dehydration and aspiration. Patients should call the surgeon's 24-hour number for antiemetic advice, hydration guidance, or reassessment. Persistent emesis with dehydration or altered mental status may require ED care.\n- Dyspnea/chest pain/syncope: These are emergencies that may signal aspiration, bronchospasm, pulmonary embolism, myocardial ischemia, or significant hemorrhage. Patients should activate emergency services (911) or go to the ED immediately.\n- VTE symptoms: New or worsening calf pain/swelling after lower-extremity procedures should prompt urgent surgeon contact due to DVT risk.\n\nContact pathways should be explicit: provide the surgeon's 24-hour number for urgent concerns, and instruct immediate 911/ED activation for life-threatening symptoms (severe shortness of breath, chest pain, syncope, uncontrolled bleeding). Include standard precautions (no driving, alcohol, or sedatives for 24 hours; adult supervision; wound care; pain regimen; when to resume medications). Clear, prioritized instructions improve safety and reduce unnecessary ED visits by matching symptom severity to the appropriate level of care.",
    "educationalObjective": "Deliver concise discharge counseling on red flags (bleeding, fever, refractory vomiting, dyspnea) and contact pathways."
  },
  {
    "id": "Core.3.1.5",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Discharge criteria and follow-up",
    "difficulty": "easy",
    "questionText": "A 62-year-old man undergoes outpatient laparoscopic inguinal hernia repair under general anesthesia. In the PACU 2 hours later, he is awake, oriented, and following commands. He swallows water without coughing and has a strong cough. Pain is 3/10 after oral acetaminophen/oxycodone, and nausea has resolved after ondansetron. Vitals are BP 128/74 mmHg, HR 76/min, RR 14/min. SpO<sub>2</sub> is 96% on 2 L/min O<sub>2</sub> by nasal cannula; when O<sub>2</sub> is removed, SpO<sub>2</sub> is 90%–91% at rest and dips to 88% with ambulation. Lungs are clear to auscultation. He has a responsible adult escort.\n\nWhich of the following is the most appropriate next step to meet routine discharge criteria?",
    "answers": [
      {
        "text": "Administer naloxone and discharge if SpO<sub>2</sub> improves immediately",
        "isCorrect": false,
        "explanation": "Empiric reversal is not indicated without clear opioid-induced ventilatory impairment; naloxone’s short duration risks renarcotization after discharge."
      },
      {
        "text": "Obtain a chest radiograph; if normal, discharge with supplemental oxygen",
        "isCorrect": false,
        "explanation": "Imaging is not routinely indicated for expected postoperative atelectasis, and discharge with O<sub>2</sub> still fails to meet standard ambulatory criteria."
      },
      {
        "text": "Prescribe home oxygen for 24 hours and discharge now",
        "isCorrect": false,
        "explanation": "Home O<sub>2</sub> does not substitute for recovery; it may mask hypoventilation and delay recognition of deterioration at home."
      },
      {
        "text": "Discharge home now with instructions to use an incentive spirometer and return if dyspnea occurs",
        "isCorrect": false,
        "explanation": "Patients should not be discharged while requiring supplemental O<sub>2</sub> or desaturating on room air; observation and optimization are needed before discharge."
      },
      {
        "text": "Continue observation and pulmonary recruitment (eg, incentive spirometry, ambulation) until SpO<sub>2</sub> is ≥94% on room air at rest and with ambulation, then discharge",
        "isCorrect": true,
        "explanation": "Routine discharge requires stable vital signs and adequate oxygenation on room air without supplemental O<sub>2</sub>, in addition to return of protective airway reflexes and symptom control."
      }
    ],
    "didactic": "Ambulatory discharge requires that patients demonstrate recovery of protective airway reflexes and stable physiology without ongoing support. Core elements typically include: \n- Normalizing vital signs near baseline (MAP, HR, RR) without vasoactive support.\n- Adequate oxygenation and ventilation on room air (eg, sustained SpO<sub>2</sub> ≥94% or at the patient’s baseline for chronic lung disease) without supplemental O<sub>2</sub> and without recurrent obstruction/apnea.\n- Return of protective reflexes and appropriate mental status (awake or easily arousable, follows commands, intact swallow/cough).\n- Acceptable pain and nausea controlled with oral medications and minimal bleeding.\n- Ability to ambulate as appropriate and a responsible adult escort with clear instructions.\n\nPatients who desaturate on room air or require supplemental O<sub>2</sub> have not met routine discharge criteria. Postoperative hypoxemia is commonly due to atelectasis, residual anesthetic/opioid effect, or upper airway obstruction. Management is supportive: wean O<sub>2</sub> while encouraging pulmonary recruitment (head-up positioning, incentive spirometry, deep breathing, early ambulation) and reassess. Discharge should occur only after sustained normal oxygenation on room air at rest and with light activity.\n\nHome oxygen is not a substitute for recovery because it can conceal hypoventilation and delay recognition of clinical deterioration. Similarly, empiric naloxone is inappropriate without clear evidence of opioid-induced ventilatory impairment and carries a risk of renarcotization after discharge due to its shorter duration than many opioids. Imaging is rarely necessary for expected mild atelectasis in an otherwise stable patient. An important exception is patients with chronic hypoxemia (eg, COPD), for whom the target is their documented baseline saturation on room air rather than a fixed threshold.",
    "educationalObjective": "Ensure return of protective reflexes and stable vital signs without supplemental oxygen for routine discharge."
  },
  {
    "id": "Core.3.1.6",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Discharge criteria and follow-up",
    "difficulty": "medium",
    "questionText": "A 32-year-old woman (nonsmoker) with a strong history of motion sickness and severe postoperative nausea after prior anesthesia is scheduled for ambulatory laparoscopic gynecologic surgery. She will receive general anesthesia and likely require some postoperative opioids despite planned multimodal analgesia. She lives alone and asks how to avoid nausea and vomiting at home because she previously required an ED visit for dehydration after day-surgery.\n\nWhich risk-based perioperative and discharge plan best reduces her risk of postdischarge nausea and vomiting (PDNV)?",
    "answers": [
      {
        "text": "Give ondansetron 4 mg IV at case end only and discharge without an antiemetic prescription; advise the patient to call if symptoms occur.",
        "isCorrect": false,
        "explanation": "Single short-acting prophylaxis without a prescription or written plan is inadequate for high-risk patients and does not address PDNV, which frequently occurs after the drug’s effect has waned."
      },
      {
        "text": "Administer aprepitant 80 mg PO immediately preop as sole prophylaxis and discharge with promethazine 25 mg PO q6h as needed.",
        "isCorrect": false,
        "explanation": "Aprepitant 40 mg is the typical PONV dose; monotherapy is insufficient for very high risk. Promethazine at 25 mg is sedating and not ideal for ambulatory rescue without clear instructions."
      },
      {
        "text": "Administer dexamethasone 8 mg IV after induction and palonosetron 0.075 mg IV at case end plus aprepitant 40 mg PO preoperatively; provide a written rescue plan and prescribe metoclopramide 10 mg PO q6h as needed at first sign of nausea.",
        "isCorrect": true,
        "explanation": "High PDNV risk warrants 2–3 antiemetics from different classes including a long-acting agent (aprepitant or palonosetron) and early dexamethasone, along with a written home rescue plan using a different class (dopamine antagonist) and a prescription."
      },
      {
        "text": "Use propofol TIVA to avoid volatile agents and nitrous oxide; omit intraoperative antiemetics; discharge with oral ondansetron 4 mg as needed without specific instructions.",
        "isCorrect": false,
        "explanation": "TIVA reduces early PONV but does not reliably prevent PDNV. High-risk patients still require multimodal prophylaxis and structured, written rescue instructions."
      },
      {
        "text": "Place a scopolamine patch in PACU, give dexamethasone 8 mg IV at case end, and discharge with an oxycodone prescription only.",
        "isCorrect": false,
        "explanation": "Scopolamine requires several hours for onset and should be placed preoperatively; dexamethasone is most effective when given at induction. No antiemetic prescription or plan increases PDNV risk."
      }
    ],
    "didactic": "Postdischarge nausea and vomiting (PDNV) is common after ambulatory anesthesia and peaks after patients leave the PACU, when short-acting antiemetics (eg, ondansetron) have waned. Risk is highest in patients with predictors such as female sex, age <50, history of PONV/motion sickness, nausea in PACU, and receipt of PACU opioids. For high-risk patients, prevention requires multimodal prophylaxis with agents from different receptor classes and at least one with prolonged duration, plus a structured home rescue plan with prescriptions.\n\nEffective, risk-based prophylaxis includes:\n- Dexamethasone 4–8 mg IV at induction (glucocorticoid synergy and late PONV benefit)\n- A long-acting agent for PDNV coverage: palonosetron 0.075 mg IV near case end (t½ ≈ 40 h, minimal QT effect) or aprepitant 40 mg PO 1–3 h preop (NK<sub>1</sub> antagonist with ≥24 h effect)\n- Consider adding a third class (eg, scopolamine patch placed preop) in very high risk\n- Opioid-sparing analgesia and adequate hydration\n\nDischarge planning is essential. Provide written instructions describing when and how to take a prescribed rescue antiemetic and when to seek help (eg, persistent vomiting, inability to tolerate fluids). Rescue should ideally use a different class than prophylaxis, such as a dopamine antagonist (eg, metoclopramide 10 mg PO q6h as needed). Phenothiazines (eg, promethazine) can be effective but are sedating and less favorable in ambulatory patients. Oral ondansetron ODT is convenient but may be less effective if a long-acting 5-HT<sub>3</sub> antagonist (palonosetron) was already used.\n\nCommon pitfalls include relying on a single short-acting agent, giving dexamethasone late (reducing efficacy), placing scopolamine at discharge (delayed onset), and failing to send prescriptions or written rescue plans. High-risk patients do best with 2–3 complementary agents and explicit home instructions to reduce ED visits and unplanned care after discharge.",
    "educationalObjective": "Prevent PDNV with risk-based prophylaxis and provide written rescue plans and prescriptions if needed."
  },
  {
    "id": "Core.3.1.7",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Discharge criteria and follow-up",
    "difficulty": "easy",
    "questionText": "A 54-year-old man undergoes outpatient colonoscopy under monitored anesthesia care with propofol (total 150 mg) and fentanyl 50 μg. In PACU 45 minutes later, he is awake, oriented, pain 2/10, hemodynamically stable, tolerating oral fluids, and has an Aldrete score of 10. He lives alone and requests discharge to a rideshare. He plans to drive later to pick up his child, operate a lawn mower this evening, and sign mortgage documents tonight. Which of the following discharge instructions and requirements are most appropriate?",
    "answers": [
      {
        "text": "Permit driving after 6 hours if the patient feels alert, but avoid alcohol for 24 hours.",
        "isCorrect": false,
        "explanation": "Subjective alertness underestimates sedation-related psychomotor deficits; driving and other high-risk activities should be avoided for 24 hours."
      },
      {
        "text": "Discharge to rideshare with return to routine activities as tolerated because recovery scores are normal.",
        "isCorrect": false,
        "explanation": "Meeting physiologic discharge criteria does not eliminate residual cognitive/psychomotor impairment after sedation; rideshare alone does not meet the requirement for a responsible adult escort."
      },
      {
        "text": "No escort is needed if propofol was the only sedative, given its rapid offset; resume normal activities after a brief nap.",
        "isCorrect": false,
        "explanation": "Despite rapid emergence with propofol, subtle neurocognitive deficits can persist; an adult escort and 24-hour activity restrictions remain standard."
      },
      {
        "text": "Allow signing documents immediately but advise against driving only if opioids were administered.",
        "isCorrect": false,
        "explanation": "Both sedatives and opioids impair memory and judgment; legal decision-making should be deferred for 24 hours regardless of drug class."
      },
      {
        "text": "Require a responsible adult escort and advise no driving, operating machinery, alcohol use, or signing important legal documents for 24 hours.",
        "isCorrect": true,
        "explanation": "After sedation/anesthesia, patients should be accompanied by a responsible adult and avoid activities requiring judgment or coordination for 24 hours due to residual impairment and risk of complications."
      }
    ],
    "didactic": "Postanesthesia discharge has two components: readiness to leave a monitored setting and postdischarge safety restrictions. Scores such as Aldrete or PADSS assess immediate physiologic recovery but do not ensure restoration of complex cognitive and psychomotor function. Even with rapidly acting agents (eg, propofol) and apparently normal behavior, studies show residual deficits in reaction time, attention, and memory for several hours; when sedatives are combined with opioids (eg, fentanyl), impairment can be prolonged and unpredictable.\n\nAccordingly, ambulatory anesthesia best practice is to require a responsible adult escort for patients who received sedation, deep sedation, or general anesthesia, and to restrict high-risk activities for 24 hours. Key instructions include:\n- No driving, bicycling, or operating machinery/power tools for 24 hours.\n- No important financial or legal decisions and no signing of binding documents for 24 hours due to impaired judgment and potential anterograde amnesia.\n- No alcohol or sedating medications, and use prescribed analgesics cautiously.\n- Have a responsible adult remain with the patient to assist, monitor for complications (eg, bleeding, syncope, hypoventilation), and seek help if needed.\n\nA rideshare driver is not a substitute for a responsible adult because they cannot provide supervision, assist at home, or make health-related judgments. Normal recovery scores permit discharge from PACU but do not shorten activity restrictions. Patients who received only local anesthesia without sedatives may not require these limitations; however, once any sedative or opioid is given for the procedure, a conservative 24-hour restriction is recommended to reduce accident risk and medicolegal concerns. Clear counseling and written instructions improve safety and help set expectations before the procedure.",
    "educationalObjective": "Set adult escort and activity restrictions (no driving, machinery, legal decisions) for 24 hours after sedation/anesthesia."
  },
  {
    "id": "Core.3.2.1",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "MRI and remote safety",
    "difficulty": "medium",
    "questionText": "A 55-year-old man (BMI 36) with obstructive sleep apnea on nightly CPAP and severe claustrophobia is scheduled for a 60-minute 3T brain MRI after an aborted attempt last week due to movement and panic under light sedation. He is otherwise healthy, NPO, and has normal airway exam. The MRI suite has MRI-conditional monitors, an anesthesia machine, and an infusion pump. You aim to ensure immobility, maintain airway safety in the remote environment, and prevent acoustic injury from scanner noise. \n\nWhich anesthetic and hearing-protection plan is most appropriate for this patient today?",
    "answers": [
      {
        "text": "Ketamine infusion (0.5 mg/kg/h) with midazolam adjunct, nasal cannula O<sub>2</sub>, and foam earplugs only",
        "isCorrect": false,
        "explanation": "Ketamine is associated with nystagmus, increased secretions, and patient movement—undesirable for MRI. Airway support and hearing protection are inadequate."
      },
      {
        "text": "Dexmedetomidine infusion (1 µg/kg load, then 0.7 µg/kg/h) with facemask O<sub>2</sub> and foam earplugs only",
        "isCorrect": false,
        "explanation": "Dexmedetomidine preserves ventilation but often yields incomplete immobility for prolonged head MRI in claustrophobic adults; facemask in an OSA patient in a remote site increases airway risk. Single earplugs are suboptimal hearing protection."
      },
      {
        "text": "Deliver sevoflurane via nasal cannula with spontaneous ventilation and foam earplugs only",
        "isCorrect": false,
        "explanation": "Volatile anesthetic cannot be reliably or safely delivered via nasal cannula; depth will be inconsistent and patient movement likely. Single earplugs provide limited attenuation and may be inadequate at 3T."
      },
      {
        "text": "Propofol TIVA (100–150 µg/kg/min) ± low-dose remifentanil with a second-generation LMA, controlled ventilation on the MRI-conditional ventilator, and double hearing protection (foam earplugs plus MRI-compatible earmuffs)",
        "isCorrect": true,
        "explanation": "Propofol-based TIVA with a secured airway provides reliable immobility and airway control in OSA within the remote MRI environment. Double hearing protection best mitigates high acoustic levels during 3T sequences."
      },
      {
        "text": "Sevoflurane 1.0 MAC via LMA with low-flow anesthesia and over-the-ear headphones only",
        "isCorrect": false,
        "explanation": "While GA with an LMA can reduce motion, relying on headphones alone may not provide sufficient attenuation at 3T. TIVA also minimizes equipment demands near the magnet and avoids inhalational pollution in the suite."
      }
    ],
    "didactic": "High-field (3T) MRI generates peak acoustic levels that can exceed 110–120 dB, risking temporary threshold shifts and tinnitus. Because anesthetized or deeply sedated patients cannot report discomfort or adjust devices, **double hearing protection**—foam earplugs plus MRI-compatible earmuffs/headphones—provides superior attenuation and should be applied before the coil is placed and the table enters Zone IV.\n\nFor motion-sensitive neuroimaging, the primary goal is **reliable immobility** with a safe airway in a remote environment. **Propofol-based TIVA** produces rapid-on/offset hypnosis and stable immobility with minimal interference from the MRI environment. In adults with severe claustrophobia and OSA, securing the airway (eg, second-generation LMA) and using controlled ventilation reduces motion, simplifies gas sampling, and provides a rescue pathway should obstruction or hypoventilation occur. Remifentanil at low effect-site concentrations can blunt responses to stimulation without prolonging recovery.\n\n**Dexmedetomidine** is valuable for cooperative sedation with preserved ventilation, particularly in pediatrics or when airway instrumentation is undesirable. However, it may not consistently prevent motion during long, noise-intense head MRI in highly anxious adults, and bradycardia/hypotension can occur. If dexmedetomidine is chosen, be prepared to escalate to a secured airway if motion or obstruction develops.\n\nRemote-site anesthesia requires: \n- MRI-conditional monitors and ventilator, with all ferromagnetic items kept outside the 5-gauss line. \n- TIVA via MRI-conditional infusion pump in Zone IV or from Zone III using extension tubing secured to prevent dislodgement. \n- Placement verification of hearing protection and airway position before entering the bore.\n\nThus, propofol TIVA with a secured airway and double hearing protection best balances immobility, airway safety, and auditory protection.",
    "educationalObjective": "Choose anesthetic techniques minimizing motion (TIVA or dexmedetomidine) and protect hearing with appropriate measures."
  },
  {
    "id": "Core.3.2.2",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "MRI and remote safety",
    "difficulty": "medium",
    "questionText": "A 62-year-old man with severe claustrophobia is scheduled for brain MRI under monitored anesthesia care. He reports a surgically treated intracranial aneurysm in 2010 but has no device card or operative note. He is currently in MRI Zone II with standard monitors applied; the technologist suggests proceeding into the 1.5 T scanner because “modern clips are safe,” and the schedule is delayed. \n\nWhat is the most appropriate next step to comply with MRI safety standards before entering MRI Zones III/IV?",
    "answers": [
      {
        "text": "Proceed with a low-SAR protocol and keep the head in neutral position to minimize RF heating and torque on the clip.",
        "isCorrect": false,
        "explanation": "Reducing SAR addresses RF heating but not static/gradient magnetic forces; unverified implants must not be exposed to B<sub>0</sub> regardless of positioning or protocol adjustments."
      },
      {
        "text": "Use a strong handheld magnet at bedside to assess for ferromagnetism; if no movement is detected, proceed with the scan.",
        "isCorrect": false,
        "explanation": "Bedside magnet tests are unsafe, nonstandard, and do not replicate the static (B<sub>0</sub>) or spatial gradient forces in the MRI environment; negative testing does not establish safety."
      },
      {
        "text": "Proceed with the 1.5 T study using MR-compatible monitors because aneurysm clips implanted after the 1990s are generally nonferromagnetic.",
        "isCorrect": false,
        "explanation": "Implant era is not a reliable surrogate for MRI safety; proceeding without primary-source verification of clip model and conditions violates ACR MR safety guidance and risks catastrophic torque/displacement."
      },
      {
        "text": "Obtain skull radiographs to identify the clip, verify its MR-conditional status (field strength, spatial gradient, SAR limits) using the manufacturer/ACR database, and do not enter Zones III/IV until confirmed.",
        "isCorrect": true,
        "explanation": "Primary-source identification of the clip and confirmation of MR-conditional parameters are required before granting Zone III/IV access; if status cannot be verified, the MRI should be deferred or alternative imaging pursued."
      },
      {
        "text": "Proceed after detailed informed consent acknowledging the risks, with neurosurgery on standby in case of clip movement or hemorrhage.",
        "isCorrect": false,
        "explanation": "Informed consent and surgical standby do not mitigate the primary hazard; MRI access requires confirmed MR-safe/conditional status, not risk acceptance."
      }
    ],
    "didactic": "MRI safety relies on strict control of access and verified device compatibility. The suite is divided into **Zones I–IV**, with Zones III/IV restricted to screened and cleared individuals only. Zone II is where screening occurs under supervision of MR personnel; no patient with an implant should enter Zones III/IV until device safety is confirmed.\n\nImplants are labeled **MR Safe**, **MR Conditional**, or **MR Unsafe**. MR-conditional devices are approved only under specific conditions, such as field strength (1.5 T vs 3 T), maximum spatial gradient, RF coil use, and **SAR** limits (eg, ≤2 W/kg). For intracranial aneurysm clips, unverified ferromagnetic models can experience powerful **B<sub>0</sub>**-related torque and displacement, risking hemorrhage. Therefore, proceeding based on assumptions (eg, “modern clips are safe”) is unacceptable.\n\nWhen the patient lacks documentation, recommended steps include:\n- Obtain primary-source identification (device card, operative note, or imaging). Skull radiographs can reveal clip configuration/markers that allow model identification.\n- Verify MR-conditional status and exact scanning conditions via the manufacturer or a vetted database (eg, ACR resources, institutional MR safety listings, MR safety officer consultation).\n- If MR compatibility cannot be confirmed, **do not** enter Zones III/IV; defer MRI and consider alternative imaging (eg, CT/CTA) or obtain records.\n\nUnsafe practices—bedside magnet testing, relying on consent/neurosurgical standby, or simply using lower SAR—do not mitigate static or gradient magnetic forces and violate the ACR MR Safety Manual. Anesthesia teams must ensure MR-compatible equipment, adhere to zone controls, and partner with MR personnel to enforce verification before scanning.",
    "educationalObjective": "Implement MRI zone safety, screen for ferromagnetic implants/devices, and verify MR-conditional status."
  },
  {
    "id": "Core.3.2.3",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "MRI and remote safety",
    "difficulty": "medium",
    "questionText": "An otherwise healthy 5-month-old (6.5 kg) is scheduled for a 90-minute brain MRI under deep sedation with a propofol infusion. The head coil will cover the face, access to the airway during sequences is limited, and the room temperature is maintained at 19°C. The MRI suite has MR-conditional monitors, including ECG, NIBP, SpO<sub>2</sub>, a sidestream capnograph with a 3 m sampling line, and an MR-conditional forced-air warming system with long hose extensions.\n\nWhich monitoring and adjunct plan best addresses respiratory safety and thermoregulation for this case?",
    "answers": [
      {
        "text": "Use impedance respiratory rate and SpO<sub>2</sub> alarms in lieu of capnography; add an esophageal temperature probe and a heat lamp placed just outside the bore; avoid forced-air warming to reduce RF burn risk.",
        "isCorrect": false,
        "explanation": "Impedance respiratory rate is unreliable for apnea detection, and capnography should not be omitted. Heat lamps are generally not MRI-safe and pose burn/ignition risks; an esophageal probe is impractical without a secured airway in deep sedation."
      },
      {
        "text": "Apply continuous sidestream capnography via an MR-compatible nasal cannula; monitor temperature continuously (eg, axillary probe) and use an MR-conditional forced-air warmer with warmed IV fluids throughout the scan.",
        "isCorrect": true,
        "explanation": "Continuous capnography detects apnea/hypoventilation early despite sampling-line delay, which is critical when the face is obscured. Continuous temperature monitoring with active forced-air warming and warmed fluids mitigates substantial hypothermia risk during prolonged MRI in infants."
      },
      {
        "text": "Obtain intermittent capnography waveforms only between image sequences to avoid long-line delay; use warmed gel packs for insulation; forgo continuous temperature monitoring.",
        "isCorrect": false,
        "explanation": "Intermittent ETCO<sub>2</sub> misses clinically significant events during imaging runs. Gel packs provide inconsistent warming and risk thermal injury; continuous temperature monitoring is indicated for long scans in infants."
      },
      {
        "text": "Use standard ASA monitors limited to ECG, NIBP, and SpO<sub>2</sub>; rely on mirror-assisted visual observation of the chest; place a cotton blanket for warmth; omit capnography due to unreliable nasal sampling in infants.",
        "isCorrect": false,
        "explanation": "SpO<sub>2</sub> lags in detecting hypoventilation, and visual observation is limited by the head coil and remote access. Continuous capnography is recommended for deep sedation; passive blankets alone are inadequate warming for a 90-minute scan in an infant."
      },
      {
        "text": "Connect the capnography sampling line to the scavenger port to avoid dead space; defer active warming to prevent overheating in the bore; check tympanic temperature intermittently every 30 minutes.",
        "isCorrect": false,
        "explanation": "Sampling from a scavenger port does not reflect patient CO<sub>2</sub> and defeats monitoring. Intermittent tympanic checks are unreliable during scanning, and avoiding active warming increases hypothermia risk in infants."
      }
    ],
    "didactic": "In remote locations such as MRI, apply the ASA Standards for Basic Anesthetic Monitoring and the sedation guidelines. For moderate to deep sedation—especially when the face and chest are obscured by the head coil—continuous capnography is essential to detect apnea and hypoventilation before oxygen desaturation occurs. SpO<sub>2</sub> alone is a lagging indicator, and impedance respiratory rate is unreliable. A sidestream capnograph with a long sampling line introduces delay but still provides trend and waveform morphology that promptly reveals airway obstruction, hypoventilation, and apnea. Use MR-conditional nasal cannulae with integrated sampling when the patient is breathing spontaneously; if an airway device is placed, sample from the airway adaptor.\n\nInfants are highly susceptible to hypothermia due to a large surface area-to-mass ratio, immature thermoregulation, anesthetic-induced vasodilation, cool ambient temperatures, and dry gases. Prolonged scans (≥60–90 minutes) in a 19°C bore significantly increase heat loss. Continuous temperature monitoring is indicated whenever significant thermal perturbations are anticipated. In sedated infants without a secured airway, an axillary or skin probe provides continuous trending; with a secured airway, an esophageal or rectal probe offers more core-reflective measurements. \n\nEffective prevention includes:\n- MR-conditional forced-air warming with properly routed hoses and nonconductive blankets\n- Warmed IV fluids and minimizing exposed surface area (hat, insulation over torso/extremities)\n- Avoiding conductive loops and ensuring all equipment is MR-conditional\n\nThis approach minimizes hypoventilation-related morbidity through continuous end-tidal CO<sub>2</sub> monitoring and mitigates hypothermia, which can delay emergence, provoke shivering, and degrade image quality. The best plan is continuous capnography plus vigilant, active temperature monitoring and management throughout the scan.",
    "educationalObjective": "Maintain continuous capnography and vigilant temperature management in infants and long scans."
  },
  {
    "id": "Core.3.2.4",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "MRI and remote safety",
    "difficulty": "hard",
    "questionText": "A 68-year-old man with ischemic cardiomyopathy (EF 25%) and a biventricular ICD (CRT-D) implanted for complete heart block presents for urgent 1.5 T brain MRI after new-onset hemiparesis. CT/CTA are nondiagnostic. Device interrogation this morning confirms pacemaker dependence (no intrinsic ventricular activity at 30 bpm) and a fully MR-conditional system when scanned at 1.5 T with SAR ≤2 W/kg. Current settings are DDDR 60–130 with ICD antitachy therapies active. The MRI suite has MRI-compatible monitors and an external defibrillator with pacing; electrophysiology staff are available for reprogramming and post-scan checks.\n\nWhich pre-scan management plan is most appropriate to safely proceed with MRI?",
    "answers": [
      {
        "text": "Have EP reprogram the device to DOO 80 bpm and disable ICD tachy therapies; apply MRI-compatible ECG and pulse oximetry, place external pacing/defibrillation pads, and perform immediate post-scan interrogation/restoration.",
        "isCorrect": true,
        "explanation": "Pacemaker-dependent patients require asynchronous pacing to avoid inhibition from MRI-induced EMI; ICD therapies must be disabled with external defibrillation capability and post-scan interrogation/restoration."
      },
      {
        "text": "Leave the device unchanged and proceed with low-SAR, short sequences while keeping atropine and vasopressors immediately available for bradycardia.",
        "isCorrect": false,
        "explanation": "Demand pacing can be inhibited by MRI-induced EMI in pacemaker-dependent patients; device reprogramming and ICD therapy suspension are required."
      },
      {
        "text": "Reprogram to ODO (pacing off) and disable ICD therapies to minimize lead heating; use capnography only to reduce ECG artifact; keep external pacing pads outside Zone IV.",
        "isCorrect": false,
        "explanation": "Turning pacing off in a pacemaker-dependent patient risks asystole; monitoring and external pacing must be MRI-compatible and applied before entering the scanner room."
      },
      {
        "text": "Place a magnet over the device during the scan to suspend ICD shocks while leaving DDDR pacing; monitor with pulse oximetry and NIBP; post-scan interrogation is optional.",
        "isCorrect": false,
        "explanation": "A magnet does not ensure asynchronous pacing and is unreliable in the MRI environment; ICD therapy suspension without reprogramming and inadequate monitoring is unsafe."
      },
      {
        "text": "Perform the study on a 3 T scanner for better image quality because the system is MR-conditional; briefly suspend the ICD with a magnet during sequences and resume between runs.",
        "isCorrect": false,
        "explanation": "MR-conditional labeling is field-strength specific; a system cleared for 1.5 T should not be scanned at 3 T, and magnet-based management is insufficient."
      }
    ],
    "didactic": "Safely performing MRI in patients with cardiac implantable electronic devices (CIEDs) requires a structured, multidisciplinary protocol. For MR-conditional systems, adherence to the manufacturer’s conditions (field strength, SAR limits, lead configuration) and careful periprocedural management reduce the risks of pacing inhibition, inappropriate shocks, and thermal injury.\n\nKey steps include:\n- Pre-scan device evaluation with **electrophysiology (EP)** to confirm MR-conditional status, battery longevity, lead integrity, underlying rhythm, and **pacemaker dependence**.\n- Device reprogramming tailored to dependence:\n  - **Pacemaker-dependent:** set **asynchronous pacing (VOO/DOO)** at a fixed rate (typically 70–90 bpm) to prevent inhibition from MRI-induced electromagnetic interference.\n  - **Nondependent:** use a demand mode (eg, VVI/DDD with rate response off) per local protocol.\n- For any **ICD/CRT-D**, **disable tachyarrhythmia detection/therapy** to avoid inappropriate shocks; ensure **external defibrillation and pacing** capability with pads applied before entering Zone IV.\n- Use **MRI-compatible monitoring** (ECG and pulse oximetry; add capnography if sedated), maintain ACLS-trained staff, and keep the **programmer immediately available**.\n- Scan within device labeling (eg, **1.5 T** if specified) and **stay within SAR limits** to reduce lead heating risk.\n- Perform **immediate post-scan interrogation** to restore baseline settings and confirm stable sensing, thresholds, and impedances.\n\nMagnets are not a substitute for reprogramming: they may suspend ICD therapies but do not ensure asynchronous pacing, and magnet behavior can be unpredictable in the MRI environment. Similarly, proceeding without reprogramming risks **pacing inhibition** and hemodynamic collapse in dependent patients. When systems are non-conditional or have complicating factors (eg, abandoned leads), EP-led risk–benefit assessment and specialized protocols at 1.5 T are required; otherwise, consider alternative imaging. The most appropriate plan here is EP reprogramming to **DOO** with ICD therapies off, full MRI-compatible monitoring and external rescue capability, and mandatory post-scan device checks.",
    "educationalObjective": "Manage pacemakers/ICDs and other implants per MR-conditional protocols with cardiology support when needed."
  },
  {
    "id": "Core.3.2.5",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "MRI and remote safety",
    "difficulty": "hard",
    "questionText": "A 58-year-old man (BMI 42) with severe OSA on nightly CPAP, symptomatic GERD, Mallampati IV airway, limited mouth opening (3 cm), and prior difficult mask ventilation presents for a 90-minute MRI brain and cervical spine with contrast after aborting a previous attempt due to claustrophobia and obstructive snoring with desaturation while supine. The head coil will enclose the face; the patient’s head will be >1.5 m inside a 60-cm bore, making airway access impractical once scanning begins. The MRI suite has an MRI-conditional anesthesia machine, MR-safe monitors, and circuit/line extensions; standard ferromagnetic airway carts must remain in Zone III.\n\nWhich airway and extraction plan is most appropriate to maximize safety in this setting?",
    "answers": [
      {
        "text": "Begin with light sedation and plan to intubate inside the scanner if needed using an MRI-compatible video laryngoscope kept in Zone IV.",
        "isCorrect": false,
        "explanation": "Planning airway rescue inside the bore is unsafe; even MRI-compatible devices are difficult to deploy rapidly, and the head coil/bore geometry severely restricts access."
      },
      {
        "text": "Induce general anesthesia and intubate with a cuffed endotracheal tube in Zone III, secure all lines with MR-safe extensions and MR-conditional monitoring, then pre-brief a rehearsed extraction plan (clear stop phrase, immediate table-out by technologist, MR-safe BMV/suction staged at the doorway, roles assigned) before entering the bore.",
        "isCorrect": true,
        "explanation": "Securing the airway with an ETT before entering the scanner and rehearsing a team-based extraction plan mitigates the high risk of airway obstruction and the inability to access the airway in the bore."
      },
      {
        "text": "Provide deep propofol sedation with oral airway and nonrebreather O<sub>2</sub>, keep the airway cart just outside Zone IV, and intervene if obstruction occurs.",
        "isCorrect": false,
        "explanation": "Deep sedation risks loss of airway and apnea; the distance from the head and MR restrictions make timely rescue unreliable, and non-MR-safe equipment cannot enter the room quickly enough."
      },
      {
        "text": "Proceed with dexmedetomidine-based moderate sedation using MR-safe nasal cannula O<sub>2</sub>, position the patient carefully within the head coil, and rely on spontaneous ventilation with MRI technologist observation.",
        "isCorrect": false,
        "explanation": "Moderate/deep sedation in a high-risk OSA patient deep in the bore invites airway obstruction without feasible rescue; observation alone is insufficient when access to the airway is severely limited."
      },
      {
        "text": "Induce general anesthesia and place an MRI-conditional supraglottic airway, secure it within the head coil, and proceed with spontaneous ventilation to avoid intubation.",
        "isCorrect": false,
        "explanation": "A supraglottic airway is vulnerable to displacement within the head coil and is suboptimal in severe OSA with symptomatic GERD when access is limited; conversion inside the bore would be hazardous."
      }
    ],
    "didactic": "Remote MRI anesthesia combines constrained access, strong magnetic fields, and device limitations that raise the risk of unrescuable airway events. In patients with severe OSA, prior difficult mask ventilation, and a head coil that encloses the face, sedation (even with dexmedetomidine) frequently provokes obstruction and hypoventilation that cannot be promptly addressed once the head is >1 m inside the bore.\n\nThe safest strategy is to secure the airway before entering the scanner. A cuffed endotracheal tube provides reliable ventilation, protection against aspiration in symptomatic GERD, and positional stability within the head coil. Supraglottic airways are more prone to leak or displacement when transferring to the MRI table or manipulating the coil and are ill-suited when airway access will be impossible for prolonged periods.\n\nA rehearsed extraction plan is essential because many standard rescue tools are ferromagnetic and must remain outside Zone IV. Before scanning:\n- Conduct a team brief with a clear “stop” phrase and predetermined triggers (eg, loss of capnography, airway leak, desaturation, circuit disconnect).\n- Assign roles: technologist immediately performs table-out; anesthesia manages airway at the threshold; runner brings the Zone III airway cart.\n- Stage MR-safe equipment (bag-mask with O<sub>2</sub> source, suction) at the doorway; keep standard carts in Zone III.\n- Use MR-conditional monitors and long circuit/line extensions; ensure audible EtCO<sub>2</sub> and SpO<sub>2</sub> alarms.\n\nDo not plan to initiate or rescue an airway inside the bore. Intubate in Zone III, verify bilateral breath sounds and EtCO<sub>2</sub>, secure/tape lines, and pad interfaces with the head coil. This approach anticipates limited access, respects MR safety, and provides a reliable path to oxygenation/ventilation if deterioration occurs.",
    "educationalObjective": "Plan airway strategy in the scanner bore with limited access and have a rehearsed extraction plan."
  },
  {
    "id": "Core.3.2.6",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "MRI and remote safety",
    "difficulty": "easy",
    "questionText": "A busy outpatient MRI suite with anesthesia support has had a recent near-miss when a ferrous O<sub>2</sub> E-cylinder brought in on a transport cart was pulled toward the magnet as the door to Zone IV opened. Staff from multiple services rotate through, and equipment frequently moves in and out of the scanner room. To reduce projectile risk without unduly slowing workflow, the service director asks you to recommend a single, high-yield change to the entry process at the Zone III→IV threshold. Which intervention will most effectively prevent future projectile incidents?",
    "answers": [
      {
        "text": "Have anesthesia visually verify MR compatibility labels on monitors, pumps, and gas tanks before each case and keep Zone IV doors unlocked for rapid access.",
        "isCorrect": false,
        "explanation": "Visual checks are error-prone and labels can be misread; leaving doors unlocked undermines access control and increases the risk of inadvertent ferrous entry."
      },
      {
        "text": "Post prominent \"No metal beyond this point\" signs and require annual MRI safety education for all staff.",
        "isCorrect": false,
        "explanation": "Education and signage improve awareness but do not consistently stop ferromagnetic objects in high-turnover, high-throughput environments; they lack a hard, auditable barrier at the threshold."
      },
      {
        "text": "Store \"MRI-safe\" O<sub>2</sub> cylinders and emergency carts just inside Zone III for rapid deployment into the scanner if needed.",
        "isCorrect": false,
        "explanation": "Proximity storage without threshold screening increases the chance of inadvertent ferrous entry; decals alone are unreliable and do not replace ferromagnetic detection at the doorway."
      },
      {
        "text": "Use a handheld metal detector to screen patients and staff in preprocedure holding before transport to MRI.",
        "isCorrect": false,
        "explanation": "Handheld detectors are operator-dependent, detect nonferrous metals (creating false positives), and miss small ferrous items; screening away from the threshold allows items to be added later."
      },
      {
        "text": "Install a fixed ferromagnetic detection portal at the Zone III-to-Zone IV threshold and require every person and item of equipment to pass through it after final checks; restrict entry to MR Safe/MR Conditional items only.",
        "isCorrect": true,
        "explanation": "Ferromagnetic detection at the threshold reliably intercepts ferrous objects at the last possible control point and, combined with strict equipment control (MR Safe/MR Conditional), is the most effective measure to prevent projectile events."
      }
    ],
    "didactic": "Projectile incidents in MRI result from the powerful static magnetic field (B0) attracting **ferromagnetic** objects. Most events occur during transitions into Zone IV, often when workflow is busy and items are added late. A high-reliability strategy is to create a hard stop at the doorway: enforce **ferromagnetic detection** of every person and object at the Zone III→IV threshold.\n\nKey elements to reduce projectile risk:\n- **Ferromagnetic detection portal at the threshold:** Fixed portals specifically detect ferrous materials (iron, steel) that become dangerous projectiles. Positioning at the Zone III→IV doorway captures last-minute items and provides an auditable barrier. Handheld wands are operator-dependent and less sensitive/specific, and preholding screening allows items to be added later.\n- **Strict equipment control:** Maintain a curated inventory of **MR Safe** and **MR Conditional** devices. Verify MR Conditional details (eg, field strength, spatial gradient, orientation limits) before entry. Use MR-compatible monitors, ventilators, and infusion pumps; avoid ad hoc substitutions.\n- **Controlled access:** Keep Zone IV doors secured and access mediated by trained MRI personnel; everyone and everything passes through the portal on every entry. Re-screen after any exit/re-entry.\n- **Gas supplies and cylinders:** Prefer pipeline O<sub>2</sub> and MRI-compatible delivery systems. If cylinders are required, ensure truly aluminum or MR Conditional devices and screen them at the threshold; do not rely on decals alone or store ferrous cylinders near the doorway.\n\nEducation and signage support safety culture but are insufficient alone. The combination of a threshold **ferromagnetic detection portal** with **strict equipment control** and controlled access most effectively prevents projectile incidents while preserving workflow in ambulatory and remote anesthesia MRI settings.",
    "educationalObjective": "Prevent projectile incidents by strict equipment control and ferromagnetic detection at the threshold."
  },
  {
    "id": "Core.3.2.7",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "MRI and remote safety",
    "difficulty": "medium",
    "questionText": "A 58-year-old man with severe claustrophobia is scheduled for a 45-minute brain MRI under general anesthesia in a 1.5 T scanner. The anesthesia machine will remain in Zone III with a 3 m breathing circuit extension passed through the waveguide to the patient in Zone IV. MRI-conditional monitors (ECG, SpO<sub>2</sub>, NIBP) and a sidestream capnograph are available. A propofol infusion will run from a pump located outside the scanner room using long extension tubing.\n\nTo minimize patient injury and equipment hazards while maintaining reliable ventilation and gas monitoring, which setup is best before starting the scan?",
    "answers": [
      {
        "text": "Coil excess ECG and SpO<sub>2</sub> cable under the patient’s shoulders to reduce trip hazards and keep the bore clear, and move the ETCO<sub>2</sub> sampling port to the machine end to reduce patient-end weight.",
        "isCorrect": false,
        "explanation": "Cable coils create conductive loops that can cause RF burns; moving the sampling site away from the patient increases ETCO<sub>2</sub> lag and inaccuracy with long tubing."
      },
      {
        "text": "Place a standard ICU infusion pump at the foot of the table in Zone IV to shorten extension tubing and reduce drug delivery delay, keeping all other lines as currently arranged.",
        "isCorrect": false,
        "explanation": "Non–MRI-conditional pumps are ferromagnetic and unsafe in Zone IV; infusion devices should remain outside the 5-gauss line with longer tubing and awareness of delivery delay."
      },
      {
        "text": "Position a steel O<sub>2</sub> cylinder behind the magnet as a backup and route breathing hoses along the bore wall to maximize available space in the isocenter.",
        "isCorrect": false,
        "explanation": "Ferromagnetic cylinders are prohibited in Zone IV; hoses should not hug the bore wall and should be routed straight without contact points that increase burn and entanglement risk."
      },
      {
        "text": "Place the HME filter at the machine end to reduce dead space and remove the ECG leads to avoid artifact; rely on pulse oximetry and NIBP for monitoring.",
        "isCorrect": false,
        "explanation": "The HME belongs at the patient end to condition inspired gas and protect the circuit; ECG is required for GA and MRI-conditional leads can be used safely when routed properly."
      },
      {
        "text": "Route all monitoring cables and the breathing circuit straight down the bore along the midline, avoid any loops, pad where cables/tubing contact skin, secure strain relief at the head, and place the ETCO<sub>2</sub> sampling port at the patient connector.",
        "isCorrect": true,
        "explanation": "Straight, non-looped routing with padding reduces RF burns and dislodgement risk, and placing the capnography sampling port at the patient end minimizes waveform delay and dilution over long tubing."
      }
    ],
    "didactic": "MRI environments demand **MR-conditional equipment** and meticulous line management. Only MRI-conditional devices should enter Zone IV (inside the 5-gauss line). Ferromagnetic items (eg, standard infusion pumps, steel O<sub>2</sub> cylinders) are prohibited due to projectile risk. When the anesthesia machine is remote (Zone III) and long extensions are used, the safest configuration is to route all tubing and cables straight, parallel to the scanner bore, without loops or crossings, and to pad any contact points with insulating material. Looped or coiled wires act as antennas, concentrating RF energy and causing **contact thermal burns**.\n\nFor long breathing circuits, secure the airway and provide **strain relief** near the head to prevent torque and accidental disconnection during table motion. Keep excess circuit length and monitoring cable outside the bore when feasible. Hoses and leads should not touch the bore wall; maintain clearance and padding where skin contact is unavoidable.\n\nCapnography should remain **sidestream with the sampling port at the patient connector**. With long lines, placing the sampling site at the machine end increases dead space mixing and waveform delay (delay ≈ sampling line volume/sampling flow), degrading ventilatory monitoring. Accept a small, predictable lag by keeping the sampling point at the patient and ensuring an unobstructed sampling line.\n\nInfusions should run from outside Zone IV with **extension tubing**; anticipate delivery delays (priming volume) and verify line patency before the scan. Use MRI-conditional ECG, SpO<sub>2</sub>, and NIBP, and route them straight with no skin-to-skin loops, padding under cables, and minimal slack. If backup O<sub>2</sub> is needed in Zone IV, use an **aluminum MRI-conditional cylinder** only. This approach minimizes RF burns, projectile/entanglement hazards, and monitoring artifacts while preserving accurate ETCO<sub>2</sub> and hemodynamic monitoring.",
    "educationalObjective": "Use MRI-compatible anesthesia equipment and remote monitors; route long circuits and tubing safely."
  },
  {
    "id": "Core.3.3.1",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Patient selection and optimization",
    "difficulty": "medium",
    "questionText": "You are covering a freestanding ambulatory surgery center that cannot provide overnight monitoring. The surgeon asks which child can be scheduled today for elective inguinal hernia repair under general anesthesia with same‑day discharge. Preoperative evaluations are summarized below.\n\nWhich patient is the most appropriate candidate for ambulatory surgery at this facility today?",
    "answers": [
      {
        "text": "Former 30‑week GA infant, now 29 weeks postnatal age (postconceptual age 59 weeks), Hgb 9 g/dL, asymptomatic, ASA II",
        "isCorrect": false,
        "explanation": "Ex‑preterm infants <60 weeks postconceptual age and/or with anemia have a significant risk of postanesthetic apnea and typically require admission for monitoring, which this center cannot provide."
      },
      {
        "text": "Former 36‑week GA infant, now 25 weeks postnatal age (postconceptual age 61 weeks), mild URI 10 days ago with cough resolving 4 days ago, afebrile today, ASA II",
        "isCorrect": false,
        "explanation": "Although ≥60 weeks postconceptual age lowers apnea risk, proceeding within 2 weeks of URI symptom resolution still increases perioperative respiratory adverse events; elective cases are generally deferred ≥2 weeks after resolution."
      },
      {
        "text": "Full‑term (39‑week GA) infant, now 6 weeks old (postconceptual age 45 weeks), recovered from RSV bronchiolitis 3 weeks ago, lungs clear today, ASA II",
        "isCorrect": false,
        "explanation": "Term infants ≥44–46 weeks postconceptual age have low apnea risk, but recent lower respiratory tract infection (eg, RSV) carries prolonged airway reactivity; many defer 4–6 weeks after severe URI/bronchiolitis before elective anesthesia."
      },
      {
        "text": "2‑year‑old, ASA II with reactive airway disease, afebrile but with productive cough and wheeze on exam today after a “cold” this week",
        "isCorrect": false,
        "explanation": "Active respiratory symptoms (productive cough, wheeze) increase risk of laryngospasm/bronchospasm; elective ambulatory anesthesia should be postponed until symptom resolution (often ≥2–4 weeks depending on severity)."
      },
      {
        "text": "Former 34‑week GA infant, now 31 weeks postnatal age (postconceptual age 65 weeks), Hgb 12 g/dL, no URI for 1 month, ASA I",
        "isCorrect": true,
        "explanation": "Ex‑preterm infants ≥60 weeks postconceptual age without anemia and without recent URI have a low risk of postanesthetic apnea and respiratory events, making this patient appropriate for same‑day ambulatory surgery."
      }
    ],
    "didactic": "Ambulatory selection in infants and young children must account for both **postanesthetic apnea risk** (age/prematurity) and **perioperative respiratory adverse events** (recent URI severity/timing). Key principles:\n\n- Prematurity and age: The risk of postanesthetic apnea is highest in former preterm infants and declines with increasing postconceptual age (PCA = gestational age at birth + postnatal age). Most guidelines recommend inpatient monitoring for ex‑preterm infants until ≥60 weeks PCA, with a lower risk threshold for term infants around ≥44–46 weeks PCA.\n- Anemia: Low Hgb magnifies apnea risk after anesthesia in young infants, particularly ex‑preterm; correcting anemia or providing postoperative monitoring is advised if proceeding earlier.\n- Recent URI: Airway hyperreactivity increases the risk of laryngospasm, bronchospasm, desaturation (low SpO<sub>2</sub>), and unplanned admission. Elective cases are commonly deferred ≥2 weeks after complete symptom resolution for mild URIs, and 4–6 weeks after severe or lower respiratory tract infections (eg, bronchiolitis/RSV, pneumonia), especially if airway surgery or an endotracheal tube is planned.\n\nApplying these criteria:\n\n- Ex‑preterm <60 weeks PCA or any with anemia → avoid same‑day discharge; admit for monitoring if proceeding.\n- Term infants ≥44–46 weeks PCA without comorbidity and no recent URI can be considered for ambulatory anesthesia.\n- Active URI symptoms or surgery within the high‑risk window after URI/bronchiolitis → postpone.\n\nTherefore, the former 34‑week GA infant at 65 weeks PCA, with normal Hgb and no recent URI, is appropriate for ambulatory surgery. The other choices are limited by heightened apnea risk (ex‑preterm <60 weeks PCA and/or anemia) or increased respiratory complication risk due to recent or ongoing URI. This approach aligns patient selection with safety in facilities lacking overnight monitoring or advanced respiratory support (eg, inability to escalate FiO<sub>2</sub> and observe overnight).",
    "educationalObjective": "Apply pediatric ambulatory selection criteria (age, prematurity-related apnea risk, recent URI)."
  },
  {
    "id": "Core.3.3.2",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Patient selection and optimization",
    "difficulty": "medium",
    "questionText": "A 49-year-old man is scheduled for elective open umbilical hernia repair at a freestanding ambulatory surgery center. BMI is 52 kg/m<sup>2</sup>; comorbidities include well-controlled HTN and type 2 diabetes. He has severe OSA (AHI 42) and uses CPAP only a few nights per week; he did not bring the device. STOP-BANG is 7. Airway exam: Mallampati III, neck circumference 49 cm, thyromental distance 6 cm; prior anesthetics were uneventful. The plan is general anesthesia with multimodal analgesia, but moderate postoperative opioid use is anticipated. The center has standard difficult-airway equipment. Mechanical VTE prophylaxis and early ambulation are planned; he had a provoked DVT 2 years ago and is not on anticoagulation.\n\nWhich single patient factor most strongly necessitates selecting an inpatient venue rather than proceeding at the ambulatory center?",
    "answers": [
      {
        "text": "Mallampati III airway and large neck circumference without prior difficulty",
        "isCorrect": false,
        "explanation": "Potential difficult airway increases preparation needs but, with equipment and expertise, does not by itself mandate inpatient management for a short, low-physiologic-stress procedure."
      },
      {
        "text": "Need for weight-based adjustments in anesthetic and neuromuscular blocker dosing",
        "isCorrect": false,
        "explanation": "Obesity alters pharmacokinetics, but appropriate dose scaling (eg, by lean or total body weight) is standard practice and does not determine venue selection."
      },
      {
        "text": "BMI 52 kg/m<sup>2</sup> in an otherwise optimized patient",
        "isCorrect": false,
        "explanation": "Super-obesity increases perioperative risk and many centers set BMI cutoffs, but BMI alone—without additional high-risk features—is a relative (not absolute) exclusion; venue can be individualized if resources are adequate."
      },
      {
        "text": "Remote, provoked DVT with planned mechanical prophylaxis and early ambulation",
        "isCorrect": false,
        "explanation": "Obesity and prior VTE increase risk, but for a brief ambulatory procedure, mechanical prophylaxis and early ambulation are usually adequate; this alone does not necessitate admission."
      },
      {
        "text": "Severe OSA (AHI 42) with poor CPAP adherence and anticipated postoperative opioid use",
        "isCorrect": true,
        "explanation": "Severe OSA with nonadherence to CPAP and expected opioid requirement markedly increases risk of postoperative airway obstruction and hypoventilation; guidelines favor monitored inpatient care rather than same-day discharge in this setting."
      }
    ],
    "didactic": "Obesity-specific risk assessment for ambulatory surgery must integrate airway/OSA risk, pharmacologic dosing, VTE risk, procedure invasiveness, and facility capability. The feature most likely to necessitate inpatient care is severe OSA with nonadherence to CPAP when postoperative opioids are anticipated. These patients are at high risk for recurrent airway obstruction and hypoventilation after discharge; ASA/SAMBA guidance supports extended monitored recovery and avoidance of unmonitored settings when severe OSA, poor CPAP use, and opioid needs co-exist.\n\nKey considerations in obese patients:\n- OSA and airway: STOP-BANG ≥5 and AHI ≥30 indicate high-risk OSA. Nonadherence to CPAP and expected opioid use substantially increase postoperative respiratory events. If opioids are required and CPAP use is uncertain, an inpatient venue with overnight monitoring is prudent. Mallampati III or large neck alone does not mandate admission if difficult-airway resources are available.\n- BMI thresholds: Super-obesity (BMI ≥50 kg/m<sup>2</sup>) is associated with higher complication rates. Many ASCs adopt BMI cutoffs based on staffing/equipment, but BMI alone is a relative—not absolute—exclusion when other risks are low and resources are robust.\n- Dosing in obesity: Tailor drugs to body composition to avoid overdose/underdose and downstream respiratory depression. Examples: succinylcholine by total body weight; propofol induction and opioids (eg, fentanyl) by lean body weight; nondepolarizing NMBs generally by ideal/lean body weight; titrate volatile and maintenance infusions to effect.\n- VTE risk: Obesity and prior VTE elevate risk. Use mechanical prophylaxis and early ambulation for short ambulatory cases; consider weight-adjusted pharmacologic prophylaxis when procedural/immobility risk is higher (eg, enoxaparin 40 mg BID for BMI ≥40 when indicated).\n\nBottom line: In severe OSA with poor CPAP adherence and anticipated opioids, choose an inpatient venue for monitored recovery and respiratory safety.",
    "educationalObjective": "Assess obesity-specific risks (airway, dosing, VTE) and define thresholds that necessitate inpatient venue."
  },
  {
    "id": "Core.3.3.3",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Patient selection and optimization",
    "difficulty": "hard",
    "questionText": "A 72-year-old man with atrial fibrillation and a drug-eluting coronary stent placed 1 month ago presents for ambulatory trigger finger release. Medications include apixaban 5 mg twice daily (last dose 12 hours ago) and clopidogrel 75 mg daily; aspirin was discontinued after PCI. Creatinine is 1.1 mg/dL (estimated CrCl 65 mL/min), platelets 220,000/µL, and hemoglobin 13 g/dL. The surgeon prefers an upper arm tourniquet and requests a regional anesthetic; the anesthesia plan proposed is a single-shot supraclavicular block with light sedation.\n\nWhich perioperative plan best balances thrombotic and bleeding risks while complying with current ASRA regional/neuraxial anticoagulation recommendations?",
    "answers": [
      {
        "text": "Proceed today using surgeon-performed local infiltration and/or distal wrist/forearm nerve blocks at a compressible site while continuing apixaban and clopidogrel; avoid deep plexus block.",
        "isCorrect": true,
        "explanation": "For minor hand surgery at a compressible site, continuing antithrombotics and avoiding neuraxial/deep plexus blocks aligns with ASRA and minimizes thrombotic risk early after PCI."
      },
      {
        "text": "Proceed as scheduled with a supraclavicular block without holding apixaban or clopidogrel, using ultrasound guidance and careful technique.",
        "isCorrect": false,
        "explanation": "ASRA treats deep plexus/peripheral blocks similarly to neuraxial; concurrent apixaban and clopidogrel without appropriate holds is contraindicated due to noncompressible bleeding risk."
      },
      {
        "text": "Stop apixaban 48 hours preoperatively and bridge with therapeutic LMWH; continue clopidogrel and perform a supraclavicular block.",
        "isCorrect": false,
        "explanation": "Bridging DOACs with LMWH is not recommended and increases bleeding; a deep plexus block remains contraindicated with ongoing P2Y12 inhibition."
      },
      {
        "text": "Hold apixaban for 72 hours and clopidogrel for 5 days to allow a supraclavicular block; proceed under regional anesthesia thereafter.",
        "isCorrect": false,
        "explanation": "Interrupting clopidogrel at 1 month after drug-eluting stent substantially increases stent thrombosis risk; neuraxial/deep plexus timing compliance should not override critical antiplatelet therapy so soon after PCI."
      },
      {
        "text": "Postpone surgery for 5 additional months to complete antiplatelet therapy and then perform supraclavicular block after stopping agents per ASRA.",
        "isCorrect": false,
        "explanation": "Deferral is unnecessary for a low-bleeding-risk, compressible-site procedure that can be safely performed while continuing antithrombotics by modifying the anesthetic technique."
      }
    ],
    "didactic": "Coordinating antithrombotic therapy for minor ambulatory procedures requires integrating procedural bleeding risk, thrombotic risk, and ASRA regional/neuraxial timing. Early after drug-eluting stent placement, interruption of P2Y12 therapy (eg, clopidogrel) carries a high risk of stent thrombosis; elective procedures that require antiplatelet interruption should be deferred for at least 3 months (often 6 months). However, many superficial, compressible-site procedures can proceed without interrupting antithrombotics by modifying the anesthetic plan.\n\nASRA 5th edition treats **neuraxial and deep plexus/peripheral blocks** similarly. For these techniques, recommended minimum holds include:\n- **Direct factor Xa inhibitors (eg, apixaban high dose 5 mg BID): ≥72 hours** before neuraxial or deep plexus/peripheral block.\n- **P2Y12 inhibitors (eg, clopidogrel): 5–7 days** before neuraxial or deep plexus/peripheral block.\n\nWhen such holds are unsafe (eg, 1 month post-DES), deep plexus blocks should be avoided. In contrast, **superficial, compressible peripheral techniques** (eg, wrist/forearm nerve blocks, local infiltration, subcutaneous field blocks) have a low bleeding risk in sites that can be compressed; ASRA does not mandate specific hold intervals for these, and they can typically be performed while continuing antithrombotics with appropriate ultrasound guidance, meticulous technique, and postprocedure observation.\n\nBridging **DOACs** with LMWH is generally **not recommended** for atrial fibrillation because it increases bleeding without reducing thromboembolism, and it does not mitigate the bleeding risk of P2Y12 therapy. For this patient, the safest, guideline-consistent approach is to maintain apixaban and clopidogrel, avoid neuraxial/deep plexus blocks (eg, supraclavicular), and use local infiltration or distal, compressible-site blocks with minimal sedation. This strategy minimizes stent thrombosis risk while complying with ASRA regional/neuraxial anticoagulation recommendations.",
    "educationalObjective": "Coordinate antithrombotic management for minor procedures and ensure neuraxial/regional timing compliance."
  },
  {
    "id": "Core.3.3.4",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Patient selection and optimization",
    "difficulty": "easy",
    "questionText": "A 62-year-old man undergoes ambulatory arthroscopic meniscectomy under general anesthesia with an LMA. Two hours in the PACU, he is awake, follows commands, and has a responsible escort. Preoperatively his room-air SpO<sub>2</sub> was 97%. He is hemodynamically stable, has pain 3/10 on an oral regimen, and nausea resolved after ondansetron; he is tolerating crackers and liquids. On room air, his SpO<sub>2</sub> is 88–89%, improving to 93–94% only with 3 L/min nasal cannula. \n\nWhich of the following post-PACU findings most clearly requires conversion to inpatient observation/admission rather than same-day discharge?",
    "answers": [
      {
        "text": "Pain 7/10 improved to 3/10 with oral oxycodone/acetaminophen; tolerating oral intake",
        "isCorrect": false,
        "explanation": "Adequate pain control on an oral regimen with toleration of PO meets ambulatory discharge criteria; no inpatient conversion is needed."
      },
      {
        "text": "Single episode of emesis treated with ondansetron and scopolamine; now tolerating fluids without nausea",
        "isCorrect": false,
        "explanation": "Controlled PONV with ability to tolerate oral fluids/medications supports safe discharge; recurrent or refractory emesis would be concerning."
      },
      {
        "text": "Transient hypotension to 96/58 mmHg responsive to 500 mL lactated Ringer’s; asymptomatic on ambulation; current BP 110/65 mmHg",
        "isCorrect": false,
        "explanation": "Hemodynamic stability after minimal intervention without ongoing vasopressor/IV fluid requirements is acceptable for discharge."
      },
      {
        "text": "Persistent need for 3 L/min nasal cannula to maintain SpO<sub>2</sub> 93–94% (SpO<sub>2</sub> 88–89% on room air) 2 hours postoperatively",
        "isCorrect": true,
        "explanation": "Inability to maintain adequate oxygenation on room air is a clear ambulatory discharge failure; persistent supplemental O<sub>2</sub> need warrants admission to monitor and treat potential hypoventilation, atelectasis, or opioid/sedative effects."
      },
      {
        "text": "Aldrete score 9 due to mild drowsiness; easily arousable; SpO<sub>2</sub> 96% on room air with stable vitals; has a responsible adult escort",
        "isCorrect": false,
        "explanation": "Meets standard recovery metrics, including adequate oxygenation on room air and appropriate mentation; discharge is reasonable."
      }
    ],
    "didactic": "Ambulatory discharge requires that patients reliably maintain physiology and function at home without continuous monitoring or IV support. Key domains are: \n\n- Hemodynamics: **stable BP and HR** without ongoing resuscitation or vasoactive infusions (eg, MAP ≈ baseline; no persistent hypotension/tachyarrhythmia). \n- Oxygenation/ventilation: **SpO<sub>2</sub> ≥ 92% on room air**, no airway support, and no recurrent obstructive events or hypoventilation. Persistent supplemental O<sub>2</sub> need indicates failure to meet discharge criteria. \n- Symptoms and function: **pain controlled on oral regimen**, **PONV controlled** with ability to tolerate oral fluids/medications, safe ambulation as appropriate, and the presence of a responsible escort. \n- Recovery metrics: acceptable mental status (eg, Aldrete near baseline) and no active bleeding requiring observation.\n\nA persistent requirement for supplemental O<sub>2</sub> is a clear trigger to convert to inpatient observation. Home environments cannot provide continuous monitoring, and supplemental O<sub>2</sub> may **mask opioid/sedative-induced hypoventilation** or evolving atelectasis, increasing risk of delayed respiratory events. Patients should demonstrate adequate oxygenation on room air before discharge, especially when risk factors (opioids, residual anesthetics, OSA, obesity, or pulmonary disease) are present. \n\nIn contrast, issues that are controlled and compatible with home care—eg, pain improved to a tolerable level on oral agents or PONV responsive to antiemetics with toleration of PO—do not mandate admission. Transient, corrected hypotension without ongoing IV/pressor needs is also not a barrier to discharge. \n\nTherefore, conversion-to-inpatient criteria in ambulatory practice include: (1) **hemodynamic instability** requiring IV fluids/vasopressors, (2) **inability to maintain SpO<sub>2</sub> ≥ 92% on room air** or any need for airway support, and (3) **uncontrolled pain or refractory PONV** preventing oral intake or necessitating ongoing parenteral therapy.",
    "educationalObjective": "Define clear conversion-to-inpatient criteria (hemodynamic instability, uncontrolled pain/PONV, oxygen requirement)."
  },
  {
    "id": "Core.3.3.5",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Patient selection and optimization",
    "difficulty": "medium",
    "questionText": "A 65-year-old man is scheduled for elective arthroscopic rotator cuff repair at a freestanding ambulatory surgery center with no overnight capability. Two months ago, he had an NSTEMI treated with a drug-eluting stent to the proximal LAD. He takes aspirin 81 mg daily and ticagrelor 90 mg twice daily. He is asymptomatic with good functional capacity (8 METs), BP 128/74 mmHg, HR 68/min, ECG normal, and labs within reference limits. The surgeon asks if ticagrelor can be stopped 5 days preoperatively to reduce bleeding. Which of the following is the most appropriate perioperative plan for this patient?",
    "answers": [
      {
        "text": "Proceed at the ambulatory center as scheduled while continuing aspirin and ticagrelor.",
        "isCorrect": false,
        "explanation": "Even with DAPT continuation, elective noncardiac surgery within 3 months of DES for ACS is generally deferred; a freestanding ASC lacks capacity for escalation if perioperative ischemia occurs."
      },
      {
        "text": "Proceed now at a hospital with postoperative telemetry while continuing DAPT.",
        "isCorrect": false,
        "explanation": "Changing the site does not mitigate the heightened early post-DES thrombotic risk for elective surgery; deferral remains appropriate when the case is not time-sensitive."
      },
      {
        "text": "Bridge ticagrelor with therapeutic low–molecular weight heparin and proceed at the ambulatory center.",
        "isCorrect": false,
        "explanation": "Heparin does not prevent platelet-mediated stent thrombosis and is not an evidence-based bridge for P2Y12 interruption after DES."
      },
      {
        "text": "Defer surgery; re-evaluate after completion of at least 12 months of DAPT following ACS-DES. If P2Y12 interruption is later necessary, schedule at a hospital and continue aspirin perioperatively.",
        "isCorrect": true,
        "explanation": "After DES for ACS, elective noncardiac surgery should be delayed when possible for 12 months to avoid premature P2Y12 interruption; later procedures should favor hospital settings if antiplatelet changes are required."
      },
      {
        "text": "Proceed at the ambulatory center after holding ticagrelor for 5 days and continuing aspirin.",
        "isCorrect": false,
        "explanation": "Interrupting P2Y12 therapy within 3 months of DES markedly increases stent thrombosis risk; elective surgery requiring P2Y12 interruption should be delayed."
      }
    ],
    "didactic": "Preoperative selection for ambulatory surgery must integrate cardiac risk, procedure urgency/bleeding risk, and facility resources. Recent coronary stenting is a major determinant of perioperative major adverse cardiac events (MACE). After drug-eluting stent (DES) placement for acute coronary syndrome (ACS), early interruption of P2Y12 therapy greatly increases stent thrombosis risk, which carries high mortality.\n\nKey guidance (ACC/AHA and perioperative consensus):\n- After DES for ACS, delay elective noncardiac surgery for 12 months when possible to avoid premature cessation of dual antiplatelet therapy (DAPT). Time-sensitive surgery may be considered earlier only when the risk of delay exceeds cardiac risk, preferably ≥3–6 months, with DAPT continuation whenever feasible.\n- Surgery that necessitates P2Y12 interruption within 30 days of any stent (BMS or DES) is harmful; within 3 months of DES is generally high risk and should be avoided if elective.\n- Continue aspirin perioperatively unless bleeding risk is prohibitive; if P2Y12 must be stopped (eg, ticagrelor ~3–5 days, clopidogrel 5 days, prasugrel 7 days), do so only after multidisciplinary discussion.\n- **Heparin/LMWH bridging does not protect against platelet-driven stent thrombosis** and is not a substitute for P2Y12 therapy. Cangrelor bridging is reserved for exceptional, high-risk scenarios in monitored hospital settings, not freestanding ASCs.\n\nAmbulatory considerations: A freestanding ASC lacks overnight monitoring and emergent catheterization, making it unsuitable for early post-PCI patients who may require intensive management if ischemia occurs. Good functional capacity (≥4 METs) reduces non-stent-related risk but does not offset stent-specific thrombosis risk. Therefore, this elective case should be deferred; later, if P2Y12 interruption is necessary, a hospital setting with telemetry and cardiology support is preferred while maintaining aspirin. This approach optimizes cardiovascular outcomes and aligns site-of-service with patient risk.",
    "educationalObjective": "Optimize cardiovascular disease preoperatively and identify cases requiring inpatient monitoring or delay."
  },
  {
    "id": "Core.3.3.6",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Patient selection and optimization",
    "difficulty": "hard",
    "questionText": "A 59-year-old man with BMI 42 kg/m², OSA, GERD, and type 2 diabetes presents for elective ambulatory laparoscopic inguinal hernia repair this afternoon. Home medications include semaglutide (weekly; dose increased 1 week ago; last dose 2 days ago), empagliflozin 25 mg daily (last dose this morning), metformin, and glargine 20 U nightly. He reports persistent nausea and early satiety since the dose increase. He has been NPO 8 h for solids and 2 h for clear liquids. Vitals are normal; glucose is 162 mg/dL, HCO₃⁻ 24 mEq/L. Which perioperative plan best reduces the risks of aspiration and ketoacidosis in this ambulatory patient?",
    "answers": [
      {
        "text": "Postpone surgery; stop empagliflozin for ≥3 days (≥4 days if ertugliflozin) and reschedule once semaglutide-related GI symptoms resolve or dose escalation stabilizes; use a 24-h liquid diet and full-stomach precautions if symptoms persist; continue reduced-dose basal insulin.",
        "isCorrect": true,
        "explanation": "Holding SGLT2 inhibitors for the appropriate interval mitigates euglycemic DKA risk, and deferring elective surgery during GLP-1 RA dose escalation with active GI symptoms lowers aspiration risk; basal insulin should be continued (eg, 70–80%)."
      },
      {
        "text": "Convert to MAC with local anesthesia and minimal sedation to avoid general anesthesia; continue all diabetes medications; standard NPO is sufficient.",
        "isCorrect": false,
        "explanation": "Sedation does not eliminate aspiration risk from delayed gastric emptying, and continuing SGLT2 inhibitors still risks euglycemic DKA in the perioperative fasting/stress state."
      },
      {
        "text": "Admit for overnight insulin infusion and proceed tomorrow; hold semaglutide for 24 h but continue empagliflozin to aid glycemic control.",
        "isCorrect": false,
        "explanation": "An insulin infusion treats hyperglycemia but does not offset the ketogenesis promoted by perioperative SGLT2 inhibitor use; a 24-h GLP-1 RA hold is not the key problem here."
      },
      {
        "text": "Proceed today with rapid sequence induction and full-stomach precautions; continue all diabetes medications except hold metformin morning-of.",
        "isCorrect": false,
        "explanation": "RSI does not eliminate aspiration risk in symptomatic GLP-1 RA use, and proceeding while taking an SGLT2 inhibitor maintains significant euglycemic DKA risk."
      },
      {
        "text": "Proceed today after gastric antral ultrasound if empty; continue semaglutide; hold empagliflozin only on the morning of surgery.",
        "isCorrect": false,
        "explanation": "A morning-of hold is inadequate for SGLT2 inhibitors (risk of euglycemic DKA persists for 3–4 days), and symptomatic GLP-1 RA use during dose escalation remains high risk for aspiration even with a normal scan."
      }
    ],
    "didactic": "SGLT2 inhibitors and GLP-1 receptor agonists pose distinct perioperative hazards that require different strategies.\n\n- SGLT2 inhibitors (eg, empagliflozin, canagliflozin, dapagliflozin; ertugliflozin has a longer half-life) increase glucagon-to-insulin signaling, promote lipolysis, and cause ketone overproduction. Fasting, surgical stress, and reduced insulin doses amplify this, predisposing to euglycemic DKA. The risk persists for several days after the last dose. Best practice is to hold for ≥3 days (≥4 days for ertugliflozin) before elective procedures and continue basal insulin (eg, 70–80% of the usual dose), with ketone monitoring if symptoms or acidosis develop.\n- GLP-1 receptor agonists delay gastric emptying and can leave residual solids despite standard fasting, especially during dose escalation and when patients have GI symptoms (nausea, bloating, early satiety) or concomitant gastroparesis/GERD. A 2024 multi-society update supports continuing GLP-1 RAs in most patients but recommends risk stratification: defer elective surgery during dose escalation or active GI symptoms, or mitigate with a 24-h liquid-only diet, gastric POCUS, and full-stomach precautions if urgent.\n\nIn this ambulatory patient, proceeding today would expose him to both aspiration (symptomatic GLP-1 RA during dose escalation) and euglycemic DKA (ongoing SGLT2 inhibitor). The safest plan is to postpone, discontinue empagliflozin for the recommended interval (≥72 h; ≥96 h for ertugliflozin), and reschedule after GI symptoms resolve or dose escalation stabilizes. On the rescheduled date, consider a 24-h liquid diet and treat as a full stomach if symptoms persist (eg, RSI with cuffed ETT). Maintain basal insulin, hold prandial agents while NPO, check glucose frequently, and avoid large insulin reductions that can precipitate ketosis. This approach aligns optimization with aspiration and ketoacidosis risk reduction in the ambulatory setting.",
    "educationalObjective": "Plan perioperative management of diabetes, including GLP-1 agonists and SGLT2 inhibitors, to reduce aspiration and ketoacidosis risk."
  },
  {
    "id": "Core.3.3.7",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Patient selection and optimization",
    "difficulty": "easy",
    "questionText": "An 82-year-old man is scheduled for elective laparoscopic inguinal hernia repair at an ambulatory surgery center. He is independent in basic ADLs, uses a cane, and reports 4 METs. Preoperative screening shows Timed Up and Go 16 s, grip strength below age norms, Mini-Cog 2/5 with an abnormal clock draw, STOP-Bang 3, and CKD stage 3 (eGFR 48 mL/min/1.73 m²). He lives alone and plans to take a rideshare home; his daughter lives 2 hours away and cannot stay with him overnight. Standard ambulatory discharge criteria require a responsible adult to accompany the patient home and remain available for 24 h.\n\nWhich preoperative finding most strongly indicates that same-day discharge from the ambulatory center is unsafe and should prompt an alternative disposition plan?",
    "answers": [
      {
        "text": "Timed Up and Go of 16 s indicating frailty",
        "isCorrect": false,
        "explanation": "Frailty increases postoperative complications and unplanned admissions, but with reliable home support many frail patients can still be discharged safely; it is not an absolute barrier by itself."
      },
      {
        "text": "Intermediate obstructive sleep apnea risk (STOP-Bang 3)",
        "isCorrect": false,
        "explanation": "Moderate OSA risk can often be managed with opioid-sparing techniques and monitoring; it does not, by itself, preclude ambulatory discharge."
      },
      {
        "text": "Mini-Cog score 2/5 with abnormal clock draw",
        "isCorrect": false,
        "explanation": "Cognitive impairment raises delirium and self-care risk, but with a capable caregiver, safe same-day discharge can still be achieved; the critical issue is the availability of supervision."
      },
      {
        "text": "No responsible adult available to accompany and stay with the patient for 24 h after discharge",
        "isCorrect": true,
        "explanation": "Lack of postdischarge supervision is a common absolute barrier to ambulatory discharge after anesthesia; safe discharge requires an escort and reliable home support."
      },
      {
        "text": "Chronic kidney disease stage 3 (eGFR 48 mL/min/1.73 m²)",
        "isCorrect": false,
        "explanation": "CKD stage 3 requires medication and fluid adjustments but does not inherently preclude ambulatory surgery or discharge if other criteria and social supports are met."
      }
    ],
    "didactic": "Safe same-day discharge after anesthesia depends on more than physiology; it requires screening for three domains: **frailty**, **cognitive impairment**, and **social support**. While frailty and cognitive deficits increase the risk of complications, **absence of a responsible escort and reliable home supervision is an immediate, modifiable barrier** to ambulatory discharge.\n\n- Frailty screening (eg, Timed Up and Go >12 s, slow gait speed, weak grip) predicts postoperative complications, falls, and unplanned admissions. Frail patients can still be discharged safely if perioperative plans are optimized (regional anesthesia, multimodal analgesia, fall precautions) and robust support is present.\n- Cognitive screening (eg, Mini-Cog, abnormal clock draw) identifies risk for delirium, medication mismanagement, and inability to follow instructions. Cognitive impairment does not automatically preclude ambulatory care, but it mandates a reliable caregiver for monitoring, medication administration, and access to help.\n- Social support is the gating factor for same-day discharge. After sedation or anesthesia, patients must have a responsible adult to accompany them home and remain available for 24 h to assist with mobility, medications, nutrition, and urgent help if complications occur. A rideshare driver is not a caregiver, and living alone without supervision is unsafe.\n\nWhen social support is inadequate, the safest options are to postpone until an escort is arranged, add home health services, or convert to 23-h observation/inpatient admission. Proactively integrating frailty and cognitive screens with a targeted social support assessment during the preoperative visit prevents day-of-surgery cancellations and improves outcomes by aligning anesthesia plans with the patient’s functional and home environment.",
    "educationalObjective": "Screen for frailty, cognitive impairment, and social support that affect same-day discharge safety."
  },
  {
    "id": "Core.3.3.8",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Patient selection and optimization",
    "difficulty": "easy",
    "questionText": "You are evaluating today’s list at a freestanding ambulatory surgery center (ASC) without overnight observation or transfusion capability. The facility routinely uses multimodal analgesia and regional blocks and discharges patients the same day with an adult escort. Which of the following scheduled patients is the best candidate for ambulatory surgery at this ASC today?",
    "answers": [
      {
        "text": "45F (ASA III) with type 1 diabetes, A1c 10.5%, fasting glucose 280 mg/dL, peripheral neuropathy; scheduled for wide excision/drainage of perirectal abscess.",
        "isCorrect": false,
        "explanation": "Poorly controlled diabetes with active infection increases perioperative complications and may require admission for glycemic control, IV antibiotics, and pain management—unsuitable for a freestanding ASC."
      },
      {
        "text": "72M (ASA IV) with HFrEF (EF 25%) and orthopnea/edema after ED visit 1 week ago for volume overload; scheduled for laparoscopic cholecystectomy for symptomatic cholelithiasis.",
        "isCorrect": false,
        "explanation": "Decompensated heart failure (unstable ASA IV) and a moderate-complexity intra-abdominal procedure carry high risk and warrant hospital-based care with capability for postoperative monitoring."
      },
      {
        "text": "39F (ASA II), 2 weeks postpartum, Hgb 9 g/dL; scheduled for laparoscopic tubal ligation; plans rideshare home and no adult to stay overnight.",
        "isCorrect": false,
        "explanation": "Lack of a responsible escort and home support is a contraindication to same-day discharge from an ASC, regardless of procedure simplicity."
      },
      {
        "text": "66M (ASA III) with severe OSA (AHI 45) nonadherent to CPAP, BMI 48; scheduled for uvulopalatopharyngoplasty.",
        "isCorrect": false,
        "explanation": "Severe, untreated OSA undergoing airway surgery has high risk of postoperative airway obstruction and opioid sensitivity; inpatient monitoring is recommended rather than a freestanding ASC."
      },
      {
        "text": "58M (ASA III) with prior MI (5 y) and drug-eluting stent (4 y), no angina, functional capacity 6–7 METs, adherent to nightly CPAP for mild OSA, BMI 32, on aspirin and β-blocker; scheduled for unilateral open inguinal hernia repair (≈60 min) with planned ilioinguinal/TAP block; has adult escort and home support.",
        "isCorrect": true,
        "explanation": "Stable ASA III with well-controlled CAD, CPAP-adherent OSA, low-complexity and short-duration procedure with regional analgesia, and reliable home support is appropriate for ambulatory surgery."
      }
    ],
    "didactic": "Appropriate ambulatory candidates are typically **ASA I–II** and selected, well-controlled **ASA III** patients undergoing **low- to moderate-complexity procedures** with limited bleeding, short duration, and manageable pain. The safest choices have stable comorbidities, good functional capacity, and a plan for **opioid-sparing analgesia** (eg, regional blocks, NSAIDs, acetaminophen). A reliable escort and home support are mandatory for same-day discharge.\n\nKey considerations when selecting ASC patients:\n- **Disease stability (ASA class):** Decompensated conditions (eg, CHF exacerbation, unstable angina, severe valvular disease) are poor ASC candidates. Stable CAD with good METs on guideline-directed therapy is generally acceptable.\n- **OSA risk:** Mild–moderate OSA adherent to CPAP may be acceptable if the procedure is low risk and analgesia is opioid-sparing. **Severe or untreated OSA**, especially with airway surgery, increases risk of postoperative airway obstruction and hypoxemia and often necessitates monitored inpatient care with titrated O<sub>2</sub> and potential CPAP.\n- **Procedure complexity:** Superficial or peripheral procedures (eg, hernia repair with block) fit ASC care. Operations with significant pain, PONV, fluid shifts, or bleeding risk (eg, intra-abdominal laparoscopy in high-risk patients) are better in a hospital setting.\n- **Glycemic control:** Marked hyperglycemia (eg, fasting glucose ≈280 mg/dL) and active infection increase infection, wound, and metabolic risks; such cases may require optimization and hospital resources.\n- **Social factors:** An adult escort and capable home supervision are required for discharge; their absence is a strict barrier to ambulatory surgery.\n\nIn this scenario, the 58-year-old with stable CAD and CPAP-adherent OSA undergoing a **short, low-risk hernia repair with regional analgesia** and reliable home support is an appropriate ambulatory candidate. In contrast, decompensated heart failure, poorly controlled diabetes with active infection, lack of escort, and severe untreated OSA with airway surgery each independently argues against freestanding ASC care.",
    "educationalObjective": "Select appropriate ambulatory candidates using ASA class, comorbidity control, and procedure complexity."
  },
  {
    "id": "Core.3.3.9",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Patient selection and optimization",
    "difficulty": "medium",
    "questionText": "You are triaging cases for a freestanding ambulatory surgery center without overnight capability. The team aims to minimize postoperative respiratory risk related to obstructive sleep apnea (OSA) by considering disease severity, expected opioid requirements, and home CPAP adherence. Which patient is the most appropriate candidate for same-day surgery and discharge at this facility?\n\n- All patients have stable cardiopulmonary comorbidities unless otherwise noted, and the center can deliver supplemental O<sub>2</sub> and apply patients’ home CPAP in PACU.",
    "answers": [
      {
        "text": "67-year-old man, BMI 30, AHI 12 (mild OSA), does not own CPAP, scheduled for open inguinal hernia repair; surgeon declines regional block; moderate opioid use anticipated.",
        "isCorrect": false,
        "explanation": "Even with mild OSA, the absence of regional analgesia and anticipated opioid requirements increase risk; a setting with capacity for extended monitoring is preferable if opioid-sparing strategies are not used."
      },
      {
        "text": "48-year-old woman, BMI 33, AHI 24 (moderate OSA), cannot tolerate CPAP, scheduled for laparoscopic cholecystectomy; moderate expected opioid requirement.",
        "isCorrect": false,
        "explanation": "Lack of CPAP adherence combined with a painful intra-abdominal procedure and moderate opioid needs increases risk of postoperative airway obstruction and hypoxemia in a setting without overnight monitoring."
      },
      {
        "text": "60-year-old woman, BMI 35, AHI 35 (severe OSA), adherent to CPAP, scheduled for shoulder arthroscopy; plan for general anesthesia plus interscalene block; moderate pain expected.",
        "isCorrect": false,
        "explanation": "Although CPAP adherence and a nerve block are beneficial, severe OSA plus potential hemidiaphragmatic paresis and moderate postoperative pain make same-day discharge at a facility without observation less suitable."
      },
      {
        "text": "55-year-old man, BMI 41, STOP-Bang 7 (suspected severe OSA, no sleep study), scheduled for septoplasty with turbinate reduction; anticipated nasal packing and moderate opioid use.",
        "isCorrect": false,
        "explanation": "Airway surgery with anticipated edema/obstruction and opioid use in a patient with likely severe OSA is inappropriate for freestanding ambulatory discharge."
      },
      {
        "text": "62-year-old man, BMI 36, AHI 42 (severe OSA), adherent to CPAP (uses ≥6 h/night and will bring device), scheduled for 4-cm posterior neck lipoma excision under local infiltration with light sedation; multimodal analgesia; minimal expected opioid use.",
        "isCorrect": true,
        "explanation": "Severe OSA can be acceptable for ambulatory surgery when postoperative pain is minimal and managed with opioid-sparing techniques, and the patient is reliably adherent to CPAP with plans to use it in PACU and at home."
      }
    ],
    "didactic": "Ambulatory selection for patients with obstructive sleep apnea (OSA) should integrate OSA severity, expected opioid exposure, and home CPAP adherence. Society for Ambulatory Anesthesia and ASA guidance support ambulatory surgery when comorbidities are optimized, the procedure is superficial or minimally painful, postoperative analgesia is predominantly non-opioid, and the patient can use CPAP in PACU and at home. Conversely, high opioid needs, airway surgery, and poor CPAP adherence increase risk of airway obstruction and hypoxemia after discharge.\n\nKey principles:\n- Severity: AHI 5–15 (mild), 15–30 (moderate), >30 (severe). Severe OSA is not an absolute contraindication to ambulatory care if other risk factors are minimized.\n- Opioids: Systemic opioids synergize with OSA to worsen ventilatory drive and upper-airway collapsibility, increasing risk of hypoventilation and desaturation. Favor local/field blocks, neuraxial or peripheral nerve blocks, acetaminophen, NSAIDs, and adjuncts to minimize opioids.\n- CPAP adherence: Reliable nightly use and bringing the device enable postoperative application in PACU and at home, reducing apnea-hypopnea burden and desaturation events. Poor adherence or lack of access to CPAP increases risk, especially with painful procedures.\n- Procedure type: Airway surgeries (eg, tonsillectomy, UPPP, nasal surgery with packing) and painful intra-abdominal/orthopedic procedures with expected opioids are higher risk, especially without overnight monitoring.\n\nApplication:\n- The best ambulatory candidate is the patient with severe OSA who is strongly CPAP-adherent undergoing a superficial procedure under local with minimal sedation and minimal opioid needs. This aligns with opioid-sparing analgesia and allows safe use of CPAP in PACU and at home.\n- Patients with poor CPAP adherence, airway surgery, or moderate-to-high opioid requirements are better managed in settings with capacity for prolonged observation or admission.\n\nIn freestanding centers without overnight capability, strict use of CPAP, multimodal non-opioid analgesia, and careful procedure selection are essential to reduce postoperative respiratory risk in OSA.",
    "educationalObjective": "Stratify OSA patients for ambulatory surgery using severity, opioid needs, and home CPAP adherence."
  },
  {
    "id": "Core.3.4.1",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Procedural sedation and MAC",
    "difficulty": "medium",
    "questionText": "A 45-year-old man (BMI 32) presents to an ambulatory procedure suite for urgent closed reduction of an anterior shoulder dislocation sustained 1 hour ago. Radial pulse and sensation are intact, but pain is 9/10 and muscle spasm limits reduction attempts. He ate a cheeseburger 3 hours ago and has symptomatic GERD controlled with a proton pump inhibitor. The team has propofol, ketamine, and ultrasound available. The surgeon requests reduction as soon as feasible to minimize soft-tissue injury. Which management is most appropriate to minimize aspiration risk while accomplishing timely reduction?",
    "answers": [
      {
        "text": "Perform an ultrasound-guided interscalene block and proceed with minimal sedation in a head-elevated position with suction and airway equipment immediately available.",
        "isCorrect": true,
        "explanation": "A regional technique avoids deep sedation and airway manipulation, allowing urgent reduction while minimizing aspiration risk in a nonfasted patient. Head-up positioning and readiness to manage the airway further reduce risk."
      },
      {
        "text": "Induce general anesthesia with rapid sequence intubation to secure the airway before reduction.",
        "isCorrect": false,
        "explanation": "RSI provides airway protection but adds unnecessary risk for a brief extremity procedure that can be accomplished with regional anesthesia and minimal sedation. Reserve RSI for cases where deep sedation or airway instrumentation is unavoidable."
      },
      {
        "text": "Proceed now with dissociative ketamine sedation because it preserves airway reflexes and eliminates aspiration risk.",
        "isCorrect": false,
        "explanation": "Ketamine often preserves reflexes, but this is not reliable protection; aspiration can still occur with deep sedation. It should not be used to justify proceeding as if the patient has an empty stomach."
      },
      {
        "text": "Proceed now with deep propofol sedation in the supine position because aspiration risk is minimal during procedural sedation.",
        "isCorrect": false,
        "explanation": "Deep sedation blunts airway reflexes and increases aspiration risk in a recently fed patient, especially supine. Sedation does not eliminate aspiration risk, and propofol offers no airway protection."
      },
      {
        "text": "Delay the reduction until 6 hours after the meal to satisfy fasting guidelines, then perform deep sedation with propofol.",
        "isCorrect": false,
        "explanation": "ASA fasting guidance applies to elective sedation; however, this is an urgent procedure. Prolonged delay risks harm (ongoing pain, spasm, potential neurovascular issues) and is not necessary if safer alternatives exist now."
      }
    ],
    "didactic": "ASA fasting guidance for elective sedation mirrors general anesthesia: wait at least 2 hours after clear liquids, 4 hours after breast milk, 6 hours after a light meal/nonhuman milk, and 8 hours after a fatty/fried meal. These intervals reduce, but do not eliminate, aspiration risk because even “moderate sedation” can blunt airway reflexes unpredictably, and “deep sedation” commonly abolishes protective reflexes.\n\nFor urgent procedures when fasting criteria are not met, the approach should change from delaying care to mitigating aspiration risk while achieving the procedural goal. The safest strategy is to avoid deep sedation or positive-pressure ventilation when possible by using regional or local techniques and only minimal sedation. For a shoulder reduction, an ultrasound-guided interscalene (or supraclavicular) block can provide excellent analgesia and muscle relaxation, enabling timely reduction without airway manipulation. Additional risk-reduction steps include:\n- Head-elevated positioning, supplemental O<sub>2</sub>, and immediate access to suction and airway equipment\n- Titrating the lightest sedation needed (eg, small midazolam or fentanyl doses) and maintaining spontaneous ventilation\n- Avoiding bag-mask ventilation if possible; if necessary, use gentle pressures\n\nKetamine’s relative preservation of airway reflexes does not equate to airway protection; aspiration can still occur during dissociative or deep sedation. Conversely, rapid sequence intubation with endotracheal tube provides airway protection but introduces unnecessary risk for brief, non–airway-stimulating procedures that can be managed with regional anesthesia.\n\nIn summary, apply fasting guidelines to elective sedation. When urgent care is needed in a nonfasted patient, prioritize techniques that obviate deep sedation (regional/local anesthesia), use head-up positioning and preparedness for airway rescue, and reserve RSI for situations where airway instrumentation is likely or deep sedation cannot be avoided.",
    "educationalObjective": "Apply fasting guidance for elective sedation and adapt for urgent procedures while mitigating aspiration risk."
  },
  {
    "id": "Core.3.4.2",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Procedural sedation and MAC",
    "difficulty": "medium",
    "questionText": "A 64-year-old man (BMI 40) with severe OSA on nightly CPAP and coronary artery disease on metoprolol presents for outpatient colonoscopy under MAC in a remote endoscopy suite. Vitals: BP 145/80 mmHg, HR 52/min, SpO<sub>2</sub> 98% on room air. The endoscopist anticipates significant looping and requests deep sedation for a potentially prolonged exam. The patient reports prior “stopped breathing” during sedation. Which initial sedation strategy is most appropriate to provide effective analgesia while preserving spontaneous ventilation and hemodynamic stability in this setting?\n\nWhich option is best?",
    "answers": [
      {
        "text": "Midazolam 2 mg IV plus fentanyl 100 mcg IV, titrated to effect",
        "isCorrect": false,
        "explanation": "This combination offers amnesia and analgesia but has synergistic respiratory depression and upper-airway obstruction, particularly hazardous in OSA."
      },
      {
        "text": "Propofol 1 mg/kg IV bolus followed by 100 mcg/kg/min infusion",
        "isCorrect": false,
        "explanation": "Propofol provides rapid, titratable hypnosis but no analgesia and causes dose-dependent hypotension and apnea, increasing risk in OSA and remote settings."
      },
      {
        "text": "Dexmedetomidine 1 mcg/kg loading over 10 min, then 0.4 mcg/kg/h",
        "isCorrect": false,
        "explanation": "Dexmedetomidine preserves ventilation but commonly causes bradycardia and hypotension—problematic in a β-blocked patient with HR 52/min—and provides limited analgesia for painful colonoscopy."
      },
      {
        "text": "Ketamine 0.5 mg/kg IV bolus, then 0.25 mg/kg IV every 5 min as needed",
        "isCorrect": true,
        "explanation": "Ketamine provides potent analgesia with minimal respiratory depression and maintains sympathetic tone, supporting BP without exacerbating bradycardia—well suited for OSA in a remote location."
      },
      {
        "text": "Propofol 0.5 mg/kg IV plus fentanyl 50 mcg IV, titrated to deep sedation",
        "isCorrect": false,
        "explanation": "Combining propofol with an opioid increases risk of apnea and hypotension and still lacks intrinsic analgesia from the hypnotic, making it unfavorable in OSA."
      }
    ],
    "didactic": "Selecting sedatives for procedural sedation requires aligning drug properties with procedural pain, airway risk, and hemodynamics—especially in remote locations. This patient has severe OSA, is β-blocked with baseline bradycardia, and is undergoing a painful procedure (colonoscopy with anticipated looping), necessitating analgesia while preserving ventilation and stable BP.\n\n- Propofol: Rapid onset/recovery and excellent titratability but no analgesia. It causes dose-dependent hypotension and apnea, increasing risk of hypoxemia and airway obstruction in OSA, particularly outside the OR.\n- Midazolam ± opioids: Midazolam provides anxiolysis and amnesia but minimal analgesia; opioids add analgesia but synergistically increase respiratory depression and upper-airway collapsibility—high risk in OSA.\n- Dexmedetomidine: An α<sub>2</sub>-agonist that produces cooperative sedation with minimal effect on ventilation. However, it often causes bradycardia and hypotension (exacerbated by loading doses and concomitant β-blockade) and provides limited analgesia for visceral/colonic stretch. Onset is slower, which can be problematic when rapid titration is needed.\n- Ketamine: A dissociative anesthetic that provides strong analgesia, preserves spontaneous ventilation and airway reflexes, and maintains or increases BP/HR via sympathetic stimulation—advantages in OSA and remote settings. Low IV doses (0.25–1 mg/kg, with 0.25–0.5 mg/kg supplements) are effective for painful endoscopy. Adverse effects include hypersalivation and emergence phenomena; small, judicious benzodiazepine doses can mitigate dysphoria, but caution is warranted in OSA due to respiratory effects.\n\nIn an OSA patient with baseline bradycardia on a β-blocker, ketamine is the best initial choice to meet the goals of analgesia, preserved ventilation, and hemodynamic stability. Supplemental O<sub>2</sub>, capnography, and airway rescue equipment remain essential regardless of agent.",
    "educationalObjective": "Choose sedatives/analgesics (midazolam, fentanyl, propofol, ketamine, dexmedetomidine) based on procedure and patient factors."
  },
  {
    "id": "Core.3.4.3",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Procedural sedation and MAC",
    "difficulty": "easy",
    "questionText": "A 68-year-old man (BMI 36) with severe obstructive sleep apnea on nightly CPAP, hypertension, and type 2 diabetes presents to an ambulatory surgery center for open carpal tunnel release (anticipated duration 25 minutes). The surgeon plans a forearm tourniquet and is comfortable supplementing with local infiltration at the incision. Preoperative vitals are stable; airway exam is Mallampati III, baseline SpO<sub>2</sub> 96% on room air. The patient strongly prefers same-day discharge and wishes to avoid “heavy anesthesia.”\n\nWhich anesthetic plan best optimizes safety and facilitates rapid recovery for this patient?",
    "answers": [
      {
        "text": "Bier block (IVRA with lidocaine) under deep sedation for comfort",
        "isCorrect": false,
        "explanation": "Although effective, IVRA requires an upper extremity tourniquet (often uncomfortable), carries local anesthetic systemic toxicity risk with cuff issues, and deep sedation in OSA still threatens airway safety and delays recovery."
      },
      {
        "text": "General anesthesia with LMA and volatile anesthetic, supplemented with IV opioids for tourniquet tolerance",
        "isCorrect": false,
        "explanation": "Unnecessary airway instrumentation and systemic opioids increase risk of airway obstruction and postoperative respiratory events in OSA, as well as PONV and delayed discharge."
      },
      {
        "text": "Deep propofol sedation without regional or local anesthetic",
        "isCorrect": false,
        "explanation": "Deep sedation in OSA increases risk of airway collapse and hypoventilation, and the absence of regional/local analgesia leads to higher propofol requirements and tourniquet-related discomfort."
      },
      {
        "text": "Ultrasound-guided median nerve block at the forearm with surgeon local infiltration, combined with light, titrated sedation (eg, low-dose propofol) and spontaneous ventilation",
        "isCorrect": true,
        "explanation": "A distal peripheral nerve block plus limited local infiltration provides targeted analgesia, minimizes sedative and opioid needs, preserves airway reflexes, and shortens recovery—an optimal MAC strategy for an OSA patient in ambulatory surgery."
      },
      {
        "text": "Interscalene brachial plexus block with moderate sedation for surgical anesthesia",
        "isCorrect": false,
        "explanation": "Interscalene block is unnecessary for distal hand surgery and commonly causes hemidiaphragmatic paresis; moderate sedation still risks airway obstruction in OSA without improving efficiency."
      }
    ],
    "didactic": "For ambulatory hand surgery in patients with obstructive sleep apnea (OSA), combining a targeted peripheral nerve block with light sedation (monitored anesthesia care) improves safety and recovery compared with deep sedation or general anesthesia. Distal blocks (eg, median nerve at the forearm for carpal tunnel release) provide dense surgical analgesia at the operative site while avoiding the unnecessary risks of proximal plexus blocks (eg, interscalene), which frequently cause hemidiaphragmatic paresis and are mismatched to the dermatomal distribution for hand surgery.\n\nLeveraging regional/local techniques reduces the sedative and opioid doses required to maintain comfort, thereby preserving airway patency and spontaneous ventilation—critical in OSA. Light, titrated sedation (eg, small boluses or a low-dose propofol infusion) minimizes respiratory depression and facilitates fast emergence and discharge. When using MAC in OSA:\n\n- Prefer minimal to moderate sedation; avoid deep sedation that blunts protective reflexes.\n- Use targeted regional anesthesia to cover the surgical stimulus (and tourniquet location) to limit systemic anesthetic needs.\n- Monitor with capnography, provide supplemental O<sub>2</sub>, and maintain readiness for airway support.\n- Minimize benzodiazepines and opioids; consider short-acting agents titrated to effect.\n\nAlternatives highlight trade-offs. General anesthesia with an LMA introduces airway manipulation, greater anesthetic exposure, and more PONV—counterproductive for rapid discharge. Deep propofol sedation without local/regional analgesia increases the risk of airway obstruction and requires higher drug doses, especially with tourniquet discomfort. Bier block (IVRA) can work but relies on an upper arm tourniquet (often uncomfortable), has local anesthetic systemic toxicity risk if the cuff fails, and typically still requires significant sedation in OSA. A distal nerve block plus light sedation best aligns with ambulatory goals: enhanced safety, stable respiration, superior analgesia, and faster recovery.",
    "educationalObjective": "Combine local/regional techniques with light sedation to improve safety and recovery profiles."
  },
  {
    "id": "Core.3.4.4",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Procedural sedation and MAC",
    "difficulty": "easy",
    "questionText": "A 58-year-old man (BMI 34) with known OSA presents to an ambulatory endoscopy center for screening colonoscopy. The plan is “moderate sedation” with propofol under monitored anesthesia care. Shortly after scope insertion, he becomes unresponsive to verbal and tactile stimulation with absent capnography waveform and SpO₂ 89% on 3 L/min nasal cannula. According to the sedation continuum, which statement best describes the required capability of the sedation team in this setting to manage this deeper-than-intended sedation?",
    "answers": [
      {
        "text": "Because the intended plan is moderate sedation, only recognition of deep sedation is required; conversion to general anesthesia is not necessary in the ambulatory endoscopy setting.",
        "isCorrect": false,
        "explanation": "Providers of moderate/deep sedation must be able to rescue from the next deeper level, including managing a general anesthesia-level airway if needed, regardless of location."
      },
      {
        "text": "Continuous capnography is sufficient to prevent apnea; if apnea occurs, verbal stimulation and dose reduction are adequate without advanced airway equipment on site.",
        "isCorrect": false,
        "explanation": "Capnography facilitates early detection but does not prevent apnea. Providers must be prepared to perform airway maneuvers and provide positive-pressure ventilation with advanced airway equipment immediately available."
      },
      {
        "text": "Maintain the ability to rescue from a deeper level than intended—recognize progression to deep sedation/general anesthesia and provide airway support with positive-pressure ventilation and advanced airway management as needed to restore the intended level.",
        "isCorrect": true,
        "explanation": "The sedation continuum is dynamic; providers must have the skills, personnel, and equipment to rescue from the next deeper level, including airway support, PPV, and advanced airway management when indicated."
      },
      {
        "text": "Rescue from deeper sedation is the responsibility of the proceduralist; the anesthesia clinician’s role is to titrate sedatives and monitor vital signs.",
        "isCorrect": false,
        "explanation": "The clinician administering sedation is responsible for recognizing deeper sedation and performing rescue, including airway management and ventilation support."
      },
      {
        "text": "Ensure availability of flumazenil and naloxone; pharmacologic reversal alone constitutes adequate rescue from oversedation.",
        "isCorrect": false,
        "explanation": "Rescue from propofol-induced deep sedation/apnea requires airway management and positive-pressure ventilation; reversal agents do not reverse propofol and are insufficient as the primary rescue strategy."
      }
    ],
    "didactic": "Sedation exists on a **continuum** in which patients can easily and unintentionally drift to deeper levels, especially with agents like propofol and in patients with OSA. The key domains that change with depth are responsiveness, airway, ventilation, and cardiovascular (CV) function:\n\n- Minimal sedation: normal response to verbal command; airway/ventilation unaffected; CV unaffected.\n- Moderate sedation: purposeful response to verbal/tactile; no airway intervention required; adequate spontaneous ventilation; CV usually maintained.\n- Deep sedation: purposeful response only after repeated or painful stimulation; airway intervention may be required; spontaneous ventilation may be inadequate; CV usually maintained.\n- General anesthesia: unarousable even with painful stimulation; airway intervention often required; ventilation frequently inadequate; CV function may be impaired.\n\nBecause transitions are **unpredictable**, the clinician administering sedation must be able to **rescue from the next deeper level** of sedation. This means having the skills, personnel, and equipment to:\n\n- Recognize deeper-than-intended sedation promptly (eg, loss of responsiveness, absent capnogram, hypoxemia).\n- Perform airway maneuvers and provide **positive-pressure ventilation** (mask) with O<sub>2</sub>, and use airway adjuncts (OPA/NPA). \n- Escalate to advanced airway management (eg, supraglottic airway, endotracheal intubation) and support hemodynamics as needed.\n- Maintain appropriate monitors (eg, pulse oximetry, capnography) and immediate access to suction, O<sub>2</sub>, and resuscitation drugs/equipment.\n\nUnder monitored anesthesia care (MAC) or procedural sedation, patients may transiently reach **deep sedation or general anesthesia**. Therefore, anesthesia professionals must be prepared to convert to and manage a GA-level airway when necessary, even in ambulatory or remote locations. Monitoring tools (eg, capnography) and reversal agents (eg, naloxone, flumazenil) are adjuncts but do not replace the requirement for **airway and ventilation rescue capability**.",
    "educationalObjective": "Describe the sedation continuum and the requirement for rescue capability from a deeper-than-intended level."
  },
  {
    "id": "Core.3.4.5",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Procedural sedation and MAC",
    "difficulty": "easy",
    "questionText": "A 58-year-old man (ASA II) undergoes screening colonoscopy in an ambulatory endoscopy suite with moderate sedation provided by anesthesia. He receives midazolam 2 mg IV and fentanyl 75 µg IV, followed by small propofol boluses (total 80 mg). Continuous ECG, noninvasive BP q5 min, SpO<sub>2</sub>, and capnography are monitored; level of consciousness and airway patency are documented every 5 minutes. The procedure lasts 25 minutes without complications.\n\nAt the end, he is spontaneously ventilating on nasal O<sub>2</sub> with SpO<sub>2</sub> 98%, arousable to voice, and hemodynamically stable. You escort him to Phase II recovery where a trained RN will continue standardized post-sedation monitoring. You have recorded all drugs with doses/times and the serial vital signs/assessments, and you will document a discharge score when criteria are met. Per institutional policy, you must also enter sedation start and end times. Which time point should be recorded as the sedation end time?",
    "answers": [
      {
        "text": "The time the patient departs the facility with an escort",
        "isCorrect": false,
        "explanation": "Facility discharge occurs well after recovery monitoring and is not the endpoint of the anesthesia provider’s sedation service."
      },
      {
        "text": "The time the last sedative or opioid dose is administered",
        "isCorrect": false,
        "explanation": "Drug administration time does not mark the end of sedation care; the patient still requires direct monitoring after the final dose."
      },
      {
        "text": "The time the patient first achieves an Aldrete (or modified Aldrete) score ≥9",
        "isCorrect": false,
        "explanation": "Aldrete scoring reflects discharge readiness in recovery, which may occur after the anesthesia provider’s continuous attendance has ended."
      },
      {
        "text": "The time you end continuous face-to-face monitoring and formally transfer care to a qualified recovery nurse for ongoing protocolized monitoring",
        "isCorrect": true,
        "explanation": "Sedation end time is when the anesthesia provider’s continuous attendance ends and care is handed off to qualified personnel who continue recovery monitoring."
      },
      {
        "text": "The first time the patient maintains SpO<sub>2</sub> ≥94% on room air with RR >10/min",
        "isCorrect": false,
        "explanation": "Specific physiologic thresholds do not define the endpoint of sedation care; end time is tied to provider attendance and transfer of care."
      }
    ],
    "didactic": "Institutional policies for procedural sedation typically require complete, time-stamped documentation of the sedation episode and recovery. Sedation time should bracket the period of continuous anesthesia provider attendance: start at administration of the first sedative/analgesic (or initiation of sedation care) and end when the provider terminates continuous face-to-face monitoring and formally transfers the patient to qualified personnel for protocolized recovery monitoring. This distinction separates the provider’s sedation care from the subsequent recovery phase and prevents conflating end-of-sedation with facility discharge.\n\nRequired elements commonly include:\n- Baseline assessment: airway risk, NPO status, ASA class, consent/time-out, vital signs.\n- Medications: all sedatives/analgesics/adjuncts with dose, route, and times; any reversal agents.\n- Monitoring during sedation: continuous SpO<sub>2</sub> and ECG, BP at least q5 min, assessment of ventilation (capnography preferred for moderate and required for deep sedation) and airway patency, level of consciousness/responsiveness.\n- Events and interventions: airway maneuvers, supplemental O<sub>2</sub> (document FiO<sub>2</sub>/delivery device), fluid/vasoactive therapy, complications.\n- Handoff: time and recipient when transferring to recovery staff; end time of continuous attendance.\n- Recovery/discharge: serial vitals and sedation scores, pain/nausea control, ability to ambulate as appropriate, and a documented standardized discharge score (eg, Aldrete or PADSS) meeting institutional threshold, along with discharge time and responsible escort.\n\nCommon pitfalls include using the last drug dose as the end time, omitting serial ventilation/LOC assessments, and failing to record an objective discharge score. Properly distinguishing sedation end time (end of continuous attendance and handoff) from discharge readiness (meeting objective criteria in recovery) ensures accurate documentation, patient safety, and compliance with institutional policy.",
    "educationalObjective": "Document sedation times, medications, monitoring, and discharge readiness according to institutional policy."
  },
  {
    "id": "Core.3.4.6",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Procedural sedation and MAC",
    "difficulty": "medium",
    "questionText": "A 28-year-old 80-kg man with asthma presents to the ED for closed reduction of a painful anterior shoulder dislocation. He is NPO for 4 hours and has a functioning IV. Vital signs: BP 132/78 mmHg, HR 96/min, SpO<sub>2</sub> 98% on room air. You plan dissociative procedural sedation with ketamine in a monitored setting. He reports having “vivid dreams” after prior ketamine sedation. You want to achieve reliable dissociation while minimizing airway secretions and emergence reactions.\n\nWhich of the following medication strategies is most appropriate for this patient?",
    "answers": [
      {
        "text": "Ketamine 160 mg IV and atropine 0.6 mg IV to prevent salivation; avoid benzodiazepines due to paradoxical reactions",
        "isCorrect": false,
        "explanation": "2 mg/kg IV is the high end of dissociative dosing; atropine increases tachycardia/CNS effects, and small-dose benzodiazepines actually reduce (not increase) ketamine emergence phenomena."
      },
      {
        "text": "Ketamine 320 mg IM without adjuncts",
        "isCorrect": false,
        "explanation": "IM 4 mg/kg may be used without IV access but has slower onset, prolonged recovery, higher vomiting, and does not address emergence reactions or hypersalivation."
      },
      {
        "text": "Ketamine 40 mg IV followed by propofol 80 mg IV to reduce emergence delirium",
        "isCorrect": false,
        "explanation": "0.5 mg/kg ketamine is sub-dissociative and 1 mg/kg propofol commonly causes apnea; this combination risks airway loss and inadequate analgesia."
      },
      {
        "text": "Ketamine 120 mg IV, with midazolam 1 mg IV to blunt emergence, and glycopyrrolate 0.2 mg IV available to treat troublesome secretions",
        "isCorrect": true,
        "explanation": "1.5 mg/kg IV ketamine provides dissociation; a small benzodiazepine dose reduces emergence reactions with minimal respiratory impact, and glycopyrrolate treats sialorrhea without CNS effects or tachycardia."
      },
      {
        "text": "Ketamine 16 mg IV and fentanyl 100 mcg IV, with a scopolamine patch for secretion control",
        "isCorrect": false,
        "explanation": "0.2 mg/kg ketamine is sub-analgesic for dissociation; adding high-dose opioid increases respiratory depression risk, and scopolamine has delayed onset and central anticholinergic effects."
      }
    ],
    "didactic": "Ketamine provides potent analgesia and dissociative sedation with relative preservation of airway reflexes, spontaneous ventilation, and sympathetic tone. For IV procedural sedation, dissociation is achieved with 1–2 mg/kg IV (onset 30–60 s; duration 10–20 min). Sub-dissociative analgesia is 0.1–0.3 mg/kg IV; this dose relieves pain but does not reliably permit painful manipulations. IM dosing (4–6 mg/kg) is an alternative without IV access but has slower onset, longer recovery, and higher emetogenicity.\n\nCommon adverse effects include hypersalivation and emergence reactions (vivid dreams, dysphoria), which are more common in anxious adults. Management is targeted:\n- Hypersalivation: suction as needed; glycopyrrolate 0.2 mg IV (or 0.004 mg/kg) effectively reduces secretions without crossing the blood–brain barrier or causing tachycardia. Routine prophylaxis is not mandatory; treat if clinically significant. Atropine increases tachycardia and has central effects; scopolamine has delayed onset and central anticholinergic effects, making both less desirable.\n- Emergence reactions: small benzodiazepine doses (eg, midazolam 0.02 mg/kg, 1–2 mg IV in adults) given just before or during emergence reduce incidence/severity. Alternatively, small propofol boluses (eg, 0.25–0.5 mg/kg) can treat agitation. Avoid large sedative coadministration that negates ketamine’s respiratory safety.\n\nIn monitored procedural settings, using 1–1.5 mg/kg IV ketamine for dissociation, coupled with a small benzodiazepine dose to mitigate emergence, and having glycopyrrolate available to treat problematic sialorrhea provides a balanced approach. Co-administration of opioids or large propofol doses increases risk of apnea and airway loss, undermining ketamine’s advantages. Always ensure standard monitoring, supplemental O<sub>2</sub> as needed, and readiness for airway interventions despite ketamine’s favorable profile.",
    "educationalObjective": "Dose ketamine safely for analgesic and dissociative sedation and manage hypersalivation or emergence reactions."
  },
  {
    "id": "Core.3.4.7",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Procedural sedation and MAC",
    "difficulty": "medium",
    "questionText": "A 67-year-old man (80 kg) undergoing MRI-guided prostate biopsy in the IR suite is receiving dexmedetomidine (loading 1 μg/kg over 10 min, then 0.6 μg/kg/hr). Five minutes into the loading dose, he becomes diaphoretic with HR 38 bpm and BP 70/40 mmHg. He is arousable, breathing spontaneously with EtCO₂ 36 mmHg and SpO₂ 99% on 2 L/min O<sub>2</sub> via nasal cannula. ECG shows sinus bradycardia without AV block. You immediately pause the dexmedetomidine infusion and increase O<sub>2</sub> delivery; total IV fluid given so far is 100 mL LR via an 18-gauge IV. Despite these measures, BP and HR remain unchanged.\n\nWhich of the following is the most appropriate next step to rapidly restore blood pressure and heart rate?",
    "answers": [
      {
        "text": "Ephedrine 10 mg IV bolus",
        "isCorrect": true,
        "explanation": "Mixed α/β agonism (β₁ to increase HR/contractility and α₁ to increase SVR) rapidly reverses dexmedetomidine-induced hypotension with bradycardia and improves MAP by addressing both components of MAP = CO × SVR."
      },
      {
        "text": "Atropine 0.5 mg IV",
        "isCorrect": false,
        "explanation": "Anticholinergic therapy may raise HR but does not address reduced SVR; isolated chronotropy is often insufficient for profound hypotension in this setting."
      },
      {
        "text": "Epinephrine 10 μg IV bolus",
        "isCorrect": false,
        "explanation": "Push-dose epinephrine can treat refractory instability, but its potency and arrhythmia risk make it less appropriate as first-line therapy compared with ephedrine here."
      },
      {
        "text": "Phenylephrine 100 μg IV bolus",
        "isCorrect": false,
        "explanation": "Pure α₁ agonism will raise SVR but can worsen reflex bradycardia and may decrease CO in a patient whose hypotension is partly due to low HR."
      },
      {
        "text": "250 mL crystalloid bolus",
        "isCorrect": false,
        "explanation": "Volume loading is appropriate adjunctive therapy in NPO patients, but a small bolus alone is unlikely to rapidly correct severe hypotension with bradycardia from α₂-mediated sympatholysis."
      }
    ],
    "didactic": "Dexmedetomidine is an α₂-agonist that decreases central sympathetic outflow and increases vagal tone, leading to **bradycardia** and **hypotension** (reduced SVR and CO). Propofol similarly lowers MAP via vasodilation and negative inotropy and can precipitate bradycardia (eg, Bezold–Jarisch reflex), especially in hypovolemic patients. When sedation-related hypotension with bradycardia occurs, rapidly restore perfusion while addressing the causative mechanism.\n\n- Initial actions: ensure airway/ventilation, increase O<sub>2</sub>, pause/reduce the sedative, and give crystalloid (eg, 250–500 mL) if NPO or preload-depleted. These steps may not be sufficient for severe instability.\n- Choose vasoactive agents based on physiology (MAP = CO × SVR):\n  - **Ephedrine 5–10 mg IV** (mixed α/β) is preferred for hypotension with bradycardia because it increases HR/contractility (β₁) and SVR (α₁), improving both CO and afterload. It is effective for sympatholysis from dexmedetomidine or propofol.\n  - **Phenylephrine 50–100 μg IV** (pure α₁) is best for hypotension with adequate or high HR; in bradycardia, it can worsen HR via baroreflex and lower CO.\n  - **Atropine 0.5 mg IV** or **glycopyrrolate 0.2–0.4 mg IV** treats predominant bradycardia but may not correct low SVR; consider when HR is the primary driver of hypotension or in vagal surges.\n  - **Push-dose epinephrine 10–20 μg IV** (from 10 μg/mL) is reserved for refractory or profound instability, given higher arrhythmia/ischemia risk.\n\nIn remote or ambulatory settings, promptly reverse the sedative, administer O<sub>2</sub>, and use **targeted vasoactive therapy** rather than fluid alone for severe hypotension with bradycardia. For this patient, ephedrine most efficiently addresses both low HR and low SVR, restoring MAP and perfusion quickly.",
    "educationalObjective": "Manage hypotension and bradycardia during propofol or dexmedetomidine sedation with fluids and vasoactive agents."
  },
  {
    "id": "Core.3.4.8",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Procedural sedation and MAC",
    "difficulty": "medium",
    "questionText": "A 63-year-old man undergoes closed reduction of a distal radius fracture under procedural sedation with fentanyl 50 µg IV and propofol 60 mg IV, followed by a 20 mg propofol bolus for breakthrough pain. He is on 4 L/min O<sub>2</sub> via nasal cannula with sidestream capnography. One minute after the bolus, the capnogram shows slowing respirations with rising ETCO<sub>2</sub>, then becomes flat with no waveform. He is unresponsive, there is no visible chest movement, and snoring ceases. SpO<sub>2</sub> remains 98%, BP 128/74 mmHg, HR 72/min. After verbal/tactile stimulation and a firm jaw thrust in a head-elevated sniffing position, there is still no capnogram and no chest excursion.\n\nWhich of the following is the best next step to manage this patient?",
    "answers": [
      {
        "text": "Reposition the head and continue to observe for the capnogram to return",
        "isCorrect": false,
        "explanation": "Airway repositioning has already failed. Continued observation without assisted ventilation risks progression to hypoxemia and cardiac events."
      },
      {
        "text": "Assist ventilation with a bag-mask at 10–12 breaths/min using 100% O<sub>2</sub>",
        "isCorrect": true,
        "explanation": "Absent ETCO<sub>2</sub> plus no chest excursion after airway maneuvers indicates apnea requiring immediate bag-mask ventilation to restore ventilation and prevent hypoxemia; definitive airway can be considered if ventilation remains inadequate."
      },
      {
        "text": "Proceed to endotracheal intubation to secure the airway definitively",
        "isCorrect": false,
        "explanation": "Intubation may be required if mask ventilation is inadequate, but the appropriate next step is prompt bag-mask ventilation; many sedation-related apneas resolve with assisted ventilation and lightening sedation."
      },
      {
        "text": "Administer naloxone 0.04 mg IV for suspected opioid-induced respiratory depression",
        "isCorrect": false,
        "explanation": "Opioids may contribute, but the immediate life-saving action is to ventilate. Naloxone has an onset lag and can precipitate severe pain; it should not delay assisted ventilation."
      },
      {
        "text": "Increase nasal cannula O<sub>2</sub> flow to 10 L/min and continue observation",
        "isCorrect": false,
        "explanation": "Raising FiO<sub>2</sub> treats oxygenation, not ventilation. With absent ETCO<sub>2</sub> and no chest movement, delaying assisted ventilation risks rapid deoxygenation once the O<sub>2</sub> reservoir is depleted."
      }
    ],
    "didactic": "Capnography provides an early, real-time measure of ventilation during procedural sedation. In hypoventilation, the capnogram shows decreased respiratory rate with rising ETCO<sub>2</sub>; with upper airway obstruction, an upslope “shark-fin” pattern may appear. **Apnea** presents as an abrupt loss of the waveform. In contrast, pulse oximetry reflects oxygenation and can remain normal for prolonged periods on supplemental O<sub>2</sub>, creating a dangerous lag that delays recognition of ventilatory failure.\n\nPropofol and opioids have additive respiratory depressant effects, reducing ventilatory drive and upper airway muscle tone. The recommended stepwise response under monitored anesthesia care (MAC) or procedural sedation is:\n- Recognize early ventilatory compromise on capnography and clinical exam (snoring, paradoxical breathing, rising ETCO<sub>2</sub>).\n- Prompt stimulation and airway maneuvers: head-elevated sniffing position, chin lift/jaw thrust, and insertion of an oral or nasopharyngeal airway as needed.\n- If apnea or ineffective ventilation persists (absent ETCO<sub>2</sub> with no chest excursion), **immediately provide bag-mask ventilation** with 100% O<sub>2</sub> at 10–12 breaths/min, using a good mask seal and appropriate airway adjuncts. Reassess for return of ETCO<sub>2</sub> and chest rise.\n- Consider reversal agents (eg, naloxone) and reduce/hold sedatives only after ventilation is restored. Escalate to supraglottic airway or endotracheal intubation if mask ventilation is difficult or repeatedly fails.\n\nAn absent capnogram with preserved chest movement may suggest sampling line disconnection or obstruction; however, **absent ETCO<sub>2</sub> plus absent chest excursion** indicates true apnea requiring immediate assisted ventilation. Prioritizing ventilation prevents the rapid decline in SpO<sub>2</sub> that follows once the supplemental O<sub>2</sub> reservoir is consumed.",
    "educationalObjective": "Prevent hypoventilation with capnography and early airway maneuvers; escalate to bag-mask ventilation when needed."
  },
  {
    "id": "Core.3.4.9",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Procedural sedation and MAC",
    "difficulty": "hard",
    "questionText": "A 62-year-old man (BMI 32) with gastric outlet obstruction from a pancreatic head mass presents for ERCP in the fluoroscopy suite under MAC with a propofol infusion and nasal cannula O<sub>2</sub> with capnography. Despite NG decompression earlier (800 mL bilious output), midway through the sphincterotomy in the semi-prone position he begins to gag and cough; copious bilious fluid fills the oropharynx. SpO<sub>2</sub> falls from 99% to 86%, the capnography trace becomes erratic, and coarse airway sounds are heard. Jaw thrust and Yankauer suction provide only transient improvement, with persistent obstruction and SpO<sub>2</sub> 88–90%. The endoscopist asks to “finish quickly.”\n\nWhich is the most appropriate next step to manage this situation?",
    "answers": [
      {
        "text": "Abort the procedure, remove the endoscope, turn the patient supine, and perform rapid-sequence induction with cuffed endotracheal intubation and aggressive suctioning",
        "isCorrect": true,
        "explanation": "Active regurgitation with persistent airway obstruction and hypoxemia during MAC mandates aborting/pausing the procedure and securing the airway via RSI and cuffed endotracheal intubation to prevent further aspiration and restore oxygenation."
      },
      {
        "text": "Insert a laryngeal mask airway in the current position and continue, as a supraglottic airway provides an adequate seal",
        "isCorrect": false,
        "explanation": "LMAs do not reliably protect against aspiration, can be difficult with an endoscope in situ, and are inappropriate during active regurgitation."
      },
      {
        "text": "Apply continuous cricoid pressure while proceeding to completion to reduce aspiration risk",
        "isCorrect": false,
        "explanation": "Cricoid pressure is not a definitive airway, may worsen airway obstruction and ventilation, and its efficacy is uncertain; proceeding risks continued aspiration and hypoxemia."
      },
      {
        "text": "Increase the propofol infusion to deepen sedation and relieve upper airway reactivity while allowing the endoscopist to complete the ERCP",
        "isCorrect": false,
        "explanation": "Deeper sedation further suppresses airway tone and protective reflexes, increasing aspiration risk and potentially worsening hypoventilation without securing the airway."
      },
      {
        "text": "Place a nasopharyngeal airway, elevate the head, and continue with frequent oropharyngeal suctioning",
        "isCorrect": false,
        "explanation": "Adjuncts and suction do not protect against ongoing aspiration and are inadequate in the face of persistent obstruction and hypoxemia."
      }
    ],
    "didactic": "In procedural sedation/MAC, clinicians must be prepared to abort or convert to general anesthesia when red flags emerge: persistent airway obstruction, recurrent hypoxemia, active regurgitation/aspiration, or inability to maintain adequate conditions with basic maneuvers. Sedation reduces upper airway tone and protective reflexes, increasing the risk of obstruction and aspiration—especially in high-risk scenarios such as ERCP/EGD, gastric outlet obstruction, ileus, pregnancy, morbid obesity/OSA, or delayed gastric emptying.\n\nWhen copious regurgitation with desaturation occurs, the priority is airway protection and oxygenation. The correct response is to stop the procedure, remove the scope, reposition to facilitate airway control (typically supine), and perform rapid-sequence induction with a cuffed endotracheal tube, using aggressive suctioning of the oropharynx and trachea. A cuffed ETT provides the most reliable protection against further pulmonary contamination while allowing controlled ventilation and application of PEEP. Continuing with deeper sedation, simple adjuncts (oral/nasal airways), or high-flow O<sub>2</sub> does not mitigate aspiration and can worsen hypoventilation.\n\nKey points:\n- Abort/convert for: persistent obstruction unresponsive to jaw thrust/airway adjuncts, repeated desaturation, paradoxical respiratory patterns, or active emesis/regurgitation.\n- Choose ETT over LMA when aspiration is suspected or ongoing; supraglottic devices do not reliably protect the lower airway and may be incompatible with concurrent endoscopy.\n- Cricoid pressure is not a substitute for a definitive airway and may hinder ventilation or visualization; its benefit is uncertain.\n- Optimize prior to RSI: suction ready, additional personnel, remove endoscope, preoxygenate with 100% O<sub>2</sub> as feasible, and avoid delays that prolong hypoxemia.\n\nRecognizing when procedural goals conflict with patient safety is critical; timely conversion to GA with endotracheal intubation prevents further aspiration, restores gas exchange, and allows safe completion later under protected-airway conditions.",
    "educationalObjective": "Recognize when to abort or convert to GA for persistent airway obstruction, aspiration, or inadequate conditions."
  },
  {
    "id": "Core.3.4.10",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Procedural sedation and MAC",
    "difficulty": "medium",
    "questionText": "A 58-year-old man (BMI 36) with severe OSA (AHI 40/h) uses home CPAP at 12 cm H2O and presents to an ambulatory endoscopy center for colonoscopy with anticipated polypectomy. He is asymptomatic, SpO<sub>2</sub> 96% on room air, Mallampati III with full neck motion, and has brought his CPAP device. The endoscopist requests deep sedation. The unit has capnography and standard monitors available. \n\nWhich perioperative plan best minimizes hypoxemia and airway obstruction risk while preserving suitability for same-day discharge?",
    "answers": [
      {
        "text": "Midazolam-leaning conscious sedation with low-dose ketamine, nasal O<sub>2</sub> without capnography, and standard discharge criteria; CPAP only if hypoxemia occurs.",
        "isCorrect": false,
        "explanation": "Benzodiazepines worsen airway collapsibility; omission of capnography and reactive rather than planned CPAP use increase risk in OSA."
      },
      {
        "text": "General anesthesia with endotracheal intubation to eliminate obstruction risk, supine positioning, hydromorphone-based analgesia, and routine PACU discharge.",
        "isCorrect": false,
        "explanation": "ETT avoids obstruction but is unnecessary for colonoscopy in OSA and increases airway/respiratory risks; opioid-heavy analgesia and routine discharge are ill-suited to OSA physiology."
      },
      {
        "text": "Propofol plus fentanyl boluses, supine positioning for procedural convenience, pulse oximetry without capnography, discharge once standard criteria are met.",
        "isCorrect": false,
        "explanation": "Opioids increase upper airway collapsibility and respiratory depression in OSA; supine positioning and lack of capnography further elevate hypoventilation risk."
      },
      {
        "text": "Propofol infusion titrated to effect without opioids, left lateral with head elevation, nasal O<sub>2</sub> with capnography, resume CPAP in PACU with extended observation before discharge.",
        "isCorrect": true,
        "explanation": "Opioid-sparing propofol MAC plus lateral/head-elevated positioning, continuous capnography, and planned CPAP with prolonged PACU observation specifically target OSA-related obstruction and desaturation risks while maintaining outpatient feasibility."
      },
      {
        "text": "Dexmedetomidine bolus followed by infusion with small-dose morphine, supine positioning, routine monitoring, and mandatory overnight admission for severe OSA.",
        "isCorrect": false,
        "explanation": "Although dexmedetomidine is relatively respiratory-sparing, adding opioids, supine positioning, and blanket admission are not necessary if optimized outpatient strategies and monitoring are used."
      }
    ],
    "didactic": "Patients with OSA are highly susceptible to sedation-induced upper airway collapse and blunted ventilatory responses, especially with opioids and benzodiazepines. A MAC plan should prioritize minimizing respiratory depressants, optimizing airway patency, and ensuring robust monitoring and recovery strategies.\n\nKey elements that reduce risk:\n- Analgesia/sedation: Prefer an opioid-sparing approach. A propofol-based technique titrated to effect can be used without routine opioids for colonoscopy. If additional analgesia is needed, consider non-opioid adjuncts (eg, low-dose ketamine or dexmedetomidine), but avoid combining multiple respiratory depressants.\n- Positioning: Use left lateral decubitus (standard for colonoscopy) and head elevation/ramping to enhance upper airway caliber and reduce pharyngeal collapsibility.\n- Monitoring: Continuous capnography detects hypoventilation/apnea earlier than pulse oximetry, particularly with supplemental O<sub>2</sub>. Capnography is recommended for moderate/deep sedation to promptly identify airway obstruction.\n- Oxygenation/airway: Administer nasal O<sub>2</sub> with EtCO<sub>2</sub> sampling; be prepared for simple airway maneuvers and adjuncts. Have the patient’s CPAP available.\n- Postanesthesia care: Resume CPAP promptly in PACU. Extend observation and ensure the patient maintains baseline SpO<sub>2</sub> on room air in an unstimulated environment without recurrent obstruction before same-day discharge.\n\nStrategies that increase risk include routine opioid boluses, benzodiazepine-heavy regimens, supine positioning, and reliance on pulse oximetry alone. General anesthesia with endotracheal intubation is rarely indicated for colonoscopy in OSA and adds airway and respiratory risks while hindering ambulatory flow. By using an opioid-sparing sedative (eg, carefully titrated propofol), lateral/head-elevated positioning, capnography, and proactive CPAP with extended PACU observation, clinicians can safely tailor MAC to OSA while preserving outpatient suitability.",
    "educationalObjective": "Tailor MAC for OSA by minimizing opioids, using positional strategies, and planning postoperative observation."
  },
  {
    "id": "Core.3.4.11",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Procedural sedation and MAC",
    "difficulty": "easy",
    "questionText": "A 35-year-old man undergoing screening colonoscopy under moderate sedation receives midazolam 2 mg IV and fentanyl 50 μg IV. Within 2 minutes he becomes loudly talkative, disinhibited, and combative, pulling at monitors. HR 110/min, BP 132/78 mmHg, SpO<sub>2</sub> 99% on 2 L/min O<sub>2</sub> via nasal cannula. Capnography shows a normal EtCO<sub>2</sub> waveform. He is benzodiazepine-naïve with no seizure disorder, chronic sedative use, or tricyclic antidepressant exposure. The endoscopist asks for “more sedation.”\n\nWhich is the most appropriate next step to manage this reaction?",
    "answers": [
      {
        "text": "Administer ketamine 0.5 mg/kg IV for dissociation.",
        "isCorrect": false,
        "explanation": "Ketamine can exacerbate agitation and sympathetic activation in an already dysphoric patient; it does not address the benzodiazepine-induced paradoxical reaction."
      },
      {
        "text": "Reduce stimulation, provide verbal de-escalation, and administer flumazenil 0.2 mg IV, titrating as needed.",
        "isCorrect": true,
        "explanation": "Non-pharmacologic de-escalation plus selective benzodiazepine reversal with flumazenil (0.2 mg IV q1 min to effect, typical total ≤1 mg) is first-line when paradoxical agitation occurs and no seizure/benzodiazepine-dependence risks exist."
      },
      {
        "text": "Administer additional midazolam 1 mg IV to deepen sedation.",
        "isCorrect": false,
        "explanation": "Paradoxical agitation from midazolam typically worsens with additional benzodiazepine; stacking benzos increases risk of respiratory depression without resolving the disinhibition."
      },
      {
        "text": "Administer naloxone 0.04 mg IV to reverse opioid effects.",
        "isCorrect": false,
        "explanation": "Opioids cause respiratory depression and sedation, not disinhibited agitation; naloxone will not treat a benzodiazepine paradoxical reaction and may precipitate pain and catecholamine surge."
      },
      {
        "text": "Apply physical restraints and give propofol 50 mg IV bolus.",
        "isCorrect": false,
        "explanation": "Escalating to deep sedation increases airway risk and obscures diagnosis; physical restraint can worsen agitation and is not first-line for a benzodiazepine paradoxical reaction."
      }
    ],
    "didactic": "Paradoxical reactions to benzodiazepines (eg, midazolam) present as **disinhibition, agitation, combativeness, and emotional lability** shortly after administration—often after small doses. Risk is increased at age extremes and in patients with psychiatric disease or alcohol use disorder, but they can occur in healthy, benzodiazepine‑naïve patients. Escalating benzodiazepine dosing typically **worsens agitation** and increases the risk of hypoventilation and airway compromise.\n\nManagement prioritizes safety and stimulus control: pause the procedure, speak calmly, dim lights, remove nonessential personnel, and ensure monitors are secure. When a benzodiazepine paradoxical reaction is suspected and there is no seizure disorder, tricyclic antidepressant ingestion, or benzodiazepine dependence, administer **flumazenil**, a competitive **GABA<sub>A</sub>** benzodiazepine-site antagonist. Dose 0.2 mg IV over 15 s; repeat 0.2 mg every 1 min to effect (typical total ≤1 mg; up to 3 mg may be required). Observe for **re-sedation** because flumazenil’s duration can be shorter than some benzodiazepines; redose as needed. Continuous monitoring is essential.\n\nAvoid strategies that increase physiologic stress or mask the diagnosis:\n- Additional benzodiazepine: reinforces the paradoxical state and depresses respiration.\n- Ketamine: may intensify dysphoria and sympathetic surge.\n- Propofol/“deepening” sedation: raises airway risk without addressing etiology.\n- Naloxone: treats opioid effects, not benzodiazepine-driven agitation.\n\nIf flumazenil is contraindicated (chronic benzodiazepine use, seizure disorder, suspected TCA overdose), use supportive, nonpharmacologic de-escalation and consider alternative agents (eg, low-dose propofol or dexmedetomidine) with airway readiness. Recognizing and promptly reversing benzodiazepine paradoxical reactions improves patient safety in ambulatory and procedural sedation settings by preventing **sedative stacking** and unnecessary airway interventions.",
    "educationalObjective": "Treat paradoxical reactions to benzodiazepines with de-escalation and flumazenil when appropriate."
  },
  {
    "id": "Core.3.4.12",
    "category": "Ambulatory, Procedural & Remote",
    "subcategory": "Procedural sedation and MAC",
    "difficulty": "hard",
    "questionText": "A 56-year-old man (BMI 52 kg/m²) with severe OSA on home CPAP (12 cmH₂O) presents for an ERCP in the endoscopy suite under deep sedation. He previously desaturated to 82% within 60 seconds during upper endoscopy despite standard preoxygenation. He will be in the prone/semi-prone position, and the endoscopist anticipates brief periods of apnea during scope insertion. Baseline SpO₂ is 95% on room air; airway exam shows Mallampati IV and limited neck extension.\n\nTo maximize the safe apnea time during scope insertion while maintaining access to the shared airway, which oxygenation strategy is most appropriate?",
    "answers": [
      {
        "text": "Tight-fitting face-mask CPAP at 10 cmH₂O with 100% O<sub>2</sub> during preoxygenation, then remove the mask for scope insertion while the patient is apneic",
        "isCorrect": false,
        "explanation": "CPAP improves preoxygenation and FRC but provides no oxygenation during apnea once the mask is removed; loss of PEEP in an obese/OSA patient leads to rapid desaturation."
      },
      {
        "text": "Intermittent bag-mask ventilation with 100% O<sub>2</sub> between propofol boluses as needed",
        "isCorrect": false,
        "explanation": "Intermittent ventilation risks gastric insufflation and disrupts the procedure; it does not provide continuous oxygenation during apnea at scope insertion and may be impractical in prone positioning."
      },
      {
        "text": "Preoxygenate with a nonrebreather at 15 L/min for 3 minutes, then proceed with deep sedation without supplemental oxygen during scope insertion",
        "isCorrect": false,
        "explanation": "Nonrebreather preoxygenation improves alveolar O<sub>2</sub> content, but removal of oxygen at apnea provides no apneic oxygenation; obese/OSA patients desaturate rapidly once PEEP is lost."
      },
      {
        "text": "High-flow nasal oxygen at 60 L/min with FiO<sub>2</sub> 1.0 during preoxygenation and continued throughout scope insertion",
        "isCorrect": true,
        "explanation": "HFNO delivers high FiO<sub>2</sub>, generates low-level PEEP, and flushes nasopharyngeal dead space while allowing unobstructed oral access, thereby prolonging safe apnea time in high-risk obese/OSA patients."
      },
      {
        "text": "Low-flow nasal cannula at 6 L/min during preoxygenation and continued through apnea",
        "isCorrect": false,
        "explanation": "Low-flow apneic oxygenation can delay desaturation modestly but provides limited FiO<sub>2</sub> and negligible PEEP, which is insufficient for severe obesity/OSA and shared upper-airway procedures."
      }
    ],
    "didactic": "High-flow nasal oxygen (HFNO) extends safe apnea time by combining continuous high FiO<sub>2</sub> delivery with low-level positive airway pressure and nasopharyngeal dead space washout, all while preserving access to the shared upper airway. In severe obesity/OSA, reduced FRC and rapid airway collapse shorten desaturation time; strategies that both raise alveolar O<sub>2</sub> stores and prevent derecruitment are essential.\n\nKey mechanisms:\n- Apneic oxygenation: O<sub>2</sub> continues to diffuse into blood during apnea due to ongoing O<sub>2</sub> uptake, delaying desaturation even without ventilation. However, CO<sub>2</sub> accumulates (≈6 mmHg in the first minute, then 3–4 mmHg/min); HFNO does not eliminate hypercapnia.\n- HFNO benefits: FiO<sub>2</sub> up to 1.0 at 40–60 L/min, heated/humidified for comfort; generation of low-level PEEP (≈2–7 cmH₂O, flow- and mouth-position–dependent) to increase FRC and mitigate atelectasis; and nasopharyngeal washout that reduces rebreathing and improves oxygenation during spontaneous or apneic conditions.\n- Procedure compatibility: Unlike face-mask CPAP/NIV, HFNO maintains oral access for upper endoscopy/ERCP and can be continued throughout scope insertion, supporting continuous oxygen delivery when brief apnea is expected.\n\nComparisons:\n- Nonrebreather-only preoxygenation raises alveolar O<sub>2</sub> stores but provides no oxygen during apnea and loses PEEP upon mask removal.\n- Low-flow nasal cannula (eg, 4–6 L/min) offers limited apneic oxygenation and negligible PEEP, often inadequate in morbid obesity/OSA.\n- CPAP during preoxygenation improves FRC, but removing the mask for endoscopy eliminates both oxygen delivery and PEEP at the critical moment.\n\nPractical use: Preoxygenate with HFNO (FiO<sub>2</sub> 1.0, 40–60 L/min), position head-up/ramped to increase FRC, and continue HFNO during deep sedation and scope insertion. Monitor for airway obstruction—HFNO cannot oxygenate through a completely obstructed airway—and be prepared for airway maneuvers or conversion to secured airway if ventilation is inadequate.",
    "educationalObjective": "Use high-flow nasal oxygen or apneic oxygenation in high-risk patients to extend safe apnea time."
  },
  {
    "id": "Core.12.1.1",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Anticoagulants and antiplatelets",
    "difficulty": "medium",
    "questionText": "A 74-year-old man is scheduled for elective total knee arthroplasty under planned spinal anesthesia. He had an NSTEMI 8 months ago treated with a drug-eluting stent to the LAD and has been stable on aspirin 81 mg daily since completing initial dual antiplatelet therapy. He has no history of bleeding, platelets are 210 ×10<sup>9</sup>/L, creatinine is 1.0 mg/dL, and functional capacity is good. The orthopedic surgeon requests stopping aspirin 7 days preoperatively to reduce bleeding and “to allow spinal anesthesia.”\n\nWhich perioperative aspirin strategy is most appropriate for this patient?",
    "answers": [
      {
        "text": "Continue aspirin through surgery and proceed with spinal anesthesia as planned.",
        "isCorrect": true,
        "explanation": "In patients with prior coronary stents, perioperative continuation of aspirin is recommended whenever possible; total knee arthroplasty is not a closed-space procedure, and aspirin does not contraindicate neuraxial anesthesia per ASRA guidelines."
      },
      {
        "text": "Stop aspirin 3 days preoperatively and bridge with therapeutic LMWH until the morning of surgery.",
        "isCorrect": false,
        "explanation": "Heparin bridging does not prevent platelet-mediated stent thrombosis and increases bleeding risk; bridging is not indicated for antiplatelet interruption."
      },
      {
        "text": "Switch to clopidogrel 75 mg daily and continue it through surgery.",
        "isCorrect": false,
        "explanation": "Substituting a P2Y12 inhibitor increases bleeding risk without benefit and would preclude neuraxial anesthesia; it is not recommended in place of aspirin."
      },
      {
        "text": "Delay surgery until 12 months after PCI if aspirin cannot be stopped.",
        "isCorrect": false,
        "explanation": "Elective noncardiac surgery after a drug-eluting stent is reasonable ≥3 months when antiplatelet therapy can be managed; at 8 months, routine delay to 12 months is unnecessary."
      },
      {
        "text": "Stop aspirin 7 days preoperatively and proceed with spinal anesthesia.",
        "isCorrect": false,
        "explanation": "Stopping aspirin increases the risk of stent thrombosis in a patient with recent PCI and is unnecessary for neuraxial anesthesia; the bleeding risk increase from continuing aspirin is generally modest in this context."
      }
    ],
    "didactic": "Balancing thrombotic and bleeding risks is central to perioperative antiplatelet management. For patients with prior PCI, **ACC/AHA guidelines recommend continuing aspirin perioperatively whenever possible**, regardless of stent type or time from PCI, because aspirin withdrawal increases the risk of **stent thrombosis** and myocardial infarction. Elective noncardiac surgery after a drug-eluting stent can generally proceed ≥3 months after PCI if antiplatelet therapy can be managed. At 8 months post-PCI, thrombotic risk persists but is substantially mitigated by continuing aspirin.\n\nAspirin continuation modestly increases surgical bleeding in many procedures but rarely causes clinically significant harm outside of **closed-space surgeries** where even small hematomas can be catastrophic (eg, intracranial, intramedullary spine, posterior chamber eye). Total knee arthroplasty is not a closed-space procedure, and bleeding is typically manageable. Importantly, **ASRA guidelines** state that aspirin alone is not a contraindication to neuraxial techniques (no mandatory hold interval), so neuraxial anesthesia does not require stopping aspirin.\n\nIf aspirin must be interrupted due to very high bleeding risk in a low-thrombotic-risk patient (eg, primary prevention, no stent), a **4–7 day** hold allows regeneration of functional platelets; aspirin can usually be **restarted within 24 hours** postoperatively once hemostasis is secure. **Heparin bridging is not effective** for platelet-mediated thrombosis and increases bleeding, and switching to a P2Y12 inhibitor is inappropriate. \n\n- Continue aspirin in prior-PCI patients for most noncardiac surgeries.\n- Avoid aspirin primarily for closed-space procedures where bleeding is catastrophic.\n- Neuraxial anesthesia is acceptable with aspirin monotherapy.\n- Do not bridge antiplatelet interruption with heparin; avoid unnecessary substitution with P2Y12 inhibitors.",
    "educationalObjective": "Balance aspirin continuation versus cessation for noncardiac surgery based on bleeding and thrombotic risks."
  },
  {
    "id": "Core.12.1.2",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Anticoagulants and antiplatelets",
    "difficulty": "easy",
    "questionText": "During a preoperative clinic visit 10 days before elective total knee arthroplasty, a 62-year-old woman asks about her over-the-counter products. She takes ginkgo biloba (memory), garlic extract (cholesterol), and Panax ginseng (energy). She takes no antiplatelet or anticoagulant medications. Vital signs and CBC, PT/INR, and PTT are normal. She reports occasional easy bruising. What is the most appropriate perioperative management of her supplements to minimize bleeding risk without unnecessary delay?",
    "answers": [
      {
        "text": "Discontinue ginkgo, garlic, and ginseng now and proceed with surgery as scheduled in 10 days.",
        "isCorrect": true,
        "explanation": "Ginkgo, garlic, and ginseng impair platelet function; discontinuation for at least 7 days is recommended. Stopping now provides an adequate washout before surgery in 10 days."
      },
      {
        "text": "Continue all three supplements and stop them on the morning of surgery.",
        "isCorrect": false,
        "explanation": "Day-of-surgery cessation is insufficient because these agents impair platelet function beyond 24 hours; bleeding risk persists through the lifespan of affected platelets."
      },
      {
        "text": "Continue ginseng; discontinue ginkgo and garlic 48 hours before surgery.",
        "isCorrect": false,
        "explanation": "Ginseng also has antiplatelet effects and can increase bleeding risk; 48 hours is insufficient for any of these supplements."
      },
      {
        "text": "Postpone surgery to allow at least 2 weeks off all herbal supplements.",
        "isCorrect": false,
        "explanation": "While some adopt a 2-week blanket approach for herbals, a 7-day cessation for these specific agents is generally adequate; postponement is unnecessary here."
      },
      {
        "text": "Stop garlic only 24 hours before surgery because it irreversibly inhibits platelets.",
        "isCorrect": false,
        "explanation": "Garlic’s antiplatelet effect is prolonged, and ginkgo and ginseng also increase bleeding risk; 24 hours is inadequate and does not address all offending agents."
      }
    ],
    "didactic": "Herbal supplements are common and clinically relevant perioperatively. Several widely used products increase bleeding by impairing platelet function despite normal coagulation tests. **Targeted counseling and timely discontinuation reduce bleeding risk without unnecessary surgical delay.**\n\n- **Garlic**: Contains allicin/ajoene that inhibit platelet aggregation (eg, decreased thromboxane synthesis) with an effect that persists for the lifespan of exposed platelets. This translates to a clinically meaningful antiplatelet effect for about 7 days.\n- **Ginkgo biloba**: Inhibits platelet-activating factor, increasing bleeding risk; case reports describe spontaneous and perioperative hemorrhage. Effects are not corrected by standard coagulation tests.\n- **Ginseng (Panax)**: Has antiplatelet activity and can cause **hypoglycemia**; it may also interact with anticoagulants.\n\nBest practice is to **discontinue ginkgo, garlic, and ginseng at least 7 days before surgery** to allow turnover of affected platelets and reduction of bleeding risk. Some institutions use a conservative 2-week cessation for all herbals; however, for agents with primarily platelet effects, a 7-day window is generally adequate and avoids unnecessary delays. In this patient scheduled in 10 days, stopping now permits proceeding as planned.\n\nKey counseling points:\n- A normal platelet count, PT/INR, and PTT do not exclude **platelet dysfunction** from supplements.\n- Concomitant use with aspirin or NSAIDs can further increase bleeding risk.\n- Consider deferring neuraxial techniques if recent ingestion suggests ongoing platelet dysfunction.\n- Resume these supplements only after hemostasis is secure postoperatively and bleeding risk has resolved.\n\nNot all supplements behave similarly; for example, contemporary data suggest typical **fish oil** doses do not significantly increase perioperative bleeding, highlighting the need for agent-specific counseling rather than blanket assumptions.",
    "educationalObjective": "Counsel on herbal and supplement effects (ginkgo, garlic, ginseng) on bleeding and perioperative management."
  },
  {
    "id": "Core.12.1.3",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Anticoagulants and antiplatelets",
    "difficulty": "easy",
    "questionText": "A 68-year-old man with nonvalvular atrial fibrillation (CHA<sub>2</sub>DS<sub>2</sub>-VASc 3) takes apixaban 5 mg twice daily. He is scheduled for an elective laparoscopic cholecystectomy under general anesthesia next week. Platelets are 230 × 10<sup>9</sup>/L, creatinine is 0.9 mg/dL (estimated CrCl 70 mL/min), and there are no neuraxial techniques planned. The surgeon requests a clear, patient-friendly anticoagulant plan.\n\nWhich of the following written hold/restart instructions for apixaban is most appropriate for this procedure?",
    "answers": [
      {
        "text": "Stop apixaban 48 hours before surgery; do not bridge; restart 7 days after surgery if no bleeding.",
        "isCorrect": false,
        "explanation": "Excessively long pre- and postoperative interruptions unnecessarily increase thromboembolic risk without clear benefit."
      },
      {
        "text": "Stop apixaban 24 hours before surgery and bridge with an IV heparin infusion; restart apixaban 12 hours after surgery once heparin is stopped.",
        "isCorrect": false,
        "explanation": "Heparin bridging is not indicated for DOACs and early resumption at 12 hours increases bleeding risk for this procedure."
      },
      {
        "text": "Continue apixaban through the night before surgery and take the next dose the evening of surgery if hemostasis is adequate.",
        "isCorrect": false,
        "explanation": "Continuing until the night before leaves significant anticoagulant effect; resuming the evening of surgery is too early for a moderate-bleeding-risk operation."
      },
      {
        "text": "Stop apixaban 72 hours before surgery and bridge with therapeutic enoxaparin; restart apixaban 48 hours after surgery if no bleeding.",
        "isCorrect": false,
        "explanation": "Bridging is not recommended for DOACs and a 72-hour hold is unnecessary for a moderate-bleeding-risk procedure with normal renal function; this increases bleeding risk."
      },
      {
        "text": "Stop apixaban 24 hours before surgery (last dose the morning of the day before surgery); do not bridge; restart 24 hours after surgery at the usual dose if hemostasis is secure.",
        "isCorrect": true,
        "explanation": "For apixaban with normal renal function and a moderate-bleeding-risk procedure, a 24-hour preoperative hold without bridging and resumption at 24 hours postoperatively appropriately balances bleeding and thromboembolic risks."
      }
    ],
    "didactic": "Creating a safe, patient-friendly anticoagulant plan requires matching the drug’s pharmacology to the procedure’s bleeding risk and the patient’s renal function.\n\n- For factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) with normal renal function, the typical preoperative hold is:\n  - Low–moderate bleeding risk (eg, laparoscopic cholecystectomy, inguinal hernia): hold 24 hours.\n  - High bleeding risk (eg, major cancer resection) or any planned neuraxial technique: hold 48–72 hours (ASRA suggests 72 hours for neuraxial needle/catheter placement/removal).\n- DOACs have short half-lives; bridging with heparin is not recommended and increases bleeding without reducing perioperative thromboembolism.\n- Postoperative resumption depends on hemostasis and procedural bleeding risk:\n  - Low–moderate risk: restart ~24 hours after surgery if hemostasis is secure.\n  - High risk/neuraxial: delay 48–72 hours; if a neuraxial catheter is used, remove it and wait an appropriate interval (eg, ≥6 hours after removal) before resuming, per ASRA guidance.\n\nFor this patient on apixaban with CrCl ~70 mL/min and a moderate-bleeding-risk laparoscopic cholecystectomy, the best plan is a 24-hour pre-op hold with no bridging and restart 24 hours post-op if there is no bleeding. Clear, patient-facing wording improves adherence, eg:\n\n- “Take your last apixaban dose the morning of the day before surgery.”\n- “Do not take apixaban the evening before or the morning of surgery.”\n- “After surgery, if there is no bleeding, restart apixaban 24 hours later at your usual dose/time. If you have unexpected bleeding or a drain, call the surgeon/anesthesia team before restarting.”\n\nThis approach balances bleeding and thromboembolic risks, avoids unnecessary heparin exposure, and provides practical timing the patient can follow.",
    "educationalObjective": "Create a clear, patient‑friendly anticoagulant plan with written hold/restart instructions."
  },
  {
    "id": "Core.12.1.4",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Anticoagulants and antiplatelets",
    "difficulty": "hard",
    "questionText": "A 62-year-old man with diabetes and prior NSTEMI underwent percutaneous coronary intervention with a drug-eluting stent to the proximal LAD 4 weeks ago. He takes aspirin 81 mg daily and ticagrelor 90 mg twice daily. He is scheduled for elective open radical prostatectomy next week; the surgeon plans a thoracic epidural for analgesia and asks how to manage antiplatelet therapy.\n\nHe is asymptomatic from a cardiac standpoint and his hemoglobin and renal function are normal. Which perioperative plan is most appropriate for this patient?",
    "answers": [
      {
        "text": "Defer surgery until completion of 12 months of DAPT after ACS DES; then continue aspirin and hold ticagrelor 5 days preoperatively if neuraxial analgesia is planned, in coordination with cardiology and surgery.",
        "isCorrect": true,
        "explanation": "After DES for ACS, elective noncardiac surgery should be postponed for about 12 months to complete DAPT; once safe to interrupt, continue aspirin and hold ticagrelor 5 days for neuraxial procedures with multidisciplinary coordination."
      },
      {
        "text": "Proceed next week; continue aspirin, stop ticagrelor 5 days preoperatively, place an epidural, and resume ticagrelor postoperatively when hemostasis is secure.",
        "isCorrect": false,
        "explanation": "Stopping P2Y12 therapy within the first 1–3 months after DES for ACS substantially increases stent thrombosis risk; proceeding electively at 5 weeks is inappropriate despite an adequate neuraxial hold interval."
      },
      {
        "text": "Proceed next week with aspirin continued and ticagrelor stopped 5 days prior, using cangrelor bridging until 1–2 hours before incision; avoid neuraxial techniques.",
        "isCorrect": false,
        "explanation": "Bridging with cangrelor can be considered when urgent surgery cannot be deferred in very high thrombotic-risk patients; it is not indicated for elective cases that can be postponed."
      },
      {
        "text": "Defer surgery for at least 3 months after PCI; then continue aspirin and hold ticagrelor 5 days preoperatively before neuraxial block.",
        "isCorrect": false,
        "explanation": "A 3-month delay may be considered for DES placed for chronic coronary disease when surgical delay is high risk; it is inadequate after ACS, which warrants a longer DAPT duration."
      },
      {
        "text": "Proceed next week; continue both aspirin and ticagrelor through surgery, avoid neuraxial techniques, and accept increased bleeding risk.",
        "isCorrect": false,
        "explanation": "Continuing DAPT mitigates stent thrombosis risk but markedly increases bleeding for high-risk surgery (eg, open prostatectomy); elective cases should be deferred rather than performed on full DAPT."
      }
    ],
    "didactic": "Early interruption of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention significantly increases stent thrombosis risk, particularly after drug-eluting stent (DES) placement for acute coronary syndrome (ACS). Elective noncardiac surgery should be deferred to allow adequate endothelialization and completion of guideline-directed DAPT.\n\nKey timing principles:\n- Balloon angioplasty (no stent): delay elective surgery ≥14 days.\n- Bare-metal stent (BMS): delay ≥30 days; continue aspirin if surgery must proceed thereafter.\n- DES for chronic coronary disease: ideally delay ≥6 months (≥3 months only if the risk of delay clearly exceeds the cardiac risk).\n- DES for ACS: delay ≈12 months to complete DAPT whenever feasible.\n\nPerioperative antiplatelet management:\n- Continue aspirin in most cases; it reduces ischemic events and has acceptable bleeding risk for many surgeries. High-bleeding-risk procedures may still proceed on aspirin after multidisciplinary discussion.\n- Hold P2Y12 inhibitors only when the minimum safe interval is reached and surgical/neuraxial bleeding risk warrants interruption: clopidogrel 5–7 days, prasugrel 7 days, ticagrelor 5 days.\n- Neuraxial techniques are contraindicated while on P2Y12 therapy; placement/removal requires the above drug-free intervals, with prompt postoperative resumption only after catheter removal and hemostasis.\n- If urgent surgery cannot be delayed within high-risk windows (eg, <30 days BMS or <3 months DES), continue DAPT if possible; when bleeding risk precludes this, consider cardiology-guided bridging (eg, cangrelor) acknowledging limited evidence and increased bleeding.\n\nFor this patient 4 weeks post-ACS DES facing high-bleeding-risk surgery with a planned epidural, the safest strategy is to postpone surgery until ~12 months post-PCI. When interruption becomes acceptable, continue aspirin and hold ticagrelor 5 days preoperatively for neuraxial safety, with close coordination among anesthesia, cardiology, and surgery.",
    "educationalObjective": "Handle dual antiplatelet therapy in recent stent patients in coordination with cardiology and surgical teams."
  },
  {
    "id": "Core.12.1.5",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Anticoagulants and antiplatelets",
    "difficulty": "hard",
    "questionText": "A 76-year-old woman with a femoral neck fracture requires urgent hemiarthroplasty. She has atrial fibrillation (home apixaban) and a prior drug-eluting stent (home clopidogrel). Last medication times are unknown. She has CKD (eGFR 35 mL/min/1.73 m<sup>2</sup>). You are considering neuraxial anesthesia but are concerned about bleeding risk. Labs: platelets 220 ×10<sup>9</sup>/L, INR 1.0, aPTT 30 s (normal), thrombin time normal. Platelet function testing (VerifyNow P2Y12) shows PRU 32. Chromogenic anti‑Xa with an apixaban-specific calibrator is 25 ng/mL; a heparin-calibrated anti‑Xa returns 0.3 IU/mL. PFA‑100 closure times are prolonged.\n\nWhich interpretation best guides immediate anesthetic planning for this patient?",
    "answers": [
      {
        "text": "The heparin-calibrated anti‑Xa (0.3 IU/mL) indicates residual UFH/LMWH only; apixaban does not affect this assay.",
        "isCorrect": false,
        "explanation": "Factor Xa inhibitors can produce activity in heparin-calibrated anti‑Xa assays; the value is not specific and cannot quantify apixaban or distinguish it from heparins."
      },
      {
        "text": "The apixaban-calibrated anti‑Xa level (25 ng/mL) suggests minimal residual factor Xa inhibition; however, PRU 32 indicates profound P2Y12 blockade, so neuraxial anesthesia should be avoided.",
        "isCorrect": true,
        "explanation": "Drug-specific anti‑Xa shows low apixaban, but a PRU of 32 reflects strong clopidogrel effect with high neuraxial bleeding risk; platelet dysfunction, not PT/aPTT, drives the decision here."
      },
      {
        "text": "Normal PT/aPTT effectively exclude clinically significant apixaban effect; PRU is unreliable perioperatively, so neuraxial anesthesia is reasonable now.",
        "isCorrect": false,
        "explanation": "PT/aPTT are variably insensitive to apixaban and cannot exclude residual drug; PRU from VerifyNow is specifically designed to quantify P2Y12 inhibition and a very low PRU indicates marked inhibition."
      },
      {
        "text": "A normal PFA‑100 closure time is specific for intact P2Y12 function and supersedes PRU, permitting neuraxial anesthesia despite a low PRU.",
        "isCorrect": false,
        "explanation": "PFA‑100 lacks specificity for P2Y12 inhibition and is affected by multiple variables; VerifyNow PRU directly assesses P2Y12 blockade and is the preferred interpretive guide."
      },
      {
        "text": "A normal thrombin time rules out residual apixaban effect and supports neuraxial anesthesia provided PRU is <50.",
        "isCorrect": false,
        "explanation": "Thrombin time is insensitive to factor Xa inhibitors and does not rule out apixaban; PRU <50 indicates extensive platelet inhibition and increased bleeding risk, not safety."
      }
    ],
    "didactic": "When timing of antithrombotic doses is uncertain, assay selection and interpretation determine whether urgent neuraxial techniques or high-bleeding-risk surgery can proceed safely.\n\n- Factor Xa inhibitors (eg, apixaban, rivaroxaban): PT/aPTT are variably sensitive and a normal result does not exclude clinically relevant drug effect. Thrombin time is typically normal with Xa inhibitors (highly sensitive to dabigatran), so it cannot rule out apixaban. A chromogenic anti‑Xa assay with a DOAC-specific calibrator reports a drug concentration (ng/mL) and best reflects residual activity. Although institutional thresholds vary, levels <30–50 ng/mL generally indicate minimal effect. Heparin-calibrated anti‑Xa assays may show activity in the presence of Xa inhibitors but are not specific or quantitatively reliable for DOACs.\n- Heparins (UFH/LMWH): Heparin-calibrated anti‑Xa (IU/mL) quantifies their effect; however, DOACs can artifactually elevate this assay, confounding interpretation.\n- P2Y12 inhibitors (eg, clopidogrel): Platelet count does not reflect function. VerifyNow P2Y12 reports PRU; low PRU indicates strong inhibition (eg, PRU <95 high, 95–208 moderate, >208 minimal). PFA‑100 closure time is nonspecific and influenced by anemia, thrombocytopenia, vWD, and aspirin; it should not supersede PRU for P2Y12 assessment.\n\nApplication to this case:\n- Apixaban-calibrated anti‑Xa of 25 ng/mL suggests minimal residual Xa inhibition despite CKD. The heparin-calibrated anti‑Xa (0.3 IU/mL) is uninterpretable for apixaban.\n- PRU 32 indicates profound clopidogrel effect with high neuraxial bleeding risk. Normal PT/aPTT and thrombin time do not mitigate this risk.\n\nTherefore, in urgent settings with high hemorrhagic consequence (eg, neuraxial techniques, intracranial/spine surgery), proceed only when both anticoagulant effect (via drug-specific anti‑Xa for Xa inhibitors) is minimal and platelet function (via PRU) is adequate; otherwise, avoid neuraxial or consider reversal/alternative anesthesia.",
    "educationalObjective": "Interpret platelet function and anti‑Xa assays when timing is uncertain or bleeding risk is high."
  },
  {
    "id": "Core.12.1.6",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Anticoagulants and antiplatelets",
    "difficulty": "medium",
    "questionText": "A 72-year-old man on a therapeutic unfractionated heparin infusion for pulmonary embolism requires emergent exploratory laparotomy for bowel ischemia. The infusion (1,500 U/h) was started 6 hours ago after a 5,000-U IV bolus and was stopped 30 minutes ago. His last aPTT is 95 s (laboratory control 30 s). The surgeon is ready to incise now, and you aim to normalize coagulation prior to incision.\n\nAssuming no contraindication to protamine, which of the following is the most appropriate immediate management to optimize hemostasis?",
    "answers": [
      {
        "text": "Administer protamine 20 mg IV now",
        "isCorrect": false,
        "explanation": "Underdoses reversal (neutralizes ≈2,000 U), ignoring the recent 5,000-U bolus and most of the infusion; significant anticoagulation would persist and the aPTT would likely remain elevated."
      },
      {
        "text": "Administer protamine 50 mg IV now, then recheck aPTT",
        "isCorrect": true,
        "explanation": "Heparin in the last 2 hours ≈7,250 U (5,000-U bolus at −90 min + 1,500 U/h for 90 min = 2,250 U), suggesting ≈73 mg protamine; however, an initial dose should not exceed 50 mg given slowly, followed by reassessment (aPTT/ACT) and redosing as needed."
      },
      {
        "text": "Administer protamine 70 mg IV now",
        "isCorrect": false,
        "explanation": "Approximates the calculated amount but exceeds the recommended initial single dose; larger boluses increase risks of hypotension and pulmonary vasoconstriction—split dosing is safer (eg, 50 mg, then reassess)."
      },
      {
        "text": "Administer protamine 100 mg IV now",
        "isCorrect": false,
        "explanation": "Overdose; protamine excess has anticoagulant effects (platelet dysfunction, impaired fibrin polymerization) and may worsen bleeding with paradoxical aPTT prolongation."
      },
      {
        "text": "Administer protamine 30 mg IV now",
        "isCorrect": false,
        "explanation": "Still underdoses (≈3,000 U), insufficient for the ≈7,250 U of heparin given in the last 2 hours; residual UFH would leave the aPTT supratherapeutic."
      }
    ],
    "didactic": "Therapeutic unfractionated heparin (UFH) is typically titrated to an aPTT 1.5–2.5× control (or anti-Xa 0.3–0.7 U/mL). For urgent surgery, rapid reversal with protamine is indicated to normalize coagulation before incision. Protamine (a strongly cationic peptide) neutralizes UFH (an anionic polysaccharide) via stable complexing.\n\nKey principles:\n- Dose protamine ≈1 mg per 100 U of UFH administered in the prior 2–3 hours, considering UFH’s short half-life (≈60–90 min), which diminishes contributions from earlier doses.\n- Limit the initial single dose to 50 mg and infuse slowly (≤5 mg/min) to reduce risks of hypotension, bradycardia, and acute pulmonary vasoconstriction. Reassess (aPTT or ACT) 5–10 minutes after reversal and redose (eg, 0.5 mg per 100 U estimated remaining) if needed.\n- Avoid overdosing: excess protamine is paradoxically anticoagulant (platelet inhibition, impaired fibrin polymerization) and can worsen bleeding.\n- Higher risk of anaphylactoid reactions exists in patients with fish allergy, prior vasectomy/infertility procedures, or chronic NPH insulin exposure.\n\nIn this case, heparin delivered in the last 2 hours is ≈7,250 U (5,000-U bolus 90 minutes ago + 1,500 U/h for 90 minutes = 2,250 U), implying ≈73 mg protamine for full neutralization. The best immediate approach is to administer 50 mg IV protamine slowly, then recheck aPTT (or ACT) and give additional protamine if needed. This strategy achieves timely reversal while minimizing protamine-related adverse effects. After reversal, the aPTT should approach normal (near the lab control) before incision; resumption of UFH postoperatively should target an aPTT 1.5–2.5× control when therapeutic anticoagulation is again indicated.",
    "educationalObjective": "Manage unfractionated heparin perioperatively, including aPTT targets and rapid reversal with protamine."
  },
  {
    "id": "Core.12.1.7",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Anticoagulants and antiplatelets",
    "difficulty": "hard",
    "questionText": "A 74-year-old man with nonvalvular atrial fibrillation takes dabigatran 150 mg twice daily. He has chronic kidney disease (CKD 3b) with Cockcroft–Gault creatinine clearance 35 mL/min. He is scheduled for an elective open radical prostatectomy (high bleeding risk). He has no history of bleeding, normal liver function tests, and is not taking antiplatelet agents. The surgical team asks when to stop dabigatran to minimize residual anticoagulant effect at incision while avoiding unnecessary thromboembolic risk.\n\nWhich preoperative dabigatran interruption interval is most appropriate for this patient?",
    "answers": [
      {
        "text": "24 hours before incision",
        "isCorrect": false,
        "explanation": "Insufficient for a high-bleeding-risk procedure and significantly prolonged dabigatran half-life in CKD; substantial anticoagulant activity would remain at incision."
      },
      {
        "text": "96 hours before incision",
        "isCorrect": true,
        "explanation": "For dabigatran in high-bleeding-risk surgery with CrCl 30–49 mL/min, holding for 96 hours (4 days) reduces residual anticoagulant effect to a minimal level while limiting time off therapy."
      },
      {
        "text": "72 hours before incision",
        "isCorrect": false,
        "explanation": "May be adequate for moderate bleeding risk or better renal function; however, with CrCl 30–49 mL/min and high bleeding risk, 72 hours still risks residual effect."
      },
      {
        "text": "48 hours before incision",
        "isCorrect": false,
        "explanation": "Appropriate for high-bleeding-risk procedures only when renal function is normal (CrCl ≥50 mL/min). With CrCl 35 mL/min, dabigatran clearance is delayed and requires a longer hold."
      },
      {
        "text": "120 hours before incision",
        "isCorrect": false,
        "explanation": "Generally reserved for severe renal impairment (CrCl <30 mL/min) or extremely high-risk contexts; unnecessarily prolongs thromboembolic risk for this patient."
      }
    ],
    "didactic": "Perioperative interruption of direct oral anticoagulants (DOACs) requires integrating procedural bleeding risk, the specific agent, and renal function (preferably Cockcroft–Gault CrCl). Dabigatran is a direct thrombin inhibitor with ~80% renal elimination and a half-life that lengthens substantially as CrCl declines; thus renal function drives the interruption interval more than for factor Xa inhibitors.\n\nA practical approach:\n- Identify bleeding risk: high-risk procedures (eg, major cancer surgery, open prostatectomy, intracranial/spine) warrant longer interruption intervals than low/moderate-risk procedures.\n- Identify the agent and renal function: \n  - Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban): largely unaffected by moderate renal impairment for timing; typical holds are 24 hours (low bleeding risk) and 48 hours (high bleeding risk).\n  - Dabigatran: intervals extend with worsening renal function because clearance is predominantly renal.\n\nCommon evidence-based intervals (elective surgery):\n- Factor Xa inhibitors:\n  - Low bleeding risk: 24 h\n  - High bleeding risk: 48 h\n- Dabigatran:\n  - CrCl ≥50 mL/min: 24 h (low risk), 48 h (high risk)\n  - CrCl 30–49 mL/min: 48 h (low risk), 96 h (high risk)\n  - CrCl <30 mL/min: ≥72–96 h (low risk), ≥120 h (high risk) or consider drug-level testing if available\n\nFor this patient (dabigatran, CrCl 35 mL/min, high bleeding risk), a 96-hour (4-day) interruption minimizes residual anticoagulant effect at incision while limiting time off therapy. Heparin bridging is generally not indicated for most patients with nonvalvular atrial fibrillation on DOACs due to short offset and increased bleeding risk. In urgent cases when timing cannot be met, consider qualitative assays (eg, dilute thrombin time) to assess residual dabigatran activity or reversal with idarucizumab if proceeding to surgery with unacceptable bleeding risk.",
    "educationalObjective": "Outline DOAC interruption intervals considering renal function and agent half‑life."
  },
  {
    "id": "Core.12.1.8",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Anticoagulants and antiplatelets",
    "difficulty": "hard",
    "questionText": "A 67-year-old man is postoperative day 1 after open sigmoid colectomy with a functioning T8–9 thoracic epidural (bupivacaine 0.125% at 6 mL/h; pain 2/10). Vitals are stable; platelets 180,000/µL, INR 1.1, creatinine 0.9 mg/dL. The surgeon requests to start rivaroxaban 10 mg once daily this evening for VTE prophylaxis. It is 15:00. The patient prefers to keep the epidural for pain control but also wants to “avoid clots.” According to current ASRA/ESRA guidance, which plan best balances neuraxial safety and VTE prophylaxis and should be documented after shared decision-making with the patient and surgeon?\n\nWhich is the most appropriate next step?",
    "answers": [
      {
        "text": "Remove the epidural catheter now and begin rivaroxaban ≥6 hours after catheter removal; use mechanical prophylaxis until anticoagulation starts",
        "isCorrect": true,
        "explanation": "Factor Xa inhibitors should only be initiated after neuraxial catheter removal, with at least a 6-hour interval; mechanical prophylaxis bridges the gap while maintaining hematoma safety."
      },
      {
        "text": "Switch to apixaban 2.5 mg twice daily tonight and maintain the epidural; plan to remove the catheter before tomorrow’s morning dose",
        "isCorrect": false,
        "explanation": "All direct oral factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) are contraindicated with an indwelling neuraxial catheter; catheter removal must precede the first dose by ≥6 hours."
      },
      {
        "text": "Start enoxaparin 30 mg every 12 hours now with the epidural in place; remove the catheter 12 hours after the last enoxaparin dose tomorrow, then switch to rivaroxaban",
        "isCorrect": false,
        "explanation": "Twice-daily LMWH with an indwelling neuraxial catheter is discouraged; catheters should be removed before initiating BID LMWH due to higher hematoma risk."
      },
      {
        "text": "Remove the epidural catheter now and administer rivaroxaban immediately after removal",
        "isCorrect": false,
        "explanation": "After neuraxial catheter removal, a 6-hour delay before the first dose of a factor Xa inhibitor is recommended to reduce bleeding/hematoma risk."
      },
      {
        "text": "Continue the epidural and start rivaroxaban now; remove the epidural catheter 12 hours after the last rivaroxaban dose tomorrow",
        "isCorrect": false,
        "explanation": "Concomitant rivaroxaban with an indwelling neuraxial catheter is contraindicated due to high neuraxial hematoma risk; removal 12 hours after a dose is insufficient and unsafe."
      }
    ],
    "didactic": "For direct oral anticoagulants (DOACs), neuraxial safety hinges on timing relative to placement and catheter removal. ASRA/ESRA guidance recommends the following for factor Xa inhibitors (rivaroxaban, apixaban, edoxaban):\n\n- Pre-neuraxial placement: hold for ~72 hours (longer if renal/hepatic impairment or interacting drugs), or consider drug-specific anti–factor Xa levels if timing is uncertain (a universally safe threshold is not firmly established).\n- Indwelling catheters: avoid concomitant Xa inhibitor administration; an epidural catheter should not be maintained in patients receiving these agents.\n- Initiation postoperatively: remove the catheter first, then wait ≥6 hours before the first dose of rivaroxaban/apixaban/edoxaban.\n- If a Xa inhibitor was inadvertently given with a catheter in place: defer removal for approximately one day (rivaroxaban ~22–26 hours, apixaban ~26–30 hours) or use a calibrated anti–factor Xa assay to guide timing; after removal, delay the next dose ≥6 hours.\n\nLMWH timing differs by regimen:\n\n- Once-daily prophylactic LMWH: first dose ≥12 hours after neuraxial placement; catheter removal ≥12 hours after last dose; resume LMWH ≥4 hours after removal.\n- Twice-daily prophylactic LMWH (eg, 30 mg q12h): higher hematoma risk; remove catheters before starting BID prophylaxis.\n\nOther agents: aspirin/NSAIDs do not restrict neuraxial techniques; warfarin requires INR normalization (<1.5 for catheter removal); IV heparin requires 4–6 hours off with normal aPTT before removal; P2Y<sub>12</sub> inhibitors generally require a 5–7 day hold before neuraxial procedures.\n\nIn this patient, the safest, guideline-concordant plan is to remove the epidural now and delay rivaroxaban for ≥6 hours, using mechanical prophylaxis in the interim. Document the shared discussion about analgesia benefits versus the short delay in chemoprophylaxis to mitigate neuraxial hematoma risk.",
    "educationalObjective": "Plan neuraxial anesthesia timing with antithrombotics following society guidance and document shared decisions."
  },
  {
    "id": "Core.12.1.9",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Anticoagulants and antiplatelets",
    "difficulty": "hard",
    "questionText": "A 64-year-old woman with a mechanical mitral valve (St. Jude bileaflet) on warfarin (INR goal 2.5–3.5) presents with incarcerated ventral hernia and peritonitis requiring emergent laparotomy within 6 hours. Vitals are stable. She took her usual warfarin dose last night. Labs: INR 2.9, Hgb 11.1 g/dL, platelets 210 ×10<sup>3</sup>/µL, creatinine 0.8 mg/dL. The surgeon requests rapid correction of coagulopathy to minimize intraoperative bleeding and asks about perioperative anticoagulation planning.\n\nWhich management strategy is most appropriate to balance urgent warfarin reversal and thromboembolism prevention in this patient?",
    "answers": [
      {
        "text": "Give 1–2 mg oral vitamin K and delay surgery 24–36 hours; avoid heparin bridging due to bleeding risk.",
        "isCorrect": false,
        "explanation": "Oral vitamin K acts too slowly for urgent surgery and delays source control. This patient’s very high thromboembolic risk favors perioperative bridging once surgical hemostasis allows."
      },
      {
        "text": "Hold warfarin and proceed without reversal; place an epidural for analgesia; start therapeutic LMWH 6 hours post-op until the INR is 2–3.",
        "isCorrect": false,
        "explanation": "Proceeding with INR 2.9 increases bleeding; neuraxial anesthesia is contraindicated with therapeutic anticoagulation and recent warfarin. Early therapeutic LMWH (6 h) heightens bleeding risk in major abdominal surgery."
      },
      {
        "text": "Administer 4-factor PCC 25 U/kg plus 10 mg IV vitamin K now, proceed to OR, and initiate IV unfractionated heparin post-op once hemostasis is secure, then bridge until the INR is therapeutic on resumed warfarin.",
        "isCorrect": true,
        "explanation": "4F-PCC rapidly normalizes INR within minutes, and IV vitamin K sustains reversal. Mechanical mitral valves carry very high thromboembolic risk; bridging with IV UFH post-op (given rapid on/off and reversibility) is recommended until the INR is therapeutic."
      },
      {
        "text": "Administer protamine and IV vitamin K now; proceed to OR; bridge with apixaban for 48 hours post-op, then restart warfarin.",
        "isCorrect": false,
        "explanation": "Protamine reverses heparin, not warfarin. DOACs are not used to bridge and are contraindicated in mechanical valves; warfarin remains the standard with heparin bridging when indicated."
      },
      {
        "text": "Transfuse 2 units FFP now, proceed to OR without vitamin K, and restart warfarin 12 hours post-op without bridging.",
        "isCorrect": false,
        "explanation": "FFP alone provides slow, volume-limited reversal and is inferior to 4F-PCC for rapid INR normalization; withholding vitamin K risks rebound anticoagulation. Mechanical mitral valves are high thromboembolic risk and generally require bridging."
      }
    ],
    "didactic": "Warfarin should be stopped 5 days pre-op for elective cases, targeting INR ≤1.5 before most major surgeries (more stringent for neuraxial procedures). For urgent/emergent surgery, **rapid reversal** is necessary if INR is elevated.\n\n- **Preferred rapid reversal:** 4-factor PCC (4F-PCC) + IV vitamin K. Typical dosing for 4F-PCC is INR-based (eg, 25 U/kg for INR 2–4, 35 U/kg for INR 4–6, 50 U/kg for INR >6), producing near-immediate correction. Add **10 mg IV vitamin K** to sustain reversal and prevent INR rebound.\n- **FFP** is slower, requires large volumes, and is inferior to 4F-PCC for urgent reversal; reserve if PCC is unavailable.\n\nPerioperative bridging depends on **thromboembolic risk**:\n\n- **High risk (bridge with therapeutic heparin):** mechanical **mitral** valve; caged-ball/tilting-disc aortic valve; recent (<3 months) stroke/TIA or VTE; severe thrombophilia (eg, antiphospholipid syndrome). Mechanical mitral valves have the highest baseline risk; bridging is generally indicated both pre- and post-op when feasible.\n- **Intermediate/low risk (often no bridge):** most nonvalvular AF patients without very high CHA₂DS₂-VASc or recent stroke; the BRIDGE trial showed increased bleeding without thromboembolic benefit in many AF patients.\n\nIn urgent laparotomy with INR 2.9, the best strategy is **4F-PCC + IV vitamin K** to normalize INR promptly, proceed to surgery, and then **restart anticoagulation as soon as hemostasis is secure**. For high-risk valves, choose **IV unfractionated heparin** post-op because it has a short half-life and is fully reversible; resume warfarin early and **bridge until INR is therapeutic**. Avoid neuraxial techniques when recent or planned therapeutic anticoagulation is present. This approach balances bleeding control with prevention of catastrophic valve thrombosis.",
    "educationalObjective": "Plan warfarin interruption and reversal; define when to bridge with heparin based on thromboembolic risk."
  },
  {
    "id": "Core.12.1.10",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Anticoagulants and antiplatelets",
    "difficulty": "medium",
    "questionText": "A 72-year-old man with nonvalvular atrial fibrillation (CHA2DS2-VASc 4) takes apixaban 5 mg twice daily. He underwent an open right hemicolectomy yesterday (estimated blood loss 600 mL). On postoperative day 1, he is hemodynamically stable with Hgb 10.8 g/dL (from 12.0 g/dL preop), serosanguinous drain output 50 mL over the last 8 hours, soft nontender abdomen, and no evidence of bleeding. Creatinine is 0.9 mg/dL. There is no neuraxial catheter in place. The surgeon reports secure intraoperative hemostasis and minimal drain output this morning.\n\nWhich is the most appropriate anticoagulation plan today to balance bleeding and thromboembolic risks?",
    "answers": [
      {
        "text": "Begin an intravenous unfractionated heparin infusion now and bridge back to apixaban on postoperative day 3.",
        "isCorrect": false,
        "explanation": "Heparin bridging is not indicated for patients on DOACs with nonvalvular atrial fibrillation and increases bleeding without reducing thromboembolism in this context."
      },
      {
        "text": "Delay all anticoagulation for 7 days due to high postoperative bleeding risk.",
        "isCorrect": false,
        "explanation": "Prolonged interruption unnecessarily increases stroke risk in atrial fibrillation; secure hemostasis permits earlier, stepwise anticoagulation within 24–72 hours."
      },
      {
        "text": "Use prophylactic enoxaparin 40 mg subcutaneously daily for 7 days, then restart apixaban thereafter.",
        "isCorrect": false,
        "explanation": "Prophylactic-intensity anticoagulation is reasonable early, but delaying therapeutic-dose DOAC for a full week is excessive in stable hemostasis; escalation should occur by 48–72 hours."
      },
      {
        "text": "After verifying secure hemostasis, restart apixaban 2.5 mg twice daily today and increase to 5 mg twice daily in 48–72 hours if no bleeding occurs.",
        "isCorrect": true,
        "explanation": "Staged resumption (prophylactic/half dose at 12–24 hours, then full dose at 48–72 hours once hemostasis remains secure) appropriately balances bleeding risk after high-risk surgery with the patient’s ongoing thromboembolic risk."
      },
      {
        "text": "Resume apixaban 5 mg twice daily now at full therapeutic dose.",
        "isCorrect": false,
        "explanation": "Therapeutic-dose DOAC within 24 hours of a high–bleeding-risk laparotomy increases postoperative bleeding; most patients should wait 48–72 hours for full-dose therapy once hemostasis is secure."
      }
    ],
    "didactic": "Restarting antithrombotics postoperatively requires balancing bleeding risk from the procedure with the patient’s thromboembolic risk and confirming secure hemostasis. For **direct oral anticoagulants (DOACs)**, timing is guided by surgical bleeding risk, renal function, and clinical bleeding assessment.\n\n- High–bleeding–risk procedures (eg, open abdominal surgery, major cancer surgery): avoid full-dose DOAC for 48–72 hours. If hemostasis is secure at 12–24 hours, initiate **prophylactic-intensity** anticoagulation (eg, apixaban 2.5 mg BID or LMWH prophylaxis) and escalate to **therapeutic dose** at 48–72 hours if no bleeding occurs.\n- Low–to–moderate–bleeding–risk procedures: therapeutic DOAC can often be restarted at 24 hours if hemostasis is secure.\n- Always verify hemostasis before resumption: stable hemoglobin, minimal drain/wound output, no clinical bleeding, and surgeon agreement.\n\nIn nonvalvular atrial fibrillation, **heparin bridging is not recommended** when interrupting a DOAC. Bridging increases bleeding without reducing thromboembolism because DOACs have rapid onset/offset. Similarly, **excessive delays (eg, 5–7 days)** in clinically stable patients unnecessarily increase stroke risk. Renal function modifies timing for renally cleared agents (eg, dabigatran); impaired clearance favors the longer end of the 48–72-hour window.\n\nThis patient had a high–bleeding–risk laparotomy with reassuring hemostasis on postoperative day 1 and normal renal function. The safest approach is **staged dosing**: restart **apixaban 2.5 mg BID** today after hemostasis verification and increase to **5 mg BID** at 48–72 hours if no bleeding occurs. This strategy preserves early thromboprophylaxis while minimizing the risk of postoperative hemorrhage compared with immediate full-dose DOAC, and it prevents the thromboembolic risk associated with unnecessary prolonged interruption.",
    "educationalObjective": "Restart antithrombotics postoperatively with hemostasis checks and staged dosing when warranted."
  },
  {
    "id": "Core.12.1.11",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Anticoagulants and antiplatelets",
    "difficulty": "medium",
    "questionText": "A 68-year-old man undergoes open right hemicolectomy for colon cancer. An uncomplicated T8–9 epidural catheter was placed 2 hours preoperatively for postoperative analgesia and is planned to remain for 48–72 hours. He is hemodynamically stable 6 hours postoperatively; platelets 220,000/µL, INR 1.0, creatinine 0.9 mg/dL (eGFR 80 mL/min/1.73 m<sup>2</sup>). The surgeon requests initiation of pharmacologic VTE prophylaxis today given high thrombotic risk (age, malignancy, open abdominal surgery). Which regimen and timing is most appropriate to provide effective prophylaxis while minimizing neuraxial hematoma risk?",
    "answers": [
      {
        "text": "Start UFH 5,000 U SC q8h immediately; remove the epidural catheter at any time regardless of dosing.",
        "isCorrect": false,
        "explanation": "Low-dose UFH is acceptable with epidurals, but catheter removal must be timed 4–6 hours after the last UFH dose with heparin resumed ≥1 hour later; “any time” removal is unsafe."
      },
      {
        "text": "Start fondaparinux 2.5 mg SC daily 6 hours post-op with the epidural in place to maximize VTE protection.",
        "isCorrect": false,
        "explanation": "Fondaparinux has a long half-life and is contraindicated with indwelling neuraxial catheters due to high neuraxial hematoma risk."
      },
      {
        "text": "Start enoxaparin 40 mg SC once daily beginning ≥12 hours after epidural placement; maintain the epidural, remove it ≥12 hours after the last dose, and resume LMWH ≥4 hours after removal.",
        "isCorrect": true,
        "explanation": "Once-daily prophylactic LMWH can be used with an indwelling epidural using ASRA timing: first dose ≥12 h after placement, catheter removal ≥12 h after last dose, and next dose ≥4 h after removal."
      },
      {
        "text": "Use intermittent pneumatic compression alone until the epidural is removed at 72 hours, then start LMWH.",
        "isCorrect": false,
        "explanation": "Mechanical prophylaxis alone is inadequate in high-risk patients and unnecessarily delays effective chemoprophylaxis."
      },
      {
        "text": "Start enoxaparin 30 mg SC q12h at 6 hours post-op with the epidural in place; remove the catheter 24 hours after the last dose.",
        "isCorrect": false,
        "explanation": "Twice-daily LMWH with an indwelling epidural increases neuraxial hematoma risk, and dosing at 6 hours is too early. ASRA advises avoiding BID LMWH with catheters in place."
      }
    ],
    "didactic": "Major open abdominal or pelvic cancer surgery confers high VTE risk; pharmacologic prophylaxis is indicated unless contraindicated. **LMWH** is preferred over UFH for efficacy in many high-risk surgical populations, but an indwelling epidural requires adherence to **ASRA** neuraxial timing to minimize epidural hematoma.\n\nKey LMWH neuraxial principles:\n- For prophylactic dosing, give the first LMWH dose **≥12 hours after neuraxial needle/catheter placement** to allow stable hemostasis.\n- With a once-daily regimen (eg, enoxaparin 40 mg SC q24h), an epidural catheter may remain in place. **Remove the catheter ≥12 hours after the last LMWH dose**, then **delay the next LMWH dose ≥4 hours** after removal.\n- Avoid postoperative **twice-daily LMWH** (eg, enoxaparin 30 mg q12h) while a catheter is in place due to increased neuraxial hematoma risk; if BID LMWH is desired for efficacy, remove the catheter before initiating.\n\nAlternatives and considerations:\n- **Low-dose UFH** (5,000 U SC q8–12h) can be used with an epidural; **remove the catheter 4–6 hours after the last UFH dose** and resume UFH ≥1 hour thereafter. However, LMWH often provides superior VTE reduction in high-risk surgical oncology patients.\n- **Fondaparinux and DOACs** (eg, rivaroxaban, apixaban) are generally contraindicated with indwelling neuraxial catheters due to long half-lives and potent anti-Xa activity.\n- Ensure platelets are adequate (eg, >75–100k) and consider renal function; with **CrCl <30 mL/min**, prefer UFH or adjust LMWH (eg, enoxaparin 30 mg q24h).\n\nApplying these principles, once-daily prophylactic enoxaparin initiated **≥12 hours** after epidural placement and timed catheter removal (**≥12 hours after last dose; next dose ≥4 hours after removal**) balances effective thromboprophylaxis with neuraxial safety in this high-risk patient.",
    "educationalObjective": "Select VTE prophylaxis in high‑risk surgical patients while respecting neuraxial timing constraints."
  },
  {
    "id": "Core.12.1.12",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Anticoagulants and antiplatelets",
    "difficulty": "medium",
    "questionText": "A 72-year-old man with nonvalvular atrial fibrillation (CHA<sub>2</sub>DS<sub>2</sub>-VASc 3) takes apixaban 5 mg twice daily. He is scheduled for transurethral resection of the prostate (TURP) under general anesthesia. He has normal renal function (creatinine 0.9 mg/dL, estimated CrCl 70 mL/min), normal platelet count, and no history of bleeding. The urologist anticipates a standard resection without planned neuraxial techniques.\n\nWhich is the most appropriate perioperative management of apixaban for this procedure?",
    "answers": [
      {
        "text": "Stop apixaban 5 days preoperatively, bridge with therapeutic low–molecular-weight heparin, and resume apixaban after discharge.",
        "isCorrect": false,
        "explanation": "Bridging is not recommended for DOACs and increases bleeding; a 5-day interruption is excessive for apixaban with normal renal function."
      },
      {
        "text": "Continue apixaban without interruption (last dose the night before) and resume the evening of surgery if hemostasis is adequate.",
        "isCorrect": false,
        "explanation": "TURP is a high–bleeding-risk procedure; continuing a DOAC through the perioperative period markedly increases bleeding and reoperation risk."
      },
      {
        "text": "Convert to aspirin 81 mg daily 7 days preoperatively, continue through surgery, and resume apixaban 72 hours after the procedure.",
        "isCorrect": false,
        "explanation": "Switching to aspirin does not mitigate cardioembolic risk from atrial fibrillation and exposes the patient to unnecessary bleeding risk during a high–bleeding-risk procedure."
      },
      {
        "text": "Hold apixaban for 48–72 hours preoperatively with no heparin bridging and resume 48–72 hours postoperatively once hemostasis is secure.",
        "isCorrect": true,
        "explanation": "TURP is high bleeding risk; with normal renal function, apixaban should be withheld 48–72 h preop and resumed 48–72 h postop. DOACs generally do not require bridging."
      },
      {
        "text": "Hold apixaban for 24 hours preoperatively and resume 24 hours postoperatively if hemostasis is adequate.",
        "isCorrect": false,
        "explanation": "A 24-hour hold is appropriate for low–bleeding-risk procedures; TURP requires a longer interruption to reduce bleeding complications."
      }
    ],
    "didactic": "Stratifying procedural bleeding risk determines whether and how long to interrupt antithrombotic therapy. TURP is a **high–bleeding-risk** endoscopic urologic procedure with substantial mucosal disruption and risk of hematuria/reoperation, so perioperative anticoagulation must be managed conservatively.\n\nFor **DOACs** (eg, apixaban, rivaroxaban) with normal renal function:\n- Low–bleeding-risk procedures (eg, cataract, superficial dermatologic, diagnostic endoscopy without biopsy): hold ~24 h (skip 2 apixaban doses); resume ~24 h post-op.\n- High–bleeding-risk procedures (eg, TURP/TURBT, major cancer surgery, major joint replacement): hold **48–72 h** pre-op; resume **48–72 h** post-op when hemostasis is secure.\n- Neuraxial techniques require even longer DOAC interruption (eg, apixaban typically ≥72 h per ASRA) due to catastrophic risk of spinal hematoma.\n\nKey principles:\n- DOAC half-lives are short (apixaban ~12 h with normal renal function); therefore **heparin bridging is not recommended** and increases bleeding without reducing thromboembolism.\n- Resumption should be guided by procedural bleeding risk and clinical hemostasis: earlier for low-risk, delayed 48–72 h for high-risk.\n- Warfarin is different: typically stop 5 days and confirm INR normalization; bridging is reserved for very high thrombotic risk (eg, recent VTE, mechanical mitral valve), not routine AF.\n- Antiplatelets: continue aspirin for most low/moderate bleeding-risk surgeries; hold P2Y<sub>12</sub> inhibitors ~5–7 days for high-risk procedures unless recent coronary stenting mandates continuation.\n\nApplying these concepts: This patient’s TURP (high bleeding risk) and normal renal function favor holding apixaban **48–72 h pre-op** without bridging and resuming **48–72 h post-op** once bleeding is controlled, balancing perioperative bleeding avoidance with acceptable thromboembolic risk.",
    "educationalObjective": "Stratify procedural bleeding risk to guide interruption or continuation of antithrombotic therapy."
  },
  {
    "id": "Core.12.1.13",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Anticoagulants and antiplatelets",
    "difficulty": "hard",
    "questionText": "A 68-year-old man with atrial fibrillation (CHA<sub>2</sub>DS<sub>2</sub>-VASc 5) bridged from warfarin to therapeutic-dose enoxaparin (1 mg/kg every 12 h) is scheduled for open sigmoid colectomy with a planned thoracic epidural for analgesia. The last enoxaparin dose was administered 18 hours ago. He has CrCl 35 mL/min, platelets 210,000/µL, INR 1.1, and no other antithrombotics. The surgeon plans postoperative VTE prophylaxis with enoxaparin 40 mg once daily while the epidural is in place.\n\nWhich perioperative timing strategy best minimizes spinal/epidural hematoma risk while providing effective thromboprophylaxis?",
    "answers": [
      {
        "text": "Place the epidural now (18 h after the last therapeutic dose); start enoxaparin 40 mg once daily 6 h after placement; remove the catheter at any time and resume the next dose immediately after removal.",
        "isCorrect": false,
        "explanation": "Neuraxial placement <24 h after therapeutic LMWH and giving LMWH 6 h after placement increase hematoma risk; LMWH should not be given immediately after catheter removal."
      },
      {
        "text": "Place the epidural now; begin enoxaparin 30 mg every 12 h 12 h after placement; remove the catheter before discharge while continuing twice-daily prophylaxis.",
        "isCorrect": false,
        "explanation": "Maintaining a neuraxial catheter with BID LMWH prophylaxis is not recommended; the catheter should be removed before initiating BID dosing."
      },
      {
        "text": "Place the epidural now; hold all LMWH for 24 h postoperatively; then restart therapeutic-dose enoxaparin while the epidural catheter remains in place.",
        "isCorrect": false,
        "explanation": "Therapeutic LMWH is contraindicated with an indwelling neuraxial catheter; resumption should be delayed and only after catheter removal with appropriate intervals."
      },
      {
        "text": "Withhold all LMWH until the epidural catheter is removed; then start prophylactic enoxaparin immediately after catheter removal.",
        "isCorrect": false,
        "explanation": "Delaying all prophylaxis increases VTE risk, and LMWH should not be given immediately after catheter removal; a ≥4 h interval is advised."
      },
      {
        "text": "Delay neuraxial placement until ≥24 h after the last therapeutic enoxaparin; administer the first prophylactic 40 mg dose ≥12 h after catheter placement; remove the catheter ≥12 h after the last dose; resume LMWH ≥4 h after catheter removal.",
        "isCorrect": true,
        "explanation": "This aligns with ASRA guidance: ≥24 h from therapeutic LMWH to neuraxial needle, ≥12 h from placement to first once-daily prophylactic dose, catheter removal ≥12 h after the last dose, and ≥4 h before the next dose."
      }
    ],
    "didactic": "Low–molecular-weight heparin (LMWH) has peak anti–factor Xa activity at ~3–5 h and a 4–7 h half-life, with renal elimination. Neuraxial bleeding risk is driven by the dose (therapeutic vs prophylactic), dosing frequency, renal function, and timing relative to needle placement and catheter manipulation. ASRA consensus guidance provides practical intervals that balance safety and thromboprophylaxis:\n\n- Pre-neuraxial timing:\n  - Therapeutic LMWH (eg, enoxaparin 1 mg/kg BID or 1.5 mg/kg daily): wait ≥24 h before neuraxial needle/catheter placement; consider a longer interval if CrCl <30 mL/min or additional bleeding risks.\n  - Prophylactic once-daily LMWH (eg, enoxaparin 40 mg daily): wait ≥12 h before neuraxial puncture.\n\n- Post-placement timing (first postoperative dose):\n  - Once-daily prophylaxis: give the first dose ≥12 h after neuraxial placement. An indwelling epidural catheter may be maintained with once-daily dosing.\n  - Twice-daily prophylaxis: avoid maintaining a catheter; remove the catheter before starting BID LMWH.\n\n- Catheter removal and LMWH resumption:\n  - If on once-daily prophylaxis: remove the catheter ≥12 h after the last dose, then wait ≥4 h before the next LMWH dose.\n  - If therapeutic LMWH is planned: ensure ≥24 h since the last therapeutic dose before removal, then wait ≥4 h to resume; for high–bleeding-risk surgery, delay therapeutic dosing 48–72 h and avoid any therapeutic dosing while a catheter is in place.\n\n- Additional considerations:\n  - Traumatic/bloody neuraxial placement: consider delaying LMWH ≥24 h post-procedure.\n  - Concomitant antiplatelets or other anticoagulants compound risk and generally should be avoided with indwelling neuraxial catheters.\n\nApplying these principles: delay neuraxial placement to ≥24 h after the last therapeutic dose; initiate once-daily prophylactic enoxaparin ≥12 h after placement while the catheter remains; remove the catheter ≥12 h after the last prophylactic dose; and resume LMWH ≥4 h after removal. This strategy minimizes hematoma risk and preserves effective postoperative prophylaxis.",
    "educationalObjective": "Time last LMWH dose before neuraxial procedures and surgery and schedule safe postoperative resumption."
  },
  {
    "id": "Core.12.1.14",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Anticoagulants and antiplatelets",
    "difficulty": "hard",
    "questionText": "A 68-year-old man with atrial fibrillation on rivaroxaban 20 mg nightly (last dose taken 3 hours ago) presents after a fall with a large acute subdural hematoma causing 8 mm midline shift. Creatinine is 0.9 mg/dL, INR 1.2, aPTT 30 s; anti–factor Xa level is not available. Emergent decompressive craniotomy is planned. Which of the following is the most appropriate immediate pharmacologic reversal strategy?",
    "answers": [
      {
        "text": "4-factor prothrombin complex concentrate (4F-PCC) 50 U/kg IV",
        "isCorrect": false,
        "explanation": "4F-PCC can be used when andexanet is unavailable, but it does not directly neutralize factor Xa inhibitors; specific reversal with andexanet is preferred for life-threatening bleeding."
      },
      {
        "text": "Activated PCC (FEIBA) 50 U/kg IV",
        "isCorrect": false,
        "explanation": "aPCC is a potential alternative when specific reversal is unavailable, but evidence is limited and thrombosis risk is higher; it is not first-line when andexanet can be given."
      },
      {
        "text": "Idarucizumab 5 g IV",
        "isCorrect": false,
        "explanation": "Idarucizumab specifically reverses dabigatran (direct thrombin inhibitor) and has no effect on rivaroxaban (factor Xa inhibitor)."
      },
      {
        "text": "Andexanet alfa high-dose regimen (800 mg IV bolus followed by 8 mg/min infusion for 2 hours)",
        "isCorrect": true,
        "explanation": "For life-threatening bleeding due to rivaroxaban ≥10 mg taken within 8 hours, high-dose andexanet alfa is indicated and provides targeted reversal of factor Xa inhibition."
      },
      {
        "text": "Andexanet alfa low-dose regimen (400 mg IV bolus followed by 4 mg/min infusion for 2 hours)",
        "isCorrect": false,
        "explanation": "Low-dose andexanet is used for lower-dose factor Xa inhibitor exposure (eg, rivaroxaban ≤10 mg) or when last dose was >8 hours ago; it is inadequate for recent 20 mg rivaroxaban."
      }
    ],
    "didactic": "Direct oral anticoagulant reversal should prioritize specific antidotes when available, with nonspecific prohemostatic concentrates reserved for situations where targeted agents cannot be used.\n\n- Dabigatran (direct thrombin inhibitor) is specifically reversed by **idarucizumab 5 g IV** (two 2.5 g doses), which binds dabigatran with high affinity and provides rapid, complete reversal. Dabigatran is renally cleared and dialyzable; hemodialysis can be considered if time permits and idarucizumab is unavailable.\n- Apixaban, rivaroxaban, and edoxaban (direct factor Xa inhibitors) are reversed by **andexanet alfa**, a decoy factor Xa that sequesters the drug. Dosing is exposure dependent:\n  - **High dose** (800 mg bolus → 8 mg/min × 120 min) for rivaroxaban ≥10 mg taken within 8 h (or unknown timing) or apixaban >5 mg within 8 h.\n  - **Low dose** (400 mg bolus → 4 mg/min × 120 min) for lower doses or if >8 h since the last dose.\n- If andexanet is unavailable, **4F-PCC (eg, 50 U/kg)** is commonly used off-label to improve thrombin generation, with observational data supporting hemostatic efficacy. **Activated PCC (FEIBA)** is another alternative but carries a higher thrombotic risk and less robust evidence.\n\nAdditional considerations:\n- Conventional PT/INR and aPTT are unreliable for quantifying DOAC effect; **anti–factor Xa assays** (drug-specific) are most informative for Xa inhibitors, and **thrombin time** is highly sensitive for dabigatran.\n- **FFP and vitamin K** do not reverse DOACs and should not be relied upon for urgent reversal.\n- **Activated charcoal** may reduce absorption if ingestion occurred within ~2 hours.\n\nIn this case of recent 20 mg rivaroxaban exposure with life-threatening intracranial hemorrhage, **high-dose andexanet alfa** provides the most appropriate immediate, targeted reversal.",
    "educationalObjective": "Use specific reversal agents (idarucizumab, andexanet alfa) and PCC/activated PCC when indicated."
  },
  {
    "id": "Core.12.2.1",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Cardiac evaluation and guidelines",
    "difficulty": "easy",
    "questionText": "A 68-year-old man with hypertension, type 2 diabetes, and symptomatic peripheral artery disease (intermittent claudication) is evaluated preoperatively for elective open abdominal aortic aneurysm repair tomorrow. He takes lisinopril, metformin, and aspirin 81 mg daily. He has no history of myocardial infarction or stroke. Vitals are stable; ECG shows normal sinus rhythm. Labs: creatinine 1.0 mg/dL, AST/ALT within normal limits, LDL 145 mg/dL. He is not currently taking a statin. Which of the following is the most appropriate perioperative statin management?",
    "answers": [
      {
        "text": "Hold statins during the perioperative period and restart after hemodynamics stabilize",
        "isCorrect": false,
        "explanation": "Guidelines recommend continuing chronic statins perioperatively; withholding therapy is associated with increased cardiac events and provides no benefit."
      },
      {
        "text": "Delay surgery 2–4 weeks to establish statin therapy before operative stress",
        "isCorrect": false,
        "explanation": "While earlier initiation is ideal, surgery should not be delayed solely to start a statin; begin now and continue perioperatively without postponing necessary surgery."
      },
      {
        "text": "Defer statin initiation until after surgery due to risk of perioperative myopathy",
        "isCorrect": false,
        "explanation": "The absolute risk of statin-associated myopathy is low, whereas perioperative MACE risk in major vascular surgery is high; delaying initiation forfeits cardioprotective benefit."
      },
      {
        "text": "Initiate moderate-intensity statin (eg, atorvastatin 20 mg) today and continue perioperatively",
        "isCorrect": false,
        "explanation": "Starting a statin is reasonable, but high-intensity therapy is preferred for clinical ASCVD and high-risk vascular surgery when tolerated; moderate intensity is suboptimal in this setting."
      },
      {
        "text": "Initiate high-intensity statin (eg, atorvastatin 80 mg) today and continue perioperatively",
        "isCorrect": true,
        "explanation": "Major vascular surgery patients benefit from perioperative statins; in those with clinical ASCVD (eg, PAD/AAA) and age ≤75, high-intensity therapy is recommended and should be started as soon as possible and continued through the perioperative period."
      }
    ],
    "didactic": "Perioperative statin therapy reduces myocardial infarction, atrial fibrillation, and all-cause mortality in patients undergoing noncardiac surgery, with the strongest evidence in **major vascular procedures** (eg, open AAA repair, peripheral arterial bypass, carotid endarterectomy). Statins provide rapid, pleiotropic benefits beyond LDL lowering, including **plaque stabilization**, **anti-inflammatory effects**, improved **endothelial function**, and reduced **thrombogenicity**, which translate into early perioperative cardioprotection.\n\nCurrent ACC/AHA guidance recommends:\n- **Continue** chronic statins throughout the perioperative period; withholding is associated with increased adverse cardiac events.\n- **Initiate statins** in patients undergoing **vascular surgery** or those with a clear long-term indication (eg, clinical ASCVD such as PAD/AAA, diabetes with elevated LDL). Initiation should occur **as early as possible** before surgery and continued postoperatively; do not delay needed surgery solely for statin loading.\n- Use **high-intensity statins** when indicated and tolerated (eg, atorvastatin 40–80 mg or rosuvastatin 20–40 mg) in patients ≤75 years with clinical ASCVD; consider moderate-intensity if intolerance, drug interactions, or advanced age necessitate dose reduction.\n\nCommon pitfalls include deferring initiation due to concerns about myopathy or liver injury in patients without contraindications. The absolute risk of serious myopathy/rhabdomyolysis is low, particularly with normal baseline AST/ALT and no interacting drugs. Conversely, high-risk vascular surgery carries substantial perioperative MACE risk, making the benefit of statin therapy compelling. Therefore, this patient—undergoing major vascular surgery with clinical ASCVD and normal hepatic/renal function—should have a **high-intensity statin initiated now and continued perioperatively**.",
    "educationalObjective": "Continue statins and consider initiation in high‑risk vascular procedures when appropriate."
  },
  {
    "id": "Core.12.2.2",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Cardiac evaluation and guidelines",
    "difficulty": "easy",
    "questionText": "A 72-year-old man with stable exertional angina (CCS class II), hypertension, and hyperlipidemia presents for elective laparoscopic cholecystectomy. Home medications include isosorbide mononitrate ER 60 mg each morning, amlodipine 10 mg daily, aspirin, and atorvastatin. Because he is NPO, the preoperative nurse withheld his morning medications. In the preoperative area, he reports 3/10 substernal pressure similar to prior angina; BP 138/76 mmHg, HR 72/min, SpO<sub>2</sub> 98% on room air, and ECG is unchanged from baseline.\n\nWhich perioperative management of his antianginal therapy is most appropriate to minimize myocardial ischemia risk?",
    "answers": [
      {
        "text": "Administer sublingual nitroglycerin now and continue therapy by giving amlodipine with a sip of water and initiating a low-dose IV nitroglycerin infusion intraoperatively.",
        "isCorrect": true,
        "explanation": "Abrupt nitrate withdrawal can precipitate angina; bridging with SL/IV nitroglycerin and continuing the CCB minimizes ischemia risk while allowing titration to hemodynamics."
      },
      {
        "text": "Proceed to the OR without replacing morning nitrates or CCBs and treat symptoms intraoperatively with fentanyl and vasopressors as needed.",
        "isCorrect": false,
        "explanation": "Withholding chronic antianginal therapy risks rebound ischemia; treating only symptoms intraoperatively ignores prevention and may worsen supply–demand mismatch."
      },
      {
        "text": "Stop all vasodilators and start a prophylactic phenylephrine infusion to maintain MAP; treat angina with morphine as needed.",
        "isCorrect": false,
        "explanation": "Reflexively stopping vasodilators and relying on vasopressors/morphine does not address coronary supply–demand balance and may worsen ischemia."
      },
      {
        "text": "Replace amlodipine with short-acting nifedipine preoperatively to allow rapid titration and hold nitrates to assess baseline hemodynamics.",
        "isCorrect": false,
        "explanation": "Short-acting nifedipine can cause reflex tachycardia and increase MI risk; holding nitrates further increases ischemic risk."
      },
      {
        "text": "Discontinue nitrates for 24–48 hours preoperatively to reduce tolerance, then restart postoperatively when oral intake resumes.",
        "isCorrect": false,
        "explanation": "Intentionally stopping nitrates perioperatively can trigger rebound angina; nitrate-free intervals are a chronic outpatient strategy, not a perioperative withholding plan."
      }
    ],
    "didactic": "Patients with chronic stable angina should generally **continue antianginal therapy perioperatively** to prevent supply–demand mismatch and ischemia. Abrupt **nitrate withdrawal** can produce rebound angina due to loss of preload/afterload reduction and coronary vasodilation. When oral intake is interrupted, bridging with **sublingual** or **intravenous nitroglycerin** (titrated to symptoms and blood pressure) is appropriate; long-acting preparations can be resumed when feasible.\n\n- **Nitrates:** Continue perioperatively; use SL nitroglycerin for acute symptoms and consider low-dose IV nitroglycerin intraoperatively if ongoing ischemia risk exists. Avoid intentional preoperative discontinuation solely to mitigate tolerance.\n- **Calcium channel blockers (CCBs):** Continue perioperatively. Dihydropyridines (eg, amlodipine) reduce afterload and coronary vasospasm without bradycardia. Avoid **short-acting nifedipine**, which can cause reflex tachycardia and increased MI risk. Non-dihydropyridines (verapamil/diltiazem) may depress AV conduction—use caution if combined with β-blockers.\n- Give essential cardiovascular medications with a **small sip of water** despite NPO status, or provide **IV/transdermal** alternatives when needed.\n\nManagement should prioritize prevention of ischemia rather than reactive treatment. If hypotension occurs, adjust anesthetic depth and use vasopressors judiciously while maintaining antianginal therapy, as MAP = CO × SVR does not fully capture coronary supply–demand dynamics. For this patient, administering **SL nitroglycerin now**, continuing the CCB, and bridging with **IV nitroglycerin** intraoperatively best mitigates ischemia risk while allowing real-time titration to hemodynamics.",
    "educationalObjective": "Coordinate perioperative antanginal therapy (nitrates, CCBs) and avoid abrupt withdrawal."
  },
  {
    "id": "Core.12.2.3",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Cardiac evaluation and guidelines",
    "difficulty": "hard",
    "questionText": "A 68-year-old man with ischemic cardiomyopathy (EF 30%) and complete heart block after AV node ablation has a left pectoral biventricular ICD (CRT-D) implanted 1 year ago. He is scheduled for a left radical mastectomy using monopolar electrocautery; bipolar cautery will not be available. ECG shows a paced biventricular rhythm at 70 bpm. The last device interrogation (9 months ago) documented pacemaker dependence (no intrinsic escape >30 bpm). A device representative is available preoperatively. The electrosurgery dispersive pad can be placed on the right thigh, and external defibrillator/pacing pads are available.\n\nWhich perioperative management plan is most appropriate to minimize EMI-related risk for this patient?",
    "answers": [
      {
        "text": "Apply a magnet to suspend shocks and proceed without reprogramming; place external defibrillator pads and the dispersive pad on the contralateral thigh; postoperative interrogation is unnecessary if no shocks occur.",
        "isCorrect": false,
        "explanation": "Magnet-only management leaves pacing synchronous and vulnerable to inhibition in a pacing-dependent patient; post-op interrogation is recommended after significant EMI or device mode changes."
      },
      {
        "text": "Preoperatively reprogram the ICD to asynchronous pacing (eg, DOO) and disable tachyarrhythmia therapies; place the dispersive electrode on the contralateral thigh, use short bursts of monopolar cautery, apply external defibrillation/pacing pads, and arrange postoperative device interrogation to restore settings.",
        "isCorrect": true,
        "explanation": "For a pacing-dependent ICD patient having surgery above the umbilicus with monopolar cautery near the generator, asynchronous pacing with tachy therapy disabled plus proper pad placement and post-op interrogation best mitigates EMI risks."
      },
      {
        "text": "Use bipolar electrosurgery only and leave ICD tachy therapies on; asynchronous pacing is unnecessary if the field is small.",
        "isCorrect": false,
        "explanation": "Bipolar cautery reduces EMI but is unavailable; leaving ICD therapies on risks inappropriate shocks and does not address pacing inhibition from oversensing."
      },
      {
        "text": "Make no changes to the device because EMI is unlikely; keep a magnet in the room and place the dispersive pad on the upper back to maximize current spread.",
        "isCorrect": false,
        "explanation": "Surgery above the umbilicus near a left pectoral ICD has substantial EMI risk; current paths across the chest should be avoided."
      },
      {
        "text": "Apply a magnet intraoperatively to convert the device to asynchronous pacing and disable shocks; place the dispersive electrode ipsilateral to the generator and use continuous monopolar cautery to reduce total activation time.",
        "isCorrect": false,
        "explanation": "A magnet over most ICDs disables tachy therapies but does not change pacing mode; ipsilateral pad placement and continuous cautery increase EMI and oversensing risk."
      }
    ],
    "didactic": "Comprehensive perioperative CIED management integrates device type, pacing dependence, surgical EMI risk, and magnet response.\n\n- Preoperative evaluation: Identify device (pacemaker vs ICD/CRT-D), indication, last interrogation (ICD/CRT ≤6 months), battery status, underlying rhythm, and pacing dependence. Anticipate EMI based on site and energy (monopolar > bipolar). Surgery above the umbilicus or near the generator/leads raises risk of oversensing and inhibition.\n- Magnet principles:\n  - Pacemaker: Magnet typically converts to asynchronous pacing (AOO/VOO/DOO) at a manufacturer-specific magnet rate; no antitachy therapies exist.\n  - ICD/CRT-D: Magnet suspends tachyarrhythmia detection/therapy but generally does not change pacing mode. Thus, a magnet alone does not protect a pacing-dependent ICD patient from cautery-induced oversensing and pacing inhibition.\n- EMI mitigation when EMI is likely (eg, monopolar cautery near a pectoral ICD):\n  - Reprogram to asynchronous pacing (eg, DOO/VOO) if pacing-dependent to prevent inhibition from oversensing.\n  - Disable ICD tachy therapies during EMI exposure; apply external defibrillation/pacing pads and keep a defibrillator immediately available.\n  - Optimize electrosurgery technique: lowest effective power, short bursts (<5 s) with pauses, and prefer bipolar if available.\n  - Place the dispersive (return) electrode so the current path avoids the generator/leads (eg, contralateral thigh or buttock) rather than across the chest.\n- Postoperative care: Restore original programming and perform device interrogation when reprogramming or significant EMI occurred, therapies were disabled, or hemodynamic/device concerns arose.\n\nIn this pacing-dependent CRT-D patient undergoing left chest surgery with monopolar cautery, the safest plan is preoperative reprogramming to asynchronous pacing with ICD therapies disabled, contralateral dispersive pad placement, judicious cautery use, external pads in place, and postoperative interrogation. Magnets alone would inappropriately leave pacing synchronous in an ICD and risk asystole from EMI-induced oversensing.",
    "educationalObjective": "Describe pacemaker/ICD perioperative evaluation, magnet use principles, and EMI mitigation."
  },
  {
    "id": "Core.12.2.4",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Cardiac evaluation and guidelines",
    "difficulty": "medium",
    "questionText": "A 72-year-old man is scheduled for elective total knee arthroplasty. He reports 2 months of progressive dyspnea on exertion; he now has to stop when climbing a single flight of stairs (estimated functional capacity <4 METs). He denies chest pain but notes occasional lightheadedness. BP 138/68 mmHg, HR 78/min, SpO<sub>2</sub> 98% on room air. Cardiac exam reveals a harsh, late-peaking 3/6 systolic murmur at the right upper sternal border radiating to both carotids with a soft S2 and delayed carotid upstroke; there is trace bilateral ankle edema. ECG shows sinus rhythm with LVH. Hemoglobin and creatinine are normal. He has no prior echocardiogram.\n\nWhich preoperative evaluation is most appropriate to guide management before proceeding with surgery?",
    "answers": [
      {
        "text": "No additional testing; proceed with planned surgery",
        "isCorrect": false,
        "explanation": "Proceeding without defining the suspected valvular lesion risks hemodynamic instability; guidelines recommend TTE for symptomatic murmurs and new/worsening dyspnea."
      },
      {
        "text": "Transthoracic echocardiography before surgery",
        "isCorrect": true,
        "explanation": "New/worsening dyspnea with a murmur suggestive of clinically significant aortic stenosis warrants TTE to assess valvular severity and LV function; results will directly affect perioperative management and possible need to delay surgery."
      },
      {
        "text": "BNP or NT-proBNP measurement as the sole test",
        "isCorrect": false,
        "explanation": "Natriuretic peptides can aid risk stratification but do not define valvular lesion severity or LV function and cannot replace TTE in this setting."
      },
      {
        "text": "Coronary CT angiography",
        "isCorrect": false,
        "explanation": "CCTA assesses coronary anatomy but does not evaluate valve hemodynamics; it is not first-line for unexplained dyspnea with a pathologic murmur."
      },
      {
        "text": "Exercise treadmill ECG stress test",
        "isCorrect": false,
        "explanation": "Stress testing targets ischemia risk stratification, not valve characterization, and may be unsafe with suspected severe aortic stenosis and poor functional capacity."
      }
    ],
    "didactic": "Preoperative transthoracic echocardiography (TTE) is indicated when results are likely to change management. ACC/AHA perioperative guidance supports TTE in patients with:\n\n- **Dyspnea of unknown origin** or **worsening heart failure symptoms** to assess left ventricular (LV) function and potential structural heart disease.\n- **Murmur with symptoms or signs** of valvular heart disease (eg, exertional dyspnea, syncope, carotid radiation, soft/absent S2) or when the **severity of known valve disease is unknown** or there has been a **change in clinical status**.\n\nThis patient has progressive dyspnea (<4 METs) and a classic exam for aortic stenosis (AS): harsh, late-peaking systolic murmur at the right upper sternal border radiating to the carotids with a soft S2 and delayed carotid upstroke. Identifying **AS severity** (eg, peak velocity, mean gradient, aortic valve area) and **LV function** with TTE is essential, as severe, symptomatic AS substantially increases perioperative risk (hypotension, myocardial ischemia) and may warrant deferral for valve intervention or heightened intraoperative precautions.\n\nRoutine preoperative TTE is **not** recommended solely to reassess LV function in stable, asymptomatic patients with prior normal function, nor for benign/innocent murmurs without symptoms. When clinical suspicion for significant valve disease is present, however, TTE is first-line because it directly informs anesthetic planning (hemodynamic goals, monitoring, choice of anesthesia) and surgical timing.\n\nAlternative tests are less appropriate here:\n- **Exercise ECG stress testing** evaluates ischemia but does not characterize valve lesions and may be unsafe with suspected severe AS and poor functional capacity.\n- **BNP/NT-proBNP** provide risk stratification but cannot define valve hemodynamics.\n- **Coronary CT angiography** images coronaries, not valves, and is not first-line for dyspnea with a pathologic murmur.\n\nTherefore, preoperative **TTE** is the most appropriate next step.",
    "educationalObjective": "Determine when transthoracic echocardiography is warranted for dyspnea, murmur, or heart failure assessment."
  },
  {
    "id": "Core.12.2.5",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Cardiac evaluation and guidelines",
    "difficulty": "medium",
    "questionText": "A 74-year-old man is scheduled for elective laparoscopic right hemicolectomy for colon cancer (intermediate-risk surgery). He reports 6 months of exertional dyspnea and several episodes of near-syncope when climbing stairs. He can slowly walk 2–3 blocks but must stop due to breathlessness. Vital signs are BP 138/72 mmHg and HR 82/min. Cardiac exam reveals a late-peaking, harsh systolic murmur best heard at the right upper sternal border with radiation to both carotids and a soft/absent S2; carotid upstrokes are delayed. He has not had echocardiography in >5 years.\n\nWhat is the most appropriate next step to optimize perioperative safety for this patient?",
    "answers": [
      {
        "text": "Proceed with general anesthesia using an arterial line and a prophylactic phenylephrine infusion to maintain afterload",
        "isCorrect": false,
        "explanation": "Elective noncardiac surgery should not proceed in suspected symptomatic severe aortic stenosis; invasive monitoring does not mitigate the substantially increased risk of hypotension, ischemia, and death without first addressing the valve lesion."
      },
      {
        "text": "Order pharmacologic myocardial perfusion imaging; if negative, proceed with surgery",
        "isCorrect": false,
        "explanation": "Stress testing does not address the hemodynamic hazard of severe valvular stenosis and may be contraindicated in symptomatic severe AS; a negative result does not mitigate valve-related perioperative risk."
      },
      {
        "text": "Plan neuraxial anesthesia to avoid myocardial depression and minimize tachycardia",
        "isCorrect": false,
        "explanation": "Spinal/epidural sympathectomy can cause abrupt decreases in SVR and preload, which are poorly tolerated in severe aortic stenosis; neuraxial anesthesia does not obviate the need to evaluate and treat the suspected critical valve lesion."
      },
      {
        "text": "Obtain transthoracic echocardiography and defer surgery for cardiology evaluation and consideration of aortic valve intervention",
        "isCorrect": true,
        "explanation": "Symptoms plus classic exam findings strongly suggest severe aortic stenosis. Guidelines recommend TTE and cardiology assessment, with consideration of valve intervention (eg, TAVR/SAVR) before elective intermediate/high-risk noncardiac surgery."
      },
      {
        "text": "Initiate perioperative β-blocker therapy and proceed given the intermediate surgical risk",
        "isCorrect": false,
        "explanation": "Starting β-blockers solely to proceed with elective surgery in suspected severe aortic stenosis is inappropriate and may worsen syncope; the primary issue is a high-risk valve lesion requiring evaluation and likely intervention before surgery."
      }
    ],
    "didactic": "Severe valvular stenosis fundamentally alters perioperative risk because fixed obstruction to forward flow creates profound vulnerability to hypotension, tachyarrhythmias, and ischemia. In **aortic stenosis (AS)**, severe disease is defined by any of the following: aortic valve area <1.0 cm², mean gradient ≥40 mmHg, or peak velocity ≥4.0 m/s. Clinical red flags include a late-peaking systolic murmur at the right upper sternal border radiating to the carotids, diminished/absent S2, delayed carotid upstrokes, and symptoms (dyspnea, angina, syncope/presyncope). For patients with suspected or known severe AS who are symptomatic and scheduled for elective intermediate/high-risk noncardiac surgery, guidelines recommend:\n\n- **Transthoracic echocardiography** if no recent study or change in symptoms.\n- **Cardiology evaluation** and consideration of **valve intervention (TAVR or SAVR)** prior to elective surgery.\n- If surgery is urgent and cannot be deferred, proceed with careful hemodynamic management (maintain preload/afterload, sinus rhythm, and coronary perfusion; avoid tachycardia and vasodilation) and invasive monitoring.\n\nIn contrast, carefully selected patients with **asymptomatic severe AS** may undergo necessary noncardiac surgery with vigilant monitoring and strict hemodynamic goals. Neuraxial anesthesia is relatively contraindicated in severe AS due to sympathectomy-induced hypotension, though graded techniques may be used cautiously in select circumstances after multidisciplinary discussion.\n\n**Mitral stenosis (MS)** also materially increases perioperative risk, especially when severe (valve area ≤1.5 cm², mean gradient ≥10 mmHg at normal HR) or symptomatic (dyspnea, pulmonary hypertension, atrial fibrillation). Key goals are to **avoid tachycardia**, maintain preload, and prevent increases in pulmonary vascular resistance. Preoperative **rate control** and diuretics are beneficial; selected patients may require **percutaneous mitral balloon valvotomy** before elective surgery.\n\nBottom line: symptomatic severe **AS or MS** warrants echocardiographic confirmation and cardiology-directed intervention planning before elective noncardiac surgery to meaningfully reduce perioperative risk.",
    "educationalObjective": "Identify severe valvular lesions (AS, MS) that alter anesthetic plan and may need preoperative cardiology intervention."
  },
  {
    "id": "Core.12.2.6",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Cardiac evaluation and guidelines",
    "difficulty": "medium",
    "questionText": "A 72-year-old man is scheduled for elective open abdominal aortic aneurysm repair in 4 weeks. He has a prior MI with a drug-eluting stent placed 4 years ago, ischemic cardiomyopathy (EF 35% on an echocardiogram 18 months ago), insulin-dependent diabetes, CKD (creatinine 2.2 mg/dL), and hypertension. He reports exertional chest pressure after walking 2–3 blocks that is relieved by rest and unchanged for several months. He can do light housework but cannot climb a flight of stairs (≈3 METs). Medications include aspirin 81 mg, atorvastatin 80 mg, metoprolol succinate 50 mg daily, lisinopril, and insulin. Vitals and exam are unremarkable; ECG shows old Q waves.\n\nWhich of the following is the most appropriate next step to efficiently optimize perioperative cardiac management?",
    "answers": [
      {
        "text": "Schedule preoperative coronary angiography with planned PCI to reduce perioperative myocardial infarction risk.",
        "isCorrect": false,
        "explanation": "Routine preoperative coronary angiography and prophylactic PCI are not indicated to reduce perioperative risk; revascularization should be pursued only for standard indications independent of surgery (eg, left main disease, refractory angina)."
      },
      {
        "text": "Order a dobutamine stress echocardiogram and decide on surgery based solely on the test result.",
        "isCorrect": false,
        "explanation": "Noninvasive testing is appropriate only if results will change management. Ordering a test without coordinated cardiology input may not translate into actionable changes (eg, revascularization or GDMT) and risks unnecessary delays."
      },
      {
        "text": "Start high-dose metoprolol 100 mg twice daily 24 hours before surgery to target heart rate <60 bpm and proceed without testing.",
        "isCorrect": false,
        "explanation": "Initiating or aggressively uptitrating β-blockers immediately preoperatively increases risks (hypotension, stroke). β-blockers should be continued if already prescribed and, if initiated, started and titrated days to weeks in advance."
      },
      {
        "text": "Consult cardiology to evaluate ischemia risk and pursue noninvasive testing only if results would lead to revascularization or a change in guideline-directed medical therapy before surgery.",
        "isCorrect": true,
        "explanation": "This aligns with ACC/AHA guidance: in poor METs with elevated surgical risk, involve cardiology to consider testing only if it would change management (eg, revascularization for standard indications or optimization of GDMT) rather than testing reflexively."
      },
      {
        "text": "Proceed to surgery with current medical therapy and invasive monitoring; no further cardiac evaluation is needed.",
        "isCorrect": false,
        "explanation": "Although sometimes reasonable, this patient has poor functional capacity and multiple RCRI factors undergoing high-risk vascular surgery; additional evaluation could change management (eg, revascularization or GDMT), so proceeding without further assessment is not optimal."
      }
    ],
    "didactic": "This patient faces high perioperative cardiac risk due to high-risk vascular surgery plus multiple Revised Cardiac Risk Index (RCRI) factors: ischemic heart disease, heart failure (EF 35%), insulin-treated diabetes, and creatinine >2 mg/dL. With poor functional capacity (<4 METs), the ACC/AHA algorithm supports additional evaluation only if it will change management.\n\nKey principles:\n- Identify active cardiac conditions (eg, unstable angina, decompensated heart failure, significant arrhythmia, severe valvular disease); if present, defer elective surgery for treatment. This patient’s angina is stable without decompensation.\n- In patients with poor METs and elevated surgical risk, noninvasive ischemia testing is reasonable if results would alter care. Potential actions include:\n  - Revascularization for standard indications independent of surgery (eg, left main disease, extensive multivessel disease with LV dysfunction, refractory angina despite optimal therapy)\n  - Optimization of guideline-directed medical therapy (GDMT) for CAD/HFrEF (eg, β-blocker titration over days–weeks, long-acting nitrates, ranolazine) and risk-factor control\n- Routine preoperative coronary angiography or prophylactic PCI solely to reduce perioperative events is not recommended.\n- Continue chronic β-blockers and statins. If initiating a β-blocker, start ≥2–7 days preoperatively with careful titration; avoid high-dose day-of-surgery starts due to increased stroke/hypotension risk.\n\nEfficient integration of cardiology ensures that any testing performed is actionable—ie, a high-risk ischemia result would prompt consideration of revascularization per standard indications or substantive changes to GDMT. Conversely, reflexive testing without a pathway to alter management adds delay and cost without benefit. In this high-risk, poor-METs patient, cardiology consultation to determine whether targeted noninvasive testing would change revascularization or medical therapy best aligns with guideline-directed, value-based care.",
    "educationalObjective": "Integrate cardiology consultation efficiently when testing may change revascularization or medical therapy."
  },
  {
    "id": "Core.12.2.7",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Cardiac evaluation and guidelines",
    "difficulty": "medium",
    "questionText": "A 72-year-old man with ischemic cardiomyopathy (EF 30%) is scheduled for elective laparoscopic cholecystectomy in 48 hours. Over the past week he reports new dyspnea at rest, 2-pillow orthopnea, and 3-kg weight gain. Vitals: BP 108/62 mmHg, HR 88/min, SpO<sub>2</sub> 94% on room air. Exam reveals bibasilar crackles to mid-lung fields, JVP 12 cm H<sub>2</sub>O, S3, and 2+ leg edema. Labs: Na 134 mEq/L, K 4.7 mEq/L, Cr 1.4 mg/dL (baseline 1.0), NT-proBNP 3200 pg/mL. Medications include metoprolol succinate, lisinopril, furosemide, spironolactone, and empagliflozin. His last transthoracic echocardiogram was 14 months ago. The surgeon asks if surgery can proceed as planned.\n\nWhich is the most appropriate management at this time?",
    "answers": [
      {
        "text": "Continue all heart failure medications including empagliflozin until the day of surgery and hold ACEi/ARB to limit hypotension, then proceed.",
        "isCorrect": false,
        "explanation": "Elective surgery should not proceed during decompensated HF; SGLT2 inhibitors should be stopped 3–4 days preop to avoid euglycemic DKA, and proceeding remains inappropriate."
      },
      {
        "text": "Proceed with surgery using invasive monitoring after administering an extra oral furosemide dose on the morning of surgery.",
        "isCorrect": false,
        "explanation": "Proceeding despite active decompensation risks perioperative pulmonary edema and hemodynamic instability; a single extra oral dose is inadequate optimization."
      },
      {
        "text": "Hold the β-blocker to avoid intraoperative hypotension and administer preoperative IV fluids to improve renal function, then proceed.",
        "isCorrect": false,
        "explanation": "Stopping β-blockers increases perioperative cardiac risk, and fluid loading worsens congestion in decompensated heart failure."
      },
      {
        "text": "Postpone surgery and treat decompensated heart failure with IV loop diuresis; obtain a repeat transthoracic echocardiogram before rescheduling.",
        "isCorrect": true,
        "explanation": "Acute decompensated heart failure is an active cardiac condition requiring deferral of elective surgery; optimization with IV diuresis and reassessment with TTE for new/worsening symptoms is appropriate."
      },
      {
        "text": "Order a pharmacologic stress test; if no ischemia is detected, proceed as planned.",
        "isCorrect": false,
        "explanation": "Stress testing does not address the active condition (decompensated HF); elective surgery should be delayed for medical optimization regardless of ischemia results."
      }
    ],
    "didactic": "Acute decompensated heart failure (HF) is an active cardiac condition that warrants deferring elective noncardiac surgery per ACC/AHA guidelines. This patient has multiple markers of decompensation: new dyspnea at rest, orthopnea, rapid weight gain, elevated JVP, pulmonary rales, S3, worsening renal function, and markedly elevated NT-proBNP. Proceeding increases risk of pulmonary edema, arrhythmia, myocardial injury, and prolonged ventilation.\n\nApproach:\n- Delay elective surgery and admit for optimization with IV loop diuretics (higher bioavailability and faster decongestion than oral), careful electrolyte/renal monitoring, and daily weights.\n- Obtain a repeat transthoracic echocardiogram because there is a significant change in clinical status and the prior study is >1 year old; reassess LV function, valvular disease, and pulmonary pressures.\n- Continue guideline-directed medical therapy: β-blocker and MRA should be continued; ACEi/ARB (or ARNI) are generally continued in HFrEF (balance against hypotension/AKI on a case-by-case basis). Avoid fluid loading in congestion.\n- Hold SGLT2 inhibitors (eg, empagliflozin) 3–4 days preoperatively to reduce risk of euglycemic DKA; restart when eating and hemodynamically stable.\n- Use natriuretic peptides (BNP/NT-proBNP) to help risk stratify and to follow response to decongestion, recognizing they are not stand-alone decision tools.\n\nCommon pitfalls include proceeding with “extra diuretic,” stopping β-blockers due to hypotension concerns, ordering stress tests to “clear” patients with active HF, or empirically giving IV fluids to improve creatinine despite volume overload. After achieving euvolemia and clinical stability (resolution of orthopnea and edema, improving renal function, down-trending natriuretic peptides), surgery can be rescheduled with appropriate anesthetic planning (conservative induction, avoidance of tachycardia, judicious fluids, and consideration of postoperative monitoring).",
    "educationalObjective": "Optimize chronic heart failure prior to surgery and recognize decompensation signs that warrant delay."
  },
  {
    "id": "Core.12.2.8",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Cardiac evaluation and guidelines",
    "difficulty": "medium",
    "questionText": "A 72-year-old man with hypertension and a remote myocardial infarction (3 years ago) presents for elective total hip arthroplasty. He takes metoprolol succinate 50 mg daily, atorvastatin, and aspirin. He last took his medications at 9 pm and has been NPO since midnight. He can climb 2 flights of stairs without symptoms. Preoperative vitals: HR 58/min, BP 138/76 mmHg, SpO<sub>2</sub> 98% on room air. ECG shows normal sinus rhythm without ischemia. The surgeon is concerned about the “low” heart rate and asks whether to hold the β-blocker today or increase the dose for added cardioprotection.\n\nWhich perioperative β-blocker strategy is most appropriate for this patient?",
    "answers": [
      {
        "text": "Administer his usual metoprolol dose now and continue perioperatively",
        "isCorrect": true,
        "explanation": "Chronic β-blocker therapy should be continued perioperatively to avoid withdrawal and reduce ischemic risk; asymptomatic HR 58/min with stable BP is not a contraindication."
      },
      {
        "text": "Start high-dose metoprolol (100–200 mg) now for stronger cardioprotection",
        "isCorrect": false,
        "explanation": "De novo initiation of high-dose β-blockade on the day of surgery increases bradycardia, hypotension, and stroke without mortality benefit."
      },
      {
        "text": "Switch to clonidine preoperatively to blunt sympathetic responses while avoiding β-blocker effects",
        "isCorrect": false,
        "explanation": "Initiating α<sub>2</sub>-agonists perioperatively is not recommended due to hypotension and bradycardia; it does not replace evidence-based β-blocker strategies."
      },
      {
        "text": "Withhold metoprolol today because HR <60/min and resume postoperatively",
        "isCorrect": false,
        "explanation": "Withholding chronic β-blockers can cause rebound tachycardia and ischemia; guidelines recommend continuation unless there is significant bradycardia, hypotension, or decompensated heart failure."
      },
      {
        "text": "Omit the oral dose and use intraoperative esmolol boluses to keep HR 50–60/min",
        "isCorrect": false,
        "explanation": "Substituting intermittent esmolol for a withheld chronic β-blocker does not prevent withdrawal and risks excessive bradycardia/hypotension."
      }
    ],
    "didactic": "Perioperative β-blocker management hinges on two principles: **continue chronic therapy** and **avoid de novo high-dose initiation on the day of surgery**. Abrupt withdrawal of long-term β-blockade provokes sympathetic surge and increases myocardial ischemia risk. Contemporary ACC/AHA guidance recommends continuing β-blockers in patients already taking them, unless there is **significant bradycardia**, hypotension, high-grade AV block, or decompensated heart failure. In an asymptomatic patient with HR ~58/min and normal BP, continuation is appropriate and safer than withholding.\n\nFor patients not previously on a β-blocker, consider initiation only in selected higher-risk patients (eg, ischemia on testing, multiple RCRI factors) and **start well in advance (days to weeks)** with careful titration to a reasonable target (eg, HR 60–80/min, SBP >100 mmHg). The POISE trial and subsequent analyses showed that **starting high-dose metoprolol immediately preoperatively** increased stroke, hypotension, and bradycardia despite fewer MIs, yielding no mortality benefit. Thus, avoid **same-day, high-dose de novo** β-blocker therapy.\n\nPractical points:\n- Continue the patient’s **home β-blocker dose** the morning of surgery with a sip of water; verify hemodynamics and adjust only for clear intolerance.\n- If initiation is indicated, choose a **β<sub>1</sub>-selective agent** (eg, metoprolol, bisoprolol), begin at low dose **days before surgery**, and titrate with BP/HR monitoring.\n- Do not substitute withholding oral therapy with **intraoperative esmolol alone**; this does not prevent withdrawal and may cause labile hemodynamics.\n- Avoid initiating **α<sub>2</sub>-agonists** (eg, clonidine) perioperatively for cardioprotection due to hypotension/bradycardia risk.\n\nThis patient, on stable metoprolol with acceptable vitals undergoing intermediate-risk surgery and adequate functional capacity, is best managed by **continuing his usual β-blocker perioperatively**.",
    "educationalObjective": "Outline perioperative beta‑blocker strategies: continue chronic therapy, avoid high‑dose de novo starts on day of surgery."
  },
  {
    "id": "Core.12.2.9",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Cardiac evaluation and guidelines",
    "difficulty": "hard",
    "questionText": "A 64-year-old man underwent percutaneous coronary intervention with a contemporary drug-eluting stent (DES) to the proximal LAD 7 weeks ago for NSTEMI. He is asymptomatic and taking aspirin 81 mg daily and ticagrelor 90 mg twice daily. He is scheduled for an elective robotic prostatectomy in 4 weeks, and the surgeon requests stopping all antiplatelet therapy preoperatively due to bleeding risk. Vital signs and labs are normal. \n\nWhich of the following is the most appropriate perioperative plan?",
    "answers": [
      {
        "text": "Proceed as scheduled; stop both aspirin and ticagrelor 7 days preoperatively.",
        "isCorrect": false,
        "explanation": "Stopping DAPT this early after ACS-DES is associated with a high risk of catastrophic stent thrombosis; aspirin should generally be continued and elective surgery deferred rather than interrupting both agents."
      },
      {
        "text": "Proceed as scheduled; stop ticagrelor 3 days preoperatively and continue aspirin perioperatively.",
        "isCorrect": false,
        "explanation": "Stopping the P2Y12 inhibitor at 11 weeks after DES for ACS still carries an unacceptably high risk of stent thrombosis; elective surgery should be deferred. Continuing aspirin alone does not adequately mitigate this risk so soon after ACS-DES."
      },
      {
        "text": "Defer surgery until 3 months after PCI; stop ticagrelor 3 days preoperatively and continue aspirin.",
        "isCorrect": false,
        "explanation": "A 3‑month interval may be acceptable for time‑sensitive surgery after DES for chronic coronary disease, but after ACS, guidelines recommend a 12‑month delay for elective procedures."
      },
      {
        "text": "Defer surgery until at least 12 months after PCI while continuing dual antiplatelet therapy.",
        "isCorrect": true,
        "explanation": "After DES placed for ACS, elective noncardiac surgery should be delayed for 12 months when possible, with continuation of DAPT during this period to minimize stent thrombosis risk."
      },
      {
        "text": "Proceed as scheduled with perioperative cangrelor bridging in place of ticagrelor.",
        "isCorrect": false,
        "explanation": "Bridging with short‑acting IV P2Y12 inhibitors is not routinely recommended for elective noncardiac surgery and does not replace the guideline‑preferred strategy of deferring surgery after recent ACS‑DES."
      }
    ],
    "didactic": "Perioperative planning after recent coronary stenting hinges on stent type, indication (ACS vs chronic coronary disease), and time since PCI. Premature interruption of dual antiplatelet therapy (DAPT) markedly increases the risk of acute stent thrombosis, myocardial infarction, and death.\n\nKey timing recommendations (2024 ACC/AHA):\n- Balloon angioplasty without stent: delay elective noncardiac surgery ≥14 days.\n- Bare‑metal stent (BMS): delay ≥30 days; maintain DAPT for at least 1 month. If surgery cannot be postponed, continue aspirin whenever possible.\n- Drug‑eluting stent (DES) for chronic coronary disease: ideally delay ≥6 months; time‑sensitive surgery may be considered ≥3 months if the risk of delay exceeds cardiac risk.\n- DES for acute coronary syndrome (ACS): delay elective surgery for 12 months when possible; stent thrombosis risk is highest and DAPT should be maintained for a full year.\n\nAntiplatelet management principles:\n- Continue aspirin perioperatively in all stented patients when bleeding risk permits.\n- If surgery must occur before the recommended interval and a P2Y12 inhibitor must be stopped, minimize interruption and restart promptly: clopidogrel 5 days, prasugrel 7 days, ticagrelor 3 days before surgery.\n- Bridging with short‑acting IV agents (eg, cangrelor) is reserved for exceptional high‑thrombotic‑risk situations when DAPT interruption is unavoidable and is not routine for elective surgery.\n\nIn this patient with a recent DES placed for NSTEMI (ACS), elective prostatectomy at 11 weeks would require stopping ticagrelor during the high‑risk window. The safest strategy is to defer surgery until 12 months post‑PCI while continuing DAPT, distinguishing this from BMS (≥30 days) and from DES placed for stable disease (≥6 months, ≥3 months if truly time‑sensitive).",
    "educationalObjective": "Plan perioperative management for recent coronary stents, distinguishing bare‑metal from drug‑eluting considerations."
  },
  {
    "id": "Core.12.2.10",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Cardiac evaluation and guidelines",
    "difficulty": "hard",
    "questionText": "A 45-year-old woman with idiopathic pulmonary arterial hypertension (WHO group 1) on continuous IV epoprostenol and sildenafil presents for urgent laparoscopic cholecystectomy. She is NYHA class III with exertional presyncope. Vitals: HR 88/min, BP 108/64 mmHg, SpO<sub>2</sub> 93% on 2 L/min O<sub>2</sub>. Transthoracic echo: markedly dilated RV with reduced function (TAPSE 12 mm), moderate TR, estimated PASP 70 mmHg, normal LV EF. The OR can deliver inhaled nitric oxide and inhaled epoprostenol. The surgeon requests expeditious induction.\n\nWhich perioperative plan best minimizes the risk of hemodynamic decompensation in this patient?",
    "answers": [
      {
        "text": "Proceed with standard monitors; induce with a propofol bolus; treat postinduction hypotension with phenylephrine; add 50% N<sub>2</sub>O to reduce volatile needs; place the arterial line after intubation.",
        "isCorrect": false,
        "explanation": "Propofol bolus can cause profound SVR drop; phenylephrine (pure α) and N<sub>2</sub>O can increase PVR and worsen RV failure; delaying the arterial line risks unrecognized instability."
      },
      {
        "text": "Avoid general anesthesia and perform single-shot spinal anesthesia to T8 with bupivacaine and fentanyl; hold sildenafil the morning of surgery to reduce refractory hypotension; treat hypotension with phenylephrine.",
        "isCorrect": false,
        "explanation": "Abrupt sympathectomy from spinal anesthesia is poorly tolerated in severe PH; stopping PDE5 inhibitor can increase PVR; phenylephrine may further raise PVR."
      },
      {
        "text": "Place a radial arterial line before induction; ensure inhaled nitric oxide is immediately available via the circuit for use at induction; continue epoprostenol with a backup pump; obtain central venous access for vasoactive infusions; titrate induction with etomidate and opioid while maintaining FiO<sub>2</sub> 1.0 and normocapnia.",
        "isCorrect": true,
        "explanation": "Early beat-to-beat BP monitoring, uninterrupted PAH therapy, immediate access to selective pulmonary vasodilator, and ready vasoactive support address the high risk of RV failure and pulmonary hypertensive crisis while avoiding systemic hypotension."
      },
      {
        "text": "Insert a pulmonary artery catheter after induction to guide fluids; stop the epoprostenol perioperatively to avoid vasoplegia; prepare IV nitroprusside for pulmonary hypertensive crisis.",
        "isCorrect": false,
        "explanation": "Interrupting prostacyclin can precipitate rebound PH and death; nitroprusside is not pulmonary-selective and can worsen systemic hypotension; PA catheter after induction does not address immediate induction risk."
      },
      {
        "text": "Insert a central venous catheter preinduction and delay arterial line; plan high PEEP (12–15 cm H<sub>2</sub>O) for oxygenation and inhaled milrinone if needed; use ephedrine boluses for hypotension.",
        "isCorrect": false,
        "explanation": "High PEEP impairs RV preload and output; ephedrine increases HR and O<sub>2</sub> demand; delaying arterial line forfeits early hemodynamic detection; inhaled milrinone is less available and not first-line."
      }
    ],
    "didactic": "Severe pulmonary hypertension (PH) with RV dysfunction is a major perioperative risk; induction, pneumoperitoneum, hypoxia, hypercarbia, acidosis, and sympathetic swings can abruptly increase PVR, precipitating RV ischemia and failure. Goals are to maintain RV perfusion (adequate MAP), avoid increases in PVR, and preserve preload and contractility.\n\nKey management principles:\n- Monitoring: Place an arterial line before induction for beat-to-beat BP and blood gas access. Central venous access facilitates vasoactive infusions. PA catheter/TEE may be considered case-by-case but do not replace immediate preinduction monitoring.\n- Continue PAH therapy: Never interrupt prostacyclin infusions; have a backup pump and drug available. Continue PDE5 inhibitors and endothelin antagonists unless contraindicated.\n- Pulmonary vasodilators: Ensure immediate availability of a selective, inhaled agent (eg, inhaled nitric oxide 5–40 ppm or inhaled epoprostenol 10–50 ng/kg/min). These lower PVR with minimal systemic hypotension and are critical for intraoperative pulmonary hypertensive crises. Avoid abrupt withdrawal of inhaled NO to prevent rebound PH.\n- Induction/ventilation: Use hemodynamically stable induction (eg, etomidate/opioid; cautious ketamine if needed) and avoid large propofol boluses. Maintain FiO<sub>2</sub> near 1.0, normocapnia, normothermia, and analgesia. Avoid N<sub>2</sub>O (↑PVR). Use low–moderate PEEP; high PEEP reduces RV preload and can collapse RV output.\n- Vasoactive support: Prefer norepinephrine or vasopressin to maintain MAP and RV coronary perfusion; both have favorable pulmonary/systemic effects compared with phenylephrine (pure α, ↑PVR). Consider dobutamine or epinephrine for RV inotropy if needed.\n\nThis patient’s severe PH and RV dysfunction warrant preinduction arterial access, uninterrupted PAH therapy, and immediate access to inhaled pulmonary vasodilators, with careful induction and ready vasoactive support to minimize RV decompensation.",
    "educationalObjective": "Recognize pulmonary hypertension as a major perioperative risk and tailor monitoring and vasodilator access."
  },
  {
    "id": "Core.12.2.11",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Cardiac evaluation and guidelines",
    "difficulty": "easy",
    "questionText": "You are triaging several patients in the preoperative clinic and want to follow evidence-based guidance to avoid unnecessary testing. Based on age, symptoms, and the planned procedure’s cardiac risk, for which patient is obtaining a preoperative 12‑lead ECG indicated today?\n\nWhich patient most appropriately warrants a preoperative ECG?",
    "answers": [
      {
        "text": "78-year-old man with well-controlled hypertension, asymptomatic, scheduled for open inguinal hernia repair under monitored anesthesia care",
        "isCorrect": false,
        "explanation": "Age and isolated hypertension are not indications for ECG in low-risk surgery; routine testing is not recommended in asymptomatic patients without known CVD."
      },
      {
        "text": "45-year-old woman with no medical history scheduled for cataract extraction with topical anesthesia and minimal sedation",
        "isCorrect": false,
        "explanation": "Cataract surgery is a low-risk procedure; asymptomatic patients without known cardiovascular disease (CVD) do not benefit from routine preoperative ECG."
      },
      {
        "text": "50-year-old man with well-controlled asthma scheduled for ambulatory knee arthroscopy",
        "isCorrect": false,
        "explanation": "Ambulatory knee arthroscopy is low risk; without CVD or symptoms, a preoperative ECG is not indicated."
      },
      {
        "text": "65-year-old man with prior MI and coronary stent (5 years ago), asymptomatic, scheduled for open abdominal aortic aneurysm repair",
        "isCorrect": true,
        "explanation": "Known CVD undergoing an elevated-risk (major vascular) procedure meets clear guideline-based indications for a preoperative ECG to establish baseline conduction/ischemia and guide perioperative management."
      },
      {
        "text": "55-year-old woman with type 2 diabetes, asymptomatic, scheduled for laparoscopic cholecystectomy",
        "isCorrect": false,
        "explanation": "In asymptomatic patients without known CVD, routine ECG is generally not recommended for intermediate-risk surgery; testing should be selective when it would change management."
      }
    ],
    "didactic": "Preoperative ECG should be targeted to patients in whom results will meaningfully affect perioperative management. Current ACC/AHA perioperative guidelines emphasize procedure risk, presence of **known CVD**, and **active cardiac symptoms** rather than age alone.\n\n- Indicated/reasonable: Patients with **known CVD** (eg, prior MI or PCI, heart failure, significant arrhythmia, valvular/structural disease, PAD, cerebrovascular disease) undergoing **elevated-risk** surgery (major vascular, open intraperitoneal/intrathoracic). An ECG establishes a baseline for ischemia/conduction and may prompt optimization.\n- Consider: Patients with **active cardiac symptoms** (eg, chest pain, unexplained dyspnea, syncope, sustained palpitations) typically warrant ECG and further evaluation irrespective of procedure risk because findings may change management or timing of surgery.\n- Not recommended: **Asymptomatic** patients **without known CVD** undergoing **low-risk** procedures (eg, cataract, superficial, endoscopy, ambulatory arthroscopy). Routine ECG in these settings adds cost and false positives without improving outcomes.\n\nSurgical cardiac risk is commonly stratified as:\n- **Low risk (<1%)**: Cataract, superficial, endoscopy, breast, ambulatory arthroscopy\n- **Elevated risk (≥1%)**: Major vascular (eg, open AAA), open intraperitoneal/intrathoracic, major orthopedic, head/neck\n\nKey pitfalls:\n- **Age alone** is not an indication for ECG.\n- **Diabetes or hypertension alone** do not mandate ECG absent CVD or symptoms.\n- Ordering “routine” ECGs before **low-risk** cases can trigger unnecessary downstream testing and delays.\n\nIn the vignette, the patient with prior MI and PCI undergoing **open AAA repair** (major vascular, elevated risk) clearly meets indications for a preoperative ECG. The other cases are either low risk or lack CVD/symptoms, so routine ECG is not warranted.",
    "educationalObjective": "Select indications for preoperative ECG based on age, symptoms, and procedure risk."
  },
  {
    "id": "Core.12.2.12",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Cardiac evaluation and guidelines",
    "difficulty": "hard",
    "questionText": "A 68-year-old man is scheduled for elective total hip arthroplasty in 4 weeks. Four months ago, he had an NSTEMI and underwent PCI with a drug-eluting stent to the proximal LAD. He has had no recurrent ischemia, exercises 6–7 METs, and has an echocardiogram with LVEF 55% and no wall motion abnormalities. Medications include aspirin 81 mg daily and ticagrelor 90 mg twice daily. The orthopedic surgeon asks for guidance on surgical timing and perioperative antiplatelet management to minimize both cardiac and bleeding risk. Which of the following is the best recommendation?",
    "answers": [
      {
        "text": "Delay surgery until 6 months after PCI and stop all antiplatelet therapy 7 days preoperatively to reduce bleeding risk.",
        "isCorrect": false,
        "explanation": "Six months is insufficient after ACS-DES, and stopping aspirin in a stented patient increases thrombotic risk without clear benefit for most non-neurosurgical procedures."
      },
      {
        "text": "Postpone surgery until ≥12 months after PCI, then continue aspirin and stop ticagrelor 3 days preoperatively.",
        "isCorrect": true,
        "explanation": "DES placed for ACS warrants delaying elective noncardiac surgery for 12 months; when surgery occurs, continue aspirin if feasible and hold ticagrelor for 3 days to mitigate bleeding while maintaining stent protection."
      },
      {
        "text": "Proceed in 4 weeks (5 months post-PCI), continue aspirin, and stop ticagrelor 3 days preoperatively.",
        "isCorrect": false,
        "explanation": "After DES for ACS, elective noncardiac surgery should be delayed for 12 months if possible; proceeding at 5 months carries increased stent thrombosis risk despite appropriate antiplatelet interruption."
      },
      {
        "text": "Proceed now and stop ticagrelor 7 days preoperatively to minimize bleeding risk given the surgical complexity.",
        "isCorrect": false,
        "explanation": "This approach ignores the recommended postponement after ACS-DES and overestimates ticagrelor’s washout (typically 3 days); early interruption of DAPT markedly increases stent thrombosis risk."
      },
      {
        "text": "Proceed now with cangrelor bridging after stopping ticagrelor; continue aspirin and resume a P2Y12 inhibitor promptly postoperatively.",
        "isCorrect": false,
        "explanation": "Bridging may be considered only when surgery cannot be delayed within the high-risk window; for an elective arthroplasty, optimal management is to defer until the recommended interval is complete."
      }
    ],
    "didactic": "Elective noncardiac surgery after myocardial infarction or coronary intervention should be timed to minimize perioperative myocardial ischemia and stent-related thrombotic events while balancing bleeding risk from antiplatelet therapy. Key intervals from contemporary guidelines:\n\n- Myocardial infarction without revascularization: delay elective surgery ≥60 days; risk declines further by 90 days.\n- Percutaneous transluminal coronary angioplasty (no stent): delay ≥14 days.\n- Bare-metal stent (any indication): delay ≥30 days.\n- Drug-eluting stent (stable/chronic coronary disease): delay ≥6 months; if surgery is time-sensitive and benefits of proceeding outweigh cardiac risk, consider ≥3 months.\n- Drug-eluting stent for acute coronary syndrome (ACS): delay ≥12 months for elective procedures.\n\nPerioperative antiplatelet strategy in stented patients prioritizes prevention of stent thrombosis:\n\n- Continue aspirin perioperatively if bleeding risk is acceptable; exceptions include procedures with prohibitive bleeding consequences (eg, intracranial, intraspinal), where aspirin cessation 4–5 days preop may be considered after multidisciplinary discussion.\n- Hold P2Y12 inhibitors for the minimum effective interval if interruption is necessary: clopidogrel 5 days, prasugrel 7 days, ticagrelor 3 days.\n- If surgery cannot be deferred within the high-risk window (eg, <30 days after BMS, <3–6 months after DES, and especially <12 months after ACS-DES), strategies include continuing dual antiplatelet therapy through surgery when feasible or considering short-acting intravenous bridging (eg, cangrelor) in collaboration with cardiology. Resume P2Y12 inhibition as soon as hemostasis permits.\n\nIn this case, a DES was placed for ACS 4 months ago. Elective arthroplasty should be postponed until ≥12 months post-PCI. When surgery proceeds, continue aspirin and hold ticagrelor 3 days preoperatively to balance bleeding and ischemic risks, with early postoperative resumption of P2Y12 therapy.",
    "educationalObjective": "Summarize timing of noncardiac surgery after MI or coronary intervention and adjust antiplatelet strategy accordingly."
  },
  {
    "id": "Core.12.2.13",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Cardiac evaluation and guidelines",
    "difficulty": "hard",
    "questionText": "A 72-year-old man with insulin-dependent type 2 diabetes, hypertension, and chronic kidney disease (creatinine 2.2 mg/dL; eGFR 32 mL/min/1.73 m²) is scheduled for open abdominal aortic aneurysm repair tomorrow. He has no active cardiac symptoms and a baseline ECG shows old inferior Q waves without acute changes. Functional capacity is limited to walking on level ground (≈3–4 METs). You practice at a center with high-sensitivity cardiac troponin (hs‑cTn) assays.\n\nYou aim to detect perioperative myocardial injury early in this high-risk patient. Which monitoring strategy is most appropriate?",
    "answers": [
      {
        "text": "Defer troponin testing unless postoperative chest pain or new ECG changes occur, as routine surveillance offers no added value.",
        "isCorrect": false,
        "explanation": "Symptom-triggered testing misses most myocardial injury after noncardiac surgery, which is frequently silent due to analgesia/sedation."
      },
      {
        "text": "Schedule an exercise or pharmacologic stress test on postoperative day 1 to screen for ischemia before discharge.",
        "isCorrect": false,
        "explanation": "Early postoperative stress testing is inappropriate in the immediate recovery period and does not reliably detect perioperative myocardial injury; biomarkers are preferred."
      },
      {
        "text": "Obtain a single hs‑cTn immediately after emergence and repeat only if intraoperative hypotension or tachycardia occurs.",
        "isCorrect": false,
        "explanation": "A single postoperative value lacks sensitivity; daily surveillance for 48–72 h captures delayed peaks and detects injury independent of hemodynamic events."
      },
      {
        "text": "Obtain a preoperative hs‑cTn and measure hs‑cTn daily for 48–72 h after surgery regardless of symptoms; obtain an ECG and evaluate if values rise from baseline.",
        "isCorrect": true,
        "explanation": "High-risk noncardiac surgery patients benefit from baseline hs‑cTn and routine postoperative hs‑cTn surveillance for 48–72 h to detect largely asymptomatic myocardial injury; baseline helps interpret changes in CKD."
      },
      {
        "text": "Monitor CK‑MB and ECG every 8 h for 24 h and obtain troponin only if CK‑MB is elevated.",
        "isCorrect": false,
        "explanation": "CK‑MB is less sensitive/specific than troponin for myocardial injury; troponin is the recommended biomarker and should be obtained routinely in high-risk patients."
      }
    ],
    "didactic": "Perioperative myocardial injury after noncardiac surgery (MINS) is common and strongly associated with 30‑day mortality. Most events are clinically silent because analgesia and sedation blunt ischemic symptoms, and ECG changes are often absent. Consequently, symptom‑triggered testing misses a substantial proportion of clinically meaningful events.\n\nHigh‑risk patients (eg, age ≥65, major vascular surgery, elevated RCRI, known atherosclerotic disease, or elevated natriuretic peptides) should have routine cardiac troponin surveillance with a high‑sensitivity assay. A practical approach supported by contemporary guidelines and the VISION data is:\n\n- Obtain a preoperative hs‑cTn to establish a baseline, especially helpful in chronic kidney disease where chronic elevations are common.\n- Measure hs‑cTn daily for 48–72 h after surgery regardless of symptoms; most MINS occurs within the first 2–3 postoperative days.\n- Interpret values using the assay’s 99th percentile and a dynamic change. When baseline is elevated (eg, CKD), a significant rise/fall (eg, ≥20% change) is more informative than an isolated value.\n- If troponin is elevated or rising, obtain an ECG, assess hemodynamics and oxygen delivery (optimize MAP, Hgb, SpO<sub>2</sub>), and consider cardiology consultation and medical optimization (eg, statin, antiplatelet, β‑blocker if indicated and hemodynamically tolerated).\n\nTroponin testing outperforms CK‑MB and routine ECG for early detection of myocardial injury. Telemetry and vitals are necessary but insufficient. Early postoperative stress testing is not appropriate for screening and may be unsafe or uninterpretable. By implementing baseline and scheduled postoperative hs‑cTn surveillance for 48–72 h in high‑risk noncardiac surgery, anesthesiologists can identify MINS early and initiate therapies that may improve outcomes.",
    "educationalObjective": "Use pre‑ and postoperative troponin surveillance in high‑risk patients to detect myocardial injury early."
  },
  {
    "id": "Core.12.2.14",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Cardiac evaluation and guidelines",
    "difficulty": "medium",
    "questionText": "A 72-year-old man is scheduled for elective open abdominal aortic aneurysm repair in 4 weeks. Medical history includes insulin-treated type 2 diabetes, chronic kidney disease (creatinine 2.4 mg/dL), and a myocardial infarction 5 years ago without revascularization. He denies chest pain or dyspnea but is limited by knee osteoarthritis; he can do light housework but cannot climb a flight of stairs (<4 METs). Medications include aspirin and a statin. ECG shows sinus rhythm with old inferior Q waves. He would agree to coronary angiography and revascularization if a preoperative test suggested high-risk ischemia.\n\nWhich is the most appropriate next step in his preoperative cardiac evaluation?",
    "answers": [
      {
        "text": "Initiate high-dose β-blocker therapy on the morning of surgery",
        "isCorrect": false,
        "explanation": "Starting high-dose β-blockers on the day of surgery increases stroke and hypotension risk; initiation, if indicated, should occur well in advance with careful titration, often guided by test results."
      },
      {
        "text": "Obtain resting transthoracic echocardiography to measure left ventricular ejection fraction",
        "isCorrect": false,
        "explanation": "Resting echocardiography is not indicated in clinically stable patients without heart failure symptoms or unexplained dyspnea and does not assess inducible ischemia relevant to perioperative risk."
      },
      {
        "text": "Proceed to surgery without further testing and use postoperative troponin surveillance only",
        "isCorrect": false,
        "explanation": "Skipping testing is reasonable only when risk is low/intermediate or results would not change management. Here, high surgical risk and multiple RCRI factors make stress testing useful to guide potential coronary evaluation or surgical timing."
      },
      {
        "text": "Order pharmacologic stress testing (eg, dobutamine stress echocardiography) prior to surgery",
        "isCorrect": true,
        "explanation": "Poor functional capacity with elevated perioperative risk (open vascular surgery, multiple RCRI factors) justifies noninvasive stress testing when results would change management; dobutamine stress echo is appropriate given limited exercise capacity and CKD."
      },
      {
        "text": "Refer directly for diagnostic coronary angiography before surgery",
        "isCorrect": false,
        "explanation": "Invasive angiography is not performed routinely before noncardiac surgery and is reserved for standard indications (eg, ACS or high-risk findings on noninvasive testing)."
      }
    ],
    "didactic": "ACC/AHA perioperative guidelines recommend a stepwise approach: (1) identify active cardiac conditions (eg, ACS, decompensated heart failure, severe arrhythmias, critical valvular disease), (2) estimate perioperative risk using surgical risk plus a clinical tool (eg, RCRI/NSQIP), and (3) assess functional capacity. Patients with ≥4 METs typically proceed without testing. In contrast, those with poor functional capacity (<4 METs) and elevated predicted risk (>1% major adverse cardiac events) may benefit from noninvasive testing only if the results would change management.\n\nThis patient faces high-risk surgery (open vascular) and has multiple RCRI factors (high-risk surgery, ischemic heart disease, insulin therapy, creatinine >2 mg/dL), conferring substantial cardiac risk. Because he lacks unstable symptoms but would consent to coronary evaluation/revascularization if high-risk ischemia is demonstrated, selective noninvasive stress testing is reasonable to guide management. For patients unable to exercise, pharmacologic tests are preferred:\n- Dobutamine stress echocardiography (assesses inducible wall motion abnormalities; no contrast, favorable in CKD)\n- Vasodilator nuclear perfusion imaging (assesses perfusion defects; also avoids iodinated contrast)\n\nRoutine testing that will not alter care should be avoided. Resting transthoracic echocardiography is reserved for unexplained dyspnea, suspected new/worsening heart failure, or significant valvular disease—not for stable coronary disease alone. Routine preoperative coronary angiography is not indicated absent standard triggers (eg, ACS or high-risk noninvasive findings). β-blockers should be continued if already prescribed; if initiating for ischemia risk, start weeks before surgery and titrate. If the patient would not undergo revascularization or surgery is urgent, stress testing should be deferred and perioperative management optimized instead.",
    "educationalObjective": "Use stress testing selectively in patients with poor functional capacity when results would change management."
  },
  {
    "id": "Core.12.3.1",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Chronic meds and optimization",
    "difficulty": "medium",
    "questionText": "A 55-year-old man with major depressive disorder treated with venlafaxine XR 150 mg daily presents for elective laparoscopic cholecystectomy. He is otherwise healthy and asks whether to take his antidepressant the morning of surgery. The default postoperative order set includes tramadol for moderate pain and meperidine for shivering. Standard PONV prophylaxis at your institution is dexamethasone and ondansetron. Which perioperative medication plan is most appropriate to minimize risk while maintaining psychiatric stability?\n\nWhich of the following is the best plan?",
    "answers": [
      {
        "text": "Continue venlafaxine on the day of surgery; avoid tramadol and meperidine; use hydromorphone for analgesia and dexmedetomidine for shivering if needed.",
        "isCorrect": true,
        "explanation": "Most SSRIs/SNRIs should be continued perioperatively. Avoid strongly serotonergic agents (eg, tramadol, meperidine) and select nonserotonergic alternatives (eg, morphine/hydromorphone for pain, dexmedetomidine for shivering)."
      },
      {
        "text": "Switch venlafaxine to phenelzine 1 week preoperatively and use meperidine for shivering because the MAOI will prevent serotonin excess.",
        "isCorrect": false,
        "explanation": "MAOIs markedly increase the risk of hypertensive crisis and serotonin syndrome with multiple perioperative drugs; meperidine is contraindicated with MAOIs."
      },
      {
        "text": "Hold venlafaxine for 2 weeks preoperatively; use tramadol for analgesia and ondansetron for PONV prophylaxis.",
        "isCorrect": false,
        "explanation": "Abrupt discontinuation of SNRIs can cause withdrawal and relapse. Tramadol is serotonergic and increases risk of serotonin syndrome when combined with SNRIs."
      },
      {
        "text": "Continue venlafaxine and use methylene blue intraoperatively if vasoplegia occurs.",
        "isCorrect": false,
        "explanation": "Methylene blue is a potent MAO inhibitor and can precipitate life-threatening serotonin syndrome in patients taking SSRIs/SNRIs."
      },
      {
        "text": "Hold venlafaxine on the morning of surgery to reduce bleeding risk; use ketorolac for opioid-sparing analgesia and meperidine for shivering.",
        "isCorrect": false,
        "explanation": "Withholding a single dose does not meaningfully change bleeding risk and risks withdrawal. Ketorolac plus an SSRI/SNRI increases bleeding risk, and meperidine is serotonergic."
      }
    ],
    "didactic": "Most patients should continue SSRIs/SNRIs perioperatively to avoid discontinuation syndrome (anxiety, agitation, dizziness) and relapse of depression. Abrupt cessation does not meaningfully reduce bleeding or interaction risks in the short term and may worsen postoperative outcomes. The major anesthetic considerations are platelet dysfunction and drug–drug interactions that can precipitate serotonin syndrome.\n\nSSRIs/SNRIs inhibit platelet 5‑HT uptake, modestly increasing bleeding risk, which is amplified by NSAIDs and other antiplatelet agents. This effect does not warrant routine discontinuation; instead, minimize additional platelet inhibitors when feasible.\n\nSerotonin syndrome presents with mental status changes, autonomic instability (hyperthermia, tachycardia), and neuromuscular hyperactivity (clonus, hyperreflexia). It is most often triggered when chronic serotonergic antidepressants are combined with potent serotonergic or MAO‑inhibiting drugs. High‑risk perioperative agents include:\n\n- MAO inhibitors: methylene blue (potent), linezolid\n- Serotonergic opioids: tramadol, meperidine > methadone; fentanyl has rare case reports\n- Others: dextromethorphan, St. John’s wort\n\nPreferred strategies:\n\n- Continue SSRI/SNRI on the day of surgery.\n- Use nonserotonergic analgesics (eg, morphine, hydromorphone) and multimodal adjuncts (acetaminophen, regional techniques). Avoid tramadol and meperidine.\n- Treat postoperative shivering with nonserotonergic options (eg, dexmedetomidine or clonidine) rather than meperidine.\n- Standard antiemetics (eg, dexamethasone, 5‑HT3 antagonists like ondansetron) are generally safe; case reports of serotonin syndrome with 5‑HT3 antagonists are rare and mechanistically unlikely.\n- If an MAO‑inhibiting agent (eg, methylene blue, linezolid) is essential, consult psychiatry; avoid the MAOI if possible, or plan a supervised antidepressant washout with appropriate timing.\n\nThus, the safest plan is to continue venlafaxine and avoid strongly serotonergic perioperative drugs, selecting hydromorphone for analgesia and dexmedetomidine for shivering.",
    "educationalObjective": "Continue SSRIs/SNRIs and most antidepressants while preparing for potential drug interactions (e.g., serotonin syndrome)."
  },
  {
    "id": "Core.12.3.2",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Chronic meds and optimization",
    "difficulty": "easy",
    "questionText": "A 45-year-old man with focal epilepsy controlled on carbamazepine ER 400 mg BID and lamotrigine 150 mg BID presents for emergent laparotomy for small-bowel obstruction. He has been vomiting, an NG tube is placed to low continuous suction, and the surgeon anticipates a postoperative ileus for 2–3 days. He took his last antiepileptic doses yesterday evening and cannot tolerate oral medications. Renal and hepatic function are normal.\n\nWhich perioperative management is most appropriate to prevent withdrawal seizures?",
    "answers": [
      {
        "text": "Place an NG tube and administer crushed carbamazepine ER and lamotrigine via the tube in PACU.",
        "isCorrect": false,
        "explanation": "Enteral absorption is unreliable with ileus and NG suction, and carbamazepine ER should not be crushed; this does not ensure therapeutic levels."
      },
      {
        "text": "Initiate scheduled IV levetiracetam 1 g q12h now and continue until enteral intake returns.",
        "isCorrect": true,
        "explanation": "Chronic antiepileptics should be continued perioperatively; in patients who are NPO without IV forms of home agents (eg, carbamazepine, lamotrigine), substitute a parenteral agent such as IV levetiracetam on a scheduled basis until oral therapy resumes."
      },
      {
        "text": "Increase sevoflurane to ≥1.5 MAC intraoperatively to suppress seizures; no additional prophylaxis needed.",
        "isCorrect": false,
        "explanation": "Volatile anesthetics do not prevent postoperative withdrawal seizures once discontinued and are not a substitute for ongoing antiepileptic therapy."
      },
      {
        "text": "Administer a single IV lorazepam 2 mg dose preinduction for seizure prophylaxis.",
        "isCorrect": false,
        "explanation": "A single benzodiazepine dose is short-acting and insufficient to replace scheduled antiepileptic therapy over days of NPO status."
      },
      {
        "text": "Hold antiepileptic drugs until oral intake resumes; treat seizures PRN with midazolam.",
        "isCorrect": false,
        "explanation": "Withholding chronic antiepileptics markedly increases withdrawal seizure risk; PRN benzodiazepines do not provide continuous seizure prophylaxis."
      }
    ],
    "didactic": "Patients on chronic antiepileptic drugs (AEDs) should have therapy **continued perioperatively** to avoid withdrawal seizures. Missing even 1–2 scheduled doses can precipitate seizures, particularly when physiologic stress, sleep deprivation, and fluctuating anesthetic depth coexist. If the patient cannot take oral medications, a **parenteral substitution** should be instituted on a scheduled basis.\n\nKey principles:\n- Continue home AEDs with sips of water preoperatively when safe; otherwise plan **IV substitution** in advance.\n- Many AEDs lack IV formulations (eg, **carbamazepine, lamotrigine, oxcarbazepine, topiramate**), necessitating substitution.\n- AEDs with available IV forms include **levetiracetam, valproate, fosphenytoin/phenytoin, phenobarbital, lacosamide**.\n- **Levetiracetam** is often preferred for substitution due to minimal drug–drug interactions, 1:1 IV:PO conversion, and convenient dosing (eg, 500–1500 mg IV q12h; adjust for renal impairment).\n- Enteral delivery via NG/OG is acceptable only when GI absorption is reliable; **ileus or NG suction** makes absorption unpredictable, and some formulations (eg, **carbamazepine ER**) should not be crushed.\n\nBenzodiazepines are appropriate for treatment of **acute seizures**, but intermittent dosing does not provide continuous prophylaxis during prolonged NPO periods. Increasing volatile anesthetic depth intraoperatively does not protect against **postoperative** withdrawal once anesthetic delivery ceases. Coordination with neurology and early orders for scheduled IV AEDs help maintain therapeutic drug exposure and prevent breakthrough seizures. Resume the patient’s home regimen as soon as enteral intake is feasible, transitioning off the temporary IV agent. Consider comorbidities when selecting a substitute (eg, avoid valproate in thrombocytopenia or significant hepatic disease; phenytoin/fosphenytoin induces CYP enzymes and may increase nondepolarizing neuromuscular blocker requirements).",
    "educationalObjective": "Continue antiepileptic drugs and plan IV substitution if NPO to prevent withdrawal seizures."
  },
  {
    "id": "Core.12.3.3",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Chronic meds and optimization",
    "difficulty": "medium",
    "questionText": "A 65-year-old man with hypertension and stable coronary artery disease (remote MI 5 years ago, EF 55%) is scheduled for elective total knee arthroplasty under general anesthesia. He takes metoprolol succinate 50 mg daily, amlodipine 10 mg daily, atorvastatin 40 mg nightly, hydrochlorothiazide 25 mg daily, and furosemide 20 mg as needed (last taken 2 weeks ago). He reports no angina, dyspnea, or orthopnea. Vitals today: BP 128/72, HR 62, SpO<sub>2</sub> 98% on room air. Exam shows clear lungs, normal JVP, no edema. Labs: Na 138 mEq/L, K 3.6 mEq/L, creatinine 0.9 mg/dL. He is NPO since midnight and appears euvolemic.\n\nWhich of the following medication plans is most appropriate for the morning of surgery?",
    "answers": [
      {
        "text": "Continue metoprolol, amlodipine, and atorvastatin; hold hydrochlorothiazide and furosemide",
        "isCorrect": true,
        "explanation": "Best choice: continue chronic β-blocker, statin, and calcium channel blocker; individualize diuretics—hold in a euvolemic patient to reduce perioperative hypotension, electrolyte derangements, and AKI risk."
      },
      {
        "text": "Continue metoprolol and atorvastatin; hold amlodipine, hydrochlorothiazide, and furosemide",
        "isCorrect": false,
        "explanation": "Unnecessarily withholding a calcium channel blocker can worsen perioperative blood pressure control; most CCBs should be continued."
      },
      {
        "text": "Hold all antihypertensives; continue only atorvastatin",
        "isCorrect": false,
        "explanation": "Global withholding of antihypertensives risks rebound hypertension and β-blocker withdrawal; targeted continuation of β-blockers and CCBs is preferred, with diuretics individualized."
      },
      {
        "text": "Continue amlodipine and diuretics; hold metoprolol and atorvastatin",
        "isCorrect": false,
        "explanation": "Abrupt β-blocker withdrawal increases perioperative tachycardia and ischemia; statins should be continued given cardioprotective benefits."
      },
      {
        "text": "Hold metoprolol due to bradycardia; continue amlodipine, atorvastatin, and diuretics",
        "isCorrect": false,
        "explanation": "A resting HR of 62 bpm is not a contraindication to continuing a chronic β-blocker; continuing diuretics in a euvolemic NPO patient increases hypotension and electrolyte risk."
      }
    ],
    "didactic": "Perioperative management of chronic cardiovascular medications should balance prevention of adverse hemodynamics with avoidance of withdrawal phenomena and cardiac events.\n\n- β-blockers: Chronic β-blockers should be continued perioperatively. Abrupt cessation can provoke rebound tachycardia, hypertension, and myocardial ischemia due to β-receptor upregulation. Continuation reduces perioperative myocardial ischemia and arrhythmias. Dose adjustments may be considered for significant bradycardia or AV block, but HR 60–70 bpm is acceptable.\n- Statins: Continue statins. They reduce perioperative major adverse cardiac events via plaque stabilization, anti-inflammatory effects, and improved endothelial function. Initiation is reasonable in high-risk vascular surgery, but withholding chronic therapy is not indicated.\n- Calcium channel blockers: Most CCBs (dihydropyridine and non-dihydropyridine) are continued. They provide stable BP control and coronary vasodilation. Caution is warranted only with significant bradycardia/AV block when using verapamil/diltiazem or in severe LV dysfunction, but routine withholding is not recommended.\n- Diuretics: Individualize based on volume status and indication. In euvolemic NPO patients, holding morning thiazide and loop diuretics reduces risks of intravascular depletion, hypotension, hypokalemia, and perioperative AKI. Continue diuretics if there is clear volume overload (eg, decompensated heart failure with edema, elevated JVP), pulmonary congestion, or difficult BP control that depends on diuresis.\n\nIn this stable, euvolemic patient, the optimal plan is to continue metoprolol, amlodipine, and atorvastatin while holding hydrochlorothiazide and furosemide on the morning of surgery. This strategy preserves cardioprotection and hemodynamic stability while minimizing renal and electrolyte complications from unnecessary diuresis.",
    "educationalObjective": "Continue beta‑blockers, statins, and most calcium channel blockers; individualize diuretics based on volume status."
  },
  {
    "id": "Core.12.3.4",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Chronic meds and optimization",
    "difficulty": "easy",
    "questionText": "A 68-year-old man with moderate COPD (FEV1 55% predicted) is scheduled for elective laparoscopic cholecystectomy under general anesthesia. He takes tiotropium daily and a salmeterol/fluticasone inhaler twice daily, with albuterol as needed (about twice weekly). He skipped his morning inhalers because he is NPO. Vitals are normal; SpO<sub>2</sub> is 94% on room air. Examination reveals mild expiratory wheezes without distress and no signs of acute infection. Which preoperative management is most appropriate to reduce the risk of perioperative bronchospasm?",
    "answers": [
      {
        "text": "Withhold the inhaled corticosteroid to reduce the risk of oropharyngeal candidiasis and proceed without bronchodilator therapy.",
        "isCorrect": false,
        "explanation": "Inhaled corticosteroids should be continued perioperatively; withholding them increases airway inflammation. Preoperative bronchodilator therapy decreases perioperative bronchospasm risk."
      },
      {
        "text": "Administer 100 mg IV hydrocortisone as stress-dose steroids because he uses inhaled fluticasone and avoid β<sub>2</sub>-agonists due to tachycardia risk.",
        "isCorrect": false,
        "explanation": "Stress-dose steroids are indicated for chronic systemic steroid use, not for isolated inhaled corticosteroids. β<sub>2</sub>-agonists are first-line for preoperative bronchodilation and are safe in stable patients."
      },
      {
        "text": "Continue his inhaled tiotropium and salmeterol/fluticasone on the day of surgery and administer a nebulized albuterol/ipratropium treatment before induction.",
        "isCorrect": true,
        "explanation": "Continuing long-acting inhaled bronchodilators and steroids and giving short-acting bronchodilator therapy preoperatively optimizes airway caliber and reduces bronchospasm risk without delaying surgery."
      },
      {
        "text": "Delay surgery and start a 5-day course of oral prednisone to optimize lung function, then reassess.",
        "isCorrect": false,
        "explanation": "Short systemic steroid courses are reserved for poorly controlled disease or acute exacerbation. This patient is near baseline; optimization can be achieved with inhaled therapy without delaying surgery."
      },
      {
        "text": "Obtain preoperative spirometry and a chest radiograph to guide risk stratification before proceeding.",
        "isCorrect": false,
        "explanation": "Routine PFTs and chest imaging do not improve outcomes in stable, known COPD and may delay care. Immediate optimization with inhaled bronchodilators is more impactful."
      }
    ],
    "didactic": "Patients with COPD/asthma are at heightened risk for perioperative bronchospasm due to airway hyperreactivity, particularly with airway manipulation. To minimize this risk, continue all **inhaled maintenance therapies** on the day of surgery, including long-acting β<sub>2</sub>-agonists (LABA), long-acting muscarinic antagonists (LAMA), and inhaled corticosteroids (ICS). Being NPO does not preclude the use of inhalers or nebulized treatments.\n\nPreoperative optimization typically includes a dose of **short-acting bronchodilator** therapy (eg, albuterol) shortly before induction; combining with an anticholinergic (ipratropium) provides additive bronchodilation in COPD. This strategy improves airway caliber, reduces dynamic hyperinflation during positive-pressure ventilation, and lowers the incidence of intraoperative bronchospasm.\n\nSystemic corticosteroids should be reserved for patients with an **acute exacerbation** or poorly controlled symptoms (eg, increased dyspnea, wheeze, or rescue inhaler use) despite optimal inhaled therapy. In such cases, a short course of oral prednisone or IV methylprednisolone can be considered. Importantly, isolated ICS use **does not warrant stress-dose steroids**; adrenal suppression is primarily a concern with chronic systemic glucocorticoids.\n\nRoutine preoperative spirometry or chest imaging is **not indicated** in stable patients with known COPD/asthma because results rarely change immediate perioperative management and can delay care. Instead, focus on therapies that directly improve airflow before induction.\n\nAdditional intraoperative considerations include minimizing airway irritation (eg, use sevoflurane for its bronchodilatory properties), ensuring adequate depth of anesthesia before instrumentation, and promptly treating bronchospasm with inhaled β<sub>2</sub>-agonists ± anticholinergics; refractory cases may respond to epinephrine, ketamine, or magnesium. In summary, continue inhaled bronchodilators and steroids on the day of surgery and provide preoperative bronchodilator therapy when needed to reduce perioperative pulmonary complications.",
    "educationalObjective": "Continue inhaled bronchodilators and steroids in COPD/asthma and give preop bronchodilator optimization when needed."
  },
  {
    "id": "Core.12.3.5",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Chronic meds and optimization",
    "difficulty": "hard",
    "questionText": "A 62-year-old man with type 2 diabetes mellitus, obesity, OSA, and CKD stage 3b (eGFR 35 mL/min/1.73 m²) is scheduled for elective laparoscopic cholecystectomy today. His diabetes regimen includes insulin glargine 40 units at 22:00, insulin lispro with meals, metformin 1000 mg twice daily, empagliflozin 25 mg daily, and weekly semaglutide. His case was moved from 07:30 to 15:00. He took empagliflozin yesterday morning, semaglutide 5 days ago, and his usual glargine at 22:00. He is NPO since midnight, denies GI symptoms, and has a preop glucose of 85 mg/dL with negative urine ketones. Vitals are stable.\n\nWhich perioperative diabetes plan is most appropriate for this elective case?",
    "answers": [
      {
        "text": "Proceed today; hold empagliflozin only the morning of surgery, hold metformin, give 100% basal insulin, use subcutaneous correction scale, and target 110–140 mg/dL.",
        "isCorrect": false,
        "explanation": "Holding an SGLT2 inhibitor only on the day of surgery is insufficient (requires ≥3 days); full basal dose with afternoon surgery and low glucose increases hypoglycemia risk, and subcutaneous correction alone is suboptimal for prolonged cases."
      },
      {
        "text": "Proceed today; stop all insulin to avoid hypoglycemia, start a D5 infusion only, and target 70–110 mg/dL intraoperatively.",
        "isCorrect": false,
        "explanation": "Withholding basal insulin risks ketosis/DKA, especially with SGLT2 exposure; dextrose alone worsens hyperglycemia and a 70–110 mg/dL target is too strict."
      },
      {
        "text": "Postpone surgery until ≥3 days after the last empagliflozin dose; on the rescheduled date hold metformin, give 70–80% of usual glargine the night before, manage intraoperatively with dextrose and insulin infusion to maintain 140–180 mg/dL.",
        "isCorrect": true,
        "explanation": "SGLT2 inhibitors should be held for at least 3 days preop to reduce euglycemic DKA risk; with CKD, hold metformin on the day of surgery; reduce but continue basal insulin to prevent ketosis, and use insulin/dextrose to maintain a 140–180 mg/dL target during anesthesia."
      },
      {
        "text": "Proceed today; continue full basal insulin without dextrose, hold only prandial insulin, and target 80–110 mg/dL intraoperatively.",
        "isCorrect": false,
        "explanation": "Continuing full basal without dextrose risks hypoglycemia (glucose 85 mg/dL, prolonged fast), and a tight 80–110 mg/dL target increases hypoglycemia; this plan ignores SGLT2-associated euglycemic DKA risk."
      },
      {
        "text": "Delay surgery 24 hours; continue all oral agents, give half-dose basal insulin, and target <140 mg/dL intraoperatively.",
        "isCorrect": false,
        "explanation": "A 24-hour delay is inadequate for SGLT2 washout; continuing orals while NPO is unsafe, and a <140 mg/dL target is unnecessarily tight."
      }
    ],
    "didactic": "Perioperative diabetes management balances hypoglycemia avoidance with prevention of ketosis and hyperglycemia-related complications. For most noncritically ill adults, intraoperative glucose targets of 140–180 mg/dL are recommended; tighter targets increase hypoglycemia without clear outcome benefit.\n\nSGLT2 inhibitors (eg, empagliflozin) increase ketogenesis and can cause euglycemic DKA during fasting, illness, or insulin deficiency. For elective surgery, hold SGLT2 inhibitors for at least 3 days (ertugliflozin 4 days). If the medication was taken within this window, postponing elective procedures is prudent; proceeding risks euglycemic DKA despite normal or mildly elevated glucose. Monitor for ketosis if recent exposure is suspected.\n\nLong-acting basal insulin should typically be continued but reduced to mitigate hypoglycemia during fasting. A practical approach is 70–80% of the usual dose the night before (or morning-of if that is the patient’s schedule). Do not stop basal insulin entirely, as this promotes lipolysis and ketone production. Prandial insulin is held while NPO; use IV insulin infusion for major or prolonged cases, particularly when timing is variable, to achieve a 140–180 mg/dL target with frequent monitoring. Provide dextrose (eg, D5 or D10) when needed to prevent hypoglycemia and to allow safe insulin administration.\n\nMetformin is generally held on the morning of surgery and avoided perioperatively in patients with renal impairment, tissue hypoperfusion, or anticipated contrast exposure due to lactic acidosis risk. Sulfonylureas are held the day of surgery to avoid hypoglycemia. GLP-1 receptor agonists can delay gastric emptying; many centers individualize continuation versus holding based on GI symptoms and aspiration risk.\n\nIn this case, recent empagliflozin necessitates delaying an elective operation until adequate washout, holding metformin on the operative day (CKD), continuing reduced basal insulin, and using dextrose/insulin intraoperatively to maintain 140–180 mg/dL.",
    "educationalObjective": "Create a perioperative diabetes plan: basal insulin adjustments, perioperative glucose targets, and hold of hypoglycemics that increase risk."
  },
  {
    "id": "Core.12.3.6",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Chronic meds and optimization",
    "difficulty": "medium",
    "questionText": "A 68-year-old man with hypertension and CKD stage 3 (Cr 1.7 mg/dL) is scheduled for elective laparoscopic sigmoid resection under general anesthesia with pneumoperitoneum and PEEP. Home medications include amlodipine 10 mg daily, valsartan 160 mg daily, and hydrochlorothiazide 25 mg daily. He took no medications this morning and is euvolemic on exam; BP in preop is 128/72 mmHg, HR 72/min. You anticipate hemodynamic lability with insufflation and induction. Which preoperative antihypertensive plan and vasopressor readiness is most appropriate for this patient?",
    "answers": [
      {
        "text": "Hold valsartan and give a large crystalloid bolus before induction; no vasopressors need to be prepared if the patient is euvolemic",
        "isCorrect": false,
        "explanation": "Volume loading alone does not prevent vasoplegia and may be harmful in CKD; vasopressor readiness, particularly vasopressin, is still indicated."
      },
      {
        "text": "Hold both valsartan and amlodipine; plan to treat hypotension with ephedrine and avoid vasopressin",
        "isCorrect": false,
        "explanation": "Calcium channel blockers are typically continued; ephedrine may be less effective in vasoplegia, and avoiding vasopressin removes a key therapy for ACEI/ARB-associated hypotension."
      },
      {
        "text": "Continue valsartan on the morning of surgery and prepare phenylephrine as the primary rescue vasopressor",
        "isCorrect": false,
        "explanation": "Continuing an ARB increases the risk of refractory intraoperative hypotension, and catecholamines like phenylephrine may be less effective when the renin–angiotensin system is blocked."
      },
      {
        "text": "Hold only hydrochlorothiazide and continue valsartan; treat expected hypotension with a norepinephrine infusion alone",
        "isCorrect": false,
        "explanation": "Holding the diuretic can mitigate hypovolemia, but continuing the ARB still predisposes to vasoplegia; norepinephrine may help but vasopressin often provides superior response in RAS-blocked patients."
      },
      {
        "text": "Hold valsartan on the morning of surgery, continue amlodipine, and have vasopressin immediately available for hypotension refractory to catecholamines",
        "isCorrect": true,
        "explanation": "Withholding ACEIs/ARBs reduces the risk of vasoplegic hypotension; if hypotension occurs, vasopressin targets V1 receptors and is effective when catecholamines are less responsive."
      }
    ],
    "didactic": "ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) impair physiologic vasoconstriction mediated by the renin–angiotensin–aldosterone system. During anesthesia—especially with induction, pneumoperitoneum, and PEEP—sympathetic tone falls and afterload can drop precipitously. When the RAS is blocked, patients are at increased risk of **vasoplegic hypotension** that may be resistant to catecholamines. Multiple observational studies and meta-analyses show higher rates of intraoperative hypotension and vasopressor use when ACEIs/ARBs are continued on the day of surgery, without clear mortality benefit. Accordingly, many perioperative pathways recommend withholding the morning dose (≈24 hours preop) in patients at risk for hypotension undergoing noncardiac surgery.\n\nIn contrast, most other antihypertensives are continued. **Calcium channel blockers** (eg, amlodipine) are generally maintained perioperatively. **Diuretics** are often held the morning of surgery to reduce hypovolemia and electrolyte derangements, particularly in CKD.\n\nWhen hypotension occurs in RAS-blocked or vasoplegic states, **vasopressin** is effective because it activates V1 receptors causing potent vasoconstriction independent of α-adrenergic pathways. Catecholamines (phenylephrine, ephedrine, norepinephrine) may still be used, but response can be blunted when the RAS is inhibited; adding vasopressin often restores vascular tone. Practical readiness includes having vasopressin available for bolus (eg, 0.5–1 unit) and/or infusion (eg, 0.03 units/min) if hypotension is refractory to fluids and catecholamines.\n\nFor this CKD patient on an ARB undergoing laparoscopic surgery with anticipated hemodynamic swings, the best approach is to:\n- **Hold the ARB the morning of surgery** (reduce vasoplegia risk)\n- **Continue the calcium channel blocker** (safe and maintains BP control)\n- **Prepare vasopressin** for catecholamine-refractory hypotension, while using balanced fluids judiciously\n\nThis strategy minimizes preventable hypotension and ensures an effective rescue plan if vasoplegia develops.",
    "educationalObjective": "Decide on holding ACE inhibitors/ARBs preop in patients at risk of hypotension and plan vasopressor readiness."
  },
  {
    "id": "Core.12.3.7",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Chronic meds and optimization",
    "difficulty": "medium",
    "questionText": "A 68-year-old man with Parkinson disease (PD) takes carbidopa-levodopa 25/100 mg every 3 hours and rasagiline 1 mg daily. He reports marked worsening of tremor and rigidity if doses are delayed. He is scheduled for elective laparoscopic cholecystectomy at 11:00 and has been NPO since midnight. He has a history of severe postoperative nausea and vomiting after general anesthesia. Vitals and exam are otherwise unremarkable.\n\nWhich perioperative plan is most appropriate to minimize PD symptom exacerbation while providing effective PONV prophylaxis?",
    "answers": [
      {
        "text": "Convert PD therapy to IV haloperidol while NPO; give promethazine at induction to prevent PONV.",
        "isCorrect": false,
        "explanation": "Haloperidol and promethazine have dopamine antagonism and can markedly worsen PD symptoms; there is no role for haloperidol to substitute PD therapy."
      },
      {
        "text": "Apply a scopolamine patch preoperatively and give metoclopramide at emergence; resume levodopa only after oral intake returns.",
        "isCorrect": false,
        "explanation": "Delaying levodopa risks parkinsonism–hyperpyrexia–like deterioration, and metoclopramide’s D2 blockade can worsen PD despite scopolamine use."
      },
      {
        "text": "Hold PD medications the morning of surgery; administer metoclopramide 10 mg IV at induction and postoperatively as needed.",
        "isCorrect": false,
        "explanation": "Withholding levodopa risks acute PD worsening; metoclopramide is a central D2 antagonist that can precipitate rigidity, akinesia, and dystonia in PD patients."
      },
      {
        "text": "Administer the usual morning carbidopa-levodopa dose with a small sip of water up to 1 hour preoperatively; give ondansetron and dexamethasone for PONV prophylaxis.",
        "isCorrect": true,
        "explanation": "Continuing levodopa minimizes perioperative PD exacerbation, and ondansetron plus dexamethasone provide effective prophylaxis without dopamine antagonism."
      },
      {
        "text": "Continue rasagiline but hold levodopa to reduce aspiration risk; avoid ondansetron and use prochlorperazine for PONV prophylaxis.",
        "isCorrect": false,
        "explanation": "Holding levodopa is inappropriate; prochlorperazine is a D2 antagonist that worsens PD, and ondansetron is safe in PD."
      }
    ],
    "didactic": "Patients with Parkinson disease should have dopaminergic therapy **continued on schedule** perioperatively to prevent rigidity, akinesia, and parkinsonism–hyperpyrexia–like syndromes. Levodopa has a short half-life (1–3 hours); even brief interruptions can cause symptom rebound. Practical strategies include: scheduling early case times, administering the morning dose with a small sip of water despite NPO status, and planning enteral dosing (eg, via NG/duodenal tube) if prolonged NPO is expected. For longer NPO courses, transdermal rotigotine can be considered in consultation with neurology.\n\nAvoid **dopamine antagonists** that worsen PD, including:\n- Metoclopramide (D2 antagonist)\n- Droperidol and haloperidol (butyrophenones)\n- Prochlorperazine and promethazine (phenothiazines with D2 activity)\nThese agents can precipitate severe rigidity, tremor, and dystonia, complicating ventilation and recovery.\n\nUse **non–dopaminergic antiemetics** for PONV prophylaxis:\n- Ondansetron (5-HT3 antagonist)\n- Dexamethasone\n- Scopolamine\n- Aprepitant\nThese provide effective prophylaxis without antagonizing dopamine receptors.\n\nSelective MAO-B inhibitors (eg, rasagiline, selegiline) are typically **continued** perioperatively. Be cautious with serotonergic or monoaminergic analgesics (eg, meperidine, tramadol, methadone) due to rare but serious interaction risk; standard opioids (eg, fentanyl, hydromorphone) and 5-HT3 antagonists are generally acceptable. When oral intake is delayed, early reinitiation of dopaminergic therapy via non-oral routes prevents decompensation.\n\nBottom line: Continue levodopa on schedule and avoid D2-blocking antiemetics; choose ondansetron ± dexamethasone (and other non-dopaminergic options) for PONV prophylaxis in PD patients.",
    "educationalObjective": "Maintain Parkinson disease medications and avoid dopamine antagonists that worsen symptoms."
  },
  {
    "id": "Core.12.3.8",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Chronic meds and optimization",
    "difficulty": "hard",
    "questionText": "A 58-year-old woman with BMI 40 kg/m<sup>2</sup>, type 2 diabetes mellitus, and obstructive sleep apnea presents for an elective laparoscopic hysterectomy under general anesthesia. She started weekly semaglutide 5 weeks ago and her dose was increased 7 days ago. Since the dose increase, she reports persistent nausea and early satiety. Her last semaglutide dose was 3 days ago. She has followed standard fasting guidelines (no solids for 10 hours, clear liquids until 3 hours preop). Vitals and exam are unremarkable; point-of-care glucose is 142 mg/dL.\n\nWhich perioperative plan is the best next step to mitigate aspiration risk while appropriately managing her GLP‑1 therapy?",
    "answers": [
      {
        "text": "Defer elective surgery until gastrointestinal symptoms resolve and the dose‑escalation phase is complete; continue semaglutide and coordinate interim glycemic management.",
        "isCorrect": true,
        "explanation": "Symptomatic patients in the GLP‑1 dose‑escalation phase are at highest risk for delayed gastric emptying; deferring elective surgery is preferred. Continuing therapy avoids destabilizing diabetes while outpatient optimization occurs."
      },
      {
        "text": "Perform bedside gastric ultrasound now; if the antrum appears empty in supine and right lateral decubitus, proceed with standard induction today.",
        "isCorrect": false,
        "explanation": "Gastric ultrasound is useful when surgery cannot be delayed, but in a symptomatic, elective case during dose escalation, deferral is safer; ultrasound is operator dependent and may miss retained solids."
      },
      {
        "text": "Proceed today with rapid-sequence induction and endotracheal intubation, and hold semaglutide for 1 week postoperatively.",
        "isCorrect": false,
        "explanation": "RSI reduces but does not eliminate risk from retained solids; withholding the drug postoperatively does not address the current high-risk state and may worsen glycemic control."
      },
      {
        "text": "Administer metoclopramide and erythromycin preoperatively and proceed after 2 hours of clear liquids.",
        "isCorrect": false,
        "explanation": "Prokinetics and additional clear liquids do not reliably clear retained solids in GLP‑1–related delayed gastric emptying and are insufficient for aspiration risk mitigation."
      },
      {
        "text": "Proceed with general anesthesia today using standard fasting guidelines and continue semaglutide perioperatively.",
        "isCorrect": false,
        "explanation": "Standard fasting does not mitigate the elevated aspiration risk from delayed gastric emptying in symptomatic patients during GLP‑1 dose escalation."
      }
    ],
    "didactic": "GLP‑1 receptor agonists (eg, semaglutide, tirzepatide, liraglutide) slow gastric emptying via vagal and central mechanisms, increasing the risk of residual solids despite standard fasting. Cases of retained gastric contents and aspiration during anesthesia have been reported, particularly in patients with high‑risk features. According to 2024 multi‑society guidance, most patients can continue GLP‑1 therapy perioperatively; risk mitigation focuses on identifying patients at increased risk and tailoring the plan accordingly.\n\nHigh‑risk features include:\n- Active gastrointestinal symptoms (nausea, vomiting, early satiety, abdominal pain)\n- Early dose‑escalation phase or high doses\n- Known or suspected gastroparesis, prior gastric surgery, or other causes of delayed emptying\n\nFor elective procedures in high‑risk patients, the preferred approach is to defer surgery until symptoms resolve and the dose‑escalation phase is complete. When surgery must proceed, risk‑reduction strategies include a 24‑hour liquid‑only diet, point‑of‑care gastric ultrasound to assess for retained contents, and “full‑stomach” precautions (eg, RSI with cuffed endotracheal tube, avoidance of supraglottic devices). In urgent or emergent cases, manage as a full stomach regardless of fasting duration.\n\nWithholding GLP‑1 agents may worsen glycemic control and appetite regulation; routine discontinuation is not recommended for most patients. If therapy is held for specific reasons, coordinate alternative diabetes management (eg, basal insulin adjustments) to maintain euglycemia and avoid ketosis. Prokinetics (metoclopramide, erythromycin) and additional clear liquids do not reliably resolve retained solids from GLP‑1–induced gastric stasis. Gastric ultrasound is valuable when available and performed by trained clinicians, but a negative study does not supersede concerning symptoms in an elective case. The safest course for this symptomatic patient during dose escalation is to postpone the procedure and optimize outpatient management.",
    "educationalObjective": "Manage GLP‑1 receptor agonists with attention to delayed gastric emptying and aspiration risk mitigation."
  },
  {
    "id": "Core.12.3.9",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Chronic meds and optimization",
    "difficulty": "hard",
    "questionText": "A 67-year-old man with treatment-resistant major depression managed with phenelzine 60 mg/day for 8 months presents for urgent open reduction and internal fixation of an intertrochanteric femur fracture in 6 hours. He took his morning dose today. Other medications include amlodipine and atorvastatin. He is hemodynamically stable, and the surgeon prefers not to delay surgery. You anticipate neuraxial or general anesthesia with possible intraoperative hypotension and postoperative shivering.\n\nWhich perioperative plan best minimizes serious drug interaction risk related to this medication while maintaining hemodynamic safety?",
    "answers": [
      {
        "text": "Continue phenelzine; prefer ephedrine over direct-acting vasopressors because MAO inhibition reduces responsiveness to direct agonists; meperidine is acceptable if carefully titrated.",
        "isCorrect": false,
        "explanation": "Direct-acting vasopressors are preferred and effective; indirect agents like ephedrine are risky. Meperidine is contraindicated with MAOIs due to serotonin toxicity."
      },
      {
        "text": "Proceed without delaying surgery; continue phenelzine; treat hypotension with small, titrated doses of direct-acting vasopressors (eg, phenylephrine, epinephrine); avoid meperidine and indirect sympathomimetics (eg, ephedrine); involve psychiatry only if considering longer-term changes to antidepressant therapy.",
        "isCorrect": true,
        "explanation": "Irreversible MAOIs should generally be continued for urgent surgery; use direct-acting vasopressors and avoid meperidine and indirect sympathomimetics to prevent serotonin syndrome and hypertensive crisis. Psychiatry consultation is appropriate only if planning a washout, which requires at least 2 weeks."
      },
      {
        "text": "Continue phenelzine; add perioperative linezolid prophylaxis for surgical site infection coverage; treat hypotension with ephedrine boluses as needed.",
        "isCorrect": false,
        "explanation": "Linezolid is a reversible MAOI and can precipitate serotonin syndrome when combined with MAOI therapy. Ephedrine should be avoided due to unpredictable and potentially exaggerated pressor responses."
      },
      {
        "text": "Hold phenelzine on the morning of surgery; use ephedrine as first-line vasopressor for neuraxial hypotension and meperidine for postoperative shivering.",
        "isCorrect": false,
        "explanation": "Morning-of discontinuation does not reverse irreversible MAO inhibition, and ephedrine can cause exaggerated pressor responses. Meperidine with MAOIs risks life-threatening serotonin syndrome."
      },
      {
        "text": "Delay surgery for 48 hours to allow partial washout; then manage hypotension with indirect sympathomimetics and use tramadol for analgesia to reduce opioid requirements.",
        "isCorrect": false,
        "explanation": "Irreversible MAOIs require 14 days for enzyme regeneration; 48 hours is inadequate and delay is inappropriate for urgent surgery. Indirect agents and tramadol increase risks of hypertensive crisis and serotonin toxicity, respectively."
      }
    ],
    "didactic": "Monoamine oxidase inhibitors (MAOIs) such as phenelzine and tranylcypromine are irreversible, nonselective inhibitors of MAO-A and MAO-B. Because inhibition persists until new enzyme is synthesized, clinically meaningful recovery requires at least 14 days. For urgent surgery, MAOIs are typically continued; risk mitigation focuses on avoiding triggering drugs and using appropriate hemodynamic management.\n\nKey perioperative principles for patients on MAOIs:\n- Use direct-acting vasopressors for hypotension (phenylephrine, epinephrine, norepinephrine) in small, titrated doses. Avoid indirect sympathomimetics (ephedrine, metaraminol) due to unpredictable and potentially exaggerated hypertensive responses.\n- Avoid meperidine, tramadol, methylene blue, linezolid, and dextromethorphan because of the risk of serotonin syndrome (hyperthermia, clonus, autonomic instability, encephalopathy). Cocaine and tyramine-rich agents can also provoke hypertensive crises.\n- Opioids without meaningful serotonergic activity (morphine, hydromorphone, fentanyl, sufentanil) are generally safe when titrated. For postoperative shivering, use alternatives (eg, clonidine, dexmedetomidine) rather than meperidine.\n- Local anesthetics with epinephrine and direct-acting vasoconstrictors can be used cautiously with careful titration and monitoring. Avoid pseudoephedrine and phenylpropanolamine.\n- If considering discontinuation for an elective case, coordinate with psychiatry to balance relapse risk against interaction risk; any washout requires at least 2 weeks and should be planned and monitored by the psychiatric team.\n\nPractical approach: For urgent procedures, proceed while continuing the MAOI, avoid meperidine and indirect sympathomimetics, and treat hypotension with direct-acting vasopressors. Reserve psychiatry consultation for scenarios in which elective tapering or substitution is contemplated. This strategy minimizes the risks of serotonin toxicity and hypertensive crisis while maintaining reliable hemodynamic control.",
    "educationalObjective": "Manage MAOI therapy safely by avoiding meperidine and indirect sympathomimetics; coordinate with psychiatry if changes are needed."
  },
  {
    "id": "Core.12.3.10",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Chronic meds and optimization",
    "difficulty": "medium",
    "questionText": "A 66-year-old woman with rheumatoid arthritis takes prednisone 7.5 mg every morning for the past 2 years and has cushingoid features. She presents for elective laparoscopic cholecystectomy for symptomatic cholelithiasis. Vital signs and electrolytes are normal. She took her usual prednisone dose this morning with a sip of water. The procedure is expected to last 90 minutes with anticipated same-day admission. \n\nWhich perioperative steroid regimen is most appropriate to provide surgical stress coverage while minimizing unnecessary dosing?",
    "answers": [
      {
        "text": "Continue her usual prednisone dose only; no supplemental steroids are needed.",
        "isCorrect": false,
        "explanation": "Chronic daily prednisone with cushingoid features indicates likely HPA axis suppression. For a moderate-stress procedure, supplemental perioperative glucocorticoid is recommended; continuing the home dose alone risks adrenal insufficiency."
      },
      {
        "text": "Hydrocortisone 100 mg IV at induction, then 50 mg IV every 8 h for 24–48 h, then resume home dose.",
        "isCorrect": false,
        "explanation": "This is a major-stress regimen and is excessive for laparoscopic cholecystectomy (moderate stress), increasing risk of hyperglycemia, infection, and poor wound healing without benefit."
      },
      {
        "text": "Perform a cosyntropin stimulation test and delay surgery until results are available.",
        "isCorrect": false,
        "explanation": "Testing can be useful for equivocal risk, but in a patient with chronic steroids and cushingoid features, empiric coverage is appropriate and surgery need not be delayed."
      },
      {
        "text": "Hydrocortisone 25 mg IV at induction only, then resume home dose.",
        "isCorrect": false,
        "explanation": "This is a minor-stress regimen and is inadequate for a moderate-stress operation such as laparoscopic cholecystectomy."
      },
      {
        "text": "Hydrocortisone 50 mg IV at induction, then 25 mg IV every 8 h for 24 h, then resume home dose the next day.",
        "isCorrect": true,
        "explanation": "For likely HPA axis suppression undergoing a moderate-stress operation, this regimen approximates physiologic stress secretion while limiting exposure, aligning with guideline-based dosing."
      }
    ],
    "didactic": "Chronic glucocorticoid therapy can suppress the hypothalamic-pituitary-adrenal (HPA) axis, impairing the normal cortisol surge needed to tolerate surgical stress. Risk of suppression is high with prednisone >20 mg/day for >3 weeks, any dose with cushingoid features, or recent high-dose exposure; it is low with <5 mg/day in the morning or <3 weeks of therapy. Patients at low risk should continue their usual dose without “stress-dose” steroids. If NPO, give an IV equivalent of the daily dose (hydrocortisone 20 mg ≈ prednisone 5 mg ≈ dexamethasone 0.75 mg).\n\nPerioperative supplementation is guided by surgical stress when HPA suppression is likely:\n- Minor (eg, colonoscopy, inguinal hernia): continue home dose; if suppressed, hydrocortisone 25 mg IV once at induction.\n- Moderate (eg, laparoscopic cholecystectomy, total joint): hydrocortisone 50 mg IV at induction, then 25 mg IV every 8 h for 24 h; resume home dose the next day.\n- Major (eg, open abdominal, cardiac): hydrocortisone 100 mg IV at induction, then 50 mg IV every 8 h for 24–48 h, taper to baseline.\n\nThis patient’s chronic prednisone 7.5 mg daily with cushingoid features indicates HPA suppression, and laparoscopic cholecystectomy is a moderate-stress operation; therefore, hydrocortisone 50 mg at induction followed by 25 mg every 8 h for 24 h is appropriate. Excessive dosing (eg, major-stress regimens or prolonged courses) increases hyperglycemia, infection risk, delirium, and impaired wound healing without proven benefit. Cosyntropin testing can be considered preoperatively when risk is uncertain (eg, prednisone 5–20 mg/day >3 weeks without cushingoid features), but it should not delay indicated surgery; empiric, stress-tiered dosing is safe and effective when suppression is likely.",
    "educationalObjective": "Plan perioperative steroid coverage in chronic users or adrenal insufficiency and avoid unnecessary high dosing."
  },
  {
    "id": "Core.12.3.11",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Chronic meds and optimization",
    "difficulty": "medium",
    "questionText": "A 45-year-old man with a deceased-donor kidney transplant 2 years ago presents for elective laparoscopic cholecystectomy. He takes tacrolimus 2 mg at 06:00/18:00, mycophenolate mofetil 1 g twice daily, prednisone 5 mg daily, and TMP-SMX nightly. His last tacrolimus trough was 6 ng/mL, creatinine is 1.2 mg/dL, and he has no signs of infection. He has been NPO since midnight for a 07:30 start and asks whether he should take his morning medications.\n\nWhich perioperative management of his immunosuppression is most appropriate to minimize rejection risk while avoiding unnecessary infection risk?",
    "answers": [
      {
        "text": "Convert to an intravenous tacrolimus infusion via a central venous catheter for the perioperative period",
        "isCorrect": false,
        "explanation": "IV tacrolimus requires central access and close monitoring and increases line-related infection risk; it is reserved for prolonged inability to take enteral medications, not routine elective cases where oral dosing is feasible."
      },
      {
        "text": "Administer the morning tacrolimus and mycophenolate with a small sip of water and resume dosing as soon as possible postoperatively; continue prednisone",
        "isCorrect": true,
        "explanation": "Continuing critical immunosuppressants through the perioperative period prevents rejection; small sips of water are acceptable when NPO, and early postoperative resumption limits trough variability without adding infection risk."
      },
      {
        "text": "Hold tacrolimus and mycophenolate on the morning of surgery to reduce perioperative infection risk",
        "isCorrect": false,
        "explanation": "Withholding calcineurin inhibitors or antimetabolites increases acute rejection risk; continuing baseline immunosuppression does not meaningfully increase immediate perioperative infection risk in a stable, afebrile patient."
      },
      {
        "text": "Give stress-dose hydrocortisone and hold tacrolimus and mycophenolate to balance rejection and infection risks",
        "isCorrect": false,
        "explanation": "Even if stress-dose steroids are considered for chronic prednisone use, they are not a substitute for calcineurin inhibitors/antimetabolites; holding these agents increases rejection risk without proven infection benefit."
      },
      {
        "text": "Delay the morning tacrolimus dose until after perioperative cefazolin to avoid a drug–drug interaction",
        "isCorrect": false,
        "explanation": "Cefazolin does not significantly interact with tacrolimus. Important tacrolimus interactions include macrolides and azoles (CYP3A4 inhibitors) and should be avoided or monitored, not routine cefazolin."
      }
    ],
    "didactic": "Solid-organ transplant recipients should generally **continue critical immunosuppressants** (eg, tacrolimus/cyclosporine and mycophenolate/azathioprine) throughout the perioperative period to prevent acute rejection. For most elective cases, patients may take their morning doses with a **small sip of water** despite NPO status, and medications should be **resumed early postoperatively**. Skipping even a single dose of a calcineurin inhibitor can lower trough levels and increase rejection risk without conferring a meaningful reduction in immediate infection risk.\n\nKey considerations to minimize both rejection and infection:\n\n- Continue baseline **calcineurin inhibitor** and **antimetabolite** dosing; arrange trough monitoring only if clinically indicated or if interacting drugs are used.\n- Maintain **strict asepsis** and use standard, procedure-specific antibiotic prophylaxis (eg, cefazolin for clean-contaminated abdominal surgery). Avoid unnecessary broad-spectrum therapy.\n- Avoid **unnecessary lines and catheters**; central venous access increases infection risk and is not required solely for immunosuppressant administration.\n- Be vigilant for **drug interactions** that raise calcineurin inhibitor levels (eg, macrolides, azoles, diltiazem/verapamil, grapefruit) or increase nephrotoxicity (eg, aminoglycosides, NSAIDs). Cefazolin does not meaningfully interact with tacrolimus.\n- Continue chronic **prednisone**; consider procedure-specific stress-dose steroids if there is suspected HPA axis suppression and moderate/major surgical stress, but steroids do not replace calcineurin inhibitors/antimetabolites.\n- Continue indicated **opportunistic prophylaxis** (eg, TMP-SMX) and optimize glycemic control and normothermia to reduce infection risk.\n\nWhen prolonged NPO status is anticipated, alternatives include **enteral suspensions via NG/OG** or carefully monitored **IV tacrolimus** (usually via central access) in coordination with the transplant team. For routine elective cases with short fasting intervals, oral continuation with a sip of water is the safest and most effective strategy to protect the graft while minimizing infection risk.",
    "educationalObjective": "Protect immunosuppressed and transplant patients by continuing critical agents and minimizing infection risk."
  },
  {
    "id": "Core.12.3.12",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Chronic meds and optimization",
    "difficulty": "hard",
    "questionText": "A 62-year-old man with type 2 diabetes (A1c 7.6%), CAD, and CKD stage 3 presents for elective laparoscopic sigmoid colectomy. Medications include metformin 1 g BID, insulin glargine 10 U nightly, and empagliflozin 25 mg daily, which he mistakenly stopped only yesterday morning. He has been NPO since midnight and reports mild nausea without abdominal pain. Vitals are stable. Preoperative labs show capillary glucose 158 mg/dL, VBG pH 7.29, HCO<sub>3</sub> 15 mEq/L, PCO<sub>2</sub> 30 mmHg; Na 138 mEq/L, K 4.8 mEq/L, Cl 100 mEq/L (anion gap 23), lactate 1.5 mmol/L, and serum β-hydroxybutyrate 4.2 mmol/L. Urinalysis shows 3+ glucosuria and 1+ ketones. The surgeon asks if the case can proceed today. Which of the following is the most appropriate next step to optimize perioperative management?",
    "answers": [
      {
        "text": "Treat as starvation ketosis with dextrose-only infusion and proceed once glucose is ≤180 mg/dL",
        "isCorrect": false,
        "explanation": "Starvation ketosis alone is unlikely with this degree of anion gap and β-hydroxybutyrate; euglycemic DKA requires insulin plus dextrose, not dextrose alone, and surgery should be delayed."
      },
      {
        "text": "Proceed with surgery under general anesthesia and manage glucose with subcutaneous correctional insulin",
        "isCorrect": false,
        "explanation": "Proceeding despite an anion gap metabolic acidosis with elevated β-hydroxybutyrate is unsafe; euglycemic DKA requires insulin infusion plus dextrose and resolution of the anion gap before elective surgery."
      },
      {
        "text": "Initiate an IV insulin infusion with dextrose-containing fluids and postpone surgery until the anion gap closes; hold the SGLT2 inhibitor for ≥3 days before rescheduling",
        "isCorrect": true,
        "explanation": "Findings are diagnostic of euglycemic DKA from recent SGLT2 inhibitor use; best management is insulin infusion, dextrose, and fluids with postponement until the acidosis resolves. For future elective surgery, stop SGLT2 inhibitors at least 3 days (4 days for ertugliflozin) beforehand."
      },
      {
        "text": "Administer 1–2 L isotonic crystalloid now and proceed if symptoms improve",
        "isCorrect": false,
        "explanation": "Fluids are necessary but insufficient; SGLT2-related euglycemic DKA requires insulin to suppress ketogenesis with concurrent dextrose to avoid hypoglycemia, and elective surgery should be postponed."
      },
      {
        "text": "Give IV sodium bicarbonate to correct acidosis and proceed once HCO<sub>3</sub> is ≥20 mEq/L",
        "isCorrect": false,
        "explanation": "Bicarbonate is not indicated for mild–moderate DKA and does not treat the underlying ketogenesis; proceeding before closing the anion gap risks instability."
      }
    ],
    "didactic": "SGLT2 inhibitors (eg, empagliflozin, canagliflozin, dapagliflozin, ertugliflozin) increase urinary glucose loss, lowering circulating insulin and increasing glucagon. This hormonal shift promotes lipolysis and hepatic ketogenesis, predisposing to **euglycemic DKA (EDKA)**, particularly with perioperative fasting, low-carbohydrate intake, dehydration, acute illness, or reduced insulin dosing. Because glycemia is often 100–250 mg/dL, EDKA can be missed unless ketones and acid–base status are assessed.\n\nDiagnosis is suggested by an **anion gap metabolic acidosis** (low HCO<sub>3</sub>, elevated anion gap), **elevated serum β-hydroxybutyrate** (preferred over urine ketones, which may underestimate severity), and relatively modest glucose, with lactate not explaining the gap. In this case, pH 7.29, HCO<sub>3</sub> 15 mEq/L, anion gap 23, and β-hydroxybutyrate 4.2 mmol/L are diagnostic of EDKA.\n\nManagement mirrors DKA but requires early dextrose because glucose is not markedly elevated:\n- **Fluids:** Isotonic crystalloid resuscitation.\n- **Insulin:** IV infusion (eg, 0.05–0.1 U/kg/h) to suppress ketogenesis; monitor K<sup>+</sup> and replace as needed.\n- **Dextrose:** Add D5/D10 to maintain euglycemia while continuing insulin until the anion gap closes and β-hydroxybutyrate normalizes.\n- **Hold SGLT2 inhibitor** and treat precipitating factors.\n\nElective surgery should be **postponed** until acidosis resolves and the patient is clinically stable. For prevention, **stop SGLT2 inhibitors ≥3 days** (72 h) before elective procedures to allow resolution of pharmacodynamic effects; **ertugliflozin should be held 4 days**. If the drug was not held appropriately, or in high-risk patients, obtain a VBG/ABG, basic metabolic panel, and serum β-hydroxybutyrate before proceeding. Postoperatively, resume SGLT2 inhibitors only when the patient is hemodynamically stable, eating, and free of acidosis. This approach reduces perioperative EDKA risk while maintaining safe glycemic control.",
    "educationalObjective": "Recognize risk of euglycemic ketoacidosis with SGLT2 inhibitors and manage preoperative discontinuation and monitoring."
  },
  {
    "id": "Core.12.4.1",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Comorbidities with anesthetic impact",
    "difficulty": "hard",
    "questionText": "A 58-year-old man with decompensated alcoholic cirrhosis presents for urgent open repair of an incarcerated umbilical hernia within 4 hours. He has refractory ascites requiring monthly large-volume paracenteses and episodic hepatic encephalopathy controlled with lactulose and rifaximin. Vitals are stable; exam shows tense ascites and mild asterixis. Labs: Hb 9.4 g/dL, platelets 54,000/μL, INR 2.0, aPTT 40 s, fibrinogen 95 mg/dL, total bilirubin 4.2 mg/dL, albumin 2.5 g/dL, creatinine 1.4 mg/dL, Na 129 mEq/L. He is Child-Pugh class C; MELD-Na is 23. The team requests guidance on preoperative optimization.\n\nWhich preoperative intervention is most appropriate to optimize hemostasis before induction?",
    "answers": [
      {
        "text": "Administer cryoprecipitate to target fibrinogen ≥150 mg/dL before surgery",
        "isCorrect": true,
        "explanation": "Hypofibrinogenemia (<100–150 mg/dL) is a correctable contributor to bleeding in cirrhosis; cryoprecipitate (or fibrinogen concentrate) raises fibrinogen efficiently and is recommended to achieve ≥150 mg/dL for surgical hemostasis."
      },
      {
        "text": "Transfuse fresh frozen plasma to normalize INR to <1.5 preoperatively",
        "isCorrect": false,
        "explanation": "In cirrhosis, INR does not predict bleeding risk due to rebalanced hemostasis; prophylactic FFP to “normalize” INR adds volume (worsening portal hypertension/ascites) without clear benefit and is not recommended unless there is active bleeding or planned high-risk invasive procedure guided by viscoelastic testing."
      },
      {
        "text": "Initiate 3% hypertonic saline to correct Na from 129 to 135 mEq/L over the next 4 hours",
        "isCorrect": false,
        "explanation": "Rapid correction of chronic hyponatremia risks osmotic demyelination; Na should be corrected slowly (generally ≤6–8 mEq/L per 24 h) and this intervention does not address hemostasis."
      },
      {
        "text": "Transfuse platelets to raise the count to ≥100,000/μL before incision",
        "isCorrect": false,
        "explanation": "For most non-neurosurgical operations, a platelet threshold of ≥50,000/μL is adequate; routine escalation to ≥100,000/μL is unnecessary and exposes the patient to transfusion risks without proven reduction in bleeding."
      },
      {
        "text": "Withhold lactulose and give midazolam 2 mg for anxiolysis to reduce aspiration risk and agitation",
        "isCorrect": false,
        "explanation": "Withholding lactulose risks precipitating encephalopathy, and benzodiazepines can worsen encephalopathy; this does not improve hemostasis and may harm the patient’s neurocognitive status."
      }
    ],
    "didactic": "Severe cirrhosis increases perioperative risk through portal hypertension, impaired synthetic function, and multisystem effects. Risk stratification with **Child-Pugh** (bilirubin, albumin, INR, ascites, encephalopathy) and **MELD-Na** (bilirubin, INR, creatinine, Na) helps determine urgency and feasibility; Child-Pugh C or MELD-Na >20 predicts high morbidity/mortality, favoring deferral unless surgery is urgent.\n\nCirrhotic coagulopathy is **rebalanced**: decreases in procoagulants are offset by reductions in anticoagulants and increased von Willebrand factor. Consequently, **INR is unreliable** for bleeding risk and should not be prophylactically “corrected” with FFP. Instead, target correctable defects that correlate with bleeding:\n- **Fibrinogen**: Levels <100–150 mg/dL predict bleeding; give **cryoprecipitate** (or fibrinogen concentrate) to achieve ≥150 mg/dL.\n- **Platelets**: For most non-neurosurgical procedures, a threshold of **≥50,000/μL** is adequate; higher targets are generally unnecessary.\n- **Viscoelastic testing (TEG/ROTEM)** can guide product therapy if available, especially during active bleeding or high-risk cases.\n\nOptimize other decompensation features:\n- **Ascites**: When time allows, perform large-volume paracentesis with **albumin replacement** (≈6–8 g per liter removed when >5 L) to improve respiratory mechanics and reduce wound complications/hernia recurrence.\n- **Encephalopathy**: **Continue lactulose** (± rifaximin) to maintain 2–3 soft stools/day; **avoid benzodiazepines** and minimize opioids that can precipitate encephalopathy.\n- **Hyponatremia (Na<sup>+</sup>)**: Correct slowly (generally ≤6–8 mEq/L per 24 h) to avoid osmotic demyelination; reserve hypertonic saline for severe symptomatic cases.\n\nKey takeaway: In cirrhosis, do not chase the INR. Prioritize targeted correction of hypofibrinogenemia and severe thrombocytopenia, use VET when available, control ascites with albumin-supported paracentesis, and maintain encephalopathy therapy to safely navigate the perioperative period.",
    "educationalObjective": "Assess cirrhosis severity (e.g., MELD/Child‑Pugh) and mitigate coagulopathy, ascites, and encephalopathy."
  },
  {
    "id": "Core.12.4.2",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Comorbidities with anesthetic impact",
    "difficulty": "hard",
    "questionText": "A 56-year-old woman with idiopathic pulmonary arterial hypertension (WHO group 1) on sildenafil and ambrisentan presents for laparoscopic cholecystectomy. Preoperative echocardiography shows severe RV dilation with reduced function (TAPSE 1.2 cm), moderate tricuspid regurgitation, and estimated RVSP 70 mmHg; LV function is normal. A radial arterial line and central venous catheter are placed pre-induction.\n\nAfter insufflation and Trendelenburg, she becomes acutely unstable: MAP 48 mmHg, HR 110/min, SpO<sub>2</sub> 90% on FiO<sub>2</sub> 0.6, ETCO<sub>2</sub> 55 mmHg, CVP 16 mmHg, peak airway pressure 35 cm H2O. An ABG shows pH 7.27, PaCO<sub>2</sub> 58 mmHg, PaO<sub>2</sub> 62 mmHg. A 100 μg phenylephrine bolus yields minimal improvement. Inhaled nitric oxide and inhaled epoprostenol are available in the OR.\n\nWhich immediate intervention is most appropriate to improve systemic perfusion while reducing RV afterload in this patient?",
    "answers": [
      {
        "text": "Start dobutamine infusion and hyperventilate to PaCO<sub>2</sub> 30 mmHg",
        "isCorrect": false,
        "explanation": "Dobutamine may improve RV inotropy but often lowers SVR and can aggravate hypotension; aggressive hyperventilation risks dynamic hyperinflation and increased intrathoracic pressure, potentially worsening RV output."
      },
      {
        "text": "Administer a 1 L crystalloid bolus and increase FiO<sub>2</sub> to 1.0",
        "isCorrect": false,
        "explanation": "Raising FiO<sub>2</sub> is appropriate, but a large fluid bolus risks RV overdistension, worsening septal shift and CO; volume should be judicious and guided by hemodynamics or TEE."
      },
      {
        "text": "Start vasopressin infusion (eg, 0.01–0.03 U/min) and initiate inhaled epoprostenol via the circuit",
        "isCorrect": true,
        "explanation": "Vasopressin increases SVR with minimal effect on PVR (and may decrease PVR at low doses), augmenting RV coronary perfusion, while inhaled epoprostenol provides selective pulmonary vasodilation to acutely reduce RV afterload without systemic hypotension."
      },
      {
        "text": "Start milrinone infusion and nitroglycerin",
        "isCorrect": false,
        "explanation": "Milrinone reduces PVR but causes systemic vasodilation and hypotension; adding nitroglycerin further lowers preload and SVR, likely worsening perfusion in an already hypotensive patient."
      },
      {
        "text": "Begin phenylephrine infusion and increase PEEP to 15 cm H2O",
        "isCorrect": false,
        "explanation": "Phenylephrine (pure α) increases PVR and can worsen RV output; high PEEP impedes venous return and elevates RV afterload via alveolar overdistension, further compromising RV stroke volume."
      }
    ],
    "didactic": "Severe pulmonary hypertension with RV dysfunction is highly vulnerable to precipitants that increase PVR or decrease RV perfusion pressure. Hypoxemia, hypercarbia, acidosis, high intrathoracic pressures (eg, pneumoperitoneum, excessive PEEP, overdistension), sympathetic surges, and embolic phenomena all raise PVR and precipitate acute RV failure. In this scenario, hypoxemia, hypercarbia, and pneumoperitoneum have increased PVR while systemic hypotension has reduced RV coronary perfusion pressure.\n\nImmediate goals are to: \n- Optimize oxygenation and ventilation (FiO<sub>2</sub> 1.0, avoid hypercarbia and acidosis, target PaCO<sub>2</sub> ~35–40 mmHg) \n- Reduce RV afterload with selective pulmonary vasodilators \n- Support systemic perfusion pressure without increasing PVR \n- Avoid RV overdistension and minimize airway pressures (moderate V<sub>T</sub> 6–8 mL/kg, PEEP 5–8 cm H2O)\n\nInhaled nitric oxide (20–40 ppm) or inhaled epoprostenol (eg, 20–50 ng/kg/min) is preferred for acute decompensation because these agents vasodilate ventilated lung units, lowering PVR and improving V/Q matching without systemic hypotension. Systemic vasodilators (eg, milrinone, nitroglycerin) can further decrease SVR and worsen shock unless robust vasopressor support is in place.\n\nTo maintain RV perfusion, use vasopressors that raise SVR while minimizing pulmonary vasoconstriction. Vasopressin (0.01–0.03 U/min) is advantageous because it increases SVR with neutral or reduced PVR; norepinephrine is also acceptable and often first-line. Avoid phenylephrine because pure α-agonism can increase PVR and reduce RV output. Inotropes (dobutamine, epinephrine) may be necessary for cardiogenic components but can lower SVR; combine cautiously with vasopressors.\n\nMonitoring should include an arterial line and consideration of TEE or a PA catheter to guide preload, RV function, and afterload therapy. Additionally, request lower insufflation pressures or conversion to open if pneumoperitoneum is driving RV failure. The combination of an inhaled pulmonary vasodilator with a PVR-sparing vasopressor rapidly addresses both elevated PVR and low systemic pressure.",
    "educationalObjective": "Identify pulmonary hypertension and right‑heart dysfunction and plan vasodilators, vasopressors, and monitoring."
  },
  {
    "id": "Core.12.4.3",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Comorbidities with anesthetic impact",
    "difficulty": "medium",
    "questionText": "A 62-year-old man with type 1 diabetes mellitus for 30 years presents for laparoscopic cholecystectomy. He reports lightheadedness when standing and early satiety. Preoperative vitals: supine BP 128/76 mmHg, HR 96; standing BP 98/62 mmHg, HR 98. HbA1c is 8.7%; preoperative glucose is 174 mg/dL. After induction with propofol, fentanyl, and rocuronium and initiation of sevoflurane at 1.0 MAC, his MAP falls to 52 mmHg with HR 88. SpO<sub>2</sub> 100%, ETCO<sub>2</sub> 34 mmHg. He has received 200 mL lactated Ringer’s. \n\nWhich intraoperative management is most appropriate to address both the hemodynamic instability and diabetes-related risk in this patient?",
    "answers": [
      {
        "text": "Administer phenylephrine 100 µg IV and give a 250–500 mL crystalloid bolus; begin glucose checks every 60 min",
        "isCorrect": true,
        "explanation": "Direct-acting α-agonists (eg, phenylephrine) more reliably restore SVR in autonomic neuropathy, and a modest fluid bolus addresses preload dependence after induction. Hourly glucose monitoring mitigates hypoglycemia unawareness under anesthesia."
      },
      {
        "text": "Start an epinephrine infusion at 0.02 µg/kg/min, avoid α-agonists, and check glucose every 2–3 h",
        "isCorrect": false,
        "explanation": "Epinephrine is unnecessarily β-stimulatory for isolated vasodilatory hypotension and can increase lactate and dysglycemia. Avoiding α-agonists is incorrect; direct α-agonists are preferred. Glucose checks every 2–3 h are inadequate."
      },
      {
        "text": "Give metoclopramide 10 mg IV and decrease sevoflurane; recheck glucose in 2 h",
        "isCorrect": false,
        "explanation": "Metoclopramide treats gastroparesis/aspiration risk but does not correct autonomically mediated hypotension. Reducing anesthetic depth alone is insufficient, and 2-hour glucose intervals are too infrequent for high-risk diabetics."
      },
      {
        "text": "Give a 500 mL crystalloid bolus only and avoid vasopressors; check glucose only if >250 mg/dL",
        "isCorrect": false,
        "explanation": "Volume alone often fails to correct vasodilatory hypotension from autonomic failure and anesthetic agents; vasopressors are typically required. Restricting glucose checks risks missing hypoglycemia, which may be clinically silent under anesthesia."
      },
      {
        "text": "Administer ephedrine 10 mg IV now and plan to check glucose at the end of the case",
        "isCorrect": false,
        "explanation": "Ephedrine (indirect sympathomimetic) relies on endogenous norepinephrine release, which is blunted in autonomic neuropathy; it is often ineffective. Deferring glucose checks risks unrecognized hypo-/hyperglycemia in a patient with impaired counterregulation."
      }
    ],
    "didactic": "Long-standing diabetes can cause **autonomic neuropathy** with impaired baroreflexes, resting tachycardia, orthostatic hypotension, and **hypoglycemia unawareness**. After induction, these patients are prone to profound vasodilatory hypotension with minimal reflex tachycardia. Because presynaptic sympathetic function is impaired, **indirect-acting agents** (eg, ephedrine, which releases endogenous norepinephrine) may be ineffective. In contrast, **direct-acting vasopressors** (eg, phenylephrine, vasopressin) reliably increase SVR and MAP when hypotension follows induction or pneumoperitoneum.\n\nKey intraoperative priorities:\n- Hemodynamics: Expect **preload dependence** and vasodilation with anesthetic agents. Treat acute hypotension with a **direct-acting α-agonist** and a modest crystalloid bolus; titrate to maintain MAP ≥65 mmHg. Consider an arterial line if instability persists or major fluid shifts are expected.\n- Glucose monitoring: Autonomic neuropathy blunts adrenergic warning signs; anesthesia further masks symptoms. Use **frequent glucose checks (eg, every 60 min)**—especially if any insulin is administered—to avoid occult hypoglycemia and wide excursions. Target 140–180 mg/dL and avoid “tight control” to reduce hypoglycemia risk.\n- Adjuncts: Gastroparesis raises aspiration risk; consider RSI and pharmacologic prophylaxis, but these do not treat hypotension. Reduce volatile dose as tolerated (diabetics may need less anesthetic) while prioritizing perfusion.\n\nIn this patient with orthostatic hypotension and minimal heart rate response, the best immediate strategy is **phenylephrine** to restore SVR, plus a **250–500 mL crystalloid bolus** to support preload, along with institution of **hourly glucose monitoring** to mitigate hypoglycemia unawareness. Indirect agents (ephedrine), delayed glucose checks, or relying on fluids alone are common pitfalls that fail to address the pathophysiology of diabetic autonomic neuropathy.",
    "educationalObjective": "Manage diabetes and autonomic neuropathy intraoperatively with tight glucose monitoring and hemodynamic vigilance."
  },
  {
    "id": "Core.12.4.4",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Comorbidities with anesthetic impact",
    "difficulty": "medium",
    "questionText": "A 68-year-old man with severe COPD (FEV1 35% predicted) presents for elective open inguinal hernia repair. He smokes 1 pack/day, uses tiotropium daily and albuterol as needed, and finished antibiotics for a “chest cold” 3 days ago. He reports ongoing wheeze and productive cough. On exam, he has diffuse expiratory wheezes; SpO<sub>2</sub> 90% on room air. ABG: pH 7.36, PaCO<sub>2</sub> 52 mmHg, PaO<sub>2</sub> 60 mmHg. CXR shows hyperinflation without infiltrate. The surgeon is willing to delay if needed.\n\nWhich perioperative strategy is most appropriate to minimize intraoperative air trapping and postoperative pulmonary complications?",
    "answers": [
      {
        "text": "Start prophylactic antibiotics and proceed; increase RR to normalize ETCO<sub>2</sub> and apply PEEP 10 cm H2O to prevent atelectasis.",
        "isCorrect": false,
        "explanation": "Antibiotics are not indicated without infection; normalizing ETCO<sub>2</sub> by increasing RR shortens expiratory time, and high PEEP worsens air trapping in severe obstruction."
      },
      {
        "text": "Proceed with spinal anesthesia to avoid general anesthesia; no additional optimization is necessary if the block is adequate.",
        "isCorrect": false,
        "explanation": "Neuraxial anesthesia does not address active bronchospasm and may still require sedation; optimization and obstructive-friendly ventilatory strategy remain important if conversion or sedation is needed."
      },
      {
        "text": "Proceed as scheduled; use desflurane for rapid titration and volume control ventilation with Vt 8 mL/kg ideal body weight (IBW), RR 16/min, I:E 1:2, and PEEP 8 cm H2O to maintain oxygenation.",
        "isCorrect": false,
        "explanation": "Desflurane is airway-irritating and can provoke bronchospasm; a high RR and shorter expiratory time with higher PEEP promote dynamic hyperinflation and auto-PEEP."
      },
      {
        "text": "Delay surgery to optimize with scheduled inhaled short-acting bronchodilator plus anticholinergic and a short (3–5 day) prednisone course; then use sevoflurane with Vt 6 mL/kg IBW, RR 8/min, I:E 1:4, minimal PEEP (0–3 cm H2O), and permissive hypercapnia.",
        "isCorrect": true,
        "explanation": "Treating active bronchospasm and prolonging expiratory time with low Vt/low RR minimizes air trapping; sevoflurane provides bronchodilation, and minimal PEEP reduces dynamic hyperinflation risk."
      },
      {
        "text": "Begin a long-acting β<sub>2</sub>-agonist and avoid anticholinergics; use nitrous oxide with Vt 10 mL/kg IBW, RR 12/min, and I:E 1:1 to improve ventilation.",
        "isCorrect": false,
        "explanation": "Anticholinergics are first-line in COPD; N<sub>2</sub>O can expand bullae, and larger Vt with short expiratory time increases dynamic hyperinflation."
      }
    ],
    "didactic": "Patients with obstructive lung disease are at risk for intraoperative bronchospasm and dynamic hyperinflation (auto-PEEP) due to prolonged expiratory time constants. Preoperative priorities are to avoid surgery during an exacerbation and optimize airflow: delay elective procedures when wheezing persists, intensify inhaled bronchodilators (short-acting β<sub>2</sub>-agonist plus anticholinergic), and consider a short course of systemic corticosteroids (eg, prednisone 20–40 mg daily for 3–5 days) if bronchospasm is present. Encourage smoking cessation, airway clearance, and treat infection only when clinical criteria are met. \n\nIntraoperatively, the ventilatory strategy should reduce gas trapping by allowing complete exhalation:\n- Low Vt (6–8 mL/kg ideal body weight) and low RR (eg, 8–10/min) to lower minute ventilation demands.\n- Prolonged expiratory time (I:E 1:3 to 1:5) by shortening inspiratory time and avoiding unnecessary inspiratory pause.\n- Minimal external PEEP (0–5 cm H2O), as excessive PEEP can add to intrinsic PEEP in severe COPD and worsen hyperinflation; titrate to oxygenation while monitoring for auto-PEEP via an expiratory hold.\n- Accept permissive hypercapnia with adequate oxygenation (eg, FiO<sub>2</sub> titrated to SpO<sub>2</sub> 88%–92%) rather than increasing RR, which shortens expiratory time.\n- Use volatile agents with bronchodilatory properties (eg, sevoflurane, isoflurane) and avoid airway irritants (desflurane) and histamine-releasing drugs when possible.\n\nIf severe dynamic hyperinflation occurs (rising plateau/peak pressures, hypotension, expiratory flow not returning to baseline), transiently disconnect the circuit to allow full exhalation, deepen anesthesia, administer inhaled β<sub>2</sub>-agonists, and re-set the ventilator with a longer expiratory phase. Avoid N<sub>2</sub>O in suspected bullous disease. This combined preoperative optimization and obstructive-friendly ventilation reduces perioperative pulmonary complications and hemodynamic instability from auto-PEEP.",
    "educationalObjective": "Optimize COPD and asthma preoperatively and tailor intraoperative ventilation to avoid air trapping."
  },
  {
    "id": "Core.12.4.5",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Comorbidities with anesthetic impact",
    "difficulty": "medium",
    "questionText": "A 48-year-old man (BMI 52 kg/m<sup>2</sup>) with obstructive sleep apnea on nightly CPAP, hypertension, and type 2 diabetes presents for laparoscopic cholecystectomy. He is appropriately fasted but has symptomatic GERD. Sitting, his SpO<sub>2</sub> is 95% on room air, which falls to 90% when supine. Airway exam: Mallampati III, thyromental distance 6 cm, neck circumference 48 cm. You plan a rapid-sequence induction.\n\nWhich intraoperative plan best optimizes first-pass intubation and oxygenation while using appropriate dosing scalars and ventilation in this patient?",
    "answers": [
      {
        "text": "Reverse Trendelenburg only after intubation; preoxygenation via high-flow nasal cannula alone; propofol 1 mg/kg ideal body weight; rocuronium 1.2 mg/kg total body weight; V<sub>T</sub> 6 mL/kg total body weight; PEEP 5 cm H<sub>2</sub>O.",
        "isCorrect": false,
        "explanation": "Head-up during preoxygenation is omitted, propofol is underdosed, nondepolarizer is overdosed using TBW, V<sub>T</sub> is inappropriately scaled to TBW, and PEEP is inadequate."
      },
      {
        "text": "Ramped, head-elevated (20–25°) position with CPAP 10 cm H<sub>2</sub>O during preoxygenation; induction with propofol 2 mg/kg lean body weight and succinylcholine 1.5 mg/kg total body weight; post-intubation V<sub>T</sub> 6–8 mL/kg ideal body weight with PEEP 10–12 cm H<sub>2</sub>O.",
        "isCorrect": true,
        "explanation": "This integrates optimal positioning and preoxygenation to increase FRC, correct dosing scalars (propofol by LBW; succinylcholine by TBW), and lung-protective ventilation with adequate PEEP in morbid obesity."
      },
      {
        "text": "Ramped position; preoxygenation with 100% O<sub>2</sub> without PEEP; propofol 2 mg/kg ideal body weight; succinylcholine 1 mg/kg total body weight; V<sub>T</sub> 6 mL/kg ideal body weight; PEEP 5 cm H<sub>2</sub>O.",
        "isCorrect": false,
        "explanation": "Although ramping is appropriate, preoxygenation without PEEP and low intraoperative PEEP are suboptimal; propofol by IBW underdoses induction and succinylcholine at 1 mg/kg TBW is less reliable for RSI in morbid obesity."
      },
      {
        "text": "Supine sniffing position; preoxygenation with 100% O<sub>2</sub> by facemask only; propofol 2 mg/kg total body weight; succinylcholine 1 mg/kg ideal body weight; V<sub>T</sub> 10 mL/kg total body weight; zero PEEP.",
        "isCorrect": false,
        "explanation": "Overdoses propofol and tidal volume, underdoses succinylcholine, omits PEEP, and forgoes head-elevated positioning—promoting rapid desaturation and poor intubating conditions."
      },
      {
        "text": "Sniffing position with apneic oxygenation via nasal cannula; propofol 3 mg/kg lean body weight; succinylcholine 0.6 mg/kg total body weight; V<sub>T</sub> 8 mL/kg ideal body weight; zero PEEP.",
        "isCorrect": false,
        "explanation": "Excessive propofol risks hypotension, succinylcholine is underdosed for RSI, and absence of PEEP with non-head-elevated positioning accelerates desaturation."
      }
    ],
    "didactic": "Morbid obesity reduces FRC and ERV, increases O<sub>2</sub> consumption, and moves closing capacity toward tidal breathing, producing rapid desaturation during apnea and difficult mask ventilation. Airway and ventilation strategies should increase oxygen reserve and maintain alveolar patency. A ramped, head-elevated laryngoscopy position (HELP) aligned with the external auditory meatus–sternal notch and 20–25° head-up improves preoxygenation, glottic view, and mask ventilation by increasing FRC and decreasing airway collapsibility. Preoxygenate with 100% O<sub>2</sub> using CPAP or NIV (eg, 10 cm H<sub>2</sub>O) and consider apneic oxygenation; these prolong safe apnea time more than facemask alone.\n\nDrug dosing must reflect altered pharmacokinetics:\n- Propofol induction is best based on lean body weight (LBW) to avoid overdose from excess adipose mass; maintenance requirements increase with cardiac output and can be higher per kg.\n- Succinylcholine should be dosed to total body weight (TBW) (eg, 1–1.5 mg/kg) due to increased volume of distribution and pseudocholinesterase activity, ensuring reliable RSI conditions.\n- Nondepolarizing NMBs (eg, rocuronium, vecuronium) are typically dosed on ideal or lean body weight to avoid prolonged paralysis.\n- Most opioids scale better to LBW; remifentanil is commonly dosed on IBW/LBW.\n\nUse lung-protective ventilation: V<sub>T</sub> 6–8 mL/kg based on ideal body weight (reflecting lung size), with moderate-to-high PEEP (≈10–12 cm H<sub>2</sub>O) and recruitment maneuvers to counter atelectasis. Avoid large V<sub>T</sub> based on TBW and zero PEEP, which worsen volutrauma and shunt. When feasible, maintain a modest reverse Trendelenburg to reduce diaphragmatic load. Extubate fully awake in the ramped position, resume CPAP early, and ensure adequate analgesia without excessive opioids to minimize hypoventilation and airway collapse.",
    "educationalObjective": "Plan anesthesia for morbid obesity focusing on airway, dosing scalars, and positioning for ventilation."
  },
  {
    "id": "Core.12.4.6",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Comorbidities with anesthetic impact",
    "difficulty": "medium",
    "questionText": "A 45-year-old woman is scheduled next week for an elective laparoscopic cholecystectomy for biliary colic. She reports 2 months of palpitations, heat intolerance, and 6-kg weight loss. Vitals: BP 138/68 mmHg, HR 128/min (irregularly irregular), T 37.8°C, SpO<sub>2</sub> 99% on room air. Exam reveals fine tremor, warm moist skin, and mild lid lag. ECG shows atrial fibrillation with rapid ventricular response. Labs: TSH <0.01 mIU/L, free T<sub>4</sub> 3.5 ng/dL (elevated). She takes no medications and has no heart failure or infection. The surgeon asks if the case can proceed as planned.\n\nWhich perioperative plan is most appropriate regarding surgical timing and preoperative optimization?",
    "answers": [
      {
        "text": "Postpone surgery and start levothyroxine, reassessing thyroid status in 6 weeks before rescheduling",
        "isCorrect": false,
        "explanation": "Levothyroxine treats hypothyroidism. This patient has overt hyperthyroidism and requires antithyroid therapy and β-blockade before elective surgery."
      },
      {
        "text": "Proceed with surgery as scheduled with an esmolol infusion to control heart rate and administer potassium iodide preoperatively",
        "isCorrect": false,
        "explanation": "Elective surgery should be postponed in overt hyperthyroidism due to risk of thyroid storm; iodine given without prior thionamide can acutely increase hormone synthesis (Jod-Basedow) in some settings."
      },
      {
        "text": "Proceed with general anesthesia and have dantrolene available to mitigate hypermetabolic complications",
        "isCorrect": false,
        "explanation": "Dantrolene treats malignant hyperthermia, not thyrotoxicosis. Proceeding without thyroid control risks precipitating thyroid storm."
      },
      {
        "text": "Proceed using regional anesthesia to avoid sympathetic stimulation and reduce risk of thyroid storm",
        "isCorrect": false,
        "explanation": "Regional anesthesia does not eliminate the risk of thyroid storm; the underlying uncontrolled hyperthyroidism remains the primary hazard."
      },
      {
        "text": "Postpone surgery; initiate a β-blocker and methimazole, add iodine ≥1 hour after the first thionamide dose, and reschedule once clinically euthyroid",
        "isCorrect": true,
        "explanation": "Overt hyperthyroidism with atrial fibrillation warrants delaying elective surgery and starting β-blockade plus a thionamide (methimazole preferred). Iodine is added after thionamide to block hormone release; proceed once euthyroid/controlled."
      }
    ],
    "didactic": "Uncontrolled overt hyperthyroidism increases perioperative risk for tachyarrhythmias, high-output failure, and thyroid storm. Elective surgery should be deferred until the patient is stabilized. Clinical features (weight loss, tremor, heat intolerance), suppressed TSH with elevated free T<sub>4</sub>, and atrial fibrillation indicate significant thyrotoxicosis. Surgery and anesthesia are potent stressors that can precipitate thyroid storm, which carries high morbidity and mortality.\n\nPreoperative optimization targets both hormone synthesis and adrenergic symptoms:\n- β-blockade (eg, propranolol or atenolol) controls heart rate and reduces peripheral T<sub>4</sub>→T<sub>3</sub> conversion (propranolol effect).\n- Thionamides (methimazole preferred, PTU if first-trimester pregnancy or severe thyroid storm) inhibit new hormone synthesis.\n- Iodine (eg, potassium iodide or Lugol solution) acutely blocks hormone release but must be given ≥1 hour after the first thionamide dose to avoid fueling synthesis.\n- Glucocorticoids are useful adjuncts to reduce T<sub>4</sub>→T<sub>3</sub> conversion and treat possible relative adrenal insufficiency.\n\nFor truly urgent/emergent operations, proceed with aggressive β-blockade, thionamide, iodine (after thionamide), and corticosteroids, with vigilant temperature and hemodynamic control. However, for elective cases, postponement until clinical euthyroidism (or at minimum well-controlled heart rate and symptoms with improving labs) is recommended.\n\nBy contrast, hypothyroidism is stratified by severity. Mild/moderate hypothyroidism may allow elective surgery with precautions, but severe disease (eg, altered mental status, hypothermia, bradycardia, hyponatremia, or pericardial effusion) warrants delay and treatment with levothyroxine ± liothyronine and supportive therapy. Recognizing the phenotype and timing elective procedures only after stabilization reduces anesthetic risk and prevents catastrophic decompensation such as thyroid storm or myxedema coma.",
    "educationalObjective": "Recognize severe hypothyroidism or hyperthyroidism that warrants delay and stabilization before elective surgery."
  },
  {
    "id": "Core.12.4.7",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Comorbidities with anesthetic impact",
    "difficulty": "medium",
    "questionText": "A 58-year-old man presents for ambulatory umbilical hernia repair. He reports loud snoring, daytime fatigue, and his spouse has witnessed apneas. History includes hypertension; BMI is 38 kg/m² and neck circumference is 44 cm. He is male and age >50 years. He is not formally diagnosed with OSA but brought his home auto-CPAP. Intraoperatively he received fentanyl 150 μg; in PACU he received hydromorphone 0.6 mg IV. Ninety minutes postoperatively, while awake on 2 L/min O<sub>2</sub> via nasal cannula, SpO<sub>2</sub> is 94%. When he dozes off on room air, he has intermittent obstructive apneas with desaturation to 88%.\n\nWhich postoperative plan is most appropriate to minimize respiratory complications in this patient?",
    "answers": [
      {
        "text": "Initiate CPAP in PACU and admit for overnight monitoring with continuous pulse oximetry using an opioid-sparing regimen.",
        "isCorrect": true,
        "explanation": "High STOP‑BANG risk with recurrent PACU obstruction and recent opioids warrants CPAP use and monitored admission to reduce postoperative respiratory events."
      },
      {
        "text": "Discharge home once SpO<sub>2</sub> ≥92% on room air while awake; instruct to resume CPAP at bedtime.",
        "isCorrect": false,
        "explanation": "Awake room-air SpO<sub>2</sub> does not address recurrent sleep-related obstruction in PACU; same-day discharge is unsafe given events and opioid exposure."
      },
      {
        "text": "Administer naloxone and flumazenil, avoid CPAP due to aspiration risk, and discharge once fully alert.",
        "isCorrect": false,
        "explanation": "Empiric reversal is unnecessary and CPAP is first-line for obstructive events; avoiding CPAP and discharging is inappropriate."
      },
      {
        "text": "Continue supplemental O<sub>2</sub> in PACU until saturations stabilize, then discharge with home O<sub>2</sub> for 24 hours.",
        "isCorrect": false,
        "explanation": "Supplemental O<sub>2</sub> without CPAP and monitoring can mask hypoventilation and prolong apneas in OSA."
      },
      {
        "text": "Transition to high‑flow nasal cannula in PACU and discharge after 2 hours without desaturation.",
        "isCorrect": false,
        "explanation": "HFNC does not stent the pharynx like CPAP and is not a substitute for monitored care in high‑risk OSA with PACU events."
      }
    ],
    "didactic": "STOP‑BANG is a simple screening tool for obstructive sleep apnea (OSA) that uses 8 items: Snoring, Tiredness, Observed apneas, high Blood pressure, BMI >35 kg/m², Age >50, Neck circumference >40 cm, and male Gender. Scores 0–2 are low risk, 3–4 intermediate, and ≥5 high risk for moderate–severe OSA. This patient’s STOP‑BANG is 8, indicating very high risk. Anesthetic agents and systemic opioids increase upper airway collapsibility and depress ventilatory drive, predisposing to postoperative obstruction, especially during sleep.\n\nKey postoperative principles in suspected/known OSA include:\n- Use **CPAP** in PACU for observed obstruction or hypoxemia and resume the patient’s home device when available.\n- Employ **opioid‑sparing multimodal analgesia** (eg, acetaminophen, NSAIDs if appropriate, local infiltration); avoid background infusions with PCA.\n- Position non‑supine and use the **lowest effective FiO<sub>2</sub>**; supplemental O<sub>2</sub> can mask hypoventilation, so continuous monitoring is essential when O<sub>2</sub> is needed.\n- Provide **continuous pulse oximetry** (and consider capnography if high risk or receiving supplemental O<sub>2</sub>).\n\nDisposition hinges on PACU course. Ambulatory discharge may be reasonable only if the patient maintains airway patency and adequate ventilation on room air without recurrent events and has minimal opioid requirements. In contrast, recurrent PACU obstruction/desaturation, need for CPAP, or significant opioid use warrants **admission to a monitored setting** with CPAP and continuous oximetry. This strategy reduces unrecognized hypoventilation and cardiopulmonary complications. Simply raising FiO<sub>2</sub>, sending the patient home with oxygen, or substituting high‑flow nasal cannula does not address pharyngeal collapse and risks masking deterioration. Initiating CPAP in PACU and admitting for overnight monitoring is therefore the safest plan for this high‑risk patient with documented PACU events.",
    "educationalObjective": "Screen for obstructive sleep apnea with STOP‑BANG and implement postoperative monitoring and CPAP plans."
  },
  {
    "id": "Core.12.4.8",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Comorbidities with anesthetic impact",
    "difficulty": "medium",
    "questionText": "A 72-year-old woman with long-standing hypertension and diabetes presents for urgent laparoscopic cholecystectomy. Preoperative labs: creatinine 2.3 mg/dL, eGFR 28 mL/min/1.73 m<sup>2</sup>, urine albumin-to-creatinine ratio 450 mg/g, K 5.0 mEq/L, HCO<sub>3</sub><sup>−</sup> 20 mEq/L. BP is 154/78 mmHg. She takes lisinopril and amlodipine. She has no neuromuscular disease. The plan is general anesthesia with neuromuscular blockade.\n\nWhich intraoperative strategy is most appropriate to minimize kidney injury risk and avoid drug accumulation in this patient?",
    "answers": [
      {
        "text": "Restrict fluids to minimize overload, use morphine for analgesia, choose vecuronium, and tolerate MAP 55–60 mmHg to limit vasopressor use",
        "isCorrect": false,
        "explanation": "Under-resuscitation and permissive hypotension in CKD increase AKI risk. Morphine and vecuronium accumulate active metabolites in CKD, and MAP 55–60 mmHg may be inadequate for chronically hypertensive patients."
      },
      {
        "text": "Infuse 0.9% saline at 4–6 mL/kg/h, administer ketorolac 30 mg IV for multimodal analgesia, and use rocuronium for neuromuscular blockade",
        "isCorrect": false,
        "explanation": "High-chloride saline promotes renal vasoconstriction and hyperchloremic acidosis; ketorolac increases AKI risk in CKD. Rocuronium is acceptable but not optimal when safer organ-independent options exist."
      },
      {
        "text": "Avoid lactated Ringer’s due to K 5.0 mEq/L and use 0.9% saline, use succinylcholine for intubation, and run a remifentanil infusion for analgesia",
        "isCorrect": false,
        "explanation": "The small K content of LR does not raise serum K meaningfully; saline is inferior to balanced fluids for kidney outcomes. Remifentanil is safe in CKD, but succinylcholine may further raise K and is unnecessary here."
      },
      {
        "text": "Give prophylactic furosemide to ensure urine output, administer vancomycin for prophylaxis, and use hydromorphone for analgesia",
        "isCorrect": false,
        "explanation": "Diuretics do not prevent AKI and can worsen hypovolemia; vancomycin is nephrotoxic and not indicated for routine prophylaxis. Hydromorphone’s metabolite can accumulate and is not clearly advantageous."
      },
      {
        "text": "Use a balanced crystalloid at 2–3 mL/kg/h, avoid NSAIDs, and choose cisatracurium for neuromuscular blockade",
        "isCorrect": true,
        "explanation": "Balanced crystalloids reduce hyperchloremia-associated renal vasoconstriction; NSAIDs are nephrotoxic in CKD; cisatracurium undergoes Hofmann elimination and is preferred in advanced CKD to avoid accumulation."
      }
    ],
    "didactic": "This patient has CKD G4 (eGFR 15–29 mL/min/1.73 m<sup>2</sup>) with severely increased albuminuria (A3), placing her at high risk for perioperative AKI and drug accumulation. Intraoperative strategies should preserve renal perfusion, avoid nephrotoxins, and select agents with predictable clearance in renal impairment.\n\n- Fluids: **Balanced crystalloids** (eg, lactated Ringer’s, Plasma-Lyte) are preferred over 0.9% saline because high chloride loads reduce renal blood flow via tubuloglomerular feedback and increase hyperchloremic metabolic acidosis. The 4 mEq/L K in LR does not meaningfully increase serum K in typical volumes, even when baseline K is mildly elevated. Target euvolemia with modest rates and adjust to hemodynamics and blood loss.\n- Hemodynamics: Avoid hypotension; many patients with chronic hypertension require **MAP ≥65–70 mmHg** to maintain renal perfusion. Treat vasodilation with vasopressors rather than excessive chloride-rich fluids.\n- Nephrotoxins: **Avoid NSAIDs** (eg, ketorolac), which reduce prostaglandin-mediated afferent arteriolar dilation and can precipitate AKI. Avoid unnecessary IV contrast and aminoglycosides.\n- Drug selection: For neuromuscular blockade, **cisatracurium** (Hofmann elimination/ester hydrolysis) provides organ-independent metabolism and predictable recovery. Vecuronium and rocuronium can have prolonged effects in CKD (vecuronium more so due to active metabolite). For opioids, fentanyl, sufentanil, and remifentanil are preferred; **morphine** and to a lesser extent **hydromorphone** have renally cleared metabolites that may accumulate. If using reversal, note that **sugammadex is renally cleared** and may have prolonged residence in eGFR <30 mL/min/1.73 m<sup>2</sup>; neostigmine/glycopyrrolate is an alternative.\n\nOverall, balanced crystalloids, avoidance of NSAIDs, and selection of organ-independent NMB (cisatracurium) best minimize kidney injury and drug accumulation in advanced CKD.",
    "educationalObjective": "Stage chronic kidney disease, avoid nephrotoxins, and adjust drug dosing and fluid strategy."
  },
  {
    "id": "Core.12.5.1",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Fasting and aspiration prophylaxis",
    "difficulty": "medium",
    "questionText": "A 12-year-old boy (BMI 98th percentile) with moderate OSA (AHI 15/h) and type 1 diabetes (HbA1c 7.2%) is scheduled for elective adenotonsillectomy at 08:00. He last ate solid food at 22:00 the previous night and drank 200 mL of apple juice at 06:00 per a carbohydrate-loading protocol. He denies reflux, nausea, vomiting, abdominal pain, or early satiety, and has no known autonomic neuropathy. Glucose on arrival is 132 mg/dL; vital signs are normal.\n\nWhich of the following is the most appropriate plan regarding fasting and aspiration prophylaxis for this patient?",
    "answers": [
      {
        "text": "Proceed at 08:00 with standard IV induction; no additional NPO time or routine aspiration prophylaxis is necessary.",
        "isCorrect": true,
        "explanation": "ASA pediatric fasting allows clear liquids up to 2 h preoperatively; in well-controlled diabetes without symptoms of gastroparesis, routine aspiration prophylaxis or RSI is not indicated."
      },
      {
        "text": "Administer metoclopramide and sodium citrate and require 6 hours since last clear liquids before induction.",
        "isCorrect": false,
        "explanation": "Clear liquids require only a 2 h fast; pharmacologic prophylaxis is not routinely indicated without elevated aspiration risk (eg, symptomatic GERD, gastroparesis)."
      },
      {
        "text": "Delay anesthesia until at least 4 hours after clear liquids because pediatric obesity/OSA increases aspiration risk.",
        "isCorrect": false,
        "explanation": "Obesity and OSA do not by themselves necessitate extended fasting intervals; ASA fasting guidelines are unchanged for these populations without additional risk factors."
      },
      {
        "text": "Place a nasogastric tube after induction to decompress the stomach before airway instrumentation.",
        "isCorrect": false,
        "explanation": "Routine gastric decompression is unnecessary and may add risk (eg, epistaxis). It is reserved for suspected gastric distention or bowel obstruction."
      },
      {
        "text": "Proceed at 08:00 but perform rapid-sequence induction with cricoid pressure due to obesity and OSA.",
        "isCorrect": false,
        "explanation": "RSI is reserved for high aspiration risk (eg, active reflux, gastroparesis, bowel obstruction). Obesity/OSA alone do not warrant RSI and may complicate difficult-airway management."
      }
    ],
    "didactic": "Pediatric fasting recommendations from the ASA support ingestion of clear liquids up to 2 hours before anesthesia, breast milk up to 4 hours, and infant formula or a light meal up to 6 hours; a fatty meal generally requires 8 hours. These intervals apply broadly, including to children with obesity and OSA, because these conditions alone do not reliably increase gastric volume or acidity to justify longer fasting. In fact, allowing clear liquids until 2 hours preinduction reduces thirst, hypovolemia, and hypoglycemia without increasing aspiration.\n\nFor patients with diabetes, the aspiration risk hinges on the presence of **gastroparesis** or **autonomic neuropathy** (eg, early satiety, postprandial fullness, vomiting), not diabetes alone. In a well-controlled pediatric patient without gastrointestinal symptoms, clear carbohydrate beverages are acceptable up to 2 hours prior. Conversely, symptomatic gastroparesis should prompt a full-stomach approach (eg, consider rapid-sequence induction, head-up positioning, minimize bag-mask ventilation, and use nonparticulate antacid ± H<sub>2</sub> blocker/metoclopramide).\n\nRoutine pharmacologic aspiration prophylaxis (sodium citrate, H<sub>2</sub> antagonists, metoclopramide) and gastric decompression are not indicated for low-risk, fasted patients. Rapid-sequence induction is reserved for clearly elevated aspiration risk (eg, active reflux/vomiting, bowel obstruction, pregnancy in the third trimester, symptomatic gastroparesis). In children with OSA and/or obesity, prioritize airway management strategies that improve upper airway patency (ramped positioning, optimal preoxygenation, two-handed mask seal) but do not alter fasting timelines.\n\nIn this scenario, the child meets ASA fasting criteria (solids 10 hours, clear liquid 2 hours), has controlled diabetes without gastroparesis, and lacks reflux symptoms. Proceeding on time with a standard induction and no routine aspiration prophylaxis is appropriate while preparing for potential airway challenges due to OSA/obesity.",
    "educationalObjective": "Adapt fasting and aspiration strategies for pediatrics and special populations (diabetes, obesity, OSA)."
  },
  {
    "id": "Core.12.5.2",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Fasting and aspiration prophylaxis",
    "difficulty": "easy",
    "questionText": "A healthy 7-month-old (ASA I) is scheduled for elective umbilical hernia repair at 09:00. There is no history of GERD, prematurity, or gastrointestinal pathology. The parent reports the following intake today:\n\n- 02:15 – 120 mL infant formula\n- 03:45 – 2 tbsp oatmeal cereal\n- 05:30 – 60 mL breast milk\n- 07:15 – 30 mL clear apple juice\n\nAccording to standard fasting guidelines for elective anesthesia, what is the earliest time anesthesia can be safely induced today?",
    "answers": [
      {
        "text": "09:15",
        "isCorrect": false,
        "explanation": "Matches 2 h after clear liquids at 07:15, but breast milk (4 h) and solids (6 h) still mandate a later start."
      },
      {
        "text": "08:15",
        "isCorrect": false,
        "explanation": "Corresponds to 6 h after infant formula at 02:15, but later intakes (breast milk at 05:30 and solid cereal at 03:45) impose longer fasting intervals."
      },
      {
        "text": "09:45",
        "isCorrect": true,
        "explanation": "Oatmeal cereal is a solid/light meal requiring 6 h of fasting; 03:45 → 09:45 is the longest applicable interval and thus determines the earliest safe induction time."
      },
      {
        "text": "09:30",
        "isCorrect": false,
        "explanation": "Meets the 4-h interval for breast milk (05:30 → 09:30), but does not satisfy the 6-h interval for solids (03:45 → 09:45)."
      },
      {
        "text": "09:00",
        "isCorrect": false,
        "explanation": "Insufficient fasting for breast milk (requires 4 h from 05:30 → 09:30) and solid cereal (requires 6 h from 03:45 → 09:45)."
      }
    ],
    "didactic": "Pulmonary aspiration risk is mitigated by preoperative fasting tailored to the type of intake. Standard elective fasting intervals are based on gastric emptying characteristics and evidence that permissive clear liquids improve hydration without increasing gastric volume or acidity.\n\n- Clear liquids (eg, water, pulp-free juice, oral rehydration solutions, black coffee/tea without dairy): 2 h\n- Breast milk: 4 h (empties faster than formula due to lower protein/fat content and different casein/whey profile)\n- Infant formula and nonhuman milk: 6 h (behaves like a solid because of higher fat/protein content)\n- Light meal/solids: 6 h (eg, toast, cereal). Fatty/fried foods or meat: 8 h\n\nIn this case, several categories apply simultaneously. The earliest safe induction is determined by the latest-expiring interval among all recent intakes:\n\n- Clear apple juice at 07:15 → 2 h → 09:15\n- Breast milk at 05:30 → 4 h → 09:30\n- Infant formula at 02:15 → 6 h → 08:15\n- Oatmeal cereal at 03:45 (solid/light meal) → 6 h → 09:45\n\nTherefore, 09:45 is the earliest time that satisfies all requirements. For practical scheduling, clinicians should verify the exact composition of recent foods; a “light meal” (eg, toast/cereal) requires 6 h, whereas fried/fatty meals or meat necessitate 8 h due to delayed gastric emptying. Clear liquids up to 2 h preoperatively are encouraged to reduce dehydration, improve comfort, and may decrease difficult IV starts without increasing aspiration risk in healthy patients. These intervals apply to elective cases; in emergencies, risk mitigation (eg, rapid-sequence induction, airway protection strategies) takes precedence over fasting duration.",
    "educationalObjective": "Apply standard fasting intervals for clear liquids, breast milk, infant formula, and solids in elective cases."
  },
  {
    "id": "Core.12.5.3",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Fasting and aspiration prophylaxis",
    "difficulty": "medium",
    "questionText": "A 58-year-old man with long-standing type 2 diabetes complicated by symptomatic gastroparesis and stage 4 chronic kidney disease (creatinine 3.0 mg/dL; estimated GFR 25 mL/min/1.73 m²) presents for urgent intramedullary nailing of a femur fracture. He ate a light meal 7 hours ago and reports persistent nausea. You plan a rapid-sequence induction due to elevated aspiration risk and consider metoclopramide to improve gastric emptying and provide antiemetic prophylaxis. He has no Parkinson disease or bowel obstruction. Which metoclopramide regimen is most appropriate to balance prokinetic/antiemetic benefit with side-effect risk in this patient?\n\n",
    "answers": [
      {
        "text": "Metoclopramide 5 mg IV 15–30 min before induction",
        "isCorrect": true,
        "explanation": "Halving the usual 10 mg IV dose in advanced CKD reduces CNS adverse effects while maintaining prokinetic (LES tone, gastric emptying) and antiemetic benefits when given with appropriate lead time."
      },
      {
        "text": "Metoclopramide 10 mg PO 1 hour preoperatively",
        "isCorrect": false,
        "explanation": "Oral administration is inappropriate in an urgent case with aspiration risk and uncertain gastric emptying; IV dosing is preferred for reliable onset and absorption."
      },
      {
        "text": "Metoclopramide 10 mg IV 15–30 min before induction",
        "isCorrect": false,
        "explanation": "This standard dose/timing provides prokinetic and antiemetic effects, but it is not renally adjusted; with eGFR 25 mL/min, accumulation increases risks of akathisia and dystonia."
      },
      {
        "text": "Metoclopramide 20 mg IV 5 min before induction",
        "isCorrect": false,
        "explanation": "Higher dosing increases extrapyramidal and QT risks and giving it only 5 min pre-induction is too early for meaningful prokinetic effect (peak 30–60 min)."
      },
      {
        "text": "Metoclopramide 10 mg IV immediately before induction",
        "isCorrect": false,
        "explanation": "Immediate pre-induction dosing does not allow time for gastric emptying or LES tone augmentation; it may offer some antiemetic effect but not aspiration prophylaxis."
      }
    ],
    "didactic": "Metoclopramide is a dopamine D<sub>2</sub> receptor antagonist with 5-HT<sub>4</sub> agonism and weak 5-HT<sub>3</sub> antagonism. These actions enhance cholinergic activity in the gut, increasing lower esophageal sphincter tone, coordinating antral–duodenal contractions, and accelerating gastric emptying while also providing antiemetic activity via the chemoreceptor trigger zone. For perioperative aspiration prophylaxis in patients with delayed gastric emptying (eg, diabetic gastroparesis, opioid use), **IV metoclopramide is typically given 10 mg** with an onset of central antiemetic effect within minutes and peak prokinetic effect at approximately 30–60 min; therefore, administer **15–30 min pre-induction** to allow meaningful gastric emptying.\n\nBecause the drug is primarily renally cleared, **dose reduction is recommended when CrCl <40 mL/min** to limit accumulation and CNS adverse effects. A practical approach is **5 mg IV** (half-dose) in advanced CKD or frail older adults while maintaining standard timing for prokinetic benefit. Metoclopramide’s side effects include **akathisia, dystonia, sedation**, and, rarely, neuroleptic malignant syndrome; it can modestly **prolong QT**. Important contraindications/precautions include **Parkinson disease** (worsens rigidity/akinesia via D<sub>2</sub> blockade), **suspected mechanical GI obstruction or perforation**, **pheochromocytoma** (hypertensive crises), and **seizure disorders**.\n\nIn aspiration-risk patients, metoclopramide should be used as an adjunct—not a substitute—for appropriate airway strategy (eg, RSI). It can be combined with agents that reduce gastric acidity/volume (eg, H<sub>2</sub> blockers, nonparticulate antacids) for additive protection. In contrast, **immediate pre-induction dosing** does not permit prokinetic effects, and **oral dosing** is inappropriate when gastric emptying is unreliable. Selecting a **renal-adjusted IV dose with adequate lead time** maximizes prokinetic and antiemetic benefits while minimizing adverse effects.",
    "educationalObjective": "Dose metoclopramide selectively for prokinetic and antiemetic effects while considering side effects."
  },
  {
    "id": "Core.12.5.4",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Fasting and aspiration prophylaxis",
    "difficulty": "medium",
    "questionText": "A 55-year-old man is scheduled for first-start elective laparoscopic right hemicolectomy. He has type 2 diabetes managed with metformin and weekly semaglutide; for several weeks he reports early satiety, postprandial nausea, and intermittent bloating. His last semaglutide injection was 3 days ago. BMI is 36 kg/m<sup>2</sup> and HbA1c is 8.2%. He has fasted from solids for 8 hours and had small sips of water 3 hours ago. The ERAS pathway orders a clear carbohydrate drink (400 mL containing 50 g maltodextrin) to be consumed 2 hours before induction. Vitals are normal; he denies prior aspiration. \n\nWhich recommendation regarding the preoperative carbohydrate drink is most appropriate for this patient?",
    "answers": [
      {
        "text": "Administer half the carbohydrate drink 2 hours pre-induction to balance metabolic benefit with reduced gastric volume.",
        "isCorrect": false,
        "explanation": "Reducing volume does not address delayed gastric emptying; even small volumes may remain in the stomach when gastroparesis is present."
      },
      {
        "text": "Withhold the carbohydrate drink because obesity (BMI 36 kg/m<sup>2</sup>) alone is a contraindication even without symptoms of gastroparesis.",
        "isCorrect": false,
        "explanation": "Obesity alone is not a contraindication to carbohydrate loading; the key issue here is symptomatic delayed gastric emptying, not BMI."
      },
      {
        "text": "Administer the carbohydrate drink 4 hours pre-induction to allow more time for gastric emptying.",
        "isCorrect": false,
        "explanation": "Extending the interval is not evidence-based for gastroparesis; delayed emptying is unpredictable and may persist despite prolonged fasting."
      },
      {
        "text": "Withhold the carbohydrate drink due to symptomatic delayed gastric emptying from a GLP-1 receptor agonist; proceed with aspiration precautions rather than carbohydrate loading.",
        "isCorrect": true,
        "explanation": "GLP-1–related GI symptoms indicate delayed gastric emptying, a contraindication to preoperative carbohydrate loading; avoid the drink and consider full-stomach precautions or bedside gastric ultrasound."
      },
      {
        "text": "Administer the full carbohydrate drink 2 hours pre-induction because clear liquids empty by 2 hours and reduce postoperative insulin resistance.",
        "isCorrect": false,
        "explanation": "Although carbohydrate loading is beneficial for most elective patients, symptomatic delayed gastric emptying from a GLP-1 receptor agonist increases aspiration risk even with clear liquids."
      }
    ],
    "didactic": "Preoperative carbohydrate drinks (eg, 50 g maltodextrin in ~400 mL clear liquid 2 hours before anesthesia) are a core ERAS element for low-risk elective patients. Compared with overnight fasting, carbohydrate loading attenuates postoperative insulin resistance, preserves lean body mass, and improves well-being (reduced thirst, hunger, anxiety) without increasing gastric volume or acidity when given ≥2 hours pre-induction. Clear carbohydrate solutions empty rapidly in healthy patients (gastric half-time ~10–20 minutes), such that gastric volumes typically reach minimal levels by 2 hours.\n\nHowever, the safety of carbohydrate loading hinges on normal gastric emptying. Contraindications include conditions with delayed emptying or obstruction:\n- Symptomatic gastroparesis (eg, diabetes with early satiety, nausea, vomiting)\n- Active GLP-1 receptor agonist effects with GI symptoms (eg, semaglutide-associated nausea/early satiety)\n- Mechanical obstruction/ileus, acute GI bleeding, achalasia, or severe regurgitation\n- Pregnancy in labor and many urgent/emergent cases with unknown fasting status\n\nGLP-1 receptor agonists can slow gastric emptying; the presence of ongoing GI symptoms is a practical marker of risk regardless of the timing of the last dose. In such patients, carbohydrate loading should be withheld, and aspiration risk mitigated (eg, consider rapid-sequence induction, nonparticulate antacid/H<sub>2</sub> blocker, head-up positioning, and/or point-of-care gastric ultrasound when available). Obesity and diabetes alone are not absolute contraindications; many ERAS pathways permit carbohydrate drinks in well-controlled diabetics without gastroparesis, with glucose monitoring and insulin adjustments as needed.\n\nBottom line: Use preoperative carbohydrate drinks to reduce catabolic stress and insulin resistance in elective, low-aspiration-risk patients. Withhold carbohydrate loading when delayed gastric emptying is suspected, such as in symptomatic patients on GLP-1 receptor agonists, and prioritize aspiration precautions.",
    "educationalObjective": "Explain the rationale for carbohydrate drinks in ERAS and identify contraindications."
  },
  {
    "id": "Core.12.5.5",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Fasting and aspiration prophylaxis",
    "difficulty": "medium",
    "questionText": "A 42-year-old man (BMI 43 kg/m²) with small-bowel obstruction and ongoing emesis is brought to the OR for emergent laparotomy. He is tachypneic but hemodynamically stable and cooperative. SpO₂ is 93% on room air in the semi-upright position and 88% when supine. Airway exam is unremarkable. You plan rapid-sequence induction due to a full stomach.\n\nWhich approach best maintains oxygenation while minimizing aspiration risk during RSI in this patient?",
    "answers": [
      {
        "text": "Supine positioning, no mask ventilation after induction, immediate laryngoscopy with cricoid pressure.",
        "isCorrect": false,
        "explanation": "Classic no-ventilation RSI minimizes insufflation but, in severe obesity with low FRC, markedly shortens safe apnea time and increases risk of hypoxemia."
      },
      {
        "text": "Nonrebreather mask at 10 L/min for 2 min in the supine position; avoid mask ventilation and proceed directly to laryngoscopy.",
        "isCorrect": false,
        "explanation": "A nonrebreather delivers variable FiO<sub>2</sub> and provides no PEEP; brief supine preoxygenation is inadequate in high-risk patients and predisposes to rapid desaturation."
      },
      {
        "text": "Supine positioning; preoxygenate with 8 vital capacity breaths; provide bag-mask ventilation with PIP 20–25 cmH₂O until paralysis.",
        "isCorrect": false,
        "explanation": "High inspiratory pressures increase gastric insufflation and regurgitation risk; the 8-breath method is less reliable in obese or dyspneic patients."
      },
      {
        "text": "Head-up (≈25°) ramped position; 3–5 min of 100% O<sub>2</sub> via tight mask with PEEP 5–10 cmH₂O plus nasal cannula 15 L/min; after induction, gentle mask ventilation with PIP ≤ 12–15 cmH₂O until laryngoscopy.",
        "isCorrect": true,
        "explanation": "Head-up positioning increases FRC, PEEP improves denitrogenation, and apneic oxygenation prolongs safe apnea; gentle, pressure-limited ventilation maintains oxygenation while minimizing gastric insufflation and aspiration risk."
      },
      {
        "text": "Induce anesthesia, place a nasogastric tube for decompression, then intubate without ventilation to prevent regurgitation.",
        "isCorrect": false,
        "explanation": "NG/OG tube placement after induction delays airway control and may provoke regurgitation; decompression is best done pre-induction if time allows, not after loss of airway reflexes."
      }
    ],
    "didactic": "In patients at high risk of hypoxemia and aspiration (eg, morbid obesity with bowel obstruction), RSI should be modified to preserve oxygenation without materially increasing regurgitation risk. Three complementary strategies are effective:\n\n- **Head-up/ramped position (~20–30°):** Elevation increases functional residual capacity (FRC) and improves diaphragmatic mechanics, delaying desaturation compared with supine. Ramped alignment also optimizes laryngoscopic view.\n- **Optimized preoxygenation:** A tight-fitting mask delivering 100% O<sub>2</sub> with **PEEP 5–10 cmH<sub>2</sub>O** for 3–5 minutes denitrogenates the FRC and increases the alveolar O<sub>2</sub> reservoir. Obese and dyspneic patients benefit from PEEP/CPAP to counteract atelectasis; nonrebreather masks are inferior because FiO<sub>2</sub> is variable and no PEEP is provided.\n- **Gentle ventilation during RSI:** After induction, provide two‑hand mask ventilation with a pressure‑limited technique (PIP ≤ 12–15 cmH<sub>2</sub>O) and small V<sub>T</sub> as needed until laryngoscopy. Limiting inspiratory pressure below lower esophageal sphincter pressure reduces gastric insufflation while maintaining oxygenation. Evidence suggests pressure‑limited ventilation during RSI does not increase aspiration compared with no ventilation, but markedly reduces critical hypoxemia in high‑risk patients.\n\nAdd **apneic oxygenation** (eg, nasal cannula 10–15 L/min during laryngoscopy) to prolong the time to desaturation by entraining O<sub>2</sub> into the alveoli during apnea. Use a two‑hand mask seal with jaw thrust; apply cricoid pressure only if it does not impede ventilation or view, and release if it does. When feasible, decompress the stomach with an NG/OG tube before induction; avoid inserting one after loss of airway reflexes. This integrated approach balances aspiration prophylaxis with oxygenation, which is especially critical in obesity and pregnancy where safe apnea time is short.",
    "educationalObjective": "Incorporate head‑up positioning, preoxygenation, and gentle mask ventilation into RSI to maintain oxygenation."
  },
  {
    "id": "Core.12.5.6",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Fasting and aspiration prophylaxis",
    "difficulty": "hard",
    "questionText": "A 58-year-old man with bowel obstruction presents for urgent laparotomy after repeated bilious emesis. He is obese (BMI 40), tachypneic, and hypoxemic (SpO<sub>2</sub> 92% on room air). Exam shows a distended, tympanitic abdomen and Mallampati III airway. You preoxygenate in a 25° head-up position with tight mask and PEEP. The surgical team is ready and requests a rapid sequence induction. The resident asks how to manage cricoid pressure and whether any mask ventilation is acceptable before intubation.\n\nWhich peri-induction approach to cricoid pressure and mask ventilation best balances aspiration prevention with oxygenation for this patient?",
    "answers": [
      {
        "text": "After loss of consciousness, apply cricoid pressure at approximately 30 N; allow gentle, pressure-limited mask ventilation (≤10–12 cm H<sub>2</sub>O) while maintaining cricoid pressure, and reduce or release pressure if it worsens ventilation or laryngoscopic view.",
        "isCorrect": true,
        "explanation": "This balances aspiration mitigation with oxygenation: standard RSI cricoid pressure applied after induction at ~30 N, permissive low-pressure ventilation to prevent hypoxemia, and readiness to adjust cricoid pressure if it hinders ventilation or visualization."
      },
      {
        "text": "After loss of consciousness, apply constant 40 N cricoid pressure and persist despite impaired laryngoscopic view, using a bougie to intubate without altering pressure.",
        "isCorrect": false,
        "explanation": "Excessive cricoid force can worsen bag-mask ventilation and glottic view; pressure should be adjusted or released if it impedes oxygenation or intubation."
      },
      {
        "text": "Place a nasogastric tube immediately after induction while cricoid pressure is applied, then ventilate with higher pressures to ensure adequate oxygenation before laryngoscopy.",
        "isCorrect": false,
        "explanation": "NG decompression is best performed before induction if time permits; attempting it during RSI with cricoid pressure risks delay and regurgitation. High mask pressures increase gastric insufflation and aspiration risk."
      },
      {
        "text": "Apply firm cricoid pressure before induction and maintain it until after surgical incision; avoid any mask ventilation to eliminate aspiration risk.",
        "isCorrect": false,
        "explanation": "Applying cricoid pressure before loss of consciousness is poorly tolerated and unnecessary; maintaining until incision is excessive. Strictly avoiding ventilation increases hypoxemia risk in high-risk desaturators."
      },
      {
        "text": "Omit cricoid pressure entirely because trials show it does not reduce aspiration and increases failed intubation rates; proceed with no mask ventilation until intubation.",
        "isCorrect": false,
        "explanation": "Evidence for cricoid pressure is mixed, not definitively negative. Many guidelines endorse applying it with a low threshold to modify or release if it impairs airway management; completely omitting it and forbidding ventilation risks hypoxemia in this patient."
      }
    ],
    "didactic": "Rapid sequence induction (RSI) aims to minimize time with an unprotected airway in patients at high aspiration risk (eg, bowel obstruction, pregnancy, recent emesis) while preserving oxygenation. Key elements include meticulous preoxygenation (head-up, tight mask with PEEP or CPAP), full neuromuscular blockade, prompt intubation, and thoughtful use of **cricoid pressure (CP)** and mask ventilation.\n\nEvidence for CP (Sellick maneuver) to prevent aspiration is equivocal: the esophagus may be lateral to the cricoid, and CP can worsen mask ventilation and laryngoscopic view. Nonetheless, many guidelines recommend applying CP with a low threshold to adjust. Practical points:\n\n- Apply CP only after loss of consciousness; target ~30 N (≈3 kgf) once reflexes are obtunded. Avoid pre-induction application.\n- If CP impairs bag-mask ventilation or glottic exposure, **reduce or release** it to restore ventilation/visualization. Discontinue CP if the patient actively vomits to avoid esophageal injury and permit egress/suction.\n- Maintain CP during induction and intubation, then release after cuff inflation and confirmation of tracheal position.\n\nIn hypoxemia-prone patients (obesity, low FRC, bowel distension), a “modified” RSI with **gentle, pressure-limited mask ventilation** is appropriate. Use the lowest inspiratory pressures that achieve chest rise (typically ≤10–12 cm H<sub>2</sub>O) with CP applied to minimize gastric insufflation. Randomized data in emergency settings suggest that controlled pre-intubation ventilation reduces hypoxemia without increasing aspiration when airway pressures are limited.\n\nAdditional best practices: suction ready and functioning, head-up positioning, consider gastric decompression before induction if time allows, and select rapid-onset neuromuscular blockade (eg, succinylcholine 1–1.5 mg/kg or rocuronium 1.2 mg/kg with sugammadex available). The optimal strategy in this case is to apply CP after induction at ~30 N, permit low-pressure ventilation, and dynamically adjust CP if it hinders ventilation or laryngoscopy.",
    "educationalObjective": "Perform a rapid sequence induction when indicated and tailor cricoid pressure use based on current evidence and context."
  },
  {
    "id": "Core.12.5.7",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Fasting and aspiration prophylaxis",
    "difficulty": "medium",
    "questionText": "A 58-year-old man with type 2 diabetes complicated by autonomic neuropathy, BMI 38 kg/m², and symptomatic GERD presents with fever, right upper quadrant pain, and jaundice. He is diagnosed with ascending cholangitis, and the endoscopist requests urgent ERCP within the next hour. In the ED he ate a sandwich and drank coffee with cream 3 hours ago. Vitals: T 38.5°C, HR 105, BP 118/64, SpO₂ 97% on room air. ERCP will be performed in the prone/semi-prone position. The endoscopy suite has standard monitors, suction, and nasal capnography; the OR is available. Which anesthetic plan best minimizes aspiration risk while allowing timely therapy?",
    "answers": [
      {
        "text": "Proceed now in the endoscopy suite with propofol deep sedation and insertion of a supraglottic airway (LMA) to limit aspiration risk.",
        "isCorrect": false,
        "explanation": "An LMA does not reliably protect against regurgitation/aspiration, especially in prone ERCP and with a recent solid meal and delayed gastric emptying."
      },
      {
        "text": "Proceed now in the endoscopy suite with moderate sedation (fentanyl/midazolam), head-elevated positioning, supplemental O<sub>2</sub> via nasal cannula, and capnography.",
        "isCorrect": false,
        "explanation": "Moderate sedation preserves airway reflexes variably and can inadvertently deepen; recent solid intake and gastroparesis, combined with prone positioning, make an unprotected airway unsafe despite monitoring and positioning."
      },
      {
        "text": "Proceed now in the endoscopy suite using awake fiberoptic intubation followed by general anesthesia.",
        "isCorrect": false,
        "explanation": "While a cuffed ETT protects the airway, the endoscopy suite is suboptimal for airway rescue and logistics; awake fiberoptic adds delay and complexity without clear benefit over RSI in this urgent, full-stomach scenario."
      },
      {
        "text": "Move to the OR for general anesthesia with rapid-sequence induction and cuffed endotracheal intubation, with full ASA monitoring, suction immediately available, and head-up preoxygenation.",
        "isCorrect": true,
        "explanation": "Urgent source control is needed, and this patient has a full stomach and gastroparesis; securing the airway in the OR with RSI and a cuffed ETT best mitigates aspiration risk while enabling timely ERCP."
      },
      {
        "text": "Delay the ERCP until at least 8 hours after the last solid intake and administer metoclopramide and an H<sub>2</sub>-blocker before proceeding with deep sedation.",
        "isCorrect": false,
        "explanation": "Cholangitis requires urgent intervention; delaying to satisfy fasting times increases sepsis risk, and prokinetics/antacids do not eliminate aspiration risk with an unprotected airway."
      }
    ],
    "didactic": "Patients with recent solid intake (<6 hours) and **conditions that delay gastric emptying** (eg, diabetic autonomic neuropathy), plus **prone positioning** for ERCP, are at high risk for regurgitation and aspiration if managed with moderate/deep sedation and an unprotected airway. ASA fasting recommendations are generally 2 hours for clear liquids, 4 hours for breast milk, and 6 hours for a light meal; fatty meals often require 8 hours. In emergencies or when fasting guidelines are not met, the priority shifts to risk mitigation rather than cancellation when the procedure is urgent.\n\nKey strategies to reduce aspiration risk when NPO status is inadequate:\n- **Venue:** Prefer the OR for difficult or high-risk airways to ensure optimal staffing, equipment, and rescue capabilities.\n- **Airway:** Use a **cuffed endotracheal tube** to definitively protect the airway. For a full stomach, perform **rapid-sequence induction (RSI)** with head-up preoxygenation and immediate availability of suction. Routine cricoid pressure has uncertain benefit and may hinder laryngoscopy.\n- **Monitoring:** Apply full ASA monitors with continuous **capnography**. Capnography is also recommended for moderate/deep sedation, but monitoring alone does not mitigate aspiration without airway protection.\n- **Positioning and preparation:** Head-up or ramped positioning improves preoxygenation and glottic view. Have rescue devices ready (videolaryngoscope, bougie) and ensure two functioning suctions.\n- **Adjuncts:** Prokinetics (eg, metoclopramide), nonparticulate antacids, or H<sub>2</sub>-blockers may reduce acidity/volume but **do not substitute** for a protected airway. Point-of-care gastric ultrasound can inform risk but should not delay urgent care.\n\nFor this patient with recent solids, gastroparesis, and urgent cholangitis, proceeding in the **OR with RSI and a cuffed ETT** best balances timely source control and aspiration risk mitigation; sedation in the endoscopy suite, with or without an LMA, is inadequate.",
    "educationalObjective": "Plan safe sedation in NPO deviations by risk‑mitigating venue, monitoring, and airway preparation."
  },
  {
    "id": "Core.12.5.8",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Fasting and aspiration prophylaxis",
    "difficulty": "medium",
    "questionText": "A 61-year-old man with type 2 diabetes (longstanding peripheral/autonomic neuropathy) presents with 2 days of crampy abdominal pain, nausea, and multiple episodes of bilious emesis. CT shows adhesive small-bowel obstruction. An NGT has drained 1.2 L of bilious fluid. He is scheduled for urgent exploratory laparotomy. Last solid intake was 18 hours ago and last clear liquid was 10 hours ago. He remains nauseated. BMI is 32 kg/m²; airway exam: Mallampati III, thyromental distance 6 cm, full neck mobility. Vitals are stable and SpO<sub>2</sub> is 98% on room air.\n\nWhich anesthetic plan modification is most appropriate to minimize aspiration risk during induction for this surgery?",
    "answers": [
      {
        "text": "Awake fiberoptic intubation after topicalization and light sedation to avoid positive-pressure ventilation",
        "isCorrect": false,
        "explanation": "Awake intubation is reasonable for anticipated difficult airways or extreme aspiration risk with poor mask/RSI feasibility; here, standard RSI is preferred given an acceptable airway and urgent surgery."
      },
      {
        "text": "Inhalational induction with sevoflurane to maintain spontaneous ventilation and avoid coughing, followed by gentle mask ventilation and ETT placement",
        "isCorrect": false,
        "explanation": "Inhalational induction prolongs time to airway protection in a full-stomach patient and still requires mask ventilation, increasing aspiration risk."
      },
      {
        "text": "Rapid-sequence induction in a head-up position with cricoid pressure, no mask ventilation, immediate cuffed endotracheal intubation, and preinduction sodium citrate + metoclopramide",
        "isCorrect": true,
        "explanation": "Small-bowel obstruction confers high aspiration risk regardless of fasting time; RSI with head-up positioning, avoidance of mask ventilation, cuffed ETT, and nonparticulate antacid/prokinetic prophylaxis best mitigates risk."
      },
      {
        "text": "Standard IV induction with gentle mask ventilation (PEEP 10 cmH2O) followed by placement of an LMA to maintain spontaneous ventilation",
        "isCorrect": false,
        "explanation": "Positive-pressure mask ventilation and LMA use do not reliably protect against regurgitation/aspiration in a full-stomach patient; higher mask pressures increase gastric insufflation risk."
      },
      {
        "text": "Delay surgery until NGT output is minimal and the patient has fasted an additional 8 hours to reduce gastric volume",
        "isCorrect": false,
        "explanation": "Prolonged fasting does not normalize aspiration risk in mechanical obstruction; delaying urgent surgery is inappropriate and does not ensure gastric emptying."
      }
    ],
    "didactic": "Patients with a “full stomach” remain at high risk for pulmonary aspiration despite prolonged fasting when pathophysiology prevents gastric emptying. High-risk groups include:\n- Mechanical obstruction (eg, small-bowel obstruction, pyloric stenosis)\n- Gastroparesis (diabetes with autonomic neuropathy, opioids, uremia, neurologic disease)\n- Late pregnancy (≥18–20 weeks) due to progesterone-mediated LES relaxation and increased intraabdominal pressure\n\nIn small-bowel obstruction, gastric and proximal intestinal contents accumulate despite NPO status; thus, fasting time does not equate to an empty stomach. The safest approach is a **rapid-sequence induction (RSI)** with measures to limit regurgitation and rapidly secure the airway:\n- Preoxygenate with 100% O<sub>2</sub> in a 20–30° head-up position to extend safe apnea time and reduce reflux\n- Apply cricoid pressure during induction (acknowledging mixed evidence) and avoid mask ventilation; if absolutely necessary, keep inspiratory pressures <10–12 cmH2O\n- Intubate promptly with a cuffed ETT and decompress the stomach with an OGT after the cuff is inflated\n- Administer nonparticulate antacid (eg, sodium citrate) and consider H<sub>2</sub>-blocker and metoclopramide (useful for gastroparesis; limited effect in mechanical obstruction but may reduce gastric volume)\n\nSupraglottic airways do not protect against aspiration and are inappropriate for high-risk patients. Inhalational (slow) induction prolongs time without airway protection. Awake intubation is reserved for anticipated difficult airways or when RSI is unsafe (eg, severe airway distortion); it is not routinely required solely for aspiration risk when the airway is manageable. Urgent surgery for obstruction should not be delayed to extend fasting, as gastric contents will persist. Recognizing scenarios such as obstruction, gastroparesis, and late pregnancy and modifying the plan with RSI-based strategies reduces aspiration risk.",
    "educationalObjective": "Recognize patients at high aspiration risk (bowel obstruction, gastroparesis, late pregnancy) and modify the plan."
  },
  {
    "id": "Core.12.5.9",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Fasting and aspiration prophylaxis",
    "difficulty": "easy",
    "questionText": "A 62-year-old man with type 2 diabetes complicated by gastroparesis, symptomatic GERD, and a high-grade small-bowel obstruction is brought for urgent exploratory laparotomy. He last ate 4 hours ago and has persistent nausea but no active emesis. Induction is planned in 10 minutes with rapid-sequence technique. You plan to minimize the severity of potential pulmonary aspiration should it occur.\n\nWhich of the following is the most appropriate pharmacologic prophylaxis to administer now?",
    "answers": [
      {
        "text": "Administer 30 mL of magnesium trisilicate antacid orally immediately before induction",
        "isCorrect": false,
        "explanation": "Particulate antacids can cause severe chemical pneumonitis if aspirated and should be avoided; nonparticulate formulations are preferred for aspiration prophylaxis."
      },
      {
        "text": "Administer 30 mL of 0.3 M sodium citrate orally immediately before induction",
        "isCorrect": true,
        "explanation": "Nonparticulate sodium citrate rapidly neutralizes existing gastric acid within minutes and increases gastric pH; it is the preferred agent when induction is imminent because it works immediately and is safer if aspirated."
      },
      {
        "text": "Administer famotidine 20 mg IV immediately before induction",
        "isCorrect": false,
        "explanation": "H2 blockers decrease acid secretion but require approximately 30–60 minutes for meaningful effect; given with such short lead time, they will not reliably raise gastric pH before induction."
      },
      {
        "text": "No pharmacologic prophylaxis is indicated because the patient last ate 4 hours ago",
        "isCorrect": false,
        "explanation": "This patient has multiple risk factors (bowel obstruction, GERD, diabetic gastroparesis) and a nonideal NPO interval; pharmacologic prophylaxis that acts immediately is indicated."
      },
      {
        "text": "Administer omeprazole 40 mg IV immediately before induction",
        "isCorrect": false,
        "explanation": "PPIs have delayed onset and achieve maximal effect after repeated dosing; a single immediate preinduction dose provides little immediate benefit in raising gastric pH."
      }
    ],
    "didactic": "Pulmonary aspiration risk is driven by gastric volume and acidity; severe pneumonitis is more likely when gastric pH is low and volume is high. Pharmacologic prophylaxis aims to increase gastric pH and, secondarily, reduce volume. In urgent cases with induction imminent, a nonparticulate antacid is the most effective immediate intervention.\n\n- Nonparticulate antacid: 0.3 M sodium citrate 30 mL orally raises gastric pH within minutes by neutralizing existing acid. Duration is short (~30–60 minutes), making it ideal immediately before induction. Because it is nonparticulate, it is less injurious if aspirated.\n- H2 blockers (eg, famotidine 20 mg IV or 20–40 mg PO) reduce acid secretion but require time (≈30–60 minutes) to meaningfully elevate pH. They are useful when sufficient lead time exists (eg, preoperatively or in labor) and can be combined with sodium citrate.\n- PPIs (eg, omeprazole/pantoprazole 40 mg IV/PO) are potent acid suppressants but have delayed onset; maximal effect typically requires repeated dosing over 1–3 days. A single immediate preinduction dose is unlikely to substantially increase gastric pH.\n- Particulate antacids (eg, aluminum/magnesium hydroxide, magnesium trisilicate) pose a risk of severe pneumonitis if aspirated and should be avoided.\n\nApplication:\n- Elective, planned cases: Prefer a PPI the night before and morning of surgery or an H2 blocker the evening before and morning of; add sodium citrate immediately preinduction if residual risk persists.\n- Urgent/emergent with imminent induction: Give sodium citrate immediately before induction; add an H2 blocker if ≥30–60 minutes are available. Consider gastric decompression and rapid-sequence induction in high-risk patients (eg, bowel obstruction, GERD, pregnancy, obesity, diabetic gastroparesis).",
    "educationalObjective": "Use nonparticulate antacids, H2 blockers, and/or PPIs appropriately for pharmacologic prophylaxis."
  },
  {
    "id": "Core.12.5.10",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Fasting and aspiration prophylaxis",
    "difficulty": "hard",
    "questionText": "A 60-year-old woman (60 kg, BMI 31) with long-standing diabetes and peripheral neuropathy presents for urgent debridement of an infected foot ulcer. Her last oral intake is uncertain. To clarify aspiration risk, you perform point-of-care gastric ultrasound in preop holding. In the supine position, the gastric antrum is distended with anechoic fluid. In the right lateral decubitus (RLD) position, the antrum remains fluid-filled without particulate/solid echoes. The outer antral diameters in RLD measure anteroposterior (AP) 3.5 cm and craniocaudal (CC) 6.5 cm. \n\nUsing the antral cross-sectional area (CSA = π × AP × CC / 4) and an adult model for volume estimation (V ≈ 27 + 14.6 × CSA − 1.28 × age), which induction plan is most appropriate for this patient today?",
    "answers": [
      {
        "text": "Administer metoclopramide and nonparticulate antacid, then proceed with routine induction and endotracheal intubation",
        "isCorrect": false,
        "explanation": "Prokinetics/antacids do not promptly or reliably reduce gastric volume to low-risk levels; routine induction still risks regurgitation during mask ventilation."
      },
      {
        "text": "Place a nasogastric tube while awake to decompress the stomach before induction",
        "isCorrect": false,
        "explanation": "NG placement in an unprotected airway can provoke regurgitation/aspiration; if needed, decompress after securing the airway with an ETT."
      },
      {
        "text": "Proceed with a supraglottic airway after standard induction because fluid appears clear and likely to empty quickly",
        "isCorrect": false,
        "explanation": "A grade 2 stomach with high estimated volume remains high risk despite clear fluid; a supraglottic airway does not protect against aspiration."
      },
      {
        "text": "Delay surgery for 2 hours to allow further gastric emptying, then perform routine induction with a supraglottic airway",
        "isCorrect": false,
        "explanation": "Gastric emptying is unpredictable in diabetes/gastroparesis, and urgent surgery is needed; delaying briefly does not reliably reduce high-risk volume."
      },
      {
        "text": "Rapid-sequence induction with endotracheal intubation while minimizing positive-pressure mask ventilation",
        "isCorrect": true,
        "explanation": "Supine and RLD fluid (Perlas grade 2) and estimated volume ≈211 mL (>1.5 mL/kg threshold of 90 mL) indicate a high-risk stomach; RSI with ETT best mitigates aspiration risk."
      }
    ],
    "didactic": "Point-of-care gastric ultrasound (GUS) augments fasting assessment when history is unreliable or gastric emptying is impaired (eg, diabetes). The gastric antrum is scanned epigastrically between the left lobe of the liver and pancreas/IVC. Sensitivity increases in the right lateral decubitus (RLD) position because fluid preferentially pools in the antrum.\n\nGUS uses a qualitative grade and a quantitative volume estimate:\n- Qualitative Perlas grading:\n  - Grade 0: Empty antrum in supine and RLD (low risk)\n  - Grade 1: Fluid only in RLD (small volume, typically <1.5 mL/kg)\n  - Grade 2: Fluid visible in supine and RLD or any solid/particulate content (higher risk)\n- Quantitative estimate: Calculate antral cross-sectional area (CSA) as an ellipse: CSA = π × AP × CC / 4 (cm²). In adults, a validated model estimates volume: V (mL) ≈ 27 + 14.6 × CSA (cm²) − 1.28 × age (y). A commonly used high-risk threshold is >1.5 mL/kg of clear fluid or any solid/particulate content.\n\nIn this patient, CSA ≈ π × 3.5 × 6.5 / 4 ≈ 17.9 cm². Estimated volume ≈ 27 + 14.6 × 17.9 − 1.28 × 60 ≈ 211 mL, exceeding the 1.5 mL/kg threshold for 60 kg (90 mL). Fluid in both supine and RLD (grade 2) corroborates a “full stomach.” The most appropriate plan is rapid-sequence induction (RSI) with endotracheal intubation, avoiding or minimizing positive-pressure mask ventilation. Consider head-up positioning, adequate preoxygenation, and gentle laryngoscopy; orogastric decompression can be performed after intubation.\n\nPitfalls and limitations:\n- Clear vs solid: Anechoic fluid is lower viscosity than echogenic/heterogeneous content, but large fluid volumes still pose significant risk.\n- Patient factors (obesity, pregnancy, prior gastric surgery) and poor windows can limit accuracy.\n- Prokinetics/antacids do not reliably or rapidly reduce volume; nasogastric placement before securing the airway may precipitate regurgitation.\n\nWhen fasting status is uncertain, GUS-derived grade and volume guide risk stratification and airway strategy to reduce aspiration.",
    "educationalObjective": "Use point‑of‑care gastric ultrasound to assess gastric content and volume when fasting status is uncertain."
  },
  {
    "id": "Core.12.6.1",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Risk stratification and ASA",
    "difficulty": "medium",
    "questionText": "A 68-year-old man is scheduled for elective open inguinal hernia repair under general anesthesia. He has hypertension and type 2 diabetes managed with basal-bolus insulin. He denies chest pain or syncope and can climb 2 flights of stairs without stopping (≈5 METs). ECG shows normal sinus rhythm. Serum creatinine is 1.0 mg/dL. A transthoracic echocardiogram 2 months ago demonstrated severe aortic stenosis (aortic valve area 0.7 cm², mean gradient 45 mmHg) with LVEF 60%.\n\nWhich of the following statements best reflects the appropriate use and interpretation of the Revised Cardiac Risk Index (RCRI) for this patient?",
    "answers": [
      {
        "text": "His RCRI is 0 because hernia repair is not high-risk and valvular disease is not an RCRI criterion, implying negligible risk.",
        "isCorrect": false,
        "explanation": "This miscalculates the score by omitting insulin-treated diabetes, which contributes 1 point."
      },
      {
        "text": "RCRI cannot be applied in the presence of severe valvular disease; an alternative risk tool must be used instead.",
        "isCorrect": false,
        "explanation": "RCRI can still be calculated, but it must be interpreted alongside clinical factors it omits (eg, severe valvular disease)."
      },
      {
        "text": "His RCRI is 1 (insulin therapy), estimating ≈1% major adverse cardiac event risk, and no further cardiac risk consideration is needed.",
        "isCorrect": false,
        "explanation": "This over-relies on RCRI and ignores a major blind spot: severe aortic stenosis is a strong independent risk factor not captured by RCRI."
      },
      {
        "text": "His RCRI is 1 (insulin therapy), suggesting low predicted risk, but this likely underestimates actual risk because severe aortic stenosis is not captured by RCRI and warrants additional evaluation/planning.",
        "isCorrect": true,
        "explanation": "Correct: RCRI = 1 (insulin use) for a non–high-risk procedure. However, severe aortic stenosis is a key blind spot; RCRI underestimates risk and should be supplemented with condition-specific assessment."
      },
      {
        "text": "His RCRI is 2 (insulin therapy + severe aortic stenosis), predicting ≈6% risk; invasive arterial monitoring is indicated solely on this basis.",
        "isCorrect": false,
        "explanation": "Severe aortic stenosis is not an RCRI variable; adding it to the score is incorrect. Monitoring decisions should integrate the valvular lesion but not by altering the RCRI."
      }
    ],
    "didactic": "The Revised Cardiac Risk Index (RCRI) estimates the risk of major cardiac complications after noncardiac surgery using 6 variables:\n\n- High-risk surgery (intraperitoneal, intrathoracic, suprainguinal vascular)\n- History of ischemic heart disease\n- History of congestive heart failure\n- History of cerebrovascular disease\n- Insulin therapy for diabetes\n- Preoperative creatinine >2.0 mg/dL\n\nRisk rises with the number of predictors (original estimates: 0 = ~0.4%, 1 = ~0.9%, 2 = ~6.6%, ≥3 = ~11%). Although absolute rates are lower in contemporary cohorts, relative stratification remains useful. Importantly, RCRI predicts perioperative major adverse cardiac events (eg, MI, ventricular fibrillation/cardiac arrest, complete heart block), not all-cause complications, and it was derived for adults undergoing noncardiac, nonemergent surgery.\n\nRCRI’s scope has notable blind spots. It does not include:\n\n- Valvular disease severity (eg, severe aortic stenosis)\n- Pulmonary hypertension or arrhythmias\n- Surgical urgency/emergency, frailty/age, or functional capacity\n- Granular surgical factors (duration, bleeding risk)\n\nTherefore, RCRI may underestimate risk in patients with conditions like severe aortic stenosis, even when the calculated score is low. In this case, the patient has one RCRI point (insulin therapy) and a non–high-risk procedure (inguinal hernia repair), yielding a low predicted risk by RCRI. However, severe aortic stenosis is an independent perioperative hazard and is treated as an “active” cardiac condition in guideline frameworks. Risk assessment should integrate the lesion’s severity, symptom status, and recency of echocardiography, and inform anesthetic planning and monitoring.\n\nBottom line: Use RCRI to quantify baseline cardiac risk but contextualize it with clinical factors it omits. A low RCRI does not negate elevated risk conferred by severe valvular disease; additional evaluation and tailored perioperative management are warranted.",
    "educationalObjective": "Apply the Revised Cardiac Risk Index (RCRI) appropriately and explain its scope and blind spots."
  },
  {
    "id": "Core.12.6.2",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Risk stratification and ASA",
    "difficulty": "easy",
    "questionText": "A 58-year-old man is scheduled for an elective laparoscopic cholecystectomy for biliary colic. He has hypertension and type 2 diabetes mellitus controlled with lisinopril and metformin (HbA1c 6.7%) and no end-organ disease. BMI is 33 kg/m². He walks 2 miles daily without limitation and denies chest pain or dyspnea. Vitals are normal; labs and ECG are unremarkable. The case is not urgent or emergent.\n\nWhich ASA Physical Status classification is most appropriate for this patient?",
    "answers": [
      {
        "text": "ASA III",
        "isCorrect": false,
        "explanation": "Incorrect. ASA III implies severe systemic disease with substantive functional limitation or end-organ dysfunction, which is not present here."
      },
      {
        "text": "ASA III-E",
        "isCorrect": false,
        "explanation": "Incorrect. Overestimates disease severity and incorrectly applies the emergency suffix to an elective case."
      },
      {
        "text": "ASA II-E",
        "isCorrect": false,
        "explanation": "Incorrect. The “E” suffix denotes an emergency procedure; this is an elective operation."
      },
      {
        "text": "ASA I",
        "isCorrect": false,
        "explanation": "Incorrect. ASA I is a normal healthy patient without systemic disease; this patient has well-controlled hypertension and diabetes."
      },
      {
        "text": "ASA II",
        "isCorrect": true,
        "explanation": "Correct. Well-controlled hypertension and diabetes without functional limitation represent mild systemic disease (ASA II) for an elective case."
      }
    ],
    "didactic": "ASA Physical Status (ASA PS) classifies the patient’s preoperative health, not the procedural risk. Core definitions:\n- **ASA I**: Normal healthy patient\n- **ASA II**: Mild systemic disease without functional limitation (eg, well-controlled HTN/DM, mild asthma, pregnancy, social alcohol use, cigarette smoking)\n- **ASA III**: Severe systemic disease with substantive functional limitation (eg, poorly controlled DM/HTN, stable angina, prior MI >3 months, COPD with frequent exacerbations, morbid obesity BMI ≥40 when accompanied by comorbidity)\n- **ASA IV**: Severe systemic disease that is a constant threat to life (eg, unstable angina, decompensated HF, ESRD not regularly dialyzed, severe valve disease with symptoms)\n- **ASA V**: Moribund, not expected to survive without the operation (eg, ruptured AAA, massive trauma with shock)\n- **ASA VI**: Brain-dead organ donor\n- Add **“E”** for emergencies (delay increases threat to life or limb).\n\nThis patient has well-controlled HTN and type 2 DM without end-organ dysfunction or functional limitation, consistent with **ASA II**. The case is elective, so no “E” suffix applies. Obesity alone does not mandate ASA III; many patients with BMI 30–39.9 and no physiologic impairment are ASA II.\n\nImportant limits of ASA PS as a risk predictor:\n- It reflects patient comorbidity severity but **does not include** surgical invasiveness, duration, anesthesia technique, or postoperative care.\n- **Age, functional capacity, and specific procedure risk** are not part of the classification.\n- Interrater reliability is moderate; use alongside procedure-specific risk tools (eg, RCRI, NSQIP) and functional assessment to estimate perioperative risk.\n\nBottom line: Assign ASA PS from stable comorbidity severity and add “E” only for emergencies; use ASA PS as one component—not the sole determinant—of perioperative risk.",
    "educationalObjective": "Assign the correct ASA Physical Status from brief clinical vignettes and recognize its limits as a risk predictor."
  },
  {
    "id": "Core.12.6.3",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Risk stratification and ASA",
    "difficulty": "easy",
    "questionText": "A 67-year-old man with hypertension and prior MI (5 years ago, no angina since, on β-blocker and statin) has 7 METs (mows lawn without symptoms). He undergoes elective open infrarenal abdominal aortic aneurysm repair via midline laparotomy. Intraoperative course is stable (aortic cross-clamp 45 min, EBL 400 mL, 2 L crystalloid, urine output 0.7 mL/kg/h). He is extubated in the OR and arrives to PACU hemodynamically stable with SpO<sub>2</sub> 98% on 4 L O<sub>2</sub>.\n\nWhich postoperative monitoring and disposition plan is most appropriate for this patient?",
    "answers": [
      {
        "text": "Admission to a stepdown/telemetry unit with a single 12-lead ECG in the morning",
        "isCorrect": false,
        "explanation": "Telemetry is helpful, but high-risk open AAA repair typically warrants ICU-level monitoring rather than stepdown alone."
      },
      {
        "text": "PACU recovery followed by same-day discharge if standard criteria are met",
        "isCorrect": false,
        "explanation": "Major open vascular surgery is high-risk; same-day discharge is inappropriate despite an uncomplicated case and good functional capacity."
      },
      {
        "text": "Admission to the ICU with continuous hemodynamic monitoring and postoperative troponin/ECG surveillance for 48–72 h",
        "isCorrect": true,
        "explanation": "Open AAA repair is a high-risk (≥5% MACE) procedure; ICU-level care with continuous monitoring and early myocardial injury surveillance is appropriate even with good functional capacity."
      },
      {
        "text": "Extended PACU observation (6 h) followed by discharge home if stable",
        "isCorrect": false,
        "explanation": "Observation-only strategies are inadequate after major open vascular surgery; inpatient monitored care is indicated."
      },
      {
        "text": "Admission to a general medical-surgical floor without telemetry",
        "isCorrect": false,
        "explanation": "Floor-level care without continuous monitoring is insufficient for high-risk major vascular surgery with substantial risk of myocardial injury and hemodynamic instability."
      }
    ],
    "didactic": "Surgical risk category is a primary driver of perioperative monitoring and disposition. **High-risk (≥5% MACE)** procedures include major open vascular operations (eg, open AAA repair, peripheral arterial revascularization). These surgeries are associated with significant risks of myocardial injury, bleeding, arrhythmias, and hemodynamic instability in the immediate postoperative period. Accordingly, patients generally warrant **ICU-level care with continuous arterial blood pressure monitoring and telemetry**, with consideration of **postoperative troponin and ECG surveillance for 48–72 h** to detect myocardial injury after noncardiac surgery (MINS), which is often clinically silent.\n\nBy contrast, **intermediate-risk (1–5% MACE)** procedures include intraperitoneal/intrathoracic surgery, carotid endarterectomy, head and neck, most orthopedic, prostate, and endovascular AAA repair; these typically merit monitored floor care or telemetry based on comorbidity and intraoperative course. **Low-risk (<1% MACE)** procedures include superficial, cataract, breast, endoscopic, and ambulatory hernia repairs, for which routine PACU recovery and same-day discharge are often appropriate if criteria are met.\n\nASA Physical Status complements surgical risk by estimating baseline physiologic reserve (eg, ASA III for stable prior MI). However, **good functional capacity alone does not negate the need for heightened monitoring after high-risk surgery**. In this case, an uncomplicated intraoperative course and 7 METs reduce preoperative testing needs but do not change the elevated postoperative risk inherent to open AAA repair. Appropriate triage is therefore ICU admission with continuous monitoring and early myocardial injury surveillance. This risk-stratified approach improves timely detection of complications and aligns resource use with expected postoperative risk.",
    "educationalObjective": "Differentiate low-, intermediate-, and high-risk surgery categories and adjust monitoring and disposition plans."
  },
  {
    "id": "Core.12.6.4",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Risk stratification and ASA",
    "difficulty": "easy",
    "questionText": "A 78-year-old woman with severe COPD (FEV1 35% predicted), HFpEF, and a frailty phenotype presents to the preoperative clinic for elective laparoscopic cholecystectomy after two ED visits for biliary colic. She lives alone and says, “My biggest goal is to stay independent at home and avoid a long hospital stay.” NSQIP estimates a 10% serious complication risk and a 25% chance of discharge to a facility if she has surgery; if managed nonoperatively, her surgeon estimates a 30%/year chance of recurrent biliary events. She asks, “What would you do?”\n\nWhich communication approach best aligns the perioperative recommendation with this patient’s goals and values?",
    "answers": [
      {
        "text": "Provide her RCRI class and recommend surgery to minimize future biliary events, emphasizing that laparoscopic procedures are generally safe.",
        "isCorrect": false,
        "explanation": "Using a risk index alone and steering toward a single option is directive and does not elicit patient values or address outcomes she prioritizes (eg, disposition, function)."
      },
      {
        "text": "Elicit what matters most to her, present operative and nonoperative choices using absolute risks in natural frequencies (eg, “10 out of 100”), include likely disposition/functional outcomes, and use teach-back to confirm understanding.",
        "isCorrect": true,
        "explanation": "This is shared decision-making: it centers the patient’s goals, presents balanced absolute risk/benefit for all options, incorporates outcomes she values, and checks comprehension."
      },
      {
        "text": "Explain her ASA class and note that anesthesia risk is manageable; obtain consent now to prevent scheduling delays.",
        "isCorrect": false,
        "explanation": "ASA class is not a validated outcome predictor and this approach bypasses value elicitation and comprehension checks."
      },
      {
        "text": "Refer detailed decision-making to the surgeon because procedure-specific risks determine appropriateness; focus the anesthesia visit on optimization.",
        "isCorrect": false,
        "explanation": "Shared decision-making is interprofessional; anesthesiologists should help align risks, benefits, and alternatives with patient goals."
      },
      {
        "text": "Highlight her elevated mortality risk and advise canceling surgery to avoid potentially life-threatening complications.",
        "isCorrect": false,
        "explanation": "Paternalistic, mortality-focused framing can bias decisions and overlooks symptom relief and the patient’s stated priorities."
      }
    ],
    "didactic": "Effective perioperative risk communication should use **shared decision-making (SDM)** to align recommendations with patient goals and values. Key steps include:\n\n- **Elicit goals and priorities:** Ask, “What matters most if things don’t go as planned?” For many older adults, maintaining independence and avoiding prolonged hospitalization may outweigh small reductions in future event risk.\n- **Present all reasonable options**, including nonoperative management when appropriate, and clarify expected trajectories (eg, pain control, recurrence risk, possible need for urgent surgery vs scheduled elective repair).\n- **Use absolute risk in natural frequencies** (eg, “10 out of 100”) rather than isolated percentages or relative risk. Include outcomes patients value (eg, discharge to facility, delirium, functional decline), not just mortality.\n- **Balance framing** by presenting both benefits and harms for each option and avoid coercive language (“too risky,” “must do”).\n- **Confirm understanding with teach-back:** “Can you tell me in your own words what you’re choosing and why?” This identifies misperceptions and supports informed consent.\n- **Incorporate validated tools** (eg, NSQIP) to estimate event rates but avoid substituting **ASA class** (a severity index) for outcome prediction. Use risk indices to inform—not dictate—recommendations.\n- **Document preferences** (eg, code status, disposition priorities) and consider decision aids or involving caregivers when appropriate.\n\nIn this scenario, aligning care with the patient’s stated goal of independence requires discussing both the operative path (eg, ~10/100 serious complications, ~25/100 likelihood of facility discharge) and nonoperative path (eg, ~30/100 annual recurrence), ensuring she understands trade-offs that matter to her. The best communication centers her values, uses clear absolute risks, includes functional outcomes and disposition, and employs teach-back—hallmarks of SDM that improve decision quality and satisfaction.",
    "educationalObjective": "Discuss risk communication strategies that align recommendations with patient goals and values."
  },
  {
    "id": "Core.12.6.5",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Risk stratification and ASA",
    "difficulty": "easy",
    "questionText": "A 67-year-old man with COPD (FEV1 60% predicted), OSA on CPAP, hypertension, type 2 diabetes, and BMI 36 presents for elective open inguinal hernia repair. He can climb 2 flights of stairs (≈4 METs), denies angina, has a normal ECG, creatinine 1.3 mg/dL, and hemoglobin 12 g/dL. He prefers to avoid “a breathing tube” if possible; the surgeon is amenable to spinal anesthesia with sedation. You estimate his Revised Cardiac Risk Index (RCRI) as 1 and anticipate using his home CPAP postoperatively with consideration for extended monitoring.\n\nWhich of the following documentation entries best supports informed consent for anesthesia in this patient?",
    "answers": [
      {
        "text": "ASA III. Plan spinal anesthesia with sedation. Discussed risk of hypotension, urinary retention, and post–dural puncture headache; patient agrees.",
        "isCorrect": false,
        "explanation": "Lists only limited neuraxial risks and omits key elements of informed consent: reasonable alternatives and explicit contingency plans tailored to this patient’s cardiopulmonary comorbidities and OSA."
      },
      {
        "text": "ASA II with low risk; plan MAC only to avoid airway instrumentation; no intubation will be performed per patient request; consent obtained.",
        "isCorrect": false,
        "explanation": "Misclassifies ASA and inappropriately promises to avoid intubation, while failing to outline alternatives or a conversion plan if sedation is inadequate."
      },
      {
        "text": "RCRI 2 (elevated risk). Advised cancellation pending cardiology clearance; patient insists on proceeding and accepts responsibility for outcomes.",
        "isCorrect": false,
        "explanation": "Misstates risk and focuses on deferral rather than documenting a balanced, patient-specific risk discussion with alternatives and contingency plans for proceeding safely."
      },
      {
        "text": "Risks, benefits, and alternatives discussed; all questions answered; patient signed consent.",
        "isCorrect": false,
        "explanation": "Overly generic and not patient-specific; it lacks explicit alternatives, quantification of risk, and contingency planning (eg, conversion to GA, postoperative OSA management)."
      },
      {
        "text": "ASA III; RCRI 1 (~1% risk of perioperative major adverse cardiac events). Discussed patient-specific risks (cardiopulmonary events, aspiration, awareness, dental injury, PONV, nerve injury, neuraxial failure), alternatives (general anesthesia with ETT or LMA, peripheral nerve block with MAC, or postponement for further optimization), and contingencies (possible conversion to GA with ETT if block inadequate or respiratory compromise; consent to blood transfusion if needed; plan for CPAP use and extended PACU/overnight monitoring). Patient verbalized understanding and agrees.",
        "isCorrect": true,
        "explanation": "Comprehensively documents risk stratification, reasonable alternatives, and concrete contingency plans (conversion to GA, blood products, and OSA-focused postoperative care), satisfying informed consent requirements."
      }
    ],
    "didactic": "Informed consent for anesthesia should be a patient-specific conversation and documentation that clearly addresses three pillars: risks, alternatives, and contingency plans. For risk stratification, it is appropriate to include the **ASA Physical Status** (a qualitative comorbidity scale) and, when applicable, a quantitative metric such as the **Revised Cardiac Risk Index (RCRI)** to frame absolute risk (eg, RCRI 1 ≈ 1% risk of perioperative MACE). Documenting generic risks alone is insufficient; the note should reflect material risks relevant to the patient and procedure (eg, cardiopulmonary complications in COPD/OSA, aspiration, dental injury, PONV, neuraxial failure/nerve injury).\n\nHigh-quality documentation explicitly lists reasonable **alternatives** to the proposed anesthetic (eg, neuraxial with sedation, general anesthesia with ETT or LMA, peripheral nerve block with monitored anesthesia care, or postponement for optimization) and acknowledges patient preferences. It is inappropriate to guarantee outcomes (eg, \"no intubation\"); instead, include **contingency plans**, such as conversion to general anesthesia if the block is inadequate or respiratory compromise occurs, availability and consent for blood products if needed, and anticipated postoperative disposition (eg, CPAP use, extended PACU or overnight monitoring for OSA).\n\nEffective notes also state that questions were answered and the patient **verbalized understanding and agreement**. Consider documenting special issues (eg, interpreter use, DNR status clarification, regional anesthesia consent including potential failure and local anesthetic systemic toxicity). Compared with vague statements (\"risks/benefits discussed\"), a patient-specific entry that quantifies risk, delineates alternatives, and outlines concrete contingency steps best supports informed consent and shared decision-making.",
    "educationalObjective": "Document risk, alternatives, and contingency plans clearly to support informed consent."
  },
  {
    "id": "Core.12.6.6",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Risk stratification and ASA",
    "difficulty": "medium",
    "questionText": "A 62-year-old woman is scheduled for elective laparoscopic colectomy for colon adenocarcinoma. She reports 2 days of fever, dysuria, and fatigue. Vitals: T 38.9°C, HR 115/min, BP 95/55 mmHg, RR 22/min, SpO<sub>2</sub> 97% on room air. She appears ill and dry. Labs: Hb 7.8 g/dL (10.2 g/dL two weeks ago), WBC 17,000/µL, creatinine 2.1 mg/dL (baseline 0.9), lactate 3.2 mmol/L, and urine nitrite positive. ECG is normal. The surgeon asks to proceed due to oncologic urgency.\n\nWhich management is the most appropriate to reduce this patient’s perioperative mortality risk?",
    "answers": [
      {
        "text": "Start erythropoietin and IV iron today and proceed if hemoglobin improves tomorrow.",
        "isCorrect": false,
        "explanation": "Erythropoietin and IV iron require weeks to have effect and do not address the immediate risks of sepsis and acute kidney injury."
      },
      {
        "text": "Proceed with surgery now using invasive monitoring and norepinephrine as needed.",
        "isCorrect": false,
        "explanation": "Proceeding while septic and hypotensive increases mortality; vasopressors without initial source control optimization and fluid resuscitation is inadequate for an elective case."
      },
      {
        "text": "Delay surgery and initiate a sepsis bundle (early broad-spectrum antibiotics, 30 mL/kg crystalloid, target MAP ≥65 mmHg with lactate clearance), then reassess for surgery after stabilization.",
        "isCorrect": true,
        "explanation": "Sepsis with hypotension, lactate elevation, and new renal dysfunction indicates high perioperative risk; early antibiotics and hemodynamic optimization before elective surgery reduce morbidity and mortality."
      },
      {
        "text": "Administer a single dose of ceftriaxone and perform the surgery under neuraxial anesthesia to avoid general anesthesia.",
        "isCorrect": false,
        "explanation": "A single antibiotic dose without full resuscitation is insufficient, and neuraxial anesthesia does not mitigate sepsis-related hemodynamic instability; neuraxial techniques are relatively contraindicated in untreated sepsis."
      },
      {
        "text": "Transfuse 2 units of PRBCs to raise hemoglobin above 10 g/dL and proceed to surgery.",
        "isCorrect": false,
        "explanation": "A liberal transfusion strategy to Hb >10 g/dL is not evidence-based and transfusion carries risks; the immediate priority is treating sepsis. Transfusion is typically reserved for Hb ≤7–8 g/dL or symptomatic anemia."
      }
    ],
    "didactic": "This patient meets criteria for sepsis with hypotension and elevated lactate, plus new renal dysfunction, conferring markedly increased perioperative risk. Elective surgery should be delayed to perform a **sepsis bundle**: early broad-spectrum antibiotics, prompt source evaluation, and aggressive crystalloid resuscitation (eg, 30 mL/kg) to achieve MAP ≥65 mmHg, with repeated reassessment for lactate clearance and end-organ perfusion. If hypotension persists, start vasopressors (eg, norepinephrine) after adequate fluids. Anesthesia-induced vasodilation and myocardial depression can unmask or worsen shock; proceeding before stabilization increases mortality.\n\nRenal dysfunction is both an indicator of sepsis severity and an independent perioperative risk factor. A creatinine ≥2.0 mg/dL earns a point on the Revised Cardiac Risk Index, increasing the risk of major cardiac complications. Optimization includes restoring intravascular volume, avoiding nephrotoxins, dose-adjusting renally cleared drugs, and close urine output and electrolyte monitoring. Acute kidney injury also influences intraoperative fluid and vasopressor strategy.\n\nAnemia lowers oxygen delivery (DO<sub>2</sub> = CO × CaO<sub>2</sub>), where CaO<sub>2</sub> ≈ 1.34 × Hb × SaO<sub>2</sub> + 0.003 × PaO<sub>2</sub>. In stable surgical patients, a restrictive transfusion threshold (Hb ≤7–8 g/dL) is associated with outcomes comparable to liberal strategies, while avoiding transfusion risks (TRALI, TACO, infection, immunomodulation). With Hb 7.8 g/dL, the priority is hemodynamic stabilization and infection control; transfusion can be considered if there is active bleeding, myocardial ischemia, or persistent instability after resuscitation.\n\nBy ASA Physical Status, uncontrolled sepsis with hypotension represents **ASA IV** (severe systemic disease that is a constant threat to life); adding the E suffix applies only to emergent cases. ASA class correlates with perioperative mortality and underscores the need to stabilize sepsis and renal function before elective surgery.",
    "educationalObjective": "Explain how anemia, renal dysfunction, and sepsis elevate perioperative risk and prompt optimization."
  },
  {
    "id": "Core.12.6.7",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Risk stratification and ASA",
    "difficulty": "medium",
    "questionText": "A 72-year-old man is seen in preoperative clinic before an elective total knee arthroplasty. He had a drug-eluting stent placed after a non–ST-elevation MI 2 years ago and has had no chest pain, dyspnea, orthopnea, or syncope since. He walks his dog briskly on hills for 30 minutes daily and climbs 2 flights of stairs without stopping. Medications include aspirin 81 mg daily, metoprolol succinate 50 mg daily, atorvastatin 40 mg nightly, and metformin. Vital signs and exam are normal; ECG shows normal sinus rhythm with anterior Q waves unchanged from prior. The surgeon requests “cardiac clearance.”\n\nWhich is the most appropriate next step?",
    "answers": [
      {
        "text": "Order a transthoracic echocardiogram to reassess left ventricular function given prior myocardial infarction",
        "isCorrect": false,
        "explanation": "Preoperative TTE is reserved for new or worsening heart failure symptoms, significant valvular disease, or unexplained dyspnea; a remote MI without symptoms is not an indication."
      },
      {
        "text": "Schedule invasive coronary angiography to determine need for revascularization before surgery",
        "isCorrect": false,
        "explanation": "Coronary angiography and revascularization are indicated only for standard cardiac reasons (eg, ACS, refractory angina, left main disease), not solely to reduce perioperative risk in stable, asymptomatic patients."
      },
      {
        "text": "Obtain coronary CT angiography to refine perioperative cardiac risk stratification",
        "isCorrect": false,
        "explanation": "Coronary CTA is not routinely recommended for preoperative assessment; it rarely changes management in stable patients and may lead to delays and downstream testing without outcome benefit."
      },
      {
        "text": "Obtain a pharmacologic nuclear stress test to screen for inducible ischemia and delay surgery if positive",
        "isCorrect": false,
        "explanation": "Noninvasive testing is not indicated in asymptomatic patients with ≥4 METs when results will not alter management; preoperative revascularization based solely on screening does not improve outcomes."
      },
      {
        "text": "Proceed to surgery without additional cardiac testing and continue the statin and β-blocker perioperatively",
        "isCorrect": true,
        "explanation": "Good functional capacity (≥4 METs), stable symptoms, and low predicted risk (RCRI ≈1) indicate no benefit from further testing; results would not change management. Optimization includes continuing guideline-directed medical therapy and routine intraoperative monitoring."
      }
    ],
    "didactic": "In preoperative cardiac assessment, the key question is whether a test will change management. This patient has stable coronary artery disease, **good functional capacity (≥4 METs)**, and is undergoing an **intermediate-risk** noncardiac surgery. Using the ACC/AHA stepwise approach:\n\n- No **acute coronary syndrome** and the surgery is elective.\n- Estimated perioperative major adverse cardiac event risk is low (RCRI ≈1 for history of ischemic heart disease, with no high-risk surgery, CHF, cerebrovascular disease, insulin use, or creatinine >2 mg/dL).\n- Functional capacity is ≥4 METs (walks hills, climbs 2 flights) without symptoms.\n\nIn this scenario, **no additional testing** (stress imaging, TTE, coronary angiography/CTA) is indicated because results would not alter management. Even if a screening stress test were abnormal, routine preoperative revascularization has not shown benefit in stable patients; revascularization should be pursued only for usual indications (eg, ACS, left main disease, refractory angina).\n\nAppropriate optimization focuses on continuing **guideline-directed medical therapy** and employing standard monitoring:\n\n- Continue the **statin** and existing **β-blocker** perioperatively; avoid initiating high-dose β-blockers immediately preop.\n- Address general risk modifiers (eg, glycemic control, blood pressure), and use routine ASA monitors intraoperatively with vigilance for ischemia.\n\nTesting is warranted when it could change care, such as:\n\n- Poor/unknown functional capacity with elevated surgical risk where stress test results would influence decisions (eg, deferring surgery, intensifying therapy).\n- New/worsening heart failure or significant valvular disease prompting **TTE**.\n- **Coronary angiography** only for standard cardiac indications.\n\nThus, proceed to surgery without additional cardiac testing and maintain indicated therapies and monitoring.",
    "educationalObjective": "Identify scenarios where formal testing will not alter management and proceed with optimization and monitoring instead."
  },
  {
    "id": "Core.12.6.8",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Risk stratification and ASA",
    "difficulty": "medium",
    "questionText": "A 78-year-old man is scheduled for elective laparoscopic right hemicolectomy for colon cancer. He has hypertension and type 2 diabetes controlled with oral medications, is independent with activities of daily living, and denies dyspnea climbing 2 flights of stairs. ECG is normal. His Revised Cardiac Risk Index is 0, and you assign ASA II. He reports becoming \"slower\" over the past year with a 4-kg unintentional weight loss; he lives alone, and his daughter is concerned about the likelihood of complications and the need for a skilled-nursing facility after surgery.\n\nWhich additional preoperative assessment would best refine risk stratification and guide postoperative disposition planning?",
    "answers": [
      {
        "text": "Calculate the Revised Cardiac Risk Index despite good functional capacity",
        "isCorrect": false,
        "explanation": "RCRI estimates perioperative MACE, not global outcomes or discharge needs; with RCRI 0 and adequate functional capacity, it offers minimal incremental information."
      },
      {
        "text": "Obtain preoperative BNP to estimate overall morbidity and disposition needs",
        "isCorrect": false,
        "explanation": "BNP improves prediction of major cardiac events but adds little for global surgical morbidity, delirium, and discharge disposition in a patient with good functional capacity."
      },
      {
        "text": "Check preoperative serum albumin as the principal tool to refine risk",
        "isCorrect": false,
        "explanation": "Low albumin is a nonspecific illness/inflammation marker; it is less actionable for functional planning and does not directly assess physiologic reserve like frailty tests."
      },
      {
        "text": "Increase ASA class to III based on advanced age to reflect higher risk",
        "isCorrect": false,
        "explanation": "ASA class does not incorporate age alone and is a coarse comorbidity measure that does not capture frailty or predict discharge disposition reliably."
      },
      {
        "text": "Measure 5-m gait speed at usual pace and treat ≥6 s (≤0.8 m/s) as high risk",
        "isCorrect": true,
        "explanation": "Gait speed is a practical frailty metric that independently predicts postoperative complications, delirium, length of stay, and discharge to facility beyond age, ASA class, and cardiac risk indices."
      }
    ],
    "didactic": "Frailty is a multidimensional syndrome of decreased physiologic reserve across cardiovascular, pulmonary, musculoskeletal, and cognitive systems. In older surgical patients, frailty is an independent predictor of postoperative complications, delirium, prolonged length of stay, and discharge to facility—beyond traditional tools such as ASA class, self-reported METs, and cardiac risk indices.\n\nSimple bedside frailty measures outperform age alone and refine counseling and postoperative planning:\n- 5-m gait speed: a usual-pace time ≥6 s (≈≤0.8 m/s) identifies high risk for morbidity, mortality, and institutional discharge. It is quick, reproducible, and integrates multiple organ systems.\n- Timed Up-and-Go (TUG): ≥15 s suggests increased complications and functional decline.\n- Clinical Frailty Scale (CFS): a validated 9-point global assessment predicting complications and LOS.\n\nCardiac-specific tools (eg, BNP, RCRI) primarily estimate perioperative major adverse cardiac events and add little when functional capacity is adequate; they do not capture global vulnerability or disposition needs. ASA class is a coarse, subjective comorbidity summary and does not measure frailty. Serum albumin correlates with illness severity and inflammation but is not a direct assessment of functional reserve and is less actionable for perioperative functional planning.\n\nIncorporating frailty into risk assessment enables targeted interventions:\n- Prehabilitation (nutrition optimization, protein supplementation, resistance and balance training)\n- Multimodal, opioid-sparing analgesia and regional techniques to facilitate early mobilization\n- Delirium prevention (sleep hygiene, vision/hearing aids, avoid anticholinergics/benzodiazepines)\n- Early PT/OT, clear mobility goals, and proactive discharge planning with social work\n- Consideration of higher-acuity postoperative monitoring for markedly frail patients\n\nThus, measuring 5-m gait speed provides high-yield, incremental information to refine counseling and guide postoperative disposition planning in older adults.",
    "educationalObjective": "Incorporate frailty measures into risk assessment to refine counseling and postoperative planning."
  },
  {
    "id": "Core.12.6.9",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Risk stratification and ASA",
    "difficulty": "medium",
    "questionText": "A 72-year-old woman (ASA III) with hypertension, type 2 diabetes (A1c 7.4%), and stage 3 CKD (creatinine 1.6 mg/dL, eGFR ≈45 mL/min/1.73 m<sup>2</sup>) is evaluated before an elective laparoscopic cholecystectomy for symptomatic cholelithiasis. She is independent in activities of daily living but can only walk one block slowly (≈3–4 METs) due to fatigue. She denies chest pain or dyspnea at rest. ECG shows normal sinus rhythm. Medications include metoprolol, atorvastatin, and amlodipine. Using the NSQIP MICA calculator with this procedure and her patient factors, you estimate a 0.8% risk of perioperative myocardial infarction or cardiac arrest.\n\nShe asks whether additional heart testing is needed and what you will do to reduce her risk. Which management choice best aligns with this NSQIP/MICA estimate and current guidelines to support shared decision-making?",
    "answers": [
      {
        "text": "Proceed to surgery without additional cardiac testing; continue her β-blocker and statin; no routine postoperative troponin surveillance is planned.",
        "isCorrect": true,
        "explanation": "With a MICA risk <1% (low cardiac risk) and no active cardiac conditions, guidelines support proceeding without further testing; continue chronic β-blocker/statin therapy and avoid routine biomarker surveillance reserved for elevated-risk patients."
      },
      {
        "text": "Obtain a preoperative pharmacologic stress test because functional capacity is <4 METs.",
        "isCorrect": false,
        "explanation": "Poor functional capacity alone does not mandate testing when overall cardiac risk by MICA is <1%; stress testing should be reserved for cases in which results would change management."
      },
      {
        "text": "Delay surgery to perform coronary angiography and possible revascularization given diabetes and CKD.",
        "isCorrect": false,
        "explanation": "Prophylactic revascularization is not indicated in stable, asymptomatic patients solely to lower perioperative risk; angiography is reserved for standard indications independent of surgery."
      },
      {
        "text": "Admit postoperatively for routine troponin surveillance for 48–72 h because MICA exceeds 0.5%.",
        "isCorrect": false,
        "explanation": "Routine postoperative troponin monitoring is generally reserved for patients at elevated cardiac risk (eg, MICA ≥1%) undergoing elevated-risk surgery; it is not recommended for low-risk cases."
      },
      {
        "text": "Start a new high-dose β-blocker the day before surgery to further reduce risk below 1%.",
        "isCorrect": false,
        "explanation": "Initiating β-blockers immediately before surgery increases risks (eg, hypotension, stroke); β-blockers should be continued if already prescribed and started/titrated weeks in advance only when clearly indicated."
      }
    ],
    "didactic": "NSQIP MICA estimates the probability of perioperative myocardial infarction or cardiac arrest by integrating patient comorbidities, ASA class, and—critically—procedure category. A threshold of approximately 1% is commonly used in ACC/AHA perioperative algorithms to differentiate low from elevated cardiac risk. In this patient, a laparoscopic cholecystectomy plus her factors yields a MICA of 0.8%, placing her in a low-risk category despite limited functional capacity.\n\nFor low cardiac risk (MICA <1%) and no active cardiac conditions (eg, unstable angina, decompensated heart failure, significant arrhythmias, severe valvular disease), further cardiac testing is not indicated. Noninvasive stress testing should be pursued only if results would change management, such as leading to coronary revascularization or substantial alteration of the surgical plan. Prophylactic coronary angiography/revascularization to lower perioperative risk is not recommended in stable patients without standard indications.\n\nMedication management integrates patient factors with surgery risk:\n- Continue chronic **β-blockers**; avoid initiating immediately preoperatively due to increased hypotension and stroke risk.\n- Continue **statins**; initiation is reasonable in vascular surgery or when otherwise indicated for dyslipidemia.\n- Reasonable intraoperative goals include maintaining MAP ≳65 mmHg and avoiding tachycardia to minimize myocardial oxygen supply–demand mismatch.\n\nPostoperative surveillance should be tailored to risk. Routine **troponin monitoring** is generally reserved for patients at elevated cardiac risk (eg, MICA ≥1%) undergoing elevated-risk surgery, or those with concerning symptoms/signs. For this low-risk case, routine troponin checks and telemetry are not required.\n\nShared decision-making includes communicating the numeric risk (eg, ~0.8% risk of MI/cardiac arrest by MICA), explaining that additional testing is unlikely to improve outcomes, and outlining risk-mitigation steps (continue β-blocker/statin, meticulous hemodynamic control, glycemic optimization). This approach aligns surgery-specific risk with patient factors to guide evidence-based perioperative care.",
    "educationalObjective": "Interpret NSQIP/MICA estimates and integrate surgery-specific risk with patient factors for shared decisions."
  },
  {
    "id": "Core.12.6.10",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Risk stratification and ASA",
    "difficulty": "medium",
    "questionText": "A 65-year-old man (BMI 41 kg/m²) with hypertension, insulin-treated type 2 diabetes, coronary artery disease s/p drug-eluting stent 3 years ago, and suspected severe obstructive sleep apnea (STOP-Bang 7) presents for elective laparoscopic ventral hernia repair. He uses chronic opioids (morphine ER 60 mg/day), is nonadherent with CPAP, and lives alone 60 minutes from the facility. The case is booked at a freestanding ambulatory surgery center without overnight capability. Surgeon anticipates moderate-to-severe postoperative pain despite a planned TAP block. Vitals: BP 138/78, HR 74, SpO<sub>2</sub> 94% on room air. ECG is normal; labs are within normal limits. Estimated RCRI is 1.\n\nWhich perioperative disposition is most appropriate to safely proceed with surgery while mitigating postoperative risk?",
    "answers": [
      {
        "text": "Proceed at the freestanding ASC with routine PACU discharge the same day and instruct the patient to avoid opioids at home.",
        "isCorrect": false,
        "explanation": "Same-day discharge from an ASC is inappropriate given severe OSA risk, chronic opioid use, and lack of home support; avoiding opioids is unrealistic for expected painful surgery."
      },
      {
        "text": "Proceed at the freestanding ASC with extended PACU observation (4–6 hours) and discharge home with an opioid-sparing regimen.",
        "isCorrect": false,
        "explanation": "Extended PACU time does not mitigate overnight risk; OSA-related respiratory events often occur after discharge and during REM rebound, particularly with systemic opioids."
      },
      {
        "text": "Move the case to the hospital with a planned postoperative admission to a monitored bed for continuous oximetry and use of the patient’s CPAP, employing multimodal, opioid-sparing analgesia.",
        "isCorrect": true,
        "explanation": "Hospital-based surgery with planned monitored admission addresses elevated OSA and opioid-related respiratory risk, enables CPAP use, and provides rescue resources if deterioration occurs."
      },
      {
        "text": "Defer surgery pending a formal sleep study and documented CPAP adherence before scheduling at the ASC.",
        "isCorrect": false,
        "explanation": "Formal sleep testing is not required to proceed; risk can be managed by changing venue and monitoring. Deferral for testing delays care without improving immediate safety if monitoring is planned."
      },
      {
        "text": "Move the case to a hospital outpatient OR but plan same-day discharge with instructions to resume CPAP at home.",
        "isCorrect": false,
        "explanation": "Venue change without monitored overnight care still leaves the patient at high risk for unmonitored respiratory depression at home, especially as he lives alone and is CPAP-nonadherent."
      }
    ],
    "didactic": "Ambulatory suitability hinges on a patient’s perioperative risk profile, the procedure’s analgesic needs, and the facility’s ability to rescue when complications occur. This patient has high-risk features for postoperative respiratory compromise: **STOP-Bang 7 (probable severe OSA), BMI 41, chronic opioid therapy, expected moderate–severe pain, nonadherence to CPAP, and no home supervision**. Although his cardiac risk (RCRI 1) is low–intermediate for this intermediate-risk surgery, the dominant hazard is hypoventilation and airway obstruction after discharge.\n\nOSA-related respiratory events are potentiated by systemic opioids and sedatives and may worsen several hours after emergence (eg, during REM rebound on postoperative nights 1–3). Freestanding ambulatory centers without overnight capability cannot provide the **continuous oximetry, nursing surveillance, and rapid escalation** needed if deterioration occurs. Extended PACU observation does not protect against late events, and discharging a patient who lives alone is unsafe. Deferring surgery for polysomnography rarely changes immediate perioperative management when OSA is strongly suspected; instead, mitigate risk with venue and monitoring.\n\nThe most appropriate plan is to move the case to a hospital with a **planned postoperative admission to a monitored bed** (eg, continuous pulse oximetry or stepdown), instruct the patient to bring and use CPAP, and employ **opioid-sparing multimodal analgesia** (regional anesthesia, acetaminophen, NSAIDs if appropriate, gabapentinoids with caution). Cardiac risk remains acceptable (RCRI 1), so cancellation is unnecessary.\n\nIndicators that should prompt changing venue or postoperative level of care include:\n- High OSA risk (eg, STOP-Bang ≥5), especially with expected opioids or sedatives\n- Severe obesity, difficult airway, or baseline hypoxemia/hypercapnia\n- Significant pulmonary disease or elevated pulmonary complication risk\n- Lack of home supervision or long distance from care\n- Facility lacks overnight monitoring or rescue capability",
    "educationalObjective": "Recognize when an elevated risk estimate should change venue (ambulatory vs inpatient) or postoperative level of care."
  },
  {
    "id": "Core.12.6.11",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Risk stratification and ASA",
    "difficulty": "medium",
    "questionText": "A 68-year-old man is scheduled for an elective open right hemicolectomy for colon cancer. He has hypertension, type 2 diabetes managed with insulin, and a myocardial infarction 6 years ago treated with a stent. He denies chest pain, dyspnea, orthopnea, or syncope. He routinely climbs 2 flights of stairs while carrying groceries and plays doubles tennis without limitation. Medications include metoprolol, atorvastatin, insulin glargine, and aspirin. Vitals and exam are normal; ECG shows old inferior Q waves unchanged from prior. Creatinine is 1.0 mg/dL.\n\nWhich preoperative strategy is most appropriate to minimize perioperative cardiac risk?",
    "answers": [
      {
        "text": "Proceed to surgery without additional cardiac testing while continuing guideline-directed medical therapy",
        "isCorrect": true,
        "explanation": "Adequate functional capacity (≥4 METs) in an asymptomatic patient means additional testing is unlikely to change management; proceed while continuing β-blocker and statin and addressing antiplatelet management per surgical bleeding risk."
      },
      {
        "text": "Order a pharmacologic stress test (eg, dobutamine stress echocardiography) to screen for inducible ischemia",
        "isCorrect": false,
        "explanation": "Stress testing is reserved for patients with elevated risk and poor/unknown functional capacity when results would change management; it is not indicated with good functional capacity and no symptoms."
      },
      {
        "text": "Postpone surgery and refer for coronary angiography and possible revascularization",
        "isCorrect": false,
        "explanation": "Prophylactic coronary angiography/revascularization is not indicated solely to reduce perioperative risk; it is reserved for ACS or unstable symptoms suggestive of high-risk coronary disease."
      },
      {
        "text": "Obtain a transthoracic echocardiogram to reassess left ventricular function",
        "isCorrect": false,
        "explanation": "Preoperative echocardiography is indicated for new or worsening heart failure symptoms or significant valvular disease; it is not recommended for stable, asymptomatic patients with a remote MI."
      },
      {
        "text": "Check a preoperative high-sensitivity troponin to establish a baseline",
        "isCorrect": false,
        "explanation": "Biomarkers (BNP/NT-proBNP or troponin) may be reasonable in elevated-risk patients with poor/unknown functional capacity; they are not routinely indicated when functional capacity is adequate."
      }
    ],
    "didactic": "Functional capacity is a key determinant of perioperative cardiac risk and testing decisions. Tasks such as climbing 2 flights of stairs, brisk walking, and playing doubles tennis indicate ≥4 METs (often 5–7 METs), which correlates with a lower risk of major adverse cardiac events (MACE) and, importantly, a low likelihood that additional cardiac testing will change management.\n\nA stepwise approach (ACC/AHA):\n- Assess surgical urgency and active cardiac conditions (eg, ACS, decompensated heart failure, severe valvular disease). If present, treat first.\n- Estimate surgical risk (eg, intraperitoneal surgery is elevated risk) and clinical risk (eg, RCRI). This patient likely has an elevated risk by RCRI (high-risk surgery, ischemic heart disease, insulin therapy).\n- Evaluate functional capacity. If ≥4 METs and asymptomatic, proceed to surgery without further cardiac testing because test results are unlikely to alter perioperative management.\n- If functional capacity is <4 METs or unknown, consider noninvasive testing only if the results would change management (eg, lead to revascularization for standard indications or substantial changes in medical therapy or surgical timing).\n\nRoutine preoperative echocardiography is not recommended in stable, asymptomatic patients without new/worsening heart failure or significant valvular disease. Routine stress testing is not indicated with adequate METs. Biomarkers (BNP/NT-proBNP or high-sensitivity troponin) may aid risk stratification in elevated-risk patients with poor/unknown METs but are not routinely needed when METs are adequate. Prophylactic coronary angiography or revascularization is reserved for usual cardiology indications (eg, ACS), not simply to lower perioperative risk.\n\nIn this patient with good functional capacity and no symptoms, the best approach is to proceed to surgery while continuing guideline-directed medical therapy (eg, β-blocker, statin) and managing antiplatelet therapy based on bleeding and stent considerations.",
    "educationalObjective": "Use functional capacity (METs) to stratify perioperative risk and decide when further testing is unlikely to change management."
  },
  {
    "id": "Core.12.6.12",
    "category": "Perioperative Evaluation & Medicine",
    "subcategory": "Risk stratification and ASA",
    "difficulty": "hard",
    "questionText": "A 74-year-old man with hypertension, insulin-dependent diabetes, chronic kidney disease (eGFR 35 mL/min/1.73 m<sup>2</sup>), and prior MI (8 years ago) presents after a femoral neck fracture for urgent hemiarthroplasty within 24 h. He has no chest pain or dyspnea; functional capacity is <4 METs due to arthritis. Medications: amlodipine, insulin, atorvastatin. Vitals are stable; exam shows no volume overload. ECG shows sinus rhythm with old Q waves. Labs: hemoglobin 10.2 g/dL, creatinine 1.9 mg/dL. Given limited functional capacity, preoperative biomarkers are obtained: NT‑proBNP 1,100 pg/mL (lab ULN 125) and high-sensitivity troponin T 19 ng/L (99th percentile 14 ng/L). A repeat troponin 3 h later is 18 ng/L without dynamic rise.\n\nWhich perioperative strategy is most appropriate to apply based on these biomarker results?",
    "answers": [
      {
        "text": "Cancel surgery and obtain urgent coronary angiography due to the elevated troponin",
        "isCorrect": false,
        "explanation": "A small, non-dynamic troponin elevation without ischemic symptoms or ECG changes suggests chronic myocardial injury (common in CKD). Coronary angiography is not indicated absent ACS features."
      },
      {
        "text": "Delay surgery to obtain noninvasive stress testing because the NT‑proBNP is elevated",
        "isCorrect": false,
        "explanation": "In urgent hip fracture repair, delaying surgery for testing increases morbidity and mortality. Elevated NT‑proBNP identifies higher risk but does not mandate preoperative stress testing in the absence of unstable symptoms."
      },
      {
        "text": "Proceed to surgery with planned 48–72 h postoperative high-sensitivity troponin surveillance and continuous telemetry",
        "isCorrect": true,
        "explanation": "Elevated NT‑proBNP (≥~300 pg/mL) and preoperative hs‑troponin above the 99th percentile predict higher perioperative cardiac risk. Best practice is to proceed with urgent surgery while instituting postoperative troponin surveillance and telemetry to detect myocardial injury and guide management."
      },
      {
        "text": "Ignore the biomarkers and proceed without cardiac monitoring because chronic kidney disease explains the elevations",
        "isCorrect": false,
        "explanation": "Although CKD can chronically elevate NT‑proBNP and troponin, these biomarkers remain independently prognostic. Enhanced perioperative monitoring is warranted."
      },
      {
        "text": "Initiate high-dose β‑blocker immediately to target heart rate 60/min to mitigate myocardial injury",
        "isCorrect": false,
        "explanation": "Starting high-dose β‑blocker immediately preoperatively increases risk of stroke, bradycardia, and hypotension. If indicated, β‑blockers should be initiated and titrated over days to weeks; day-of-surgery initiation is not recommended."
      }
    ],
    "didactic": "Perioperative natriuretic peptides (BNP/NT‑proBNP) and high-sensitivity troponin are powerful adjuncts to identify patients at increased risk of myocardial injury and major adverse cardiac events after noncardiac surgery. Elevated NT‑proBNP (eg, ≥300 pg/mL) or BNP (≈92–100 pg/mL) signals elevated risk in patients with poor functional capacity undergoing intermediate-to-high risk surgery and should prompt risk communication, hemodynamic optimization, and postoperative surveillance rather than automatic cancellation or routine preoperative stress testing.\n\n- In urgent procedures (eg, hip fracture repair), delaying surgery for cardiac testing is associated with harm. Biomarkers refine risk but should not postpone time-sensitive operations in the absence of unstable cardiac conditions.\n- Preoperative hs‑troponin above the 99th percentile identifies higher risk, even when chronic (eg, CKD). A non-dynamic value without symptoms or ECG changes typically reflects chronic myocardial injury, not acute coronary syndrome. Prognostic value remains high; the clinical action is enhanced surveillance.\n- Recommended strategy for high-risk profiles (elevated NT‑proBNP and/or troponin): proceed with surgery while implementing 48–72 h postoperative hs‑troponin surveillance and continuous telemetry to detect myocardial injury after noncardiac surgery (MINS), which often occurs silently. Management focuses on optimizing oxygen supply–demand balance (avoid hypotension/tachycardia, treat anemia/hypoxemia, maintain MAP ≥65 mmHg) and continuing guideline-directed therapy (eg, statins). \n- β‑blockers should be continued if already prescribed, but initiating high-dose therapy on the day of surgery increases adverse events; if considered, start weeks prior with careful titration.\n\nBottom line: Elevated NT‑proBNP and modest preoperative troponin elevation (without dynamic change) identify a patient at high perioperative cardiac risk. For urgent surgery, the safest evidence-based response is to proceed while instituting postoperative hs‑troponin monitoring and telemetry to detect and treat MINS early.",
    "educationalObjective": "Use perioperative biomarkers (BNP/NT‑proBNP, troponin) as adjuncts to identify patients at higher cardiac risk."
  },
  {
    "id": "Core.7.1.1",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Catheters and acute pain pathways",
    "difficulty": "medium",
    "questionText": "A 72-year-old woman (BMI 35) with OSA on CPAP and diabetic peripheral neuropathy undergoes primary total knee arthroplasty under spinal anesthesia as part of an ERAS pathway with planned same-day ambulation. The surgeon requests effective opioid-sparing analgesia, but physical therapy notes baseline quadriceps strength 4/5 and emphasizes minimizing fall risk. Which postoperative regional analgesic plan best balances analgesia with preservation of quadriceps strength to facilitate early ambulation?\n\nWhich of the following is the most appropriate choice?",
    "answers": [
      {
        "text": "Periarticular infiltration alone without peripheral nerve blocks",
        "isCorrect": false,
        "explanation": "Local infiltration can reduce pain but is often insufficient as a sole strategy for early mobilization and opioid-sparing in high-risk patients with OSA."
      },
      {
        "text": "Continuous adductor canal catheter with 0.2% ropivacaine at 6 mL/h alone",
        "isCorrect": false,
        "explanation": "While quadriceps-sparing, an isolated adductor canal catheter may inadequately treat posterior knee pain after TKA, potentially increasing opioid use in an OSA patient."
      },
      {
        "text": "Continuous adductor canal catheter with 0.2% ropivacaine at 6 mL/h plus a single-shot IPACK block",
        "isCorrect": true,
        "explanation": "An adductor canal catheter preserves quadriceps strength while providing anterior/medial knee analgesia; combining with an IPACK targets posterior capsule pain without motor blockade, optimizing analgesia and ambulation."
      },
      {
        "text": "Single-shot femoral plus single-shot sciatic nerve blocks with 0.5% bupivacaine",
        "isCorrect": false,
        "explanation": "Adding a sciatic block may improve posterior knee analgesia but risks foot drop and further motor impairment; femoral block still weakens quadriceps, increasing fall risk."
      },
      {
        "text": "Continuous femoral nerve catheter with 0.2% ropivacaine at 8 mL/h",
        "isCorrect": false,
        "explanation": "Femoral catheters provide good analgesia but significantly weaken quadriceps, increasing fall risk and impairing early mobilization, especially problematic in patients with baseline weakness."
      }
    ],
    "didactic": "For total knee arthroplasty (TKA), the choice of peripheral nerve catheter should optimize analgesia while preserving motor function to reduce falls and enable early ambulation. A **femoral nerve block (FNB)** reliably decreases pain but commonly causes **quadriceps weakness**, impairing knee extension and increasing fall risk. In contrast, an **adductor canal block (ACB)** targets the saphenous nerve and articular branches within the adductor canal, largely sparing quadriceps motor fibers; although the nerve to vastus medialis may be variably affected, functional strength is better preserved than with FNB.\n\nPosterior knee pain after TKA is mediated by genicular branches from the tibial component of the sciatic nerve. An **IPACK (interspace between the popliteal artery and posterior capsule of the knee) block** provides posterior capsular analgesia without motor blockade of the tibial or common peroneal nerves, avoiding foot drop. Therefore, a **continuous ACB** (eg, ropivacaine 0.1%–0.2% at 5–10 mL/h) combined with a **single-shot IPACK** yields multimodal, motor-sparing coverage of anterior/medial and posterior knee pain.\n\nThis approach is particularly advantageous in patients with:\n- Baseline lower-extremity weakness or neuropathy (higher fall risk)\n- OSA, where **opioid-sparing** reduces risk of hypoventilation and desaturation (eg, improved O<sub>2</sub> reserve and reduced need for high FiO<sub>2</sub>)\n- ERAS pathways prioritizing same-day physical therapy and discharge\n\nComparatively, FNB catheters, even at lower concentrations, still reduce quadriceps strength and are associated with increased fall risk. Adding a sciatic block further increases motor impairment and can cause foot drop, hindering ambulation. Surgeon periarticular infiltration is valuable but is generally insufficient as a sole modality for opioid-sparing, early-mobility goals.\n\nThus, for TKA patients in whom fall risk is a key concern, prefer an **adductor canal catheter** over a femoral catheter and augment posterior coverage with an **IPACK** to maintain motor function while achieving robust analgesia.",
    "educationalObjective": "Balance motor block and fall risk by preferring adductor canal over femoral catheters when appropriate."
  },
  {
    "id": "Core.7.1.2",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Catheters and acute pain pathways",
    "difficulty": "hard",
    "questionText": "A 72-kg man undergoes total knee arthroplasty with an adductor canal catheter. Intraoperatively he received ropivacaine 0.5% 20 mL via the catheter and the surgeon infiltrated ropivacaine 0.2% 100 mL periarticularly. Postoperatively you plan a ropivacaine 0.2% infusion with patient-controlled 4 mL boluses (45-min lockout). Based on prior experience, he typically uses 12 boluses in the first 24 h. You also plan a 0.2% ropivacaine 10 mL top-up through the catheter at hour 8. To avoid exceeding the recommended 24-hour maximum cumulative ropivacaine dose, what is the highest basal infusion rate you can safely program?",
    "answers": [
      {
        "text": "6 mL/h",
        "isCorrect": false,
        "explanation": "Safe but not maximal (adds 288 mg from basal). This choice often reflects underestimating PCA/top-up doses or using an arbitrary safety margin rather than calculating the allowable basal from the 24 h cap."
      },
      {
        "text": "4 mL/h",
        "isCorrect": false,
        "explanation": "Overly conservative; this corresponds to 192 mg from basal infusion (2 mg/mL × 4 mL/h × 24 h). Some choose this by incorrectly applying lower daily caps (eg, bupivacaine’s ≤400 mg/24 h) to ropivacaine."
      },
      {
        "text": "7 mL/h",
        "isCorrect": true,
        "explanation": "Correct. Fixed ropivacaine: 0.5% 20 mL = 100 mg; 0.2% 100 mL = 200 mg; top-up 0.2% 10 mL = 20 mg; 12 PCA boluses × 4 mL × 2 mg/mL = 96 mg; total fixed = 416 mg. Remaining to the 24 h limit (770 mg) = 354 mg for basal. At 0.2% (2 mg/mL), 24 h basal dose = 48 × rate (mg); 354/48 ≈ 7.4, so the highest safe whole-step rate is 7 mL/h."
      },
      {
        "text": "8 mL/h",
        "isCorrect": false,
        "explanation": "Clearly exceeds the cap: basal adds 384 mg; total 416 + 384 = 800 mg. This reflects ignoring additive doses from boluses/top-up/infiltration."
      },
      {
        "text": "7.5 mL/h",
        "isCorrect": false,
        "explanation": "Too high. Basal would contribute 360 mg (2 mg/mL × 7.5 × 24), and total 416 + 360 = 776 mg, exceeding the 24 h recommended maximum."
      }
    ],
    "didactic": "Calculate cumulative local anesthetic exposure by converting concentration to mg/mL and summing all sources (bolus, infusion, infiltration). For percent solutions, mg/mL = % × 10, so ropivacaine 0.5% = 5 mg/mL and 0.2% = 2 mg/mL.\n\nStepwise for this patient:\n- Initial block: 0.5% 20 mL = 100 mg.\n- Surgical infiltration: 0.2% 100 mL = 200 mg.\n- Scheduled top-up: 0.2% 10 mL = 20 mg.\n- PCA use: 12 boluses × 4 mL × 2 mg/mL = 96 mg.\n- Fixed subtotal = 416 mg.\n- Ropivacaine’s recommended maximum cumulative adult dose over 24 h ≈ 770 mg (label-based). Remaining allowance for basal infusion = 770 − 416 = 354 mg.\n- Basal infusion dose over 24 h at 0.2% is 2 mg/mL × rate (mL/h) × 24 h = 48 × rate (mg). Solve 48 × rate ≤ 354 → rate ≤ 7.375 mL/h. The highest practical rate not exceeding the limit is 7 mL/h.\n\nCommon pitfalls:\n- Misconverting % to mg/mL (eg, treating 0.2% as 1 mg/mL) underestimates dose and risks LAST.\n- Ignoring additive contributions from surgeon infiltration, scheduled top-ups, or PCA boluses leads to exceeding the 24 h limit.\n- Applying bupivacaine’s more restrictive 24 h cap (≤400 mg) to ropivacaine is unnecessarily conservative for ropivacaine but appropriate when using bupivacaine.\n\nClinical nuances:\n- Toxicity risk is additive across amide local anesthetics; when multiple agents are used, sum total amide exposure.\n- Reduce maximums in patients with reduced clearance (eg, hepatic dysfunction, pregnancy, extremes of age) and adjust real-time for actual PCA use.\n- Programs should track delivered mL and mg to avoid exceeding daily limits and to respond promptly to early signs of local anesthetic systemic toxicity (eg, perioral numbness, tinnitus, agitation, seizures).",
    "educationalObjective": "Calculate 24-hour maximum local anesthetic dose from combined boluses and infusion to avoid toxicity."
  },
  {
    "id": "Core.7.1.3",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Catheters and acute pain pathways",
    "difficulty": "medium",
    "questionText": "You are programming ambulatory pumps for three continuous peripheral nerve catheters placed under ultrasound with excellent initial block and no intravascular signs. The service uses ropivacaine for all infusions with patient-controlled boluses. Patients are: (1) a 72-year-old with moderate COPD and OSA after arthroscopic rotator cuff repair with an interscalene catheter; (2) a 65-year-old after primary TKA with a femoral catheter who will start PT today; and (3) a healthy 40-year-old after ankle ORIF with a popliteal (sciatic) catheter, admitted overnight. Lockout intervals of 45–60 min are acceptable. Which combination of concentration and basal/bolus settings best balances analgesia with respiratory safety, fall risk mitigation, and local anesthetic systemic toxicity (LAST) avoidance across these catheters?",
    "answers": [
      {
        "text": "Interscalene: ropivacaine 0.15% at 6 mL/h, 6 mL q45 min; Femoral: ropivacaine 0.2% at 6 mL/h, 6 mL q60 min; Popliteal: ropivacaine 0.15% at 5 mL/h, 4 mL q60 min",
        "isCorrect": false,
        "explanation": "The femoral plan uses a higher concentration that increases quadriceps weakness and fall risk; interscalene settings are relatively aggressive for a patient with COPD/OSA."
      },
      {
        "text": "Interscalene: ropivacaine 0.1% at 2 mL/h, 2 mL q90 min; Femoral: ropivacaine 0.1% at 2 mL/h, 2 mL q90 min; Popliteal: ropivacaine 0.1% at 3 mL/h, 3 mL q90 min",
        "isCorrect": false,
        "explanation": "Very low basal and bolus volumes are likely to provide inadequate analgesia for all three catheters, especially the popliteal site with higher volume requirements."
      },
      {
        "text": "Interscalene: ropivacaine 0.2% at 4 mL/h, 2 mL q60 min; Femoral: ropivacaine 0.15% at 4 mL/h, 2 mL q45 min; Popliteal: ropivacaine 0.2% at 4 mL/h, 2 mL q60 min",
        "isCorrect": false,
        "explanation": "Bolus volumes are too small to provide meaningful patient-controlled rescue; popliteal basal is on the low side for ankle surgery, and interscalene concentration remains higher than necessary."
      },
      {
        "text": "Interscalene: ropivacaine 0.1% at 5 mL/h, 4 mL q60 min; Femoral: ropivacaine 0.1% at 5 mL/h, 4 mL q60 min; Popliteal: ropivacaine 0.2% at 7 mL/h, 5 mL q45 min",
        "isCorrect": true,
        "explanation": "Dilute ropivacaine and modest basal/bolus for interscalene and femoral limit respiratory compromise and falls, while a slightly higher-concentration/higher-flow popliteal provides reliable distal analgesia without excessive cumulative dose."
      },
      {
        "text": "Interscalene: ropivacaine 0.2% at 8 mL/h, 8 mL q30 min; Femoral: ropivacaine 0.2% at 8 mL/h, 8 mL q30 min; Popliteal: ropivacaine 0.2% at 5 mL/h, 3 mL q60 min",
        "isCorrect": false,
        "explanation": "High concentration and basal rates at the interscalene and femoral sites increase phrenic nerve paresis and quadriceps weakness with short lockout increasing cumulative dose and LAST risk."
      }
    ],
    "didactic": "Continuous peripheral nerve block (CPNB) dosing should match anatomic site, comorbidities, and functional goals while minimizing motor block and LAST. Ropivacaine is favored over bupivacaine for CPNB because it provides similar analgesia with less motor blockade and lower cardiotoxicity, allowing use of more dilute solutions.\n\n- Interscalene (shoulder): Use dilute local anesthetic and modest basal/bolus to limit cephalad spread and phrenic nerve blockade. Typical settings are ropivacaine 0.1–0.15% at 4–6 mL/h with 3–5 mL bolus and 60-min lockout. In COPD/OSA, err toward lower concentration and longer lockout to reduce dyspnea and hypoventilation risk.\n- Femoral (TKA): Prioritize quadriceps strength to reduce falls. Use ropivacaine 0.1–0.15% at 4–6 mL/h with small boluses (3–5 mL) and 45–60 min lockout. Higher concentrations (eg, 0.2%) and high basal rates increase motor weakness and fall risk; many centers now prefer adductor canal blocks for this reason.\n- Popliteal (sciatic): Distal distribution and larger tissue volume often require a slightly higher concentration/flow to maintain analgesia for ankle/foot surgery. Common settings are ropivacaine 0.15–0.2% at 6–8 mL/h with 4–6 mL boluses and 45–60 min lockout.\n\nCumulative dose should remain within safe ranges. Example daily totals for the regimen in the correct answer: interscalene 0.1% at 5 mL/h ≈ 5 mg/h (120 mg/day), femoral 0.1% at 5 mL/h ≈ 120 mg/day, and popliteal 0.2% at 7 mL/h ≈ 14 mg/h (336 mg/day)—all reasonable in adults without hepatic impairment, while allowing patient-controlled boluses with conservative lockouts. Short lockouts (eg, 30 min) and large boluses (≥6–8 mL) increase run time and systemic exposure without clear benefit. Always reassess for dyspnea (interscalene), quadriceps weakness/falls (femoral), and signs of LAST; adjust basal rate downward before concentration changes when motor effects are limiting.",
    "educationalObjective": "Choose local anesthetic concentration and basal/bolus settings for interscalene, femoral, and popliteal catheters."
  },
  {
    "id": "Core.7.1.4",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Catheters and acute pain pathways",
    "difficulty": "hard",
    "questionText": "A 72-year-old woman undergoes open reduction and internal fixation of an acetabular fracture. For postoperative analgesia, a continuous lumbar plexus (psoas compartment) catheter is placed and infused with ropivacaine 0.2% at 6 mL/h. She has atrial fibrillation normally treated with apixaban 5 mg twice daily; her last dose was 4 days preoperatively. Current labs: Hgb 11.2 g/dL, platelets 230 ×10<sup>9</sup>/L, creatinine 1.6 mg/dL (CrCl ≈35 mL/min). The orthopedic team requests resumption of apixaban this evening for stroke prophylaxis. She has excellent analgesia, a soft, nontender catheter site, and no neurologic deficits.\n\nWhich management most appropriately balances analgesia with anticoagulation safety in this patient?",
    "answers": [
      {
        "text": "Restart apixaban this evening and plan lumbar plexus catheter removal tomorrow morning (≈12 hours after the dose).",
        "isCorrect": false,
        "explanation": "Direct oral factor Xa inhibitors are contraindicated while an indwelling neuraxial or deep plexus catheter is in place; giving apixaban before catheter removal markedly increases risk of occult retroperitoneal hematoma."
      },
      {
        "text": "Continue the catheter and begin low-dose subcutaneous UFH prophylaxis now; remove the catheter when analgesia is no longer needed, then start apixaban ≥6 hours after catheter removal.",
        "isCorrect": true,
        "explanation": "Deep plexus blocks should follow neuraxial anticoagulation precautions. Low-dose SC UFH is compatible with indwelling catheters. The first DOAC dose should be delayed until at least 6 hours after catheter removal to minimize hematoma risk."
      },
      {
        "text": "Restart apixaban at a reduced dose (2.5 mg twice daily) while the catheter remains in place due to impaired renal function.",
        "isCorrect": false,
        "explanation": "Dose reduction does not mitigate the contraindication of DOAC therapy with an indwelling neuraxial/deep plexus catheter; bleeding risk remains unacceptable regardless of dose."
      },
      {
        "text": "Remove the catheter now and administer the first dose of apixaban immediately after removal.",
        "isCorrect": false,
        "explanation": "Following catheter removal, a minimum 6-hour interval before the first apixaban dose is recommended to reduce bleeding into the deep, noncompressible psoas compartment."
      },
      {
        "text": "Switch to enoxaparin 40 mg once daily now, keep the catheter in place, remove it in 2 hours, and resume enoxaparin immediately after removal.",
        "isCorrect": false,
        "explanation": "With LMWH, catheters should be removed ≥12 hours after the last prophylactic dose and the next dose delayed ≥4 hours; removing 2 hours after dosing and immediately redosing increases hematoma risk."
      }
    ],
    "didactic": "Deep plexus/peripheral blocks in noncompressible locations (eg, lumbar plexus/psoas compartment, proximal sciatic, paravertebral) carry bleeding risks similar to neuraxial techniques. A retroperitoneal hematoma after a lumbar plexus catheter can be occult and catastrophic. Therefore, **apply neuraxial anticoagulation timing to these deep blocks**, especially when an indwelling catheter is present.\n\nKey timing principles (ASRA consensus-based recommendations):\n- **Direct oral factor Xa inhibitors (apixaban, rivaroxaban, edoxaban):** Avoid while a neuraxial or deep plexus catheter is in place. If a catheter is present, remove it first and delay the initial DOAC dose by **≥6 hours**. If a DOAC dose was given unexpectedly, delay catheter removal for ~26–30 hours or check a calibrated anti–factor Xa level.\n- **Dabigatran:** Similar concept; renal function heavily influences timing. Catheters should be removed prior to dosing; allow ≥6 hours before the first postoperative dose (longer preprocedure holds with reduced CrCl).\n- **LMWH prophylaxis (eg, enoxaparin 40 mg daily):** Catheters may remain in place with once-daily dosing; remove the catheter **≥12 hours after** the last prophylactic dose and delay the next dose **≥4 hours**. Avoid indwelling catheters with BID or therapeutic LMWH regimens.\n- **Low-dose SC UFH (eg, 5,000 units q8–12h):** Compatible with indwelling catheters. Remove the catheter **4–6 hours after** the last dose; the next UFH dose may follow shortly thereafter.\n\nIn this patient with a continuous lumbar plexus catheter, **do not resume a DOAC while the catheter is in situ**. Maintain thromboprophylaxis with low-dose SC UFH (and mechanical measures) until the catheter is no longer needed; then remove the catheter and wait **≥6 hours** before administering the first apixaban dose. Common pitfalls include restarting DOACs with a catheter in place, ignoring the 6-hour post-removal window, and misapplying LMWH timing (eg, removing catheters too soon after a dose).",
    "educationalObjective": "Coordinate regional techniques with anticoagulation timing and deep block bleeding risk to enhance safety."
  },
  {
    "id": "Core.7.1.5",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Catheters and acute pain pathways",
    "difficulty": "medium",
    "questionText": "A 58-year-old man is POD 1 after open sigmoid colectomy under general anesthesia with a thoracic epidural placed at T8–9. Loss of resistance occurred at 6 cm; the catheter was threaded to 12 cm at the skin. The infusion (bupivacaine 0.1% with hydromorphone 5 mcg/mL at 8 mL/h) has been running continuously. Overnight analgesia was adequate. This morning, pain is 8/10 over the right upper abdomen, while pinprick is decreased on the left from T4–T12 but normal on the right. Motor strength is intact. The epidural site is clean without erythema or tenderness. The pump displays normal line pressure, and a 5 mL clinician bolus injected easily but only deepened the left-sided block.\n\nWhich of the following is the most appropriate next step to restore effective epidural analgesia?",
    "answers": [
      {
        "text": "Withdraw the epidural catheter 1–2 cm and reassess after a test dose and incremental bolus",
        "isCorrect": true,
        "explanation": "Unilateral block after threading 6 cm suggests lateral migration; withdrawing 1–2 cm recenters the tip. A test dose (eg, 3 mL 1.5% lidocaine with epinephrine 1:200,000) confirms placement before an incremental bolus to reestablish bilateral spread."
      },
      {
        "text": "Place the patient in the right lateral decubitus position for 30 minutes",
        "isCorrect": false,
        "explanation": "Positioning has minimal and unreliable influence on epidural spread compared with subarachnoid block and is not definitive therapy for a unilateral epidural block."
      },
      {
        "text": "Replace the epidural catheter at a different interspace now",
        "isCorrect": false,
        "explanation": "Immediate replacement is unnecessary when a high-probability correctable cause (excessive threading with lateral migration) can be addressed by withdrawing the catheter."
      },
      {
        "text": "Administer 10 mL of 2% lidocaine with epinephrine 1:200,000 through the catheter",
        "isCorrect": false,
        "explanation": "A large, rapid thoracic epidural bolus risks high block and hypotension; if unrecognized intrathecal or intravascular migration occurred, severe toxicity could result. It also does not fix lateral malposition."
      },
      {
        "text": "Increase the epidural infusion rate from 8 to 12 mL/h",
        "isCorrect": false,
        "explanation": "Raising the rate increases local anesthetic dose and adverse effects without correcting a malpositioned tip; unilateral spread will likely persist."
      }
    ],
    "didactic": "Unilateral thoracic epidural analgesia is most commonly due to catheter malposition, particularly when the tip is threaded >5 cm into the epidural space. The catheter can course laterally through an intervertebral foramen, producing a hemisegmental block with ipsilateral sympathectomy and contralateral pain. In this scenario, prior good analgesia, an asymmetric sensory level (left T4–T12), stable hemodynamics, a clean site, normal pump pressures, and easy injection argue against occlusion or infection and point to lateral migration.\n\nThe most appropriate intervention is to withdraw the catheter 1–2 cm to recenter the tip, then confirm safety and efficacy:\n- Give a **test dose** (eg, 3 mL 1.5% lidocaine with epinephrine 1:200,000) to screen for intrathecal or intravascular placement (look for rapid motor block or tachycardia, respectively).\n- If negative, administer an **incremental bolus** of local anesthetic (eg, 5–8 mL of dilute bupivacaine or lidocaine) to reestablish bilateral spread, then resume the basal infusion.\n\nEscalating the rate or concentration does not address malposition and increases risk of hypotension, motor block, and local anesthetic systemic toxicity. Large, rapid thoracic boluses are hazardous and should be avoided unless placement is verified. Patient positioning has limited impact on epidural distribution and is unreliable as definitive management.\n\nWhen troubleshooting catheter-related analgesia failure, systematically assess:\n- **Occlusion:** high injection resistance, pump occlusion alarms, or subcutaneous swelling → stop infusion, gentle flush, reposition/replace if unresolved.\n- **Infection:** erythema, warmth, tenderness, or fever → stop infusion, remove catheter; consider cultures and antibiotics.\n- **Dislodgement/migration:** change in block level, unilateral block, or loss of effect after movement → adjust depth (withdraw 1–2 cm) and reassess; replace if ineffective. This structured approach restores function while minimizing risk.",
    "educationalObjective": "Diagnose catheter-related complications such as dislodgement, occlusion, or local infection and manage promptly."
  },
  {
    "id": "Core.7.1.6",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Catheters and acute pain pathways",
    "difficulty": "easy",
    "questionText": "A 45-year-old man undergoes outpatient ankle open reduction and internal fixation with a continuous popliteal sciatic nerve catheter placed preoperatively. He is discharged home with an elastomeric pump infusing ropivacaine 0.2% at 6 mL/h with a 4 mL bolus available every 60 minutes. During discharge teaching, he asks what problems should prompt him to contact the anesthesia team urgently.\n\nWhich instruction best addresses red flags that warrant immediate contact while using an ambulatory peripheral nerve catheter?",
    "answers": [
      {
        "text": "Remove the water-resistant dressing before showering so the site can air dry afterward.",
        "isCorrect": false,
        "explanation": "The catheter site should be kept dry and covered; do not remove the dressing until instructed or at planned catheter removal."
      },
      {
        "text": "If you notice ringing in your ears, a metallic taste, or circumoral numbness, stop the infusion and call the anesthesia service immediately.",
        "isCorrect": true,
        "explanation": "These are early signs of local anesthetic systemic toxicity (LAST); stopping the infusion and seeking urgent help can prevent progression to seizures or cardiac toxicity."
      },
      {
        "text": "It is safe to bear weight without assistance as long as the knee feels stable.",
        "isCorrect": false,
        "explanation": "Sciatic block impairs sensation and proprioception, increasing fall risk; use assistance/orthosis and protect the limb until the block resolves."
      },
      {
        "text": "Use a heating pad to keep the numb foot warm during the first 24 hours.",
        "isCorrect": false,
        "explanation": "Heat on an insensate limb risks thermal injury; patients should avoid heat/ice on a numb extremity."
      },
      {
        "text": "If pain increases, double the basal infusion rate on the pump to catch up.",
        "isCorrect": false,
        "explanation": "Patients should not change basal rates; use prescribed boluses and adjunct analgesics, and contact the service for uncontrolled pain to avoid overdose and toxicity."
      }
    ],
    "didactic": "Ambulatory continuous peripheral nerve blocks (CPNBs) provide effective analgesia while reducing opioids, but safe home use requires clear education on pump operation, limb protection, catheter care, and red flags. Patients should understand that local anesthetic infusion can cause systemic toxicity; early neurologic symptoms include perioral numbness, metallic taste, tinnitus, dizziness, and agitation, which can progress to seizures and cardiovascular collapse. If these occur, patients should immediately stop/clamp the infusion and contact the anesthesia team or emergency services; severe symptoms (seizure, syncope) warrant calling 911.\n\nKey home instructions include:\n- Pump operation: Do not alter basal rate. Use the patient-controlled bolus as prescribed. If pain remains uncontrolled, add scheduled multimodal oral analgesics and call the service rather than increasing the basal rate.\n- Limb protection: The insensate limb is injury-prone. Avoid heat/ice on numb skin, protect with splints/orthoses, use assistance for ambulation, and follow weight-bearing restrictions to reduce falls. Elevate and visually check the limb rather than relying on sensation.\n- Catheter care: Keep the site clean/dry; avoid submersion (no baths/pools). Shower with the site covered; reinforce, do not remove, the dressing unless instructed. Inspect daily for erythema, swelling, drainage, or dislodgement.\n- Red flags to report: Signs of LAST (tinnitus, metallic taste, circumoral numbness), rapidly worsening pain despite boluses, pump malfunction/alarms, signs of infection (fever, spreading erythema, purulence), new dyspnea/voice change with interscalene catheters, or expanding hematoma.\n\nProviding a simple action plan—stop the infusion for suspected toxicity, do not change pump settings, protect the limb, and call the anesthesia service—improves safety and outcomes with ambulatory CPNBs.",
    "educationalObjective": "Educate patients on ambulatory catheter care, pump operation, limb protection, and red flags warranting contact."
  },
  {
    "id": "Core.7.1.7",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Catheters and acute pain pathways",
    "difficulty": "medium",
    "questionText": "A 62-year-old man (BMI 34) with severe OSA on nightly CPAP, CAD with a remote drug-eluting stent on aspirin 81 mg/day, and CKD stage 3 (Cr 1.9 mg/dL, eGFR 40 mL/min/1.73 m<sup>2</sup>) is scheduled for an open sigmoid colectomy via midline laparotomy under an ERAS colorectal pathway. Platelets are 230 ×10<sup>9</sup>/L and INR is 1.0. The surgeon emphasizes early feeding and ambulation and wants to minimize ileus and opioid-related respiratory events. The patient is opioid-naïve and has normal liver function.\n\nWhich perioperative analgesic strategy best aligns with ERAS principles while addressing this patient’s risk profile?",
    "answers": [
      {
        "text": "Place a thoracic epidural (T8–T10) for local anesthetic infusion postoperatively and schedule acetaminophen; avoid gabapentinoids and NSAIDs; use opioid rescue only as needed while continuing aspirin.",
        "isCorrect": true,
        "explanation": "For open colorectal surgery, thoracic epidural local anesthetic provides superior opioid-sparing analgesia and reduces ileus; low-dose aspirin is not a contraindication to neuraxial techniques. Acetaminophen is core ERAS therapy, while NSAIDs (CKD) and gabapentinoids (OSA sedation) should be avoided."
      },
      {
        "text": "Place bilateral continuous quadratus lumborum catheters with ropivacaine and schedule acetaminophen 4 g/day plus ketorolac 15 mg q6h; avoid an epidural due to daily aspirin use.",
        "isCorrect": false,
        "explanation": "QL catheters have less robust evidence than thoracic epidural for open laparotomy. Low-dose aspirin is not a contraindication to neuraxial anesthesia, and NSAIDs are inadvisable in CKD stage 3."
      },
      {
        "text": "Administer intrathecal morphine 300 μg preoperatively and schedule gabapentin 600 mg q8h with ketorolac 15 mg q6h; avoid acetaminophen.",
        "isCorrect": false,
        "explanation": "Neuraxial opioids increase risk of delayed respiratory depression in OSA, and gabapentinoids further worsen sedation. NSAIDs are inappropriate in CKD, and omitting acetaminophen conflicts with ERAS multimodal care."
      },
      {
        "text": "Avoid regional techniques; provide hydromorphone PCA with scheduled gabapentin; avoid NSAIDs and acetaminophen to protect renal and hepatic function.",
        "isCorrect": false,
        "explanation": "Opioid-centric strategies contradict ERAS goals and increase OSA-related risk. Routine gabapentinoids are discouraged, and acetaminophen is safe with normal liver function and beneficial for opioid-sparing."
      },
      {
        "text": "Perform bilateral single-shot subcostal TAP blocks, schedule ibuprofen 600 mg q6h, and provide PCA oxycodone; do not give acetaminophen to avoid hepatotoxicity.",
        "isCorrect": false,
        "explanation": "Single-shot TAP is often insufficient for open midline incisions compared with thoracic epidural. Nonselective NSAIDs are risky in CKD, and withholding acetaminophen removes a safe, foundational ERAS adjunct."
      }
    ],
    "didactic": "Enhanced Recovery After Surgery (ERAS) pathways emphasize multimodal, opioid-sparing analgesia tailored to procedure and patient risk. For open colorectal surgery via midline laparotomy, a thoracic epidural with local anesthetic is preferred because it provides superior dynamic analgesia, reduces systemic opioid requirements, and is associated with decreased postoperative ileus and earlier return of bowel function.\n\nKey considerations for this patient:\n- OSA: Avoid long-acting neuraxial opioids (eg, intrathecal morphine) and minimize systemic opioids to reduce risk of late respiratory depression. Epidural local anesthetic infusions deliver excellent pain control without neuraxial opioids.\n- Antiplatelet therapy: Per ASRA guidance, low-dose aspirin alone is not a contraindication to neuraxial techniques and does not require timing adjustments for epidural placement or removal.\n- CKD stage 3: Avoid nonselective NSAIDs (eg, ketorolac, ibuprofen) due to renal vasoconstriction and potential worsening of kidney function. If any NSAID is considered, COX-2–selective agents may be relatively safer but still warrant caution and surgeon input given concerns about anastomotic healing.\n- Gabapentinoids: Routine perioperative use is discouraged in ERAS due to limited incremental analgesia and increased sedation, dizziness, and respiratory events—particularly problematic in OSA.\n- Acetaminophen: A foundational ERAS component that is safe in CKD with normal hepatic function; scheduled dosing provides consistent opioid-sparing benefit.\n\nAlternatives when epidural is contraindicated include continuous abdominal wall catheters (eg, TAP/QL) and intraperitoneal or wound infiltration, though evidence for open midline incisions is generally less robust than for thoracic epidural. Intraoperative IV lidocaine infusion can be considered in open abdominal surgery to reduce ileus and opioid use; monitor for toxicity and tailor to comorbidities. Aligning the plan with patient risks and surgical approach—thoracic epidural local anesthetic plus acetaminophen and avoidance of NSAIDs and gabapentinoids—best meets ERAS goals in this case.",
    "educationalObjective": "Implement ERAS-aligned acute pain pathways tailored to procedure and patient risk factors."
  },
  {
    "id": "Core.7.1.8",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Catheters and acute pain pathways",
    "difficulty": "easy",
    "questionText": "A 68-year-old man on postoperative day 1 after total knee arthroplasty has an ultrasound-guided adductor canal catheter infusing ropivacaine 0.2% at 8 mL/h. Despite scheduled acetaminophen 1 g q6h and oxycodone 10 mg q4h PRN (40 mg used in the last 24 h), his pain is 7/10, worst with movement. He has obstructive sleep apnea (uses CPAP), CKD stage 3 (creatinine 2.0 mg/dL; baseline 1.9), hypertension, and no psychiatric history. Vitals: BP 130/75 mmHg, HR 62 bpm, RR 14/min, SpO<sub>2</sub> 95% on 2 L/min O<sub>2</sub> by nasal cannula. Exam shows decreased sensation over the medial calf with quadriceps strength 4/5; pain is primarily posterior knee. LFTs are normal; he takes aspirin 81 mg daily.\n\nWhich addition to this multimodal regimen is most appropriate to reduce opioid consumption while minimizing risk?",
    "answers": [
      {
        "text": "Initiate a low-dose IV ketamine infusion at 0.1 mg/kg/h for 24–48 h",
        "isCorrect": true,
        "explanation": "Subanesthetic ketamine (0.1–0.3 mg/kg/h) provides opioid-sparing analgesia without respiratory depression, is safe in CKD, and is well suited for an OSA patient already on acetaminophen with limited regional coverage of posterior knee pain."
      },
      {
        "text": "Start gabapentin 600 mg PO q8h",
        "isCorrect": false,
        "explanation": "High-dose gabapentin increases sedation and respiratory depression risk, particularly in OSA and when combined with opioids; it also requires renal dose adjustment."
      },
      {
        "text": "Begin dexmedetomidine infusion 0.2–0.4 μg/kg/h on the surgical ward",
        "isCorrect": false,
        "explanation": "Dexmedetomidine can be opioid-sparing but often requires monitored/ICU settings and may cause bradycardia and hypotension; its analgesic effect alone is modest in this context."
      },
      {
        "text": "Add ketorolac 15 mg IV q6h for 48 h",
        "isCorrect": false,
        "explanation": "NSAIDs reduce opioids but are relatively contraindicated in CKD stage 3 due to risk of worsened renal function and bleeding; safer alternatives should be used."
      },
      {
        "text": "Increase the adductor canal catheter rate to 12 mL/h",
        "isCorrect": false,
        "explanation": "Adductor canal blocks primarily cover anteromedial knee; posterior knee pain is typically not improved by higher rates and increased infusion risks motor impairment and local anesthetic systemic toxicity."
      }
    ],
    "didactic": "Multimodal analgesia strategically combines nonopioid agents to target different pain pathways and reduce opioid requirements. Selection should be individualized to comorbidities and the type of surgical pain. In total knee arthroplasty, adductor canal catheters primarily cover anteromedial knee pain; persistent posterior knee pain often reflects sciatic/popliteal and obturator contributions. When regional coverage is incomplete, systemic adjuncts become critical.\n\n- Acetaminophen: Foundation therapy (eg, 1 g q6h; daily max 3–4 g depending on age/liver status). Safe in CKD and OSA, with minimal adverse effects.\n- NSAIDs (eg, ketorolac): Potent opioid-sparing agents but reduce renal prostaglandin synthesis and can worsen kidney function; avoid or use cautiously in CKD stage ≥3. Also increase bleeding and GI risk.\n- Gabapentinoids: May modestly reduce opioid use, but benefits are inconsistent. They require renal dose adjustment and increase sedation/respiratory depression risk, especially in OSA and when combined with opioids; start low (eg, gabapentin 100–300 mg qHS) if chosen.\n- α<sub>2</sub>-agonists (clonidine, dexmedetomidine): Provide analgesic-sparing effects but can cause bradycardia and hypotension. Dexmedetomidine infusions typically require close monitoring; oral clonidine is limited by hemodynamics.\n- Ketamine: A subanesthetic NMDA antagonist (eg, 0.1–0.3 mg/kg/h, with or without a small bolus) that reduces central sensitization, hyperalgesia, and opioid tolerance. It is opioid-sparing without causing respiratory depression, making it advantageous in OSA. It does not require dose adjustment in CKD. Monitor for psychomimetic effects and sympathetic stimulation; low-dose infusions are generally well tolerated.\n\nIn this patient with OSA, CKD stage 3, and residual posterior knee pain despite an adductor canal catheter and acetaminophen, adding a low-dose ketamine infusion best reduces opioid use while minimizing renal, hemodynamic, and respiratory risks.",
    "educationalObjective": "Integrate multimodal analgesia (acetaminophen, NSAIDs, gabapentinoids, alpha-2 agonists, ketamine) to reduce opioid use."
  },
  {
    "id": "Core.7.1.9",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Catheters and acute pain pathways",
    "difficulty": "medium",
    "questionText": "A 62-year-old man on postoperative day 0 after primary total knee arthroplasty has an ultrasound-confirmed adductor canal catheter infusing 0.2% ropivacaine at 6 mL/h with a 5 mL patient-controlled bolus option. He reports severe posterior knee pain (8/10) despite a recent catheter bolus. Exam shows decreased cold sensation over the medial leg to the ankle, intact dorsiflexion/plantarflexion, soft compartments, and normal distal pulses. The dressing is dry; the pump is functioning without alarms. He has received acetaminophen but no NSAID due to CKD stage 3. Which intervention is the most appropriate next step to manage his breakthrough pain while preserving motor function?\n\n",
    "answers": [
      {
        "text": "Initiate a hydromorphone PCA without additional regional anesthesia",
        "isCorrect": false,
        "explanation": "Systemic opioids can reduce pain but do not specifically target posterior knee innervation and increase adverse effects; a targeted rescue block is preferred."
      },
      {
        "text": "Ultrasound-guided IPACK block with 20 mL 0.25% bupivacaine",
        "isCorrect": true,
        "explanation": "IPACK targets the popliteal plexus (tibial/common peroneal articular branches) responsible for posterior knee pain, complements an adductor canal catheter, and preserves foot motor function."
      },
      {
        "text": "Perform a femoral nerve block to augment medial knee coverage",
        "isCorrect": false,
        "explanation": "A femoral block duplicates saphenous coverage and increases quadriceps weakness without treating posterior knee pain."
      },
      {
        "text": "Replace the adductor canal catheter and restart 0.2% ropivacaine at 6 mL/h",
        "isCorrect": false,
        "explanation": "The catheter appears functional (appropriate sensory changes, bolus delivered); replacement does not address posterior knee pain outside the catheter’s coverage."
      },
      {
        "text": "Increase the adductor canal basal infusion from 6 to 10 mL/h",
        "isCorrect": false,
        "explanation": "Raising the basal rate risks proximal spread with quadriceps weakness and increases systemic toxicity risk while failing to address posterior knee innervation."
      }
    ],
    "didactic": "Effective management of breakthrough pain with continuous peripheral nerve catheters requires confirming catheter function, localizing the pain to the involved dermatomes/articular branches, and deploying targeted rescue techniques or systemic adjuncts before escalating infusion rates. After total knee arthroplasty, an adductor canal catheter anesthetizes the saphenous nerve (medial knee/leg) while largely sparing quadriceps strength. Persistent posterior knee pain commonly arises from articular branches of the tibial and common peroneal nerves that form the popliteal plexus. An ultrasound-guided IPACK block deposits local anesthetic between the popliteal artery and posterior capsule to cover these branches, providing posterior analgesia while preserving foot motor function.\n\nIn this scenario, the catheter is likely functioning (medial sensory loss, working pump, recent bolus), and the pain is in a distribution not covered by the adductor canal. Increasing the basal rate would not reliably treat posterior innervation and may promote proximal spread to the femoral nerve, increasing quadriceps weakness and fall risk, while also raising local anesthetic systemic toxicity risk. Replacing a functional catheter is unnecessary and nonbeneficial. Although systemic opioids can be used as adjuncts, a targeted rescue block offers superior, site-specific analgesia with fewer systemic effects.\n\nA practical approach includes:\n- Verify catheter/pump function and assess block spread with sensory testing.\n- Map pain to nerve distributions; consider wound/compartment assessment when indicated.\n- Use rescue blocks to cover uncovered territories (eg, IPACK for posterior knee, popliteal sciatic for lateral/posterior foot if appropriate, distal ulnar block for ulnar-sparing after interscalene).\n- Add multimodal systemic adjuncts (eg, acetaminophen, NSAIDs if safe, low-dose ketamine, gabapentinoids), reserving infusion rate increases for refractory cases after targeted measures.\n\nFor TKA, pairing an adductor canal catheter with an IPACK or posterior capsule infiltration optimizes analgesia while preserving early mobilization.",
    "educationalObjective": "Manage breakthrough pain and catheter failure with rescue blocks or systemic adjuncts before increasing infusion rates."
  },
  {
    "id": "Core.7.1.10",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Catheters and acute pain pathways",
    "difficulty": "medium",
    "questionText": "A 65-year-old man undergoing ankle ORIF receives a popliteal sciatic catheter under ultrasound guidance. He is sedated with midazolam and fentanyl and takes metoprolol for hypertension (HR 56 bpm, BP 132/76 mmHg). During the initial catheter bolus, an inline manometer shows an opening injection pressure of 25 psi. Aspiration is negative, ultrasound shows little to no perineural spread, and the patient reports deep calf pressure but no paresthesia. You plan to use an epinephrine-containing test dose. \n\nWhich is the best next step to safely proceed and reduce intraneural and intravascular injection risk?",
    "answers": [
      {
        "text": "Stop injection; withdraw the catheter in 1–2 mm steps until opening pressure ≤15 psi with circumferential perineural spread, then administer 3 mL 1.5% lidocaine with epinephrine 1:200,000 while monitoring for an SBP rise ≥15 mmHg or ECG T-wave changes; proceed with incremental dosing and frequent aspiration.",
        "isCorrect": true,
        "explanation": "Reducing injection pressure to ≤15 psi with visible perineural spread minimizes intraneural risk; an epinephrine test dose with BP/ECG endpoints (rather than HR in a β-blocked patient) helps detect intravascular injection before incremental dosing."
      },
      {
        "text": "Remove the catheter and proceed under general anesthesia; ultrasound alone obviates the need for a test dose.",
        "isCorrect": false,
        "explanation": "Catheters can often be salvaged by minor repositioning guided by injection pressure and ultrasound. Ultrasound does not eliminate the need for intravascular detection with a test dose."
      },
      {
        "text": "Flush the catheter briskly with saline to relieve resistance, avoid epinephrine due to β-blockade, and proceed with the full bolus if no paresthesia occurs.",
        "isCorrect": false,
        "explanation": "Forcing saline against high resistance may worsen intraneural injection. Avoiding an epinephrine test dose removes a key safety check for intravascular placement."
      },
      {
        "text": "Continue a slow injection under ultrasound despite 25 psi, then give 3 mL 1.5% lidocaine with epinephrine 1:200,000 and monitor for a ≥10 bpm HR increase.",
        "isCorrect": false,
        "explanation": "High opening pressure suggests intrafascicular/intraneural needle/catheter position; continuing to inject risks nerve injury. β-blockade blunts the HR response to epinephrine."
      },
      {
        "text": "Inject 1–2 mL local anesthetic to “open the space,” advance the catheter, and rely on pain/paresthesia to exclude intraneural injection.",
        "isCorrect": false,
        "explanation": "Even small volumes at high pressure can be intrafascicular and harmful, and sedation diminishes reliable paresthesia reporting; pressure monitoring and ultrasound spread are safer guides."
      }
    ],
    "didactic": "High injection pressures during peripheral nerve block injection are a red flag for intrafascicular/intraneural placement. An opening injection pressure >15 psi is strongly associated with intrafascicular injection; injection should be stopped and the needle/catheter repositioned before proceeding. The safest strategy is to obtain a low-pressure injection (≤15 psi) with ultrasound confirmation of a perineural, circumferential spread rather than nerve expansion.\n\nSafety steps integrate multiple modalities:\n- Stop when pressure is high, there is nerve swelling, or the patient reports pain/paresthesia. Sedation blunts symptoms, so objective cues (pressure, ultrasound) are critical.\n- Reposition in small increments (eg, withdraw 1–2 mm) until opening pressure ≤15 psi and low-resistance flow produces a perineural halo on ultrasound.\n- Use incremental dosing (3–5 mL aliquots) with frequent aspiration; negative aspiration reduces but does not eliminate intravascular risk.\n- Administer an epinephrine-containing test dose to detect intravascular injection. A common regimen is 3 mL of 1.5% lidocaine with epinephrine 1:200,000 (5 μg/mL), delivering 15 μg epinephrine.\n- Interpret test dose based on patient physiology: β-blockade blunts the usual ≥10 bpm HR rise, so rely on an SBP increase ≥15 mmHg or ECG T-wave amplitude changes. Monitor continuously and wait 30–60 seconds before further dosing.\n\nCombining low-pressure injection, ultrasound visualization of spread, frequent aspiration, and an epinephrine test dose tailored to the patient’s medications markedly reduces the risks of intraneural injury and intravascular local anesthetic delivery. Avoid attempts to “force open” a space with saline or local anesthetic when resistance is high, as even small volumes at high pressure can cause nerve injury.",
    "educationalObjective": "Measure injection pressures and use aspiration and test doses to reduce intravascular or intraneural placement risk."
  },
  {
    "id": "Core.7.1.11",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Catheters and acute pain pathways",
    "difficulty": "easy",
    "questionText": "A 68-year-old man with diabetes is scheduled for ankle ORIF. You plan a continuous popliteal sciatic catheter with an anticipated 5-day dwell. In your block area, the current workflow uses clean gloves, povidone–iodine prep with immediate insertion, and a gauze/tape dressing changed daily. To reduce catheter-related infection while maintaining effective analgesia, which bundled practice should be adopted?",
    "answers": [
      {
        "text": "Administer daily prophylactic cefazolin while the catheter is in place to suppress skin flora.",
        "isCorrect": false,
        "explanation": "Routine prophylactic antibiotics for peripheral nerve catheters are not recommended and do not reliably prevent catheter-related infections; they add adverse-effect and resistance risks."
      },
      {
        "text": "Switch to povidone–iodine prep and continue daily gauze/tape dressing changes to maintain a dry site.",
        "isCorrect": false,
        "explanation": "Povidone–iodine is inferior to chlorhexidine–alcohol for skin antisepsis, and daily dressing changes increase manipulation and contamination risk."
      },
      {
        "text": "Exchange the catheter over a guidewire every 72 hours to prevent colonization from progressing to infection.",
        "isCorrect": false,
        "explanation": "Routine exchange increases manipulation and contamination; removal when no longer needed is preferred over scheduled exchanges."
      },
      {
        "text": "Implement maximum sterile barrier precautions and 2% chlorhexidine in 70% isopropyl alcohol skin prep (allow to dry), secure/tunnel the catheter, and use a sterile transparent occlusive dressing with planned changes every 5–7 days or sooner if soiled.",
        "isCorrect": true,
        "explanation": "A bundled approach—full sterile barrier, chlorhexidine–alcohol with complete drying, meticulous securement, and an occlusive dressing with infrequent scheduled changes—most effectively lowers colonization and infection risk."
      },
      {
        "text": "Place the catheter with clean gloves to minimize setup delays and reinforce the site with additional tape instead of a transparent dressing.",
        "isCorrect": false,
        "explanation": "Clean technique and nonocclusive dressings increase contamination and do not provide a sterile barrier; maximum sterile precautions and an occlusive dressing are standard."
      }
    ],
    "didactic": "Preventing infection in continuous peripheral nerve and neuraxial catheters depends on minimizing microbial inoculation at insertion and limiting subsequent contamination. The most effective, evidence-based bundle includes:  \n- Hand hygiene and maximum sterile barrier precautions (cap, mask, sterile gown, sterile gloves, large sterile drape).  \n- Skin antisepsis with 2% chlorhexidine in 70% isopropyl alcohol; allow the prep to dry completely before needle entry. For neuraxial procedures, avoid pooling and ensure full drying to reduce neurotoxicity risk.  \n- Sterile ultrasound technique (sterile probe cover and sterile gel).  \n- Securement to prevent pistoning (eg, adhesive anchor, subcutaneous tunneling, or suture) and minimize hub manipulation using a closed system.  \n- Sterile, transparent occlusive dressing; consider chlorhexidine-impregnated dressings in high-risk patients. Plan sterile dressing changes every 5–7 days (or sooner if loose/soiled), which reduces manipulation compared with daily changes while maintaining a barrier.  \n- Daily site inspection and prompt removal if erythema, purulence, fever without source, or inadequate analgesia develops. Routine prophylactic antibiotics or scheduled catheter exchanges are not recommended.  \n\nChlorhexidine–alcohol outperforms povidone–iodine in reducing catheter colonization and infectious complications because it provides rapid, persistent activity. Maximum sterile barrier precautions reduce inoculum during placement. Transparent occlusive dressings create a continuous barrier and permit visualization; frequent changes increase contamination opportunities. Securement limits micro-motion that can wick skin flora along the catheter tract. Together, these elements form a high-yield, practical bundle to lower infection risk while preserving the benefits of continuous regional analgesia.",
    "educationalObjective": "Prevent infection with sterile insertion technique, securement, and scheduled dressing changes."
  },
  {
    "id": "Core.7.1.12",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Catheters and acute pain pathways",
    "difficulty": "medium",
    "questionText": "A 58-year-old man with obesity (BMI 38) and moderate obstructive sleep apnea (AHI 32) on home CPAP undergoes laparoscopic colectomy under general anesthesia. He is opioid-naive and received fentanyl 100 μg and hydromorphone 1.0 mg intraoperatively. In PACU he required an additional 0.6 mg hydromorphone for pain, which is now 7/10. He is hemodynamically stable with RR 14/min and SpO<sub>2</sub> 95% on 2 L/min O<sub>2</sub> via nasal cannula. Creatinine is 0.9 mg/dL; there is no hepatic disease. The surgical team requests an IV hydromorphone PCA for the surgical ward. You are asked to program the PCA and specify monitoring to minimize oversedation while providing effective analgesia.\n\nWhich of the following PCA settings and monitoring plan is most appropriate?",
    "answers": [
      {
        "text": "Morphine demand 2 mg, lockout 6 min, basal 1 mg/h; continuous pulse oximetry only",
        "isCorrect": false,
        "explanation": "Aggressive dosing with a basal rate in an opioid-naive, OSA patient is unsafe; using morphine does not mitigate risk, and pulse oximetry alone may miss hypoventilation on supplemental O<sub>2</sub>."
      },
      {
        "text": "Hydromorphone demand 0.05 mg, lockout 20 min, no basal infusion; no continuous monitoring to avoid alarm fatigue",
        "isCorrect": false,
        "explanation": "Underdosing risks poor analgesia, and eschewing continuous monitoring in a high-risk OSA patient is unsafe; alarm fatigue is not a justification to forgo appropriate surveillance."
      },
      {
        "text": "Fentanyl demand 50 μg, lockout 10 min, basal 25 μg/h; continuous pulse oximetry and increase O<sub>2</sub> to 4 L/min overnight",
        "isCorrect": false,
        "explanation": "A basal fentanyl infusion in an opioid-naive OSA patient increases respiratory depression risk; raising FiO<sub>2</sub> may delay recognition of hypoventilation without capnography."
      },
      {
        "text": "Hydromorphone demand 0.4 mg, lockout 6 min, basal 0.2 mg/h, 1-hour limit 3 mg; intermittent pulse oximetry spot checks every 4 hours",
        "isCorrect": false,
        "explanation": "High demand dose with a basal infusion and infrequent spot-checks increases oversedation risk, particularly in opioid-naive patients with OSA; lack of continuous monitoring can miss hypoventilation."
      },
      {
        "text": "Hydromorphone demand 0.2 mg, lockout 8–10 min, no basal infusion, 1-hour limit 1.5 mg; continuous pulse oximetry with capnography while on supplemental O<sub>2</sub>, sedation assessments with a validated scale, resume CPAP during sleep",
        "isCorrect": true,
        "explanation": "This regimen limits maximum hourly dose (0.2 mg × 60/8–10 ≈ 1.2–1.5 mg/h), avoids basal infusion in an opioid-naive OSA patient, and implements continuous oximetry plus capnography (to detect hypoventilation despite O<sub>2</sub>) with structured sedation monitoring and CPAP use."
      }
    ],
    "didactic": "Patient-controlled analgesia (PCA) balances analgesia with safety by titrating small IV boluses separated by a lockout. In opioid-naive patients—especially those with OSA—avoid a basal infusion, which raises steady-state opioid levels and the risk of cumulative hypoventilation during sleep. A hydromorphone demand dose of 0.2 mg with an 8–10 min lockout is appropriate; the 1-hour dose limit can be estimated as dose × (60/lockout), yielding ≈1.2–1.5 mg/h, which provides titratable analgesia while limiting exposure.\n\nOSA and supplemental O<sub>2</sub> increase the likelihood of unrecognized respiratory depression because pulse oximetry may remain normal despite hypoventilation. Use continuous pulse oximetry plus capnography (EtCO<sub>2</sub>) when feasible while the patient receives O<sub>2</sub>, as capnography detects ventilation failure earlier than SpO<sub>2</sub>. Implement regular sedation assessments (eg, a validated scale such as POSS) and hold/downtitrate opioids for excessive sedation or RR decline. Resume home CPAP during sleep to mitigate upper airway collapse.\n\nKey practices to prevent oversedation in high-risk patients:\n- Avoid basal PCA in opioid-naive or OSA patients; prefer demand-only dosing.\n- Choose conservative demand doses and appropriate lockouts (eg, hydromorphone 0.2 mg, 8–10 min; morphine 1 mg, 6–10 min).\n- Set a reasonable 1-hour limit aligned with dose and lockout.\n- Use continuous SpO<sub>2</sub> and add capnography while on supplemental O<sub>2</sub>.\n- Perform structured sedation/respiratory assessments; avoid concomitant sedatives and ensure only the patient activates PCA.\n\nMorphine and hydromorphone are both acceptable in normal renal function, but hydromorphone avoids active morphine-6-glucuronide accumulation in renal impairment. Regardless of drug, preventing oversedation hinges on eliminating basal infusions in opioid-naive/OSA patients and using continuous monitoring that includes a ventilation measure when FiO<sub>2</sub> is elevated.",
    "educationalObjective": "Program PCA settings (demand dose, lockout, basal rate) and implement monitoring to prevent oversedation."
  },
  {
    "id": "Core.7.1.13",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Catheters and acute pain pathways",
    "difficulty": "medium",
    "questionText": "A 62-year-old man with diabetes undergoes total knee arthroplasty under spinal anesthesia with a continuous adductor canal catheter (0.2% ropivacaine at 8 mL/h). Tourniquet time is 90 minutes. On postoperative day 2, eight hours after the infusion is stopped for planned catheter removal, he reports new foot drop and numbness over the lateral leg and dorsum of the foot. Exam shows 0/5 ankle dorsiflexion with preserved plantarflexion, decreased sensation in the superficial/deep peroneal distributions, normal distal pulses, and a snug compressive dressing at the proximal tibia. Calf is soft without pain out of proportion. There is no hematoma at the catheter site.\n\nWhich management plan is most appropriate now to screen for nerve injury and ensure appropriate follow-up?",
    "answers": [
      {
        "text": "Obtain urgent MRI of the lumbar spine to rule out neuraxial pathology causing L5 radiculopathy.",
        "isCorrect": false,
        "explanation": "The focal distribution at the fibular head with preserved plantarflexion and recent knee surgery strongly favor a common peroneal neuropathy rather than proximal neuraxial disease."
      },
      {
        "text": "Start systemic corticosteroids and discharge the patient with an outpatient EMG/nerve conduction study today.",
        "isCorrect": false,
        "explanation": "Steroids are not routinely indicated, and EMG/NCS performed immediately are often nondiagnostic; early management should focus on compression relief, documentation, and short-interval follow-up."
      },
      {
        "text": "Remove the catheter and reassure that block effects can last up to 72 hours; no further workup or follow-up is necessary unless pain worsens.",
        "isCorrect": false,
        "explanation": "An adductor canal block should not cause foot drop; reassurance alone risks missing a surgical or compressive peroneal neuropathy and delays necessary follow-up."
      },
      {
        "text": "Resume the local anesthetic infusion overnight and reassess motor function after catheter removal tomorrow.",
        "isCorrect": false,
        "explanation": "Continuing the infusion can mask neurologic deficits, delay diagnosis, and increase fall risk; it does not address a likely compressive or surgical neuropathy."
      },
      {
        "text": "Stop the infusion, remove/loosen constrictive dressings and reposition to reduce nerve stretch, perform and document a focused neuro exam, notify the surgical team for suspected common peroneal palsy, and arrange close follow-up within 24–48 h with neurology referral if no improvement.",
        "isCorrect": true,
        "explanation": "This approach prioritizes identifying and relieving reversible compression, documents the deficit, engages the surgeon, and ensures timely reassessment with escalation if the motor deficit persists beyond expected block duration."
      }
    ],
    "didactic": "Peripheral nerve injury after regional anesthesia must be distinguished from expected block effects and from surgical or compressive etiologies. An adductor canal catheter primarily affects the saphenous nerve and nerve to vastus medialis, sparing motor innervation to foot dorsiflexors; new foot drop with sensory loss over the lateral leg/dorsum foot is classic for common peroneal neuropathy at the fibular head. Risk factors include diabetes, prolonged tourniquet, limb positioning, and tight dressings.\n\nInitial screening prioritizes identifying reversible causes and preventing progression:\n- Stop local anesthetic infusion to avoid masking deficits and increasing fall risk.\n- Perform and document a focused neuro exam (myotomes, dermatomes, reflexes), mapping the deficit to a peripheral nerve vs root/plexus level.\n- Remove/loosen constrictive dressings/casts and position to reduce nerve tension (eg, slight knee flexion, avoid external compression at the fibular head); assess for compartment syndrome (pain out of proportion, tense compartments, pain with passive stretch) and vascular compromise.\n- Notify the surgical team promptly to evaluate for compressive or surgical injury (tourniquet, retractor, hematoma) and address reversible causes.\n\nFollow-up is essential when deficits persist beyond expected block duration (typically hours after stopping a dilute ropivacaine infusion):\n- Arrange reassessment within 24–48 h by the acute pain team; provide protective measures (fall precautions, ankle-foot orthosis) to prevent injury.\n- Escalate urgently for any progressive deficit, severe neuropathic pain, or motor deficit persisting beyond the expected resolution; consider neurology consultation. Imaging is guided by suspicion for compressive hematoma; EMG/NCS are most informative after 2–3 weeks when Wallerian degeneration is detectable.\n\nMost neuropraxias improve over weeks to months. Early recognition, relief of compression, careful documentation, and structured short-interval follow-up optimize outcomes and ensure timely specialty involvement if recovery lags.",
    "educationalObjective": "Screen for nerve injury after block or catheter and arrange follow-up if deficits persist beyond expected duration."
  },
  {
    "id": "Core.7.1.14",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Catheters and acute pain pathways",
    "difficulty": "medium",
    "questionText": "In the preoperative holding area, the regional anesthesia service has only one ambulatory infusion pump available for a continuous peripheral nerve catheter to minimize postoperative opioids. Five cases are scheduled today. Considering surgical pain severity, comorbidities, anticipated anticoagulation, and discharge logistics, which patient is the best candidate for a continuous peripheral nerve catheter to improve analgesia and reduce opioid use?\n\nSelect the best candidate.",
    "answers": [
      {
        "text": "45-year-old man on chronic opioids undergoing outpatient ankle arthrodesis who lives alone and has unreliable phone access.",
        "isCorrect": false,
        "explanation": "Popliteal catheters can markedly reduce opioids after ankle fusion, but lack of home support and poor follow-up make ambulatory catheter management unsafe."
      },
      {
        "text": "58-year-old woman scheduled for revision total hip arthroplasty with LMWH prophylaxis beginning 6 h postoperatively.",
        "isCorrect": false,
        "explanation": "Deep plexus/peripheral catheters for hip (eg, lumbar plexus) carry higher bleeding risk and generally follow neuraxial-like anticoagulation precautions; early LMWH initiation makes a continuous deep catheter unfavorable."
      },
      {
        "text": "72-year-old woman with BMI 36 and severe OSA on CPAP, undergoing primary total knee arthroplasty with plan for early ambulation and apixaban starting 12 h postoperatively; reliable spouse at home.",
        "isCorrect": true,
        "explanation": "A continuous adductor canal catheter offers potent opioid-sparing analgesia while preserving quadriceps strength for ambulation; it is superficial/compressible and reasonable with postoperative VTE prophylaxis, and home support is adequate."
      },
      {
        "text": "68-year-old man with severe COPD (FEV<sub>1</sub> 35%) on home O<sub>2</sub>, admitted for open total shoulder arthroplasty.",
        "isCorrect": false,
        "explanation": "An interscalene catheter provides excellent analgesia but commonly causes hemidiaphragmatic paresis, which can precipitate respiratory failure in severe COPD; alternative diaphragm-sparing strategies are preferred."
      },
      {
        "text": "35-year-old man having outpatient distal radius ORIF with expected mild-to-moderate pain and no major comorbidities.",
        "isCorrect": false,
        "explanation": "Single-shot brachial plexus block typically suffices for distal radius ORIF; a continuous catheter is unnecessary for expected pain severity."
      }
    ],
    "didactic": "Continuous peripheral nerve catheters are best reserved for surgeries with severe, prolonged postoperative pain and where opioid-sparing improves safety or facilitates rehabilitation. Ideal use cases include total knee arthroplasty, shoulder arthroplasty, and foot/ankle fusion. Key selection principles:\n\n- Match block to surgical and functional goals: For TKA, an adductor canal catheter provides excellent analgesia while sparing quadriceps strength, reducing falls risk and enabling early ambulation compared with femoral nerve catheters.\n- Prioritize opioid-sparing in high-risk patients: Patients with OSA are vulnerable to opioid-induced ventilatory impairment; continuous regional analgesia can substantially reduce opioid requirements and nocturnal desaturations.\n- Account for pulmonary reserve: Interscalene techniques produce near-universal ipsilateral hemidiaphragmatic paresis and reduce FVC/FEV<sub>1</sub> by ~25–30%. In patients with severe COPD or marginal reserve, continuous interscalene catheters may precipitate respiratory failure; consider diaphragm-sparing alternatives (eg, suprascapular + axillary or superior trunk approaches) and multimodal analgesia.\n- Consider anticoagulation and compressibility: Deep plexus/peripheral catheters (eg, lumbar plexus/psoas, proximal sciatic) carry higher bleeding risk and generally follow neuraxial-like precautions. Superficial, compressible catheters (eg, adductor canal) are more favorable when early postoperative pharmacologic VTE prophylaxis is planned, though timing of insertion/removal should still respect anticoagulation.\n- Ensure safe outpatient management: Ambulatory catheters require reliable caregiver support, patient education, phone access, and follow-up for troubleshooting and removal. Lack of support is a relative contraindication to home discharge with a catheter.\n\nAccordingly, a patient with OSA undergoing TKA and early rehab is an excellent candidate for a continuous adductor canal catheter—potent analgesia, opioid-sparing benefits, and preserved motor function—whereas severe COPD (interscalene), early LMWH after hip surgery (deep plexus), or minor procedures favor alternative strategies.",
    "educationalObjective": "Select candidates for peripheral nerve catheters to improve analgesia and reduce opioids after major joint and limb surgery."
  },
  {
    "id": "Core.7.1.15",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Catheters and acute pain pathways",
    "difficulty": "easy",
    "questionText": "A 62-year-old man undergoes uncomplicated total knee arthroplasty with an adductor canal catheter connected to an elastomeric pump infusing ropivacaine 0.2% at 8 mL/h with patient-controlled 4 mL boluses q60 min. He will be discharged home today with his spouse and a walker. You plan to transition him to home catheter management.\n\nWhich discharge instruction plan is most appropriate to minimize complications and ensure safe home catheter removal?",
    "answers": [
      {
        "text": "Provide 24/7 contact information and daily follow-up calls; enforce fall precautions and limb protection; keep dressing dry (no baths/heat); continue scheduled acetaminophen/NSAID with limited opioid rescue; stop the pump and remove on POD 3 using clean technique with steady traction; inspect for an intact tip and cover the site; call for signs of LAST (eg, tinnitus, perioral numbness), infection, resistance/pain on removal, or persistent numbness >24 h after removal.",
        "isCorrect": true,
        "explanation": "Comprehensive ambulatory CPNB instructions address safety, multimodal analgesia, catheter care, explicit removal steps/timing, and clear triggers for escalation, reducing risks of falls, infection, and LAST."
      },
      {
        "text": "Weight-bear without assistance; use a heating pad and ice directly on the numb limb as needed; remove the catheter if the site feels itchy; call only for fever >102°F.",
        "isCorrect": false,
        "explanation": "Insensate limbs are vulnerable to thermal injury and falls; pruritus is not a removal trigger; infection and neurologic red flags require earlier contact."
      },
      {
        "text": "Remove the catheter the evening of surgery while the infusion is running; take a hot shower to loosen the dressing; resume driving if pain is controlled; no routine follow-up needed unless severe pain develops.",
        "isCorrect": false,
        "explanation": "Removing while infusing increases toxicity risk; heat and showers increase burn/infection risk; driving with an insensate limb is unsafe; structured follow-up is standard for ambulatory catheters."
      },
      {
        "text": "Increase the basal rate if pain exceeds 4/10 and use unlimited boluses; opioids are unnecessary; remove the catheter once the bag empties, trimming the catheter if it catches on the dressing.",
        "isCorrect": false,
        "explanation": "Escalating local anesthetic dosing at home increases LAST risk; opioids may be needed for breakthrough pain; never cut catheters; removal should be deliberate and not solely tied to pump emptying."
      },
      {
        "text": "Keep the dressing dry and limb protected, but delay removal until full motor and sensory recovery; continue the infusion until numbness resolves, regardless of duration.",
        "isCorrect": false,
        "explanation": "Prolonging infusion until complete recovery can unnecessarily extend exposure to local anesthetic; most programs remove at a predefined time (eg, 48–72 h) when pain is manageable."
      }
    ],
    "didactic": "Ambulatory continuous peripheral nerve blocks (CPNB) improve analgesia and reduce opioid needs but require explicit discharge education to prevent complications. A safe home program standardizes: (1) safety precautions, (2) catheter/pump care, (3) multimodal analgesia, (4) removal steps and timing, and (5) clear escalation pathways.\n\nKey instructions include:\n- Safety: Do not drive or operate machinery while the limb is insensate. Use assistive devices and avoid unassisted ambulation to reduce falls. Protect the numb limb from heat/cold and pressure injuries; keep pets and heating pads away.\n- Catheter/pump care: Keep dressing clean, dry, and intact; no soaking (baths/pools). Shower with occlusive protection if permitted by the surgeon. Do not alter pump settings at home.\n- Analgesia: Continue scheduled nonopioids (eg, acetaminophen ± NSAID if appropriate) with a small supply of rescue opioid and clear dosing limits. Avoid alcohol and sedatives.\n- LAST and infection awareness: Stop the infusion and call immediately for tinnitus, metallic taste, perioral numbness, dizziness, or seizures; if severe symptoms occur, call EMS. Monitor for redness, swelling, drainage, or fever at the site.\n- Removal plan: Predefine removal (commonly POD 2–3). To remove, wash hands, stop/clamp the pump, gently peel the dressing, and withdraw the catheter with steady traction. Stop if resistance, sharp pain, or nerve symptoms occur and call. Inspect for the colored/marked tip to confirm intact removal; never cut the catheter. Apply pressure, then an occlusive dressing. Mild oozing is expected; persistent bleeding or expanding hematoma warrants contact.\n- Follow-up: Provide 24/7 contact information and daily outreach to assess pain, block function, and adverse effects. Advise patients to call if numbness/weakness persists >24 h after removal or if pain is uncontrolled despite the plan.\n\nClear, written instructions and proactive follow-up are central to safe transition from inpatient catheter to home management.",
    "educationalObjective": "Transition from inpatient catheter to home management with clear instructions and removal plan."
  },
  {
    "id": "Core.7.1.16",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Catheters and acute pain pathways",
    "difficulty": "medium",
    "questionText": "A 62-year-old man on postoperative day 1 after an open thoracotomy has a continuous erector spinae plane (ESP) catheter placed at T5 infusing ropivacaine 0.2% at 8 mL/h with patient-controlled 5 mL boluses. He reports severe incision pain after coughing. The infusion pump shows expected volume decline, and there is no motor block. You suspect catheter migration and scan the insertion site with a high-frequency linear probe in a transverse orientation, identifying skin/subcutaneous tissue, erector spinae muscle, and the underlying transverse process. You inject 3 mL of saline through the catheter while imaging the tip.\n\nWhich ultrasound finding most reliably confirms the catheter tip is correctly positioned in the ESP plane before resuming the infusion?",
    "answers": [
      {
        "text": "Echogenic swirling within a small vessel near the catheter tip on color Doppler during injection",
        "isCorrect": false,
        "explanation": "Intravascular injection is hazardous and indicates malposition; correct ESP placement should show plane spread, not intraluminal flow."
      },
      {
        "text": "Anechoic spread superficial to the erector spinae muscle within subcutaneous tissue at the insertion site",
        "isCorrect": false,
        "explanation": "Superficial subcutaneous spread indicates the catheter has backed out; the target is deep to the erector spinae muscle and superficial to the transverse process."
      },
      {
        "text": "Expansion of the intercostal muscle layer lateral to the transverse process without erector spinae displacement",
        "isCorrect": false,
        "explanation": "Spread confined to intercostal muscle indicates a wrong plane lateral to the target and will not produce typical ESP analgesia."
      },
      {
        "text": "Pleural indentation with transient loss of pleural sliding during injection",
        "isCorrect": false,
        "explanation": "Pleural deformation suggests too-deep or paravertebral/intrapleural extension; loss of sliding is concerning for pleural violation, not correct ESP placement."
      },
      {
        "text": "Anechoic spread deep to the erector spinae muscle that lifts it off the transverse process with longitudinal cephalocaudal tracking",
        "isCorrect": true,
        "explanation": "Hydrodissection deep to the erector spinae muscle with visible lifting off the transverse process and longitudinal spread confirms correct ESP plane positioning."
      }
    ],
    "didactic": "The erector spinae plane (ESP) block targets the fascial plane deep to the erector spinae muscle and superficial to the transverse process. Under ultrasound, correct placement is confirmed by a small test injection (eg, 2–5 mL saline or D5W) that creates visible hydrodissection in this plane. The hallmark finding is the erector spinae muscle being lifted off the hyperechoic transverse process as the injectate spreads longitudinally in a cephalocaudal direction along the plane. This pattern predicts effective catheter analgesia because it facilitates multilevel dorsal ramus and ventral ramus spread to the paravertebral space.\n\nCommon malpositions include:\n- Superficial/subcutaneous spread: no displacement of the erector spinae muscle; catheter often backed out—rethread or replace.\n- Intercostal muscle plane spread lateral to the transverse process: inadequate coverage—redirect deeper and more medial to the transverse process.\n- Too-deep/pleural-adjacent spread: pleural indentation or loss of sliding—abort injection and reposition to avoid pneumothorax.\n- Intravascular injection: intraluminal color flow or swirling—stop, aspirate, and reposition away from vessels.\n\nTroubleshooting suspected migration involves: (1) visualizing the catheter tip as a hyperechoic line/dot with reverberation artifact, (2) using a small test bolus to confirm appropriate hydrodissection that elevates the erector spinae muscle off the transverse process, and (3) adjusting depth by 1–2 cm and rescanning longitudinally to ensure cephalocaudal spread. Securement (adhesive anchoring, tunneling, minimized slack) reduces secondary dislodgement. Confirming correct plane spread under ultrasound before resuming infusion improves block reliability and reduces local anesthetic systemic toxicity risk.",
    "educationalObjective": "Use ultrasound to confirm catheter tip location and spread and troubleshoot migration."
  },
  {
    "id": "Core.7.2.1",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "LAST prevention and treatment",
    "difficulty": "medium",
    "questionText": "A 58-year-old, 80-kg man develops seizures and then profound hypotension (MAP 50 mmHg) minutes after an interscalene block with bupivacaine. He is ventilated with 100% O<sub>2</sub>, seizures are treated with midazolam, and 20% lipid emulsion is started with a 1.5 mL/kg IV bolus over 1 minute followed by a continuous infusion at 0.25 mL/kg/min. Two minutes later, he remains hemodynamically unstable.\n\nWhich of the following is the most appropriate lipid emulsion dosing step now?",
    "answers": [
      {
        "text": "Stop the lipid infusion now to avoid exceeding the 10 mL/kg maximum in the first 30 minutes.",
        "isCorrect": false,
        "explanation": "After a 1.5 mL/kg bolus and 2 minutes at 0.25 mL/kg/min (0.5 mL/kg), only 2.0 mL/kg total has been given—well below the 10 mL/kg limit."
      },
      {
        "text": "Give an additional 0.5 mL/kg bolus (40 mL) and continue the infusion at 0.25 mL/kg/min (20 mL/min).",
        "isCorrect": false,
        "explanation": "The bolus dose is insufficient; ASRA recommends repeating a full 1.5 mL/kg bolus for persistent instability."
      },
      {
        "text": "Repeat a 1.5 mL/kg bolus (120 mL) and increase the infusion to 0.5 mL/kg/min (40 mL/min).",
        "isCorrect": true,
        "explanation": "For ongoing cardiovascular instability in LAST, repeat the full bolus and double the infusion rate; continue for ≥10 minutes after stability while observing the 10 mL/kg 30-minute maximum."
      },
      {
        "text": "Switch to 10% lipid emulsion and give a 2 mL/kg bolus (160 mL).",
        "isCorrect": false,
        "explanation": "Guidelines specify 20% lipid emulsion; 10% is not recommended for LAST and the dosing here is incorrect."
      },
      {
        "text": "Increase the infusion to 1 mL/kg/min (80 mL/min) without another bolus.",
        "isCorrect": false,
        "explanation": "Increasing to 1 mL/kg/min exceeds guideline recommendations (0.5 mL/kg/min when unstable) and omits the indicated repeat bolus."
      }
    ],
    "didactic": "Local anesthetic systemic toxicity (LAST) causes CNS excitation/seizures and cardiovascular collapse via myocardial depression, conduction block, and vasodilation. Early administration of **20% lipid emulsion** improves outcomes by sequestering lipophilic anesthetic (“lipid sink”) and supporting myocardial energetics. ASRA guidelines recommend: \n\n- Initial bolus: **1.5 mL/kg of 20% lipid emulsion IV** over 1 minute.\n- Continuous infusion: **0.25 mL/kg/min** immediately after the bolus.\n- If instability persists: **repeat the 1.5 mL/kg bolus** (up to 2 additional times) and **increase the infusion to 0.5 mL/kg/min**.\n- Continue the infusion for **≥10 minutes after hemodynamic stability** is achieved and limit the total dose to **10 mL/kg during the first 30 minutes**.\n\nFor this 80-kg patient, the initial bolus is 120 mL and the starting infusion is 20 mL/min. At 2 minutes, the infusion has delivered 40 mL (0.5 mL/kg). The total administered (160 mL = 2.0 mL/kg) is well below the 10 mL/kg maximum, so the correct next step is to **repeat the full bolus and double the infusion to 40 mL/min** until stable.\n\nImportant adjuncts include airway management with 100% O<sub>2</sub>, benzodiazepines for seizures, and avoidance of drugs that impair resuscitation. Use **small-dose epinephrine** (≤1 μg/kg boluses) if needed; avoid vasopressin, calcium channel blockers, and β-blockers. Treat ventricular arrhythmias with **amiodarone** rather than lidocaine. Do not substitute propofol or 10% lipid; **20% lipid emulsion** is the recommended formulation for LAST. Early recognition, correct dosing, and timely repeat boluses with infusion escalation are critical to restoring perfusion and limiting local anesthetic redistribution.",
    "educationalObjective": "Administer 20% lipid emulsion with correct bolus and infusion dosing and repeat boluses if instability persists."
  },
  {
    "id": "Core.7.2.2",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "LAST prevention and treatment",
    "difficulty": "hard",
    "questionText": "A 64-year-old man (80 kg) undergoing distal radius fixation receives an ultrasound-guided infraclavicular block with 40 mL of 0.5% bupivacaine. Two minutes after injection, he develops circumoral numbness, tinnitus, and agitation that progress to a generalized tonic–clonic seizure. Monitors show SpO<sub>2</sub> 98% on nasal O<sub>2</sub> (4 L/min), HR 142/min, BP 82/46 mmHg, and a wide-complex tachycardia. Bag-mask ventilation with FiO<sub>2</sub> 1.0 is initiated, and IV access is patent; 20% lipid emulsion is available at the bedside.\n\nWhich of the following is the most appropriate immediate pharmacologic management?",
    "answers": [
      {
        "text": "Administer propofol 100 mg IV to terminate the seizure",
        "isCorrect": false,
        "explanation": "Large propofol boluses can worsen myocardial depression and hypotension during LAST and should be avoided; benzodiazepines are preferred. Small, titrated doses of propofol may be considered only if hemodynamics are stable and benzodiazepines are unavailable."
      },
      {
        "text": "Administer esmolol 30 mg IV to control the tachycardia",
        "isCorrect": false,
        "explanation": "β-blockade can exacerbate bradyarrhythmias, conduction block, and negative inotropy in LAST. Rate control does not address the toxin and may precipitate cardiovascular collapse."
      },
      {
        "text": "Administer amiodarone 150 mg IV for the wide-complex tachycardia",
        "isCorrect": false,
        "explanation": "Although amiodarone is acceptable for refractory ventricular arrhythmias in LAST, the immediate priorities are seizure termination and lipid rescue. Initiating lipid therapy early may resolve arrhythmias; amiodarone can also worsen hypotension."
      },
      {
        "text": "Administer diltiazem 20 mg IV for rate control",
        "isCorrect": false,
        "explanation": "Calcium channel blockers worsen hypotension and myocardial depression and can potentiate conduction block in sodium channel toxicity. They are contraindicated in LAST resuscitation."
      },
      {
        "text": "Administer midazolam 2 mg IV and initiate 20% lipid emulsion (1.5 mL/kg bolus, then infusion)",
        "isCorrect": true,
        "explanation": "Benzodiazepines are first-line for LAST-related seizures, and early 20% lipid emulsion (1.5 mL/kg bolus followed by infusion) mitigates cardiotoxicity. This approach treats CNS excitation while addressing the underlying toxin without worsening hypotension or myocardial depression."
      }
    ],
    "didactic": "Local anesthetic systemic toxicity (LAST) presents with a spectrum from CNS excitation (tinnitus, perioral numbness, agitation) to seizures and cardiovascular collapse due to sodium channel blockade, impaired myocardial energetics, and decreased contractility. Management priorities are to support airway/breathing/circulation, rapidly terminate seizures, and reduce circulating toxin burden with early lipid emulsion therapy.\n\n- Airway/ventilation: Provide 100% O<sub>2</sub>, avoid hypercarbia and acidosis (which increase ionized drug and toxicity), and secure the airway if needed.\n- Seizure control: Use benzodiazepines first-line (eg, midazolam). Large propofol boluses should be avoided because they can exacerbate myocardial depression and hypotension; small, titrated propofol may be used only if hemodynamics are stable and benzodiazepines are unavailable.\n- Lipid rescue: Start 20% lipid emulsion early (1.5 mL/kg bolus over ~1 min, then 0.25 mL/kg/min infusion; repeat bolus and increase infusion to 0.5 mL/kg/min for persistent instability; typical upper limit ~10–12 mL/kg total). Lipid therapy acts via a lipid sink and improves cardiac energetics/inotropy.\n- Hemodynamics/arrhythmias: Use small-dose epinephrine (≤1 μg/kg) and vasopressors as needed. For ventricular arrhythmias, amiodarone is preferred; avoid additional sodium channel blockers (lidocaine, procainamide). Critically, avoid β-blockers and calcium channel blockers, which worsen negative inotropy and conduction depression in LAST.\n\nAgents to avoid during resuscitation include large propofol boluses, β-blockers, and calcium channel blockers because they can precipitate or worsen cardiovascular collapse. Early benzodiazepines plus lipid emulsion, alongside careful hemodynamic support, are central to preventing progression to refractory cardiac toxicity.",
    "educationalObjective": "Avoid agents that may worsen toxicity (propofol boluses, beta blockers, calcium channel blockers) during resuscitation."
  },
  {
    "id": "Core.7.2.3",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "LAST prevention and treatment",
    "difficulty": "medium",
    "questionText": "A 34-year-old woman undergoes shoulder arthroscopy after a single-shot interscalene block with 30 mL of 0.5% bupivacaine. Within minutes she develops perioral numbness, tinnitus, a generalized seizure, and then hypotension with a wide-complex rhythm. She is ventilated with 100% O<sub>2</sub>, given midazolam and small-dose epinephrine (10–20 μg aliquots), and receives 20% lipid emulsion (1.5 mL/kg bolus) followed by an infusion at 0.25 mL/kg/min. Five minutes later she is awake, in sinus rhythm, and her MAP is 70 mmHg without vasopressors. The circulating nurse asks if the lipid infusion can be stopped and the patient transferred to PACU for routine recovery.\n\nWhich of the following is the most appropriate management to minimize the risk of recurrent local anesthetic systemic toxicity (LAST)?",
    "answers": [
      {
        "text": "Stop the lipid infusion now that vital signs are stable and observe in PACU for 1 hour",
        "isCorrect": false,
        "explanation": "Early discontinuation and brief observation increase the risk of missing recurrent toxicity; rebound hypotension or arrhythmias may occur after apparent recovery."
      },
      {
        "text": "Switch to a propofol infusion for seizure prophylaxis and discontinue lipid to avoid hypertriglyceridemia",
        "isCorrect": false,
        "explanation": "Propofol is not indicated for prophylaxis and can worsen hypotension; lipid emulsion is the cornerstone therapy and should be continued briefly after stabilization."
      },
      {
        "text": "Continue the 20% lipid infusion at 0.25 mL/kg/min for at least 10 minutes after hemodynamic stability, and admit for continuous monitoring for ≥6 hours due to prior cardiovascular involvement",
        "isCorrect": true,
        "explanation": "Lipid therapy should be continued beyond initial stabilization (eg, ≥10 minutes) and patients with cardiovascular involvement require monitored observation for several hours (eg, ≥6 hours) because recurrent toxicity can occur as drug redistributes from tissue depots."
      },
      {
        "text": "Administer epinephrine 1 mg IV per standard ACLS dosing to prevent recurrent hypotension and discontinue lipid",
        "isCorrect": false,
        "explanation": "High-dose epinephrine is avoided in LAST (use small doses ≤1 μg/kg) as it can worsen arrhythmias and impair resuscitation; lipid therapy should not be discontinued prematurely."
      },
      {
        "text": "Start a prophylactic amiodarone infusion and transfer to an unmonitored floor after 2 hours",
        "isCorrect": false,
        "explanation": "Amiodarone is preferred if arrhythmias recur, but prophylaxis is unnecessary; given prior cardiovascular involvement, extended monitored care (≥6 hours) is recommended."
      }
    ],
    "didactic": "Local anesthetic systemic toxicity (LAST) results from excessive plasma levels of potent, lipophilic agents (eg, bupivacaine), producing a typical sequence of CNS excitation (tinnitus, perioral numbness, seizures) followed by cardiovascular depression and arrhythmias due to myocardial Na<sup>+</sup> channel blockade. Acidosis and hypercarbia increase the unbound fraction and worsen toxicity; immediate airway control and ventilation with 100% O<sub>2</sub> to avoid hypoxia and normalize PaCO<sub>2</sub> are essential.\n\nManagement centers on early 20% lipid emulsion and supportive care:\n- Seizures: benzodiazepines; avoid large-dose propofol in unstable patients.\n- Lipid emulsion: 1.5 mL/kg bolus, then 0.25 mL/kg/min infusion. If instability persists, repeat bolus and increase infusion to 0.5 mL/kg/min; keep within commonly recommended upper limits in the initial 30 minutes. Continue the infusion for at least 10 minutes after hemodynamic stability is achieved to prevent rebound toxicity as drug redistributes from tissue depots.\n- Vasopressors/antiarrhythmics: use small-dose epinephrine (≤1 μg/kg); avoid vasopressin, β-blockers, and calcium channel blockers. Amiodarone is preferred for ventricular arrhythmias.\n\nRecurrent LAST can occur after apparent recovery, particularly with highly lipophilic agents (eg, bupivacaine) or large/depot injections. Therefore, patients require prolonged monitoring after symptom resolution:\n- Isolated, mild CNS symptoms: observe for at least 2 hours.\n- Any cardiovascular involvement (hypotension, arrhythmias, or cardiac arrest): continuous monitoring for at least 4–6 hours (many experts favor ≥6 hours), with readiness to re-bolus lipid if instability recurs.\n\nIn this patient with prior cardiovascular compromise, the correct approach is to continue the lipid infusion briefly beyond stabilization and provide extended monitored care, rather than stopping lipid early, giving high-dose epinephrine, or discharging from PACU prematurely.",
    "educationalObjective": "Continue lipid infusion until hemodynamic stability is sustained and monitor for recurrence for at least several hours."
  },
  {
    "id": "Core.7.2.4",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "LAST prevention and treatment",
    "difficulty": "easy",
    "questionText": "A high-volume ambulatory center performs peripheral nerve blocks in a block bay and provides sedation in GI and MRI suites. During a recent LAST simulation, the team delayed lipid therapy due to uncertainty about dosing, administered a full 1 mg epinephrine push during hypotension, and could not locate an antiarrhythmic in the procedure room. You are tasked with standardizing the facility’s LAST kit and rehearsal plan across all anesthetizing locations.\n\nWhich single change is most likely to improve the speed and accuracy of initial LAST management across sites?",
    "answers": [
      {
        "text": "Affix a laminated, weight-based dosing card to each 20% lipid bag (bolus 1.5 mL/kg; infusion 0.25 mL/kg/min) and stock ≥1000 mL of 20% lipid in every anesthetizing location.",
        "isCorrect": true,
        "explanation": "Posting the exact 20% lipid dosing and ensuring sufficient on-site volume directly reduces cognitive load and delays, enabling guideline-concordant bolus/infusion without pharmacy dependence."
      },
      {
        "text": "Keep amiodarone in central pharmacy to reduce kit complexity and obtain it if ventricular arrhythmias occur.",
        "isCorrect": false,
        "explanation": "Amiodarone should be immediately available in the kit; pharmacy-only storage delays treatment of malignant arrhythmias."
      },
      {
        "text": "Add vasopressin 40 units for refractory hypotension because catecholamines are often ineffective in LAST.",
        "isCorrect": false,
        "explanation": "Vasopressin is discouraged in LAST due to potential worsening of outcomes; it should not be included in the kit."
      },
      {
        "text": "Standardize to prefilled 1 mg epinephrine syringes for hypotension/bradycardia to simplify dosing during resuscitation.",
        "isCorrect": false,
        "explanation": "High-dose epinephrine can exacerbate arrhythmias; guidelines recommend small doses (≤1 μg/kg) in LAST."
      },
      {
        "text": "Stock propofol as the primary anticonvulsant for seizures and remove midazolam to simplify the kit.",
        "isCorrect": false,
        "explanation": "Benzodiazepines are first-line for LAST-related seizures; propofol can worsen hypotension and is not preferred when cardiovascular instability is possible."
      }
    ],
    "didactic": "An effective LAST kit and rehearsal plan prioritize immediate access to the correct drugs and cognitive aids that standardize early actions. The cornerstone of initial therapy is 20% lipid emulsion with **weight-based dosing**: bolus 1.5 mL/kg IV over ~1 min, then infusion 0.25 mL/kg/min. If instability persists, repeat the bolus and/or increase infusion to 0.5 mL/kg/min; limit total dose to ≈10 mL/kg during the first 30 min. Posting a laminated, weight-based dosing card directly on the lipid bag and stocking adequate volume (eg, ≥1000 mL to cover large patients) in every anesthetizing location prevents delays from drug retrieval and calculation errors.\n\nKey kit contents and cues should include:\n- 20% lipid emulsion with attached dosing card and large-bore tubing/syringes\n- Benzodiazepines for seizures; avoid large-dose propofol (may worsen hypotension)\n- Epinephrine for hemodynamic support but restricted to small doses (≤1 μg/kg) if needed\n- Amiodarone for ventricular arrhythmias; avoid lidocaine\n- Standard airway equipment, suction, oxygen, and basic resuscitation supplies\n- A concise checklist highlighting actions to avoid: vasopressin, calcium channel blockers, β-blockers, and high-dose epinephrine\n\nA rehearsed plan—brief in-situ simulations, role assignments, and visible cognitive aids—improves team performance under stress. Distributing complete kits to block bays, GI/MRI suites, and remote sites ensures uniform readiness; reliance on central pharmacy or generic code carts contributes to delays and dosing errors. By combining point-of-care availability with clear, weight-based guides, teams can rapidly deliver guideline-concordant therapy and improve outcomes in LAST.",
    "educationalObjective": "Develop an institution-specific LAST kit and rehearsal plan and verify drug availability and dosing guides."
  },
  {
    "id": "Core.7.2.5",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "LAST prevention and treatment",
    "difficulty": "hard",
    "questionText": "A 28-year-old G1P0 (70 kg) receiving a labor epidural has an uncomplicated placement. After negative aspiration and a negative test dose, she is given 12 mL of 0.25% bupivacaine over 90 seconds. Two minutes later, she becomes anxious and says, “I can’t take a deep breath,” and her voice becomes a whisper. She cannot lift her arms and reports numbness in her hands. She denies tinnitus, metallic taste, or perioral numbness. Vital signs: BP 65/30 mmHg, HR 38/min, SpO<sub>2</sub> 99% on 2 L/min nasal O<sub>2</sub>. ECG shows sinus bradycardia without ectopy or QRS widening. No seizure activity is observed.\n\nWhich immediate management is most appropriate for this patient?",
    "answers": [
      {
        "text": "Administer 1 mg IV epinephrine per ACLS for impending cardiac arrest due to LAST.",
        "isCorrect": false,
        "explanation": "Code-dose epinephrine is inappropriate in a perfusing bradycardic patient and is not first-line for suspected high spinal; titrated vasopressors and atropine are preferred. In LAST, small epinephrine doses (≤1 μg/kg) are recommended if needed."
      },
      {
        "text": "Administer sodium bicarbonate for sodium-channel blockade and prepare for lipid therapy.",
        "isCorrect": false,
        "explanation": "Bicarbonate is not first-line for this presentation and is reserved for severe acidosis or specific toxicologic indications; the clinical picture favors high spinal rather than LAST."
      },
      {
        "text": "Initiate 20% lipid emulsion (1.5 mL/kg bolus, then infusion) for suspected severe local anesthetic systemic toxicity (LAST).",
        "isCorrect": false,
        "explanation": "Lipid emulsion is first-line for severe LAST with CNS prodrome, seizures, or arrhythmias; this patient lacks CNS excitation and arrhythmias and instead has signs of an ascending high neuraxial block with profound sympathectomy."
      },
      {
        "text": "Provide positive-pressure ventilation with 100% O<sub>2</sub>; treat hypotension and bradycardia with vasopressors (eg, phenylephrine or ephedrine) and atropine for high neuraxial block.",
        "isCorrect": true,
        "explanation": "Rapid onset of dyspnea/aphonia, upper-extremity weakness, and profound hypotension/bradycardia without CNS prodrome or arrhythmias is most consistent with high spinal; immediate airway support and hemodynamic resuscitation are indicated."
      },
      {
        "text": "Give midazolam and propofol to abort seizures and then secure the airway.",
        "isCorrect": false,
        "explanation": "There is no seizure activity. Sedatives without airway/pressor support risk worsening hypotension in high spinal and delay definitive management."
      }
    ],
    "didactic": "Differentiating high neuraxial block from severe LAST hinges on onset, symptoms, and hemodynamics. After an epidural bolus, **high spinal** typically presents within minutes with rapid cephalad spread of block causing:\n- Ascending sensory/motor symptoms (eg, upper-extremity weakness, hand numbness)\n- **Dyspnea/hoarseness/aphonia** from intercostal and possible phrenic involvement; SpO<sub>2</sub> may remain normal initially\n- Early and profound **sympathetic blockade** with hypotension and **bradycardia** (Bezold–Jarisch reflex), often without dysrhythmias\n- Clear mentation until hypoperfusion occurs; no **CNS prodrome** (eg, tinnitus, metallic taste)\n\nBy contrast, **LAST** from intravascular injection often occurs within seconds to 1–3 minutes and commonly begins with CNS excitation (tinnitus, circumoral numbness, metallic taste, agitation) progressing to seizures and CNS depression, followed by cardiovascular toxicity (hypotension, reduced contractility, conduction delay, wide QRS, ventricular arrhythmias). Severe LAST may occur without prodrome under sedation, but dysrhythmias or seizure activity are typical red flags. A negative test dose does not exclude intrathecal catheter placement or high spread after a large/rapid epidural bolus.\n\nManagement differs fundamentally:\n- High spinal: immediate **airway support** (bag-mask ventilation with 100% O<sub>2</sub>, early intubation if apnea), **hemodynamic support** with vasopressors (phenylephrine if pure vasodilation; ephedrine or small epinephrine boluses if bradycardic), **atropine** for severe bradycardia, and left uterine displacement in pregnancy.\n- LAST: **20% lipid emulsion** (1.5 mL/kg bolus, then 0.25 mL/kg/min infusion), treat seizures with benzodiazepines, avoid large epinephrine doses (≤1 μg/kg if needed), and use amiodarone for ventricular arrhythmias.\n\nIn this scenario, the combination of rapid-onset dyspnea/aphonia, upper-extremity weakness, profound hypotension with sinus bradycardia, and absence of CNS prodrome or arrhythmia strongly supports **high spinal**, warranting airway and vasopressor management rather than lipid therapy.",
    "educationalObjective": "Differentiate high spinal from severe LAST during neuraxial procedures using onset timing, symptoms, and hemodynamics."
  },
  {
    "id": "Core.7.2.6",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "LAST prevention and treatment",
    "difficulty": "easy",
    "questionText": "A 68-year-old man undergoing laparoscopic inguinal hernia repair receives an ultrasound-guided transversus abdominis plane block with 0.5% bupivacaine with epinephrine. Within minutes he develops perioral numbness, agitation, and a generalized tonic–clonic seizure followed by hypotension (MAP 45 mmHg) and a wide-complex tachycardia. He is treated per a LAST checklist with airway support and supplemental O<sub>2</sub>, midazolam, small-dose epinephrine, and 20% lipid emulsion (bolus and infusion), with rapid normalization of rhythm and blood pressure. In the PACU 45 minutes later, he is asymptomatic with stable vitals and normal mentation. The surgery was planned as ambulatory.\n\nWhich of the following is the most appropriate next step regarding documentation, patient counseling, and follow-up?",
    "answers": [
      {
        "text": "Discharge today once asymptomatic with instructions to avoid all local anesthetics in the future and a short benzodiazepine prescription for recurrent symptoms.",
        "isCorrect": false,
        "explanation": "Immediate discharge after severe LAST is unsafe, and labeling all local anesthetics as an “allergy” is inappropriate; monitored observation and structured follow-up are required."
      },
      {
        "text": "File an institutional incident report and FDA MedWatch form, defer patient counseling to the surgeon, and schedule routine postoperative follow-up only.",
        "isCorrect": false,
        "explanation": "Event reporting may be appropriate, but it does not replace urgent patient-centered steps: monitoring, thorough documentation, and direct counseling with specific return precautions."
      },
      {
        "text": "Obtain an outpatient brain MRI and neurology clinic visit within 1 week without inpatient monitoring because symptoms resolved rapidly after lipid therapy.",
        "isCorrect": false,
        "explanation": "Neuroimaging is not indicated when neurologic symptoms fully resolve; the priority is monitored observation for recurrence risk and counseling, not routine MRI."
      },
      {
        "text": "Document “probable LAST” without specific doses or timing, keep the patient NPO overnight in PACU without telemetry, and forgo outpatient follow-up if still asymptomatic.",
        "isCorrect": false,
        "explanation": "Documentation should be detailed and telemetry-level monitoring is indicated after cardiovascular instability; lack of follow-up misses evaluation of potential cardiac/neurologic sequelae."
      },
      {
        "text": "Admit to a monitored unit (telemetry) for continued observation, thoroughly document the event details and lipid dosing, counsel about possible delayed neurologic/cardiac symptoms, and arrange anesthesia follow-up within 24–48 h plus cardiology evaluation.",
        "isCorrect": true,
        "explanation": "Severe LAST with cardiovascular instability warrants hospital observation on telemetry, comprehensive documentation (drug, dose, timing, manifestations, treatments, lipid regimen, and response), explicit counseling about delayed recurrence/sequelae, and planned follow-up including cardiology."
      }
    ],
    "didactic": "Local anesthetic systemic toxicity (LAST) can recur after initial stabilization and may lead to delayed neurologic or cardiac sequelae. Postevent care focuses on safe disposition, high-fidelity documentation, patient counseling, and planned follow-up.\n\n- Disposition: After severe LAST (eg, cardiovascular instability, dysrhythmia, or need for lipid emulsion), admit to a monitored setting (telemetry/ICU capability). Patients with only brief CNS symptoms that resolve may be observed for several hours, but cardiovascular involvement warrants longer observation due to risk of recurrence.\n- Documentation: Record the local anesthetic name, concentration, total dose (mg), site/technique, timing of symptom onset, progression of signs (CNS and cardiovascular), airway/ventilation management, vasoactive drugs (with doses), and the complete lipid emulsion regimen (20% solution, bolus and infusion rates, total volume). Include ECG/rhythm data, hemodynamics, and time-to-resolution.\n- Counseling: Explain that delayed symptoms can occur over the next several hours, including perioral numbness, tinnitus, confusion, seizures, palpitations, chest pain, or syncope. Provide clear return precautions and written instructions. Emphasize that this is a toxicity, not an allergy; future regional anesthesia may be possible with risk-mitigation (dose limits, incremental injection with aspiration, ultrasound guidance, intralipid availability).\n- Follow-up: Arrange anesthesia follow-up within 24–48 h to reassess for neurocognitive complaints and review the event. Cardiology follow-up (and ECG ± troponin as indicated) is advisable after significant dysrhythmia/hypotension. Consider neurology referral if residual deficits occurred. Communicate the event to the surgical and primary teams.\n\nKey resuscitation nuances (context): Use supplemental O<sub>2</sub>, treat seizures with benzodiazepines, initiate 20% lipid promptly, and avoid or minimize drugs that may worsen toxicity (eg, large-dose epinephrine, vasopressin, β-blockers, calcium channel blockers). These principles complement, not replace, the essential steps of observation, documentation, counseling, and follow-up.",
    "educationalObjective": "Document the event, counsel the patient, and arrange follow-up to evaluate neurologic and cardiac sequelae."
  },
  {
    "id": "Core.7.2.7",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "LAST prevention and treatment",
    "difficulty": "medium",
    "questionText": "A 54-year-old man (90 kg) in the PACU develops agitation, circumoral numbness, tinnitus, and then a generalized tonic–clonic seizure 10 minutes after an ultrasound-guided TAP block with bupivacaine. He is on 3 L/min O<sub>2</sub> by nasal cannula. Vital signs: SpO<sub>2</sub> 81%, HR 110/min, BP 148/86 mmHg. Intravenous access is patent, and the block injection has been stopped. A nurse is present to assist.\n\nAccording to the ASRA-based LAST algorithm, which immediate action is the most appropriate next step to initiate management?",
    "answers": [
      {
        "text": "Treat the seizure with propofol 1–2 mg/kg IV to achieve rapid suppression.",
        "isCorrect": false,
        "explanation": "Large-dose propofol can worsen myocardial depression and hypotension in LAST; benzodiazepines are preferred, and only small doses of propofol may be considered if hemodynamically stable."
      },
      {
        "text": "Begin bag-mask ventilation with 100% O<sub>2</sub> and administer midazolam 2 mg IV to terminate the seizure.",
        "isCorrect": true,
        "explanation": "Airway/oxygenation and prompt seizure control are the first priorities in LAST to prevent hypoxemia and acidosis, which exacerbate toxicity; benzodiazepines are first-line for seizures."
      },
      {
        "text": "Give epinephrine 1 mg IV and begin ACLS protocols preemptively.",
        "isCorrect": false,
        "explanation": "High-dose epinephrine (1 mg) is reserved for cardiac arrest and can worsen outcomes in LAST; use small, titrated doses (≤1 μg/kg) only if needed for hypotension after airway and seizure control."
      },
      {
        "text": "Administer lidocaine 1 mg/kg IV to suppress central neuronal excitability.",
        "isCorrect": false,
        "explanation": "Intravenous lidocaine is contraindicated in LAST because it is itself a local anesthetic and can exacerbate toxicity."
      },
      {
        "text": "Administer a 20% lipid emulsion 1.5 mL/kg IV bolus immediately as the first and sole initial intervention.",
        "isCorrect": false,
        "explanation": "Lipid therapy should be started early, but the immediate priority during an active seizure with hypoxemia is to secure ventilation/oxygenation and stop the seizure; lipid can follow promptly."
      }
    ],
    "didactic": "Local anesthetic systemic toxicity (LAST) demands immediate, protocolized management. The ASRA algorithm prioritizes: (1) stop injection and call for help; (2) support airway, breathing, and circulation; and (3) control seizures. Active seizures rapidly produce hypoxemia and acidosis, which increase the ionized fraction of local anesthetics in the myocardium and CNS, worsening toxicity. Therefore, the first actionable steps are to provide 100% O<sub>2</sub> (eg, bag-mask ventilation or early intubation if needed) and terminate seizures with a **benzodiazepine**. Small doses of propofol may be used if benzodiazepines are unavailable or ineffective, but **large doses of propofol** can precipitate myocardial depression and should be avoided in suspected LAST.\n\nEarly **lipid emulsion therapy** is recommended once airway/oxygenation and seizures are addressed or concurrently if help is available. Dosing of 20% lipid: bolus 1.5 mL/kg over 2–3 minutes, then infusion 0.25 mL/kg/min; repeat bolus up to twice and increase infusion to 0.5 mL/kg/min for persistent instability, with a typical maximum of ~10 mL/kg in the first 30 minutes. Use lean body weight if obesity is present.\n\nHemodynamic management includes **small, titrated epinephrine** doses (≤1 μg/kg) if needed; avoid vasopressin, calcium channel blockers, and β-blockers. For ventricular arrhythmias, **amiodarone** is preferred; avoid lidocaine. Maintain normocapnia and normoxia—avoid hypoventilation and acidosis. Consider early consultation for extracorporeal support if refractory cardiovascular collapse occurs.\n\nKey priorities in the first minutes are: \n- 100% O<sub>2</sub> with assisted ventilation; prepare for intubation if needed\n- Benzodiazepine for seizure control\n- Prompt initiation of lipid emulsion therapy\nThese steps interrupt the pathophysiologic spiral of hypoxemia/acidosis and facilitate recovery.",
    "educationalObjective": "Initiate the ASRA-based LAST algorithm promptly, prioritizing airway, oxygenation, and seizure control."
  },
  {
    "id": "Core.7.2.8",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "LAST prevention and treatment",
    "difficulty": "medium",
    "questionText": "A 78-year-old, 55-kg woman with ischemic cardiomyopathy (EF 25%), mild congestive hepatopathy, and chronic β-blocker therapy is scheduled for surgical fixation of multiple right rib fractures. She is hemodynamically stable and will receive light sedation. To optimize postoperative pulmonary mechanics, you plan regional analgesia. Several options are being considered; all will be performed under ultrasound guidance with frequent aspiration and incremental dosing.\n\nWhich plan most increases this patient’s risk of local anesthetic systemic toxicity (LAST)?",
    "answers": [
      {
        "text": "Bilateral transversus abdominis plane blocks using 0.25% bupivacaine with epinephrine 1:200,000, 40 mL total",
        "isCorrect": false,
        "explanation": "TAP plane has relatively low vascularity and the total bupivacaine dose (100 mg) is below toxic thresholds; epinephrine further lowers systemic uptake."
      },
      {
        "text": "Multilevel intercostal nerve blocks (T4–T8) using 0.5% bupivacaine, 30 mL total, without epinephrine",
        "isCorrect": true,
        "explanation": "Intercostal blocks have the highest vascular uptake, bupivacaine is highly cardiotoxic, and omission of epinephrine increases systemic absorption; 150 mg exceeds the recommended 2.5 mg/kg limit for 55 kg. Advanced age and low cardiac output further reduce clearance, compounding risk."
      },
      {
        "text": "Thoracic epidural after a negative epinephrine test dose, followed by 1.5% lidocaine with epinephrine, 10 mL in divided doses",
        "isCorrect": false,
        "explanation": "Epidural uptake is moderate, the total lidocaine dose (150 mg) is well within epinephrine-augmented limits, and test dosing plus fractionation mitigate intravascular injection risk."
      },
      {
        "text": "Single-shot thoracic paravertebral block at T6 using 2% chloroprocaine, 20 mL, without epinephrine",
        "isCorrect": false,
        "explanation": "Chloroprocaine (an ester) is rapidly hydrolyzed by plasma cholinesterase, reducing systemic accumulation; paravertebral uptake is less than intercostal, lowering LAST risk compared with option A."
      },
      {
        "text": "Single-shot erector spinae plane block at T6 using 0.5% ropivacaine, 30 mL, with epinephrine 1:200,000",
        "isCorrect": false,
        "explanation": "Ropivacaine is less cardiotoxic than bupivacaine, plane blocks have lower vascular uptake than intercostal injections, and epinephrine reduces systemic absorption and helps detect intravascular injection."
      }
    ],
    "didactic": "Local anesthetic systemic toxicity (LAST) risk reflects the interaction of patient factors, procedural factors (site and technique), and the drug/dose used. **Patient factors** that increase risk include extremes of age (neonates and elderly), **cardiac disease** (ischemia, reduced EF, conduction disease), **reduced hepatic blood flow** (eg, CHF, shock), **hepatic dysfunction**, pregnancy, low **α<sub>1</sub>-acid glycoprotein** (↑free fraction), and metabolic derangements (acidosis, hypercarbia, hypoxia) that potentiate CNS/cardiac toxicity. Sedation or general anesthesia can mask early CNS signs, delaying recognition.\n\n**Procedural factors** driving systemic absorption include injection site vascularity and intravascular injection. Vascular uptake generally ranks: **intercostal > caudal > epidural > brachial plexus > femoral/sciatic > subcutaneous/TAP**. Techniques that mitigate risk include ultrasound guidance, careful aspiration, **incremental/fractionated dosing**, and adding **epinephrine (1:200,000)** to reduce absorption and serve as an intravascular marker (HR/BP changes) when not contraindicated.\n\n**Drug/dose factors** are pivotal. **Bupivacaine** is highly potent and cardiotoxic with slow dissociation from myocardial Na<sup>+</sup> channels; **ropivacaine** is less cardiotoxic; **lidocaine** has intermediate toxicity; and **esters** (eg, chloroprocaine) are rapidly hydrolyzed, limiting accumulation. Dose should be weight-based (mg/kg) and consider additive dosing when multiple blocks are performed.\n\nIn this elderly, low-EF patient, multilevel intercostal blocks with high-dose bupivacaine and no epinephrine combine the most hazardous elements: highly vascular site, potent/cardiotoxic agent, borderline-to-excessive dose, and reduced clearance from low cardiac output/hepatic congestion—maximizing LAST risk. Safer alternatives use less cardiotoxic agents, lower total doses, less vascular planes, and epinephrine with fractionated dosing. Recognizing and modifying these **patient**, **procedural**, and **drug** factors is central to preventing LAST.",
    "educationalObjective": "List patient and procedural risk factors for LAST, including extremes of age, cardiac disease, and highly vascular injection sites."
  },
  {
    "id": "Core.7.2.9",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "LAST prevention and treatment",
    "difficulty": "hard",
    "questionText": "A 62-kg woman undergoing shoulder arthroscopy receives an interscalene block with 30 mL of 0.5% ropivacaine. Within minutes she develops perioral numbness, agitation, and a generalized tonic-clonic seizure treated with midazolam. She then becomes pulseless with ventricular fibrillation on the monitor. High-flow O<sub>2</sub> is applied, chest compressions are initiated, a 20% lipid emulsion bolus (1.5 mL/kg) is given followed by an infusion (0.25 mL/kg/min), and two biphasic defibrillation attempts are delivered without conversion. A single small epinephrine bolus (50 mcg) was administered.\n\nYou remind the team that standard ACLS must be modified in local anesthetic systemic toxicity (LAST). Which of the following is the most appropriate medication to administer now for this refractory arrhythmia?",
    "answers": [
      {
        "text": "Vasopressin 40 units IV",
        "isCorrect": false,
        "explanation": "Vasopressin should be avoided in LAST; it has been associated with worse outcomes and may impair resuscitation by reducing myocardial perfusion in this context."
      },
      {
        "text": "Magnesium sulfate 2 g IV",
        "isCorrect": false,
        "explanation": "Magnesium is indicated for torsades de pointes; it is not the preferred antiarrhythmic for refractory VF/VT due to LAST."
      },
      {
        "text": "Epinephrine 1 mg IV every 3–5 minutes",
        "isCorrect": false,
        "explanation": "High-dose epinephrine can worsen arrhythmias and impairs lipid resuscitation; in LAST, epinephrine should be limited to ≤1 mcg/kg boluses and used sparingly."
      },
      {
        "text": "Amiodarone 300 mg IV push",
        "isCorrect": true,
        "explanation": "Amiodarone is the preferred antiarrhythmic for refractory VF/VT in LAST because it avoids additional Na<sup>+</sup> channel blockade; 300 mg IV is recommended after failed defibrillation."
      },
      {
        "text": "Lidocaine 1.5 mg/kg IV",
        "isCorrect": false,
        "explanation": "Class Ib agents add Na<sup>+</sup> channel blockade and can exacerbate LAST-induced conduction abnormalities and cardiac depression."
      }
    ],
    "didactic": "Local anesthetic systemic toxicity (LAST) requires immediate airway/ventilation support, seizure control, and lipid emulsion therapy, with targeted modifications to standard ACLS. After airway management with 100% O<sub>2</sub>, seizures are best treated with benzodiazepines, and 20% lipid emulsion is initiated (bolus 1.5 mL/kg, then 0.25 mL/kg/min; repeat bolus and increase infusion to 0.5 mL/kg/min as needed, up to ≈10 mL/kg in the first 30 minutes). During cardiac arrest from LAST, the resuscitation algorithm diverges from conventional ACLS in key ways:\n\n- Limit epinephrine dosing: use small boluses (≤1 mcg/kg) only as needed for hemodynamic support. Large doses (eg, 1 mg q3–5 min) increase afterload, worsen arrhythmias, and reduce the efficacy of lipid-mediated resuscitation.\n- Avoid vasopressin: it can impair myocardial perfusion and is associated with poorer outcomes in LAST-related arrests.\n- Prefer amiodarone for refractory VF/V<sub>T</sub>: after defibrillation attempts, amiodarone is the antiarrhythmic of choice because it provides rhythm stabilization without additional Na<sup>+</sup> channel blockade. Avoid lidocaine and procainamide, which exacerbate sodium channel blockade and conduction slowing inherent to LAST.\n- Avoid β-blockers and calcium channel blockers, which can further depress myocardial contractility and conduction.\n\nMechanistically, LAST produces profound Na<sup>+</sup> channel blockade (and at higher concentrations, K<sup>+</sup> and Ca<sup>2+</sup> effects), leading to wide-complex arrhythmias, decreased contractility, and hypotension. Excess catecholamines increase myocardial oxygen demand and may worsen dysrhythmias, while vasopressin can reduce coronary perfusion. Amiodarone stabilizes membranes and supports defibrillation success without compounding Na<sup>+</sup> channel blockade. Thus, in a patient with persistent VF after defibrillation and appropriate lipid therapy, administering amiodarone is preferred, while epinephrine dosing is minimized, and vasopressin is avoided.",
    "educationalObjective": "Modify ACLS in LAST by limiting epinephrine doses, avoiding vasopressin, and preferring amiodarone for refractory arrhythmias."
  },
  {
    "id": "Core.7.2.10",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "LAST prevention and treatment",
    "difficulty": "medium",
    "questionText": "A 4-year-old boy (16 kg) undergoing open inguinal hernia repair receives an ilioinguinal/iliohypogastric block with bupivacaine. Within 1 minute, he becomes agitated and develops a generalized tonic–clonic seizure. You secure the airway, ventilate with 100% O<sub>2</sub>, administer midazolam 0.1 mg/kg, and note HR 55/min and BP 60/35 mmHg. You suspect local anesthetic systemic toxicity (LAST). A 20% lipid emulsion (100 mL vials) and a syringe pump are immediately available.\n\nWhich of the following best describes the initial lipid therapy and vasoactive strategy you should implement now?",
    "answers": [
      {
        "text": "20% lipid emulsion 8 mL IV bolus over 1 min, then infusion at 240 mL/h; use small-dose epinephrine ≤1 µg/kg if needed.",
        "isCorrect": false,
        "explanation": "The bolus is too small; the correct initial bolus is 1.5 mL/kg (24 mL for 16 kg)."
      },
      {
        "text": "20% lipid emulsion 24 mL IV bolus over 1 min, then infusion at 24 mL/h; use epinephrine boluses of 10 µg/kg if needed.",
        "isCorrect": false,
        "explanation": "The infusion rate is underdosed by a factor of 10 (should be 240 mL/h). In LAST, epinephrine should be minimized (≤1 µg/kg), not 10 µg/kg."
      },
      {
        "text": "20% lipid emulsion 24 mL IV bolus over 1 min, then infusion at 480 mL/h from the outset; use small-dose epinephrine ≤1 µg/kg if needed.",
        "isCorrect": false,
        "explanation": "Starting at 0.5 mL/kg/min (480 mL/h) is premature; begin with 0.25 mL/kg/min and increase only if instability persists after boluses."
      },
      {
        "text": "20% lipid emulsion 160 mL IV bolus over 1 min, then infusion at 240 mL/h; avoid epinephrine and use vasopressin 0.8 U for hypotension.",
        "isCorrect": false,
        "explanation": "A 10 mL/kg bolus is dangerously excessive, and vasopressin is discouraged in LAST because it can worsen cardiac instability."
      },
      {
        "text": "20% lipid emulsion 24 mL IV bolus over 1 min, then infusion at 240 mL/h; if instability persists, give small-dose epinephrine ≤1 µg/kg and consider repeating the bolus and increasing the infusion to 0.5 mL/kg/min.",
        "isCorrect": true,
        "explanation": "For a 16-kg child, the ASRA-recommended initial dosing is 1.5 mL/kg (24 mL) bolus and 0.25 mL/kg/min (4 mL/min = 240 mL/h) infusion; epinephrine should be used in small doses (≤1 µg/kg), with escalation of lipid only if instability persists."
      }
    ],
    "didactic": "Pediatric LAST management mirrors adult protocols but requires precise weight-based calculations and child-appropriate equipment. After airway control and seizure suppression (benzodiazepines preferred; avoid large propofol doses), initiate **20% lipid emulsion** promptly.\n\n- Initial bolus: **1.5 mL/kg** IV over ~1 minute.\n- Continuous infusion: **0.25 mL/kg/min** (increase to 0.5 mL/kg/min if instability persists).\n- Repeat bolus: Every 5 minutes up to 2 additional times for refractory hypotension/arrhythmias.\n- Continue the infusion for at least **10 minutes after hemodynamic stability**.\n- Upper limit: Approximately **10 mL/kg during the first 30 minutes**.\n\nFor a 16-kg child, the correct initial dosing is a 24 mL bolus (1.5 mL/kg × 16 kg) and a 4 mL/min infusion (0.25 mL/kg/min × 16 kg) which equals **240 mL/h**. Use a 50 mL syringe for the bolus and a syringe pump capable of pediatric high-flow rates for the infusion; have additional 20% lipid vials immediately available to avoid interruptions.\n\nVasoactive support during LAST should be tailored to minimize arrhythmogenicity. Use **small-dose epinephrine (≤1 µg/kg boluses)** if needed for hypotension/bradycardia. Avoid **vasopressin**, **calcium channel blockers**, and **β-blockers**. For refractory ventricular arrhythmias, prefer **amiodarone** over lidocaine. Maintain adequate oxygenation/ventilation with 100% O<sub>2</sub> and avoid severe hyperventilation.\n\nPediatric readiness includes appropriately sized equipment (airway adjuncts, IV/IO access, defibrillation pads/energy) and dosing cards or checklists to reduce error. Because lipid dosing is volume-based, pre-calculating bolus and infusion rates from patient weight and programming the pump in mL/h help prevent under- or overdosing. This weight-based, stepwise lipid strategy with cautious epinephrine use is the standard initial therapy for pediatric LAST.",
    "educationalObjective": "Plan pediatric LAST dosing using weight-based lipid protocols and equipment sized for children."
  },
  {
    "id": "Core.7.2.11",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "LAST prevention and treatment",
    "difficulty": "medium",
    "questionText": "A 58-year-old man is undergoing an ultrasound-guided popliteal sciatic nerve block for foot surgery. After positioning the needle adjacent to the nerve, you attempt to inject 1 mL of normal saline for hydrodissection through an in-line injection pressure monitor. The opening injection pressure reads 22 psi, the patient reports sharp paresthesia radiating to the foot, and the nerve briefly appears to swell without clear perineural spread. Aspiration is negative for blood, and there is no motor response at 0.5 mA with a nerve stimulator. What is the most appropriate next step to minimize the risk of intraneural injection?\n\n",
    "answers": [
      {
        "text": "After negative aspiration, inject an epinephrine-containing test dose to rule out intravascular injection and proceed if hemodynamics are unchanged.",
        "isCorrect": false,
        "explanation": "Test dosing helps detect intravascular injection (LAST prevention) but does not mitigate intraneural risk indicated by high opening pressure and nerve swelling."
      },
      {
        "text": "Administer additional midazolam and fentanyl to improve tolerance and proceed under continuous ultrasound visualization.",
        "isCorrect": false,
        "explanation": "Sedation can mask warning symptoms (pain/paresthesia) and does not address unsafe needle position or high injection pressure."
      },
      {
        "text": "Decrease the injection rate and continue at the current needle position using 0.5–1 mL aliquots.",
        "isCorrect": false,
        "explanation": "Slower injection does not resolve intraneural tip location; opening pressure reflects a noncompliant space and elevated pressure persists, risking nerve injury."
      },
      {
        "text": "Stop injection immediately, withdraw/reposition the needle until opening pressure is ≤15 psi with easy perineural spread on ultrasound, then proceed in small aliquots with frequent aspiration.",
        "isCorrect": true,
        "explanation": "High opening pressure, paresthesia, and nerve swelling suggest intraneural/intrafascicular placement. The correct response is to stop, reposition, and only resume when pressure is ≤15 psi with clear extra-neural spread."
      },
      {
        "text": "Rely on the absence of a motor response at 0.5 mA to exclude intraneural placement and continue with injection.",
        "isCorrect": false,
        "explanation": "Nerve stimulation is insensitive for intrafascicular injection; a negative response does not ensure safe extraneural location."
      }
    ],
    "didactic": "Preventing intraneural (especially intrafascicular) injection requires integrating ultrasound imaging with **injection pressure monitoring** and patient feedback. The **opening injection pressure** is the pressure required to initiate flow; when the needle tip is in a compliant, extra-neural tissue plane, this pressure is low. An opening pressure >15 psi suggests entry into a **noncompliant compartment** (eg, fascicle) or the needle tip abutting a tight fascial boundary. In this situation—high opening pressure, paresthesia, and nerve swelling without clear perineural spread—the safest action is to **stop injection**, withdraw/reposition the needle, and only resume when the opening pressure is ≤15 psi with visible extra-neural spread.\n\nKey points for safe injection:\n- Use an in-line manometer or a “compressed air/half-the-air” technique to maintain opening pressure ≤15 psi.\n- Inject in small aliquots (0.5–1 mL) with frequent aspiration and continuous ultrasound to confirm perineural spread rather than nerve expansion.\n- Heed patient-reported **pain or paresthesia**; avoid deep sedation that can mask symptoms.\n- Recognize that a **negative nerve stimulator response** does not exclude intrafascicular placement; stimulation is insensitive and can be absent even with unsafe needle location.\n- Understand that **negative aspiration** and epinephrine test dosing address intravascular injection (important for LAST prevention) but do not mitigate intraneural risk.\n\nUltrasound findings concerning for intraneural injection include **nerve enlargement, loss of fascicular definition, and atypical expansion** without tracking along expected fascial planes. Proper technique emphasizes low opening pressure, correct needle tip position, and confirmation of perineural spread before delivering local anesthetic. Stopping immediately when high resistance is encountered is critical to prevent nerve injury and improve block safety.",
    "educationalObjective": "Prevent intraneural injection by monitoring opening injection pressure and stopping when high resistance is encountered."
  },
  {
    "id": "Core.7.2.12",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "LAST prevention and treatment",
    "difficulty": "easy",
    "questionText": "A 62-year-old man undergoing shoulder arthroscopy receives an ultrasound-guided interscalene block with 30 mL of 0.5% bupivacaine. Within 2 minutes, he becomes agitated and reports circumoral numbness, a metallic taste, tinnitus, and lightheadedness. Vital signs are HR 112/min, BP 165/95 mmHg, SpO<sub>2</sub> 99% on room air; no seizures have occurred. \n\nRecognizing these as prodromal CNS signs of LAST, which immediate intervention is most appropriate to prevent progression to cardiovascular collapse?",
    "answers": [
      {
        "text": "Give lidocaine 1 mg/kg IV to prevent ventricular arrhythmias",
        "isCorrect": false,
        "explanation": "Additional Na<sup>+</sup> channel blockade (e.g., lidocaine) can exacerbate LAST cardiotoxicity and is contraindicated."
      },
      {
        "text": "Treat hypertension and tachycardia with an esmolol bolus to blunt CNS excitation",
        "isCorrect": false,
        "explanation": "β-blockade does not treat LAST and can worsen myocardial depression and conduction block, removing compensatory tachycardia and predisposing to hypotension and bradyarrhythmias."
      },
      {
        "text": "Administer propofol 1 mg/kg IV for agitation and defer lipid unless seizures occur",
        "isCorrect": false,
        "explanation": "Propofol can transiently suppress seizures but is a myocardial depressant; benzodiazepines are preferred, and lipid therapy should not be delayed in suspected evolving LAST."
      },
      {
        "text": "Observe for 10 minutes because symptoms are likely from an epinephrine test dose",
        "isCorrect": false,
        "explanation": "Epinephrine test doses cause palpitations and transient tachycardia; circumoral numbness, metallic taste, and tinnitus are classic early LAST symptoms and warrant immediate treatment."
      },
      {
        "text": "Initiate 20% lipid emulsion therapy now (1.5 mL/kg IV bolus, then 0.25 mL/kg/min infusion) while providing 100% O<sub>2</sub>",
        "isCorrect": true,
        "explanation": "Early lipid emulsion at the first signs of LAST—especially after a large bupivacaine dose—limits progression to seizures and cardiotoxicity; simultaneous airway/oxygenation reduces hypoxemia/acidosis that exacerbate toxicity."
      }
    ],
    "didactic": "Local anesthetic systemic toxicity (LAST) typically begins with **prodromal CNS excitation**—tinnitus, circumoral numbness, metallic taste, agitation, dizziness—followed by **seizures** and then **cardiovascular depression** (hypotension, bradyarrhythmias, wide-complex tachycardia, ventricular fibrillation, and cardiac arrest). Potent amide agents (especially **bupivacaine**) and large-volume peripheral blocks increase risk. Hypoxemia, hypercarbia, and acidosis increase cerebral blood flow and the free fraction of drug, worsening toxicity.\n\nImmediate management priorities are to stop local anesthetic injection, call for help, and support airway/ventilation with **100% O<sub>2</sub>** to avoid hypoxemia and acidosis. Treat seizures with **benzodiazepines**; avoid large doses of propofol due to negative inotropy. Importantly, **early lipid emulsion therapy** is recommended at the first signs of LAST—especially with bupivacaine or rapidly evolving symptoms—to mitigate progression to cardiovascular collapse. A common regimen is:\n- 20% lipid emulsion **1.5 mL/kg IV bolus** (over ~1 min)\n- Then **0.25 mL/kg/min infusion**; repeat bolus and increase to 0.5 mL/kg/min for persistent instability\n- Avoid exceeding ~10 mL/kg over 30 min\n\nFor hemodynamics, use **small epinephrine doses** (≤1 µg/kg) if needed. Avoid **vasopressin**, **β-blockers**, **calcium channel blockers**, and additional **Na<sup>+</sup> channel blockers** (e.g., lidocaine) as they can worsen myocardial depression or conduction block. **Amiodarone** is acceptable for refractory ventricular arrhythmias.\n\nDistinguish LAST from an epinephrine test dose: the latter causes transient palpitations and tachycardia, whereas **tinnitus, metallic taste, and perioral numbness** strongly suggest intravascular local anesthetic exposure. Early recognition and prompt lipid therapy, coupled with aggressive airway/ventilatory support, are key to preventing **cardiovascular collapse**.",
    "educationalObjective": "Recognize prodromal CNS symptoms of LAST and anticipate progression to cardiovascular collapse."
  },
  {
    "id": "Core.7.2.13",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "LAST prevention and treatment",
    "difficulty": "medium",
    "questionText": "A 68-year-old man (82 kg) on metoprolol undergoes an ultrasound-guided infraclavicular brachial plexus block for distal radius ORIF. Planned local anesthetic is ropivacaine 0.5%, 25 mL. You plan light sedation with midazolam 1 mg and fentanyl 25 μg. To minimize the risk of unrecognized intravascular injection and reduce LAST, which approach is best for this β-blocked patient?\n\nWhich of the following is the best strategy to reduce LAST risk in this setting?",
    "answers": [
      {
        "text": "After a single negative aspiration, inject the entire 25 mL bolus under ultrasound while observing for patient symptoms.",
        "isCorrect": false,
        "explanation": "Negative aspiration has limited sensitivity, and a single large bolus increases the risk of rapid intravascular delivery and LAST, especially when sedation blunts early symptoms."
      },
      {
        "text": "Avoid epinephrine because of β-blockade and rely on ultrasound guidance alone to prevent vascular puncture.",
        "isCorrect": false,
        "explanation": "Ultrasound lowers but does not eliminate intravascular injection; epinephrine remains useful (BP response often persists) and also reduces systemic uptake via vasoconstriction."
      },
      {
        "text": "Give a one-time 15 μg epinephrine test dose; if no ≥10 bpm HR increase occurs, proceed with the full injection without further pauses.",
        "isCorrect": false,
        "explanation": "A single test dose can miss later intravascular migration; continuous epinephrine marker within the solution and incremental aliquots improve detection, and HR criteria are unreliable in β-blocked patients."
      },
      {
        "text": "Add epinephrine 5 μg/mL to the local anesthetic and inject under real-time ultrasound in 3–5 mL aliquots with frequent aspiration, treating a ≥15 mmHg SBP rise within 30–60 s as a positive intravascular marker.",
        "isCorrect": true,
        "explanation": "Combining ultrasound visualization with incremental injection, epinephrine marker, and a blood pressure endpoint (in β-blocked patients) optimizes detection of intravascular injection and reduces systemic uptake."
      },
      {
        "text": "Reduce volume to 15 mL ropivacaine 0.5% and inject as a single bolus after negative aspiration to lower total dose.",
        "isCorrect": false,
        "explanation": "Lowering dose helps but does not address unrecognized intravascular injection; incremental injection with epinephrine provides superior safety monitoring."
      }
    ],
    "didactic": "Preventing LAST requires layered risk-reduction strategies because no single method is failsafe. **Ultrasound guidance** decreases vascular puncture by visualizing the needle tip and local anesthetic spread, but it cannot fully prevent intravascular injection. Use **incremental injection** (3–5 mL aliquots) with **frequent aspiration** and brief pauses (≈15–30 s) to detect early hemodynamic changes before delivering a large intravascular bolus.\n\nAdding **epinephrine 1:200,000 (5 μg/mL)** to the local anesthetic creates a continuous intravascular marker throughout the injection. Typical intravascular entry produces an increase in **HR ≥10 bpm** or **SBP ≥15 mmHg** within 30–60 s. In patients on **β-blockers**, the chronotropic response is blunted, so a **blood pressure rise** is a more reliable endpoint. Epinephrine also **reduces systemic absorption** by vasoconstriction, lowering peak plasma levels and further decreasing LAST risk.\n\nOther practices are less protective when used alone:\n- **Negative aspiration** has limited sensitivity and can be falsely reassuring.\n- A **single test dose** may miss late intravascular migration; keeping epinephrine in the solution with incremental dosing is superior.\n- **Nerve stimulation** and **low injection pressure** techniques help avoid intraneural injection but do not reliably prevent intravascular injection.\n- Heavy **sedation** can mask early CNS symptoms of LAST; maintain light, purposeful sedation and vigilant monitoring.\n\nAdditional safeguards include using the **lowest effective dose/volume**, selecting less cardiotoxic agents (eg, ropivacaine over bupivacaine), avoiding highly vascular injection sites when possible, and having **lipid emulsion** immediately available. Together, **ultrasound guidance**, **incremental injection with aspiration**, and **epinephrine test dosing (with BP endpoints in β-blocked patients)** provide the most effective, practical approach to reduce LAST during peripheral nerve blocks.",
    "educationalObjective": "Reduce LAST risk using ultrasound guidance, incremental injection with aspiration, and epinephrine test dosing where applicable."
  },
  {
    "id": "Core.7.2.14",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "LAST prevention and treatment",
    "difficulty": "hard",
    "questionText": "A 30-year-old G2P1 at 36 weeks (weight 80 kg) develops perioral numbness, tinnitus, and then a generalized tonic–clonic seizure 1 minute after a 10 mL bolus of epidural local anesthetic for labor analgesia. BP is 75/40 mmHg, HR 130/min, SpO<sub>2</sub> 96% on nasal cannula. A large gravid uterus is present, and 20% lipid emulsion is immediately available in the room. Fetal heart tracing shows recurrent late decelerations. \n\nWhich immediate management is most appropriate to optimize maternal resuscitation and uteroplacental perfusion?",
    "answers": [
      {
        "text": "Give lidocaine 1 mg/kg IV for ventricular ectopy and keep the patient supine; use large-dose epinephrine boluses to treat hypotension.",
        "isCorrect": false,
        "explanation": "Lidocaine and other sodium channel–blocking antiarrhythmics are contraindicated in LAST, supine positioning worsens aortocaval compression, and large epinephrine doses impair resuscitation in LAST."
      },
      {
        "text": "Administer 20% lipid emulsion 1.5 mL/kg IV bolus and start 0.25 mL/kg/min infusion while performing manual left uterine displacement and treating the seizure with a benzodiazepine and 100% O<sub>2</sub>.",
        "isCorrect": true,
        "explanation": "Early lipid therapy at the first signs of severe LAST (seizure/hypotension) improves outcomes; simultaneous manual left uterine displacement reduces aortocaval compression, and benzodiazepines plus 100% O<sub>2</sub> address seizures and oxygenation."
      },
      {
        "text": "Start a vasopressin infusion for hypotension and give amiodarone to stop the seizure; keep the patient supine while preparing for ECMO.",
        "isCorrect": false,
        "explanation": "Vasopressin is contraindicated in LAST, amiodarone treats arrhythmias (not seizures), and supine positioning without left uterine displacement exacerbates aortocaval compression."
      },
      {
        "text": "Rapid sequence intubation with hyperventilation to PaCO<sub>2</sub> 25 mmHg and epinephrine 1 mg IV; initiate lipid only if pulseless.",
        "isCorrect": false,
        "explanation": "Severe hyperventilation can reduce uteroplacental blood flow, and a 1 mg epinephrine bolus is inappropriate in LAST; lipid should be given early at seizure onset or hemodynamic instability."
      },
      {
        "text": "Treat the seizure with propofol 2 mg/kg, then consider lipid therapy if cardiovascular collapse occurs; place a wedge under the left hip afterward.",
        "isCorrect": false,
        "explanation": "High-dose propofol can worsen hypotension in LAST, and lipid should not be delayed until collapse. Wedge under the left hip tilts the patient rightward, worsening aortocaval compression."
      }
    ],
    "didactic": "Pregnancy increases susceptibility to local anesthetic systemic toxicity (LAST) due to higher cardiac output, engorged epidural veins (greater intravascular injection risk), and reduced α<sub>1</sub>-acid glycoprotein binding (higher free drug). When LAST occurs in a viable pregnancy, maternal resuscitation takes priority, with obstetric-specific modifications.\n\nKey steps for pregnant patients with suspected LAST:\n- Immediate airway/ventilation support with 100% O<sub>2</sub> to prevent hypoxemia/acidosis; secure the airway if needed.\n- Control seizures with a benzodiazepine (eg, midazolam). Avoid large propofol doses because they can worsen hypotension; small aliquots may be used only if benzodiazepines are unavailable.\n- Initiate 20% lipid emulsion early at the first signs of serious toxicity (eg, seizure, hypotension, arrhythmia): 1.5 mL/kg IV bolus over 1 minute, then 0.25 mL/kg/min infusion; repeat the bolus up to twice and increase infusion to 0.5 mL/kg/min if instability persists (maximum 10 mL/kg in 30 minutes). Early lipid improves return of spontaneous circulation and limits tissue exposure.\n- Perform manual left uterine displacement (or 15–30° left tilt) to relieve aortocaval compression, improving venous return, cardiac output, and uteroplacental perfusion.\n- ACLS with LAST-specific adjustments: use small epinephrine doses (≤1 μg/kg boluses), avoid vasopressin and sodium channel–blocking antiarrhythmics (eg, lidocaine, procainamide), and use amiodarone for ventricular arrhythmias if needed.\n- Avoid severe hyperventilation; extreme hypocapnia can reduce uterine blood flow. Target normal maternal ventilation (pregnant baseline PaCO<sub>2</sub> ≈ 30–32 mmHg).\n- If cardiac arrest persists despite interventions, consider perimortem cesarean delivery at 4–5 minutes (≥20 weeks) to improve maternal resuscitation and fetal outcome; consider ECMO for refractory cases.\n\nThus, in a seizing, hypotensive parturient with suspected LAST, the best immediate approach is to provide 100% O<sub>2</sub>, abort the seizure with a benzodiazepine, deliver early lipid therapy, and apply left uterine displacement to optimize maternal and fetal perfusion.",
    "educationalObjective": "Tailor LAST management in pregnancy with left uterine displacement and early lipid therapy."
  },
  {
    "id": "Core.7.3.1",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Local anesthetic pharmacology",
    "difficulty": "medium",
    "questionText": "A 60-kg man with multiple rib fractures has severe chest wall pain limiting ventilation. You plan ultrasound-guided intercostal nerve blocks from T4–T9 bilaterally (12 injections). The initial plan is ropivacaine 0.5%, 3 mL per level (total 36 mL = 180 mg ≈ 3 mg/kg), without epinephrine. He is hemodynamically stable with normal hepatic/renal function. You recall that intercostal and interpleural injections have among the highest systemic absorption of local anesthetics.\n\nWhich of the following is the most appropriate modification to dosing and monitoring to minimize systemic toxicity while maintaining effective analgesia?",
    "answers": [
      {
        "text": "Replace with a serratus anterior plane block using the same dose because interfascial plane blocks have negligible systemic absorption.",
        "isCorrect": false,
        "explanation": "Interfascial plane blocks still have substantial systemic uptake; using the same dose does not address toxicity risk."
      },
      {
        "text": "Deepen sedation with midazolam and fentanyl to blunt early CNS symptoms of LAST; routine PACU monitoring is sufficient.",
        "isCorrect": false,
        "explanation": "Sedation masks early LAST signs and does not reduce absorption; heightened monitoring is needed after high-uptake blocks."
      },
      {
        "text": "Add epinephrine 1:200,000 to ropivacaine, reduce total dose (eg, 0.375% at 2 mL/level; total ≈90 mg), inject incrementally with frequent aspiration, and observe closely for 45–60 min after completion.",
        "isCorrect": true,
        "explanation": "Intercostal blocks have the highest systemic uptake; lowering total dose and adding epinephrine reduces peak plasma levels, while incremental dosing with aspiration and extended observation mitigates LAST risk without sacrificing efficacy."
      },
      {
        "text": "Maintain the planned ropivacaine dose but inject very slowly at each level; injection rate primarily determines peak plasma concentration.",
        "isCorrect": false,
        "explanation": "Peak concentrations are driven mainly by site vascularity and total dose, not injection speed; intercostal vascularity yields high uptake despite slow injections."
      },
      {
        "text": "Switch to 0.5% bupivacaine at the same total milligrams because its longer duration is associated with lower systemic absorption.",
        "isCorrect": false,
        "explanation": "Longer duration does not imply lower absorption; bupivacaine has greater cardiotoxicity and equal or higher risk if dosed similarly."
      }
    ],
    "didactic": "Systemic absorption of local anesthetics depends on site vascularity, total dose/concentration, addition of vasoconstrictors, surface area injected, and tissue inflammation. Vascular uptake is greatest with thoracic **intercostal/interpleural** injections, followed by caudal/epidural, brachial plexus, femoral/sciatic, and subcutaneous sites. Multi-level intercostal blocks markedly expand absorptive surface area and often produce the highest peak plasma levels among peripheral techniques.\n\nTo reduce toxicity risk during high-uptake blocks:\n- Use the **lowest effective total dose** and consider a **more dilute concentration** to achieve spread while limiting milligrams delivered.\n- Add **epinephrine 1:200,000 (5 µg/mL)** to reduce systemic absorption via α-mediated vasoconstriction and to serve as an intravascular marker (transient HR increase ≥10 bpm or SBP rise ≥15 mmHg).\n- Inject **incrementally with frequent aspiration** under ultrasound guidance to limit inadvertent intravascular dosing.\n- Maintain **minimal sedation** to detect early CNS symptoms of LAST (tinnitus, perioral numbness, metallic taste) and **observe closely for 30–60 min**, as intercostal peaks typically occur within this window.\n- Ensure **lipid emulsion** is immediately available and standard monitors are applied.\n\nTypical single-injection upper dosing guidelines (without epinephrine) are approximately: bupivacaine 2.5 mg/kg, ropivacaine 3 mg/kg, and lidocaine 5 mg/kg; these limits may overestimate safety for highly vascular sites such as intercostal or interpleural injections. Thus, a practical approach is to **reduce the planned dose** and **add epinephrine** rather than merely slowing injection or substituting a more cardiotoxic drug. Interfascial plane blocks also demonstrate meaningful systemic uptake and are not inherently protective if equivalent doses are used. Proactive dose reduction, vasoconstrictor use, and enhanced monitoring most effectively mitigate LAST risk while preserving analgesia.",
    "educationalObjective": "Anticipate higher systemic absorption from intercostal and interpleural blocks and adjust dose and monitoring."
  },
  {
    "id": "Core.7.3.2",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Local anesthetic pharmacology",
    "difficulty": "hard",
    "questionText": "A 58-year-old, 70-kg man is scheduled for ambulatory endovenous laser ablation under tumescent anesthesia. The surgeon plans to infiltrate 3 L of 0.1% lidocaine with epinephrine 1:1,000,000 and sodium bicarbonate. He has nonalcoholic fatty liver disease (mildly elevated transaminases) and is taking erythromycin for bronchitis. No liposuction will be performed, and the center plans discharge 2 hours postprocedure. The planned lidocaine dose is 3,000 mg (≈43 mg/kg).\n\nWhich perioperative plan best minimizes systemic lidocaine toxicity risk while maintaining adequate anesthesia?",
    "answers": [
      {
        "text": "Use 0.05% lidocaine with epinephrine, cap total dose at ≤30 mg/kg, and arrange 12–24 hours of observation for delayed peak absorption.",
        "isCorrect": true,
        "explanation": "Diluting to 0.05% and limiting total to ≤30 mg/kg accounts for non-liposuction use, hepatic impairment, and CYP3A4 inhibition; overnight monitoring addresses the 12–18-hour delayed peak of tumescent lidocaine."
      },
      {
        "text": "Administer prophylactic 20% lipid emulsion at the end of the case while keeping 0.1% lidocaine at planned volumes, then discharge the patient.",
        "isCorrect": false,
        "explanation": "Prophylactic lipid emulsion is not recommended and does not replace dose limitation or monitoring; it is reserved for treating LAST, not preventing it."
      },
      {
        "text": "Maintain 0.1% lidocaine but add IV dexmedetomidine for analgesia, and discharge after 4 hours with return precautions.",
        "isCorrect": false,
        "explanation": "Adjunct sedation/analgesia does not reduce systemic absorption or toxicity risk. A 4-hour observation period is inadequate given delayed peak lidocaine levels after tumescent infiltration."
      },
      {
        "text": "Proceed as planned, limiting total lidocaine to 50 mg/kg due to epinephrine-mediated vasoconstriction, with routine same-day discharge.",
        "isCorrect": false,
        "explanation": "Dose limits of 45–55 mg/kg apply to liposuction cases where aspirate removes drug; non-liposuction procedures require lower limits. Early discharge ignores the delayed peak with tumescent lidocaine."
      },
      {
        "text": "Substitute ropivacaine 0.2% without epinephrine at ≤3 mg/kg to avoid lidocaine metabolism interactions and allow standard discharge.",
        "isCorrect": false,
        "explanation": "Tumescent use of long-acting, more cardiotoxic amides (eg, ropivacaine/bupivacaine) is discouraged; safe doses are far lower, and absence of epinephrine increases absorption. This does not mitigate the risk or enable safe early discharge."
      }
    ],
    "didactic": "Tumescent anesthesia uses very large volumes of **dilute lidocaine** (typically 0.05%–0.1%; 0.5–1 mg/mL) with **epinephrine 1:1,000,000 (1 µg/mL)** and often bicarbonate. Profound vasoconstriction and slow uptake from subcutaneous fat allow markedly higher apparent dose limits compared with standard infiltration, and in liposuction, drug removal with aspirate further reduces systemic absorption.\n\nKey principles:\n- **Dose limits differ by procedure**:\n  - With liposuction: commonly cited 45–55 mg/kg may be tolerated because substantial lidocaine is removed with aspirate.\n  - Without liposuction (eg, endovenous ablation): limit to about **28–35 mg/kg**; use the lower end for risk factors.\n- **Peak plasma lidocaine is delayed** after tumescent infiltration, typically **12–18 hours** postinjection (sometimes longer), due to vasoconstriction and depot effect. Thus, **late-onset LAST** can occur after discharge if monitoring is inadequate.\n- **Patient factors lowering safe dose** include hepatic impairment and **CYP1A2/CYP3A4 inhibitors** (eg, erythromycin, fluvoxamine), older age, and reduced cardiac reserve. Lidocaine is primarily metabolized hepatically; reduced clearance raises systemic levels.\n\nIn this case, 3 L of 0.1% lidocaine contains 3,000 mg (≈43 mg/kg for 70 kg) for a **non-liposuction** procedure, already exceeding recommended limits. Erythromycin (CYP3A4 inhibitor) and NAFLD further decrease clearance, increasing LAST risk. The best strategy is to **lower concentration (eg, 0.05%) and cap the total dose at ≤30 mg/kg**, while **planning 12–24 hours of observation** to span the delayed peak. Epinephrine should be retained to slow absorption.\n\nAlternatives are inferior: increasing the dose toward 50 mg/kg is appropriate only with liposuction; substituting long-acting amides (eg, ropivacaine/bupivacaine) for tumescent use is discouraged due to **greater cardiotoxicity and prolonged toxicity**; adjunct sedatives/analgesics do not mitigate LAST risk; and **prophylactic lipid emulsion** is not evidence-based and does not replace dose limitation or monitoring.",
    "educationalObjective": "Apply tumescent lidocaine principles including very high dilute dosing and delayed peak levels."
  },
  {
    "id": "Core.7.3.3",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Local anesthetic pharmacology",
    "difficulty": "medium",
    "questionText": "A 68-year-old woman (55 kg, normal renal/hepatic function) is scheduled for open reduction and internal fixation of a distal radius fracture. You plan an ultrasound-guided axillary brachial plexus block for surgical anesthesia and postoperative analgesia. The surgeon will infiltrate the incision with 20 mL of 1% lidocaine with epinephrine. To balance block spread, duration, and risk of local anesthetic systemic toxicity, which choice of local anesthetic concentration and volume for the axillary block is most appropriate?\n\nWhich option best balances adequate spread and safety for this patient?",
    "answers": [
      {
        "text": "20 mL of 2% lidocaine with epinephrine (400 mg) for the axillary block, plus the planned infiltration",
        "isCorrect": false,
        "explanation": "Exceeds typical lidocaine with epinephrine limits (≈7 mg/kg; 385 mg for 55 kg), increasing risk of local anesthetic systemic toxicity."
      },
      {
        "text": "15 mL of 0.75% bupivacaine (112.5 mg) for the axillary block, plus the planned infiltration",
        "isCorrect": false,
        "explanation": "Volume is often insufficient to reliably cover all terminal branches at the axilla; 0.75% bupivacaine is unnecessarily concentrated for peripheral block and increases toxicity risk if intravascular injection occurs."
      },
      {
        "text": "35 mL of 0.25% bupivacaine (87.5 mg) for the axillary block, plus the planned infiltration",
        "isCorrect": false,
        "explanation": "While volume supports spread, the low concentration may not provide a dense, reliable surgical block and has slower onset compared with 0.5% long-acting agents."
      },
      {
        "text": "40 mL of 0.5% bupivacaine (200 mg) for the axillary block, plus the planned infiltration",
        "isCorrect": false,
        "explanation": "This dose exceeds typical bupivacaine limits (≈2.5 mg/kg without epinephrine; max ~175 mg), markedly increasing cardiotoxicity risk despite good volume for spread."
      },
      {
        "text": "25 mL of 0.5% ropivacaine (125 mg) for the axillary block, plus the planned infiltration",
        "isCorrect": true,
        "explanation": "Provides adequate volume for plexus spread with a long-acting agent that has a wider safety margin than bupivacaine; total amide load remains within weight-based limits, and surgical infiltration with epinephrine reduces systemic uptake."
      }
    ],
    "didactic": "Choosing local anesthetic concentrations and volumes requires matching the technique’s needs (spread vs density) while staying within safe dose limits. Dose (mg) = volume (mL) × concentration (%) × 10.\n\n- Infiltration: Use larger volumes of more dilute solutions; epinephrine decreases systemic absorption and increases safe dosing (eg, lidocaine ≈4.5 mg/kg plain, ≈7 mg/kg with epinephrine).\n- Peripheral nerve blocks: Volume drives spread along fascial planes, while concentration contributes to block density and duration. Brachial plexus blocks typically require 20–30 mL for reliable coverage. Ropivacaine provides long duration with less motor block and lower cardiotoxicity than bupivacaine at equipotent doses.\n- Neuraxial: Spinal anesthesia uses small volumes of higher concentration (eg, hyperbaric bupivacaine 0.75%), whereas epidural anesthesia requires larger volumes of lower concentrations (eg, bupivacaine 0.125%–0.25%) to promote segmental spread while limiting motor block.\n\nIn this case, the surgeon plans 20 mL of 1% lidocaine with epinephrine (200 mg), which is below the ≈7 mg/kg limit for a 55-kg patient (≈385 mg). For the axillary block, 25 mL of 0.5% ropivacaine (125 mg) offers an appropriate volume for plexus spread, provides dense surgical anesthesia with prolonged postoperative analgesia, and remains within the common ropivacaine limit (≈3 mg/kg; ≈165 mg for 55 kg). Bupivacaine 0.5% at 40 mL (200 mg) exceeds typical safety thresholds and increases cardiotoxicity risk. Conversely, very low volumes (eg, 15 mL) may result in patchy axillary blocks even when ultrasound-guided. Lower concentrations (eg, 0.25% bupivacaine) can slow onset and may not yield a reliable surgical block.\n\nWhen combining amide local anesthetics (eg, ropivacaine and lidocaine), toxicity is additive; a practical approach is to keep each agent well under its individual maximum and avoid large doses of multiple long-acting agents. This strategy balances spread, density, duration, and safety across infiltration, peripheral, and neuraxial techniques.",
    "educationalObjective": "Choose concentrations and volumes for infiltration, peripheral nerve, and neuraxial techniques to balance spread and toxicity."
  },
  {
    "id": "Core.7.3.4",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Local anesthetic pharmacology",
    "difficulty": "medium",
    "questionText": "A 56-year-old man with Child-Pugh B cirrhosis (albumin 2.3 g/dL, INR 1.7, bilirubin 3.1 mg/dL) presents for urgent open reduction of a distal radius fracture. He reports prolonged apnea after succinylcholine; chart review shows a dibucaine number of 20 (homozygous atypical butyrylcholinesterase). You plan a single-injection supraclavicular block as the primary anesthetic. Surgical time is estimated at 60–90 minutes.\n\nWhich local anesthetic choice best provides timely surgical anesthesia while minimizing the risk of prolonged block and systemic toxicity in this patient?",
    "answers": [
      {
        "text": "2% lidocaine with epinephrine 1:200,000 and bicarbonate",
        "isCorrect": true,
        "explanation": "As an amide, lidocaine’s clearance is hepatic but independent of pseudocholinesterase; adding epinephrine limits vascular uptake and bicarbonate accelerates onset, providing adequate duration for a 60–90 minute case with lower toxicity risk."
      },
      {
        "text": "3% 2-chloroprocaine with epinephrine 1:200,000",
        "isCorrect": false,
        "explanation": "As an ester local anesthetic, chloroprocaine depends on plasma pseudocholinesterase for hydrolysis; deficiency markedly prolongs block and increases toxicity risk despite reduced systemic uptake from epinephrine."
      },
      {
        "text": "1.5% mepivacaine without epinephrine",
        "isCorrect": false,
        "explanation": "An amide is appropriate, but omitting epinephrine increases systemic absorption in a patient with impaired hepatic clearance; onset is slower than alkalinized lidocaine for urgent surgical anesthesia."
      },
      {
        "text": "0.5% bupivacaine with epinephrine 1:200,000",
        "isCorrect": false,
        "explanation": "Although an amide (unaffected by pseudocholinesterase deficiency), bupivacaine’s long duration and high cardiotoxicity with reduced hepatic clearance and altered protein binding in cirrhosis make it suboptimal for a 60–90 minute case."
      },
      {
        "text": "0.5% tetracaine without epinephrine",
        "isCorrect": false,
        "explanation": "Tetracaine is an ester with very long duration; pseudocholinesterase deficiency would markedly prolong block and increase risk of LAST."
      }
    ],
    "didactic": "Amide and ester local anesthetics differ fundamentally in metabolism, which drives clinical decision-making in hepatic dysfunction and pseudocholinesterase deficiency.\n\n- Amides (eg, lidocaine, mepivacaine, bupivacaine, ropivacaine) undergo hepatic biotransformation via CYP enzymes. In cirrhosis, reduced hepatic blood flow and enzyme capacity decrease clearance; hypoalbuminemia increases the free fraction, heightening toxicity risk. Practical implications: reduce dose, avoid prolonged infusions, and prefer shorter-acting agents when feasible. Vasoconstrictors (eg, epinephrine 1:200,000) lower systemic uptake, and alkalinization (bicarbonate) hastens onset for time-sensitive needs.\n- Esters (eg, chloroprocaine, procaine, tetracaine) are hydrolyzed rapidly by plasma butyrylcholinesterase (pseudocholinesterase), with minimal hepatic dependence (exception: cocaine). In genetic pseudocholinesterase deficiency (low dibucaine number), ester metabolism is markedly impaired, causing prolonged block and increased risk of local anesthetic systemic toxicity (LAST). Succinylcholine and mivacurium are similarly prolonged in these patients.\n\nApplying these principles: the patient has both cirrhosis and homozygous atypical pseudocholinesterase. Although severe hepatic disease can favor an ester to bypass the liver, pseudocholinesterase deficiency contraindicates ester local anesthetics because hydrolysis is unreliable. Therefore, choose an amide but mitigate hepatic risk. **Lidocaine 2% with epinephrine** decreases vascular uptake and, when alkalinized, provides a rapid onset suitable for urgent surgical anesthesia with a duration adequate for a 60–90 minute case. In contrast, **bupivacaine** offers unnecessarily long duration with greater cardiotoxicity and higher risk if plasma protein binding is reduced. **Chloroprocaine or tetracaine (esters)** may be profoundly prolonged and unsafe in pseudocholinesterase deficiency. When using amides in hepatic dysfunction, use the lowest effective dose, avoid continuous high-dose techniques, and monitor closely for signs of LAST.",
    "educationalObjective": "Compare amide versus ester metabolism and identify implications for hepatic dysfunction and pseudocholinesterase deficiency."
  },
  {
    "id": "Core.7.3.5",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Local anesthetic pharmacology",
    "difficulty": "medium",
    "questionText": "A 68-year-old man with ischemic cardiomyopathy (EF 25%) and prior ventricular tachycardia on amiodarone is scheduled for open reduction and internal fixation of a distal radius fracture. You plan a single-shot supraclavicular block using approximately 30 mL of a long-acting local anesthetic to provide surgical anesthesia and prolonged postoperative analgesia. Given his high risk if local anesthetic systemic toxicity occurs, you aim to minimize cardiotoxicity while maintaining block duration.\n\nWhich local anesthetic choice is most appropriate?",
    "answers": [
      {
        "text": "0.5% levobupivacaine",
        "isCorrect": false,
        "explanation": "Levobupivacaine (S-enantiomer) is less cardiotoxic than racemic bupivacaine, but ropivacaine is generally considered even less cardiotoxic due to lower lipid solubility and reduced myocardial penetration."
      },
      {
        "text": "3% chloroprocaine",
        "isCorrect": false,
        "explanation": "Chloroprocaine has very low cardiotoxicity but is short acting and unsuitable for the intended long-duration surgical anesthesia and postoperative analgesia."
      },
      {
        "text": "0.5% bupivacaine with epinephrine 1:200,000",
        "isCorrect": false,
        "explanation": "Although epinephrine reduces systemic absorption, racemic bupivacaine remains the most cardiotoxic long-acting amide due to high-affinity, slow-dissociation binding to cardiac Na<sup>+</sup> channels."
      },
      {
        "text": "2% lidocaine with epinephrine 1:200,000",
        "isCorrect": false,
        "explanation": "Lidocaine has lower cardiotoxicity but provides only intermediate duration, making it suboptimal for prolonged postoperative analgesia in a single-shot brachial plexus block."
      },
      {
        "text": "0.5% ropivacaine",
        "isCorrect": true,
        "explanation": "Ropivacaine (pure S-enantiomer) has lower lipid solubility and less potent blockade of cardiac Na<sup>+</sup> channels than bupivacaine, conferring a lower risk of cardiotoxicity while providing long-duration block suitable for postoperative analgesia."
      }
    ],
    "didactic": "Bupivacaine’s cardiotoxicity stems from stereoselective, high-affinity binding and slow dissociation from cardiac Na<sup>+</sup> channels (and to a lesser extent Ca<sup>2+</sup> channels), which depresses conduction, reduces contractility, and predisposes to malignant ventricular arrhythmias. The racemic formulation contains the R(+) enantiomer that disproportionately contributes to myocardial toxicity. In contrast, **levobupivacaine** (the S-enantiomer of bupivacaine) and **ropivacaine** (a pure S-enantiomer with lower lipid solubility) have less potent cardiac channel blockade and reduced myocardial penetration, translating to a higher dose threshold for severe local anesthetic systemic toxicity (LAST).\n\nAmong long-acting amide local anesthetics, relative cardiotoxicity is often summarized as:\n- **Bupivacaine > Levobupivacaine ≈ Ropivacaine** (with ropivacaine generally least cardiotoxic)\n\nFor high-volume peripheral nerve blocks where inadvertent intravascular injection could deliver a large bolus, choosing an agent with a safer cardiac profile is prudent—especially in patients with cardiomyopathy or prior ventricular arrhythmias. **Ropivacaine 0.5%** provides long-duration anesthesia/analgesia comparable to bupivacaine while offering a lower risk of cardiotoxicity. Levobupivacaine is also safer than racemic bupivacaine, but ropivacaine’s lower lipid solubility likely confers a further margin of safety.\n\nEpinephrine (eg, 1:200,000) can reduce systemic absorption and aid intravascular injection detection, but it does not change an agent’s intrinsic cardiotoxicity; a less cardiotoxic drug remains preferable in high-risk patients. Short-acting alternatives (eg, lidocaine, chloroprocaine) do not meet the clinical need for prolonged postoperative analgesia with a single-shot block.\n\nRisk mitigation for LAST should accompany agent selection: ultrasound guidance, incremental injection with frequent aspiration, appropriate dose calculations, vigilant monitoring, and immediate availability of lipid emulsion therapy. Avoid exacerbating conditions (acidosis, hypercarbia, hypoxia) that potentiate cardiotoxic effects. Choosing ropivacaine here balances duration with the lowest cardiac risk profile.",
    "educationalObjective": "Contrast cardiotoxicity of bupivacaine with ropivacaine and levobupivacaine and select safer alternatives when appropriate."
  },
  {
    "id": "Core.7.3.6",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Local anesthetic pharmacology",
    "difficulty": "medium",
    "questionText": "A 32-year-old ASA I man presents for ambulatory knee arthroscopy expected to last 30–40 minutes. He requests a spinal anesthetic to avoid general anesthesia and hopes to ambulate and void soon after surgery. Available intrathecal options include preservative-free and epinephrine-containing local anesthetic preparations. You want a rapid onset, reliable surgical block of short duration while minimizing risk of neurotoxicity and delayed discharge.\n\nWhich intrathecal choice is most appropriate for this patient?",
    "answers": [
      {
        "text": "3% chloroprocaine with epinephrine (contains sodium bisulfite) 40 mg",
        "isCorrect": false,
        "explanation": "Epinephrine-containing chloroprocaine solutions historically contain sodium bisulfite; intrathecal use of preserved solutions has been linked to neurotoxicity and should be avoided."
      },
      {
        "text": "Preservative-free 2-chloroprocaine 40 mg",
        "isCorrect": true,
        "explanation": "Ester local anesthetic with very rapid onset and 40–60 min duration due to rapid plasma cholinesterase hydrolysis; preservative-free formulation avoids neurotoxicity concerns and is well suited for short ambulatory spinal anesthesia with low TNS risk."
      },
      {
        "text": "Mepivacaine 1.5% 60 mg",
        "isCorrect": false,
        "explanation": "Provides intermediate duration (typically 90–120 min) and carries a risk of TNS similar to lidocaine; also not FDA-approved for spinal use in many regions."
      },
      {
        "text": "Hyperbaric bupivacaine 0.75% 10 mg",
        "isCorrect": false,
        "explanation": "Produces a reliable block but often lasts 2–3+ hours with higher risk of urinary retention and delayed discharge—longer than needed for a 30–40 minute case."
      },
      {
        "text": "5% lidocaine with dextrose 50 mg",
        "isCorrect": false,
        "explanation": "Although onset is rapid, lidocaine spinal anesthesia has a high incidence of transient neurologic symptoms and can still outlast very short procedures, making it less favorable for ambulatory neuraxial anesthesia."
      }
    ],
    "didactic": "Chloroprocaine is an ester local anesthetic characterized by very rapid onset and short duration due to swift hydrolysis by plasma cholinesterase. These pharmacokinetics make it an excellent choice for short ambulatory neuraxial anesthesia, where quick recovery of motor function and early voiding are priorities.\n\n- Onset/duration: Intrathecal 2-chloroprocaine (PF) typically provides dense surgical anesthesia within minutes and resolves in ≈40–60 minutes, matching brief procedures and facilitating timely discharge.\n- Metabolism/toxicity: Rapid plasma cholinesterase metabolism limits systemic accumulation and toxicity. Compared with lidocaine, preservative-free chloroprocaine has a low incidence of transient neurologic symptoms (TNS), improving patient comfort postoperatively.\n- Preservatives matter: Historical reports of neurotoxicity with intrathecal chloroprocaine were associated with preserved solutions (eg, sodium bisulfite) and possibly low pH. Modern preservative-free (PF) formulations have demonstrated safety for spinal anesthesia. Epinephrine-containing chloroprocaine solutions often include sodium bisulfite and should not be used intrathecally. EDTA, previously used in some epidural formulations, has been associated with transient back pain and is also inappropriate for intrathecal use.\n- Ambulatory advantages: Short block duration reduces risks of urinary retention and prolonged PACU stays compared with longer-acting agents (eg, bupivacaine). It also avoids the higher TNS rates linked to lidocaine and mepivacaine.\n\nPractical selection for a 30–40 minute procedure prioritizes rapid onset, reliable but brief block, and safety of the formulation. Preservative-free 2-chloroprocaine (eg, 30–50 mg intrathecal) best meets these goals. In contrast, hyperbaric bupivacaine often lasts hours with higher urinary retention risk, lidocaine and mepivacaine carry increased TNS risk, and any preserved chloroprocaine (eg, with sodium bisulfite) must be avoided intrathecally. This combination of pharmacology and formulation safety explains chloroprocaine’s utility for short ambulatory spinal anesthesia.",
    "educationalObjective": "Describe chloroprocaine properties, preservative issues, and utility for short ambulatory neuraxial anesthesia."
  },
  {
    "id": "Core.7.3.7",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Local anesthetic pharmacology",
    "difficulty": "hard",
    "questionText": "A 68-year-old man with ischemic cardiomyopathy (EF 30%) undergoes open colectomy under general anesthesia. During mesenteric traction, he develops monomorphic wide-complex tachycardia at 170 bpm with a systolic BP of 80 mmHg. Amiodarone is unavailable, so he receives lidocaine 1.5 mg/kg IV followed by an infusion. The VT slows and terminates; subsequent sinus rhythm at 70 bpm shows minimal PR/QRS prolongation compared with baseline. \n\nWhich mechanism best explains lidocaine’s greater efficacy in ischemic VT with little effect on normal atrioventricular conduction?",
    "answers": [
      {
        "text": "Primary inhibition of L-type Ca2+ channels in ischemic myocardium with relative sparing of Na+ channels at usual doses",
        "isCorrect": false,
        "explanation": "Lidocaine’s antiarrhythmic effect is via voltage-gated Na+ channel blockade (class IB), not L-type Ca2+ channel inhibition."
      },
      {
        "text": "Preferential binding to open/inactivated Na+ channels in depolarized, rapidly firing myocardium with rapid diastolic unbinding, producing use-dependent block during VT but minimal effect in sinus rhythm",
        "isCorrect": true,
        "explanation": "Lidocaine exhibits state- and frequency-dependent Na+ channel block: it binds open/inactivated channels more avidly and dissociates quickly between beats. Rapid firing and depolarization in ischemic VT increase channel occupancy, while slower sinus rates allow recovery with little conduction slowing."
      },
      {
        "text": "Preferential accumulation in ischemic tissue based on lipid solubility, leading to greater local drug concentration regardless of channel state or rate",
        "isCorrect": false,
        "explanation": "Lidocaine is moderately lipophilic, but its selective suppression of VT is explained by state/use dependence and rapid unbinding kinetics rather than passive accumulation."
      },
      {
        "text": "Equivalent affinity for resting Na+ channels irrespective of activation state or heart rate, making its effect independent of frequency and voltage",
        "isCorrect": false,
        "explanation": "Lidocaine does not block resting channels to a major degree; its clinical selectivity relies on state- and rate-dependent binding, not state-independent effects."
      },
      {
        "text": "Enhanced intracellular access in ischemic zones due to acidosis increasing the unionized fraction of lidocaine",
        "isCorrect": false,
        "explanation": "Acidosis decreases the unionized fraction of this weak base, slowing membrane penetration; selectivity in ischemia is primarily due to depolarization/inactivation and high firing rates, not improved access."
      }
    ],
    "didactic": "Local anesthetics (and class I antiarrhythmics) block voltage-gated Na+ channels from the intracellular side. They exhibit state-dependent affinity, binding most strongly to the open and especially the inactivated states, and least to the resting state. Because inactivation predominates when the membrane is depolarized and during repetitive depolarizations, Na+ channel blockade becomes both voltage dependent and frequency dependent (use dependent).\n\nIschemic myocardium is relatively depolarized (eg, from hyperkalemia/acidosis and ATP-sensitive K<sup>+</sup> channel activation), increasing the fraction of Na+ channels in the inactivated state. During ventricular tachycardia, channels cycle rapidly through open/inactivated states with shortened diastolic intervals. Class IB agents like lidocaine have rapid on–off kinetics: they bind open/inactivated channels during depolarization and dissociate quickly during diastole. Thus, they accumulate block in fast, depolarized tissue (use dependent) while exerting minimal effect at normal heart rates and resting potentials, explaining selective suppression of ischemic VT with little slowing of baseline conduction.\n\nClinical implications of frequency/voltage dependence:\n- Antiarrhythmia: Lidocaine preferentially suppresses ischemic VT because depolarized, rapidly firing fibers favor open/inactivated states. Minimal effect occurs in healthy, normally polarized tissue due to rapid unbinding between beats.\n- Differential neural block: High-frequency nociceptor firing increases local anesthetic block compared with low-frequency motor activity (along with fiber size/myelination effects).\n- Toxicity: Highly lipophilic agents with slow unbinding (eg, bupivacaine) show pronounced use-dependent myocardial depression; tachycardia and depolarization exacerbate QRS widening and refractory arrest. Acidosis/hypercarbia/hyperkalemia increase toxicity by shifting channels toward inactivation and reducing drug dissociation.\n\nPractically, use-dependent physiology explains why lidocaine terminates VT without major sinus conduction slowing and why treating LAST includes correcting acidosis and avoiding tachycardia while administering lipid emulsion.",
    "educationalObjective": "Describe frequency- and voltage-dependent sodium channel blockade and its clinical implications for use-dependent effects."
  },
  {
    "id": "Core.7.3.8",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Local anesthetic pharmacology",
    "difficulty": "medium",
    "questionText": "A healthy 29-year-old G2P1 at 39 weeks presents for urgent cesarean delivery for nonreassuring fetal heart tracing. You plan a single-shot spinal with hyperbaric bupivacaine, fentanyl, and preservative-free morphine. You recall that term pregnancy is associated with greater cephalad spread of intrathecal local anesthetics and lower dose requirements compared with nonpregnant patients of similar height. Which pregnancy-related change most directly accounts for this increased intrathecal spread and reduced dose requirement?",
    "answers": [
      {
        "text": "Increased α<sub>1</sub>-acid glycoprotein concentration increasing protein binding of bupivacaine",
        "isCorrect": false,
        "explanation": "Pregnancy decreases α<sub>1</sub>-acid glycoprotein; regardless, plasma protein binding does not determine intrathecal potency or spread at the time of spinal injection."
      },
      {
        "text": "Decreased cerebrospinal fluid volume from engorgement of the epidural venous plexus",
        "isCorrect": true,
        "explanation": "Engorgement of epidural veins from increased intra-abdominal pressure and caval compression reduces lumbar CSF volume, concentrating a given intrathecal dose and promoting greater cephalad spread; thus, lower doses achieve the same block height."
      },
      {
        "text": "Increased hepatic clearance of amide local anesthetics via CYP induction",
        "isCorrect": false,
        "explanation": "Changes in hepatic metabolism alter systemic pharmacokinetics but do not explain the immediate segmental anesthetic effect of a spinal dose acting within the CSF."
      },
      {
        "text": "Progesterone-mediated reduction in minimum alveolar concentration (MAC) by approximately 30%",
        "isCorrect": false,
        "explanation": "Decreased MAC reflects heightened sensitivity to volatile anesthetics, not the intrathecal pharmacodynamics of local anesthetics."
      },
      {
        "text": "Increased epidural fat decreasing epidural space compliance and augmenting spread of neuraxial drugs",
        "isCorrect": false,
        "explanation": "Greater epidural fat can enhance epidural spread, but it has minimal direct effect on intrathecal distribution compared with the dominant effect of reduced CSF volume."
      }
    ],
    "didactic": "Pregnancy reduces neuraxial dose requirements and increases cephalad spread of intrathecal local anesthetics primarily because lumbar **CSF volume is decreased**. The gravid uterus elevates intra-abdominal pressure and compresses the inferior vena cava, causing **engorgement of the epidural venous plexus**. These veins protrude through the intervertebral foramina into the spinal canal, effectively shrinking the subarachnoid volume. A fixed intrathecal dose is therefore distributed within a smaller CSF volume, yielding higher local concentration at the cord and greater rostral spread, so a lower dose achieves the same block height.\n\nAdditional pregnancy-related factors contribute but are secondary:\n- **Hormonal sensitization**: Progesterone and endogenous endorphins increase neuronal sensitivity to local anesthetics and neuraxial opioids, modestly reducing epidural/spinal dose requirements.\n- **Epidural space changes**: Increased epidural fat and venous engorgement reduce epidural space compliance and volume, enhancing spread for epidural dosing; their direct effect on intrathecal spread is less than the CSF-volume effect.\n\nIn contrast, systemic pharmacokinetic changes do not explain spinal dose reduction:\n- **Protein binding**: Pregnancy decreases α<sub>1</sub>-acid glycoprotein and albumin, increasing free fractions of amide local anesthetics in plasma, which affects systemic toxicity risk—not intrathecal potency or distribution.\n- **Hepatic metabolism**: Altered CYP activity changes systemic clearance but is irrelevant to the immediate spinal block, which depends on CSF distribution and neural uptake.\n- **MAC reduction (~30%)** applies to inhaled anesthetics and does not determine neuraxial local anesthetic requirements.\n\nClinical implication: At term, consider reducing intrathecal bupivacaine dose by ~10–20% and titrate epidural doses incrementally, anticipating faster and higher spread. Vigilantly monitor for high spinal and avoid excessive head-down positioning once block onset begins.",
    "educationalObjective": "Discuss pregnancy-related changes that enhance neuraxial sensitivity and reduce dose requirements."
  },
  {
    "id": "Core.7.3.9",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Local anesthetic pharmacology",
    "difficulty": "medium",
    "questionText": "A 68-year-old man (80 kg) with severe aortic stenosis and stable coronary artery disease requires an awake nasal fiberoptic intubation for anticipated difficult airway. You plan to topicalize the nasal passages, oropharynx, and larynx/trachea while minimizing the risk of local anesthetic systemic toxicity from high-absorption mucosal surfaces. Which regimen is most appropriate to achieve adequate anesthesia with the lowest systemic risk?\n\nNote: Lidocaine 4% = 40 mg/mL; lidocaine 2% = 20 mg/mL.",
    "answers": [
      {
        "text": "Oxymetazoline to each nare, lidocaine 2% jelly 2 mL per nare (80 mg total), atomized lidocaine 4% 2 mL to oropharynx (80 mg), and transtracheal lidocaine 2% 3 mL (60 mg)",
        "isCorrect": true,
        "explanation": "This provides nasal, oropharyngeal, and tracheal anesthesia with a measured total lidocaine dose of 220 mg (2.75 mg/kg) and reduced mucosal absorption with vasoconstrictor, minimizing systemic toxicity."
      },
      {
        "text": "Nebulized lidocaine 4% 10 mL (400 mg) plus transtracheal lidocaine 2% 5 mL (100 mg) just before endoscopy",
        "isCorrect": false,
        "explanation": "Total lidocaine 500 mg (6.25 mg/kg) greatly exceeds recommended airway topical doses (≈3–4 mg/kg) and risks LAST due to rapid tracheobronchial absorption."
      },
      {
        "text": "Benzocaine 20% spray to oropharynx (3 short sprays) plus transtracheal lidocaine 2% 3 mL (60 mg)",
        "isCorrect": false,
        "explanation": "Benzocaine has unpredictable dosing and a known risk of methemoglobinemia, especially on oropharyngeal mucosa; safer alternatives exist for airway topicalization."
      },
      {
        "text": "Topical 4% cocaine 2 mL total (80 mg) to nares, plus atomized lidocaine 4% 4 mL to oropharynx (160 mg) and transtracheal lidocaine 2% 3 mL (60 mg)",
        "isCorrect": false,
        "explanation": "Although lidocaine load is modest, cocaine can precipitate tachycardia and hypertension and is undesirable in severe aortic stenosis/CAD; toxicity of local anesthetics is additive across agents."
      },
      {
        "text": "Nebulized lidocaine 4% 8 mL (320 mg) plus lidocaine 2% jelly 5 mL per nare (200 mg total)",
        "isCorrect": false,
        "explanation": "Total lidocaine 520 mg (6.5 mg/kg) substantially exceeds recommended limits for airway topicalization and risks LAST in this high-absorption setting."
      }
    ],
    "didactic": "High-absorption mucosal sites (eg, oropharynx, larynx/trachea, nasal turbinates) rapidly transfer local anesthetic to the circulation, increasing the risk of **local anesthetic systemic toxicity (LAST)**. For airway topicalization, a conservative total lidocaine dose of ≈3–4 mg/kg is recommended due to brisk tracheobronchial uptake. Convert concentrations to dose: lidocaine 4% = 40 mg/mL; lidocaine 2% = 20 mg/mL; doses from all routes are additive.\n\nSafe, effective awake fiberoptic regimens use measured aliquots and vasoconstrictors to minimize systemic absorption. Oxymetazoline or phenylephrine decreases nasal mucosal blood flow and does not increase allowable lidocaine dose but reduces uptake and bleeding. Combining small-volume nasal jelly (eg, lidocaine 2% 2 mL per nare), limited oropharyngeal atomization (eg, lidocaine 4% 1–2 mL), and a modest transtracheal injection (eg, lidocaine 2% 2–3 mL) typically provides adequate anesthesia while keeping total lidocaine ≤3–4 mg/kg. Avoid “spray-as-you-go” without tracking dose; instead, use premeasured syringes/atomizers and tally cumulative mg.\n\nAgents with additional risks should be avoided when safer options exist. **Cocaine** (limit ≈3 mg/kg, max 200 mg) provides anesthesia and vasoconstriction but can cause tachycardia, hypertension, and myocardial ischemia; it is undesirable in severe aortic stenosis, CAD, and arrhythmias. **Benzocaine 20%** spray has unpredictable delivered dose and a well-described risk of **methemoglobinemia** after oropharyngeal use, particularly in older, anemic, or G6PD-deficient patients.\n\nIf LAST occurs: stop dosing, secure airway/ventilation with 100% O<sub>2</sub>, treat seizures with benzodiazepines, and initiate **20% lipid emulsion** (eg, 1.5 mL/kg bolus, then infusion) per ASRA guidelines. Preventing toxicity hinges on conservative dosing, accounting for all sources, and using vasoconstrictors and nerve blocks strategically to reduce mucosal load.",
    "educationalObjective": "Dose topical anesthetics safely for mucosal use and prevent systemic toxicity in high-absorption sites."
  },
  {
    "id": "Core.7.3.10",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Local anesthetic pharmacology",
    "difficulty": "medium",
    "questionText": "A 54-year-old man with polytrauma arrives hypothermic (33°C) and acidemic (arterial pH 7.10) for urgent tibial fixation. An ultrasound-guided fascia iliaca block is performed with 30 mL of 0.5% bupivacaine with epinephrine (1:200,000). Despite correct needle position and circumferential spread around the femoral nerve, the block has slow onset and provides only partial analgesia at 20 minutes. Which physiologic mechanism best explains the reduced efficacy of the local anesthetic under these conditions?",
    "answers": [
      {
        "text": "Acidosis increases the nonionized (B) fraction, improving membrane transfer but reducing receptor binding, which delays block onset.",
        "isCorrect": false,
        "explanation": "Acidosis decreases the nonionized fraction of weak bases; it does not increase it. Binding to the Na<sup>+</sup> channel occurs from the intracellular side after diffusion."
      },
      {
        "text": "Epinephrine-induced vasoconstriction in hypothermia prevents drug contact with the nerve, lowering perineural concentration and block quality.",
        "isCorrect": false,
        "explanation": "Vasoconstriction generally prolongs perineural residence time and can enhance block, not impair it; the primary issue here is altered ionization, not perfusion."
      },
      {
        "text": "Because the ionized (BH<sup>+</sup>) species cannot block Na<sup>+</sup> channels, acidosis leaves too little active drug to produce anesthesia.",
        "isCorrect": false,
        "explanation": "The charged form is the species that binds the Na<sup>+</sup> channel once inside the axon; the problem is reduced transmembrane entry due to a lower fraction of nonionized base."
      },
      {
        "text": "Hypothermia decreases the local anesthetic pK<sub>a</sub>, increasing the nonionized fraction and thereby lowering potency at the Na<sup>+</sup> channel.",
        "isCorrect": false,
        "explanation": "Hypothermia typically increases pK<sub>a</sub> of local anesthetics, shifting toward more ionization at physiologic pH and reducing membrane permeability, not potency per se."
      },
      {
        "text": "Low pH and hypothermia increase the ionized (BH<sup>+</sup>) fraction by decreasing extracellular pH and increasing pK<sub>a</sub>, reducing lipid solubility and transmembrane diffusion into the axoplasm.",
        "isCorrect": true,
        "explanation": "Acidosis shifts weak bases toward the ionized form, and hypothermia increases pK<sub>a</sub>, further increasing BH<sup>+</sup>. Less nonionized base (B) is available to cross the lipid membrane, slowing onset and weakening block."
      }
    ],
    "didactic": "Local anesthetics are weak bases that exist as nonionized base (B) and ionized conjugate acid (BH<sup>+</sup>). Only the nonionized form readily crosses lipid barriers (perineurium and axolemma); once inside the axoplasm, protonation to BH<sup>+</sup> allows binding to the intracellular site on the voltage-gated Na<sup>+</sup> channel. The nonionized fraction is governed by pH and pK<sub>a</sub> via Henderson–Hasselbalch: $\\text{fraction nonionized} = \\frac{1}{1 + 10^{(pK_a - pH)}}$. \n\n- Acidosis (lower pH) increases $pK_a - pH$, reducing the nonionized fraction (B). In infected or hypoperfused tissue (low pH), less drug penetrates the nerve, slowing onset and weakening block.\n- Hypothermia raises the pK<sub>a</sub> of most local anesthetics, further increasing the ionized fraction at a given pH and compounding poor membrane permeability.\n\nExample: For bupivacaine (pK<sub>a</sub> ≈ 8.1 at 37°C), at pH 7.4 the nonionized fraction is ≈16%. With pH 7.1, it drops to ≈9%. If hypothermia increases pK<sub>a</sub> to ≈8.3, the nonionized fraction at pH 7.1 falls to ≈6%. This marked reduction explains delayed onset and incomplete block in acidemic, hypothermic patients despite correct needle placement.\n\nClinical implications:\n- Expect slower or failed blocks in acidotic, hypothermic, or infected tissues due to increased ionization.\n- Mitigation strategies include choosing agents with lower pK<sub>a</sub> (eg, lidocaine), warming solutions, and modest alkalinization (eg, adding NaHCO<sub>3</sub> to lidocaine) to increase the nonionized fraction. Epinephrine primarily alters vascular uptake/duration, not ionization.\n\nThus, acidosis and hypothermia reduce local anesthetic efficacy by shifting the equilibrium toward BH<sup>+</sup>, decreasing lipid permeation into nerves and diminishing block quality.",
    "educationalObjective": "Explain how acidosis and hypothermia reduce local anesthetic efficacy by shifting the ionized fraction."
  },
  {
    "id": "Core.7.3.11",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Local anesthetic pharmacology",
    "difficulty": "medium",
    "questionText": "A 54-year-old man is scheduled for open reduction and internal fixation of a distal radius fracture under a single-shot supraclavicular block. To provide prolonged postoperative analgesia (goal 12–18 hours) without a catheter, you must choose among prefilled syringes available in the block room. Motor weakness is acceptable. Which option will most likely provide the longest duration of analgesia for this peripheral nerve block?\n\n- 0.5% bupivacaine; high lipid solubility; ~95% protein binding; pKa 8.1; no epinephrine\n- 1.5% mepivacaine with epinephrine 1:200,000; moderate lipid solubility; ~77% protein binding; pKa 7.6\n- 2% lidocaine with epinephrine 1:200,000; low–moderate lipid solubility; ~65% protein binding; pKa 7.9\n- 3% chloroprocaine; very low lipid solubility; minimal protein binding; pKa 8.7; no epinephrine\n- 0.5% ropivacaine; high lipid solubility (slightly less than bupivacaine); ~94% protein binding; pKa 8.1",
    "answers": [
      {
        "text": "3% chloroprocaine; very low lipid solubility; minimal protein binding; pKa 8.7; no epinephrine",
        "isCorrect": false,
        "explanation": "Chloroprocaine is short-acting due to low lipid solubility and protein binding; high concentration does not overcome its inherently brief duration."
      },
      {
        "text": "1.5% mepivacaine with epinephrine 1:200,000; moderate lipid solubility; ~77% protein binding; pKa 7.6",
        "isCorrect": false,
        "explanation": "Epinephrine reduces systemic uptake and prolongs duration, but mepivacaine’s moderate lipid solubility and protein binding yield a shorter block than long-acting agents like bupivacaine."
      },
      {
        "text": "2% lidocaine with epinephrine 1:200,000; low–moderate lipid solubility; ~65% protein binding; pKa 7.9",
        "isCorrect": false,
        "explanation": "Although epinephrine extends lidocaine’s duration, its lower lipid solubility and protein binding limit duration compared with bupivacaine or ropivacaine."
      },
      {
        "text": "0.5% bupivacaine; high lipid solubility; ~95% protein binding; pKa 8.1; no epinephrine",
        "isCorrect": true,
        "explanation": "High lipid solubility increases potency and tissue sequestration, and high protein binding slows vascular washout and receptor dissociation—together conferring the longest duration among common amide local anesthetics."
      },
      {
        "text": "0.5% ropivacaine; high lipid solubility (slightly less than bupivacaine); ~94% protein binding; pKa 8.1",
        "isCorrect": false,
        "explanation": "Ropivacaine is long-acting, but slightly lower lipid solubility than bupivacaine typically produces a modestly shorter duration for single-shot blocks."
      }
    ],
    "didactic": "Local anesthetics are weak bases that must reach the intracellular side of the voltage-gated Na<sup>+</sup> channel to work. Three physicochemical properties primarily determine clinical behavior:\n\n- **Lipid solubility**: Higher lipid solubility increases membrane partitioning and receptor access, correlating with greater potency and typically a longer duration due to tissue sequestration. Rank (high → low): bupivacaine ≳ ropivacaine ≫ mepivacaine ≳ lidocaine ≫ chloroprocaine.\n- **Protein binding**: Greater binding (eg, to α<sub>1</sub>-acid glycoprotein and tissue proteins) correlates with longer duration by reducing free drug available for vascular washout and slowing dissociation from the Na<sup>+</sup> channel. Bupivacaine/ropivacaine (~94%–95%) > mepivacaine (~77%) > lidocaine (~65%) ≫ chloroprocaine (minimal).\n- **pKa**: Determines onset, not duration. Agents with pKa closer to physiologic pH have more unionized fraction and faster onset (eg, mepivacaine). High pKa slows onset (eg, chloroprocaine, bupivacaine) but does not prolong duration.\n\nDuration is also modified by clinical factors: site blood flow, total dose and concentration, and vasoconstrictors. **Epinephrine** prolongs duration by reducing systemic uptake, with a relatively larger effect on short- and intermediate-acting agents (eg, lidocaine, mepivacaine) than on intrinsically long-acting drugs. However, even with epinephrine, lidocaine and mepivacaine generally do not exceed the duration of highly lipid-soluble, highly protein-bound agents like bupivacaine.\n\nFor single-shot peripheral nerve blocks targeting 12–18 hours of analgesia, **bupivacaine** (high lipid solubility and ~95% protein binding) typically provides the longest duration, with **ropivacaine** close behind but modestly shorter due to slightly lower lipid solubility. Recognizing that potency and duration track with lipid solubility and protein binding—while onset tracks with pKa—helps select the appropriate local anesthetic and anticipate how adjuncts like epinephrine will modify block characteristics.",
    "educationalObjective": "Explain how lipid solubility and protein binding correlate with potency and duration among common local anesthetics."
  },
  {
    "id": "Core.7.3.12",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Local anesthetic pharmacology",
    "difficulty": "medium",
    "questionText": "A 68-year-old man undergoes open sigmoid colectomy with a T8 epidural placed preoperatively. Postoperatively, he receives ropivacaine 0.2% at 6 mL/h with patient-controlled 4 mL boluses (lockout 15 min). Pain is well controlled for 6 hours, after which he sleeps and does not use the PCEA. Three hours later he awakens with severe incisional pain (8/10). Two PCEA boluses provide only brief, diminishing relief. Exam shows a regressed cold level at T10, normal motor strength, and stable hemodynamics. You suspect epidural local anesthetic tachyphylaxis after allowing the block to wear off.\n\nWhich intervention is most likely to restore effective analgesia?",
    "answers": [
      {
        "text": "Add 1 mL of 8.4% sodium bicarbonate to the ropivacaine bolus to alkalinize the solution",
        "isCorrect": false,
        "explanation": "Alkalinization can speed onset for lidocaine/mepivacaine, but ropivacaine has limited benefit and carries precipitation risk when mixed with bicarbonate in clinically useful amounts."
      },
      {
        "text": "Double the ropivacaine basal infusion rate to 12 mL/h without a bolus",
        "isCorrect": false,
        "explanation": "Simply increasing the basal rate does not overcome tachyphylaxis and provides delayed, incremental spread; a reactivating bolus is needed to reestablish a dense block."
      },
      {
        "text": "Replace the epidural catheter for suspected migration",
        "isCorrect": false,
        "explanation": "Transient analgesia after boluses argues the catheter remains epidural; regression and diminishing responses are more consistent with tachyphylaxis rather than displacement."
      },
      {
        "text": "Give an epidural fentanyl 50 µg bolus and continue the current local anesthetic infusion",
        "isCorrect": false,
        "explanation": "Neuraxial opioid may modestly improve analgesia but does not reliably reverse local anesthetic tachyphylaxis; a rapid-onset local anesthetic bolus is more effective."
      },
      {
        "text": "Administer an epidural bolus of 3% chloroprocaine 12 mL with epinephrine 1:200,000, then resume the basal infusion and schedule preemptive top-ups before pain returns",
        "isCorrect": true,
        "explanation": "Reestablishing a dense block with a fast-onset local anesthetic and then maintaining analgesia before regression mitigates tachyphylaxis and restores efficacy."
      }
    ],
    "didactic": "Local anesthetic tachyphylaxis is diminished response to repeated doses after analgesia has regressed and pain returns. It is most often observed with epidural analgesia when redosing is delayed, leading to central sensitization and reduced responsiveness of spinal nociceptive pathways to subsequent local anesthetic. Proposed contributors include increased dorsal horn excitability, impaired drug penetration due to reduced non-ionized fraction in relatively acidic tissue/CSF, and altered channel state occupancy.\n\nManagement focuses on rapidly reestablishing a dense block and then preventing further regression:\n- Give a fast-onset epidural bolus (eg, 3% chloroprocaine or 2% lidocaine) to quickly re-block segments, optionally with epinephrine to improve spread/duration.\n- Resume maintenance and redose preemptively before pain returns; frequent, timely dosing prevents tachyphylaxis better than larger, delayed boluses.\n- Add adjuncts (eg, neuraxial opioid, α<sub>2</sub>-agonist) to improve quality, but use them as complements, not substitutes for reactivating the block.\n\nAlkalinization increases the non-ionized fraction (Henderson–Hasselbalch) and can hasten onset for lidocaine/mepivacaine; however, the benefit is limited with ropivacaine/bupivacaine and mixing clinically meaningful bicarbonate volumes risks precipitation. Simply increasing the basal rate without a bolus does not overcome the immediate need for spread and density and will not reliably reverse tachyphylaxis. Catheter migration should be considered when boluses fail entirely or produce unilateral/patchy block, but transient improvement after bolus supports correct placement.\n\nKey strategy: restore block with a rapid-onset local anesthetic bolus, then maintain analgesia with scheduled/preemptive dosing to avoid allowing pain to return, which perpetuates tachyphylaxis.",
    "educationalObjective": "Explain tachyphylaxis with repeated dosing and strategies to restore efficacy."
  },
  {
    "id": "Core.7.3.13",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Local anesthetic pharmacology",
    "difficulty": "hard",
    "questionText": "A 22-year-old competitive swimmer is scheduled for outpatient arthroscopic Bankart repair under general anesthesia. The surgeon requests placement of an intra-articular pain pump infusing bupivacaine 0.5% with epinephrine 5 mcg/mL at 5 mL/h for 48 hours for postoperative analgesia. The patient is healthy (ASA 1) with normal pulmonary function and desires excellent pain control to facilitate early rehabilitation.\n\nWhich postoperative analgesic strategy is most appropriate to minimize the risk of glenohumeral chondrolysis while maintaining effective analgesia?",
    "answers": [
      {
        "text": "Perform a single-shot suprascapular nerve block with bupivacaine 0.5%, 20 mL",
        "isCorrect": false,
        "explanation": "This avoids cartilage exposure but offers limited duration and generally inferior analgesia compared with a continuous interscalene catheter."
      },
      {
        "text": "Place a subacromial catheter infusing ropivacaine 0.2% at 5 mL/h for 48 h",
        "isCorrect": false,
        "explanation": "Extra-articular placement avoids direct cartilage exposure and reduces chondrolysis risk, but analgesia is inferior to a brachial plexus catheter for intra-articular shoulder surgery."
      },
      {
        "text": "Place an interscalene perineural catheter infusing ropivacaine 0.2% at 5 mL/h for 48 h",
        "isCorrect": true,
        "explanation": "Interscalene catheter provides superior shoulder analgesia while completely avoiding intra-articular cartilage exposure, thereby minimizing chondrolysis risk."
      },
      {
        "text": "Approve the surgeon’s request for an intra-articular bupivacaine 0.5% + epinephrine infusion at 5 mL/h for 48 h",
        "isCorrect": false,
        "explanation": "Continuous intra-articular bupivacaine infusions (especially 0.5% and with epinephrine/preservatives) are strongly associated with postarthroscopic glenohumeral chondrolysis and should be avoided."
      },
      {
        "text": "Administer a single intra-articular injection of ropivacaine 0.2%, 20 mL, at case end",
        "isCorrect": false,
        "explanation": "Although less chondrotoxic than bupivacaine in vitro, ropivacaine still injures chondrocytes; no intra-articular local anesthetic is proven safe, and a single-shot provides limited duration."
      }
    ],
    "didactic": "Postarthroscopic glenohumeral chondrolysis is a devastating complication characterized by rapid loss of articular cartilage, pain, and stiffness months after surgery. The strongest and most reproducible risk factor is a continuous intra-articular local anesthetic infusion, particularly with bupivacaine 0.25%–0.5%, delivered for 24–72 hours. In vitro and animal data demonstrate concentration- and time-dependent chondrocyte death from local anesthetics; bupivacaine is highly chondrotoxic, and epinephrine (acidic solutions and preservatives such as sodium metabisulfite) can exacerbate toxicity. No intra-articular local anesthetic concentration or formulation has been shown to be reliably safe, and regulatory guidance specifically discourages intra-articular use, including with liposomal bupivacaine.\n\nTo mitigate chondrolysis risk, avoid exposing articular cartilage to local anesthetics—especially via continuous intra-articular catheters. Effective alternatives include:\n- Interscalene brachial plexus block, preferably a perineural catheter with ropivacaine 0.2% at 4–8 mL/h, which provides superior analgesia for shoulder procedures and entirely avoids the joint space.\n- Extra-articular catheters (eg, subacromial) that reduce but do not eliminate analgesic gaps for intra-articular work; while safer for cartilage, they are typically less effective than interscalene catheters.\n- For patients with significant pulmonary disease (risk of hemidiaphragmatic paresis), consider suprascapular ± axillary nerve blocks as phrenic-sparing strategies, acknowledging potential analgesic trade-offs.\n\nKey points:\n- Do not use continuous intra-articular local anesthetic infusions after shoulder arthroscopy.\n- Bupivacaine is particularly chondrotoxic; ropivacaine is less so but still harmful intra-articularly.\n- Prefer regional techniques that avoid the joint (eg, interscalene catheter) to achieve excellent analgesia without cartilage exposure.",
    "educationalObjective": "Identify chondrolysis risk with intra-articular bupivacaine infusions and avoid cartilage exposure."
  },
  {
    "id": "Core.7.3.14",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Local anesthetic pharmacology",
    "difficulty": "medium",
    "questionText": "A healthy 28-year-old G1P0 at 5 cm dilation requests labor epidural analgesia. An epidural catheter is placed uneventfully at L3–4 with negative aspiration and an appropriate test dose. You plan a continuous infusion that provides effective analgesia while preserving motor function for ambulation and later pushing. Which solution is most appropriate to achieve these goals?\n\nSelect the best choice.",
    "answers": [
      {
        "text": "Bupivacaine 0.25% at 10 mL/h",
        "isCorrect": false,
        "explanation": "This concentration of a highly potent long-acting amide produces dense sensory and significant motor block, which is undesirable for labor ambulation and pushing."
      },
      {
        "text": "Ropivacaine 0.1% with fentanyl 2 μg/mL at 10 mL/h",
        "isCorrect": true,
        "explanation": "Low-concentration ropivacaine provides sensory-predominant block with less motor blockade than bupivacaine; adding epidural fentanyl allows further LA dose reduction while maintaining analgesia."
      },
      {
        "text": "Lidocaine 2% with epinephrine 1:200,000 at 10 mL/h",
        "isCorrect": false,
        "explanation": "High-concentration lidocaine produces rapid, dense motor block; epinephrine may prolong and intensify block but does not meet the goal of motor sparing for labor."
      },
      {
        "text": "Chloroprocaine 3% at 8 mL/h",
        "isCorrect": false,
        "explanation": "Chloroprocaine provides very short-duration anesthesia with prominent motor block and is used for rapid surgical dosing rather than maintenance of labor analgesia."
      },
      {
        "text": "Bupivacaine 0.5% at 6 mL/h",
        "isCorrect": false,
        "explanation": "Very high concentration bupivacaine produces surgical-level anesthesia with profound motor block, contrary to the goal of preserving motor function."
      }
    ],
    "didactic": "Local anesthetics block voltage-gated Na<sup>+</sup> channels to prevent action potential propagation. Differential blockade reflects fiber size, myelination, and sensitivity: **B (preganglionic sympathetic) > C (pain, temperature) ≥ Aδ (pain) > Aβ (touch) > Aα (motor)**. Thus, **sympathetic and sensory** fibers are inhibited at lower concentrations, whereas **motor (Aα)** fibers require higher concentrations for comparable block. Clinically, tailoring drug and concentration exploits this gradient to match goals (eg, labor analgesia vs surgical anesthesia).\n\nFor labor epidurals, the aim is effective analgesia with minimal motor block to facilitate ambulation and pushing. Two strategies achieve this:\n- Use a **low concentration** of a long-acting amide to favor sensory over motor block.\n- Add a **neuraxial opioid** (eg, fentanyl 1–3 μg/mL), which provides synergistic analgesia and permits further reduction of local anesthetic dose.\n\n**Ropivacaine** is the S-enantiomer with slightly lower lipid solubility than bupivacaine, yielding a more **motor-sparing profile** at equipotent analgesic doses and lower cardiotoxicity. Typical labor regimens use ropivacaine 0.08%–0.2% or bupivacaine 0.0625%–0.125% with fentanyl, often via continuous infusion and/or PCEA. In contrast, higher concentrations of long-acting agents (eg, bupivacaine 0.25%–0.5%) produce dense motor block suitable for surgical anesthesia, not labor. **Lidocaine 1.5%–2%** and **chloroprocaine 2%–3%** provide rapid, dense blocks with prominent motor effects and short duration, making them more appropriate for urgent surgical dosing or epidural top-ups rather than maintenance of labor analgesia. Vasoconstrictors (epinephrine) may prolong block but can also intensify motor blockade and are not typically used for labor epidural maintenance.\n\nTherefore, a **low-concentration ropivacaine + fentanyl** infusion best meets the goal of sensory-predominant, motor-sparing labor analgesia aligned with the principles of differential blockade.",
    "educationalObjective": "Interpret differential blockade (sympathetic, sensory, motor) and tailor drug and concentration to clinical goals."
  },
  {
    "id": "Core.7.3.15",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Local anesthetic pharmacology",
    "difficulty": "hard",
    "questionText": "A 76-year-old man undergoing transesophageal echocardiography under monitored anesthesia care receives several sprays of topical benzocaine to the oropharynx and light sedation with midazolam and fentanyl. Ten minutes later, he becomes cyanotic with SpO<sub>2</sub> 85% despite O<sub>2</sub> by facemask at 10 L/min. He is anxious but protecting his airway. End-tidal CO<sub>2</sub> via nasal sampling is 38 mmHg. An arterial blood gas on 100% O<sub>2</sub> shows pH 7.44, PaCO<sub>2</sub> 39 mmHg, PaO<sub>2</sub> 287 mmHg, Hgb 11 g/dL; the blood appears chocolate-brown. Co-oximetry reveals methemoglobin 28%. His history includes depression treated with sertraline. Weight is 80 kg.\n\nWhich is the most appropriate next step to rapidly correct his hypoxia?",
    "answers": [
      {
        "text": "Proceed to endotracheal intubation and increase FiO<sub>2</sub> to 1.0",
        "isCorrect": false,
        "explanation": "Intubation and higher FiO<sub>2</sub> will not correct methemoglobinemia, as PaO<sub>2</sub> is already high; the issue is impaired O<sub>2</sub> carrying capacity from Fe3+, not inadequate alveolar oxygen. Airway intervention is reserved for impending failure, not first-line therapy here."
      },
      {
        "text": "Administer methylene blue 1 mg/kg IV over 5 minutes, monitor for response",
        "isCorrect": true,
        "explanation": "Methemoglobinemia after benzocaine is treated with methylene blue 1–2 mg/kg IV; it reduces Fe3+ to Fe2+ via NADPH-dependent methemoglobin reductase. Despite sertraline (serotonergic) increasing serotonin syndrome risk, symptomatic MetHb 28% warrants methylene blue with monitoring."
      },
      {
        "text": "Administer naloxone 0.04 mg IV and titrate to effect",
        "isCorrect": false,
        "explanation": "Opioid-induced hypoventilation would cause hypercapnia and hypoxemia with low PaO<sub>2</sub>, not a normal/high PaO<sub>2</sub> with a saturation gap. Naloxone does not address methemoglobin formation."
      },
      {
        "text": "Give IV ascorbic acid 2 g as first-line therapy",
        "isCorrect": false,
        "explanation": "Ascorbic acid is a slower, second-line reducer used when methylene blue is contraindicated (eg, G6PD deficiency) or ineffective. In a symptomatic patient with MetHb ~28%, methylene blue is preferred for rapid reversal."
      },
      {
        "text": "Continue observation with supplemental O<sub>2</sub> alone",
        "isCorrect": false,
        "explanation": "Supportive O<sub>2</sub> may help mild, asymptomatic cases (eg, MetHb <20%), but this patient is symptomatic with MetHb 28% and requires antidotal therapy to restore O<sub>2</sub> delivery."
      }
    ],
    "didactic": "Topical benzocaine and the amide local anesthetic prilocaine are classic precipitants of acquired methemoglobinemia. Oxidation of hemoglobin iron from Fe2+ (ferrous) to Fe3+ (ferric) produces methemoglobin, which cannot bind O<sub>2</sub> and shifts the oxyhemoglobin dissociation curve left for remaining Fe2+ sites, impairing tissue delivery. Typical features include cyanosis unresponsive to supplemental O<sub>2</sub>, chocolate-brown blood, pulse oximetry readings near 85% regardless of FiO<sub>2</sub>, and a “saturation gap” (normal/high PaO<sub>2</sub> with low measured saturation). Diagnosis is confirmed by co-oximetry, which directly quantifies MetHb.\n\nHigh-yield risk factors:\n- Agents: benzocaine sprays (upper airway procedures), prilocaine (Bier block, EMLA cream, tumescent anesthesia), dapsone, nitrates/nitrites\n- Hosts: infants <3 months, anemia, sepsis, cardiopulmonary disease, G6PD or NADH-cytochrome b<sub>5</sub> reductase deficiency\n\nManagement priorities:\n- Stop the offending oxidant and administer high-flow O<sub>2</sub>.\n- Give methylene blue 1–2 mg/kg IV over 5 minutes (may repeat in 30–60 minutes if needed; typical max cumulative dose ≈7 mg/kg). Methylene blue serves as an artificial electron acceptor using NADPH to reduce MetHb back to functional hemoglobin.\n- Monitor for complications. Because methylene blue is a monoamine oxidase inhibitor, serotonergic drugs (eg, SSRIs/SNRIs) increase risk of serotonin toxicity; however, in symptomatic or significant methemoglobinemia (eg, MetHb ≥20% or lower thresholds with comorbidities), benefits outweigh risks with close observation.\n- Important exception: G6PD deficiency impairs NADPH generation, rendering methylene blue ineffective and increasing hemolysis risk—use alternatives such as high-dose ascorbic acid, exchange transfusion, or hyperbaric O<sub>2</sub> for severe cases.\n\nPractical pearls: A normal or elevated PaO<sub>2</sub> does not exclude hypoxia from dyshemoglobinemias; rely on co-oximetry. Benzocaine and prilocaine exposures in at-risk patients should prompt vigilance for early signs and rapid antidotal therapy.",
    "educationalObjective": "Recognize risk factors for methemoglobinemia with prilocaine and benzocaine and outline management with methylene blue."
  },
  {
    "id": "Core.7.3.16",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Local anesthetic pharmacology",
    "difficulty": "easy",
    "questionText": "A 28-year-old healthy man is scheduled for an ultrasound-guided axillary block for outpatient hand surgery. The tissue appears well perfused without infection. You have equal volumes of local anesthetic solutions prepared at the same molar concentration, and adjuncts (eg, bicarbonate, epinephrine) are not available. The pK<sub>a</sub> values are: lidocaine 7.9, mepivacaine 7.6, ropivacaine 8.1, bupivacaine 8.1, and chloroprocaine 8.7. Which agent will most rapidly produce sensory block under these conditions?",
    "answers": [
      {
        "text": "Mepivacaine",
        "isCorrect": true,
        "explanation": "With a pK<sub>a</sub> of 7.6 (closest to physiologic pH 7.4), mepivacaine has the largest nonionized fraction at tissue pH, enabling faster nerve membrane penetration and the quickest onset at equal concentration."
      },
      {
        "text": "Ropivacaine",
        "isCorrect": false,
        "explanation": "Ropivacaine shares a pK<sub>a</sub> near 8.1, leading to a greater ionized fraction at physiologic pH and a slower onset than mepivacaine at equal concentration."
      },
      {
        "text": "Lidocaine",
        "isCorrect": false,
        "explanation": "Although relatively fast, lidocaine’s pK<sub>a</sub> of 7.9 is farther from physiologic pH than mepivacaine, yielding a smaller nonionized fraction and slightly slower onset at equal concentration."
      },
      {
        "text": "Chloroprocaine",
        "isCorrect": false,
        "explanation": "Despite clinically rapid onset when used in high concentrations, chloroprocaine has a high pK<sub>a</sub> (8.7); at equal molar concentration it is highly ionized at pH 7.4 and would have a slower onset."
      },
      {
        "text": "Bupivacaine",
        "isCorrect": false,
        "explanation": "Bupivacaine (pK<sub>a</sub> 8.1) is more ionized at pH 7.4, so membrane penetration is slower and onset is delayed relative to agents with lower pK<sub>a</sub>."
      }
    ],
    "didactic": "Local anesthetics are weak bases that exist in equilibrium between the nonionized base (B) and the protonated cation (BH<sup>+</sup>). The **nonionized** form crosses the lipid-rich nerve membrane; once inside the axoplasm, the **ionized** form binds the voltage-gated Na<sup>+</sup> channel. The fraction of drug in each form is governed by the Henderson–Hasselbalch relationship: $pH = pK_a + \\log\\left(\\frac{[B]}{[BH^+]}\\right)$. When pH approaches pK<sub>a</sub>, a larger proportion is nonionized, accelerating membrane penetration and onset.\n\nUnder normal tissue pH (≈7.4), agents with pK<sub>a</sub> closest to 7.4 have the fastest onset, all else equal. Among common agents:\n- Mepivacaine pK<sub>a</sub> ≈ 7.6 → fastest onset\n- Lidocaine pK<sub>a</sub> ≈ 7.9 → fast, but slower than mepivacaine\n- Bupivacaine/ropivacaine pK<sub>a</sub> ≈ 8.1 → slower onset\n- Chloroprocaine pK<sub>a</sub> ≈ 8.7 → slowest at equal molar concentration\n\nKey modifiers of onset include:\n- **Tissue pH:** Acidosis (eg, infection, ischemia) shifts drug to the ionized form, slowing onset for all agents. Alkalinization (eg, adding bicarbonate) increases the nonionized fraction and speeds onset.\n- **Concentration and dose:** Higher concentration and total mass of drug increase the amount of nonionized molecules delivered, often shortening onset (eg, chloroprocaine’s clinically rapid onset at 2%–3% despite high pK<sub>a</sub>).\n- **Anatomic/physicochemical factors:** Proximity of injection to nerve, lipid solubility, and nerve fiber characteristics also influence onset, but pK<sub>a</sub> and pH primarily determine the fraction that can penetrate the membrane.\n\nTherefore, when concentration and conditions are controlled, selecting a local anesthetic with a pK<sub>a</sub> closer to physiologic pH (eg, mepivacaine) yields the **fastest onset** of peripheral nerve block.",
    "educationalObjective": "Relate pKa to onset time and predict faster onset with agents whose pKa is closer to physiologic pH."
  },
  {
    "id": "Core.7.3.17",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Local anesthetic pharmacology",
    "difficulty": "hard",
    "questionText": "A 65-year-old man with type 2 diabetes mellitus (A1c 9%), symptomatic peripheral neuropathy, peripheral arterial disease (ABI 0.6), coronary artery disease on metoprolol (β<sub>1</sub>-blocker), and obstructive sleep apnea is scheduled for open reduction and internal fixation of a distal radius fracture. You plan a single-shot supraclavicular block with 30 mL of 0.5% ropivacaine, and the surgeon requests ≥24 hours of postoperative analgesia. Baseline HR is 56/min and BP is 148/78 mmHg. You wish to prolong the block while minimizing hemodynamic instability, neuroischemic risk, and sedation.\n\nWhich adjuvant strategy is most appropriate to prolong block duration in this patient?",
    "answers": [
      {
        "text": "Add epinephrine 1:400,000 (2.5 μg/mL) plus clonidine 75 μg perineurally",
        "isCorrect": false,
        "explanation": "Combining adjuvants adds side effects (ischemia, bradycardia, sedation) without clear incremental benefit and is ill-suited for a β-blocked patient with PAD and OSA."
      },
      {
        "text": "Add clonidine 150 μg perineurally to the local anesthetic",
        "isCorrect": false,
        "explanation": "Clonidine (α<sub>2</sub>-agonist) can prolong block but commonly causes dose-dependent sedation, hypotension, and bradycardia—problematic in a β-blocked, OSA patient."
      },
      {
        "text": "Add dexamethasone 8 mg perineurally to the local anesthetic",
        "isCorrect": false,
        "explanation": "Perineural dexamethasone prolongs block but offers no clinically meaningful advantage over IV dosing for peripheral nerve blocks and is off-label with theoretical neurotoxicity concerns; IV route is safer in this high-risk patient."
      },
      {
        "text": "Administer IV dexamethasone 8 mg at induction",
        "isCorrect": true,
        "explanation": "IV dexamethasone (4–8 mg) reliably prolongs peripheral nerve block duration similarly to perineural dosing, without vasoconstrictive ischemia or α<sub>2</sub>-mediated bradycardia/sedation; transient hyperglycemia can be monitored in this diabetic patient."
      },
      {
        "text": "Add epinephrine 1:200,000 (5 μg/mL) perineurally to the local anesthetic",
        "isCorrect": false,
        "explanation": "Epinephrine prolongs block by α-mediated vasoconstriction and can help detect intravascular injection, but β-blockade blunts the HR response and PAD/diabetic neuropathy increases ischemic/neurotoxicity risk; risk-benefit is unfavorable here."
      }
    ],
    "didactic": "Adjuvants prolong local anesthetic (LA) block by complementary mechanisms but should be tailored to patient comorbidities.\n\n- Epinephrine (1–5 μg/mL; eg, 1:200,000) prolongs block via α-mediated vasoconstriction that slows systemic absorption. It can serve as an intravascular injection marker (tachycardia), but this effect is unreliable with β-blockade and may provoke hypertension or myocardial ischemia. In patients with compromised neural perfusion (diabetes, peripheral arterial disease, vasospasm), vasoconstriction increases risk of ischemia and potentiates LA neurotoxicity; avoid in end-artery fields and high-risk neuropathic limbs.\n- Dexamethasone (4–8 mg) prolongs sensory block by several hours via anti-inflammatory and anti-ectopic discharge effects on C-fibers and Aδ-fibers, with minimal hemodynamic effects. For peripheral nerve blocks, multiple RCTs and meta-analyses show IV dexamethasone provides similar prolongation to perineural dosing, making IV preferable to avoid off-label perineural injection and theoretical neurotoxicity. Adverse effects include transient hyperglycemia; monitor glucose in diabetics.\n- Clonidine (≈0.5–1 μg/kg perineural) prolongs block by α<sub>2</sub>-receptor–mediated hyperpolarization (↑ K<sup>+</sup> conductance). However, systemic absorption can cause sedation, hypotension, and bradycardia—effects magnified in older, β-blocked, or OSA patients.\n\nIn this β-blocked patient with PAD, diabetic neuropathy, and OSA, the safest high-yield strategy to extend a long-acting LA block is IV dexamethasone, which avoids epinephrine-induced ischemia and clonidine-related bradycardia/sedation while providing meaningful prolongation. Combining adjuvants increases adverse effects without clear benefit. When using steroids, counsel regarding short-lived hyperglycemia and plan postoperative glucose monitoring.",
    "educationalObjective": "Select adjuvants (epinephrine, dexamethasone, clonidine) to prolong block and describe their mechanisms and risks."
  },
  {
    "id": "Core.7.3.18",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Local anesthetic pharmacology",
    "difficulty": "medium",
    "questionText": "A 65-kg woman undergoes laparoscopic cholecystectomy under general anesthesia. At closure, you plan bilateral ultrasound-guided TAP blocks using 0.25% bupivacaine without epinephrine because she has a history of symptomatic supraventricular tachycardia. No other local anesthetics have been given. You will inject equal volumes on each side.\n\nWhat is the largest volume per side you can administer without exceeding the recommended maximum dose?",
    "answers": [
      {
        "text": "35 mL per side",
        "isCorrect": false,
        "explanation": "Exceeds the plain bupivacaine limit: 2.5 mg/mL × 70 mL = 175 mg total. This reflects using the higher with-epinephrine limit (≈3 mg/kg) or not accounting for bilateral dosing."
      },
      {
        "text": "26 mL per side",
        "isCorrect": false,
        "explanation": "Still below the limit (2.5 mg/mL × 52 mL = 130 mg total). This is conservative and not the largest safe volume."
      },
      {
        "text": "32 mL per side",
        "isCorrect": true,
        "explanation": "Bupivacaine without epinephrine: 2.5 mg/kg × 65 kg = 162.5 mg max. At 0.25% (2.5 mg/mL), the total allowable volume is 65 mL; divided bilaterally ≈ 32.5 mL/side, so 32 mL/side is the largest whole-mL volume within the limit (160 mg total)."
      },
      {
        "text": "20 mL per side",
        "isCorrect": false,
        "explanation": "Safe but not the largest; total dose would be 100 mg (2.5 mg/mL × 40 mL), well below the maximum for bupivacaine without epinephrine."
      },
      {
        "text": "40 mL per side",
        "isCorrect": false,
        "explanation": "Far exceeds the maximum (2.5 mg/mL × 80 mL = 200 mg). This risks local anesthetic systemic toxicity (LAST)."
      }
    ],
    "didactic": "Maximum recommended doses are weight-based and differ with epinephrine because vasoconstriction reduces systemic absorption. Common values (adults, typical references):\n\n- Lidocaine: 4.5 mg/kg plain (max ~300 mg); 7 mg/kg with epinephrine (max ~500 mg)\n- Mepivacaine: 5 mg/kg plain; 7 mg/kg with epinephrine\n- Bupivacaine: 2.5 mg/kg plain (max ~175 mg); 3 mg/kg with epinephrine (max ~225 mg)\n- Ropivacaine: ~3 mg/kg (epinephrine provides minimal increase clinically)\n- Chloroprocaine: 11 mg/kg plain; 14 mg/kg with epinephrine\n\nConvert % to mg/mL: 1% = 10 mg/mL, 0.5% = 5 mg/mL, 0.25% = 2.5 mg/mL. Calculate dose and volume:\n\n- Maximum mg = weight × (mg/kg limit)\n- Maximum volume (mL) = maximum mg ÷ concentration (mg/mL)\n- For bilateral blocks, the total volume is split across sides.\n\nIn this patient: bupivacaine without epinephrine = 2.5 mg/kg × 65 kg = 162.5 mg. At 0.25% (2.5 mg/mL), total allowable volume = 162.5 ÷ 2.5 = 65 mL. Dividing equally: 32.5 mL/side. The largest whole-mL volume that stays within the limit is 32 mL/side (160 mg total).\n\nEpinephrine can increase maximum dose (eg, bupivacaine 2.5 → 3 mg/kg) by slowing uptake and serving as an intravascular marker; however, it may be avoided in patients with tachyarrhythmias or when added vasoconstriction is undesirable. Patient factors (pregnancy, extremes of age, hepatic/cardiac disease, low protein states) reduce safety margins and warrant more conservative dosing. Always consider cumulative dosing when combining local anesthetics (systemic toxicity is additive), use incremental injections with frequent aspiration, and monitor for early signs of LAST (perioral numbness, tinnitus, CNS changes) to intervene promptly with lipid emulsion if needed.",
    "educationalObjective": "State maximum recommended doses with and without epinephrine and apply weight-based calculations safely."
  },
  {
    "id": "Core.7.4.1",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Lower limb and truncal blocks",
    "difficulty": "medium",
    "questionText": "A 45-year-old man is scheduled for an open umbilical hernia repair via a 5-cm midline infra- to periumbilical incision. You plan bilateral ultrasound-guided rectus sheath blocks for postoperative analgesia. With a high-frequency linear probe placed transversely at the umbilicus, you identify the rectus abdominis muscle, the hyperechoic posterior rectus sheath, and peritoneum deep to it. Color Doppler demonstrates a pulsatile vessel along the deep surface of the lateral third of the rectus muscle, consistent with the inferior epigastric artery. \n\nWhich needle trajectory and target injectate plane best provide analgesia for the planned incision while minimizing vascular and peritoneal injury?",
    "answers": [
      {
        "text": "In-plane, medial-to-lateral approach to deposit local anesthetic deep to the posterior rectus sheath in the preperitoneal space",
        "isCorrect": false,
        "explanation": "Injection deep to the posterior rectus sheath risks peritoneal puncture and does not reliably anesthetize the anterior cutaneous branches that lie superficial to the sheath."
      },
      {
        "text": "In-plane, lateral-to-medial approach to deposit local anesthetic between the internal oblique and transversus abdominis at the midline",
        "isCorrect": false,
        "explanation": "A TAP plane injection targets lateral cutaneous branches and does not reliably cover midline incisions; the TAP plane is lateral, not at the midline."
      },
      {
        "text": "Out-of-plane, medial-to-lateral approach with deposition in the subcutaneous tissue over the linea alba bilaterally",
        "isCorrect": false,
        "explanation": "Subcutaneous infiltration over the linea alba does not reach the anterior cutaneous branches within the rectus sheath and provides unreliable coverage for midline incisions."
      },
      {
        "text": "Out-of-plane, lateral-to-medial approach targeting intramuscular injection within rectus abdominis",
        "isCorrect": false,
        "explanation": "Intramuscular injection yields poor spread within the correct fascial plane and increases the chance of vessel puncture along the deep surface of the muscle."
      },
      {
        "text": "In-plane, lateral-to-medial approach to deposit local anesthetic between the posterior surface of rectus abdominis and the posterior rectus sheath, medial to the epigastric vessels, with hydrodissection confirmation",
        "isCorrect": true,
        "explanation": "The rectus sheath block targets the potential space between the posterior rectus sheath and the deep surface of rectus abdominis; staying medial to the epigastric vessels and using hydrodissection reduces vascular and peritoneal injury risk."
      }
    ],
    "didactic": "A rectus sheath block provides somatic analgesia for midline abdominal incisions (eg, umbilical hernia repair) by anesthetizing the anterior cutaneous branches of T7–T12 as they course within the rectus sheath. Under ultrasound, the goal is to place local anesthetic between the posterior surface of the rectus abdominis muscle and the posterior rectus sheath, creating a hypoechoic separation (“lift-off”) of the muscle from the sheath. This plane allows longitudinal spread to capture the segmental nerves before they pierce the anterior sheath to innervate midline skin.\n\nKey technical points:\n- Position a linear probe transversely at or just cephalad to the umbilicus (above the arcuate line when possible) to ensure a distinct posterior rectus sheath.\n- Use an in-plane lateral-to-medial needle path to maintain visualization of the tip and reduce inadvertent peritoneal entry.\n- Activate color Doppler to identify the inferior (and superior) epigastric vessels, which typically lie on the deep surface of the lateral rectus within the sheath; keep the needle and injectate medial to these vessels.\n- Confirm correct plane with hydrodissection (separation of the posterior rectus sheath from the deep surface of rectus abdominis) before incremental injection.\n\nAvoid common pitfalls:\n- Injecting deep to the posterior rectus sheath enters the preperitoneal/peritoneal space, risking bowel injury and block failure.\n- Intramuscular or subcutaneous injections do not provide reliable coverage of anterior cutaneous branches.\n- Below the arcuate line, the posterior rectus sheath is absent; extra caution is required to prevent peritoneal puncture, and cephalad probe positioning may improve safety.\n\nTypical dosing is 10–15 mL of long-acting local anesthetic per side (eg, 0.2–0.375% ropivacaine), with total dose limited by weight-based maximums. For midline incisions, bilateral blocks are required to cover both sides of the midline dermatomes.",
    "educationalObjective": "Apply rectus sheath block for midline incisions and avoid vascular injury within the sheath."
  },
  {
    "id": "Core.7.4.2",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Lower limb and truncal blocks",
    "difficulty": "hard",
    "questionText": "A 32-year-old primiparous patient is in the PACU following cesarean delivery via Pfannenstiel incision under spinal anesthesia performed without intrathecal morphine due to prior severe nausea/vomiting. She reports severe lower abdominal and deep cramping pain (NRS 8/10) despite acetaminophen and an NSAID. She wishes to ambulate and care for her newborn within hours and requests an opioid-sparing regional technique. Coagulation is normal and an ultrasound machine is available. You plan a bilateral truncal block.\n\nWhich single technique is most appropriate to address both somatic incisional and visceral pain while minimizing the risk of quadriceps weakness?",
    "answers": [
      {
        "text": "Bilateral lateral quadratus lumborum block (QLB1)",
        "isCorrect": false,
        "explanation": "QLB1 (lateral approach) provides more lateral abdominal wall coverage with less consistent paravertebral/visceral spread compared with posterior or transmuscular approaches."
      },
      {
        "text": "Unilateral erector spinae plane (ESP) block at T9",
        "isCorrect": false,
        "explanation": "Unilateral ESP at T9 is unlikely to provide reliable bilateral lower abdominal coverage for a Pfannenstiel incision and may offer inconsistent visceral analgesia at lower dermatomes."
      },
      {
        "text": "Bilateral transversus abdominis plane (TAP) block with 20 mL 0.25% bupivacaine per side",
        "isCorrect": false,
        "explanation": "TAP blocks primarily the somatic nerves of the anterolateral abdominal wall (T10–L1) and provides limited or no visceral analgesia, making it suboptimal for prominent cramping pain after cesarean."
      },
      {
        "text": "Bilateral transmuscular quadratus lumborum block (QLB3)",
        "isCorrect": false,
        "explanation": "QLB3 places local anesthetic between the quadratus lumborum and psoas major; while visceral coverage can be robust, spread to the lumbar plexus increases the risk of quadriceps weakness, impairing early ambulation."
      },
      {
        "text": "Bilateral posterior quadratus lumborum block (QLB2) with 20 mL 0.25% bupivacaine per side",
        "isCorrect": true,
        "explanation": "QLB2 deposits local anesthetic posterior to the quadratus lumborum, with spread along the thoracolumbar fascia into the paravertebral space for visceral and somatic coverage, and low likelihood of lumbar plexus spread and quadriceps weakness."
      }
    ],
    "didactic": "Quadratus lumborum blocks (QLBs) aim to extend analgesia beyond the transversus abdominis plane (TAP) by exploiting spread along the **thoracolumbar fascia (TLF)** and into the **paravertebral space**, potentially engaging ventral rami and the sympathetic chain for a **visceral component** of analgesia.\n\n- QLB1 (lateral): Injection at the anterolateral border of the QL within the TLF. Provides lateral abdominal wall somatic analgesia; paravertebral spread is variable, so visceral coverage is less consistent.\n- QLB2 (posterior): Injection posterior to the QL, deep to the erector spinae aponeurosis. Dye and imaging studies show cranio-caudal spread along the TLF with potential **paravertebral spread to T7–L1**, improving both somatic and visceral analgesia while generally sparing the lumbar plexus (low quadriceps weakness risk).\n- QLB3 (transmuscular): Injection between QL and psoas major (the “Shamrock” view). Can produce robust paravertebral/visceral spread but more readily tracks to the **lumbar plexus**, risking femoral nerve involvement and **quadriceps weakness**.\n- Intramuscular QLB: Less predictable spread; not typically favored when visceral analgesia is desired.\n\nIn contrast, the **TAP block** deposits local anesthetic between the internal oblique and transversus abdominis, reliably blocking somatic nerves (T10–L1) of the anterolateral abdominal wall but providing **minimal visceral analgesia**. For post-cesarean pain characterized by deep cramping and incisional pain, QLBs (posterior or transmuscular) better target both components. Given the patient’s need for early ambulation, **QLB2** optimally balances efficacy and safety by offering paravertebral/visceral coverage with a lower likelihood of motor block than QLB3. Typical volumes are 20–30 mL per side of a long-acting local anesthetic; bilateral application is needed for midline incisions like a Pfannenstiel. This mechanistic advantage over TAP underpins improved opioid-sparing outcomes observed in obstetric and lower abdominal surgery.",
    "educationalObjective": "Choose quadratus lumborum block variant and discuss proposed mechanisms and spread relative to TAP."
  },
  {
    "id": "Core.7.4.3",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Lower limb and truncal blocks",
    "difficulty": "easy",
    "questionText": "A 52-year-old man with burning dysesthesia over the anterolateral thigh consistent with meralgia paresthetica elects an ultrasound-guided diagnostic block to avoid quadriceps weakness. You plan a selective lateral femoral cutaneous nerve block. Which transducer position and needle target best accomplish this?",
    "answers": [
      {
        "text": "Place the transducer on the medial thigh to identify the adductor longus and adductor brevis; inject in the intermuscular plane between them.",
        "isCorrect": false,
        "explanation": "This targets the anterior branch of the obturator nerve for medial thigh analgesia, not the anterolateral thigh territory of the LFCN."
      },
      {
        "text": "Place the transducer over the inguinal canal to visualize the spermatic cord; inject around the cord structures to block the genitofemoral nerve.",
        "isCorrect": false,
        "explanation": "The genitofemoral nerve supplies upper anterior thigh and genital structures; blocking it will not reliably treat anterolateral thigh symptoms of meralgia paresthetica."
      },
      {
        "text": "Place a linear transducer just inferior and 1–2 cm medial to the ASIS, parallel to the inguinal ligament; identify sartorius (medial) and tensor fascia lata (lateral), then inject 5–10 mL in the fascial plane deep to fascia lata and superficial to fascia iliaca where a small hyperechoic oval nerve lies between the two muscles.",
        "isCorrect": true,
        "explanation": "This is the classic ultrasound approach: the LFCN typically lies under the inguinal ligament, just medial to the ASIS, in the plane between fascia lata and fascia iliaca adjacent to sartorius and tensor fascia lata."
      },
      {
        "text": "Place a high-frequency transducer at the femoral crease to identify the femoral artery and nerve; inject 20–30 mL under fascia iliaca lateral to the artery to spread cephalad.",
        "isCorrect": false,
        "explanation": "This describes a fascia iliaca compartment block, which often anesthetizes the LFCN but is not selective and risks femoral nerve blockade with quadriceps weakness."
      },
      {
        "text": "Place the transducer in the subgluteal region between the greater trochanter and ischial tuberosity; inject around the sciatic nerve.",
        "isCorrect": false,
        "explanation": "A sciatic block anesthetizes the posterior thigh and distal lower extremity, not the LFCN territory on the anterolateral thigh."
      }
    ],
    "didactic": "The lateral femoral cutaneous nerve (LFCN) is a purely sensory branch of L2–L3 that emerges from the lateral border of psoas major, courses across the iliacus, and passes under (or occasionally through) the inguinal ligament approximately 1–2 cm medial to the ASIS before supplying the anterolateral thigh. Ultrasound guidance improves selectivity and reduces spread to the femoral nerve.\n\nOptimal technique uses a high-frequency linear transducer placed just inferior and slightly medial to the ASIS, aligned parallel to the inguinal ligament. Key sonoanatomic landmarks include:\n- ASIS: a bright, shadowing bony line laterally\n- Tensor fascia lata (lateral) and sartorius (medial): adjacent muscles at this level\n- Fascia lata (superficial hyperechoic line) and fascia iliaca (deeper hyperechoic line) over the iliacus\n\nThe LFCN usually appears as a small, hyperechoic oval or honeycomb structure in the plane between the fascia lata and fascia iliaca, often between the sartorius and tensor fascia lata. After in-plane needle advancement, gentle hydrodissection confirms opening of this plane; 5–10 mL of local anesthetic reliably surrounds the nerve. Color Doppler helps avoid the lateral circumflex femoral vessels.\n\nCommon pitfalls include scanning too medially (leading to unintended femoral nerve spread) and injecting too deep beneath the fascia iliaca (producing a partial fascia iliaca block with quadriceps weakness). While a fascia iliaca compartment block can anesthetize the LFCN, it is not selective and typically requires larger volumes with higher risk of motor blockade—undesirable for a diagnostic block or for lateral thigh graft harvest. If the nerve is not visualized due to anatomic variation, depositing local anesthetic in the correct fascial plane just medial to the ASIS still provides effective spread to the LFCN.",
    "educationalObjective": "Identify landmarks and sonoanatomy for lateral femoral cutaneous nerve block for meralgia paresthetica or graft harvest."
  },
  {
    "id": "Core.7.4.4",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Lower limb and truncal blocks",
    "difficulty": "medium",
    "questionText": "A 28-year-old man is scheduled for an open appendectomy via a standard McBurney incision in the right lower quadrant (below the umbilicus). He will receive general anesthesia, and you plan an ultrasound-guided transversus abdominis plane (TAP) block for postoperative analgesia. The surgical team confirms the primary incision will be lateral in the RLQ without midline extension. Which approach best targets the dermatomes for this incision to provide optimal analgesia?\n\nWhich block approach is most appropriate for this patient?",
    "answers": [
      {
        "text": "Posterior TAP at the lumbar triangle of Petit with injectate placed deep to the transversus aponeurosis adjacent to quadratus lumborum",
        "isCorrect": false,
        "explanation": "Posterior TAP may produce broader, variable spread (sometimes more cephalad) but is less targeted; for predictable RLQ coverage, lateral TAP more reliably anesthetizes T10–T12."
      },
      {
        "text": "Bilateral subcostal TAP along the costal margin with injection between rectus abdominis and transversus abdominis near the xiphoid extending laterally",
        "isCorrect": false,
        "explanation": "Subcostal TAP primarily covers upper abdominal dermatomes (T6–T9) for supraumbilical surgery (eg, cholecystectomy), not isolated lower quadrant incisions."
      },
      {
        "text": "Unilateral lateral TAP at the midaxillary line with local anesthetic deposited between the internal oblique and transversus abdominis just superior to the iliac crest",
        "isCorrect": true,
        "explanation": "The lateral TAP reliably covers T10–T12 (±L1), matching lower abdominal incisions such as a McBurney appendectomy; the target plane is between the internal oblique and transversus abdominis."
      },
      {
        "text": "Bilateral rectus sheath blocks at the umbilicus with local anesthetic between the posterior rectus sheath and rectus muscle",
        "isCorrect": false,
        "explanation": "Rectus sheath blocks are best for midline periumbilical incisions and do not cover lateral abdominal wall innervation for a McBurney incision."
      },
      {
        "text": "Ilioinguinal/iliohypogastric nerve block alone at the anterior superior iliac spine with injection between internal oblique and transversus",
        "isCorrect": false,
        "explanation": "II/IH blocks target T12–L1 and may miss T10–T11 contributions to the McBurney incision; a lateral TAP provides more complete coverage of the RLQ field."
      }
    ],
    "didactic": "TAP blocks provide somatic analgesia to the anterolateral abdominal wall by depositing local anesthetic in fascial planes that carry thoracolumbar intercostal nerves. Selecting the approach is driven by dermatomal coverage relative to the incision location.\n\n- Lateral TAP (classic): Needle placement at the midaxillary line between the costal margin and iliac crest, targeting the plane between the internal oblique and transversus abdominis. This approach reliably covers T10–T12 (often with some L1 spread), making it well suited for lower abdominal, infraumbilical incisions such as appendectomy (McBurney), laparoscopic lower quadrant ports, and Pfannenstiel-type incisions (when combined bilaterally for midline components).\n- Subcostal TAP (oblique subcostal): Injection along the costal margin, often between the rectus abdominis and transversus abdominis from the xiphoid laterally. This technique favors upper abdominal dermatomes (T6–T9) and is preferred for supraumbilical procedures (eg, cholecystectomy, upper midline laparotomy).\n- Posterior TAP: Performed more posteriorly near the lumbar triangle of Petit; spread can be broader and less predictable, sometimes overlapping with quadratus lumborum patterns, but it is not the most targeted choice for a focal RLQ incision.\n\nFor an isolated McBurney incision, the key dermatomes are T10–T12 with potential L1 contribution. A unilateral lateral TAP best matches this target by bathing the intercostal nerves in the IO–TA fascial plane, providing reliable somatic wall analgesia without unnecessary cephalad coverage. Rectus sheath blocks primarily cover midline periumbilical pain and are inadequate for lateral incisions. While ilioinguinal/iliohypogastric blocks can help with L1-mediated pain (eg, inguinal), they may not fully address T10–T11, resulting in incomplete coverage compared with a lateral TAP.",
    "educationalObjective": "Implement TAP block for lower abdominal surgery and select subcostal versus lateral approach by dermatomal target."
  },
  {
    "id": "Core.7.4.5",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Lower limb and truncal blocks",
    "difficulty": "easy",
    "questionText": "A 58-year-old man with diabetes is scheduled for a bunionectomy and exostectomy of the medial first metatarsal. He prefers regional anesthesia. You perform an ankle block targeting the terminal nerves and plan to proceed without additional sedation. After 20 minutes, you assess pinprick sensation to confirm coverage for forefoot surgery.\n\nWhich combination of sensory findings BEST confirms successful blockade of all terminal nerves required for this procedure?",
    "answers": [
      {
        "text": "Absent sensation in the first dorsal web space; absent plantar forefoot sensation; absent sensation along the lateral border of the foot; intact sensation along the medial midfoot",
        "isCorrect": false,
        "explanation": "This misses the saphenous nerve (medial foot/medial malleolus), risking pain from a medial forefoot incision (eg, bunionectomy)."
      },
      {
        "text": "Absent sensation over the dorsum of the foot (excluding the first web space); absent sensation along the medial malleolus/medial arch; absent sensation along the lateral foot border; intact plantar sensation",
        "isCorrect": false,
        "explanation": "This omits the tibial nerve (plantar surface), which innervates the plantar forefoot via the medial/lateral plantar nerves."
      },
      {
        "text": "Absent sensation in the first dorsal web space; absent sensation across the dorsum of the forefoot; absent sensation along the medial malleolus/medial midfoot; absent sensation along the lateral border of the foot; absent plantar forefoot sensation",
        "isCorrect": true,
        "explanation": "This set confirms blockade of all five terminal nerves at the ankle: deep peroneal (first web space), superficial peroneal (dorsum), saphenous (medial foot), sural (lateral foot), and tibial (plantar surface)."
      },
      {
        "text": "Absent sensation in the first dorsal web space and over the dorsum of the forefoot; intact plantar, medial, and lateral border sensation",
        "isCorrect": false,
        "explanation": "Deep and superficial peroneal nerves are blocked, but tibial (plantar), saphenous (medial), and sural (lateral) territories are not—insufficient for forefoot surgery."
      },
      {
        "text": "Absent plantar forefoot sensation and absent sensation along the medial arch; intact dorsal foot sensation including the first web space and lateral border",
        "isCorrect": false,
        "explanation": "Only tibial and saphenous territories are covered; superficial and deep peroneal and sural distributions remain intact."
      }
    ],
    "didactic": "An ankle block provides surgical anesthesia for forefoot procedures by targeting five terminal nerves at the level of the malleoli. Four are branches of the sciatic nerve—**tibial**, **deep peroneal**, **superficial peroneal**, and **sural**—and one is a branch of the femoral nerve (**saphenous**). Reliable coverage requires blocking all five and confirming sensory loss in their key cutaneous distributions:\n\n- **Deep peroneal**: first dorsal web space between the hallux and second toe\n- **Superficial peroneal**: dorsum of the forefoot (except first web space and lateral border)\n- **Saphenous**: medial malleolus and medial midfoot/arch\n- **Sural**: lateral foot border and lateral fifth toe\n- **Tibial** (via medial/lateral plantar nerves): plantar forefoot/sole\n\nFor forefoot surgery (eg, bunionectomy, toe amputation), plantar and dorsal innervation must be covered. A common pitfall is relying on dorsal numbness alone; failure to block the **tibial** nerve leaves the plantar aspect painful. Another frequent miss is the **saphenous** nerve, leading to pain from medial incisions or traction at the first metatarsal. Ensuring loss of sensation in the first web space (deep peroneal) and the plantar surface (tibial) plus the medial (saphenous), lateral (sural), and general dorsal foot (superficial peroneal) confirms complete coverage.\n\nLandmarks at the ankle:\n- **Deep peroneal**: just lateral to the dorsalis pedis artery between the tendons of EHL and EDL\n- **Tibial**: posterior to the posterior tibial artery, behind the medial malleolus\n- **Superficial peroneal, saphenous, sural**: subcutaneous field blocks—anterior/medial to the medial malleolus (saphenous), posterior to the lateral malleolus (sural), and across the mid-dorsum (superficial peroneal)\n\nTesting these five sentinel areas after 15–20 minutes provides a rapid, objective confirmation that the ankle block is adequate for forefoot procedures.",
    "educationalObjective": "Perform ankle block by targeting five terminal nerves and confirm coverage for forefoot procedures."
  },
  {
    "id": "Core.7.4.6",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Lower limb and truncal blocks",
    "difficulty": "medium",
    "questionText": "An 82-year-old woman (60 kg) with a displaced femoral neck fracture has severe pain with minimal movement. You plan an ultrasound-guided fascia iliaca block in the ED to provide preoperative analgesia with coverage of both the femoral nerve and the lateral femoral cutaneous nerve (LFCN). You select ropivacaine 0.2% to allow a larger volume within safe dosing limits. Under a linear probe at the inguinal crease, you identify the fascia lata, fascia iliaca over the iliacus, the femoral artery, and the femoral nerve.\n\nWhich ultrasound-guided needle tip location and injectate spread pattern will most reliably block both the femoral nerve and the LFCN in this patient?",
    "answers": [
      {
        "text": "Needle tip adjacent to the femoral nerve within the femoral sheath; circumferential spread around the femoral nerve; inject 15 mL of 0.5% ropivacaine.",
        "isCorrect": false,
        "explanation": "A perineural femoral nerve block provides femoral coverage but inconsistently reaches the LFCN due to limited volume and restricted spread within the femoral sheath."
      },
      {
        "text": "Suprainguinal approach deep to the fascia iliaca with cephalad tracking under the internal oblique; inject 5–10 mL of 0.5% ropivacaine.",
        "isCorrect": false,
        "explanation": "Although the suprainguinal plane targets cephalad spread, very low volumes are unlikely to cover both the femoral nerve and the LFCN consistently."
      },
      {
        "text": "Needle tip superficial to the fascia iliaca (between fascia lata and fascia iliaca) lateral to the femoral vessels; inject 30 mL of 0.2% ropivacaine tracking superficially toward the ASIS.",
        "isCorrect": false,
        "explanation": "Injection above the fascia iliaca fails to enter the fascia iliaca compartment and will not reliably anesthetize the femoral nerve or LFCN."
      },
      {
        "text": "Needle tip deep to the fascia iliaca but medial to the femoral nerve near the pectineus; inject 10 mL of 0.2% ropivacaine with spread directed medially.",
        "isCorrect": false,
        "explanation": "Medial placement and low volume favor femoral coverage at best and will not reach the LFCN, which lies more laterally."
      },
      {
        "text": "Needle tip deep to the fascia iliaca, lateral to the femoral nerve; hydrodissection lifts the fascia iliaca off the iliacus with an anechoic layer tracking laterally toward the ASIS and cephalad; inject 30–40 mL of 0.2% ropivacaine.",
        "isCorrect": true,
        "explanation": "Placement in the fascia iliaca compartment with broad lateral and cephalad spread reliably bathes the femoral nerve and LFCN; high-volume dilute local anesthetic promotes compartment spread while staying within safe dosing."
      }
    ],
    "didactic": "The fascia iliaca compartment lies deep to the fascia iliaca over the iliacus and psoas, enveloping the femoral nerve medially and the lateral femoral cutaneous nerve (LFCN) more laterally as they course beneath the inguinal ligament. A properly performed fascia iliaca block deposits local anesthetic deep to the fascia iliaca, allowing the injectate to spread widely within this potential space. Ultrasound confirmation is hydrodissection that lifts the fascia iliaca off the iliacus, creating a wedge-shaped anechoic layer that tracks laterally toward the anterior superior iliac spine (ASIS) and cephalad. This pattern predicts reliable coverage of both the femoral nerve and the LFCN; obturator nerve coverage is variable.\n\nCompared with a perineural femoral nerve block (injection within the femoral sheath), the fascia iliaca approach targets a plane with greater anatomic continuity, enhancing lateral and cephalad spread. Placement superficial to the fascia iliaca (between fascia lata and fascia iliaca) does not enter the compartment and risks inadequate analgesia. Similarly, very medial placement or intramuscular injection limits spread and fails to reach the LFCN.\n\nHigh-volume, low-concentration local anesthetic improves compartmental spread. For ropivacaine, a commonly cited maximum is ≈3 mg/kg; in a 60-kg patient, 30–40 mL of 0.2% (2 mg/mL) provides 60–80 mg (1.0–1.3 mg/kg), which is within safe limits while promoting coverage of both nerves. Incremental injection with frequent aspiration reduces intravascular injection risk. Although suprainguinal techniques may further improve cephalad spread and LFCN capture, they still require adequate volume; very low volumes are unlikely to anesthetize both targets reliably.\n\nKey sonographic goals:\n- Needle tip just deep to the fascia iliaca over iliacus (not in muscle or above fascia)\n- Hydrodissection lifting fascia iliaca with lateral/cephalad tracking toward the ASIS\n- Sufficient volume (≈30–40 mL dilute local) to bathe the femoral nerve and LFCN",
    "educationalObjective": "Perform fascia iliaca block for hip fracture analgesia and predict spread to femoral and lateral femoral cutaneous nerves."
  },
  {
    "id": "Core.7.4.7",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Lower limb and truncal blocks",
    "difficulty": "hard",
    "questionText": "A 68-year-old woman (60 kg) with a displaced femoral neck fracture presents for urgent fixation. She takes apixaban 5 mg twice daily for atrial fibrillation; the last dose was 18 hours ago. eGFR is 45 mL/min/1.73 m<sup>2</sup>, platelets 210 ×10<sup>9</sup>/L, and INR 1.1. You plan regional analgesia to facilitate positioning for spinal anesthesia and desire coverage that includes the obturator contribution to the hip capsule. Ultrasound and lipid emulsion are immediately available.\n\nWhich regional analgesic plan is most appropriate now?",
    "answers": [
      {
        "text": "Hold apixaban for 24 hours, then perform a lumbar plexus block with 40 mL of 0.5% ropivacaine.",
        "isCorrect": false,
        "explanation": "Deep plexus blocks follow neuraxial anticoagulation guidance; apixaban typically requires ≥72 h (longer with reduced renal function). The proposed ropivacaine dose (200 mg) also increases LAST risk in a 60-kg patient."
      },
      {
        "text": "Place a lumbar epidural now to facilitate positioning for spinal anesthesia.",
        "isCorrect": false,
        "explanation": "Neuraxial techniques are contraindicated with recent factor Xa inhibitor exposure; bleeding risk parallels that of deep plexus blocks."
      },
      {
        "text": "Perform an ultrasound-guided suprainguinal fascia iliaca block now with 40 mL of 0.25% ropivacaine.",
        "isCorrect": true,
        "explanation": "This superficial, compressible block provides femoral, lateral femoral cutaneous, and often obturator coverage for hip analgesia. The ropivacaine dose (100 mg ≈1.7 mg/kg) is within safe limits and avoids deep plexus bleeding risk while anticoagulated."
      },
      {
        "text": "Perform femoral and lateral femoral cutaneous nerve blocks now, each with 20 mL of 0.5% ropivacaine.",
        "isCorrect": false,
        "explanation": "Although compressible, this approach often spares the obturator nerve and totals 200 mg ropivacaine (≈3.3 mg/kg in a 60-kg patient), exceeding common safety thresholds and increasing LAST risk."
      },
      {
        "text": "Perform a single-injection lumbar plexus (psoas compartment) block now with 30 mL of 0.5% bupivacaine.",
        "isCorrect": false,
        "explanation": "A lumbar plexus block is a deep, noncompressible plexus block with neuraxial-level bleeding risk. Recent apixaban use (18 h) makes this unsafe due to risk of retroperitoneal hematoma despite an acceptable bupivacaine dose."
      }
    ],
    "didactic": "The lumbar plexus (psoas compartment) block provides dense analgesia for hip and anterior thigh by targeting the femoral, obturator, and lateral femoral cutaneous nerves within the posterior psoas compartment. However, it is a deep, noncompressible plexus block adjacent to major vessels and the retroperitoneal space. Consequently, bleeding risk approximates neuraxial techniques. Current guidelines recommend treating deep plexus/peripheral blocks (eg, lumbar plexus, proximal sciatic) with the same anticoagulation timing as neuraxial anesthesia. For direct factor Xa inhibitors such as apixaban, a typical interval is ≥72 hours, with longer holds reasonable in reduced renal function. Performing a psoas compartment block 18 hours after apixaban risks retroperitoneal hematoma, which may present with flank pain, femoral neuropathy, hypotension, and falling hemoglobin.\n\nLocal anesthetic systemic toxicity (LAST) risk is also higher with lumbar plexus blocks due to large required volumes and relatively vascular uptake in the psoas compartment. Conservative dosing is essential (eg, ropivacaine ≈3 mg/kg without epinephrine; bupivacaine ≈2.5 mg/kg). Bilateral or combined blocks can unintentionally exceed safe limits. Risk mitigation includes ultrasound guidance, incremental injection with frequent aspiration, epinephrine test dosing (when not contraindicated), and immediate availability of lipid emulsion.\n\nWhen anticoagulation precludes a deep plexus block, a superficial, compressible alternative that still treats hip pain is preferred. The suprainguinal fascia iliaca block uses high-volume, low-concentration local anesthetic to flood the iliacus fascia, reliably capturing the femoral and lateral femoral cutaneous nerves and often the obturator nerve via cephalad spread—providing effective hip fracture analgesia and facilitating positioning for spinal anesthesia. Using 30–40 mL of 0.2%–0.25% ropivacaine balances coverage with safety. In contrast, isolated femoral and lateral femoral cutaneous blocks may spare the obturator nerve and, if dosed aggressively, can exceed safe milligram-per-kilogram limits, increasing LAST risk.\n\nBottom line: Reserve lumbar plexus (psoas compartment) blocks for appropriate indications when anticoagulation is managed per neuraxial guidance, and select superficial, compressible alternatives (eg, suprainguinal fascia iliaca) to maintain safety in anticoagulated patients while avoiding excessive local anesthetic dosing.",
    "educationalObjective": "Plan lumbar plexus or psoas compartment block indications and recognize higher bleeding and local anesthetic toxicity risks."
  },
  {
    "id": "Core.7.4.8",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Lower limb and truncal blocks",
    "difficulty": "easy",
    "questionText": "A 66-year-old man undergoes outpatient knee arthroscopy. Preoperatively he received a single-shot femoral nerve block with 20 mL 0.5% ropivacaine for postoperative analgesia. In the PACU, he has anterior thigh and medial leg numbness and cannot perform a straight-leg raise. He asks to walk to the bathroom and plans to go home the same day. Vitals are stable and pain is well controlled.\n\nWhich intervention is most appropriate to minimize fall risk and prevent nerve injury related to this femoral-based block?",
    "answers": [
      {
        "text": "Allow bathroom privileges with standby assistance without bracing to promote early mobilization",
        "isCorrect": false,
        "explanation": "Early unbraced ambulation after femoral block risks knee buckling and falls because quadriceps weakness persists despite preserved distal strength."
      },
      {
        "text": "Apply a heating pad to the anterior thigh to hasten block resolution",
        "isCorrect": false,
        "explanation": "Heat on an insensate limb risks thermal injury; protecting the numb extremity from heat/cold/pressure is essential."
      },
      {
        "text": "Convert to an adductor canal block at case end, which eliminates fall risk and obviates bracing",
        "isCorrect": false,
        "explanation": "Adductor canal blocks are more motor-sparing but do not eliminate quadriceps weakness or fall risk; counseling and precautions remain necessary."
      },
      {
        "text": "Discharge without restrictions because preserved distal motor strength indicates minimal fall risk",
        "isCorrect": false,
        "explanation": "Preserved distal strength does not ensure quadriceps function; femoral motor weakness can persist and is the main contributor to falls."
      },
      {
        "text": "Apply a knee immobilizer and allow only assisted ambulation with a walker/crutches until he can perform a straight-leg raise",
        "isCorrect": true,
        "explanation": "Femoral blocks can cause quadriceps weakness and knee buckling; a knee immobilizer plus assisted ambulation until quadriceps function returns (eg, straight-leg raise) reduces falls and protects the insensate limb."
      }
    ],
    "didactic": "Femoral-based blocks (femoral nerve and fascia iliaca) frequently produce **quadriceps weakness** due to blockade of the femoral nerve’s motor branches to the quadriceps. This weakness leads to **knee buckling** and a measurable increase in postoperative falls, even when ankle/foot strength is preserved. The safest strategy is to combine patient counseling with temporary mechanical support and supervised ambulation until motor function returns.\n\nKey elements of prevention after femoral-based blocks:\n- Use a **knee immobilizer** to stabilize the knee and prevent buckling.\n- Restrict to **assisted ambulation** with a walker or crutches; no unassisted walking until quadriceps strength returns (eg, ability to perform a straight-leg raise).\n- **Counsel** patients and staff pre- and postoperatively regarding transient weakness, fall risk, and the need for assistance.\n- **Protect the insensate limb** from heat, cold, and pressure to reduce injury risk; perform frequent skin and position checks.\n\nAdductor canal block (saphenous nerve) is relatively motor-sparing but does not completely eliminate quadriceps weakness because spread to branches (eg, nerve to vastus medialis) can occur; thus, fall precautions and counseling still apply. Single-shot techniques may last many hours depending on local anesthetic dose and concentration (eg, ropivacaine vs bupivacaine), so precautions must extend beyond PACU and be included in **discharge instructions**. A practical clinical endpoint for discontinuing the knee immobilizer and progressing ambulation is the return of a **straight-leg raise**, indicating sufficient quadriceps function.\n\nBy pairing education with a knee immobilizer and assisted ambulation, clinicians can significantly reduce **falls** and secondary **neuropathy** from stretch or trauma in patients receiving femoral-based lower extremity blocks.",
    "educationalObjective": "Prevent femoral neuropathy and falls by counseling and using knee immobilizers after femoral-based blocks."
  },
  {
    "id": "Core.7.4.9",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Lower limb and truncal blocks",
    "difficulty": "medium",
    "questionText": "A 60-kg man with multiple posterior rib fractures (T4–T9) requires analgesia. You plan bilateral multilevel intercostal nerve blocks (12 injections total). He is hemodynamically stable with normal liver and renal function. Given the high systemic uptake associated with intercostal injections, which local anesthetic dosing and monitoring plan best minimizes the risk of local anesthetic systemic toxicity while providing effective analgesia?",
    "answers": [
      {
        "text": "Bupivacaine 0.25% with epinephrine 1:200,000, 3 mL per level; aspirate and inject incrementally with 30–60 s between levels; continuous ECG and observation for ≥30 min after final injection.",
        "isCorrect": true,
        "explanation": "This plan lowers total dose (≈90 mg, 1.5 mg/kg), adds epinephrine to reduce uptake and detect intravascular injection, uses fractionated dosing, and provides extended monitoring appropriate for intercostal blocks."
      },
      {
        "text": "Bupivacaine 0.5%, 4 mL per level without epinephrine; inject sequentially; routine monitoring for 10 min after completion.",
        "isCorrect": false,
        "explanation": "Total dose is 240 mg (≈4 mg/kg), which exceeds recommended limits for bupivacaine, and lack of epinephrine and brief monitoring increase LAST risk at this high-uptake site."
      },
      {
        "text": "Ropivacaine 0.5%, 3 mL per level without epinephrine; standard monitors; observe 15 min after completion.",
        "isCorrect": false,
        "explanation": "Although the total dose is ≈180 mg (3 mg/kg), the lack of epinephrine and abbreviated monitoring are suboptimal given rapid, high systemic absorption with intercostal blocks."
      },
      {
        "text": "Mepivacaine 1.5% with epinephrine, 5 mL per level; inject all levels without pause; observe 30 min after completion.",
        "isCorrect": false,
        "explanation": "Total dose is ≈900 mg (15 mg/kg), far exceeding safe limits even with epinephrine; rapid sequential bolusing further increases peak plasma levels."
      },
      {
        "text": "Bupivacaine 0.25% with epinephrine 1:200,000, 5 mL per level under ultrasound guidance; routine monitoring for 10 min after completion.",
        "isCorrect": false,
        "explanation": "Although within some dosing limits (≈150 mg, 2.5 mg/kg), larger per-level volumes and brief monitoring are inappropriate for a high-uptake site; ultrasound does not meaningfully reduce systemic absorption."
      }
    ],
    "didactic": "Intercostal nerve blocks produce the highest peak plasma local anesthetic concentrations among common peripheral and neuraxial sites due to rich vascularity and large surface area for uptake. Approximate systemic absorption (highest to lowest) is: **intercostal > caudal > epidural > brachial plexus > femoral/sciatic > subcutaneous**. Rapid and high uptake increases the risk of local anesthetic systemic toxicity (LAST), with early peaks often within minutes of injection.\n\nKey safety strategies for intercostal blocks include:\n- **Reduce total dose**: Use lower concentrations and modest per-level volumes (eg, 2–3 mL/level of 0.25% bupivacaine) to keep mg/kg well below maximum recommended limits, especially when performing many levels or bilateral blocks.\n- **Add epinephrine (1:200,000; 5 µg/mL)**: Vasoconstriction reduces systemic absorption and provides an intravascular marker (eg, ≥10 bpm HR rise or increased BP within 30–60 s).\n- **Fractionate dosing**: Aspirate and inject incrementally (eg, 3–5 mL aliquots with 30–60 s between levels) to limit peak concentrations and permit early detection of toxicity.\n- **Monitor adequately**: Continuous ECG, BP, and SpO<sub>2</sub> during injection and observe for ≥30 min after the final injection, as intercostal blocks can yield early, high peaks. Have lipid emulsion immediately available.\n- **Technique adjuncts**: Ultrasound may reduce vascular puncture and pneumothorax risk but does not meaningfully decrease systemic absorption; dose and monitoring adjustments remain essential.\n\nIn the presented case, bupivacaine 0.25% with epinephrine, small per-level volumes, incremental injection, and extended monitoring aligns with these principles (≈90 mg total, 1.5 mg/kg for 60 kg). Plans using higher concentrations/volumes, omitting epinephrine, rapid bolusing, or abbreviated monitoring are inappropriate for the uniquely high-uptake intercostal site and increase LAST risk.",
    "educationalObjective": "Recognize higher systemic absorption with intercostal blocks and adjust dose and monitoring accordingly."
  },
  {
    "id": "Core.7.4.10",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Lower limb and truncal blocks",
    "difficulty": "medium",
    "questionText": "A 72-year-old man with well-controlled type 2 diabetes and distal sensory neuropathy is scheduled for primary unilateral total knee arthroplasty under spinal anesthesia. The orthopedic team prioritizes early ambulation within 6 h and asks to minimize quadriceps weakness to reduce fall risk. You plan multimodal analgesia (acetaminophen, NSAID, low-dose opioid) and want to avoid motor blockade that interferes with physical therapy while still providing robust knee analgesia, including posterior capsular pain. Which regional anesthesia plan is most appropriate?",
    "answers": [
      {
        "text": "Single-injection adductor canal block (20 mL 0.5% ropivacaine)",
        "isCorrect": false,
        "explanation": "Preserves quadriceps strength but may provide insufficient duration and limited coverage of posterior knee pain after total knee arthroplasty."
      },
      {
        "text": "Continuous femoral nerve catheter (0.2% ropivacaine at 6 mL/h)",
        "isCorrect": false,
        "explanation": "Extends analgesia but prolongs quadriceps weakness, which conflicts with early mobilization goals and increases fall risk compared with adductor canal techniques."
      },
      {
        "text": "Single-injection femoral nerve block (20 mL 0.5% ropivacaine)",
        "isCorrect": false,
        "explanation": "Provides strong anterior knee analgesia but frequently causes significant quadriceps weakness, increasing fall risk and delaying ambulation; posterior knee pain may persist."
      },
      {
        "text": "Adductor canal catheter (0.2% ropivacaine at 6 mL/h) plus single-injection IPACK block (20 mL 0.25% bupivacaine)",
        "isCorrect": true,
        "explanation": "An adductor canal catheter preserves quadriceps strength while providing sustained medial/anterior knee analgesia; adding an IPACK targets posterior capsular branches, yielding effective analgesia with minimal motor blockade."
      },
      {
        "text": "Popliteal sciatic block (20 mL 0.5% ropivacaine) plus distal saphenous field block at the ankle",
        "isCorrect": false,
        "explanation": "May cause foot motor weakness and does not reliably anesthetize the knee joint’s anterior/medial articular branches (eg, nerve to vastus medialis); distal saphenous block is cutaneous only."
      }
    ],
    "didactic": "For knee surgery, block selection must balance analgesia with preservation of quadriceps function to enable early mobilization and reduce falls. A **femoral nerve block (FNB)** anesthetizes femoral sensory branches (saphenous nerve, nerve to vastus medialis, anterior femoral cutaneous) but concurrently blocks motor fibers to quadriceps, producing dose-dependent weakness and an increased fall risk. Continuous femoral catheters extend this motor impairment.\n\nThe **adductor canal block (ACB)** targets the saphenous nerve and articular branches in the adductor canal while largely sparing proximal motor fibers to quadriceps. Compared with FNB, ACB provides similar pain scores at rest for many knee procedures with significantly less reduction in quadriceps strength and improved early ambulation metrics. However, ACB alone may inadequately treat **posterior knee pain**, which arises predominantly from terminal articular branches of the tibial component of the sciatic nerve.\n\nAdding an **IPACK (infiltration between the popliteal artery and capsule of the knee)** block deposits local anesthetic posterior to the femur, bathing genicular articular branches to the posterior capsule while sparing major motor branches (tibial/common peroneal), thus avoiding foot drop. Therefore, an **ACB catheter** (eg, 0.1%–0.2% ropivacaine at 5–8 mL/h) delivers sustained anterior/medial knee analgesia with preserved quadriceps strength, and a single-shot **IPACK** complements posterior coverage without motor deficits.\n\nIn contrast, a **single-shot ACB** may be too short-lived for typical post–total knee arthroplasty pain trajectories (24–48 h), and distal saphenous or popliteal sciatic blocks do not reliably cover proximal knee articular branches and can impair ambulation. For patients at high fall risk or with early physical therapy goals, an ACB-based strategy—preferably with a catheter and posterior supplementation (IPACK)—optimally balances analgesia and quadriceps preservation.",
    "educationalObjective": "Select femoral versus adductor canal block for knee surgery balancing analgesia with quadriceps strength preservation."
  },
  {
    "id": "Core.7.4.11",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Lower limb and truncal blocks",
    "difficulty": "medium",
    "questionText": "A 72-year-old man with COPD and atrial fibrillation on apixaban (last dose this morning) presents with multiple posterior rib fractures (T5–T8) after a fall. He is tachypneic with shallow breaths (V<sub>T</sub> 250 mL) and SpO<sub>2</sub> 92% on 2 L/min O<sub>2</sub> by nasal cannula. He is hemodynamically stable but frail, and you aim to improve his ventilation and cough while minimizing hypotension and bleeding risk. You have bedside ultrasound available. Which regional analgesic technique is the most appropriate next step for effective hemithoracic analgesia in this patient?",
    "answers": [
      {
        "text": "Erector spinae plane block at T5",
        "isCorrect": true,
        "explanation": "A paraspinal fascial plane block superficial to the transverse process that can spread to dorsal and ventral rami for multilevel rib analgesia; it is farther from the neuraxis, more compressible, and has lower hypotension and bleeding risk compared with neuraxial/paravertebral techniques."
      },
      {
        "text": "Thoracic epidural analgesia at T6–T7",
        "isCorrect": false,
        "explanation": "Provides excellent rib fracture analgesia but is relatively contraindicated with therapeutic anticoagulation due to neuraxial hematoma risk and may cause sympathectomy-related hypotension in a frail patient."
      },
      {
        "text": "Single-injection thoracic paravertebral block at T6",
        "isCorrect": false,
        "explanation": "Effective segmental analgesia but is a deep, noncompressible site near pleura and neuraxis with higher bleeding risk on anticoagulation; single level may not cover multiple posterior ribs without additional injections/catheter."
      },
      {
        "text": "Multiple intercostal nerve blocks at T5–T9",
        "isCorrect": false,
        "explanation": "Can work but require many injections for multilevel coverage, have short duration with high systemic absorption, and increase local anesthetic toxicity risk compared with a single high-volume fascial plane block."
      },
      {
        "text": "Serratus anterior plane block at the mid-axillary line",
        "isCorrect": false,
        "explanation": "Targets lateral cutaneous branches, providing lateral/anterior chest wall analgesia; posterior rib pain is often inadequately covered, especially with posterior fractures."
      }
    ],
    "didactic": "The erector spinae plane (ESP) block is a versatile paraspinal fascial plane technique that provides multilevel analgesia of the hemithorax and abdominal wall. Under ultrasound, the injection is performed deep to the erector spinae muscle and superficial to the transverse process, typically 2–3 cm lateral to the spinous process at the target level (eg, T<sub>5</sub>–T<sub>7</sub> for rib fractures; T<sub>7</sub>–T<sub>9</sub> for upper abdominal wall). Hydrodissection lifting the erector spinae off the transverse process confirms correct plane. A high-volume injection (eg, 20–30 mL of 0.25%–0.375% bupivacaine/ropivacaine per side) promotes craniocaudal spread and anterior diffusion through the costotransverse foramina toward the paravertebral space, engaging dorsal rami, ventral rami, and rami communicantes. This pattern explains why ESP can improve posterior rib pain and provide clinically meaningful anterolateral coverage and abdominal wall analgesia.\n\nCompared with thoracic epidural or paravertebral block, ESP is farther from the neuraxis and pleura and is performed in a more compressible tissue plane, translating to a lower risk of neuraxial bleeding and sympathectomy-related hypotension—key advantages in anticoagulated or frail patients. While no block is risk-free with anticoagulation, ESP is often preferred when neuraxial techniques are avoided. A catheter may be placed in the ESP plane for continuous infusion to sustain analgesia and facilitate pulmonary hygiene (↑V<sub>T</sub>, improved cough, ↓splinting).\n\nLimitations include variable anterior spread and potentially less dense analgesia than epidural for thoracotomy. For isolated lateral/anterior chest wall pain, a serratus anterior plane block may be superior; intercostal blocks provide focal relief but require multiple injections and have high systemic absorption. Use ultrasound to avoid pleural puncture, calculate total local anesthetic dose to mitigate LAST, and integrate multimodal analgesia. In rib fractures or abdominal wall surgery where neuraxial techniques are undesirable, the **ESP block** is a high-yield, safe, and effective option.",
    "educationalObjective": "Use erector spinae plane block as a paraspinal fascial plane option for rib or abdominal wall analgesia."
  },
  {
    "id": "Core.7.4.12",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Lower limb and truncal blocks",
    "difficulty": "medium",
    "questionText": "A 62-year-old man is scheduled for open reduction and internal fixation of a bimalleolar fracture using a lateral malleolar incision. You perform an ultrasound-guided popliteal sciatic block 8 cm proximal to the popliteal crease and note that the sciatic nerve has already bifurcated. With the needle adjacent to the medial division, nerve stimulation at 0.5 mA produces plantarflexion and inversion of the foot. You inject 15 mL of 0.5% ropivacaine around this nerve. The medial ankle will not be incised.\n\nWhich next step will best ensure complete surgical anesthesia for this incision?",
    "answers": [
      {
        "text": "Redirect the needle laterally to the more superficial lateral division, elicit dorsiflexion/eversion, and inject 10–15 mL to block the common peroneal nerve.",
        "isCorrect": true,
        "explanation": "The lateral malleolar incision is in the superficial peroneal distribution. After bifurcation, the common peroneal nerve (lateral) must be blocked separately, confirmed by dorsiflexion/eversion, to anesthetize the dorsum/lateral ankle."
      },
      {
        "text": "Deposit local anesthetic circumferentially around the popliteal artery to capture adjacent neural elements.",
        "isCorrect": false,
        "explanation": "Perivascular injection around the popliteal artery does not reliably anesthetize the sciatic divisions and risks vascular puncture."
      },
      {
        "text": "Inject an additional 10 mL around the tibial nerve to promote spread to the common peroneal nerve within the paraneural sheath.",
        "isCorrect": false,
        "explanation": "Once the sciatic has bifurcated, tibial and common peroneal nerves reside in separate sheaths; extra volume around the tibial nerve will not reliably anesthetize the common peroneal nerve."
      },
      {
        "text": "Abort the popliteal approach and perform a full ankle block (deep and superficial peroneal, tibial, sural).",
        "isCorrect": false,
        "explanation": "An ankle block could work but is unnecessary; selectively blocking the common peroneal division at the popliteal level is faster and provides equivalent coverage."
      },
      {
        "text": "Add a saphenous nerve block at the mid-calf to cover the lateral malleolus.",
        "isCorrect": false,
        "explanation": "The saphenous nerve (femoral branch) innervates the medial leg/ankle; it does not cover the lateral malleolus or dorsum of the foot."
      }
    ],
    "didactic": "A popliteal sciatic block provides anesthesia to the distal sciatic distribution and is ideal for most foot and ankle surgeries because it spares proximal hamstring function and facilitates postoperative analgesia. It does not cover the medial ankle/foot (saphenous nerve, a femoral branch), which must be added for medial incisions only.\n\nIn the popliteal fossa, the sciatic nerve typically bifurcates into the **tibial** (medial, larger) and **common peroneal** (lateral, smaller) nerves. On ultrasound, the tibial nerve is often superficial and slightly lateral to the popliteal vessels, while the common peroneal courses more laterally toward the biceps femoris tendon. When using nerve stimulation, motor responses differentiate the divisions:\n\n- **Tibial nerve**: plantarflexion, inversion, and toe flexion; sensory to the plantar foot.\n- **Common peroneal nerve**: dorsiflexion, eversion, and toe extension; sensory to the dorsum of the foot via superficial and deep peroneal branches.\n\nIf the sciatic has already bifurcated at the block level, local anesthetic must be deposited around both divisions for complete anesthesia. Increasing volume around one division is unreliable because the nerves are contained within separate fascial compartments after bifurcation. For a lateral malleolar incision (superficial peroneal territory), failure to block the **common peroneal** nerve is the most common cause of inadequate anesthesia despite a successful tibial block.\n\nPractical points:\n\n- Block before the bifurcation when possible; otherwise, individually block both divisions (10–15 mL each) with circumferential spread within the paraneural sheath while avoiding intraneural injection (monitor opening pressure and patient symptoms).\n- The **sural nerve** (lateral foot) receives contributions from both tibial and common peroneal nerves; blocking both divisions proximally reliably anesthetizes the sural territory.\n- Reserve a **saphenous** block for medial ankle/foot incisions; it is not needed for lateral malleolar surgery.",
    "educationalObjective": "Use popliteal sciatic block for foot and ankle surgery and differentiate tibial and common peroneal branches."
  },
  {
    "id": "Core.7.5.1",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Neuraxial anesthesia basics",
    "difficulty": "hard",
    "questionText": "A 68-year-old man (eGFR 35 mL/min/1.73 m²) is postoperative day 2 after open colectomy with a functioning T8–9 epidural catheter for analgesia. He is receiving enoxaparin 30 mg subcutaneously every 12 hours for VTE prophylaxis; the last dose was given at 18:00 yesterday. It is now 06:00. Cardiology resumed clopidogrel 75 mg daily (no loading dose) at 08:00 yesterday for a drug-eluting stent placed 6 months ago. Neurologic exam is normal, and the epidural site is clean. The team plans to remove the epidural this morning.\n\nWhich of the following is the most appropriate plan for safe epidural catheter removal and anticoagulation management?",
    "answers": [
      {
        "text": "Switch to IV unfractionated heparin and remove the epidural 1 h after stopping the infusion to minimize neuraxial bleeding risk.",
        "isCorrect": false,
        "explanation": "Bridging to IV heparin is unnecessary and introduces risk; neuraxial removal after IV heparin requires a 4–6 h hold with a normal aPTT."
      },
      {
        "text": "Remove the epidural now and transfuse platelets prophylactically; resume enoxaparin 2 h after removal.",
        "isCorrect": false,
        "explanation": "Prophylactic platelet transfusion is not indicated for recent maintenance-dose clopidogrel without loading. LMWH should be delayed ≥4 h after catheter removal, not 2 h."
      },
      {
        "text": "Delay epidural removal to 24 h after the last enoxaparin dose because dosing is twice daily, then resume enoxaparin immediately after removal.",
        "isCorrect": false,
        "explanation": "A 24-h interval applies to therapeutic LMWH, not prophylactic dosing. The next LMWH dose should be delayed ≥4 h after catheter removal."
      },
      {
        "text": "Hold clopidogrel for 5–7 days, then remove the epidural and restart both drugs afterward.",
        "isCorrect": false,
        "explanation": "Stopping clopidogrel for 5–7 days is required before neuraxial placement, not for urgent catheter removal in a patient already restarted on maintenance therapy; unnecessary interruption increases stent thrombosis risk."
      },
      {
        "text": "Remove the epidural now (12 h after the last enoxaparin dose), continue maintenance clopidogrel (no loading), and give the next enoxaparin dose ≥4 h after removal.",
        "isCorrect": true,
        "explanation": "ASRA recommends removing catheters ≥12 h after the last prophylactic LMWH dose and delaying the next dose ≥4 h. An indwelling catheter can be managed briefly on maintenance clopidogrel (no loading); early removal within 24 h of restart is acceptable."
      }
    ],
    "didactic": "Safe neuraxial management with antithrombotics hinges on drug class, dose, dosing frequency, timing relative to needle/catheter manipulation, and whether a loading dose is used. For LMWH prophylaxis:\n\n- Enoxaparin once daily (eg, 40 mg q24h): remove catheters ≥12 h after the last dose; give the next dose ≥4 h after removal.\n- Enoxaparin twice daily (eg, 30 mg q12h): remove catheters ≥12 h after the last dose; delay the next dose ≥4 h. If possible, remove the catheter before initiating BID prophylaxis due to higher spinal hematoma risk.\n- Therapeutic LMWH: remove catheters ≥24 h after the last dose; delay the next dose ≥4 h.\n\nFor P2Y12 inhibitors:\n\n- Clopidogrel/prasugrel: hold **5–7 days/7–10 days** before neuraxial placement. With an indwelling catheter, maintenance-dose clopidogrel (no loading) can be continued for **1–2 days**; remove the catheter as soon as feasible in that window. After removal, a maintenance dose may be given immediately; if a loading dose is planned, wait **≥6 h** after removal.\n- Ticagrelor: hold **5 days** before neuraxial techniques; due to rapid onset, avoid maintaining an indwelling catheter while on ticagrelor.\n\nUnfractionated heparin:\n\n- IV infusion: hold **4–6 h** and verify normal aPTT before catheter manipulation; resume ≥1 h after removal.\n- SC prophylaxis: variable absorption; many centers avoid catheter removal within ~4–6 h of a dose.\n\nRenal function modifies timing primarily for DOACs and fondaparinux; moderate CKD does not change the prophylactic LMWH intervals above. The key principles are to ensure sufficient time from the last anticoagulant dose to catheter removal and to delay the next dose long enough to detect early neuraxial bleeding (eg, new back pain, motor weakness) before anticoagulation is reintroduced. This approach minimizes spinal/epidural hematoma risk while avoiding unnecessary interruption of critical antiplatelet therapy.",
    "educationalObjective": "Apply general principles of anticoagulation and antiplatelet management for neuraxial techniques and catheter removal."
  },
  {
    "id": "Core.7.5.2",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Neuraxial anesthesia basics",
    "difficulty": "medium",
    "questionText": "A 28-year-old G1P0 at 6 cm dilation requests labor epidural analgesia. She has chronic hypertension treated with labetalol. After loss of resistance to saline and negative aspiration, an epidural catheter is placed at L3–4. While on continuous ECG and NIBP monitoring (baseline HR 78 bpm, BP 128/76 mmHg), you administer a test dose of 3 mL of 1.5% lidocaine with epinephrine 1:200,000.\n\nThirty to ninety seconds later, her HR remains 76–80 bpm, but she reports circumoral numbness, metallic taste, and tinnitus; BP increases to 150/86 mmHg. There is no lower-extremity weakness or sensory change. Which of the following is the most appropriate next step?",
    "answers": [
      {
        "text": "Treat for high spinal with vasopressors and airway support and continue dosing once stable",
        "isCorrect": false,
        "explanation": "High spinal presents with rapid hypotension, bradycardia, and motor weakness/respiratory compromise; those findings are absent here."
      },
      {
        "text": "Give an additional 3 mL epinephrine-containing test dose to confirm intravascular placement",
        "isCorrect": false,
        "explanation": "Repeating an epinephrine-containing test dose when intravascular injection is suspected can exacerbate toxicity and is not advised."
      },
      {
        "text": "Remove the catheter and re-site the epidural at a different interspace before further dosing",
        "isCorrect": true,
        "explanation": "Symptoms consistent with intravascular injection and a blunted epinephrine response due to β-blockade warrant abandoning the catheter; re-siting and re-testing with vigilant monitoring minimizes risk of intravascular dosing."
      },
      {
        "text": "Administer naloxone for suspected intrathecal opioid test dose",
        "isCorrect": false,
        "explanation": "No opioid was administered; intrathecal local anesthetic would produce rapid lower-extremity motor/sensory block, not isolated CNS excitation."
      },
      {
        "text": "Proceed with incremental epidural dosing because the test dose was negative",
        "isCorrect": false,
        "explanation": "A lack of tachycardic response does not rule out intravascular injection in a patient on a β-blocker, and CNS prodromes (tinnitus, metallic taste) suggest intravascular uptake; further dosing risks LAST."
      }
    ],
    "didactic": "Epidural test dosing aims to detect inadvertent intravascular or intrathecal catheter placement before full dosing. A commonly used test dose is 3 mL of 1.5% lidocaine with epinephrine 1:200,000 (45 mg lidocaine + 15 µg epinephrine). An intravascular injection typically produces an epinephrine-mediated HR increase ≥20–30 bpm within 30–60 seconds in non–β-blocked adults; CNS prodromes of local anesthetic systemic toxicity (LAST)—eg, circumoral numbness, metallic taste, tinnitus—may also occur. Intrathecal injection rapidly produces spinal anesthesia: warm sensation in legs, dense motor block, and sympathetic block (hypotension, sometimes bradycardia) within minutes. Subdural placement tends to cause a delayed, patchy, often high sensory level with minimal motor block and hemodynamic changes.\n\nIn parturients and patients on β-blockers, the epinephrine HR criterion is unreliable because pain, baseline tachycardia variability, and β-blockade blunt the chronotropic response. Alternative clues include a rise in systolic BP, subjective adrenergic symptoms, and early CNS signs of LAST. A “negative” aspiration does not exclude intravascular placement due to catheter side holes and vessel collapse.\n\nWhen intravascular injection is suspected, stop dosing, maintain monitoring, and abandon the catheter—remove and re-site at a different interspace—rather than adjust or repeat test dosing. Subsequent dosing should be fractionated (3–5 mL aliquots) with intermittent aspiration and vigilant observation of ECG, BP, and EtCO<sub>2</sub>. Treat escalating LAST promptly with airway support, seizure control (benzodiazepines), and 20% lipid emulsion if indicated. Recognizing intrathecal placement hinges on rapid bilateral motor block and hypotension; management is immediate cessation of epidural dosing and supportive care. The priority is prevention: appropriate test dosing, continuous monitoring, and incremental administration to avoid catastrophic intravascular or intrathecal dosing.",
    "educationalObjective": "Avoid accidental intravascular or intrathecal epidural dosing by test dosing and vigilant aspiration and monitoring."
  },
  {
    "id": "Core.7.5.3",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Neuraxial anesthesia basics",
    "difficulty": "easy",
    "questionText": "A 72-year-old man presents for urgent open reduction and internal fixation of a tibial plateau fracture. He is hemodynamically stable, has no coagulopathy, and prefers neuraxial anesthesia. The surgeon anticipates a 90-minute case but notes it could run longer if fixation is complex. The OR is ready to start within minutes, and the team wants reliable surgical anesthesia now with the ability to extend if needed.\n\nWhich statement about epidural versus spinal anesthesia best aligns with these requirements?",
    "answers": [
      {
        "text": "Spinal anesthesia provides a faster, denser block but cannot be titrated or reliably redosed; epidural anesthesia has a slower onset and less dense block but can be titrated and redosed via a catheter to extend duration.",
        "isCorrect": true,
        "explanation": "Intrathecal local anesthetic produces rapid, dense anesthesia within minutes but is a fixed single-shot dose. Epidural dosing is slower to establish surgical block yet allows incremental titration and redosing to match case length."
      },
      {
        "text": "Spinal and epidural blocks achieve similar density for surgery, but epidural anesthesia reaches surgical levels faster due to higher local anesthetic concentrations.",
        "isCorrect": false,
        "explanation": "Spinal blocks are generally denser and faster because the drug is deposited directly in CSF; epidurals are slower despite higher concentrations due to diffusion barriers."
      },
      {
        "text": "Epidural anesthesia cannot be redosed due to systemic toxicity risk, whereas spinal anesthesia can be incrementally dosed via the intrathecal space through an indwelling catheter.",
        "isCorrect": false,
        "explanation": "Epidural techniques are specifically designed for incremental dosing and redosing; spinals are typically single-shot without titration capability."
      },
      {
        "text": "Both techniques have similar onset if isobaric local anesthetic is used; only spinal anesthesia allows incremental titration via catheter to extend duration.",
        "isCorrect": false,
        "explanation": "Onset is not similar—spinal is much faster—and titration/redosing capability is a key advantage of an epidural catheter, not a single-shot spinal."
      },
      {
        "text": "Epidural anesthesia produces a faster onset and denser motor block than spinal anesthesia while also allowing titration, whereas spinal anesthesia has slower onset and limited ability to redose.",
        "isCorrect": false,
        "explanation": "Epidural onset is typically slower (10–20 min) and motor block is generally less dense than a spinal; the spinal is the faster, denser technique."
      }
    ],
    "didactic": "Epidural and spinal anesthesia differ in onset, block density, and the ability to titrate/redose, which drives technique selection for specific surgical needs.\n\n- Onset: **Spinal anesthesia** generally provides surgical anesthesia within 2–5 minutes because local anesthetic is deposited directly into CSF, bathing nerve roots immediately. **Epidural anesthesia** requires diffusion across dura and nerve sheaths, producing a slower onset (often 10–20 minutes to achieve a dense, bilateral surgical block).\n- Density: **Spinal blocks are typically more reliable and denser** (sensory and motor) for a given dose because the drug acts directly on intrathecal neural tissue. **Epidural blocks can be effective for surgery** using higher concentrations/volumes, but may be less dense and more segmental or patchy.\n- Titration and redosing: **Epidural catheters** allow incremental dosing, segmental titration, and **redosing to extend duration** or adjust block height and intensity during prolonged cases. In contrast, a typical **single-shot spinal is fixed** after injection; once administered, the dose cannot be titrated, and duration is limited by the chosen drug/dose and any intrathecal adjuvants.\n\nThese characteristics have practical implications:\n- When rapid, dense surgical anesthesia is required, a **spinal** is ideal if the expected case duration fits the intrathecal anesthetic’s profile.\n- When duration is uncertain or prolonged, an **epidural** offers flexibility to titrate and redose at the cost of slower onset and potentially less dense motor block.\n- A **combined spinal–epidural (CSE)** can bridge both needs (rapid, dense onset plus catheter for extension), but this is distinct from either technique alone.\n\nUnderstanding these trade-offs ensures the right neuraxial choice for the patient and procedure, aligning onset, block quality, and duration control with surgical requirements.",
    "educationalObjective": "Contrast epidural versus spinal onset, density, and ability to titrate and redose."
  },
  {
    "id": "Core.7.5.4",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Neuraxial anesthesia basics",
    "difficulty": "easy",
    "questionText": "A 70-year-old man undergoes unicompartmental knee arthroplasty under single-shot spinal anesthesia with hyperbaric bupivacaine 12 mg and intrathecal morphine 100 μg. Three hours postoperatively in the PACU, he is eager to ambulate to a chair to begin early mobilization. He has not voided since before surgery and reports suprapubic pressure. On exam, he cannot lift either leg against gravity but can wiggle his toes; sensation is diminished to the mid-thigh. Bladder ultrasound shows 650 mL of urine. Vital signs are stable.\n\nWhich of the following is the most appropriate next step to support early ambulation while minimizing urinary complications?",
    "answers": [
      {
        "text": "Give a 1 L crystalloid bolus and reassess when he senses an urge to void",
        "isCorrect": false,
        "explanation": "Additional fluids may worsen bladder overdistension and do not address neuraxial-mediated detrusor inhibition."
      },
      {
        "text": "Encourage assisted ambulation now to stimulate voiding and avoid catheterization",
        "isCorrect": false,
        "explanation": "Ambulating with persistent lower-extremity motor block increases fall risk; delaying catheterization risks bladder overdistension at 650 mL."
      },
      {
        "text": "Administer tamsulosin and observe for 2 more hours without catheterization",
        "isCorrect": false,
        "explanation": "α-blockers are not effective for acute postoperative urinary retention relief and delaying decompression risks overdistension and detrusor injury."
      },
      {
        "text": "Place an indwelling Foley catheter for 24 hours due to intrathecal morphine–related urinary retention",
        "isCorrect": false,
        "explanation": "Routine Foley placement increases CAUTI risk; most neuraxial-related retention is managed with intermittent catheterization unless retention is recurrent or prolonged."
      },
      {
        "text": "Perform intermittent straight catheterization now and defer ambulation until motor strength returns to allow safe mobilization",
        "isCorrect": true,
        "explanation": "A bladder volume >600 mL with inability to void after neuraxial anesthesia warrants intermittent catheterization to prevent overdistension; ambulation should be deferred until motor block resolves to reduce fall risk."
      }
    ],
    "didactic": "Neuraxial anesthesia can cause postoperative urinary retention (POUR) by blocking sacral parasympathetic efferents (S2–S4) that mediate detrusor contraction and by increasing sympathetic outflow that augments bladder outlet resistance. Intrathecal or epidural opioids further prolong bladder dysfunction via spinal μ-receptor activation. Risk is higher in older men, those with BPH, longer procedures, larger IV fluid loads, and concomitant systemic opioids.\n\nEarly mobilization is beneficial, but safety requires adequate motor recovery. Persistent lower-extremity weakness (eg, inability to lift legs against gravity) significantly increases fall risk. Patients should ambulate only after motor block has regressed to near baseline (eg, able to perform straight leg raise with stable hemodynamics and intact protective reflexes).\n\nBedside bladder ultrasound guides timely decompression and helps prevent detrusor overdistension, which can cause transient or persistent voiding dysfunction. Practical thresholds commonly used after neuraxial anesthesia are:\n- Inability to void with bladder volume ≥600 mL: perform intermittent straight catheterization.\n- Symptomatic patients or those at high risk (eg, BPH) may warrant lower thresholds (eg, 400–600 mL) or earlier scanning (every 2–4 h) until spontaneous voiding returns.\n- Consider an indwelling catheter only if repeated intermittent catheterizations are required, the patient will remain immobile, or there is ongoing neuraxial infusion with dense block.\n\nManagement priorities in this scenario are to decompress the bladder with intermittent catheterization (reducing overdistension and discomfort) and to defer ambulation until motor strength recovers sufficiently to minimize falls. Fluids, empiric cholinergics, or α-blockers do not acutely reverse neuraxial-mediated detrusor inhibition and may worsen retention or delay appropriate treatment. Reassess motor function and voiding regularly; once strength returns, assist with ambulation and attempt a trial of void with continued bladder scanning as needed.",
    "educationalObjective": "Counsel about urinary retention and motor block implications for early ambulation and catheter management."
  },
  {
    "id": "Core.7.5.5",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Neuraxial anesthesia basics",
    "difficulty": "medium",
    "questionText": "A 29-year-old G1P1 presents 36 hours after a vaginal delivery with a severe frontal–occipital headache that worsens when she sits or stands and improves when supine. She had an accidental dural puncture with a 17-gauge Tuohy during labor epidural placement; the epidural was replaced uneventfully. She is afebrile, her BP is 118/72 mmHg, and her neurologic exam is normal. She began enoxaparin 40 mg SC daily for VTE prophylaxis 6 hours ago due to obesity. She is breastfeeding and requests the most definitive therapy as soon as safely possible. Which is the most appropriate next step?",
    "answers": [
      {
        "text": "Institute strict bed rest and aggressive IV hydration and avoid caffeine while breastfeeding",
        "isCorrect": false,
        "explanation": "Bed rest and aggressive fluids do not hasten resolution. Moderate caffeine use is acceptable in breastfeeding and provides symptomatic benefit in PDPH."
      },
      {
        "text": "Perform an epidural blood patch now at L2–3 with 20 mL autologous blood",
        "isCorrect": false,
        "explanation": "Immediate neuraxial intervention is contraindicated shortly after prophylactic LMWH due to epidural hematoma risk; ASRA recommends waiting ≥12 h after a prophylactic enoxaparin dose."
      },
      {
        "text": "Obtain emergent noncontrast head CT before proceeding with any intervention",
        "isCorrect": false,
        "explanation": "Imaging is not indicated with a classic positional headache after known dural puncture, normal vitals, and normal neurologic exam; reserve imaging for atypical features, focal deficits, fever, or severe hypertension."
      },
      {
        "text": "Defer epidural blood patch until ≥12 h after the last enoxaparin dose; provide caffeine and oral analgesics in the interim",
        "isCorrect": true,
        "explanation": "This presentation is classic for post–dural puncture headache; the definitive therapy is an epidural blood patch, but neuraxial procedures should be delayed until ≥12 h after prophylactic LMWH. Caffeine and nonopioid analgesics can temporize and are compatible with breastfeeding."
      },
      {
        "text": "Administer subcutaneous sumatriptan and avoid neuraxial procedures for 24 h",
        "isCorrect": false,
        "explanation": "Triptans have limited and inconsistent efficacy for PDPH and are not first-line; definitive management is an epidural blood patch timed appropriately with anticoagulation."
      }
    ],
    "didactic": "Post–dural puncture headache (PDPH) results from persistent CSF leakage after dural puncture, causing low CSF pressure with traction on pain-sensitive structures and compensatory cerebral vasodilation. Typical features include onset within 24–72 h, postural worsening (sitting/standing), occipital or frontal pain, neck stiffness, tinnitus, photophobia, and a normal neurologic exam. In the postpartum patient with a known wet tap and classic postural symptoms, PDPH is the most likely diagnosis.\n\nInitial management focuses on symptom relief while the dural defect seals: \n- Analgesics (acetaminophen/NSAIDs) and reasonable oral hydration\n- Caffeine 300–500 mg PO or IV, which induces cerebral vasoconstriction; moderate use is compatible with breastfeeding\n- Adjuncts (eg, sphenopalatine ganglion block) can provide temporary relief but are not definitive\n\nThe definitive therapy is an epidural blood patch (EBP): injection of 15–20 mL autologous blood into the epidural space at or below the level of puncture. EBP provides rapid relief in 70%–90% of patients; a second EBP can be considered if symptoms persist.\n\nAnticoagulation timing is critical. Neuraxial procedures should be coordinated with anticoagulants to minimize epidural hematoma risk. For low-dose prophylactic LMWH (eg, enoxaparin 40 mg SC daily): \n- Wait ≥12 h after the last dose before performing an EBP\n- After EBP, delay the next LMWH dose ≥12 h (longer for traumatic placement or if bleeding risk is elevated)\nFor therapeutic LMWH, use ≥24 h holds before and after neuraxial procedures.\n\nImaging is not required for classic PDPH without red flags (focal deficits, fever/meningismus, severe hypertension/preeclampsia features, atypical nonpostural headache). In this patient, the best course is to defer EBP until the 12-hour interval has elapsed and provide caffeine and nonopioid analgesics in the interim to bridge symptoms while awaiting definitive treatment.",
    "educationalObjective": "Diagnose and manage post–dural puncture headache and describe options including epidural blood patch."
  },
  {
    "id": "Core.7.5.6",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Neuraxial anesthesia basics",
    "difficulty": "medium",
    "questionText": "A 67-year-old man (BMI 23 kg/m²) undergoes TURP under spinal anesthesia. While seated, he receives 10 mg 0.75% bupivacaine in 8.25% dextrose at L3–4 with free flow of CSF. He is immediately positioned supine in lithotomy with ~20° Trendelenburg to improve visualization. Ten minutes later, he reports dyspnea and numbness in his hands; exam reveals a sensory level to C8 with hypotension. Which factor most likely accounts for this unexpectedly high block height?",
    "answers": [
      {
        "text": "Decreased lumbosacral CSF volume (eg, pregnancy, obesity)",
        "isCorrect": false,
        "explanation": "Lower CSF volume increases spread, but this patient is nonpregnant with normal BMI; the immediate head-down positioning with hyperbaric solution is the key driver here."
      },
      {
        "text": "Performing the injection at a more cephalad interspace (eg, L2–3 instead of L4–5)",
        "isCorrect": false,
        "explanation": "Injection level has little effect on final block height because of rapid mixing in CSF; dose, baricity, position, and CSF volume are more important."
      },
      {
        "text": "Steep head-down positioning immediately after intrathecal dosing with a hyperbaric solution",
        "isCorrect": true,
        "explanation": "Hyperbaric local anesthetic follows gravity; Trendelenburg promotes cephalad spread early after injection, producing a higher level and potential high spinal."
      },
      {
        "text": "Use of an isobaric bupivacaine solution",
        "isCorrect": false,
        "explanation": "Isobaric solutions are minimally affected by gravity and positional changes and are less likely to produce rapid cephalad spread with head-down tilt."
      },
      {
        "text": "Administering a lower intrathecal dose of local anesthetic",
        "isCorrect": false,
        "explanation": "Dose is the primary determinant of block height and duration; a lower dose would be expected to reduce, not increase, cephalad spread."
      }
    ],
    "didactic": "Spinal block height is governed by several interacting factors, with the most important being total intrathecal dose (mass of drug), baricity relative to CSF, patient position (especially early after injection), and effective CSF volume. Dose largely determines the maximal spread and duration; higher doses generally produce higher, longer blocks. However, baricity and position can markedly modulate distribution during the early mixing phase before the drug becomes fixed to neural tissue.\n\n- Hyperbaric solutions (eg, bupivacaine with dextrose) sink under gravity to dependent regions.\n- Hypobaric solutions rise to nondependent regions.\n- Isobaric solutions are least affected by gravity and positional changes.\n\nA practical way to remember this interaction:\n\n| Baricity | Head-up (reverse Trendelenburg) | Head-down (Trendelenburg) |\n|---|---|---|\n| Hyperbaric | Caudad spread | Cephalad spread |\n| Hypobaric | Cephalad spread | Caudad spread |\n| Isobaric | Minimal effect | Minimal effect |\n\nIn this case, immediate placement in Trendelenburg after injecting a hyperbaric solution promoted cephalad movement, explaining the rapid progression to a high block. Position exerts its greatest influence within the first 10–20 minutes; after fixation, repositioning has little effect. CSF volume also matters: lower lumbosacral CSF volume (eg, pregnancy, obesity, ascites, increased intra-abdominal pressure, or epidural venous engorgement) increases intrathecal drug concentration and cephalad spread for a given dose. Conversely, larger CSF volumes reduce spread. Injection site (eg, L2–3 vs L4–5) has minimal impact on ultimate height compared with these factors.\n\nClinically, to limit cephalad spread with hyperbaric solutions, avoid head-down tilt early after injection, consider slight head-up positioning, and adjust dose in conditions that reduce CSF volume. For unilateral blocks, maintain lateral decubitus with the operative side dependent when using hyperbaric solutions.",
    "educationalObjective": "Explain factors that influence spinal block height including dose, baricity, patient position, and CSF volume."
  },
  {
    "id": "Core.7.5.7",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Neuraxial anesthesia basics",
    "difficulty": "medium",
    "questionText": "A 72-year-old man (BMI 34 kg/m²) is scheduled for total knee arthroplasty. After two unsuccessful midline attempts at L3–4 with firm bony contact and poor flexion due to spinal stenosis, you switch to a paramedian approach. A Tuohy needle is inserted 1 cm lateral to midline and directed 10–15° medially and cephalad. After traversing soft tissue, you feel a firm, elastic resistance; with steady pressure on a saline-filled syringe, a sudden loss of resistance occurs at a depth of 6 cm. You stop advancing.\n\nWhich structure lies immediately anterior to the needle tip at this point?",
    "answers": [
      {
        "text": "Posterior longitudinal ligament",
        "isCorrect": false,
        "explanation": "This ligament forms the anterior boundary of the epidural space; it is far anterior to the posterior epidural space where the needle has just entered."
      },
      {
        "text": "Ligamentum flavum",
        "isCorrect": false,
        "explanation": "The ligamentum flavum forms the posterior boundary of the epidural space; it has just been traversed at the moment of loss of resistance and lies posterior to the needle tip."
      },
      {
        "text": "Posterior dura mater",
        "isCorrect": true,
        "explanation": "After loss of resistance, the needle tip is in the posterior epidural space; the next structure anteriorly is the posterior dura mater, beyond which lies the arachnoid and subarachnoid space."
      },
      {
        "text": "Arachnoid mater",
        "isCorrect": false,
        "explanation": "The arachnoid lies deep to the dura; it is not immediately anterior upon epidural entry and must be punctured (with the dura) to obtain CSF."
      },
      {
        "text": "Interspinous ligament",
        "isCorrect": false,
        "explanation": "The paramedian approach bypasses the supraspinous and interspinous ligaments; these structures are posterior and lateral to the needle path."
      }
    ],
    "didactic": "Understanding tissue planes by approach helps interpret tactile feedback and avoid complications. In the midline approach, the sequence is:\n- Skin → subcutaneous tissue → supraspinous ligament → interspinous ligament → ligamentum flavum → epidural space → dura mater → arachnoid mater → subarachnoid space.\n\nIn the paramedian approach, the needle starts lateral and angulates medially/cephalad, bypassing the midline ligaments:\n- Skin → subcutaneous tissue → paraspinous muscle → ligamentum flavum → epidural space → dura mater → arachnoid mater → subarachnoid space.\n\nThe ligamentum flavum provides a characteristic firm, elastic resistance. When it is pierced, a sudden loss of resistance (LOR) indicates entry into the epidural space. If you stop at LOR, the structure immediately anterior to the tip is the posterior dura mater. Advancing a Tuohy several millimeters further risks puncturing the dura-arachnoid complex and entering the subarachnoid space (CSF return). Clinically, the dura and arachnoid are closely apposed; intentional passage through both is required for spinal anesthesia.\n\nKey boundaries of the epidural space are:\n- Posterior: ligamentum flavum.\n- Anterior: posterior longitudinal ligament (anterior to the venous plexus and fat).\n- Lateral: pedicles and intervertebral foramina.\n\nParamedian advantages include avoiding calcified supraspinous/interspinous ligaments, common in elderly or those with degenerative changes. A typical lumbar paramedian insertion is 1–2 cm lateral to midline with 10–15° medial and cephalad angulation to reach the interlaminar window. Integrating approach-specific anatomy with tactile cues (elastic “pop” at flavum, LOR on epidural entry, CSF after dura/arachnoid puncture) allows accurate identification of structures and safer neuraxial placement.",
    "educationalObjective": "Identify ligamentous and space anatomy from skin to epidural and subarachnoid spaces using midline and paramedian approaches."
  },
  {
    "id": "Core.7.5.8",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Neuraxial anesthesia basics",
    "difficulty": "easy",
    "questionText": "A 32-year-old G2P1 at term presents for scheduled repeat cesarean delivery under spinal anesthesia. After intrathecal hyperbaric bupivacaine 12 mg with fentanyl 15 µg and morphine 150 µg, you assess the block at 5 minutes. She has loss of cold sensation to the nipple line (approximately T4) but loss of pinprick only to T8 bilaterally; MAP 82 mmHg, HR 80/min, SpO<sub>2</sub> 99% on room air. The obstetrician is ready to incise. What is the best next step to ensure adequate anesthesia for peritoneal traction and uterine exteriorization?",
    "answers": [
      {
        "text": "Convert to general anesthesia immediately due to inadequate block",
        "isCorrect": false,
        "explanation": "Immediate conversion is premature at 5 minutes; spinal levels commonly continue to ascend. Convert only if the block fails to reach an adequate level or if urgent delivery precludes waiting."
      },
      {
        "text": "Delay incision and reassess until the pinprick level reaches T4 bilaterally",
        "isCorrect": true,
        "explanation": "For cesarean delivery, a T4 sensory level to pinprick bilaterally is recommended. Cold testing is not a reliable surrogate for surgical nociception; the block often ascends further over the next few minutes."
      },
      {
        "text": "Infiltrate local anesthetic at the planned incision and proceed",
        "isCorrect": false,
        "explanation": "Incisional infiltration does not address visceral pain from peritoneal traction and uterine manipulation, which require higher thoracic neuraxial blockade."
      },
      {
        "text": "Proceed with incision now because a T4 cold level predicts adequate cesarean anesthesia",
        "isCorrect": false,
        "explanation": "Temperature/cold testing often overestimates the block; sympathetic/temperature levels ascend higher than nociceptive pinprick. Proceeding risks visceral pain during peritoneal traction."
      },
      {
        "text": "Administer IV fentanyl and midazolam and proceed with the cesarean",
        "isCorrect": false,
        "explanation": "IV sedation/analgesia is unreliable for visceral pain under neuraxial anesthesia and may cause maternal respiratory depression and neonatal effects; it should not substitute for an adequate neuraxial level."
      }
    ],
    "didactic": "Adequate neuraxial anesthesia must match the dermatomal level of surgical stimulation. For cesarean delivery, the recommended target is loss of pinprick sensation to T4 (approximately the nipple line) bilaterally to cover peritoneal traction and uterine exteriorization. Testing modalities differ: the sympathetic and temperature (cold) components typically extend 1–2 segments higher than the nociceptive pinprick level, so relying on cold alone can overestimate the block and lead to intraoperative visceral pain.\n\nAssess block adequacy with bilateral pinprick or light touch, documenting the highest level of loss of sharp sensation in the midline and laterally. After spinal injection of hyperbaric bupivacaine, the block often continues to ascend for 5–10 minutes; brief observation and reassessment are appropriate when the level is close but not yet adequate and the patient is hemodynamically stable. If an epidural catheter is present (eg, CSE), incremental dosing can augment an insufficient block. If the level remains inadequate, conversion to general anesthesia should be considered based on urgency and patient preference.\n\nSedation, local infiltration, or relying on cold testing are common pitfalls; these do not reliably address visceral pain from peritoneal and uterine manipulation and may increase maternal and neonatal risk.\n\nTypical neuraxial targets by procedure:\n- Cesarean delivery: T4 to pinprick\n- Open inguinal hernia: T6–T8\n- TURP: T10\n- Hip arthroplasty: T10\n- Labor analgesia (first stage): T10–L1\n\nBottom line: For cesarean delivery, ensure a bilateral T4 level to pinprick before incision; cold/temperature levels alone are insufficient to judge block adequacy.",
    "educationalObjective": "Interpret dermatomal levels and test block adequacy before surgical incision."
  },
  {
    "id": "Core.7.5.9",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Neuraxial anesthesia basics",
    "difficulty": "medium",
    "questionText": "A 27-year-old G1P0 at 6 cm dilation requests labor analgesia. A combined spinal–epidural (L3–L4) is performed with intrathecal bupivacaine 2.5 mg and fentanyl 15 μg, providing rapid relief. An epidural catheter is threaded 5 cm into the epidural space. Ninety minutes later, she reports increasing rectal pressure and sacral pain. Sensory level to pinprick is T10 on the left and T12 on the right. Fetal heart tracing is reassuring; vitals are stable. She is receiving 0.1% bupivacaine with fentanyl 2 μg/mL by continuous epidural infusion at 10 mL/h with PCEA 5 mL, 15-min lockout, and has used frequent PCEA doses.\n\nWhich epidural pump strategy is most likely to improve analgesic spread and reduce breakthrough dosing in this patient?",
    "answers": [
      {
        "text": "Switch to programmed intermittent epidural bolus (PIEB) 10 mL every 45 min delivered at 250 mL/h, add PCEA 5 mL with a 15-min lockout, and no background infusion.",
        "isCorrect": true,
        "explanation": "Larger, rapid intermittent boluses promote more uniform circumferential and cephalad/sacral spread, improving block quality and decreasing PCEA use compared with continuous infusion."
      },
      {
        "text": "Increase bupivacaine concentration to 0.125% while maintaining the current infusion rate and PCEA.",
        "isCorrect": false,
        "explanation": "A higher concentration may deepen block but increases motor blockade and total drug exposure without addressing the key issue of suboptimal spread."
      },
      {
        "text": "Administer a one-time epidural bolus of 8 mL 0.25% bupivacaine and continue the same continuous infusion and PCEA settings.",
        "isCorrect": false,
        "explanation": "A clinician bolus may transiently improve analgesia but does not provide the sustained distribution benefits of PIEB; the higher concentration also risks unnecessary motor block."
      },
      {
        "text": "Increase continuous infusion to 14 mL/h; maintain current PCEA settings.",
        "isCorrect": false,
        "explanation": "Raising the basal rate increases total local anesthetic and motor block risk but does not improve the distribution within the epidural space as effectively as intermittent programmed boluses."
      },
      {
        "text": "Switch to PIEB 5 mL every 15 min delivered at 100 mL/h with PCEA 2 mL and a 10-min lockout.",
        "isCorrect": false,
        "explanation": "Small, frequent boluses at a low delivery rate approximate a continuous infusion and do not generate the higher injection pressures and volumes that optimize epidural spread."
      }
    ],
    "didactic": "Combined spinal–epidural (CSE) provides rapid onset from the intrathecal component, but maintenance depends on effective epidural drug distribution as labor progresses and sacral segments (S2–S4) are recruited. Compared with continuous infusion, **programmed intermittent epidural bolus (PIEB)** delivers larger volumes at higher transient pressures, producing more uniform circumferential spread and better rostral/sacral coverage. This improves block quality, reduces breakthrough dosing and clinician top-ups, and lowers total local anesthetic consumption and motor block in randomized trials.\n\nKey principles when configuring PIEB after CSE:\n- Use dilute local anesthetic with opioid: eg, bupivacaine 0.0625–0.1% or ropivacaine 0.08–0.1% with fentanyl 2 μg/mL or sufentanil 0.5 μg/mL.\n- Favor larger intermittent boluses delivered quickly: eg, 8–12 mL every 40–60 min at ≥200 mL/h. Rapid delivery, not just total volume, improves spread.\n- Pair with PCEA (eg, 5 mL, 15–20-min lockout) and often no basal infusion; PIEB plus PCEA typically yields fewer breakthroughs than continuous infusion strategies.\n- Avoid unnecessarily increasing concentration or basal rate, which raises motor block risk without addressing distribution.\n\nIn this patient, sacral pain and asymmetric levels despite a functioning catheter on a continuous infusion suggest suboptimal spread rather than inadequate dose. Switching to PIEB 10 mL every 45 min at a high delivery rate with PCEA 5 mL optimizes epidural distribution and provides patient-driven rescue while minimizing motor block. Small, frequent boluses at slow rates behave like a continuous infusion and are less effective. If asymmetry persists, adjunct measures (eg, repositioning to the less-blocked side, confirming catheter depth) can be added, but the most impactful pump change is instituting appropriately dosed PIEB.",
    "educationalObjective": "Manage labor analgesia with combined spinal–epidural and programmed intermittent boluses to improve spread."
  },
  {
    "id": "Core.7.5.10",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Neuraxial anesthesia basics",
    "difficulty": "easy",
    "questionText": "You are planning neuraxial anesthesia for several patients on today’s schedule. For which patient is it appropriate to proceed with a spinal/epidural now?\n\nChoose the best option.",
    "answers": [
      {
        "text": "A 24-year-old woman in active labor with a tender, erythematous pustule directly over the L3–L4 interspace",
        "isCorrect": false,
        "explanation": "Infection at the puncture site is an absolute contraindication due to the risk of introducing bacteria into the neuraxis."
      },
      {
        "text": "A 72-year-old woman with atrial fibrillation who took apixaban 5 mg 12 hours ago for stroke prevention",
        "isCorrect": false,
        "explanation": "Direct oral factor Xa inhibitors (eg, apixaban) generally require a ≥72-hour hold (longer with renal impairment) before neuraxial procedures."
      },
      {
        "text": "A 31-year-old woman requesting IV analgesia in labor who declines an epidural after counseling",
        "isCorrect": false,
        "explanation": "Patient refusal is an absolute contraindication to neuraxial anesthesia."
      },
      {
        "text": "A 67-year-old man for total knee arthroplasty who received subcutaneous heparin 5,000 units for VTE prophylaxis 8 hours ago; platelets 240,000/µL, INR 1.0, and aPTT normal",
        "isCorrect": true,
        "explanation": "Prophylactic subcutaneous unfractionated heparin (5,000 U) is compatible with neuraxial placement when ≥4–6 hours have elapsed and coagulation is otherwise normal."
      },
      {
        "text": "A 58-year-old man scheduled for TURP who took clopidogrel 75 mg daily, last dose 48 hours ago",
        "isCorrect": false,
        "explanation": "Clopidogrel requires a 5–7 day discontinuation before neuraxial techniques; 48 hours is insufficient."
      }
    ],
    "didactic": "Neuraxial anesthesia is highly effective but requires screening for absolute and relative contraindications. **Absolute contraindications** include **patient refusal**, **infection at the puncture site**, and **significant coagulopathy/unsafe anticoagulation timing**. Elevated intracranial pressure from a mass lesion is also a classic absolute contraindication. Systemic infection without hemodynamic instability is typically a relative contraindication if appropriately treated with antibiotics.\n\nKey anticoagulation considerations for placement/removal (general guidance; follow institutional/ASRA updates):\n- **Unfractionated heparin (prophylactic SC 5,000 U)**: Wait ≥4–6 h before placement; check normal coagulation; resume ≥1 h after catheter removal.\n- **LMWH**: Prophylactic dosing—wait ≥12 h; therapeutic dosing—wait ≥24 h before placement. Remove catheter ≥12 h after last prophylactic dose (≥24 h if therapeutic); delay next dose ≥4 h after removal.\n- **P2Y12 inhibitors (eg, clopidogrel)**: Hold **5–7 days** prior to neuraxial techniques; avoid while effect persists.\n- **DOACs (eg, apixaban, rivaroxaban)**: Hold **≥72 h** with normal renal function; consider longer with renal impairment/elderly. Do not dose with catheter in place.\n- **Warfarin**: Ensure **INR <1.5** before placement/removal.\n- **Aspirin/NSAIDs**: Alone do not contraindicate neuraxial techniques.\n\n**Infection**: Avoid neuraxial placement through **infected skin**. Remote infections may be acceptable after antibiotics and clinical improvement. **Bacteremia/sepsis** warrants treatment and stabilization prior to neuraxial procedures.\n\n**Platelets**: Although thresholds vary by context, neuraxial techniques are generally considered reasonable when platelets are **≥70,000–80,000/µL** with a stable trend and no additional coagulopathy; avoid when markedly low (eg, <50,000/µL) or rapidly falling.\n\nIn this question, proceeding after prophylactic SC heparin given 8 hours prior with normal labs is appropriate, whereas clopidogrel within 48 h, recent apixaban, infection at the site, and patient refusal are contraindications.",
    "educationalObjective": "Outline indications and contraindications to neuraxial anesthesia including infection, coagulopathy, and patient refusal."
  },
  {
    "id": "Core.7.5.11",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Neuraxial anesthesia basics",
    "difficulty": "medium",
    "questionText": "A 29-year-old G2P1 at 39 weeks requests labor analgesia. An epidural is attempted in the sitting position using a 17-g Tuohy needle and a 10 mL air-filled syringe for loss-of-resistance. After multiple attempts, a sudden “pop” is felt and the patient immediately develops a severe bifrontal headache with nausea. Neurologic exam is normal. A noncontrast head CT obtained shortly afterward shows intracranial air consistent with pneumocephalus. She improves with supine rest and 100% O<sub>2</sub>.\n\nWhich modification would most reduce the likelihood of this complication during future epidural placements?",
    "answers": [
      {
        "text": "Use loss-of-resistance to saline (2–3 mL) with a continuous fluid column and avoid injecting air",
        "isCorrect": true,
        "explanation": "Saline minimizes inadvertent injection of air across a dural puncture, reducing pneumocephalus and decreasing patchy blocks by avoiding epidural air pockets."
      },
      {
        "text": "Administer an epinephrine-containing test dose before threading the catheter to detect intravascular placement",
        "isCorrect": false,
        "explanation": "Test dosing is important for intravascular/intrathecal detection after catheter placement but does not prevent air-related complications during loss-of-resistance."
      },
      {
        "text": "Perform epidural placement in the lateral decubitus position to reduce venous air embolism",
        "isCorrect": false,
        "explanation": "Position changes do not address intracranial air entry from inadvertent intrathecal/subdural air injection; VAE is uncommon and not the cause of this presentation."
      },
      {
        "text": "Confirm the epidural space using intermittent 8–10 mL air boluses to ensure a clear loss-of-resistance",
        "isCorrect": false,
        "explanation": "Large or repeated air injections increase the risk of intrathecal or subdural air if the dura is breached, predisposing to pneumocephalus and patchy block."
      },
      {
        "text": "Switch to a smaller 18-g Tuohy needle to reduce the size of any potential dural puncture",
        "isCorrect": false,
        "explanation": "Needle gauge has little effect on the risk of pneumocephalus; the complication arises from air injection across a dural puncture, not the needle size per se."
      }
    ],
    "didactic": "Pneumocephalus after epidural placement presents as an immediate, severe headache following needle advancement—distinct from post–dural puncture headache, which is typically delayed (hours) and positional. The likely mechanism is inadvertent dural puncture with injection of air into the subarachnoid or subdural space during loss-of-resistance (LOR) with air. Intracranial air rises along CSF pathways and can be visualized on CT. Management is supportive with supine rest, analgesics, and high FiO<sub>2</sub> to accelerate nitrogen washout; avoid N<sub>2</sub>O, which expands air collections.\n\nUsing LOR to saline rather than air is the key preventive strategy. A small volume (≈2–3 mL) of saline, applied with gentle, continuous plunger pressure via a fluid-filled syringe or tubing, identifies the epidural space while minimizing air entry if the dura is breached. Additional advantages of saline include:\n\n- Reduced risk of **patchy or unilateral block** due to avoidance of epidural air pockets that impede local anesthetic spread.\n- Easier catheter advancement through a **fluid-distended** epidural space.\n- Lower risk of **subcutaneous emphysema** and rare venous air embolism compared with air.\n\nAir-based techniques carry several pitfalls:\n\n- Even small volumes of air can cause **pneumocephalus** if injected intrathecally/subdurally.\n- Air pockets can create **false LOR** in soft tissue planes and contribute to inadequate or asymmetric analgesia.\n\nSafe LOR technique emphasizes midline or paramedian approach, controlled needle advancement, continuous hand stabilization, and minimal-volume saline to confirm entry. Test dosing and aspiration after catheter placement remain essential for detecting intrathecal or intravascular placement but do not prevent air-related complications during LOR. Choosing saline over air directly addresses the mechanism of pneumocephalus and improves block quality.",
    "educationalObjective": "Perform loss-of-resistance technique safely and differentiate saline from air methods and related complications."
  },
  {
    "id": "Core.7.5.12",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Neuraxial anesthesia basics",
    "difficulty": "hard",
    "questionText": "A 78-year-old man with symptomatic severe aortic stenosis (aortic valve area 0.6 cm², mean gradient 55 mmHg, EF 60%) presents for urgent open reduction–internal fixation of an intertrochanteric hip fracture. He is in sinus rhythm, BP 130/70 mmHg, HR 65/min, and euvolemic on exam. He takes no antiplatelets/anticoagulants. The surgeon prefers neuraxial anesthesia. You plan to avoid hypotension and tachycardia and maintain coronary perfusion. Which neuraxial anesthetic plan is most appropriate to minimize hemodynamic instability in this patient?",
    "answers": [
      {
        "text": "Combined spinal-epidural with intrathecal bupivacaine 7.5 mg plus epidural catheter for top-up; place the arterial line after the spinal; treat hypotension with nitroglycerin to improve coronary perfusion",
        "isCorrect": false,
        "explanation": "Even “moderate” intrathecal doses can precipitate rapid hypotension; arterial line should precede neuraxial dosing, and nitroglycerin reduces preload/afterload, risking severe hypotension in a fixed obstruction."
      },
      {
        "text": "Incremental lumbar epidural after placing a radial arterial line; initiate a phenylephrine infusion (eg, 0.25–0.5 μg/kg/min) and give 250–500 mL crystalloid; titrate 0.5% bupivacaine in 3–5 mL aliquots every 5 min to a T10 block while maintaining HR 60–70/min",
        "isCorrect": true,
        "explanation": "Careful, titratable epidural dosing with invasive beat-to-beat BP monitoring and α-agonist support maintains preload/afterload and avoids sudden sympathectomy, aligning with hemodynamic goals in severe aortic stenosis."
      },
      {
        "text": "Low-dose spinal (bupivacaine 5 mg with fentanyl) in the lateral position without an arterial line; manage blood pressure with intermittent norepinephrine boluses only if MAP <55 mmHg and allow HR 90–100/min for cardiac output",
        "isCorrect": false,
        "explanation": "Although dose-reduced, single-shot spinal still risks abrupt hypotension without invasive monitoring; permissive tachycardia worsens diastolic time and coronary perfusion in severe aortic stenosis."
      },
      {
        "text": "Single-shot spinal using bupivacaine 12.5 mg with intrathecal fentanyl, standard monitors only, 1 L crystalloid preload, and ephedrine boluses for hypotension",
        "isCorrect": false,
        "explanation": "A full-dose spinal causes abrupt sympathectomy and reduced SVR/preload, which a fixed-outflow lesion poorly tolerates; ephedrine may provoke tachycardia and worsen myocardial oxygen balance."
      },
      {
        "text": "Epidural test dose followed by a single 15 mL bolus of 0.5% bupivacaine; central venous catheter afterward; treat hypotension with propofol boluses and fluids",
        "isCorrect": false,
        "explanation": "A large epidural bolus can mimic a spinal-like sympathectomy; propofol exacerbates vasodilation and hypotension and is inappropriate as a vasopressor substitute in severe aortic stenosis."
      }
    ],
    "didactic": "Severe aortic stenosis (AS) creates a fixed obstruction to left ventricular outflow, making cardiac output relatively preload- and afterload-dependent. Abrupt decreases in systemic vascular resistance (SVR) or venous return compromise coronary perfusion pressure (CPP ≈ aortic diastolic pressure − LVEDP) and can precipitate ischemia, hypotension, and collapse. Hemodynamic goals are to maintain sinus rhythm, HR ~60–70/min, adequate preload, and normal-to-high afterload while avoiding both tachycardia (↓diastolic filling/perfusion) and bradycardia (↓cardiac output).\n\nNeuraxial techniques reduce sympathetic tone. In severe AS, the key is to avoid sudden sympathectomy. Compared with single-shot spinal, an epidural allows gradual, titratable dosing and better hemodynamic control. Best practice includes:\n\n- Place a radial arterial line before dosing to allow beat-to-beat blood pressure management.\n- Ensure large-bore IV access and give cautious fluid (eg, 250–500 mL) to support preload without volume overload.\n- Use an α-agonist (eg, phenylephrine infusion) to maintain afterload and CPP; it raises SVR and often lowers HR, which is advantageous. Norepinephrine is also reasonable at low dose. Avoid ephedrine (tachycardia) and vasodilators (eg, nitroglycerin) that reduce preload/afterload.\n- Dose the epidural incrementally (eg, 0.5% bupivacaine 3–5 mL every 5 min) to the minimal level needed (hip surgery typically T10), pausing with any downward trend in MAP.\n\nSingle-shot spinals—even at “low doses”—can still produce rapid sympathectomy without the opportunity to titrate, making them risky in severe AS. Combined spinal-epidural with ultra–low-dose intrathecal local anesthetic may be considered in expert hands, but it still requires invasive monitoring and immediate vasopressor support. The physiologic priorities are maintaining MAP (MAP = CO × SVR) largely via SVR support, preserving sinus rhythm and diastolic time, and avoiding abrupt changes in preload/afterload. Accordingly, a carefully titrated epidural with an arterial line and a prophylactic phenylephrine infusion best minimizes hemodynamic instability in severe AS.",
    "educationalObjective": "Plan neuraxial anesthesia in severe aortic stenosis or fixed obstruction with careful dosing and monitoring."
  },
  {
    "id": "Core.7.5.13",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Neuraxial anesthesia basics",
    "difficulty": "hard",
    "questionText": "A 28-year-old G1P0 at 39 weeks with a functioning labor epidural is taken for urgent cesarean delivery for nonreassuring fetal status. To rapidly achieve surgical anesthesia, the epidural is bolused over 3 minutes with 20 mL of 2% lidocaine with epinephrine and bicarbonate. Two minutes later, she reports perioral and hand numbness followed by inability to speak above a whisper and dyspnea. Exam shows minimal chest rise, no ability to lift arms, and a rapidly ascending sensory level to the neck. Blood pressure is 58/30 mmHg, heart rate 38/min, and SpO<sub>2</sub> 98% on 6 L/min O<sub>2</sub> by face mask. Fetal heart tracing shows prolonged deceleration. Which immediate management is most appropriate to optimize maternal oxygenation and perfusion?",
    "answers": [
      {
        "text": "Give epinephrine 1 mg IV push and start chest compressions because cardiac arrest is imminent",
        "isCorrect": false,
        "explanation": "High-dose epinephrine (1 mg) and chest compressions are indicated only after cardiac arrest. Excessive epinephrine in a perfusing rhythm risks severe hypertension and uterine vasoconstriction, worsening fetal status."
      },
      {
        "text": "Proceed with inhalational induction using sevoflurane by mask while awaiting regression of the neuraxial block",
        "isCorrect": false,
        "explanation": "Mask inhalational induction delays protection of the airway in an evolving apnea and does not address severe hypotension/bradycardia. Early RSI with vasopressor support is safer and faster."
      },
      {
        "text": "Administer 20% lipid emulsion bolus and benzodiazepine for presumed local anesthetic systemic toxicity (LAST) while observing for recovery of the block",
        "isCorrect": false,
        "explanation": "Presentation is most consistent with high/total neuraxial block with profound sympathectomy and phrenic/intercostal involvement, not LAST (which typically presents with CNS excitation [tinnitus, seizures] and cardiovascular collapse without a rapidly ascending neuraxial level). Lipid therapy delays definitive airway/hemodynamic management."
      },
      {
        "text": "Apply left uterine displacement, deliver 100% O<sub>2</sub> with assisted ventilation, perform rapid-sequence intubation, and treat hypotension/bradycardia with phenylephrine 100 µg IV and atropine 0.4 mg IV, escalating to small-dose epinephrine if refractory",
        "isCorrect": true,
        "explanation": "High/total spinal requires immediate airway control and aggressive hemodynamic support. Maternal oxygenation/ventilation and restoration of MAP/HR (phenylephrine, atropine; epinephrine if needed) are the priorities, with left uterine displacement to relieve aortocaval compression."
      },
      {
        "text": "Place the patient in steep Trendelenburg and give a rapid 1–2 L crystalloid bolus as first-line treatment for hypotension",
        "isCorrect": false,
        "explanation": "Trendelenburg can worsen cephalad spread and respiratory compromise; crystalloid alone will not reverse sympathectomy. Left uterine displacement and vasopressors are required to restore perfusion."
      }
    ],
    "didactic": "High or total spinal anesthesia results from excessive cephalad spread of local anesthetic in the neuraxis, producing extensive sympathetic block (severe hypotension, bradycardia), intercostal/phrenic paralysis (dyspnea, hypoventilation), and potentially brainstem involvement (apnea, loss of consciousness). Obstetric patients are particularly susceptible due to decreased CSF volume, engorged epidural veins, and enhanced sensitivity to local anesthetics. Rapid, large epidural boluses—especially after catheter migration intrathecally or subdurally—are a common precipitant during labor-to-cesarean conversion.\n\nImmediate management priorities are maternal oxygenation/ventilation and perfusion:\n- Call for help; apply left uterine displacement to relieve aortocaval compression.\n- Deliver 100% O<sub>2</sub> and assist ventilation; perform early rapid-sequence intubation before complete apnea and loss of protective reflexes.\n- Treat sympathectomy: phenylephrine 50–100 µg IV boluses are first line to restore MAP in obstetrics; if bradycardic or low cardiac output, ephedrine 5–10 mg (mixed α/β<sub>1</sub>) may be advantageous. For severe bradycardia, give atropine 0.4–0.6 mg IV. If hypotension/bradycardia is refractory or there is impending collapse, titrate epinephrine 10–50 µg IV boluses, escalating per ACLS if arrest occurs.\n- Give judicious crystalloid/colloid; fluids alone cannot reverse sympathectomy.\n\nPrevention focuses on minimizing cephalad spread: reduce intrathecal dose in pregnancy, avoid rapid large epidural boluses, use incremental fractionated dosing with frequent aspiration and test dosing, and avoid Trendelenburg after dosing. Recognize subdural injection (delayed, patchy, high sensory level with relatively preserved motor) versus intrathecal migration (rapid dense block); initial airway/hemodynamic management is similar. Early definitive airway control and targeted vasopressor therapy are key to optimizing maternal–fetal outcomes.",
    "educationalObjective": "Prevent and treat high or total spinal anesthesia with prompt airway and hemodynamic support."
  },
  {
    "id": "Core.7.5.14",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Neuraxial anesthesia basics",
    "difficulty": "medium",
    "questionText": "A 28-year-old G1P0 at term with a functioning labor epidural requires an urgent cesarean delivery for nonreassuring fetal heart tracing. She is 70 kg, hemodynamically stable, and not taking β-blockers. Aspiration through the epidural catheter is negative for blood and cerebrospinal fluid. The team requests incision in 10 minutes. Which dosing strategy best minimizes the risk of local anesthetic systemic toxicity (LAST) while achieving timely surgical anesthesia?\n\nSelect the best approach.",
    "answers": [
      {
        "text": "Give 15 mL of 3% 2-chloroprocaine as a single bolus to minimize systemic toxicity because it is rapidly metabolized.",
        "isCorrect": false,
        "explanation": "Although 2-chloroprocaine is rapidly hydrolyzed, single-bolus dosing without fractionation still risks high peak plasma levels with intravascular injection; incremental dosing is still recommended."
      },
      {
        "text": "Inject 20 mL of 0.75% bupivacaine without epinephrine as a single bolus to ensure a dense block quickly.",
        "isCorrect": false,
        "explanation": "High-concentration bupivacaine has greater cardiotoxicity; a single large bolus increases risk of catastrophic LAST, especially if the catheter is intravascular or intrathecal."
      },
      {
        "text": "Administer a 3 mL test dose of 1.5% lidocaine with epinephrine, then rapidly deliver the remaining 20 mL of 2% lidocaine within 30 s to minimize time to incision.",
        "isCorrect": false,
        "explanation": "A negative test dose does not exclude intravascular/intrathecal position; rapid full-dose bolus increases risk of LAST compared with fractionated dosing."
      },
      {
        "text": "Skip the test dose and give 10 mL of 2% lidocaine, then another 10 mL if no change is observed after 1 min to avoid delaying incision.",
        "isCorrect": false,
        "explanation": "Omitting a test dose and rapidly administering large volumes reduces the chance to recognize intravascular/intrathecal placement and increases peak plasma levels."
      },
      {
        "text": "Administer a 3 mL test dose of 1.5% lidocaine with epinephrine 1:200,000, then inject 2% lidocaine with epinephrine in 5 mL aliquots every 1–2 min (to a total of 15 mL) with frequent aspiration and continuous monitoring.",
        "isCorrect": true,
        "explanation": "Test dosing followed by fractionated, incremental dosing limits peak plasma levels if intravascular migration occurs and allows early detection of intrathecal or intravascular injection while keeping total dose (300 mg) below the epinephrine-augmented maximum for 70 kg."
      }
    ],
    "didactic": "Preventing local anesthetic systemic toxicity (LAST) during neuraxial dosing hinges on both the concentration selected and how the dose is delivered. In obstetric epidurals—where epidural veins are engorged and catheters can migrate—unrecognized intravascular or intrathecal injection is a leading cause of LAST.\n\nThe safest approach is to combine a **test dose** with **fractionated (incremental) dosing**:\n- A common test dose is 3 mL of 1.5% lidocaine with epinephrine 1:200,000 (45 mg lidocaine + 15 µg epinephrine). Intravascular injection produces a ≥20 bpm HR increase within 30–60 s (blunted by β-blockade), while intrathecal injection causes rapid motor/sensory block.\n- After a negative test dose, inject in **3–5 mL aliquots every 30–90 s** with frequent aspiration and continuous monitoring. Fractionation limits peak plasma levels if part of the dose enters the circulation and provides time to detect evolving signs of toxicity.\n\nFor rapid epidural conversion to surgical anesthesia, **2% lidocaine with epinephrine** is appropriate; 15 mL equals 300 mg, which is below the typical epinephrine-augmented maximum of ~7 mg/kg (≈490 mg for 70 kg). Epinephrine both improves block quality and **reduces systemic uptake**, increasing safety. In contrast, high-concentration bupivacaine (eg, 0.75%) has greater **cardiotoxicity** and is avoided in obstetrics, especially as a large bolus. Although 2-chloroprocaine is rapidly metabolized and useful for urgent conversion, it should still be administered incrementally rather than as a single bolus to minimize peak concentrations if intravascular injection occurs.\n\nKey prevention principles:\n- Use the **lowest effective concentration** and keep within safe mg/kg limits.\n- Always **test dose**, then **inject incrementally** with aspiration and vigilance.\n- Recognize that negative aspiration/test dosing does not fully exclude malposition—ongoing fractionation is essential.\n- Maintain readiness to treat LAST (airway management, seizure control, and lipid emulsion).",
    "educationalObjective": "Prevent local anesthetic systemic toxicity during neuraxial dosing by using appropriate concentration and fractionation."
  },
  {
    "id": "Core.7.5.15",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Neuraxial anesthesia basics",
    "difficulty": "hard",
    "questionText": "A 52-year-old man undergoes ambulatory hemorrhoidectomy under single-shot spinal anesthesia at L3–4 with 5% hyperbaric lidocaine (75 mg). Surgery lasts 45 minutes in lithotomy without intraoperative issues. Six hours postoperatively, he reports persistent numbness of the perineum and bilateral posterior thighs, severe burning pain in the buttocks, and difficulty initiating urination after Foley removal. Examination shows decreased pinprick in the S2–S4 dermatomes with saddle anesthesia, diminished anal sphincter tone, an absent anal wink, and 4/5 plantarflexion bilaterally. Postvoid residual is 700 mL.\n\nWhich is the most appropriate next step?",
    "answers": [
      {
        "text": "Observe for an additional 24 hours to ensure complete resolution of intrathecal local anesthetic effect",
        "isCorrect": false,
        "explanation": "Prolonged observation risks irreversible neurologic injury; if a compressive lesion (eg, epidural hematoma) exists, decompression within hours is critical to optimize outcomes."
      },
      {
        "text": "Initiate high-dose IV methylprednisolone and arrange outpatient neurology follow-up",
        "isCorrect": false,
        "explanation": "Corticosteroids have no proven benefit for CES due to local anesthetic neurotoxicity and delay definitive evaluation; outpatient follow-up risks missing the time window for decompression if a compressive lesion is present."
      },
      {
        "text": "Start NSAIDs and reassure the patient that symptoms will resolve within 48–72 hours",
        "isCorrect": false,
        "explanation": "This approach is appropriate for transient neurologic symptoms (TNS), which present with severe buttock/posterior thigh pain but a normal neurologic exam and no bladder/bowel dysfunction. This patient has objective sacral deficits and urinary retention concerning for cauda equina syndrome (CES)."
      },
      {
        "text": "Obtain urgent MRI of the lumbosacral spine, consult neurosurgery, and maintain bladder drainage",
        "isCorrect": true,
        "explanation": "Saddle anesthesia, sphincter dysfunction, and sacral motor/sensory deficits after spinal anesthesia are red flags for CES (neurotoxicity or compressive hematoma/abscess). Emergent MRI and neurosurgical evaluation are indicated; bladder decompression should be maintained."
      },
      {
        "text": "Order serum vitamin B12 and TSH to evaluate for peripheral neuropathy",
        "isCorrect": false,
        "explanation": "Metabolic neuropathies do not present acutely with saddle anesthesia and sphincter dysfunction after neuraxial anesthesia; urgent spinal imaging is required instead."
      }
    ],
    "didactic": "Cauda equina syndrome (CES) after neuraxial anesthesia is an emergency characterized by sacral root dysfunction: **saddle anesthesia (S2–S4), bowel/bladder dysfunction**, and often lower-extremity weakness or hyporeflexia. In the perioperative setting, CES can result from:\n\n- **Neurotoxicity/maldistribution** of intrathecal local anesthetic (historically associated with 5% hyperbaric lidocaine), leading to high concentrations bathing sacral roots\n- **Compressive lesions** (eg, spinal/epidural hematoma, abscess), particularly in patients with coagulopathy, difficult placement, or infection\n\nKey distinguishing features from transient neurologic symptoms (TNS):\n\n- **TNS**: severe buttock/posterior thigh pain within 24 h of spinal—commonly after intrathecal lidocaine and lithotomy—but with a **normal neurologic exam**, intact perineal sensation, and **no sphincter dysfunction**. Management is supportive (NSAIDs, acetaminophen, short-course opioids or gabapentinoids); symptoms typically resolve in 48–72 h.\n- **CES**: **objective sacral sensory loss**, sphincter dysfunction (urinary retention/incontinence, decreased anal tone), and potential motor deficits. This mandates **urgent MRI of the lumbosacral spine** and **neurosurgical consultation** to identify compressive pathology requiring decompression. Prompt bladder decompression (eg, Foley catheter) prevents overdistention.\n\nIn any patient with persistent or progressive neurologic deficits beyond the expected duration of neuraxial block—especially with **saddle anesthesia or bladder/bowel involvement**—do not attribute symptoms to residual anesthesia or TNS. Immediate imaging is critical; delays can convert reversible deficits into permanent disability if a hematoma or abscess is present. Steroids have no proven benefit in CES due to local anesthetic neurotoxicity, and observation alone is inappropriate when red flags exist. Recognizing CES and differentiating it from TNS ensures timely, limb- and function-saving intervention.",
    "educationalObjective": "Recognize cauda equina syndrome and transient neurologic symptoms and take urgent action."
  },
  {
    "id": "Core.7.5.16",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Neuraxial anesthesia basics",
    "difficulty": "medium",
    "questionText": "A 76-year-old man with hypertension, ischemic cardiomyopathy (EF 30%), and CKD stage 3 is undergoing hip hemiarthroplasty under single-shot spinal anesthesia. Ten minutes after intrathecal bupivacaine, his sensory level is to T6. He reports lightheadedness; BP is 78/42 mmHg (MAP 54), HR 88/min, SpO<sub>2</sub> 98% on 2 L/min O<sub>2</sub>. There is no surgical bleeding and the ECG shows normal sinus rhythm. He has received 250 mL lactated Ringer’s since the block. Which of the following is the most appropriate next step to treat his hypotension while minimizing fluid administration?",
    "answers": [
      {
        "text": "Administer phenylephrine 100 μg IV bolus",
        "isCorrect": true,
        "explanation": "Pure α-agonism rapidly reverses neuraxial sympathectomy by increasing venous tone and SVR, improving preload and MAP without excess fluid; appropriate when HR is not low."
      },
      {
        "text": "Start norepinephrine infusion 0.02 μg/kg/min",
        "isCorrect": false,
        "explanation": "An α-predominant infusion is effective for severe or refractory neuraxial hypotension, but an immediate phenylephrine bolus is the fastest appropriate first step; an infusion can follow if needed."
      },
      {
        "text": "Administer 1 L lactated Ringer’s bolus IV",
        "isCorrect": false,
        "explanation": "Large crystalloid boluses provide limited benefit for sympathectomy-induced vasodilation and risk pulmonary edema in HFrEF; vasopressors are first-line for neuraxial hypotension."
      },
      {
        "text": "Administer glycopyrrolate 0.2 mg IV",
        "isCorrect": false,
        "explanation": "Anticholinergics treat bradycardia but do not correct vasodilation; HR is not low and this will not address the primary cause of hypotension."
      },
      {
        "text": "Administer ephedrine 10 mg IV bolus",
        "isCorrect": false,
        "explanation": "Mixed α/β effects increase HR and contractility, useful if hypotension is accompanied by bradycardia; here HR is 88/min and β stimulation may provoke tachycardia and higher myocardial O<sub>2</sub> demand."
      }
    ],
    "didactic": "Spinal anesthesia produces a sympathectomy that causes both arterial vasodilation (↓SVR) and venodilation (↑venous capacitance), reducing preload and MAP (MAP = CO × SVR). Decreased venous return can also trigger reflex bradycardia (Bezold–Jarisch), especially with high blocks. The hemodynamic profile in this vignette (T6 level, MAP 54 mmHg, HR 88/min, no bleeding) is most consistent with neuraxial sympathectomy rather than hypovolemia.\n\nThe most effective and fluid-sparing initial therapy is a vasopressor with strong α-adrenergic activity to restore venous tone and SVR:\n- Phenylephrine 50–100 μg IV boluses (or a titratable infusion) rapidly corrects vasodilation; it is preferred when HR is normal or elevated.\n- Ephedrine 5–10 mg IV provides mixed α/β effects and is favored when hypotension coexists with bradycardia because β<sub>1</sub> support raises HR and CO.\n- Norepinephrine (eg, 0.02–0.05 μg/kg/min) is reasonable for severe/refractory neuraxial hypotension or when minimizing reflex bradycardia is desired; start after or with a bolus for immediate effect.\n\nFluid stewardship is essential, particularly in older patients and those with HFrEF or CKD. Large crystalloid boluses (eg, 1–2 L) offer limited benefit against vasoplegia, can exacerbate hemodilution and tissue edema, and increase risk of pulmonary edema. Small-volume co-loading during spinal placement and leg elevation can help, but vasopressors are first-line to counteract sympathectomy. Anticholinergics (eg, glycopyrrolate, atropine) are reserved for clinically significant bradycardia and do not treat vasodilation.\n\nKey approach: promptly exclude hemorrhage, assess block height, and treat neuraxial hypotension with α-agonist vasopressors while avoiding unnecessary fluids. Choose phenylephrine if HR is normal/high; choose ephedrine if bradycardic; consider norepinephrine infusion when hypotension is profound or recurrent despite boluses.",
    "educationalObjective": "Recognize physiologic effects of sympathectomy and manage hypotension with vasopressors and fluid stewardship."
  },
  {
    "id": "Core.7.5.17",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Neuraxial anesthesia basics",
    "difficulty": "medium",
    "questionText": "A 76-year-old man (BMI 33) with severe obstructive sleep apnea (AHI 45) on nightly CPAP and severe aortic stenosis (valve area 0.8 cm², mean gradient 45 mmHg) is scheduled for unilateral total knee arthroplasty. He takes metoprolol with a resting HR 50/min and BP 118/64 mmHg. You plan a single-shot spinal with hyperbaric bupivacaine and wish to enhance intraoperative and early postoperative analgesia while minimizing hemodynamic instability and avoiding delayed respiratory depression.\n\nWhich intrathecal additive is most appropriate in this patient?",
    "answers": [
      {
        "text": "Intrathecal buprenorphine 60 µg",
        "isCorrect": false,
        "explanation": "Buprenorphine produces long-lasting analgesia but may cause sedation, pruritus, urinary retention, and can complicate postoperative opioid responsiveness; its prolonged effect is undesirable when avoiding late respiratory depression."
      },
      {
        "text": "Intrathecal morphine 200 µg",
        "isCorrect": false,
        "explanation": "Hydrophilic neuraxial opioids (eg, morphine) have prolonged CSF residence and rostral spread, increasing the risk of delayed respiratory depression, pruritus, and urinary retention—particularly concerning in severe OSA."
      },
      {
        "text": "Intrathecal hydromorphone 100 µg",
        "isCorrect": false,
        "explanation": "Like morphine, hydromorphone is hydrophilic with prolonged CSF spread and risk of delayed respiratory depression and urinary retention; it is not ideal in OSA when late respiratory events are a concern."
      },
      {
        "text": "Intrathecal fentanyl 15 µg",
        "isCorrect": true,
        "explanation": "Lipophilic neuraxial opioids (eg, fentanyl) provide rapid-onset, short-duration analgesia with minimal rostral spread and low risk of delayed respiratory depression, and they do not exacerbate hypotension or bradycardia."
      },
      {
        "text": "Intrathecal clonidine 75 µg",
        "isCorrect": false,
        "explanation": "Neuraxial α<sub>2</sub>-agonists prolong analgesia but commonly cause hypotension, bradycardia, and sedation—undesirable in severe aortic stenosis with baseline bradycardia."
      }
    ],
    "didactic": "Neuraxial additives enhance spinal/epidural analgesia via synergistic mechanisms with local anesthetics. Choosing among **opioids** and **α<sub>2</sub>-agonists (clonidine)** requires balancing efficacy against side effects, particularly in patients at risk for hemodynamic instability or respiratory depression.\n\n- Lipophilic neuraxial opioids (fentanyl, sufentanil): rapid onset (minutes), short duration (2–4 hours intrathecally), limited rostral CSF spread. They improve intraoperative and early postoperative analgesia and have a low risk of delayed respiratory depression. Typical intrathecal dosing: fentanyl 10–25 µg; sufentanil 2.5–10 µg.\n- Hydrophilic neuraxial opioids (morphine, hydromorphone): slower onset, long duration (12–24+ hours), and greater rostral spread. They provide extended analgesia but increase risks of pruritus, nausea/vomiting, urinary retention, and **delayed respiratory depression**. Typical intrathecal dosing: morphine 100–200 µg; hydromorphone 75–150 µg.\n- Neuraxial clonidine: an α<sub>2</sub>-agonist that prolongs sensory block and improves analgesia without respiratory depression. However, it commonly causes **hypotension, bradycardia, and sedation** (dose dependent). Intrathecal dosing ~15–75 µg; epidural doses are higher.\n\nIn severe OSA, avoiding long-acting hydrophilic neuraxial opioids reduces the risk of late respiratory depression. In severe aortic stenosis and baseline bradycardia, minimizing **sympatholysis** is critical; clonidine is contraindicated relative to alternatives due to hypotension/bradycardia risk. Thus, a **lipophilic intrathecal opioid (eg, fentanyl 10–25 µg)** best augments early analgesia with minimal hemodynamic effect and low risk of late respiratory events.\n\nEpidural parallels: adding fentanyl (eg, 25–100 µg bolus or 1–5 µg/mL infusion) improves labor or postoperative analgesia with minimal motor block; epidural morphine (2–3 mg) provides prolonged analgesia but shares hydrophilic-opioid side effects. When long-acting neuraxial opioids are used—especially in OSA—close postoperative monitoring for ≥24 hours is prudent to detect delayed respiratory depression.",
    "educationalObjective": "Select additives for spinal or epidural (opioids, clonidine) to enhance analgesia and list side effects."
  },
  {
    "id": "Core.7.5.18",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Neuraxial anesthesia basics",
    "difficulty": "medium",
    "questionText": "A 74-year-old man (80 kg, 175 cm) with ischemic cardiomyopathy (EF 35%) and well-controlled hypertension presents for left hip hemiarthroplasty after a fracture. To limit sympathectomy and hypotension, you plan a unilateral spinal anesthetic. Surgery is expected to last 90–120 minutes. Which intrathecal plan is most likely to provide dense surgical anesthesia of the left hip while minimizing bilateral spread?",
    "answers": [
      {
        "text": "15 mg hyperbaric bupivacaine with immediate supine positioning and 15° Trendelenburg",
        "isCorrect": false,
        "explanation": "A higher dose of hyperbaric solution combined with Trendelenburg promotes cephalad spread and a high bilateral block (eg, approaching T4), markedly increasing hypotension risk."
      },
      {
        "text": "7.5 mg hyperbaric bupivacaine with the patient kept in left lateral decubitus (operative side down) and slight head-up tilt for 10 minutes before turning supine",
        "isCorrect": true,
        "explanation": "Hyperbaric (glucose-containing) solution sinks to the dependent side; a lower dose plus keeping the operative side down with slight head-up limits cephalad spread, favoring a unilateral block and less hypotension."
      },
      {
        "text": "10 mg hyperbaric bupivacaine with the patient in left lateral decubitus (operative side up) and slight head-up tilt for 10 minutes",
        "isCorrect": false,
        "explanation": "Hyperbaric solution will settle on the dependent (down) side, preferentially blocking the nonoperative limb; head-up may further limit cephalad spread but does not correct the side mismatch."
      },
      {
        "text": "7.5 mg hypobaric bupivacaine with the patient in left lateral decubitus (operative side up) and 10° head-down tilt",
        "isCorrect": false,
        "explanation": "Hypobaric solution floats to the nondependent side and could favor the operative side up; however, head-down increases cephalad spread and unpredictability, risking higher bilateral block and hypotension. Hypobaric formulations are also less standardized for hip surgery."
      },
      {
        "text": "12 mg isobaric bupivacaine with immediate supine positioning and neutral table",
        "isCorrect": false,
        "explanation": "Isobaric solutions are less influenced by gravity and will typically produce a bilateral block; 12 mg increases the likelihood of a higher, denser bilateral sympathectomy than desired for a cardiomyopathy patient."
      }
    ],
    "didactic": "Selecting spinal dose and baricity requires predicting how the solution spreads with gravity before it “fixes” to nerve roots. **Baricity** drives this early distribution:\n- **Hyperbaric** (> CSF density; glucose-added) sinks to the dependent side.\n- **Hypobaric** (< CSF density) floats to the nondependent side.\n- **Isobaric** (≈ CSF density) shows minimal position-dependent spread and is more “fixed.”\n\nFor lower extremity/hip surgery in patients where hypotension is dangerous, a **unilateral hyperbaric spinal** is a common strategy. Key elements include:\n- Use a **lower dose** of long-acting local anesthetic (eg, hyperbaric bupivacaine 7.5–10 mg) to achieve sufficient duration (≈90–120 min) while limiting bilateral spread.\n- Place the patient in **lateral decubitus with the operative side down** to let the hyperbaric solution gravitate to the target side.\n- Maintain this position for several minutes (≈10 min) and apply a **slight head-up tilt** to reduce cephalad spread and sympathetic block.\n\nBy contrast:\n- **Trendelenburg** with a hyperbaric solution promotes cephalad spread and can produce an undesirably high bilateral block (eg, T4) with profound hypotension.\n- **Isobaric** solutions are less position-dependent and more likely to produce bilateral blocks at a given dose, which may be inappropriate in high-risk cardiac patients.\n- **Hypobaric** spinals float to the up side and are used selectively (eg, anorectal surgery in jackknife); they can be less predictable for hip surgery and head-down positioning risks excessive cephalad spread.\n\nOther factors increase spread at a given dose (eg, advanced **age**, pregnancy, low CSF volume), so dose and tilt should be titrated accordingly. For unilateral hip surgery in a fragile cardiac patient, **hyperbaric bupivacaine 7.5 mg with operative side down and slight head-up** most reliably achieves a dense unilateral block with less sympathectomy.",
    "educationalObjective": "Select spinal anesthetic dose and baricity for lower abdominal or lower extremity surgery and predict spread with positioning."
  },
  {
    "id": "Core.7.6.1",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Upper limb blocks",
    "difficulty": "medium",
    "questionText": "A 32-year-old man is scheduled for distal radius ORIF. An ultrasound-guided axillary brachial plexus block is performed with 25 mL 0.5% ropivacaine deposited circumferentially around the axillary artery. After 30 minutes, he lacks wrist flexion/extension and has dense anesthesia in median, ulnar, and radial distributions. However, elbow flexion is intact and sensation over the lateral volar forearm persists.\n\nYou plan to supplement the block under ultrasound. Which maneuver will most effectively anesthetize the missed nerve?",
    "answers": [
      {
        "text": "Infiltrate 5 mL local anesthetic subcutaneously along the proximal medial upper arm to block intercostobrachial and medial brachial cutaneous nerves.",
        "isCorrect": false,
        "explanation": "This treats tourniquet pain (T2, medial arm) but does not address elbow flexion or lateral forearm sensation (lateral antebrachial cutaneous) mediated by the musculocutaneous nerve."
      },
      {
        "text": "Inject an additional 10 mL local anesthetic circumferentially around the axillary artery within the neurovascular sheath.",
        "isCorrect": false,
        "explanation": "The musculocutaneous nerve lies outside the axillary sheath and is often spared by perivascular injection; more volume around the artery will not reliably capture it."
      },
      {
        "text": "Target the radial nerve posterior to the axillary artery and inject 5 mL local anesthetic within the posterior compartment.",
        "isCorrect": false,
        "explanation": "The radial nerve has already been anesthetized by the perivascular injection; supplementing it will not resolve preserved elbow flexion or lateral forearm sensation."
      },
      {
        "text": "Deposit 5 mL local anesthetic into the biceps brachii muscle belly to anesthetize the lateral antebrachial cutaneous nerve.",
        "isCorrect": false,
        "explanation": "The lateral antebrachial cutaneous nerve is a terminal branch of the musculocutaneous nerve that emerges between the biceps and brachialis; intramuscular biceps injection does not reliably block it and risks myotoxicity."
      },
      {
        "text": "Advance the needle laterally to pierce the coracobrachialis and inject 5–10 mL local anesthetic within the muscle around a small hyperechoic oval nerve (or after eliciting elbow flexion at 0.3–0.5 mA).",
        "isCorrect": true,
        "explanation": "The musculocutaneous nerve branches early and courses within the coracobrachialis; a small-volume intramuscular injection reliably anesthetizes it and its terminal lateral antebrachial cutaneous branch."
      }
    ],
    "didactic": "Failure to block the musculocutaneous nerve is the most common cause of incomplete anesthesia after an axillary brachial plexus block. The **median, ulnar, and radial nerves** are clustered around the axillary artery within the axillary sheath and are reliably covered by a perivascular injection. In contrast, the **musculocutaneous nerve (MCN)** typically branches early from the lateral cord, pierces the **coracobrachialis**, and then travels between the biceps and brachialis before terminating as the **lateral antebrachial cutaneous (LABC)** nerve. Because the MCN lies **outside** the axillary sheath at this level, it is frequently spared by circumferential injections around the artery.\n\nClinical clues to MCN sparing include **preserved elbow flexion** (biceps/brachialis) and **intact lateral forearm sensation** (LABC). The optimal supplement is to specifically target the MCN within the **coracobrachialis**: identify the axillary artery, then scan laterally to visualize the coracobrachialis (muscle with internal striations) and a small **hyperechoic oval** nerve within or at its border. Advance the needle in-plane to **pierce the coracobrachialis** and inject 5–10 mL local anesthetic to expand the muscle belly around the nerve. When using dual guidance, **elbow flexion** at 0.3–0.5 mA confirms proximity. Frequent aspiration, low injection pressure, and real-time visualization reduce intraneural risk.\n\nCommon pitfalls include adding more volume around the artery (won’t reach the MCN), targeting the already-blocked radial nerve, or performing cutaneous field blocks (eg, intercostobrachial) that do not affect MCN function. If the MCN is unusually located between the biceps and brachialis, scanning slightly distal and depositing a small volume between these muscles will still effectively anesthetize the nerve and its LABC branch.",
    "educationalObjective": "Block the musculocutaneous nerve in the coracobrachialis when not captured by axillary perivascular injection."
  },
  {
    "id": "Core.7.6.2",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Upper limb blocks",
    "difficulty": "medium",
    "questionText": "A 62-year-old man with severe COPD (FEV1 42% predicted, baseline SpO<sub>2</sub> 91% on room air) is scheduled for open fixation of a radial head fracture via a lateral elbow approach. He requests regional anesthesia with minimal sedation. The surgeon plans an upper arm tourniquet. You want a single-injection brachial plexus block that provides reliable anesthesia for the elbow and forearm, minimizes the risk of hemidiaphragmatic paresis, and avoids the need for separate musculocutaneous nerve supplementation.\n\nWhich regional technique is most appropriate?",
    "answers": [
      {
        "text": "Supraclavicular block",
        "isCorrect": false,
        "explanation": "Provides dense anesthesia for elbow/forearm/hand but carries a significant risk of hemidiaphragmatic paresis; less desirable in severe COPD despite good surgical coverage."
      },
      {
        "text": "Infraclavicular block",
        "isCorrect": true,
        "explanation": "Targets the cords of the brachial plexus, reliably anesthetizes the musculocutaneous nerve, provides excellent elbow/forearm coverage, and has a lower risk of hemidiaphragmatic paresis than more proximal approaches."
      },
      {
        "text": "Interscalene block at C5–C7",
        "isCorrect": false,
        "explanation": "Interscalene blocks are ideal for shoulder surgery, have near-universal hemidiaphragmatic paresis, and often inadequately cover the ulnar distribution—poor choice for elbow/forearm in COPD."
      },
      {
        "text": "Combined distal median, ulnar, and radial nerve blocks at the forearm",
        "isCorrect": false,
        "explanation": "Distal forearm blocks do not cover the musculocutaneous (lateral antebrachial cutaneous) territory or the elbow joint—insufficient for elbow surgery and tourniquet discomfort."
      },
      {
        "text": "Axillary block with ultrasound guidance",
        "isCorrect": false,
        "explanation": "Safe and distal, but the musculocutaneous nerve often exits the sheath proximal to this level and may require a separate injection in the coracobrachialis; less reliable as a single-injection solution."
      }
    ],
    "didactic": "For elbow and forearm surgery, an ultrasound-guided **infraclavicular block** targets the brachial plexus at the level of the **cords** deep to the pectoralis minor. Because the musculocutaneous nerve is a terminal branch of the lateral cord, blockade at the cords provides more **reliable anesthesia of the musculocutaneous nerve** (and its sensory continuation, the lateral antebrachial cutaneous nerve) than more distal approaches. In patients with significant pulmonary disease, infraclavicular block also reduces the likelihood of **hemidiaphragmatic paresis** compared with interscalene and supraclavicular blocks.\n\n- Infraclavicular: cords-level, excellent elbow/forearm/hand coverage; more consistent musculocutaneous blockade; lower phrenic involvement.\n- Supraclavicular: divisions-level, very dense distal anesthesia but a meaningful risk of hemidiaphragmatic paresis and pneumothorax; less desirable in COPD.\n- Interscalene: roots/trunks-level, designed for shoulder; high phrenic involvement (~virtually universal); often spares the ulnar distribution—suboptimal for elbow/forearm.\n- Axillary: terminal branches-level; musculocutaneous nerve commonly exits the sheath proximally and may be missed unless specifically injected within or near the coracobrachialis; thus, less reliable as a single injection for elbow surgery.\n- Distal forearm blocks: target terminal nerves distal to the elbow and do not cover the elbow joint or the lateral antebrachial cutaneous territory.\n\nA practical infraclavicular technique identifies the axillary artery under the pectoralis minor and deposits local anesthetic around the artery to circumferentially cover posterior, lateral, and medial cords. While infraclavicular block minimizes phrenic involvement, avoid large volumes directed medially/cephalad. For an upper arm tourniquet, remember the **intercostobrachial nerve (T2)** is not part of the brachial plexus and typically needs separate subcutaneous infiltration for tourniquet comfort.",
    "educationalObjective": "Choose infraclavicular block for elbow/forearm surgery and anticipate coverage of musculocutaneous nerve."
  },
  {
    "id": "Core.7.6.3",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Upper limb blocks",
    "difficulty": "medium",
    "questionText": "A 58-year-old man is scheduled for open reduction and internal fixation of a fifth metacarpal fracture. You place a high-frequency linear probe in the supraclavicular fossa in a transverse orientation. The ultrasound image shows a pulsatile, circular vessel resting on the 1st rib with sliding pleura deep to it. Lateral and slightly superior to the vessel is a compact “cluster of grapes” of hypoechoic nodules within a fascial sheath; the scalene muscles are not in view. Which brachial plexus component and anatomic relationship best explains these findings?",
    "answers": [
      {
        "text": "Terminal branches surrounding the axillary artery in the axilla, superficial to pectoralis major (axillary level).",
        "isCorrect": false,
        "explanation": "At the axillary level, the terminal branches are seen around the axillary artery in the axilla; the 1st rib and pleura are not visualized."
      },
      {
        "text": "Roots anterior to the anterior scalene and adjacent to the subclavian vein under the clavicle (costoclavicular level).",
        "isCorrect": false,
        "explanation": "Roots do not lie anterior to the anterior scalene; that position corresponds to the phrenic nerve and subclavian vein. Costoclavicular scanning targets cords, not roots, and is lateral to the vein."
      },
      {
        "text": "Roots between the anterior and middle scalene muscles at approximately C5–C7, lateral to the carotid sheath (interscalene level).",
        "isCorrect": false,
        "explanation": "This describes the interscalene view of the roots (or proximal trunks) in the interscalene groove; the subclavian artery, 1st rib, and pleura are typically not the key landmarks here."
      },
      {
        "text": "Trunks/divisions lateral and superior to the subclavian artery atop the 1st rib with pleura deep (supraclavicular level).",
        "isCorrect": true,
        "explanation": "At the supraclavicular fossa, the plexus appears as a clustered “bundle of grapes” lateral/superior to the subclavian artery on the 1st rib, with the pleura deep—an ideal window to block the trunks/divisions."
      },
      {
        "text": "Cords arranged posterolateral, posterior, and medial to the axillary artery deep to pectoralis minor (infraclavicular level).",
        "isCorrect": false,
        "explanation": "This describes the infraclavicular view around the second part of the axillary artery beneath pectoralis minor, not the supraclavicular fossa over the 1st rib."
      }
    ],
    "didactic": "The brachial plexus is organized from roots → trunks → divisions → cords → terminal branches, and its relationships to the scalene muscles and subclavian/axillary vessels define the classic block windows.\n\n- Roots (C5–T1): Emerge between the anterior and middle scalene muscles in the interscalene groove, lateral to the carotid sheath. The phrenic nerve courses on the anterior surface of the anterior scalene, anterior to the plexus.\n- Trunks: Form at the lateral border of the scalene muscles (upper C5–C6, middle C7, lower C8–T1). Just distal to this, the trunks split into divisions.\n- Supraclavicular level (divisions ± distal trunks): The plexus appears as a compact “cluster of grapes” lateral and slightly superior to the subclavian artery sitting on the 1st rib, with the pleura deep. This window provides dense anesthesia for the upper limb with a high success rate due to tight packing of fibers before they redistribute into cords.\n- Infraclavicular level (cords): The cords are named by their relationship to the second part of the axillary artery deep to pectoralis minor—lateral, posterior, and medial cords. In the costoclavicular variant, the three cords cluster lateral to the axillary artery beneath the clavicle.\n- Axillary level (terminal branches): The median, ulnar, radial, and axillary nerves lie around the axillary artery in the axilla; the musculocutaneous nerve often leaves the sheath to pierce the coracobrachialis.\n\nKey vessel relationships:\n- Subclavian artery overlies the 1st rib; the pleura lies immediately deep—recognizing the rib-pleura interface reduces pneumothorax risk.\n- Subclavian vein is anterior/medial to the artery and anterior to the anterior scalene; confusing it with the plexus risks intravascular injection.\n\nCorrectly identifying whether you are seeing roots (between scalenes), divisions (lateral/superior to the subclavian artery on the 1st rib), or cords (around the axillary artery under pectoralis minor) ensures accurate level selection and safer block performance.",
    "educationalObjective": "Map brachial plexus anatomy from roots to cords and its relationship to scalene muscles and the subclavian/axillary vessels."
  },
  {
    "id": "Core.7.6.4",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Upper limb blocks",
    "difficulty": "medium",
    "questionText": "A 34-year-old man is undergoing an ultrasound-guided axillary brachial plexus block for open reduction and internal fixation of a distal radius fracture. With the arm abducted and externally rotated, the axillary artery is centered in short axis. You identify three terminal branches within the axillary sheath and one nerve outside the sheath within the coracobrachialis. After depositing 10 mL of 0.5% ropivacaine anterolateral to the artery, spread is confined to a 12–3 o’clock sector without circumferential coverage; the oval hyperechoic nerve in the coracobrachialis remains untouched. To reliably complete the block of the median, ulnar, radial, and musculocutaneous nerves while minimizing needle passes and systemic dose, which action is best?",
    "answers": [
      {
        "text": "Perform a subcutaneous ring of local anesthetic across the axillary crease to supplement missed distributions.",
        "isCorrect": false,
        "explanation": "Field infiltration may cover cutaneous branches but will not reliably anesthetize terminal branches to the forearm and hand required for surgical anesthesia."
      },
      {
        "text": "Apply firm digital compression just distal to the injectate to promote circumferential spread within the axillary sheath, and perform a separate 3–5 mL injection around the musculocutaneous nerve within the coracobrachialis.",
        "isCorrect": true,
        "explanation": "Manual compression helps distribute local anesthetic around the artery to reach perivascular branches, while a separate small-volume injection is required for the musculocutaneous nerve, which lies outside the sheath."
      },
      {
        "text": "Inject an additional 20 mL at the same anterolateral site to rely on diffusion for complete coverage, including the musculocutaneous nerve.",
        "isCorrect": false,
        "explanation": "Single-quadrant deposition often fails to produce circumferential spread and will still spare the musculocutaneous nerve outside the sheath, while increasing local anesthetic dose and toxicity risk."
      },
      {
        "text": "Insert a perivascular catheter for continuous infusion to obviate the need for a separate musculocutaneous injection.",
        "isCorrect": false,
        "explanation": "Even with a catheter in the axillary sheath, the musculocutaneous nerve often remains unblocked unless it is specifically injected within the coracobrachialis."
      },
      {
        "text": "Advance the needle tip into the posteromedial nerve and inject until the fascicle visibly expands, ensuring radial nerve blockade.",
        "isCorrect": false,
        "explanation": "Intraneural injection (nerve expansion) risks neurologic injury and is unnecessary when safe perineural spread and compression can achieve coverage."
      }
    ],
    "didactic": "In the axilla, the cords have already divided into terminal branches. The median, ulnar, and radial nerves typically lie within the **axillary sheath** surrounding the axillary artery, whereas the **musculocutaneous nerve (MCN)** exits the sheath early and courses within the **coracobrachialis** (between the biceps brachii and coracobrachialis), lateral to the artery. On ultrasound, the artery is pulsatile and round; terminal branches appear hyperechoic with a honeycomb pattern. Because the MCN is outside the sheath, it commonly requires a **separate perineural injection**.\n\nA high-success technique is to achieve **circumferential spread** around the axillary artery for the within-sheath nerves and then block the MCN directly. Practical steps:\n- Identify the three perivascular branches (median/ulnar/radial) and the MCN in coracobrachialis.\n- Inject incrementally (eg, 3–5 mL per quadrant) with frequent aspiration to avoid intravascular injection.\n- Use **firm digital compression** just distal to the deposit (or gentle transducer pressure/massage) to **redistribute local anesthetic circumferentially** within the sheath, improving coverage of perivascular branches while minimizing needle passes and total dose.\n- Perform a **separate 3–5 mL injection around the MCN** within the coracobrachialis, visualizing spread around the nerve.\n\nIncreasing volume at a single site does not reliably produce circumferential spread and risks local anesthetic systemic toxicity. Intraneural injection (nerve expansion, high opening pressures, severe pain/paresthesia) should be avoided due to nerve injury risk. Typical total volumes are 20–30 mL of long-acting local anesthetic for adult axillary blocks, titrated in small aliquots with aspiration and hemodynamic monitoring. Ensuring circumferential perivascular spread plus a dedicated MCN injection yields dense anesthesia of the median, ulnar, radial, and MCN distributions for forearm and hand surgery.",
    "educationalObjective": "Perform axillary block with identification of median, ulnar, radial, and musculocutaneous nerves and compress to spread."
  },
  {
    "id": "Core.7.6.5",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Upper limb blocks",
    "difficulty": "hard",
    "questionText": "A 58-year-old man (80 kg) with moderate OSA (uses home CPAP) undergoes ambulatory arthroscopic rotator cuff repair. A continuous interscalene catheter was placed preoperatively under ultrasound using an in-plane posterior approach with injectate observed to spread posterolateral to the C5–C6 roots between the anterior and middle scalene muscles. After negative aspiration and a 5 mL test dose, the catheter was advanced 3 cm beyond the needle tip and secured. He is comfortable in PACU (pain 2/10, SpO<sub>2</sub> 98% on room air) and will be discharged with an ambulatory pump. The surgeon anticipates moderate pain for 48–72 hours and prefers to minimize upper extremity motor block and respiratory side effects.\n\nWhich ambulatory infusion program is most appropriate for this interscalene catheter?",
    "answers": [
      {
        "text": "Ropivacaine 0.2% at 0 mL/h basal; 8 mL patient-controlled bolus; 20-min lockout; hourly max 24 mL",
        "isCorrect": false,
        "explanation": "A pure bolus strategy with large, frequent boluses risks erratic analgesia, excessive cephalad spread, and higher peaks in local anesthetic exposure."
      },
      {
        "text": "Ropivacaine 0.1% at 10 mL/h basal; 5 mL patient-controlled bolus; 60-min lockout; hourly max 20 mL",
        "isCorrect": false,
        "explanation": "Although the total ropivacaine mass is modest, the high basal volume favors cephalad spread and hemidiaphragmatic paresis, undermining the goal of minimizing respiratory effects."
      },
      {
        "text": "Bupivacaine 0.25% at 8 mL/h basal; 8 mL patient-controlled bolus; 30-min lockout; hourly max 24 mL",
        "isCorrect": false,
        "explanation": "High-concentration bupivacaine with a large basal and bolus increases motor block, phrenic paresis, and cardiotoxicity risk; this is not ideal for ambulatory OSA patients."
      },
      {
        "text": "Lidocaine 0.5% at 3 mL/h basal; 3 mL patient-controlled bolus; 60-min lockout; hourly max 9 mL",
        "isCorrect": false,
        "explanation": "Lidocaine’s short duration and toxicity profile make it unsuitable for days-long ambulatory interscalene infusions."
      },
      {
        "text": "Ropivacaine 0.2% at 4 mL/h basal; 4 mL patient-controlled bolus; 60-min lockout; hourly max 12 mL",
        "isCorrect": true,
        "explanation": "A low basal with small, infrequent boluses using ropivacaine 0.2% provides effective shoulder analgesia while limiting volume-dependent phrenic spread, motor block, and systemic exposure—appropriate for ambulatory OSA."
      }
    ],
    "didactic": "Continuous interscalene catheters provide superior ambulatory analgesia after shoulder surgery. Optimal placement under ultrasound targets the C5–C6 roots between the anterior and middle scalene muscles; an in-plane posterior approach with injectate spreading posterolateral to the plexus within the perineural sheath improves analgesia and may reduce phrenic involvement. After negative aspiration and a small test dose, advance the catheter 2–3 cm beyond the needle tip to reduce dislodgement while limiting epidural/intrathecal migration.\n\nFor ambulatory infusions, ropivacaine is preferred over bupivacaine due to less motor block and lower cardiotoxicity. Typical programs use ropivacaine 0.2% with a low basal rate (3–6 mL/h) and small patient-controlled boluses (2–5 mL) with 30–60 min lockouts. This strategy balances steady background analgesia with activity-related rescue while limiting total volume. Because hemidiaphragmatic paresis is volume dependent at the interscalene level, minimizing basal flow reduces cephalad spread toward the phrenic nerve. Large boluses and high basal volumes increase the risk of dyspnea, hoarseness (recurrent laryngeal involvement), Horner’s syndrome, and insensate limb.\n\nA reasonable outpatient limit is an hourly maximum of 8–12 mL; with ropivacaine 0.2%, this corresponds to 16–24 mg/h (eg, ≤576 mg/24 h), within commonly accepted safety ranges while providing effective analgesia. Educate patients on pump use, expected sensory/motor effects, limb protection, and warning signs of local anesthetic systemic toxicity (perioral numbness, tinnitus, metallic taste, agitation) and phrenic paresis (new dyspnea). For concerning respiratory symptoms, instruct the patient to pause the pump, sit upright, and contact the service; many improve with reducing or discontinuing the basal infusion. Catheter removal at 48–72 h is typical, with daily follow-up calls to assess analgesia and safety. This patient benefits from ropivacaine 0.2% at a low basal rate with small, infrequent boluses to minimize respiratory compromise while maintaining analgesia.",
    "educationalObjective": "Place a continuous interscalene catheter and manage infusion settings for ambulatory shoulder analgesia."
  },
  {
    "id": "Core.7.6.6",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Upper limb blocks",
    "difficulty": "medium",
    "questionText": "A 55-year-old man is undergoing an ultrasound-guided supraclavicular brachial plexus block for ORIF of a distal radius fracture. With the needle tip adjacent to the brachial plexus, the first 1–2 mL test injection requires high force and the inline manometer reads an opening pressure of 25 psi. On ultrasound, the plexus appears to swell with hypoechoic expansion rather than tracking along the perineural sheath, and the patient reports a brief, sharp paresthesia radiating to the hand. After negative aspiration, what is the best next step to minimize the risk of intraneural injury?",
    "answers": [
      {
        "text": "Administer additional midazolam and fentanyl to improve tolerance and resume injection at the same site with slower rate.",
        "isCorrect": false,
        "explanation": "Treating symptoms without correcting needle position can mask warning signs; sedation does not reduce the risk of intraneural injection."
      },
      {
        "text": "Continue the injection slowly because negative aspiration and transient paresthesia are expected and do not indicate intraneural placement.",
        "isCorrect": false,
        "explanation": "Aspiration does not exclude intraneural placement, and pain/paresthesia with nerve swelling and high pressure are warning signs; continuing injection risks intrafascicular injury."
      },
      {
        "text": "Stop injection and withdraw/reposition the needle until perineural spread is clearly visualized and opening pressure is ≤15 psi, then inject in small aliquots with frequent aspiration.",
        "isCorrect": true,
        "explanation": "High opening pressure, nerve swelling, and paresthesia suggest intraneural placement. Reposition to achieve low-pressure injection with circumferential perineural spread before proceeding."
      },
      {
        "text": "Maintain the needle position but reduce plunger force to target an opening pressure of 20–25 psi to avoid intravascular injection.",
        "isCorrect": false,
        "explanation": "Opening pressures ≥20 psi are concerning for intraneural placement; safe injection typically requires ≤15 psi with visualization of perineural spread."
      },
      {
        "text": "Advance the needle to elicit a motor response at ≤0.2 mA and inject at that location to ensure adequate block onset.",
        "isCorrect": false,
        "explanation": "A very low stimulating current suggests intraneural or intrafascicular proximity; injecting at this location increases nerve injury risk."
      }
    ],
    "didactic": "Preventing intraneural injection during upper-limb blocks relies on combining real-time ultrasound with injection pressure monitoring and patient feedback. The safest practice is to inject only when low opening pressure (≤15 psi) and **perineural spread** are confirmed. Perineural spread appears as local anesthetic tracking along the perineural sheath, separating fascial planes and, ideally, forming a circumferential “donut” around the target. In contrast, **nerve swelling**, hypoechoic expansion within the nerve, or loss of the normal fascicular pattern suggests intraneural injection and warrants immediate cessation.\n\nHigh resistance to injection with opening pressure ≥20 psi correlates with intraneural/intrafascicular needle position. An inline manometer or low-pressure extension tubing helps detect unsafe pressures; safe injections feel effortless and register low pressure. Proceeding despite high pressure and paresthesia increases the risk of fascicular ischemia and mechanical injury.\n\nPractical steps include:\n- Maintain continuous needle tip visualization; **stop immediately** if the tip cannot be seen.\n- Use small test aliquots (1–3 mL) to confirm perineural spread; if spread is not seen, **reposition**.\n- Inject incrementally (3–5 mL) with frequent aspiration and continuous pressure monitoring (goal ≤15 psi).\n- Keep the patient responsive when feasible; **pain/paresthesia** during injection is a warning signal, not a target.\n\nNerve stimulation is not reliably protective; very low current thresholds (≤0.2 mA) may indicate intraneural proximity. Sedation can mask symptoms of nerve compromise and should not substitute for proper technique. The best way to minimize nerve injury is to confirm low-pressure injection with visible perineural spread around, not within, the nerve before delivering significant volumes.",
    "educationalObjective": "Prevent intraneural injection by monitoring injection pressure and visualizing spread around, not within, the nerve."
  },
  {
    "id": "Core.7.6.7",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Upper limb blocks",
    "difficulty": "easy",
    "questionText": "A 34-year-old man requires exploration and repair of complex lacerations spanning the volar and dorsoradial aspects of the wrist. Ultrasound is unavailable. You plan a landmark-guided wrist block to provide surgical anesthesia by blocking the median, ulnar, and superficial radial nerves using 1% lidocaine. Which combination of injection sites is most appropriate to achieve complete anesthesia while minimizing vascular injury?\n\nSelect the best set of landmark-guided injections.",
    "answers": [
      {
        "text": "Median: subcutaneous line infiltration across the volar wrist crease (10 mL). Ulnar: block at the elbow posterior to the medial epicondyle. Radial: single depot injection in the anatomic snuffbox.",
        "isCorrect": false,
        "explanation": "A superficial volar line does not reach the median nerve deep to the flexor retinaculum; a proximal ulnar block is unnecessary and may cause motor block; a single snuffbox depot may be too distal/incomplete for the superficial radial nerve."
      },
      {
        "text": "Median: inject ulnar to the flexor carpi ulnaris tendon at the ulnar wrist. Ulnar: inject just radial to the ulnar artery pulse. Radial: deep perivascular injection encircling the radial artery at the wrist.",
        "isCorrect": false,
        "explanation": "The median nerve is not near the flexor carpi ulnaris; injecting radial to the ulnar artery misses the ulnar nerve (which lies ulnar/medial to the artery), and a deep perivascular radial injection is unnecessary and increases vascular/nerve injury risk."
      },
      {
        "text": "Median: inject 3–5 mL just deep between the palmaris longus and flexor carpi radialis tendons at the proximal wrist crease. Ulnar: palpate the ulnar artery just radial to flexor carpi ulnaris; inject 3–5 mL just ulnar to the artery 0.5–1 cm deep, plus a 2–3 mL subcutaneous wheal along the ulnar dorsum. Radial: subcutaneous ring infiltration (5–10 mL) from the radial styloid across the dorsoradial wrist, lateral to the radial artery.",
        "isCorrect": true,
        "explanation": "This sequence targets the median nerve between palmaris longus and flexor carpi radialis, the ulnar nerve medial to the ulnar artery, and the superficial radial nerve with a subcutaneous dorsoradial ring—providing comprehensive wrist anesthesia and avoiding perivascular/deep injections."
      },
      {
        "text": "Median: inject within the carpal tunnel distal to the distal wrist crease. Ulnar: dorsal subcutaneous wheal only at the ulnar styloid. Radial: no separate block needed because median and ulnar blocks cover the dorsoradial wrist.",
        "isCorrect": false,
        "explanation": "Intratunnel median injection risks nerve injury; a dorsal-only ulnar wheal omits palmar ulnar distribution; the superficial radial nerve supplies dorsoradial wrist and requires its own subcutaneous block."
      },
      {
        "text": "Median: inject between the flexor carpi radialis tendon and the radial artery. Ulnar: inject within Guyon canal distal to the pisiform. Radial: palmar subcutaneous infiltration along the thenar crease.",
        "isCorrect": false,
        "explanation": "Median placement is too radial; ulnar injection within Guyon canal risks intraneural injury and misses dorsal branch; palmar infiltration does not block the superficial radial nerve on the dorsoradial wrist."
      }
    ],
    "didactic": "Wrist anesthesia for hand surgery can be reliably achieved using surface landmarks to block the **median**, **ulnar**, and **superficial radial** nerves without ultrasound. Key landmarks and techniques:\n\n- Median nerve: Identify the palmaris longus (PL) and flexor carpi radialis (FCR) by having the patient oppose thumb and little finger and flex the wrist. The median nerve lies deep between PL and FCR at the proximal wrist crease. Insert a small needle just deep to the fascia between these tendons, aspirate, and inject 3–5 mL. If PL is absent, inject just ulnar to the FCR tendon.\n- Ulnar nerve: Palpate the ulnar artery at the proximal wrist crease (just radial to flexor carpi ulnaris [FCU]). The ulnar nerve lies **ulnar (medial)** to the artery. Insert the needle just ulnar to the arterial pulse, advance 0.5–1 cm, aspirate, and inject 3–5 mL. Add a 2–3 mL subcutaneous wheal along the dorsoulnar wrist to cover the dorsal ulnar cutaneous branch.\n- Superficial radial nerve: This purely sensory branch runs subcutaneously on the dorsoradial wrist, lateral to the radial artery. Perform a subdermal field block (5–10 mL) from the radial styloid across the dorsoradial wrist toward the extensor tendons, staying superficial and lateral to the radial artery.\n\nPractical points:\n\n- Use incremental injections with frequent aspiration to avoid intravascular injection (particularly near the ulnar and radial arteries).\n- Avoid injecting within the **carpal tunnel** or **Guyon canal** to reduce intraneural injury risk; deposit local just proximal and superficial to these structures.\n- Expect onset within minutes with lidocaine; adjust volume/concentration and add epinephrine judiciously (avoid end-arterial digit infiltration).\n\nThis landmark-based approach provides dense sensory anesthesia to the palmar and dorsoradial aspects of the hand and wrist while minimizing vascular and neural complications.",
    "educationalObjective": "Provide surgical anesthesia at the wrist by blocking radial, median, and ulnar nerves using surface landmarks."
  },
  {
    "id": "Core.7.6.8",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Upper limb blocks",
    "difficulty": "medium",
    "questionText": "A 52-year-old man undergoes an ultrasound-guided right supraclavicular brachial plexus block with 25 mL of 0.5% ropivacaine for distal radius ORIF. Fifteen minutes later, he reports a “droopy” right eyelid and hoarseness. Examination shows right ptosis, miosis, and decreased facial sweating with mild facial flushing on the right. He has mild dyspnea when speaking, but vital signs are stable (BP 128/72 mmHg, HR 74/min, RR 16/min, SpO<sub>2</sub> 98% on room air). Breath sounds are equal without chest pain.\n\nWhich of the following best explains this constellation of findings?",
    "answers": [
      {
        "text": "Hemidiaphragmatic paralysis from ipsilateral phrenic nerve block",
        "isCorrect": false,
        "explanation": "Phrenic nerve block can cause dyspnea, especially in patients with limited pulmonary reserve, but it does not cause ptosis, miosis, anhidrosis, or hoarseness."
      },
      {
        "text": "Unintended blockade of the ipsilateral cervical sympathetic chain (stellate ganglion) and recurrent laryngeal nerve from cephalad spread of local anesthetic",
        "isCorrect": true,
        "explanation": "Horner syndrome (ptosis, miosis, anhidrosis) reflects ipsilateral cervical sympathetic blockade, and hoarseness reflects ipsilateral recurrent laryngeal nerve block; both can occur after interscalene/supraclavicular blocks due to cephalad spread and are typically self-limited."
      },
      {
        "text": "High neuraxial/brainstem anesthesia from inadvertent intrathecal spread",
        "isCorrect": false,
        "explanation": "High neuraxial spread causes hypotension, bradycardia, dyspnea/apnea, and bilateral neurologic deficits rather than unilateral Horner syndrome with isolated voice changes."
      },
      {
        "text": "Local anesthetic systemic toxicity from inadvertent intravascular injection",
        "isCorrect": false,
        "explanation": "LAST usually presents with CNS prodromes (tinnitus, perioral numbness, metallic taste) and can progress to seizures and cardiovascular collapse; it does not cause focal unilateral ocular findings or isolated hoarseness."
      },
      {
        "text": "Pneumothorax from pleural puncture during the supraclavicular approach",
        "isCorrect": false,
        "explanation": "Pneumothorax typically presents with pleuritic chest pain, dyspnea, hypoxemia, and decreased/unilateral breath sounds—not isolated ipsilateral Horner signs and hoarseness with normal SpO<sub>2</sub> and symmetric breath sounds."
      }
    ],
    "didactic": "Interscalene and supraclavicular brachial plexus blocks can produce unintended cranial and cervical neural blockade due to anatomic proximity and cephalad spread of local anesthetic. The triad of ipsilateral ptosis, miosis, and facial anhidrosis/flushing is **Horner syndrome**, which results from blockade of the **cervical sympathetic chain (stellate ganglion)**. Concurrent **hoarseness** reflects ipsilateral **recurrent laryngeal nerve (RLN)** blockade from spread to the vagus/RLN within the carotid sheath. These effects are typically benign and self-limited as the block resolves.\n\nKey differentiators from other complications:\n- **Phrenic nerve block** (common with interscalene; less frequent with supraclavicular) causes hemidiaphragmatic paresis and dyspnea but not Horner syndrome or hoarseness.\n- **Pneumothorax** presents with pleuritic pain, hypoxemia, and decreased/delayed breath sounds on the affected side; it is less likely with normal SpO<sub>2</sub> and symmetric auscultation.\n- **Local anesthetic systemic toxicity (LAST)** presents with CNS prodromes (tinnitus, metallic taste, perioral numbness) and can progress to seizures and dysrhythmias—findings not seen here.\n- **High neuraxial spread** would cause hypotension, bradycardia, dyspnea/apnea, and bilateral sensorimotor changes.\n\nClinical implications:\n- Horner syndrome and RLN block signify cephalad spread; they are more likely with larger volumes and higher (interscalene) approaches but can occur with supraclavicular blocks.\n- RLN block is usually well tolerated, but patients with **contralateral RLN palsy** or preexisting vocal cord dysfunction are at risk for airway compromise; avoid bilateral blocks and be prepared to manage the airway if stridor or respiratory distress develops.\n- Management is typically observation, reassurance, and supplemental O<sub>2</sub> as needed; symptoms resolve as local anesthetic regresses. Ultrasound guidance and lower volumes can reduce the incidence of these side effects.",
    "educationalObjective": "Recognize Horner syndrome and recurrent laryngeal nerve block after interscalene/supraclavicular approaches."
  },
  {
    "id": "Core.7.6.9",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Upper limb blocks",
    "difficulty": "medium",
    "questionText": "A 48-year-old man is scheduled for open reduction and internal fixation of a 5th metacarpal fracture under an ultrasound-guided supraclavicular brachial plexus block. Thirty minutes after block completion, he cannot extend his wrist and reports numbness over the first dorsal web space and the palmar surfaces of the thumb, index, and middle fingers. However, pinprick sensation remains intact over the volar little finger and ulnar half of the ring finger, and the planned incision is along the ulnar border of the hand. The surgeon is ready to start and minimal additional sedation is preferred.\n\nWhich supplemental nerve block is the most appropriate to provide surgical anesthesia for this incision?",
    "answers": [
      {
        "text": "Musculocutaneous nerve block within the coracobrachialis in the axilla",
        "isCorrect": false,
        "explanation": "The musculocutaneous nerve provides sensation to the lateral forearm (lateral antebrachial cutaneous nerve), not the hand."
      },
      {
        "text": "Radial nerve (superficial branch) block at the wrist with subcutaneous infiltration over the dorsolateral wrist",
        "isCorrect": false,
        "explanation": "The superficial radial nerve innervates the dorsolateral hand and first dorsal web space, which are already anesthetized and do not include the volar little finger."
      },
      {
        "text": "Median nerve block at the wrist, just ulnar to the palmaris longus tendon",
        "isCorrect": false,
        "explanation": "The median nerve supplies the palmar lateral 3½ digits, which are already anesthetized; it does not cover the volar little finger or ulnar palm."
      },
      {
        "text": "Ulnar nerve block at the wrist, just radial to the flexor carpi ulnaris tendon proximal to the pisiform",
        "isCorrect": true,
        "explanation": "The ulnar nerve supplies the volar little finger, ulnar half of the ring finger, and ulnar palm; a focused wrist block rapidly rescues incomplete ulnar coverage after a proximal block."
      },
      {
        "text": "Intercostobrachial nerve block via subcutaneous ring infiltration of the medial proximal arm",
        "isCorrect": false,
        "explanation": "The intercostobrachial nerve (T2) covers the medial upper arm and is relevant for proximal arm tourniquet discomfort, not ulnar-sided hand incisions."
      }
    ],
    "didactic": "In an incomplete brachial plexus block, targeted supplementation based on sensory mapping is the fastest and safest rescue strategy. The sensory pattern in this patient—anesthetized palmar thumb/index/middle (median) and first dorsal web space (radial) with preserved pinprick on the volar little finger and ulnar half of the ring finger—is classic for incomplete ulnar nerve anesthesia. A selective ulnar nerve block at the wrist efficiently rescues this deficit without repeating a proximal block.\n\nKey cutaneous distributions:\n- Median: palmar thumb, index, middle, and radial half of ring; dorsal distal tips of index/middle.\n- Ulnar: palmar little finger and ulnar half of ring; ulnar palm; dorsal ulnar hand and dorsal little/ring except distal tips.\n- Radial (superficial): dorsolateral hand and first dorsal web space.\n- Musculocutaneous (lateral antebrachial cutaneous): lateral forearm.\n- Intercostobrachial/medial brachial cutaneous: medial upper arm (tourniquet discomfort).\n\nWrist block techniques (landmark-based):\n- Ulnar: identify the pisiform and flexor carpi ulnaris (FCU) tendon; inject 3–5 mL just radial (lateral) to the FCU tendon proximal to the pisiform, after careful aspiration to avoid the adjacent ulnar artery.\n- Median: inject 3–5 mL just ulnar to the palmaris longus and radial to the flexor carpi radialis at the wrist crease.\n- Radial (superficial): subcutaneous ring infiltration lateral to the radial styloid over the dorsolateral wrist.\n\nAlthough a supraclavicular block typically provides dense anesthesia to the hand, incomplete spread or fascial septa can spare a terminal nerve. Distal, nerve-specific supplementation minimizes additional local anesthetic dose, limits risk of vascular puncture in the neck/axilla, and provides rapid onset where it matters for the incision. Always inject incrementally with frequent aspiration and avoid intraneural injection, especially near the ulnar artery at the wrist.",
    "educationalObjective": "Rescue incomplete upper limb block by supplementing specific terminal nerves based on sensory mapping."
  },
  {
    "id": "Core.7.6.10",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Upper limb blocks",
    "difficulty": "medium",
    "questionText": "A 55-year-old man scheduled for outpatient arthroscopic rotator cuff repair asks about options for postoperative pain control. He is ASA II with normal spirometry, no OSA, and SpO₂ 98% on room air. You plan an ultrasound-guided regional technique. Which of the following is the most appropriate counseling statement regarding block choice and respiratory effects for this procedure?",
    "answers": [
      {
        "text": "An interscalene block provides the most reliable analgesia for shoulder surgery but produces ipsilateral hemidiaphragmatic paresis in most patients (≈90%); in patients with significant lung disease, a diaphragm-sparing alternative such as combined suprascapular and axillary nerve blocks can be chosen.",
        "isCorrect": true,
        "explanation": "ISB is the gold standard for shoulder analgesia and nearly always blocks the phrenic nerve, transiently reducing FEV<sub>1</sub>/FVC by ~25–30%. For high-risk lungs, suprascapular + axillary nerve blocks (or a low-volume superior trunk block) are reasonable diaphragm-sparing options."
      },
      {
        "text": "An isolated axillary block is the preferred single-nerve alternative to interscalene for shoulder analgesia in patients with compromised pulmonary function.",
        "isCorrect": false,
        "explanation": "Axillary block alone does not cover the suprascapular nerve and provides inadequate shoulder analgesia; it must be combined with a suprascapular nerve block to approach ISB efficacy."
      },
      {
        "text": "Using ultrasound guidance and ≤5 mL of local anesthetic for the interscalene block consistently avoids phrenic nerve palsy, so dyspnea is unlikely even in severe COPD.",
        "isCorrect": false,
        "explanation": "Lower volumes and extrafascial techniques reduce but do not reliably eliminate hemidiaphragmatic paresis; clinically significant dyspnea can still occur in severe pulmonary disease."
      },
      {
        "text": "A supraclavicular block offers equivalent shoulder analgesia to interscalene while reliably avoiding phrenic nerve block and Horner syndrome.",
        "isCorrect": false,
        "explanation": "Supraclavicular block does not reliably cover the shoulder (suprascapular/axillary territories) and can still result in phrenic involvement; it is not preferred for shoulder surgery analgesia."
      },
      {
        "text": "A superior trunk block increases the likelihood of hemidiaphragmatic paresis compared with interscalene but better preserves hand motor function.",
        "isCorrect": false,
        "explanation": "Superior trunk block is more distal from the phrenic nerve and generally reduces (rather than increases) hemidiaphragmatic paresis compared with ISB, while preserving distal motor function."
      }
    ],
    "didactic": "The **interscalene block (ISB)** provides the most reliable analgesia for shoulder surgery because it targets C5–C7 roots/trunks, anesthetizing the **suprascapular** and **axillary** nerves that carry most nociception from the glenohumeral joint. However, due to the phrenic nerve’s proximity on the anterior scalene (C3–C5), ISB causes **ipsilateral hemidiaphragmatic paresis** in ≈90–100% of patients, with a transient ↓ in FEV<sub>1</sub> and FVC of roughly 25–30%. Most healthy patients tolerate this without symptoms, but those with limited reserve (eg, severe COPD, contralateral diaphragm paralysis, advanced restrictive disease, morbid obesity with OSA) may experience dyspnea.\n\nKey counseling points for ISB:\n- Expect temporary ipsilateral diaphragm weakness; mild dyspnea or orthopnea can occur.\n- Other transient effects include **Horner syndrome** (stellate ganglion spread) and hoarseness (recurrent laryngeal nerve involvement).\n- Benefits include superior postoperative analgesia and reduced opioid use after shoulder procedures.\n\nFor patients with high pulmonary risk, consider **diaphragm-sparing alternatives**:\n- **Suprascapular + axillary nerve blocks (SSNB + ANB):** Robust shoulder analgesia with minimal effect on the diaphragm; may have slightly less complete analgesia than ISB, especially for arthroplasty, but are excellent for arthroscopy.\n- **Superior trunk block (STB):** More distal than ISB, lowering phrenic involvement (especially with low volumes and extrafascial deposition) while preserving hand motor function; still not entirely phrenic-sparing.\n- Other strategies: reduce ISB volume (eg, 5–10 mL) and use extrafascial injection to decrease, but not eliminate, phrenic paresis.\n\nBottom line: For a healthy patient, an **ISB is the preferred** block for shoulder surgery, and counseling must include the high likelihood of **hemidiaphragmatic paresis**. In patients with compromised lungs, **SSNB + ANB** or a low-volume **STB** can provide effective analgesia while better preserving respiratory function.",
    "educationalObjective": "Select interscalene block for shoulder surgery and counsel about hemidiaphragmatic paresis and alternatives in high-risk lungs."
  },
  {
    "id": "Core.7.6.11",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Upper limb blocks",
    "difficulty": "hard",
    "questionText": "A 68-year-old man (BMI 35) with moderate COPD (FEV1 45%) and resting SpO<sub>2</sub> 92% on room air is scheduled for arthroscopic rotator cuff repair. General anesthesia with endotracheal intubation is planned, and you intend to add a regional technique for postoperative shoulder analgesia. He becomes dyspneic with minimal exertion and wishes to avoid any breathing issues postoperatively. The surgeon expects substantial early pain and requests reliable analgesia for the first postoperative day. On ultrasound, the superior trunk is easily identified.\n\nWhich block and local anesthetic regimen best balances timely onset and duration of shoulder analgesia while minimizing the risk of hemidiaphragmatic paresis?",
    "answers": [
      {
        "text": "Superior trunk block with 8 mL 0.5% ropivacaine",
        "isCorrect": true,
        "explanation": "Targets the superior trunk distal to the phrenic nerve with a modest volume to limit cephalad spread; a higher concentration speeds onset and provides durable analgesia while lowering the risk of diaphragmatic paresis compared with interscalene."
      },
      {
        "text": "Interscalene block with 20 mL 0.5% ropivacaine",
        "isCorrect": false,
        "explanation": "Provides dense, rapid analgesia but causes hemidiaphragmatic paresis in the vast majority of patients at this volume, which is unsuitable for this COPD patient."
      },
      {
        "text": "Superior trunk block with 15 mL 0.25% ropivacaine",
        "isCorrect": false,
        "explanation": "Excess volume increases the chance of proximal spread to the phrenic nerve, while the dilute concentration slows onset and reduces block density."
      },
      {
        "text": "Combined suprascapular and axillary nerve blocks with 5 mL 0.5% ropivacaine each",
        "isCorrect": false,
        "explanation": "Phrenic-sparing but may provide less dense, less reliable early analgesia compared with superior trunk techniques for arthroscopic rotator cuff repair."
      },
      {
        "text": "Interscalene block with 5 mL 0.25% ropivacaine",
        "isCorrect": false,
        "explanation": "Lower volume reduces spread, but the dilute concentration yields slower, less reliable onset and shorter duration; phrenic paresis can still occur with interscalene even at low volumes."
      }
    ],
    "didactic": "Shoulder analgesia is traditionally achieved with an interscalene block (ISB), but hemidiaphragmatic paresis is common due to phrenic nerve proximity—rates approach 70–100% with 20 mL volumes. Reducing ISB volume can decrease, but not eliminate, paresis; even 5–10 mL may still cause clinically relevant diaphragm dysfunction in susceptible patients. Thus, patients with limited pulmonary reserve (eg, COPD) benefit from phrenic-sparing strategies.\n\nA **superior trunk block (STB)** anesthetizes the C5–C6 fibers distal to the point where the phrenic nerve is most at risk, lowering the incidence and severity of hemidiaphragmatic paresis while providing comparable shoulder analgesia. The key trade-off is **volume vs spread**: higher volumes increase cephalad/medial spread toward the phrenic nerve, while lower volumes reduce unintended spread but risk block failure if not precisely deposited. Concentration primarily influences **onset and block density**, with higher concentrations producing faster, more reliable onset without necessarily increasing spread if total volume is contained.\n\nFor arthroscopic rotator cuff repair requiring robust early analgesia, **8 mL of 0.5% ropivacaine** at the superior trunk balances these factors: the modest volume limits phrenic involvement and the higher concentration yields timely onset and durable analgesia. Additional techniques that further reduce paresis risk include extrafascial injection and meticulous, ultrasound-guided hydrodissection to avoid medial spread.\n\nAlternatives include low-volume ISB (still nontrivial paresis risk) and combined **suprascapular + axillary** nerve blocks (phrenic-sparing but often provide less dense early analgesia than STB/ISB for rotator cuff repairs). Overall, for high-risk respiratory patients needing reliable shoulder analgesia, a low-volume, higher-concentration STB is preferred to balance **onset, duration, and diaphragm-sparing**.",
    "educationalObjective": "Select volumes and concentrations to balance onset and avoid diaphragmatic paresis for shoulder analgesia."
  },
  {
    "id": "Core.7.6.12",
    "category": "Local, Regional & Acute Pain",
    "subcategory": "Upper limb blocks",
    "difficulty": "hard",
    "questionText": "A 72-year-old tall, thin man with severe emphysema (barrel chest, home O<sub>2</sub>) is scheduled for open reduction and internal fixation of a distal radius fracture under regional anesthesia. You plan a single-shot, ultrasound-guided supraclavicular brachial plexus block to avoid general anesthesia. With a high-frequency linear probe just superior to the clavicle in the coronal-oblique plane, you identify the subclavian artery sitting atop the first rib, the brachial plexus “cluster of grapes” posterolateral to the artery, and a shimmering pleural line deeper and more medial. You want to maximize block success while minimizing pneumothorax risk during needle advancement.\n\nWhich ultrasound technique and probe/needle orientation best achieves this goal?",
    "answers": [
      {
        "text": "Keep a more medial probe position to deepen the corner pocket and advance in-plane from medial-to-lateral toward the subclavian artery for a perivascular spread.",
        "isCorrect": false,
        "explanation": "Medial windows often lack a rib backstop, placing the plexus over the pleura; a medial-to-lateral trajectory increases pneumothorax and vascular puncture risk."
      },
      {
        "text": "Tilt the probe cephalad to eliminate rib shadowing and advance in-plane below the first rib to spread local anesthetic under the plexus for complete coverage.",
        "isCorrect": false,
        "explanation": "Removing the rib shadow exposes the pleura rather than protecting against it; deliberately passing below the first rib directs the needle toward the lung and is unsafe."
      },
      {
        "text": "Use an out-of-plane, cephalad-to-caudad approach until the needle contacts the clavicle, then walk off inferiorly toward the plexus to prevent pleural puncture.",
        "isCorrect": false,
        "explanation": "Out-of-plane advancement obscures tip location and walking off the clavicle risks losing control of depth; contact with bone does not protect the pleura once the needle slips beyond its edge."
      },
      {
        "text": "Slide the probe laterally until the first rib lies directly beneath the plexus; advance an in-plane needle from lateral-to-medial with a shallow trajectory, keeping the tip visualized above the rib and using hydrodissection to enter the anteroinferior “corner pocket.”",
        "isCorrect": true,
        "explanation": "Lateral probe position places the first rib as a hard backstop under the plexus; a shallow, in-plane lateral-to-medial path with continuous tip visualization and hydrodissection allows safe corner-pocket spread while avoiding the pleura."
      },
      {
        "text": "Rotate the probe perpendicular to the clavicle (transverse) and perform an out-of-plane injection into the plexus cluster to shorten skin-to-plexus distance.",
        "isCorrect": false,
        "explanation": "Transverse/out-of-plane techniques reduce visualization of the first rib and pleura and impair tip tracking, increasing the risk of pleural puncture and intraneural injection."
      }
    ],
    "didactic": "The supraclavicular block anesthetizes the brachial plexus at the level of trunks/divisions, producing dense anesthesia for forearm and hand surgery. Despite ultrasound guidance, pneumothorax remains a key hazard because the pleural dome lies deep and medial to the subclavian artery, and the first rib slopes away medially so that the plexus may overlie pleura if the window is too medial.\n\nRisk mitigation relies on image optimization and needle trajectory control. Position the probe in the supraclavicular fossa in a coronal-oblique orientation parallel to the clavicle. Slide the transducer laterally until the hyperechoic first rib lies directly beneath the plexus cluster; the first rib serves as a hard barrier between the needle and pleura. Identify the subclavian artery on the first rib, with the plexus posterolateral to the artery, and confirm the shimmering pleural line medial/deep to the rib. Use color Doppler to locate and avoid vascular structures.\n\nAdvance the block needle in-plane from lateral-to-medial with a shallow angle so the needle crosses the rib contour and the tip remains above the rib at all times. Maintain continuous tip visualization and use small-volume hydrodissection to separate tissue planes safely. Deposit part of the local anesthetic in the anteroinferior “corner pocket” (between the artery and first rib) to reliably capture the lower trunk/ulnar distribution, then complete a perineural, circumferential spread around the plexus—all while keeping the tip on the rib side, never below it. Avoid medial-to-lateral or out-of-plane approaches, which decrease tip control and increase contact with unprotected pleura.\n\nIf a safe lateral window with a rib backstop cannot be obtained, consider an alternative technique (eg, infraclavicular or superior trunk block) rather than forcing a medial supraclavicular approach in patients with high pneumothorax risk.",
    "educationalObjective": "Use supraclavicular block for distal arm surgery and mitigate pneumothorax risk with ultrasound technique and probe orientation."
  }
]